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 The search for new anti-HCV therapeutics continues, as current standard of care 
based on pegINF and ribavirin is limited and can cause significant side effects.  
 Several families of modified nucleoside are known to inhibit HCV RNA 
dependent RNA polymerase (RdRp). The 2’-C-!-methylguanosine (2’CMeG) has 
been identified as one of the most potent RdRp inhibitors (IC50 = 0.26 µM as NTP). 
Despite its very good activity at the triphosphate level its poor cell uptake and 
presumably poor phosphorylation lead to significant decrease in active in HCV 
replicon assays (EC50 = 3.5µM). The
 
ProTide approach was applied to 2’-C-
methylguanosine in order to by-pass the first phosphorylation limiting step and 
enhance cellular uptake. Modified nucleoside phosphoramidates with improved 
efficacy and selectivity may become a future of HCV therapies.  
 In the present work, the pronucleotide approach based on 
aryloxyphosphoramidate, phosphorodiamidate or oxazaphosphorine cyclic prodrugs 
has been applied to 2’-C-!-methylguanosine and related nucleoside analogues bearing 
modifications in C6-, C8- and C2- of the purine base. These modifications were 
mainly introduced to increase lipophilicity of 2’CMeG and consequently enhance 
cellular uptake and to deliver the 2’-C-methylguanosine 5’-monophosphate 
intracellularly.  
 In general, most of the newly synthesised compounds exhibited excellent 
potency in HCV replicon assay. The most potent compounds were up to 1000-fold 
more active than the corresponding parent nucleoside.  
 Base modification combined with the ProTide approach provide compounds 
that possess not only excellent antiviral activity but also good cell permeability. 
Extensive in vitro and in vivo studies lead to the selection of INX-08189 that has now 
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DMF  dimethylformamide 
DMSO  dimethylsulfoxide 
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D-PhG  D-phenylglycine 
D-Val  D-valine 
EC50  50% effective concentration  
EC90  90% effective concentration 
EHNA  erythro-9-(2-hydroxy-3-nonyl)adenine 
EtOAc  ethyl acetate 
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EtOH  ethanol 
FDA  Food and Drug Administration 
FUdR  5-fluoro-2’-deoxyuridine 
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HCV  hepatitis C virus 
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HPLC  high-performance liquid chromatography 
HRMS  high resolution mass spectrometry 
Huh 7  human hepatoma cell line 
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IRES  internal ribosome entry site 
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YMPK  uridine/cytidine monophosphate kinase 







1.1 The discovery of the Hepatitis C Virus (HCV). 
      
In the late 1930’s it was believed that there are two different types of 
infectious jaundice.1 These two types were distinguished by type of exposure and 
incubation period. Infectious hepatitis (type A) was characterised by relatively short 
incubation period, faecal-oral transmission and generally mild clinical course. Serum 
hepatitis (type B) had prolonged incubation period, parenteral transmission route and 
was more severe.1  
In mid 70’s when serological tests for hepatitis B virus and later for hepatitis 
A virus were developed, transfusion related hepatitis studies were carried out.2 During 
the studies several cases of an ‘acute hepatitis’ were identified. Surprisingly infected 
patients were lacking the typical hepatitis-like symptoms or jaundice and furthermore 
the incubation period differed from hepatitis A and B.2,3 It become clear that most of 
the transfusion-related hepatitis cases were due to neither of the previously known 
viruses, leading to the term non-A, non-B (NANB) hepatitis.2 It was also discovered 
that approximately 10% of transfusions were shown to result in NANBH 4,5, which 
upon a lack of treatment caused persistent liver damage and could lead to liver 
cirrhosis.6 Interestingly, in some cases, the disease was occurring sporadically and 
was not related to the receipt of blood products.7 Regardless of ongoing progress in 
the research, all of the experiments failed to result in the molecular identification and 
isolation of the virus, antigen or antibody  associated with NANBH. Furthermore, no 
NANBH- specific virus had been propagated in vitro or observed in vivo.8 
In 1989, after 6 years of investigation at Chiron Corporation, a single cDNA 
clone (5-1-1) was isolated and was shown to encode an antigen specifically associated 
with NANB hepatitis. The clone was indentified as a flavi-like virus, named hepatitis 
C virus (HCV).8,9 Development of specific HCV antibody immunoassays confirmed 
that as many as 70-90% of NANBH cases were associated with hepatitis C virus 
infection.10 The isolation of clone 5-1-1 allowed the whole viral genome to be 
identified and sequenced. Subsequently, new blood screening tests enabled detection 
of circulating HCV antibodies and viral RNA particles, effectively eradicating the 
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transmission of transfusion related NANBH.8 Currently the main routes of HCV 
transmission are intravenous drug abuse and modern medical practice.11 
 
1.2 HCV structure and genome organisation. 
 
HCV is a small, enveloped virus with a single stranded (+) RNA genome. It 
belongs to the Hepacivirus genus of the Flaviviridae family. The HCV genome is 
approximately 9600 base pairs long, contains 5’ and 3’ untranslated (noncoding) 
regions and a single, open reading frame (ORF) encoding a polyprotein (~3000 amino 
acids) that is cleaved by viral and cellular proteases into 3 structural (core, E1 and E2) 
and 7 non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) (Figure 
1.1).12 
 
Figure 1.1. Organization of HCV genome. 
5’ and 3’ untranslated regions (5’UTR and 3’UTR) are the most conserved 
regions of viral RNA.13 Up to 90% of the 5’UTR primary sequence is identical across 
the different HCV genotypes. 5’UTR consist of four domains, three of which are 
building the internal ribosome entry site, critical for initiation of viral RNA 
translation. The 3’UTR region contains in its primary sequence the termination codon 
of the HCV polyprotein.13,14 
The core protein is derived from the N-terminus of the polyprotein. It is highly 
conserved protein. It contains three domains:  
- The N-terminal very hydrophilic domain (D1) is involved in RNA binding, 
nuclear localization and mediates capsid assembly. 
- The C-terminal hydrophobic domain (D2) is responsible for association of the 
core protein with lipids and cellular membrane proteins.12,13 
The main function of the core protein is formation of the viral nucleocapsid, 
furthermore the core protein is involved in several regulatory functions including 
modulation of host signalling pathways, cellular and viral genome expression and cell 
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apoptosis. After translation, core protein is cleaved from the polyprotein by host 
enzymes.12,15  
E1 and E2 are glycoprotein components of the envelope, essential for viral 
fusion with host cell membrane, entry and also viral particle assembly. E2 consists of 
hypervariable region 1 (HVR1). HVR1 is a basic region with positively charged 
residues that can interact with negatively charged proteins at the cell surface. 
Therefore E1 can play a crucial role in host cell recognition and attachment, as well as 
cellular compartmentalization of the virus. E1 and E2 are cleaved from the 
polyprotein by host proteases.12,16 
p7 is a small polypeptide responsible for the production of infected particles in 
vivo.17 It is thought than p7 can mediate membrane permeability by formation of an 
ion channel (calcium ion channel) in the cell membrane acting as a viroporin. It is also 
believed that p7 can play an important role in viral particle release and maturation. p7 
is cleaved from the polyprotein by host proteases.12,18 
NS2 is transmembrane protein responsible for endoplasmic reticulum 
membrane association; together with NS3 it shows autoprotease activity. After 
intramolecular cleavage from NS3, NS2 looses its protease activity and after 
phosphorylation undergoes degradation by the proteosome.12,19 
NS3 is a multifunctional protein. One third of its N-terminal region contains 
tripsyn/chymotripsin-like serine protease domain (NS3-4A) and RNA helicase 
domain (NS3) in the remaining C-terminal part of the polypeptide.12 The NS3 binds 
non-covalently to NS4A protein, which acts as an activating cofactor.20 NS4A 
increases the enzymatic activity of the NS3. NS3-4A is essential for the cleavage of 
the remaining downstream cleavages of the HCV polyprotein, into four functional 
non-structural proteins. NS4A stabilizes the N-terminal domain of the protein, by 
optimizing the orientation of the residues of the catalytic triad and by participating in 
formation of substrate recognition site. 20 Active NS3-4A protease is also thought to 
prevent interferon (INF) and pro-inflammatory cytokines induced antiviral response 
and therefore enables survival of HCV in the host.12  
The C-terminal part possesses ATPase/helicase activity. It is thought that the main 
role lies in unwinding of the double stranded RNA intermediate, which is formed 
when the single HCV genome is replicated. However the precise role of the HCV 
helicase is not yet fully understood.12 
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NS4B is an ER membrane-associated protein. It is responsible for the 
formation of a special membrane compartments: membranous web and speckle-like 
structures that may serve as a platform for viral RNA replication. Additional 
presumed properties include modulation of NS5B RNA-dependant RNA polymerase 
activity, inhibition of cellular synthases and induction of interleukins and 
inflammatory responses.12,21 
NS5A is an anchored in membrane protein, responsible for regulation of RNA 
replication by interactions with cellular and viral proteins. NS5A protein exists in two 
forms: phosphorylated and hyperphosphorylated, each of them play different roles in 
the HCV life cycle. Phosphorylation of NS5A regulates a switch from replication to 
viral capsid assembly. The hyperphosphorylated form of the protein is thought to be 
responsible for the down-regulation of HCV replication. NS5A is also considered as 
an agent modulating the response to interferon based therapy.12,22,23 
NS5B is a 68kDa protein acting as a RNA-dependant RNA polymerase 
(RdRp) that lacks proofreading function. It consists of typical ‘palm’, ‘fingers’ and 
‘thumb’ domains.24 Interactions between domains result in fully enclosed active site 
into which nucleoside triphosphates can get access through a specific tunnel.25 Two 
critical aspartic acid residues are located in the palm domain of an active site and are 
responsible for chelating metal ions (Mg2+, Mn2+) that are responsible for the 
polymerization reaction. Additionally, they coordinate the attack of the 3’-hydroxyl 
group of the growing RNA chain on the alpha-phosphate of the incoming 
nucleotide.24,25 Replication of the viral RNA has been found to proceed in the absence 
of primer (de novo synthesis). RdRp is an error-prone enzyme, responsible for the 
high degree of genetic variability.26,27 
 
1.3 HCV life cycle. 
 
There are some key steps in HCV life cycle: entry to the host cell, viral genome 
uncoating, translation and replication of the viral genome, virion assembly and 
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1.3.1 Mechanism of viral entry into the host cell. 
 
There are two suggested models of HCV cell entry. In the first one, virus entry 
is caused by direct interaction of envelope glycoproteins with specific host cell 
receptor complex SR-BI and CD81. Virus bound to the CD81 is transferred to the 
tight junctions where it interacts with claudin 1 and occludin. HCV enters the cell by 
clathrin-dependent endocytosis. Acidification of early endosome leads to the fusion of 
the viral envelope and release of nucleocapsid into the cytosol.28,29 
In the second mechanism, binding and internalization of the virus is mediated 
by interaction between HCV-associated lipoproteins with receptors on a cell surface. 
After attachment to the SR-BI-CD81 complex, the virus is subsequently transferred to 
the tight junction proteins. Then it undergoes mediated by envelope glycoproteins 
endocytosis and fusion. The last one leads to the release of viral genome from the 
early endosome. 28,29  
 
1.3.2 HCV replication. 
  
Decapsidation of viral nucleocapsid liberates free genomic RNA into the host 
cell. After exposure to the host cell machinery, it undergoes translation. As already 
mentioned 5’UTR region of HCV genome contains an internal ribosome entry site 
(IRES) that allows access of the viral genome to the host translation system. 
Translation of the HCV genome gives a single ~ 3000 amino acid polyprotein, which 
is processed by cellular and viral proteases to give structural and non-structural viral 
proteins. Translation of the viral proteins is necessary to establish the viral replication 
machinery.12 
HCV is believed to replicate in association with intercellular membranes. It is 
suggested that the intercellular membrane can provide physical support, enabling a 
high local concentration of viral factors for its replication, and it facilitates the 
structural organization of the replication complex.30 
The positive sense RNA serves as a template for the synthesis of single, 
negative-strand RNA. The two RNA strands remained base-paired, however it is not 
clear when this putative complex is unwinded. The newly synthesised (-) RNA strand 
is copied multiple times by semiconservative replication mediated by RNA dependant 
RNA polymerase (RdRp). As a result, multiple positive-strand RNA genomes are 
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obtained. These particles can be either encapsulated to form new viruses or used as 
templates for viral protein synthesis. The newly formed viral particles are secreted 
from the cell after passage through the Golgi apparatus by exocytosis (Figure 
1.2).12,14,31 
 
Figure 1.2. HCV replication.32 
  
1.4 Survival in the host. 
 
 The ease with which hepatitis C virus can persist within a host cells is 
astounding. This is mainly attributed to its capability to avoid the components of the 
adaptive and innate host immune system. 
Host cells have developed a number of mechanisms to stop usage of their own 
translation complexes as an antiviral strategy. For example, in response to viral 
infection host cap-dependant translation can be shut down. Viral IRES that permits 
ready access of the viral genome to the translation machinery is cap-independent and 
enables viral translation to continue.33  
The key sites of HCV control over the host response are found to be related 
with: 
- Reduction in IFN production in hepatocytes 
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- Suppression of cytokines signalling  
- Inhibition of NK activity 
- The INF-responsiveness of cellular factors is decreased  
- Inability of the adaptive immune system to clear viral infection 
- Enhanced permissiveness of HCV infection leading to the broader systemic 
immune defects (lack of antibody and CD8+T cell recognition).33-35 
 
1.5 HCV genetic diversity. 
 
 As was already mentioned, NS5B encodes RNA-dependant RNA polymerase 
that lacks proofreading function. With a mean frequency of nucleotide substitutions of 
1.4-1.9 x 103 substitution per site per year, very high production of virions per day 
and turn-over rate close to 99%, HCV can produce every possible mutation in every 
position each day.36 This results in a elevated generation of genetic diversity, such 
that the virus exists as quasispecies, which is a collection of closely related but not 
identical genomes.36 Based on phylogenetic analysis, HCV has been classified into six 
major genotypes (represented by numerous subtypes). Genotypes can differ from each 
other by ~30% and by less than 10% between subtypes. It has been suggested that 
potential endemic regions for the different genotypes are Guinea coast of West Africa 
for type 1, Western and Central Africa for genotype 2, Northern Indian subcontinent 
for type 3, Central Africa – 4, South-East Asia for type 6 (Table 1.1). The provenance 
of the genotype 5 is still under investigation.37 
Genotype distribution: 
Genotype Area of distribution 
1, 2, 3 USA, Europe, Australia, East Asia (Japan, Taiwan, 
Thailand and China) 
4 Middle East, Egypt and Central Africa 
5 South Africa 
6 South-East Asia and Australia 
 
Table 1.1. HCV genotype distribution. 
 
HCV genotypes are very closely associated with the response to antiviral 
therapy. Therefore, further understanding of the clinical relevance and therapeutic 
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implications of the HCV genotype is crucial for designing individualized therapies for 
patients with HCV infection.37 
 
1.6 Vaccine development 
 
There is no vaccine available for HCV infection. Lack of cell culture HCV 
(HCV could be generated in vitro in tissue culture systems only very recently) and 
proper animal models have greatly limited the development of HCV vaccines. 
Presently, various vaccines are primarily tested in chimpanzees. One of the biggest 
challenges for the HCV vaccines is fact that they will have to deal with high levels of 
viral genetic diversity and be able to eradicate HCV from the liver without inducing 
liver immunopathology. Most of the vaccines are still in preclinical development with 
some advanced into phase I or II trials. There are several therapeutic vaccine types 
including: peptide vaccines, vector vaccines, recombinant protein vaccines and DNA 
vaccines. Most of them are focused on generating cytotoxic CD8+T cells in addition 
to antibody response.38,39 
Peptide vaccines - are one of the earliest vaccines, peptide based, with 
different adjuvants. Their main role is to induce T helper cell (Th1) and cytotoxic T 
cell response in chronic HCV patients.  
 Vector vaccines - are delivered by attenuated virus vectors. Vaccines based on 
modified virus of Ankara (MVA) have been shown to induce INF! secretion by 
CD4+T and CD8+T. Vaccines based on adenoviral vectors were shown to induce 
HCV-specific T-cell response in chimpanzees. 
 Recombinant protein vaccines - with these types of vaccines, specific HCV 
response is generated by a strong Th1 adjuvant combined with recombinant HCV 
proteins. 
 DNA vaccines - are using naked DNA delivered by electroporation.38-41 
 
1.7 Current treatment. 
 
Approximately 3% of the worldwide population is infected with the hepatitis C 
virus, with an anticipated 3-4 million individuals newly infected each year. Circa 70% 
of infected individuals will develop chronic hepatitis C. Cirrhosis, hepatocellular 
carcinoma and liver failure are the main progressive liver diseases which can develop 
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in untreated patients within 25-30 years. The mortality rate associated with HCV has 
risen to 2-5% per year. End stage liver disease due to HCV infection represents the 
major indication for liver transplantation in the Western world.42   
A protective vaccination against HCV does not exist, and standard therapy with 
interferon (IFN) or pegylated interferon (Peg-IFN) plus ribavirin (RBV) (1.1, Figure 
1.3) is related to a long-term duration (12-72 weeks). Furthermore the dual regimen is 
not HCV-specific and relies on enhancing the hot immune response.43 In May 2011, 
the Food and Drug Administration (FDA) approved two novel protease inhibitors: 
telaprevir and boceprevir for the treatment of HCV. However both of these drugs still 
need to be co-administrated with the standard of care (SOC). 44  
 
Figure 1.3. Structure of ribavirin.  
 
Peg-IFN/RBV based therapy is often connected with side effects such as depression, 
anaemia, flu-like symptoms, fatigue, cognitive dysfunction, cutanous reaction, 
gastrointestinal symptoms, pulmonary effects, cytopenias, thyroid dysfunction, 
retinopathy and others.42 Interferon is also administrated as subcutaneous injection, 
which is not preferred by the patients.43 
Responses to antiviral therapy of hepatitis C are grouped into three general 
patterns: 
- Sustained virological response (SVR)  
- End-of treatment response and relapse 
- Non-response.  
An SVR is defined as achieving undetectable levels of HCV RNA (<50 IU/ml) in 
serum during the treatment course and its continued absence for at least 6 months 
after stopping the therapy. Only 34-52% of treated individuals with HCV genotypes 1 
or 4 will achieve a SVR after 48-week of therapy. By comparison approximately 80% 
of patients with genotypes 2 or 3 can achieve SVR during 24-weeks of treatment.44 
Furthermore virological response rates have been shown to depend also on various 
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host and viral factors such as: age, weight, sex, race, liver enzymes, stage of fibrosis 
and HCV RNA concentrations at the baseline (Figure 1.4).45 
 
 
Figure 1.4. Factors associated with virological response to anti-HCV treatment. 
 
1.7.1 Mechanism of action of therapeutic interferon. 
 
The type-1 interferon family includes interferons- !, ", ω, and λ. All of them 
play a crucial role in the innate antiviral immune response. IFNs have antiviral, 
immunomodulatory and antiproliferative activities, but their potencies differ. IFN-! 
has potent antiviral activity but does not act directly on the virus or replication 
complex. It has been assumed that IFN treatment works by similar mechanisms to 
endogenous IFN, with the greater effectiveness being caused by the higher 
concentrations. In addition to its direct antiviral actions, IFN has important 
interactions with the adaptive and innate immune responses. Type-1 IFNs promote 
memory T-cell proliferation, prevent T-cell apoptosis and stimulate natural-killer-cell 
activation.46,47 Similarly, pegylated interferon therapy of chronic hepatitis C has been 
reported to be associated with enhanced T-cell responses.48  
 
1.7.2 Mechanism of action of ribavirin. 
 
Ribavirin was synthesised for the first time in 1972 and was found to possess a 
broad spectrum of activity against broad range of RNA and DNA viruses. As a drug it 
was first used in mid1980s, for the treatment of respiratory syncytial virus infection in 
children. After the discovery of HCV, ribavirin was used as a monotheraphy but the 
treatment did not clear HCV levels even with prolonged treatment.49 Surprisingly, the 
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addition to the INF-! therapy led to marked improvement in SVR. Consequently 
ribavirin was approved for the treatment of HCV but only as a combination therapy 
with INF-!.50 
At present there are 4 proposed mechanisms of direct and indirect action of 
ribavirin (Figure 1.5): 
- Immunomodulation 
- Direct inhibition of HCV replication 
- Inosine monophosphate dehydrogenase (IMPGH) inhibition 
- Mutagenesis and ‘error catastrophe’ 51,52 
 
Immunomodulation- several studies suggest that ribavirin can enhance host T-
cell-mediated immunity by altering the balance between Th1/Th2. Th1 response 
patterns may lead to increased activation of cytotoxic T lymphocytes (CTL) and 
secretion of antiviral cytokines such as interferon " (INF").51,52 
Direct inhibition of HCV replication- Ribavirin undergoes intracellular 
phosphorylation by specific kineses to form the monophosphate (RMP), diphosphate 
(RDP) and triphosphate (RTP). RdRp incorporates RTP into the growing RNA chain 
opposite cytidine and uridine. This misincorporation can lead to the early chain 
termination and inhibition of replication. Non-phosphorylated ribavirin can also bind 
to the RdRp but with less affinity than RTP.51,52 
Inosine monophosphate dehydrogenase inhibition- IMPDH is an enzyme 
catalysing the de novo synthesis of guanosine. Inhibition of IMPDH by ribavirin can 
result in a depletion of the intracellular levels of guanosine triphosphate and thus 
inhibition of RNA synthesis. Therefore it may lead to the suppressed viral RNA 
replication and immunosuppression.53 
Mutagenesis and “error catastrophe”- As already mentioned HCV exists as many 
quasispecies. One feature of quasispecies is that the variety is caused by the high 
ongoing rate of mutations, which can occur during viral replication. It is suggested 
that ribavirin causes a higher frequency of mutation (mainly in the NS5A encoding 
region), which results in the threshold of ‘error catastrophe’. Consequently the 
replicative fitness of the virus is decreased and genomic diversity is narrower. As a 
biological result the effectiveness with which new viral particles transfect new cells is 
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lower, moreover ribavirin might reduce the ability of HCV to escape the immune 
system and thereby increase the effectiveness of antiviral therapies.51 
 
 
Figure 1.5. Proposed mechanism of action of ribavirin in HCV infection. 
 
 Further development of ribavirin and its analogues led to the discovery of 
taribavirin (1.2, Figure 1.6). As a prodrug of ribavirin, it is easily converted to 
ribavirin by adenosine deaminase. It possesses a better safety profile than ribavirin 
because of its preferential accumulation in the liver. 54 Additionally taribavirin was 
found to be a direct inhibitor of nucleoside phosphorylase, an enzyme responsible for 
the degradation of the newly formed phosphorylated species of ribavirin. First human 
studies of taribavirin were reported in 2004. In the phase I clinical trials taribavirin 
was found to be well tolerated, with rapid conversion to ribavirin and renal excretion. 
In phase II study, 180 chronically infected patients were randomized into 4 arms, 
receiving peg-INF and taribavirin or ribavirin. Patients from 3 arms receiving 
taribavirin were shown to develop significantly fewer cases of sever anaemia 
comparing to ribavirin group, however sustained viral response was lower 23-37% 
versus 44% of ribavirin. The results of phase II study led to two large phase III 
clinical trials. Studies were performed on treatment-naïve, chronically infected 
patients covering all genotypes. In general, SVR rates obtained for taribavirin arms 
were much lower than those for ribavirin group 30% vs. 58%, however anaemia rates 
were significantly lower in taribavirin treated patients. Although showing positive 
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outcomes from all phases of clinical trial, taribavirin has not yet been approved for the 
treatment of HCV.55 
Additional studies were performed on the L-enantiomer of ribavirin – levovirin 
(1.3, Figure 1.6). In preclinical studies for the HCV treatment, levovirin induced a 
Th1-signaling pathway. However levovirin does not undergo intracellular 
phosphorylation to its mono-, di- and triphosphate and as a result, generated 
virological response rates were lower than the ones for ribavirin.55,56 Furthermore 
IMPDH inhibition has not been observed. As an advantage, levovirin does not 
accumulate in erythrocytes and therefore no signs of haemolytic anaemia have been 
observed in both healthy and HCV infected patients. One randomized, double blind 
phase II clinical trial was conducted. Although levovirin exhibited better safety profile 
(less cases of anaemia), the compound did not improve rates of early virological 



























(1.1) (1.2) (1.3)  
Figure 1.6. Structure of ribavirin and analogues. 
 
1.7.3 Boceprevir and Telaprevir- Protease inhibitors 
 
Protease inhibitors may be divided into two groups, according to the type of 
interaction in the active site they exploit. The first group consists of non-covalent, 
product based inhibitors and second one covalent reversible inhibitors. Regarding the 
type of structure of particular inhibitors both of these groups can be further divided 
into linear and macrocyclic peptidomimetics, both of which bind to the active site of 
the enzyme.57 Ciluprevir (BILN 2061, Boehringer-Ingleheim) was the first specific 
NS3/4A macrocyclic protease inhibitor designed for the treatment of HCV. Phase I 
clinical trials showed a favorable pharmacokinetic profile without any serious adverse 
events. The compound was progressed into further development. In proof of concept 
two days study, ciluprevir induced 2-3 log decrease of HCV viral load, with no 
difference between naïve and previously treated patients. In general the drug was well 
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tolerated without considerable safety issues. However, further development of 
ciluprevir has been stopped due to cardiac toxicity observed in animals.58 
Telaprevir (1.4, Figure 1.7) was the second NS3-4A protease inhibitor to enter 
clinical trials. Telaprevir is a linear pepidomimetic that acts as a covalent inhibitor. Its 
structure contains !-ketoamide moiety, which act as a ‘serine trap’ inhibiting NS3/4A 
protease by binding to the enzyme active site. In phase I study, telaprevir induced a 
mean of 4.4 log reduction in HCV RNA levels after 14-days of treatment. In phase II, 
telaprevir was co-administrated with RBV and Peg-INF. All patients demonstrated 
undetectable levels of HCV RNA after 28-days of therapy. After successful 
completion of all stages of clinical trials, on 23rd of May 2011 FDA approved 
telaprevir as addition to the SOC. Addition of telaprevir to the RBV/Peg-INF regimen 
increased sustained viral response up to 75% after 48-weeks of therapy in treatment-



























(1.4) (1.5)  
Figure 1.7. Structures of telaprevir and boceprevir. 
 
Boceprevir (1.5, Figure 1.7) is another peptidomimetic inhibitor, which 
inhibits HCV protease. During clinical trials boceprevir was found to demonstrate 
dose-dependent activity in HCV-infected patients. In phase I clinical trials 4.7 log 
reduction in viral load was observed after 2-weeks of treatment for the highest tested 
dose. In subsequent study, when boceprevir was co-administrated with the SOC, mean 
2.4-2.9 log reduction was seen, compared to 1.1 log for RBV/PegINF alone. All 
clinical trials were successfully completed and boceprevir was approved by FDA on 
13th of May 2011, as a combinatorial therapy with RBV and Peg-INF. Rates of 
virological response for boceprevir based triple regimen were approximately 80% in 
treatment naïve patients.44,57  
 A major downfall of both protease inhibitors is their inhibitory activity 
towards cytochrome P450 CYP3A4/5 and many drug interactions. Additionally both 
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triple regimens are associated with many side effects with anemia, nausea, fatigue and 
dysgeusia being the most common ones.44 
Due to the fact that during clinical trials protease inhibitors have induced 
several cases of resistant mutations57 it is a major interest (for both the patient care 
and economics) to develop new treatments that are more efficient and better tolerated 
by all patients. Several different approaches have been undertaken in order to address 
these needs. Investigators have focused their attention on the virus itself looking for 
specific targets associated with the viral life cycle. HCV specific drugs would include 
small, orally bioavailable molecules that could possibly eradicate HCV infection. The 
main obstacle in the development of new anti-HCV drugs is lack of readily available 
laboratory models of viral infection and high genetic diversity of the virus; despite 
this several very promising molecules have entered clinical trials and will be 
discussed in Chapter 2.  
 
1.8 Polymerase inhibitors for the treatment of hepatitis C. 
 
 After revealing the structures of HCV polymerase in 1999,59 a number of 
companies used structure-based drug design to facilitate the development of inhibitors 
to these enzymes. Currently there are 89 projects running in pre-clinical and clinical 
trials, including 6 projects for combinatorial therapy.60 
Polymerase inhibitors impede viral replication by binding to the NS5B 
polymerase. NS5B inhibitors can be classified into four major groups based on their 
mechanism of action. The first class consists of nucleoside and nucleotide analogue 
inhibitors (NI). These compounds need to be converted to the corresponding 
triphosphates to inhibit HCV RdRp activity. After binding to its active site, they may 
either act as chain terminators preventing further chain elongation or prevent the 
polymerase from functioning effectively. As the active site of viral polymerase 
exhibits highly conservative profile across all six genotypes, NIs inhibitors can exhibit 
high affinity towards different HCV genotypes and subtypes.61 The second group 
consists of non-nucleoside inhibitors (NNI) acting at several allosteric binding sites of 
the HCV polymerase. NNIs prevent conformational changes needed for initiation of 
the RNA synthesis and they do not require activation for their biological activity 
(unless given as prodrugs).62 The third class is represented by pyrophosphate 
analogues. They are designed to mimic the natural pyrophosphate, which is released 
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during the chain elongation process. Pyrophosphate analogues can bind to the active 
site; disabling the binding of the next incoming nucleoside triphosphate.63 Additional 
function of pyrophosphate analogues is their ability to chelate divalent metal ions 
required by the RdRp.64 The fourth class of compounds do not target HCV 
polymerase itself, but relays on targeting cellular proteins required for HCV 
polymerase function.65  
The different classes of NS5B inhibitors may act in complementary fashion 
and can be used for combinatorial therapy. To increase sustained virological response 
rates, different treatment approaches are currently under investigation. For example, 
individualized therapies, including duration of treatment based on the HCV RNA 
concentration at baseline, and trials with direct acting antiviral drugs such as 
inhibitors of HCV specific NS3 protease and HCV NS5B RNA-dependent RNA 
polymerase (RdRp).  
The rational behind the design of nucleos(t)ide inhibitors is that they can act as 
chain terminators. Most of nucleoside analogues can function as obligate chain 
terminators, due to the lack of 3’-hydroxyl group in their sugar moiety, which is 
required for the formation of the 3’-5’ phosphodiester linkage. An incorporated 3’-
modified nucleotide analogue is no longer capable of further nucleotidyl transfer 
reaction and as a result elongation of the viral RNA is blocked. A second class 
consists of non-obligate chain terminators. These nucleos(t)ide analogues possess a 
3’-hydroxyl group however other modifications of the sugar moiety cause 
conformational changes (most likely the misalignment of the 3’-hydroxyl), sterically 
hindering the formation of subsequent phosphodiester bonds.66,67 The 2’ and 4’ 
positions of the ribose moiety have been identified as a possible alteration sites, 
resulting in inhibition of a viral replication.68 
 During the last ten years a number of ribonucleoside analogues with 2’-O-
methyl, 2’-C-methyl and 4’-C-azido modifications have been explored for their 
potential to act as a specific, non-obligate chain terminators of HCV replication. 
These classes of compounds, although potent and selective towards viral polymerase, 
suffer from poor bioavailability and cell permeability, liability to metabolic 
degradation, and also rather poor turnover to the biologically active triphosphates.68 
Several prodrug strategies, both at the nucleoside and nucleotide levels, have been 
implemented to overcome these limitations and will be discussed in Chapter 2. 
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The term prodrug was defined in 1958 by A. Albert and was expanded over the 
years.1 Prodrugs are pharmacological substances that are administered into the body in an 
inactive or significantly less active form. Once administered, the prodrug undergoes chemical 
and/or enzymatic reaction to form an active metabolite. Chemical transformation does not 
depend on the presence or relative amounts of metabolizing enzymes, and therefore less 
interpatient variability is seen.2 Prodrugs in general are most often designed to optimize 
‘drug-like’ properties (absorption, distribution, metabolism and excretion (ADME)) and 
overcome barriers through a molecular approach rather than a formulation approach. 
Application of a prodrug technology can enhance bioavailability and permeability of a drug, 
increase its metabolic stability and prolong half-life. Furthermore better site-direct delivery 
can be achieved, while systemic exposure and unwanted tissue/organ specific toxicity can be 
decreased.3 
There are several methods for prodrug classification, including those based on 
therapeutic area (e.g. antiviral prodrugs, anti-inflammatory prodrugs), site of conversion (e.g. 
intracellular or extracellular), mechanism of activation, or chemical properties of the 
promoiety.4 Based on the chemical nature of linkages or carrier moieties, prodrugs can be 
classified into 4 major categories:  
Carrier-linked prodrugs are drugs that have been attached through metabolically 
labile linkages to another molecule also called a promoiety, which can be removed 
enzymatically releasing the active molecules. A promoiety is not necessary for the activation 
of the prodrug, but may bring an advantage of increased water or lipid solubility.5 
There are two main types of carrier prodrugs: bipartate and tripartate. A bipartate 
prodrug consists of carrier and active drug, which are directly linked. A tripartate contains a 
spacer between the drug and carrier. Enzymatic cleavage removes the carrier, and then the 
spacer attached to the drug molecule undergoes spontaneous hydrolysis, releasing the drug.5   




 A slight variation of the carrier-linked prodrug approach is the mutual prodrug (co-
drug) approach in which the carrier also has activity.6 
 Bioprecursor prodrugs contain no promoiety but rather rely on metabolism to 
introduce the functionality necessary to create an active species.5 
 Macromolecular prodrugs are molecules consisting of drug linked to the 
macromolecule such as polyethylene glycol.7 




2.2 Anti-HCV Nucleoside prodrugs in clinical trials. 
 
 Following the discovery of the first antiviral compound (idoxuridine) in 1959, 
nucleoside analogues (NA) have dominated antiviral strategies for decades.8 A number of 
nucleoside analogues have been examined for their potential to provide safe and efficacious 
new treatment options for hepatitis C virus infection. Several structurally different nucleoside 
inhibitors bearing either 4’-C-azido or 2’-C-methyl modification have provided unique 
profiles of anti-HCV potency and have been advanced into clinical trials. Application of 
simple ester prodrug strategy to these nucleoside analogues has improved their 
pharmacokinetic properties following oral administration.9 
 
2.2.1 Valopicitabine (NM283). 
 
 Valopicitabine (NM283) was the first HCV polymerase inhibitor that has entered 
phase IIb clinical development. NM283 - 2.1 is an orally available 3’-O-L-valinyl ester 




























Figure 2.1. Valopicitabine - 3’-valinyl ester prodrug (NM283), 2’-C-methylcytidine nucleoside 
NM107 and corresponding triphosphate. 
 




 During the preliminary studies 2’-C-methylcytidine triphosphate was found to be a 
potent inhibitor of NS5B polymerase with IC50 = 0.09-0.2 µM (2.3, Figure 2.1).11,12 When the 
parent nucleoside 2.2 was tested in cell-based assay it exhibited much lower activity EC50 = 
2-7 µM. Initial pharmacokinetic studies in animal models revealed low oral bioavailability of 
2.2. To overcome this limitation and improve pharmacokinetic profile, the amino acid– 3’-O-
L- valinyl ester of 2’-C-methylcytidine was prepared 2.1 and advanced into clinical trials.10 
The aim of the phase I study was to evaluate safety, tolerability and pharmacokinetics of 
NM283 in healthy volunteers. In the phase Ib trial, after 2-week treatment (800 mg QD dose) 
an average of 0.7-1.00 log IU/mL reduction in circulating viral RNA levels was observed. 
Mild to moderate gastrointestinal adverse events were reported. A subsequent phase IIb trial 
was carried out on treatment-naïve genotype 1 patients and non-responders to a Peg-
INF/RBV regimen. After 24-weeks a ~3.3 log IU/mL reduction of viraemia was 
demonstrated (800 mg dose). Combination treatment with Peg-INF led to a ~4.4 log IU/mL 
reduction in viral RNA after 36-weeks in treatment naïve patients while the decline in HCV 
genotype 1 non-responders was ca. 2 log poorer. Despite the fact that NM283 showed 
efficacy in clinical studies in both treatment-naïve patients and PegINF/RBV non-responders, 
the compound was discontinued from further development due to the significant 
gastrointestinal toxicity.13-15 
 
2.2.2 Balapiravir (R1626). 
 
 4’-C-Azidocytidine (R1479, 2.4) was discovered as a specific HCV inhibitor during 
the evaluation of a broad family of 4’-modified pyrimidine analogues. R1479 did not show 
any cytotoxicity and/or cytostatic properties at concentrations up to 2 mM.16 It’s 5’-
triphosphate 2.5 was shown to be potent, competitive inhibitor of HCV RdRp with IC50 = 
0.29 µM. Due to the poor oral bioavailability of 4’-C-azidocytidine its 2’,3’,5’-tri-O-
isobutyrate ester prodrug R1626 (2.6, Figure 2.2) was selected for further development.16 The 
introduction of isobutyrate ester groups enhanced uptake of 2.6 from the gastrointestinal 
tract.16 Due to the promising results of the preclinical development, this compound was 
progressed into clinical trials. 





































Figure 2.2. 4’-C-azidocytidine nucleoside R1479, 4’-C-azidocytidine triphosphate and nucleoside 
ester prodrug R1626.  
 
 During phase Ib, balapiravir demonstrated a dose and time-dependent reduction of 
viral load up to ~3.7 log IU/mL in genotype I patients, when administrated at 500-4500 mg 
BID. In subsequent phase IIa study, combination therapy with interferon-! and/or ribavirin 
gave an average of 4.2 log IU/mL decline in HCV RNA levels. At week-4 33-80% of treated 
patients achieved non-detectable levels of HCV RNA. Balapiravir showed high and rapid 
clearance of the virus, however high rates of neutropenia (39-78%) and anaemia (32%) were 
reported. Further development of R1626 was discontinued due to unspecified adverse 
events.17-19 
 
2.2.3 Maricitabine (RG7128). 
 
 RG7128 (2.7) is a 3’,5’-bis-isobutyryl ester prodrug of PSI-6130 (2.8, Figure 2.4).20 
"-D-2’-Deoxy-2’-fluoro-2’-C-methylcytidine (PSI-6130, 2.8) was found to exhibit a potent 
and highly specific inhibitory activity against HCV replication in cell-based assay (EC50 = 
1.23 µM) and its triphosphate (2.9, Figure 2.3) was found to inhibit NS5B in vitro in low 































Figure 2.3. Structures of bis-isobutyryl ester prodrug RG7128, "-D-2’Deoxy-2’-fluoro-2’-C-
methylcytidine – PSI-6130 and PSI-6130 triphosphate. 
 




 PSI-6130 showed broad activity across all six HCV genotypes without any cytotoxicity in 
preclinical toxicology studies.21 PSI-6130 was advanced into clinical trials but during the 
human PK assessment, the compound showed only modest oral bioavailability and was found 
to undergo metabolic deactivation leading to the uridine analogue RO2433.22 To address 
these issues the bis-isobutyryl ester prodrug 2.7 of PSI-6130 was prepared (Figure 2.3). 
According to the published data RG7128 is currently the most advanced, simple nucleoside 
prodrug in clinical development.22 During phase I study, RG7128 has shown efficacy in 
patients infected with different HCV genotypes. Phase IIa combination trial with 
PegINF/RBV resulted in ~5.0 log IU/mL reduction of viraemia in genotype 1 treatment naïve 
subjects.23 No serious adverse events during the treatment course were reported. RG7128 was 
advanced into phase IIb clinical trials and is expected to complete this study in the near 
future.23 
 Summary of nucleoside and nucleoside prodrugs, which were evaluated in clinical 
trials, is reported in Table 2.1. 
 
Table 2.1. Summary of nucleoside and nucleoside prodrugs in the clinical trial development. 




2.3 Nucleotide prodrugs - ProTides. 
 
 Although nucleoside analogues possess many advantages, they have their own 
challenges, which need to be overcome in order to obtain therapeutically useful agent. As 
already mentioned, nucleoside analogues (NA) can suffer from variable aqueous solubility 
and bioavailability following oral administration. Furthermore, NA activity depends upon 
their metabolism to form active 5’-triphosphates; therefore NAs must be good substrates for 
at least three different kinases. These kinases convert the nucleoside analogue to its 
corresponding monophosphate, then to the diphosphate and finally to the triphosphate. It is 
not unusual that either the parent nucleoside or its phosphates are poor substrates for one of 
the kinases. Quite often the first phosphorylation of the nucleoside analogue is considered as 















































Scheme 2.1. Phosphorylation pathway of nucleoside analogues.  
 
Additionally it is possible that the activity of kinases may decline during therapy involving 
long-term treatment with NAs, particularly in the case of cancer chemotherapy for example.25 
Administration of the pre-formed 5’-monophosphates could overcome the problem, however 
at physiological pH the phosphates are negatively charged and therefore too hydrophilic to 
efficiently cross cell membranes. Moreover 5’-nucleotidases present in the blood and cell 
surface can rapidly convert free nucleoside 5’-monophosphates to the corresponding 
nucleosides. To overcome the limitations of administering a nucleoside monophosphate, 
various pronucleotide approaches have been employed in order to deliver masked 5’-
monophosphates and therefore improve the potential of NAs as therapeutics.26 A successful 




ProTide would need to possess sufficient chemical stability required for the formulation 
process. They should be stable in gastrointestinal fluids and undergo an efficient first-pass 
metabolism (for HCV activity). ProTides would have to enhance passive diffusion through 
the cell membrane. Once in hepatocytes, 5’-monophosphates would have to be successfully 
released and further phosphorylated to the active triphosphate species. Several prodrugs of 
modified nucleotides have demonstrated proof of concept, delivering monophosphates into 
cells, both in vitro and in vivo.27-30 
 
2.3.1 Cyclosaligenyl (CycloSal) phosphotriesters. 
 
 The CycloSal approach developed by Meier,31 was applied to a number of nucleosides 
including d4T, ACV, PCV, AZT, ddA, d4A, ddI and many others.32-36 It does not require 
enzyme activation to release the monophosphate. CycloSal prodrugs were designed to 
generate monophosphates selectively, by a controlled, chemical hydrolysis mechanism.32 The 
activation mechanism is initiated by selective hydrolysis of a phenolic ester bond. 
Subsequently, the hydroxyl group in ortho position activates the phosphate ester at the benzyl 
position. Spontaneous cleavage of the diester results in the release of nucleoside 5’-
monophosphate and the salicyl alcohol (Scheme 2.2). CycloSal prodrugs represent a unique 

































Scheme 2.2. Mechanism of activation of the first generation CycloSal ProTide. 
 
 The CycloSal approach has been further developed to the second (introduction of 
esterase cleavable function) and third generation.37,38 Recently Meier and co-workers 
reported delivery of nucleoside diphosphates using CycloSal technology.39 
 
 




2.3.2 SATE ProTides. 
 
The SATE (S-acyl-2-thioethyl) approach was firstly reported by Imbach and 
Gosselin. This strategy was successfully applied to different nucleosides such as ddU, ddA, 
ddI, AZT, isoddA, d4T and ACV.40-43 The bioenzymatic activation of bis(SATE) is initiated 
by the carboxyesterase cleavage of the thioester moiety of the SATE groups. The generated 
mercaptoethylphosphotriester is unstable and undergoes intramolecular nucleophilic attack, 
releasing ethylene sulphide and the monoSATE phosphodiester. The resultant phosphodiester 
is further hydrolyzed either by a phosphodiesterase or by carboxyesterase to release the 
nucleoside 5’-monophosphate- this step is the same for monoSATE and cyclic SATE 






























Scheme 2.3. Mechanism of activation of bis(SATE) prodrug. 
 
One concern of this class of compounds is the release of episulfide during activation. 
Episulfide is a highly potent alkylating agent and known mutagen; therefore the toxicity risk 
associated with it has mainly limited further clinical development.40 
 
2.3.3 POM approach. 
 
 The pivaloxymethyl (POM) approach proposed by Farquhar and co-workers44 was 
used for the development of bis(POM) triesters. This strategy was successfully applied to 




ddU, AZT and 5-fluoro-2’-deoxyuridine.40,41,44-46 The mechanism of activation of bis(POM) 
derivatives is similar to the bis(SATE) triesters. The decomposistion relies on 
carboxyesterase-mediated hydrolysis of POM moieties, followed by intramolecular 
nucleophilic displacement of the hydroxyethyl group to generate mono-POM phosphodiester 
and formaldehyde. Release of the 5’-monophosphate is carried out by phosphodiesterase or 






































Scheme 2.4. Mechanism of activation of bis(POM) ProTide. 
 
2.3.4 PAOB approach. 
 
 This approach was developed as an extension of the p-acyloxymethyl approach and 
was applied (as well as bis-PAOB) to the different nucleosides including AZT and ddI.48-50 
The activation of PAOB requires ester hydrolysis, followed by the C-O bond cleavage and 
release of the phosphate. The decomposition mechanism of para-acyloxybenzyl 
phosphotriesters is analogues to the bis(POM) phosphotriesters and involves esterase-
mediated hydrolysis (Scheme 2.5).48 































Scheme 2.5. Mechanism of activation of bis(PAOB) ProTide. 
 
The second application of the POAB approach involved the preparation of 
bis(nucleosidyl) PAOB phosphotriester. p-Acyloxybenzyl phosphates were prepared as a 
homodimers and heterodimers of AZT and ddI. During the activation mechanism, one 
nucleoside 5’-monophosphate and one nucleoside are released.48-50 
 One of the hydrolysis products, the p-hydroxybenzyl carbonium ion, which may react 
with DNA, proteins or other cellular nucleophiles and this is considered as the biggest 
limitations of this method.51  
  
2.3.5 Phosphoramidate di- and monoesters. 
 
 The first example of bioactive aryloxy phosphoramidates was reported by McGuigan 
et al in 1992, as prodrugs of AZT.52 Initially ProTides consisted of alkyl or haloalkyl 
phosphate triesters, subsequently one amino acid ester moiety was introduced in place of the 
alkyl or haloalkyl chain resulting in the alkyloxyphosphoramidates.53-55 Further studies led to 
the development of aryloxyphosphoramidate technology, which was successfully applied to a 
number of different nucleoside analogues, greatly improving their anticancer or antiviral 
activity. ProTide technology was used for the following NAs: ddA, d4A,56 AZU,57 AZA,58 
d4T,59,60 PMEA, PMPA,61 abacavir,62 and carbocyclic adenosine derivatives.63 The most 
recent application of phosphoramidate technology are ProTides of N-acetyl glucosamine. 
This is the first example of ProTides used on sugars.64  




The first step of the activation of an aryloxyphosphoramidate (and subsequent release of the 
monophosphate species) was found to be enzyme-mediated hydrolysis of the amino acid ester 
moiety.65,66 Subsequently, the nucleophilic carboxylic acid moiety is thought to perform 
intramolecular attack on the phosphorus atom resulting in a putative unstable cyclic 
intermediate with release of the aryloxy moiety. The intermediate is then rapidly hydrolysed 















































a) Carboxypeptidase or esterase type enzyme
b) Spontanous cyclisation
c) Water mediated hydrolysis
d) Phosphoramidase type enzyme  
 
Scheme 2.6. Possible mechanism of activation of aryloxy phosphoramidates.  
 
For the description of the synthesis and structure activity relationship studies of 
aryloxyphosphoramidates refer to Chapter 3-5. 
Wagner developed phosphoramidate monoesters as a variation of the aryloxy 
phosphoramidate approach. Phosphoramidate monoesters contain an amino acid ester as a 
masking group on one of phosphate charges. Application of only one masking group 
eliminates the chirality issue at phosphorus and provides better water solubility while 
maintaining stability in human plasma at the same time. Although cellular permeation may be 
more limited, this kind of prodrugs can represent an alternative method of nucleoside 
monophosphate delivery for intravenous applications. Activation of phosphoramidate 
monoesters requires phosphoramidase activity to cleave the P-N bond and proceeds directly 









2.3.6 Nucleoside phosphorodiamidates. 
 
Diamidate prodrugs reported by McGuigan et al have been proposed as potential 
pronucleotides since they are capable of entering cells by passive diffusion. A series of 5’-
phosphorodiamidates of AZT was synthesised but the technology was not greatly developed 
and the synthetic pathway was not optimized.70 
Application of the diamidate strategy to the 9-[2-(phosphonomethoxy)ethoxy]adenine 
(PMEA) failed to produce any detectable levels of the active drug following oral 
administration to mice.71 
Recently this approach has been successfully applied to the fructose-1,6-
bisphosphatase inhibitor (2.10, Figure 2.4) and the agent was advanced to human clinical 















Figure 2.4. Phosphorodiamidate application to the fructose-1,6-bisphosphatase inhibitor. 
 
 Despite earlier disappointing results of the diamidate prodrug application to the 
different nucleoside analogues; the approach was recently successfully applied by us to the 
2’-C-methylguanosine analogue.  
For the description of the synthetic pathways, activation and structure activity relationship 
studies of phosphorodiamidate pronucleotides refer to Chapter 8. 
 
2.3.7 Cyclic phosphoramidates. 
 
Farquahar and co-workers reported cyclic phosphoramidates as a potential method of 
monophosphate delivery.73 Cyclophosphamide analogues of 5-fluoro-2’-deoxyuridine and 
thymidine were synthesised and tested. Unlike cyclophosphamide these compounds were 
found to be stable to cytochrome P450 oxidation, hydrolysis by 5’-nucleotidase, snake venom 
phosphodiesterase and alkaline phosphatase. As a result, no activity towards 5-fluorouracil 




(5-FU) resistant cell line P-388 was found. Further studies on FUdR cyclic phosphoramidates 
showed that they can be metabolized to the corresponding monophosphates, resulting in 
lower than FUdR in vitro cytotoxicity against L1210 cell line.73  
For the synthesis and structure activity relationship studies of cyclic phosphoramidates refer 
to Chapter 7. 
 
2.3.8 3’,5’-Cyclic ProTides. 
 
 The design of 3’,5’-cyclic ProTides was based on naturally occurring cyclic 
monophosphates such as cyclic adenosine monophosphate (cAMP).74 Cyclisation of the 
phosphate moiety with the 3’-hydroxyl group was designed to decrease the ionic nature of the 
phosphate and improve lipophilicity. It was postulated that the 5’-monophosphate would be 
released upon the exposure to phosphodiesterases.74 Several studies have shown that the cell 
uptake of different analogues of cAMP was not efficient, presumably due to the remaining 
charge on the phosphate centre and/or hydrolysis to the parent 5’-monophosphate prior cell 
membrane penetration.75 To overcome this limitation a family of simple neutral triesters of 
cyclic AMP was prepared.74,76 A simple 3’,5’-cyclic triester approach was applied to anti-
HCV nucleosides giving proof of concept by delivering 5’-monophosphates into the cells 
both in vitro and in vivo.77 Other cyclic approaches including 3’,5’-cyclic phosphoramidates78 
































Figure 2.5. General structures of different 3’,5’-cyclic ProTides. 
 
2.3.9 HepDirect prodrugs. 
 
 In 2004 Erion et al. reported a specific prodrug strategy dependent on cytochrome 
P450 catalyzed cleavage, resulting in high liver-specific drug delivery.80 The HepDirect 




prodrugs are substituted cyclic 1,3-propanyl esters of NA phosphates or phosphonates, 
designed to undergo enzyme catalyzed oxidative cleavage in the liver.80 
Oxidation of the benzylic carbon by CYP3A4 results in formation of cyclic hemiketal that 
undergoes spontaneous ring opening and then b-elimination to give the active 





























Scheme 2.7. Metabolic activation of HepDirect prodrugs. 
 
The released monophosphate is further converted to the corresponding triphosphate form.80 
The formation of aryl vinyl ketone had raised toxicological concerns, due to the possible 
alkylation of DNA and essential proteins. It was postulated that high levels of glutathione 
present in the gut and liver could detoxify vinyl ketones through a rapid and quantitative 1,4-
addition reaction and thus minimize the toxicity issues.80,81 The HepDirect prodrug approach 
was successfully applied to several different nucleoside analogues resulting in the discovery 
of pradefovir (prodrug of adefovir). This compound was advanced into clinical trials for the 
treatment of hepatitis B.81  
 




 As already mentioned PSI-6130 can undergo enzymatic deamination leading to the 
formation of poorly active uridine metabolites, eg. RO2433 (PSI-6206, 2.8, Scheme 2.8).22 
Subsequent studies indicated that the triphosphate form of RO2433 was a potent inhibitor of 
viral NS5B polymerase with an IC50 value of 0.52 µM. Despite the potency exhibited in the 
enzyme assay, the nucleoside 2.11 was not active in replicon cells up to 100 µM. Additional 
studies revealed that the RO2433 is a poor substrate for the deoxycytidine kinase (dCK) and 




therefore the formation of RO2433- monophosphate species in human hepatocytes, was most 


































Scheme 2.8. Phosphorylation pathway of PSI-6130 and PSI-6206 (RO2433). 5’-MP - 5’-
monophosphate, 5’-DP - 5’-diphosphate, 5’-TP – 5’- triphosphate. dCK – deoxycytidine kinase, 
YMPK – uridine/cytidine monophosphate kinase, NDPK – nucleoside diphosphate kinase, dCMP – 
deoxycytidylate deaminase. 
 
 To overcome lack of the cellular phosphorylation, the aryloxy phosphoramidate 
approach was applied to 2.11, in order to deliver the monophosphate intracellularly.82  
SAR studies around the phosphate, resulted in the synthesis of (2.12, Figure 2.6) - PSI-7851 
(as ca. 1:1 mixture of diastereoisomers at the phosphorus centre) exhibiting submicromolar 
activity in cell based assay (EC90 = 0.52 µM). Pharmacokinetic studies revealed that high 
levels of PSI-6206-5’-triphosphate in the liver can be achieved after oral administration of 
2.12, without cellular toxicities (including mitochondrial and bone marrow toxicity).82  
In a phase Ia trial in healthy volunteers, PSI-7851 proofed to be safe and well tolerated at all 
tested doses (25mg to 800mg). During multiple ascending dose study on treatment-naïve 
subjects, HCV RNA reduction was dose-dependant; with a maximum of 1.01 log IU/mL and 
1.96 log IU/mL decline at day 3, for 200 mg and 400 mg daily dose respectively. No serious 
adverse and/or dose dependant effects were observed and compound was well tolerated 
across all tested doses.83  
Together with clinical development of PSI-7851, further work on separated isomers of 2.12 
was performed.  




























Figure 2.6. Structures of PSI-7851 (2.12) and PSI-7977 (2.13). 
During the replicon clone A studies, EC90 values of 7.5 µM and 0.42 µM for Rp and Sp 
(2.13, Figure 2.6) isomers, respectively were reported, showing that the Sp isomer was ~18 
times more potent than the Rp, furthermore Sp isomer was found to generate up to 14% 
higher concentrations of intracellular 5’-triphosphate (in human hepatocytes).84,85 As a result, 
the single Sp isomer of PSI-7851 (PSI-7977, 2.13) was progressed into phase IIa clinical 
study, where HCV treatment-naïve patients were treated with 100, 200 or 400 mg QD of PSI-
7977 in combination with SOC, for 28 days. Patients achieved an average of ~5.3 log IU/mL 
decline of vireamia, however dose-dependent activity was not observed. There were no 
serious adverse events reported during the course of the treatment. All reported adverse 
events were mild to moderate, with joint pains, fatigue and nausea being the most common 
ones. Following the positive outcomes of phase IIa clinical results, a phase IIb was initiated. 
During the 12-week study, patients with genotype 1,2 and 3 are treated with PSI-7977 at 
doses of 200 mg and 400 mg QD in combination with PegINF and RBV. PSI-7977 is 




 IDX184 is a first example of a 2’-C-methylguanosine monophosphate prodrug 
advanced into clinical trials. IDX184 (2.14) represents a family of a hybrid SATE prodrugs 
(Figure 2.7), where two different groups: S-acetyl-2-thioethyl moiety (SATE) and 
benzylamine have been used to mask the pre-formed 5’-monophosphate.90 The complete 
metabolic pathway of IDX184 is not yet fully disclosed, however it is postulated that the 
release of 5’-monophosphate relies on cytochrome 450-dependent and independent 
processes.90 IDX184 was shown to be a potent inhibitor of viral replication in replicon assay 
EC50 = 0.4 µM without any associated toxicity (CC50>100!M).91  



















Figure 2.7. Structure of IDX184.  
 
 After successful preclinical development IDX184 was advanced into clinical trials.92 
The aim of the phase I study was to evaluate safety, tolerability and pharmacokinetics of 
IDX184 in healthy volunteers. During the trial, single doses of 5-100 mg (QD, for 3 days) 
were generally well tolerated, without serious adverse events or dose-dependent toxicities.93 
The phase IIa was designed as a randomized, double blind, placebo-controlled, and dose 
escalation study. Treatment-naïve HCV genotype patients were treated with IDX184 in 
combination with PegINF/RBV for 14 days. No serious adverse events related to the tested 
doses of IDX184 (50 to 200 mg per day) were observed. A mean of 2.7 – 4.1 log IU/mL 
dose-dependent reduction of viral RNA was observed at day 14.94 Additional phase I 
combination therapy with IDX320 – an NS3 protease inhibitor, was evaluated in healthy 
volunteers. Safety data showed three cases of liver function abnormalities during a drug-drug 
interaction study and the program was placed on full clinical hold, awaiting resolution of the 
adverse events.95 The Food and Drug Administration (FDA) removed full clinical hold and 
IDX184 was placed on partial hold, after revealing that the toxicity was most likely caused 
by the IDX320. In July 2011, phase IIb trial of IDX184 in combination with SOC under a 




 INX-08189 represents the second example of a 2’-C-methylguanosine 5’-
monophosphate prodrug, also advanced into clinical trials. This compound is an aryloxy 
phosphoramidate double prodrug of 2’-C-methylguanosine (Figure 2.8). For the synthesis 
and biological evaluation refer to Chapter 5-6.  
 























 PSI-938 represents a 3’,5’-cyclic prodrugs of 6-substituted 2’-deoxy-2’-!-fluoro-2’-
C-methylguanosine. PSI-352938 - pure Rp isomer (2.15, Figure 2.9) was found to be a potent 
inhibitor of HCV replication in replicon assay (EC90=1.37 µM) without any cytotoxicity up to 












(2.16) PSI-938  
Figure 2.9. Structure of PSI-938.  
 
Studies in animal models revealed production of high levels of 2’-deoxy-2’-!-fluoro-2’-C-
methylguanosine triphosphate in rat liver, after oral administration of 50 mg/kg. The 
metabolic pathway of 2.15 is not yet fully disclosed.97 
In phase I clinical studies safety profile, tolerability and pharmacokinetics of PSI-352938 in 
healthy subjects was evaluated. The compound was generally well tolerated at all tested 
doses (100 to 800 mg). No serious adverse events or discontinuations were observed. PSI-
352938 was progressed into phase Ib clinical trials. In a blind, randomized and placebo 
controlled study carried out on 40 treatment-naïve patients, 2.15 was administrated at doses 
of 100 mg to 300 mg QD and 100 mg BID during 7-days treatment course. At day 8, a mean 
HCV RNA change from baseline of 3.94 log IU/mL, 4.31 log IU/mL, 4.64 log IU/mL, and 
4.59 log IU/mL in patients receiving 100 mg QD, 200 mg QD, 300 mg QD and 100 mg BID 
respectively was found. PSI-938 was generally well-tolerated at all tested doses. There were 
no reported adverse events or discontinuations over the study. Further development of the 




compound as a combinatorial therapy with PSI-7977 and PSI-7977/RBV was performed. 
During safety monitoring, several cases of liver abnormalities were observed in patients 
receiving 300 mg dose of PSI-938 and compound was placed on clinical hold.89,98-100 
 
 All nucleotide prodrugs (ProTides), that were/are evaluated in clinical trials are 
summarised in Table 2.2. 
 
 











2.5 Aim of work. 
 
Hepatitis C virus infection is a major health problem that leads to chronic liver 
disease, including cirrhosis and hepatocellular carcinoma, in a substantial number of infected 
individuals. Efforts to discover more effective drugs to treat HCV-infected patients have 
focused on nucleoside analogues with improved exposure, efficacy and selectivity. 
The 2’-C-!-methylguanosine triphosphate has been known as a potent inhibitor of 
HCV RNA polymerase for some time, however the parent nucleoside was found to be only 
moderately active in the cell based assays, possibly due to the poor intracellular 
phosphorylation.  
The following Chapters describe the synthesis of novel ProTides of 2’-C-
methylguanosine and related analogues, designed to bypass the rate-limiting initial 
phosphorylation of the parent nucleosides and to enhance passive cellular uptake. Their 
biological evaluation (in vitro and in vivo) and enzymatic assays are performed to investigate 
a possible mode of activation.  
 
My objectives were focused on application of ProTide technology to 2’-C-!-
methylguanosine and related analogues and their biological evaluation against hepatitis C 
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3.1 Aryl amino phosphoramidates – structure activity relationship studies. 
 
As already described in Chapter 2, aryloxy phosphoramidates were reported 
for the first time in early 90’s1 and since that time the approach was successfully 
applied to a variety of nucleoside analogues, increasing their lipophilicity, facilitating 
passive diffusion and enhancing their biological activity.2 
The two masking groups of the phosphate unit are represented by amino acid 
ester and aryl moieties. Extensive elaboration performed on different 
arylphosphoramidates led to the optimization of three main modification sites: the 
amino acid, the ester and the aryl group (Figure 3.1). 
 
Figure 3.1. Possible modification sites in phosphoramidate moiety. 
 
Amino Acid (AA) 
 Investigation of different amino acids showed that L-amino acids were found 
to be preferred, with L-alanine emerging as one of the most effective. Lack of 
substitutions at the alpha carbon (e.g. glycine) caused slight decrease of potency. 
However, when the alpha carbon was disubstituted, like in case of dimethylglycine, 
activity was retained. Bulky amino acids like L-isoleucine and L-valine proved to be 
less potent but exhibited improved stability in comparison with the corresponding L-
alanine analogues. In general L-proline derivatives were found to be poorly active. 
The presence of unnatural D-amino acids resulted in loss of activity.3 
Ester (R3) 
 Lability of an ester moiety can dramatically change biological activity of the 
phosphoramidates. A range of primary, secondary, tertiary, alkyl and benzyl, linear 
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and branched esters was prepared and evaluated.  Benzyl esters were found to be the 
most potent, whilst the activity of primary and secondary alkyl chain esters was 
similar. The t-butyl ester was found to be the least potent, probably due to its relative 
stability and poor esterase susceptibility.4 
Aryl moiety (Ar) 
 The aryl moiety is essential as the leaving group, and may play an important 
role in liver targeting. The phenyl group was found to be one of the most efficient. 
Substitutions of the ring were acceptable, with mild electron withdrawing groups (e.g. 
p-Cl, p-COOMe) showing the best results.5,6 Recently the introduction of !-naphthol 
as an aryl moiety was found to increase potency of phosphoramidates comparing to 
the corresponding phenyl derivatives.7 This difference may arise from significant 
increases of the logP of the corresponding naphthyl phosphoramidates or their better 




 The phosphoramidate derivatives were prepared by following the synthetic 
procedures adapted from Van Boom et al.8 and developed within the McGuigan 
group.9 In the three-step synthesis, a nucleoside analogue is coupled with an aryl 
amino acid phosphorochloridate resulting in formation of the 5’-phosphoramidate 
(Scheme 3.1).  
 
Reagents and Conditions: i) POCl3, Et3N, Et2O, -78 °C to rt, 2h; ii) Et3N, DCM, -78 °C to rt, 2-4h; iii) 
tBuMgCl or NMI, THF, rt, overnight. 
Scheme 3.1. General synthesis of aryl phosphoramidates. 
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Depending on the base and nucleoside, during the reaction other regioisomers can be 
formed and isolated (3’-phosphoramidate and 3’5’-bis-phosphoramidate). 
Each compound consists of a mixture of diastereoisomers, due to the chiral 
phosphate centre. 
The synthesis of phosphorochloridates is discussed in more detail in the following 
sections. 
 
3.2.1 Preparation of phosphorochloridates. 
 
 Phosphorochloridates were synthesised in a coupling reaction from an amino 
acid ester salt with an appropriate phosphorodichloridate in the presence of 
triethylamine (Et3N). 
 
3.2.1.1 Synthesis of phosphorodichloridates. 
 
 The phosphorodichloridate is the phosphorylating agent, which determines the 
properties of the aryl moiety in the final ProTide. Phenyl phosphorodichloridate (3.1) 
was commercially available whilst !-naphthyl (3.1a), "#naphthyl (3.1b) and p-NO2-
phenyl (3.1c) phosphorodichloridates were synthesised. In order to obtain the 
appropriate phosphorodichloridate, phosphorus oxychloride was added to the stirred 
solution of either naphthol or phenol in dry diethyl ether, in the presence of 
triethylamine at -78 oC (Scheme 3.1).9 The completion of reaction was monitored by 
31P NMR, followed by the disappearance of POCl3 signal.  When reaction was 
complete the triethylamine hydrochloride salts were filtered off and the solvent was 
removed under reduced pressure to give clear oil used without further purifications. 
Table 3.1 represents the data related to the phosphorodichloridate syntheses. 
 
 
Table 3.1. Summary of sythesised phosphorodichloridates, reaction yields and 31P NMR 
shifts.  
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3.2.1.2 Synthesis of amino acid esters. 
 
 The synthesis of amino acid esters that were not commercially available is 
outlined below. There are several possible synthetic routes depending on a nature of 
alcohol used for the esterification reaction. 
 In the first method used, the amino acid and the appropriate alcohol were 
heated at 75 °C overnight in the presence of thionyl chloride. After crystallisation, 
pure amino acid esters were obtained as chloridate salts (Scheme 3.2). For the 











Reagents and Conditions: i) Appropriate alcohol, SOCl2, 75 °C, overnight. 
Scheme 3.2. Synthesis of amino acid esters using thionyl chloride method.  
 
 In the second method used, the amino acid and the appropriate alcohol in 
toluene were heated at reflux overnight in a presence of para-toluenesulfonic acid 
monohydrate (pTSA), in Dean-Stark apparatus. The corresponding pure amino acid 











Reagents and Conditions: i) Appropriate alcohol, pTSA, toluene, reflux, overnight. 
Scheme 3.3. Synthesis of amino acid esters using pTSA method.  
 
 The third method was used for sterically demanding substrates. In this method 
the Boc-protected amino acid and the appropriate alcohol were stirred overnight at 
room temperature in the presence of N,N’-dicyclohexylcarbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP).10 Boc-protected amino acid esters were submitted 
for a deprotection reaction in ethyl acetate in the presence of pTSA. The pure amino 
acid esters were obtained as tosylate salts (Scheme 3.4). 
 
























Reagents and Conditions: i) Appropriate alcohol, DCC, DMAP, rt, overnight; ii) pTSA, EtOAc, 65 °C, 
overnight.  




* Yield over two steps. 
Table 3.2. Summary of amino acid esters synthesised using methods described above and 
isolated yields.  
 
All esters were obtained in very good to excellent yields (Table 3.2). For 1st 
and 2nd method, after evaporation of reaction mixtures under vacuum, pure amino 
acid esters were precipitated using diethyl ether or ethyl acetate. When the 3rd method 
was applied, BOC-protected amino acid esters were purified by column 
chromatography, using a mixture of ethyl acetate/hexane as an eluent. After 
deprotection, which was carried out in ethyl acetate, the reaction mixture was 
concentrated under vacuum and kept in low temperature (0 °C). Pure amino acid ester 
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tosylate salts were obtained as a white precipitates. All newly synthesised amino acid 
esters were used for the preparation of phosphorochloridate species or 
phosphorodiamidate ProTides (for the synthesis of phosphorodiamidates refer to 
Chapter 8). 
 
3.2.1.3 Synthesis of phosphorochloridates. 
 
Phosphorodichloridates were coupled at low temperature (-78 °C) in the 
presence of Et3N in dry DCM, with the different amino acid ester hydrochlorides or 
tosylate salts (Scheme 3.5). After 1h, the reaction mixture was left to reach room 
temperature. The formation of phosphorochloridate was monitored by 31P NMR, 
followed by the disappearance of phosphorodichloridate signal. All 
phosphorochloridates were purified by flash chromatography using mixtures of 
hexane/ethyl acetate as eluent. 
 
 
Reagents and Conditions: i) Et3N, DCM, -78 °C to rt, 2-4h. 
3.2* Amino acid esters commercially available or available in the laboratory.  
Scheme 3.5. Synthesis of phosphorochloridates.  
 
Most of phosphorochloridates obtained during non-selective coupling method 
were represented by diastereomeric mixtures determined by the unsymmetrical 
substitutions on a phosphorus stereo-centre and fixed at amino acid asymmetric 
carbon. 31P NMR of synthesised compounds showed signal splitting except of the 
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dimethylglycine species, which were obtained as a mixture of enantiomers and 
therefore showing only single peak in the phosphorus spectra (Table 3.3).  
 
AA-Amino acid; * 4 diastereoisomers present, due to the additional chiral centre of the 3,3-
dimethyl-2-butyl ester (R,S); **No diastereomeric splitting as compound is a mixture of 
enantiomers. 
Table 3.3. Yields % and 31P NMR shifts of phosphorochloridates with different amino acids, 
esters and aryl moieties. 
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3.2.2 Synthesis of phosphoramidates. 
 
 The phosphoramidates were obtained by the coupling of nucleoside analogues 
with appropriate phosphorochloridate in the presence of a base: tBuMgCl or NMI in 
























Reagents and Conditions: i) tBuMgCl, THF, rt, overnight; or NMI, THF, rt, overnight. 
Scheme 3.6. General synthesis of phosphoramidates. 
 
It was reported by Uchiyama,11 that tert-butylmagnesium chloride (the 
Grignard reagent, tBuMgCl) acts as a specific activator for O-selective 
phosphorylation. The Grignard reagent does not show selectivity towards primary 
hydroxyl groups (5’ position), therefore using nucleoside analogues bearing more 
than one hydroxyl group may lead to the undesired phosphoramidate isomers like 3’-
phosphoramidate as well as 3’, 5’-bisphosphoramidate. Despite the lack of selectivity 
for primary alcohols, tert-butyl-magnesium chloride mediated couplings were 
reasonable yielding, crude mixtures were easy to purify and recovery of parent 
nucleoside was possible. 
 
An alternative N-methylimidazole (NMI) synthetic procedure favours a 
selective phosphorylation of the primary hydroxyl group in 5’-position due to the 
different mechanism of action.12 However the crude mixtures obtained from the 
coupling required mild acidic extraction to remove NMI and were difficult to purify. 
Despite its selectivity to the primary hydroxyl groups, the NMI method was not the 
method of first choice mainly due to the low coupling yields and problematic 
purifications. 
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2’-C-methylpurines have been reported for the first time in late 60’s1 and since 
that time a number of 2’-C-branched nucleosides have been described as promising 
anticancer2-4 and antiviral agents.5 These nucleosides are usually recognised by 
different cellular kineses to form their corresponding 5’-triphosphates – the active 
species.2-4  
 Several examples of 2’-modified nucleoside analogues have been reported 
with potential anti-HCV activity.6-8 RdRp is able to distinguish ribonucleoside 
triphosphate from 2’-deoxynucleoside triphosphates making it likely that the 
modification of 2’-position will be recognized and lead to chain termination.6 
We have focus our attention on one of the 2’-modified nucleoside analogues -
2’-C-!-methylguanosine (2’CMeG) that has showed good in vitro activity (IC50= 0.13 
µM of NTP, EC50= 3.5 µM). Most importantly, the detected level of the 
corresponding 5’-triphosphate in vitro was rather poor (0.2 intercellular NTP/pmol 
per 106 cell). This might suggest that 2’-C-!-methylguanosine is a poor substrate for 
kinases responsible for conversion to its active triphosphate form.7,8 We decided to 
apply the aryloxyphosphoramidate approach to this nucleoside in order to explore the 
possibility of further increasing its anti-HCV activity. 
 
4.2 Synthesis of 2’-C-!-methylguanosine. 
 
The first procedure for the synthesis of 2’-C-methylguanosine was reported in 
1968. The nucleoside was synthesised via the reaction of 2,3,5-tri-O-benzoyl-2-C-
methyl-!-D-ribofuranosyl chloride with chloromercuripurine.1 However the synthetic 
route towards the appropriate sugar derivative required 8 steps and overall yield was 
low.9 Furthermore the glycosylation step was low yielding and regioselectivity (N7 
vs. N9) was not disclosed.1,10 Later on several research groups reported more efficient 
routes using either linear or convergent approaches.10,11 In this work a convergent 
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method was used, as it is more flexible since a variety of nucleobases can be coupled 
to the modified sugar moiety. The key glycosylating agent - 1,2,3,5-tetra-O-benzoyl-
2-C-methyl-D-ribofuranose was synthesised using two different routes. In the first 
one, the 2-position of the sugar moiety was stereoselectively alkylated to afford the 
desired 2-alkylsugar as a mixture of ! and " anomers.11 In the second method 
alkylated lactone was reduced to yield the desired sugar derivative as an anomeric 
mixture.12 
 
4.2.1 Synthesis of 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose (First 
method). 
 
The oxidation of commercially available 1,3,5-tri-O-benzoyl-D-ribofuranose 
4.1 with Dess-Martin periodinane in anhydrous conditions overnight at ambient 
temperature gave the corresponding lactone 4.2 in 95% yield. The stereoselective 
addition of a methyl in the "-2-position was performed in the presence of TiCl4 and 
MeMgBr in diethyl ether at -78 °C. The presence of the titanium reagent provided 
selectivity towards the ketone functionality in the presence of esters. Reaction gave an 
anomeric mixture of 4.3 and 4.4. The formation of 4.4 was due to the trans 
benzoylation. After purification by column chromatography, a mixture of compounds 
4.3 and 4.4 was used for the next step, where the remaining free hydroxyl groups were 
protected by 4-(dimethylamino)pyridine (DMAP) catalysed benzoylation in the 
presence of triethylamine (Et3N) (Scheme 4.1).11  
 
Reagents and Conditions: i) Dess-Martin periodinane, DCM, 0 °C to rt, 12 h; ii) TiCl4, MeMgBr, THF, 
-78 °C to -10 °C, 4 h; iii) BzCl, DMAP, Et3N, Et2O, -10 °C to rt, 3 h. 
Scheme 4.1. Synthesis of 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose via Dess-
Martin oxidation method. 
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The resulting 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose 4.5 was 
submitted for glycosylation reaction.  
 
4.2.2 Synthesis of 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose (Second 
method). 
 
The second route involved reduction of commercially available 2-C-methyl-D-
ribono-1,4-lactone 4.6. Firstly, ribonolactone was protected with benzoyl chloride to 
give compound 4.7, which was submitted for the reduction reaction without any 
purification. Red-Al mediated reduction gave anomeric mixture 4.4, which after 
extraction was used directly for the subsequent step. Protection with benzoyl chloride 














Reagents and Conditions: i) BzCl, DMAP, Et3N, DME, rt, 2 h; ii) Red-Al, EtOH, -5 °C, 40 min; iii) 
BzCl, DMAP, Et3N, THF, 5 °C to rt, overnight. 
Scheme 4.2. Synthesis of 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose via Red-Al 
reduction method. 
 
 Both synthetic pathways consist of three steps. However, Red-Al method was 
easier to handle in terms of the reagents and reaction conditions, neither of the steps 
required purification. Taking in consideration all aspects of these two syntheses the 
Red-Al reduction method was chosen for the scale-up synthesis.  
 
4.2.3 Coupling reaction. 
 
 Vorbrüggen et al!!described for the first time glycosylation of persilylated N2-
aceylguanine, under thermodynamic conditions (reflux in 1,2-dichloroethane, 
trimethylsilyl triflate (TMS-triflate) as a catalyst).13 Reaction was high yielding (79%) 
and gave 6:1 ratio of N9 and N7 products. In this work improved procedure of Li and 
Piccirilli was used.10 The coupling reaction of protected sugar derivative 4.5 and  
N2-acetylguanine 4.8 was performed in two steps: firstly, the silylated  
N2-acetylguanine was synthesised followed by the coupling reaction in the presence 
of TMS-triflate, using p-xylene as a solvent.10 Use of nonpolar p-xylene in high 
Karolina Made!a                                                                                        Chapter Four 
 
 68 
temperature afforded formation of the thermodynamic N9-product 4.9 in 73% yield. 
Formation of N9 alpha anomer and/or N7 products was not observed. N2-acetyl-
2’,3’,5’-tri-O-benzoyl-2’-C-!-methylguanosine was isolated by crystallisation from 
the mixture of chloroform and methanol.  
The final step was the cleavage of protecting groups of the sugar and base through 






























Reagents and Conditions: i) a)1,1,1,3,3,3-hexamethyldisilazane, dry pyridine, reflux, 2-5 h, b) TMS-
triflate, p-xylene, 140 °C, 6 h; ii) NH3/MeOH, rt, overnight. 
Scheme 4.3. Synthesis of 2’-C-!-methylguanosine.  
  
 
 2’-C-!-methylguanosine 4.10 was obtained in 5 steps, with overall yield of 
50%. In order to easily set up reactions and purifications during the synthetic 
pathway, 2’CMeG was synthesised several times on 5.0 g scale. 
 
4.3 Synthesis of 2’3’-isopropylidene-2’-C-!-methylguanosine. 
 
 Several ProTide coupling attempts were performed on unprotected nucleosides 
resulting in either no product formation or very low coupling yields. 2’-C-
methylguanosine was not soluble in the solvent of first choice- anhydrous 
tetrahydrofuran. Addition of pyridine to the reaction mixture did not resolve the 
solubility problems and did not result in the product formation. Reaction carried out in 
pyridine as a sole solvent, gave the desired product, but reaction mixture was very 
difficult to purify and very low yielding, therefore not suitable for scale-up synthesis.  
 To overcome solubility problems and to enhance 5’-phosphorylation, various 
protecting groups for the 2’,3’-diol were investigated. The nature of the protecting 
group was strongly related to the stability of phosphoramidate unit. The 5’-ProTide 
moiety is considered as chemically fragile, however several studies confirmed their 
acid-stable nature.14 These findings led us to acid-labile isopropylidene protecting 
group which was used for the final phosphoramidate coupling.15 
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 The synthesis in dry acetone with a catalytic amount of perchloric acid at 
ambient temperature overnight gave the desired protected diol 4.11 (Scheme 4.4) in 
90% yield. The synthesised protected nucleoside was soluble in dry THF and reacted 




















Reagents and Conditions: i) HClO4, dry acetone, rt, overnight. 
Scheme 4.4. Synthesis of 2’,3’-isopropylidene-2’-C-!-methylguanosine. 
 
4.4 Synthesis of 2’CMeG phosphoramidates. 
 
The phosphoramidate derivatives were obtained by the coupling of protected 
nucleoside with the appropriate phosphorochloridate in dry THF at ambient 
temperature, using tert-butylmagnesium chloride (tBuMgCl) as a base.15 Overnight 
reaction followed by purification on silica gel resulted in isopropylidene-protected 


























































(3.3a-d, i , l, p,
t, u,  x, 3.3*)
 
Reagents and Conditions: i) tBuMgCl, dry THF, rt, overnight; ii) 60% acetic acid, 95 °C.  
3.3*- phosphorochloridates available from the laboratory: "-naphthyl-(1-methoxy-2-propoxy-L-
alaninyl)-; "-naphthyl-(R,S-phenylethoxy-L-alaninyl)-; !-naphthyl-(benzoxy-L-alaninyl)-; "-naphthyl-
(p-chloro-benzoxy-L-valinyl)-; "-naphthyl-(o-methyl-benzoxy-L-valinyl)-; "-naphthyl-(benzoxy-L-
isolucinyl) phosphorochloridate, phenyl-(benzoxy-L-alaninyl)-;.    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Scheme 4.5. General synthesis of 2’-C-!-methylguanosine ProTides.  
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Protected phosphoramidates were finally deprotected using 60% acetic acid 
solution in water at 95 °C overnight, to give final phosphoramidate ProTides 4.13a-v 
(Scheme 4.5) in moderate to good yields (25%-58%).   
The relative stability of the ProTide unit under these conditions confirms their 
surprising acid-stability and may play an important role for oral administration of 
these compounds.  
The purified phosphoramidates were isolated as mixtures of two 
diasteroisomers at the phosphorus centre, confirmed by the presence of two peaks (in 
most cases) in the 31P NMR and HPLC.  
 
 
AA: Amino acid. 
Table 4.1. Summary of 2’CMeG ProTides and their isomer ratio determined by HPLC and 
NMR. 
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The approximate ratio of isomers determined by the HPLC (reverse phase system) is 
given in Table 4.1 and is very similar to the one given by 31P NMR. Based on these 
findings, correlation between compound polarity and NMR shift was found.  In most 
of the cases, main/major isomer peak had more downfield NMR shift, which 





Figure 4.1. Comparison between isomer ratio of 4.13f determined by 31P NMR and HPLC 
(reverse phase system). 
 
Considering HPLC retention times, all of the synthesised ProTides were more 
lipophilic than the parent nucleoside. Calculated lipophilicity values (ClogP)16 
correspond to the HPLC data, and indicate up to 100-fold increase in lipophilicity. 
However, no clear correlation between calculated ClogP values and biological activity 
(EC50 values) of ProTides was found (Table 4.2-4.4).  
 The initial series of compounds was planned considering L-alanine as the 
primary amino acid centre and phenoxy or !-naphthyloxy group as an aryl moiety 
(Table 4.1 entries 4.13a-4.13k). Several phosphoramidates containing different esters: 
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polar or lipophilic, linear or containing ! and/or " branching were prepared to 
evaluate their effect on enzymatic lability and consequent influence on biological 
activity.  
The subsequent series of compounds was designed for better understanding 
the structure activity relationships (SARs). Beside ester variation, the family consisted 
of ProTides bearing different amino acid moieties: L- and D-valine, L-isoluecine, L-
methionine, and unnatural achiral amino acid dimethylglycine (Table 4.1, entries 
4.13m-n, 4.13p-v). Most of them were prepared as benzyl esters except for 
methionine ProTide, which was synthesised as an isopropyl ester 4.13v (Table 4.1). 
The aryl unit was also modified using phenol, !-naphthol or "-naphthol (Entries 
4.13a, 4.13l and 4.13o Table 4.1). 
 
4.5 Biological evaluation of 2’-C-"-methylguanosine ProTides. 
 
2’-C-"-methylguanosine ProTides were evaluated by Inhibitex Inc., against 
hepatitis C virus in vitro using a replicon assay. The cell line used for this assay was 
human hepatoma cell line (Huh 7). 
The replicon used for assay consist of HCV 5’-NTR, the gene encoding 
luciferase (Re-Luc protein, obtained from Renilla), fused with neomycin 
phosphotransferase (NPTII) and a part of HCV genome containing NS3, NS4B, 
NS5A, NS5B and HCV 3’-NTR subunits. 
After in vitro transcription replicon RNA strand is incorporated into the Huh 
cells. Neomycin resistant colonies were isolated and used for further tests. 
  
Replicon potency 
Huh7 cells expressing the HCV genotype were seeded into 96-well plates at 
density of 2 x 104 cell/well. Then 18-24 h after plating, inhibitors (synthesised 
ProTides) were added and cells were incubated for the additional 48 h. 
Compounds were tested in triplicates and quadruplicates at 3x or 4x serial dilutions 
over a range of 0.0001-10 µM concentrations. HCV replication was monitored by 
Renilla luciferase reporter activity assay using Renilla luciferase reporter (Promega, 
Medison, WI) and a Veritas luminometer (Turner Biosystems, Sunnyvale, CA). Then 
50% inhibitory concentration (EC50) values were calculated as the concentration of 
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compound that results in 50% decrease in the reporter expression as compared to 
untreated cells. The values were determined by nonlinear regression analysis. 
 Cytotoxicity assay 
The same cells used in the replicon assay were seeded into 96-well plates at 
density of 2 x 104 cells per well. 24 h after plating, 2x compound dilutions, starting 
with 100 µM, were applied to the testing plates (three repeats per each compound 
dilution). Each testing plate was incubated for 72 h. To determine cell viability, the 
CellTiter-Glo assay (Promega, Medison, WI) was performed according to the 
manufacturer’s protocol. The compound concentration resulting in 50% luminescent 
signal was reported as the CC50 concentration. 
The phosphoramidate technology allowed to convert a nucleoside with µM 



















AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration;  
Table 4.2. Summary of 2’CMeG L-alanine ProTides.  
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Among the L-alanine series of 2’CMeG phosphoramidates, the least active were 
compounds bearing methyl 4.13b and tert-butyl 4.13d esters (Table 4.2 and Figure 
4.2). For the methylalanine ester 4.13b a low antiviral activity may correspond to the 
low calculated ClogP value -0.5. Indicating that lipophilicity of this compound was 
lower than that considered as an optimal for passive cellular uptake. The potency of 
4.13d was found to be lower than the parent nucleoside. Lower EC50 value of tert-
butyl ester may be related to the relative stability of this ester to the enzyme-mediated 
hydrolysis, during the first step of phosphoramidate activation, resulting in lack of 
efficient liberation of 5’-monophosphate.  
 
 
Figure 4.2. Potency (1/EC50) data plot of L-alanine ProTides of 2’CMeG. 
 
Further lengthening and branching of the ester unit in L-alanine series resulted in 
compounds like 4.13f and 4.13g with EC50=0.05 µM. These compounds were 
amongst the most active derivatives across the family. Introduction of an additional 
chiral centre in ester moiety 4.13h and 4.13j gave a mixture of four diastereoisomers, 
confirmed by 31P NMR and HPLC, and in case of 1-methoxy-2-propyl ester 4.13h a 
relative decrease in antiviral activity (comparing to the most active ProTides).  
Aromatization of the ester led to the compounds such as L-alanine benzyl ester 4.13i 
with a calculated ClogP=1.2 and its branched analogues 4.13j (R,S-phenylethyl  
L-alanine) and 4.13k (S-phenylethyl L-alanine) showing nanomolar activity in 
replicon assay.  
 
 





















AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 4.3. Summary of 2’CMeG ProTides bearing different amino acid ester units.  
 
Structure activity relationships of a 2’-C-methylguanosine ProTides bearing 
different amino acid esters is presented in Table 4.3. Bulky and lipophilic amino acids 
were chosen to increase logP of these compounds and therefore enhance cellular 
uptake. Additionally compounds were considered as more stable towards enzymatic 
degradation. All compounds in general were less active than L-alanine analogues, 
showing ca. 5-25-fold decrease in potency. Comparing activity of ProTides 4.13m-v it 
was observed that disubstitution of the !-carbon lead to 25-fold decrease in potency 
(4.13t vs 4.13i). Branching at "-carbon 4.13m (L-valine) gave 4-fold improvement in 
potency comparing to the 2’CMeG but ~12-fold decrease of activity in respect to the 
lead L-alanine benzyl ester 4.13i (Scheme 4.6).  
 




Scheme 4.6. Comparison of EC50 of different 2’CMeG ProTides. EC50 values in uM.  
 
Longer amino acids e.g. L-Met 4.13v kept submicromolar activity and the 
compound was found to be equipotent with the corresponding L-alanine derivative 
4.13c. 
Introduction of D-amino acid 4.13n resulted in loss of activity in case of both 
alanine and valine derivatives. 
The SAR of aryloxy unitis reported in Table 4.4. Comparison between  
!-naphthol and phenol shows 2.5-fold decrease in antiviral potency when the latter 
was used. This difference can be explained by increase in lipophilicity and leaving 
group ability. When !-naphthol was replaced by "#naphthol, ~3-fold decrease in 
activity was observed for both L-alanine and L-valine families. 
 
 
AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 4.4. Summary of 2’CMeG ProTides bearing different amino acid ester units.  




All of the synthesised ProTides displayed minimal toxicity in the Huh7 cells. CC50 
values were usually greater than 100 µM, providing compounds with very high 
selectivity indexes. Several compounds were also tested in MT4, CEM, HepG2, HEL 
and Caco2 cell lines. Similarly no significant toxicities were found. 
 
4.6 Enzymatic studies using Carboxypeptidase Y on 2’CMeG ProTides. 
  
 The putative mechanism of activation of phosphoramidate prodrugs as already 
described in Chapter 2, requires an initial hydrolysis of the ester unit by esterase or 
carboxypeptidase type enzyme. Subsequently the nucleophilic attack of the carboxyl 
group on phosphorus centre resulting in spontaneous cyclisation and elimination of 
the aryloxy moiety. A presumed five-membered ring is considered as very unstable 
and undergoes opening to give an intermediate diacid metabolite. The last step of 
bioactivation involves phosphoramidase-mediated hydrolysis of P-N bond to obtain 
the desired monophosphate. It is postulated that this deamination process relies on 
human histidine triad nucleotide binding protein 1 (HINT1) activity (Scheme 4.7).15 
The resulting monophosphate can be then phosphorylated to the corresponding  









































































a) Carboxypeptidase or esterase type enzyme
b) Spontaneous cyclisation
c) Water mediated hydrolysis
d) Phosphoramidase type enzyme
 
 
Scheme 4.7. Putative mechanism of activation of 2’CMeG ProTides. 
 
In the work carried out by Birkus et al.17 it was discovered that one of the 
lysosomal associated enzymes – cathepsin A (carboxypeptidase A, CatA,  
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EC 3.4.16.5) was responsible for the ester cleavage during activation pathway of 
nucleotide amidate prodrugs.17 
Cathepsin A is a member of !/"-fold hydrolase family. It is multifunctional 
enzyme with carboxypeptidase, esterase and deamidase catalytic activity.18 In terms 
of substrate specificity; CatA shows high affinity for hydrophobic and basic amino 
acids. Second enzyme that could be involved in the cleavage of the carboxyester 
moiety is carboxylesterase 1 (liver carboxylesterase 1, hCE-1, CES1, CES1A1,  
EC 3.1.1.56, EC 3.1.1.1). hCE-1 belongs to the same as CatA family of !/"-fold 
hydrolases.19 This enzyme was found to efficiently hydrolyse amide, ester and 
thioester bonds in aromatic and aliphatic substrates.20  
Tissue distribution assays demonstrated that both of these enzymes have high 
levels of expression in variety of tissues, especially in kidneys, liver and lungs.21 High 
levels of these enzymes present in the liver may lead to ProTides being processed 
more efficiently in hepatocytes, which could result in increased efficacy and at the 
same time reduced systemic exposure and cytotoxicity.  
To better understand the influence of different esters on potency and antiviral 
activity of 2’-C-methylguanosine aryloxyphosphoramidates, ester hydrolysis studies 
were performed. As human CatA is not commercially available; carboxypeptidase Y 
was chosen as a model enzyme. Carboxypeptidase Y (CPY, EC 3.4.16.1) is a yeast 
carboxypeptidase exhibiting a high degree of structural homology around the catalytic 
site with cathepsin A. In terms of substrate specificity, the two enzymes belong to the 
same family of C-type carboxypeptidases.22 
 The procedure used for enzymatic studies was developed within the 
McGuigan group.23 The experiments were run at 25 °C, optimal temperature for 
carboxypeptidase Y hydrolytic activity, and at pH 7.6, the enzyme reaction was 
followed by 31P NMR. Initially, the blank 31P NMR of the appropriate 
phosphoramidate in acetone-d6 and TRIZMA buffer (pH 7.6) was recorded. Then 
compound was incubated with carboxypeptidase Y for period of 14 h and the 31P 
NMR spectra were recorder every 7 minutes. 
 Described in the following section are the enzymatic assays performed on the 
2’CMeG phosphoramidate derivatives reported in the previous section of this 
Chapter. 
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  A first experiment was performed with the !-naphthyl L-alanine benzyl ester 
5’-phopshoramidate 4.13i. In the blank 31P NMR two diastereoisomers (1:1 ratio) 
signals were observed ("P= 3.69 and 4.12 ppm).  
 
Figure 4.3. Carboxypeptidase-mediated cleavage of compound 4.13i, monitored by 31P NMR. 
 
Once the enzyme was added, compound was quickly hydrolysed to the intermediate 
4.14 ("P= 4.53 and 4.85 ppm), which appeared in 1:1 ratio. At the 7-minute time 
point, a peak corresponding to the final aminoacyl intermediate 4.15 ("P= 6.98 ppm) 
was formed (Figure 4.3). The half-life of the compound is ca. 3 min.  
In the case of the isopropyl derivative 4.13c, the compound was found to be 
well processed. Interestingly, one of the 4.13c diastereoisomers was hydrolysed much 
faster, presumably indicating that this isomer fits better in the active site of the 
enzyme. However, it has to be noted that the ratio of isomers in the starting 
phosphoramidate 4.13c was roughly 2:1 and it also might have an impact on the rate 
of processing. Like in the case of benzyl derivative, the final product has similar "P of 
6.95 ppm, as both compounds are activated to the same aminoacyl intermediate. Half-
life of the compound was found to be 20 min (Figure 4.4).  
 




Figure 4.4. Carboxypeptidase-mediated cleavage of compound 4.13c, monitored by 31P 
NMR. 
 
By contrast, L-alanine tert-butyl derivative 4.13d was found to be processed 
very slowly (Figure 4.5).  
 
Figure 4.5. Carboxypeptidase-mediated cleavage of compound 4.13d, monitored by 31P 
NMR. 
 




Final intermediate peak 4.15 started to form within 1.5 hour after enzyme 
addition, and estimated half-life of the compound was 50 h (Figure 4.5).  
The experiment carried out with t-butyl ester phosphoramidate is in 
accordance with the lack of antiviral activity. As already mentioned t-butyl ester is 
probably too bulky to be processed by the enzyme and therefore 5’-monophosphate is 
not efficiently released resulting in deficiency in antiviral activity. 
The carboxypeptidase assay performed on 4.13m shows good conversion of 
the starting ProTide (Figure 4.6).  
 
 
Figure 4.6. Carboxypeptidase-mediated cleavage of compound 4.13m, monitored by 31P 
NMR. 
 
24 min after addition of carboxypeptidase, appearance of new peak at !P= 7.49 ppm 
was observed. This new species corresponds to the final L-valinyl intermediate 4.16 
(Figure 4.6). Comparing to the analogous L-alanine derivative 4.13i, processing of 
4.13m is slower (T1/2 ~30 min vs. 7 min) and it is consistent with activity found for 
these two compounds (EC50 = 0.76 vs. 0.06 µM). 
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 On the other hand D-Val analogue 4.13n was found to be both, not processed 
by carboxypeptidase and not active (Figure 4.7).  
 
 
Figure 4.7. Carboxypeptidase-mediated cleavage of compound 4.13n, monitored by 31P 
NMR. 
 
All carboxypeptidase Y assays should be considered as a model prediction of 
phosphoramidate activation. It may be possible that in vivo activation of particular 
phosphoramidate examples will differ (presence of various enzymes being potentially 
involved in ester cleavage) and may result in faster or slower release of the 
corresponding aminoacyl intermediates.  
 
4.7 Synthesis of metabolic intermediates. 
 
 In order to verify chemical structure of final metabolic intermediates present 
during carboxypeptidase Y assays, synthesis of 4.15 and 4.16 was performed (Scheme 
4.8). Subsequently 31P NMR shifts of synthesised compounds were compared to those 
obtained through enzymatic cleavage. 
 Synthesis of diacid intermediates 4.15 and 4.16 involved hydrolysis of 
previously prepared phosphoramidates 4.13g and 4.13n, respectively. Appropriate 
phosphoramidates were dissolved in a 1:1 mixture of triethylamine and water,24 and 
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reaction mixtures were stirred at room temperature for 16 h (Scheme 4.8). After 
column chromatography, products were obtained as diammonium salts. Structure of 


































(4.13g   R1=CH3, R2=H, R3=cHx 4.13m  R1=CH(CH3)2, R2=H, R3=CH2Ph)
(4.15   R1=CH3, R2=H 4.16   R1=CH(CH3)2, R2=H)  
Reagents and Conditions: i) Et3N:H2O (1:1), rt, 16 h. 
Scheme 4.8. General synthesis of 2’-C-!-methylguanosine aminoacyl intermediates.  
 
 Synthesised intermediates were dissolved in acetone-d6 and TRIZMA buffer, 
to mimic conditions used for carboxypeptidase Y experiments, and 31P NMR spectra 
were recorded (Figure 4.8).  
In the spectrum recorded during carboxypeptidase Y assay using compound 
4.13i, after complete processing, only one single peak can be seen at "P= 6.99 ppm, 
which could correspond to the achiral phosphoramidate monoester intermediate 
(Figure 4.8a). Spectra of chemically prepared 5’-aminoacyl diammonium salt of 4.15 
shows also one peak at "P= 6.93 ppm (Figure 4.8b), and as can be seen both peaks 
coincide. To further support these findings 31P NMR of both compounds together, 
were recorded and analysed (Figure 4.8c). It can be clearly noticed that both peaks 
overlap, without any 31P signal splitting being observed. These results strongly 
support the structure of the aminoacyl intermediate present during enzymatic 
activation of L-alaninyl phosphoramidates of 2’CMeG. 
 
 







Figure 4.8. 31P NMR analysis of metabolic intermediate observed during carboxypeptidase-
mediated cleavage of phosphoramidates; a) 31P NMR spectra of phosphoramidate 4.13i 
submitted for enzyme assay, b) 31P NMR spectra of synthesised L-alaninyl intermediate 4.15, 
c) 31P NMR spectra of a mixture of enzymatic 4.13i and 4.15. 
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 A similar methodology was applied to L-valine derivatives in order to verify 
the structure of the intermediate present during carboxypeptidase assay performed on 
4.13m. After complete enzymatic conversion of the L-valinyl phosphoramidate 4.13m 
to the proposed corresponding diacid intermediate 4.15, the 31P NMR spectrum was 
recorded (Figure 4.9a). Like in the case of L-alaninyl analogue, one single peak was 
observed with chemical shift of 7.49 ppm.  
When the chemically prepared compound was submitted to the NMR analysis (Figure 
4.9b), one single peak at !P= 7.44 ppm was observed. After mixing two samples 
together, both peaks overlap resulting in one 31P signal, with chemical shift of  










Figure 4.9. 31P NMR analysis of metabolic intermediate observed during carboxypeptidase-
mediated cleavage of phosphoramidates; a) 31P NMR spectra of phosphoramidate 4.13m 
submitted for enzyme assay, b) 31P NMR spectra of synthesised L-alaninyl intermediate 4.16, 
c) 31P NMR spectra of a mixture of enzymatic 4.13m and 4.16. 
 
Performed analyses gave an evidence, that compounds 4.15 and 4.16 formed 
during enzymatic assays and their equivalents prepared by chemical hydrolysis share 
the same molecular structure. 
 
4.7.1 Biological evaluation of phosphoramidate monoesters of 2’CMeG. 
  
 Both synthesised 5’-L-alaninyl and 5’-L-valinyl monoester phosphoramidates 
(4.15 and 4.16 respectively) were submitted for biological testing in HCV replicon 
assay. Results are reported in Table 4.5. 
 
 
AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 4.5. Replicon activity of 2’CMeG aminoacyl intermediates.  
 
As one might expect, based on their polarity, no improvement in antiviral 
potency comparing to the parent nucleoside 4.10 has been seen for both of these 
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synthesised compounds. However, the fact that moderate activity for this class of 
molecules has been seen at all is somewhat surprising. It can be explained that amino 
acid phosphate moiety is being cleaved outside the cell and only nucleoside is being 
delivered intracellularly. Another hypothesis is that the aminoacyl intermediates can 
in some extent facilitate cellular uptake and deliver monophosphate inside the cell, 
though the whole process is not as efficient as for the phosphoramidate ProTides.  
 
4.8 Stability of 2’CMeG ProTides. 
 
4.8.1 Plasma stability. 
 
 Replicon results revealed several interesting compounds, which could 
potentially be tested in vivo, in small animal models. Prior to animal pharmacokinetic 
studies, plasma stability was investigated at Inhibitex Inc. Data are % remaining in the 
plasma after 30 min of incubation (Figure 4.10 and 4.11). 
It was clearly noticed that in terms of L-alanine phosphoramidates, all tested 
compounds were very unstable in rodent plasmas (both rat and mouse). Simple alkyl 
L-alanine ester ProTides 4.13b (methyl) and 4.13e (butyl) were among the least stable 
in rodent plasma, and were rapidly degraded. The most stable compound across this 
family was L-alanine isopropyl derivative 4.13c exhibiting moderate stability in 
mouse plasma with 17% remaining after 30 min of incubation. Surprisingly, other 
branched esters like 4.13f or 4.13k did not improve rodent plasma stability and were 
almost completely cleaved within 30 min (Figure 4.10).  
 
 
Figure 4.10. Plasma stabilities of selected phosphoramidates bearing different amino acid 
esters.  




This profound plasma instability of L-alanine ProTides excludes these 
compounds as potential candidates for rodent pharmacokinetic studies. 
On the other hand, most of the tested L-alanine compounds showed desirable stability 
in monkey and human plasma. The only exemption was compound 4.13i (L-alanine 
benzyl ester), which was the least stable in human plasma with approximately 60% 
remaining after 30 min of incubation (Figure 4.10). 
 Considering compounds derived from different amino acids, it was noticed 
that compounds with disubstitution at alpha carbon e.g. 4.13t (Figure 4.11) did not 
provide any improvement in terms of mouse or rat plasma stability, comparing to the 
corresponding L-alanine analogue. However, compounds bearing branching at beta 
carbon resulted in significantly improved plasma stability. Thus, L-valine derivatives 
exhibited considerably less rodent plasma instability than other amino acids. 
Interestingly, when L-valine 4.13m and D-valine 4.13n were evaluated for their 
stability in mouse plasma, 4.13n was found to show a higher degree of instability than 
its L-analogue. These findings do not correlate with replicon results, where D-valine 
ProTide showed no antiviral activity, presumably because of the lack of activation.  
  
 
Figure 4.11. Plasma stabilities of selected L-alanine phosphoramidates. 
 
Furthermore, compounds bearing substitutions in ortho position of benzyl ester 4.13p 
and 4.13s where slightly less stable than unsubstituted derivatives 4.13m and 4.13o. 
In terms of stability in human and monkey plasma, all compounds showed 
satisfactory stability. 
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4.8.2 Liver and intestinal S9 stability. 
 
 Liver and intestinal S9 stability studies across different species (human, 
monkey, dog and rat) were investigated in order to establish which species best maps 
onto the human profile of intestinal to liver stability. Additionally, compounds that 
were exhibiting high stability profile in intestinal S9 extracts with rapid cleavage in 
the liver were desirable, as they are considered as liver targeting. Compounds were 
incubated in the presence or without NADPH co-factor (Table 4.6), for 60 min (unless 
otherwise stated) at 37 °C. Reaction mixtures were quenched by addition of equal 
amounts of cold acetonitrile. After centrifugation (3000 rpm for  
15 min), supernatant was submitted to HPLC analysis. Experiments were performed 
and evaluated by Inhibitex Inc. 
 
 
±: with/without NADPH co-factor. 
a: incubated for 30 min. 
Table 4.6. Intestinal and liver S9 stability of 2’CMeG ProTides.  
 
Comparing stability data derived from intestinal and liver S9 preparations, it 
was observed that majority of the compounds exhibited greater stability in intestinal 
extracts than in the ones obtained from liver (Table 4.6). These findings give support 
to liver targeting by these ProTides. Across all tested compounds L-alanine isopropyl 
ProTide 4.13c was found to be the most stable in both types of extracts, while benzyl 
analogues in general (4.13i, 4.13m, 4.13u) were more prone towards cleavage. 
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Looking at co-factor dependency, it can be clearly noticed that higher degree of 
cleavage was observed in liver S9 extracts in the presence of co-factor. NADPH 
serves as a co-factor for cytochrome P450 isozymes, which are highly expressed in the 
liver. This can be considered as a further indication for liver targeting of synthesised 
phosphoramidates.  
When stabilities in different species were compared, it was noticed that 
monkey and rat data were comparable with human results. However results obtained 
from the dog showed a different pattern, where ProTides were found to be more stable 
in the liver than in intestinal S9 preparations.  
 These results have clarified potential use of rat as a small animal model, and 
showed preference of monkey data over dog. 
 
4.8.3 Stability in simulated gastric and intestinal fluids. 
 
 During oral administration, in order to be absorbed, a drug must be stable in 
various pHs and survive in the presence of digestive enzymes. Gastrointestinal fluids, 
their volume and composition can affect drug absorption, as well as presence of bile 
and mucosa, blood perfusion or surface and nature of epithelial membranes.25 Thus, 
investigation of ProTide stability, especially in stomach and small intestine 
environment was of interest. 
 The pH of the fluids in the fasted-state stomach is usually in a range of 1.5-
2.5. Food intake results in rapid increase of the gastric pH to values between 4-7 
(depending on a content of a meal) and soon after the pH of the gastric fluids returns 
to the fasted-state values.25 
Fasted-state pH in small intestine is usually reported as ca. 6.5 and increases up to 7.5 
- in the distal small intestine, but can alter between 2 and 8. After a meal, the pH in 
this part of intestinal tract slowly decreases, as acidic gastric content enters intestine, 
before returning to fasted-state values at the completion of digestion.25 
 Stability of ProTides in simulated gastric (SGF) and intestinal fluids (SIF) was 
measured and evaluated by Inhibitex Inc. Reported data correspond to the stability of 
4.13f. The compound was incubated (10mg/ml PO formulation (5% DMA, 205 
Solutol HS 15, 20% PEG 400, 55% 50mM sodium acetate, pH 4.0), diluted 1:10) in 
the appropriate medium, and percentage of recovery was measured at 15 min, 30 min, 
1 h and 4 h time points at 37 °C. 




Figure 4.12. Stability of 4.13f, in simulated intestinal and gastric fluids. 
 
 Simulated fluids used for the experiment, correspond to the fasted-state gastric 
conditions (pH 2, without pepsin)- for SGF, and pH 7.5 without pancreatin for SIF. 
 As can be seen in the Figure 4.12, phosphoramidate 4.13f showed very good 
stability, with full recovery of 4.13f within 4 hours of incubation, in both gastric and 
intestinal simulated fluids. This profound stability in various matrices indicates that 
phosphoramidates have a pH stability profile consistent with oral administration. The 
fact that 4.13f was entirely stable during 4 h of incubation at pH 2 in SGF, at 37 °C, 
indicate, that the compound can be taken on an empty stomach and be able to pass 
through intact, and then undergo absorption in small intestine. Because the small 
intestine is the main absorption site, gastric emptying is often rate limiting step. Thus, 
food (especially fatty food) slows gastric emptying and consequently rate of 
absorption.  
Stability in intestinal fluids can guarantee optimal time for the compound to be 
absorbed while passing through the intestinal tract before being excreted. 
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4.9 Intracellular levels of 2’-C-methylguanosine triphosphate – in vitro studies. 
  
4.9.1 Intracellular metabolism in HCV replicon cells. 
 
 In order to determine whether synthesised ProTides can be converted 
intracellularly to the 2’-C-methylguanosine triphosphate (2’CMeGTP), the active 
species involved in the HCV NS5B inhibition, several ProTides were investigated in 
genotype 1b replicon cells (Inhibitex Inc.).  
Replicon cells were incubated with 4.13f and 4.13k at concentrations that produce 
50% inhibition of HCV replicon (EC50 = 0.05 µM and 0.08 µM, respectively) and 
90% of inhibition (EC90 = 0.2 µM and 0.4 µM, respectively). Cells were harvested 
after 6 h of exposure to the ProTides, and the intracellular levels of 2’-C-
methylguanosine triphosphate were measured (Figure 4.13). 
 
 
Figure 4.13. Levels of 2’CMeGTP in HCV 1b replicon system. 
 
At 0.2 µM 4.13f, the concentration of 2’CMeGTP produced in replicon cells 
was 1.9±0.42 pmol/1 x 106 cells. Taking in consideration liver cellularity of 1 x 108 
cells per g,26 the expected amount of triphosphate that would result in 90% of viral 
inhibition  in the liver tissue, was calculated to be 190 pmol/g of liver. This value was 
used as a reference for further in vivo evaluation of triphosphate levels produced from 
4.13f. Levels of the 2’CMeGTP obtained from 0.4 µM of 4.13k were very similar and 
would correspond to the 195 pmol of triphosphate per gram of liver tissue. 
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4.9.2 Intracellular metabolism in primary human hepatocytes. 
 
 Further investigation of triphosphate production was carried out in primary 
human hepatocytes and evaluated by Inhibitex Inc. ProTides were incubated in 
primary human hepatocytes at an arbitrary concentration of 2 µM. Triphosphate levels 
were measured over a period of 6 h and for the most interesting compounds in the 
prolonged incubation time of 24 and 48 h. Additionally levels of 2’CMeGTP resulting 
from the incubation of 2’-C-methylguanosine 4.10 during 24 h and 48 h were also 
measured.  
  
Figure 4.14. a) Levels of 2’CMeGTP produced from selected phosphoramidates in primary 
human hepatocyte system (6h). Black symbol = 1st analytical run; Red symbol = 2nd analytical 
run, b) 24h time course of 2’CMeGTP production in primary human hepatocytes. 
 
 Several structurally distinctive ProTides were chosen for the study, including 
L-alanine (4.13c, 4.13f, 4.13g, 4.13i and 4.13k) and L-valine derivatives (4.13m and 
4.13p), and corresponding results are shown in Figure 4.14. Incubation of all 
compounds resulted in formation of decent amounts of triphosphate within incubation 
times as short as 6 h. Looking at the L-alanine family it can be clearly seen that the 
highest production of 2’CMeG triphosphate was obtained from the incubation of 
4.13k (8.2±0.31 pmol/1 x 106 cells at 6 h) followed by 4.13g (4.1 pmol/1 x 106 cells at 
6 h) and 4.13f (2.9±0.28 pmol/1 x 106 cells at 6 h). Values for these 3 compounds 
were above EC90 calculated in replicon assay (1.9±0.42 pmol/1 x 106 cells). L-Valines 
in general were found to produce less 2’CMeG-triphosphate, comparing to L-alanine 
phosphoramidates (4.13i vs. 4.13m). These findings correlate with the ease of 
activation for the appropriate ProTides.  Additionally levels of 5’-triphosphate 
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produced from the parent nucleoside 4.10 were undetectable in this particular 
experiment (Figure 4.14b). 
Compounds 4.13f and 4.13k were chosen for prolonged (48 h) incubation studies 
(Figure 4.15). The data indicates that both phosphoramidates produce a substantial 
amount of 2’-C-methylguanosine triphosphate comparing with the parent nucleoside. 
Looking at the curve corresponding to the 4.13f, maximum concentration (Cmax) of TP 
(42 pmol/106 cells) forms within first 12 h, and then slowly decays. For compound 
4.13k, Cmax has very similar value of ca. 40 pmol/106 cells, however it was achieved 
in much shorter time (6 h vs. 12 h). Based on these data, the half-life of intracellular 
2’CMeGTP in primary human hepatocytes was calculated to be approximately 36 h 
(Figure 4.15). Levels of 5’-triphosphate resulted from the incubation of both 4.13f and 
4.13k were almost 20 times higher than the concentration required to eradicate 90% 
of the viral load, indicating their undisputed potential as anti-HCV agents. 
 
 
Figure 4.15. Levels of 2’CMeGTP produced from 4.13f and 4.13k in primary human 
hepatocytes system over 48 h incubation period.  
 
On the other hand 2’CMeG was found to slowly build up triphosphate levels, with 
much lower and delayed Cmax of around 18 pmol/106 cells at 30 h. Figure 4.15 
evidently shows advantage of phosphoramidate ProTides over parent nucleoside. 
 
4.10 Intracellular levels of 2’-C-methylguanosine triphosphate – in vivo studies. 
 
 The ability of phosphoramidate ProTides of 2’-C-methylguanosine to deliver 
monophosphate inside the liver cells and subsequent formation of 2’CMeGTP after 
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oral administration was investigated in different animal models. All animal studies 
were evaluated by Inhibitex Inc.  
 
4.10.1 Intracellular levels of 2’-C-methylguanosine triphosphate in mouse model. 
 
 A series of ProTides was evaluated in mouse model in order to evaluate their 
metabolism and pharmacokinetics. Mice were dosed orally at 50mg/kg (~240 mg 
human equivalent dose HED) in PO formulation (5% DMA, 205 Solutol HS 15,  
20% PEG 400, 55% 50 mM sodium acetate, pH 4.0). Liver samples were harvested at 
specified time points and snap frozen. Levels of 2’-C-methylguanosine were analysed 
using LC-MS/MS tandem spectroscopy. At the same time generation of metabolites 
(mainly 2’CMeG) in the plasma was measured. The main objective of this study was 
to find compound/s that would express high levels of liver triphospate and at the same 
time low systemic nucleoside exposure. It has to be noted that the oral dose of 
50mg/kg (of different compounds) is not molar equivalent dose, and therefore 
reported data are not exact comparisons. 
 For all tested phosphoramidates systemic levels of parent ProTide were not 
detectable and furthermore all ProTides resulted in low systemic exposure of parent 
nucleoside (Table 4.7). 
 
 
Table 4.7. Systemic level of nucleoside resulted from 50mg/kg dose in mouse, measured in 
plasma samples.  
 
All tested ProTides showed good conversion to the triphosphate in mouse liver 
(Figure 4.16), markedly exceeding EC90 values, with 4.13k providing Cmax (4 h) close 
to 11 x EC90 concentration (Figure 4.16). 
 




Figure 4.16. Triphosphate levels in livers of orally dosed mice.  
 
Incubation of parent nucleoside 4.10 resulted in the highest levels of triphosphate 
comparing to the ProTides (Table 4.8), which is in accordance with the systemic 
nucleoside levels.  
 
 
Table 4.8. 2’CMeGTP liver levels resulting from 50mg/kg oral dose in mouse.  
 
 This arising difference may come not only from the fact that doses were non-
molar equivalents but also from excellent oral bioavailability of 2’CMeG in mouse 
(F=85%).  
 Looking at ratio between the triphosphate dose normalized AUC (DNAUC) 
and nucleoside DNAUC it can be seen that compounds 4.13k and 4.13m have similar 
ratio to 4.10 (~2). The ratio obtained for 4.13f was close to 1. With this comparison it 
is obvious that both ProTides 4.13k and 4.13m, and parent nucleoside are producing 
at least twice as much of triphosphate in the liver comparing to systemic nucleoside 
dosing. The only exemption was compound 4.13p, which exhibited higher levels of 
systemic nucleoside than liver triphosphate. This finding is in contrast with the rodent 
stability data, where 4.13p was found to be more stable than any of L-alanine 
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derivatives. Because the DNAUC data for ProTides are calculated using 6 h data 
points extrapolated out to 24 h, it is possible that the triphosphate to systemic 
nucleoside ratio for these compounds might be better that the one obtained for parent 
nucleoside 4.10. 
 As already mentioned in previous sections, the mouse is considered as a non-
optimal model for ProTide pharmacokinetic studies, due to the fast breakdown of 
phosphoramidates to the parent nucleoside, therefore several most promising 
compounds were investigated in the cynomolgus monkey, in which oral 
bioavailability of 2’CMeG is rather poor and is close to ~10%. This significant 
difference between oral bioavailability of 2’CMeG of this two species shows that 
there is a major difference in absorption and metabolism rate of 2’-C-
methylguanosine and corresponding ProTides. 
 
4.10.2 Intracellular levels of 2’-C-methylguanosine triphosphate in nonhuman 
primate model. 
 
 In order to determine whether phosphoramidate ProTides are able to generate 
2’CMeGTP in the liver of cynomolgus monkey, four animals were orally dosed 
(single dose) with phosphoramidates 4.13f and 4.13k at 25mg/kg. Plasma samples 
were collected from portal and femoral veins to determined levels of the ProTide 
being absorbed from GI tract and systemic exposure to both, a ProTide and parent 
nucleoside 4.10. Additionally levels of 2’CMeG triphosphate were measured (two 
post-dose time points (at 3 and 8 h) for 4.13f and at one time point (at 8 h) for 4.13k) 
from samples collected upon surgical biopsies under anaesthesia. 
All results are summarised in Figure 4.17. Pharmacokinetic studies in 
nonhuman primates suggest efficient extraction of ProTides by the liver. In both cases 
phosphoramidates were detected in portal plasma samples after 30 min of dosing and 
continue to be present until 8 h. At this dose systemic levels of 4.13f were not 
detected at any time point and 4.13k was seen in low concentration and remained for 
up to 24 h post-dose. Levels of parent nucleoside started to build up 1 h post-dose for 
4.13k and 2 h for 4.13f and correlate in a linear manner with levels of 2’CMeGTP 
formed in the liver. 




EC90: Defined as the amount of intra cellular triphosphate necessary to achieve 90% inhibition in the 
HCV replicon assay. 
Figure 4.17. Oral pharmacokinetics in nonhuman primates. 
  
For compound 4.13f, liver biopsy results showed that the levels of generated 
triphosphate did not exceed EC90 value of 190 pmol/g of liver, however 
concentrations of TP obtained from oral dose of 4.13k were much greater that 




 To summarise, a series of novel 2’-C-Methylguanosine ProTides has been 
synthesised. In almost every case, the newly synthesised phosphoramidates were more 
active than the parent nucleoside, often by 10-30-fold. Structure activity relationships 
were extensively studied, including modification in ester, aryl and amino acid moiety. 
A combination of different esters and amino acids resulted in very potent compounds, 
suitable for further preclinical development. Plasma stability studies indicate that 
rodent models may not be appropriate for ProTide pharmacokinetic studies, due to the 
rapid breakdown of phosphoramidates to the parent 2’CMeG nucleoside. Comparing 
different amino acids to each other, it was noticed that L-valine phosphoramidates 
were among the most stable examples in mouse and rat plasma. On the other hand all 
tested compounds possess very good stability in dog, monkey and human plasma. 
Intestinal and liver S9 stability data gave an indication, that these compounds after 
oral administration will pass through the gastrointestinal tract and will be effectively 
absorbed and cleaved in the liver. Additionally, it was noted that dog model should 
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not be used to evaluate synthesised compounds as the ratio between intestinal to liver 
stability greatly differ from the one obtained for human S9 preparations. Experiments 
carried out in simulated gastric and intestinal fluids, confirmed acid stability of 
phosphoramidates and confirmed oral administration as feasible. Further development 
of ProTides for their ability to produce substantial levels of 2’-C-methylguanosine 
triphosphate, both in vitro and in vivo in different animal models, confirmed their 
undeniable potential. 
All collected data suggest that ProTides of 2’-C-methylguanosine represent a 
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2’-C-!-methylguanosine: new C-6 base modifications. 
 
5.1 6-C-modified 2’-C-!-methylguanosines – the rational behind the design. 
 
 Extensive studies carried out on 2’CMeG ProTides resulted in compounds like 
4.13i being ~50 times more potent than the parent nucleoside 4.10 (Figure 5.1).  
 
Figure 5.1. Comparison of 2’CMeG and its ProTide. 
 
However, subsequent studies addressing plasma stability revealed that initial 
family of L-alanine ProTides exhibits high degree of rodent plasma instability. Further 
examination of different amino acid derivatives was performed in the hope of finding 
compounds with acceptable rodent plasma stability. This investigation led to the 
compounds like 4.13m and 4.13u bearing L-valine benzyl ester and L-isoleucine 
benzyl ester respectively, possessing desired stability. Nevertheless these compounds 
were significantly less active than their corresponding L-alanine analogue 4.13i.  
As a great variety of amino acid and ester combinations was examined, 
attention was focused on the nucleoside itself. It was postulated that purine base 
modifications could enhance the uptake and the potency of phosphoramidates and 
provide better pharmacokinetic profiles. 
It is known that modification at C6-position may improve PK profiles. Studies 
carried out on guanine arabinoside (ara-G) showed that 6-O-methylation of the base 
unit provides a water-soluble prodrug of ara-G (Figure 5.2). Modification of the 
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Figure 5.2. Aqueous solubility of AraG and its prodrug nelarabine in different temperatures. 
 
This compound is known as nelarabine – a drug used in T-cell acute 
lymphoblastic leukaemia. Nelarabine is metabolised by adenosine deaminase to the 
arabinofuranosylguanine, which is further phosphorylated to the active specie.
1
 
In the case of 2’-C-!-methylguanosine different substitutions in the C-6 
position of the purine base were investigated, in order to increase lipophilicity of the 
nucleoside and thus potentially facilitate poor cellular uptake of 4.10. It has to be 
noted, that these substitutions are designed to liberate 2’-C-!-methylguanosine  
(at nucleoside level) and 2’-C-!-methylguanosine 5’-monophosphate (at nucleotide 
level) after being processed by specific deaminases, and therefore act as nucleos(t)ide 
pro-drugs.  
 
5.2 Synthesis of 6-C-modified 2’-C-!-methylguanosine analogues. 
 
 The synthetic route consists of the 1,2,3,5-tetra-O-benzoyl-2-C-methyl-!-D-
ribofuranose 4.5 synthesis
2
 followed by the glycosylation step with 2-amino-6-
chloropurine 5.1. The coupling reaction was carried out in dry acetonitrile in the 
presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and TMS-triflate at 65 °C for 
4-6 hours.
3
 Pure compound was obtained by crystallization from methanol. Regarding 
the ready access to that important precursor, synthesis was repeated several times on 
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5-10g scale. Compound 5.2 was used as synthetic intermediate for the synthesis of the 


































5.3   X=Cl
5.4   X=OCH3
5.5   X=OCH2CH3
5.6   X=NHCH3
5.7   X=SCH3
5.8   X=O(CH2)3OCH3
5.9   X=NHCH2Ph
5.10 X=NHCH2CH2Ph  
 
Reagents and Conditions: i) DBU, TMSOTf, dry ACN, 65 °C, 4-6 h; ii) NH3/MeOH, rt, 12 h, sealed 
tube (for 5.3); NaOMe/MeOH, rt, 16 h (for 5.4); NaOEt/EtOH, 50 °C, 5 h (for 5.5); 
MeNH3/MeOH/Et3N, 85 °C, 16 h, sealed tube (for 5.6); NaSMe/H2O, DMF, rt, 2 h (for 5.7); 
NH3/MeOH, rt, 12 h, sealed tube, then 3-methoxy-1-propanol, NaH, THF (for 5.8); Benzylamine, 
EtOH, reflux, 16 h (for 5.9); Phenylethylamine, EtOH, reflux, 16 h, then NH3/MeOH, rt, 16 h (for 
5.10). 
Scheme 5.1. Synthesis of 6-C-modified 2’-C-!-methylguanosine analogues. 
 
In order to obtained nucleoside analogue 5.3, protected 2-amino-6-chloro-9-
(2’-C-methyl-!-D-ribofuranosyl)purine 5.2 was suspended in methanol in a pressure 
tube, cooled to 0 °C and saturated with ammonia.
4
 Reaction mixture was allowed to 
warm to ambient temperature and was stirred for 16 h (Scheme 5.1). After that time 
solvents were evaporated under reduced pressure and crude mixture was purified on 
silica gel, using CHCl3/MeOH (9:1) as an eluent. Pure compound was obtained as a 
white solid, in 90% yield.  
Compound 5.4 was obtained in the reaction of 5.2 with sodium methoxide in 
methanol, at ambient temperature.
4
 After completion of the reaction, reaction mixture 
was neutralized with acetic acid, however this procedure resulted in a salt formation. 
As an alternative acidic form of Amberlite (H
+
) was used to neutralized the reaction 
mixture. Resin was added to the reaction mixture until the pH was adjusted to the 
value of 7-8. After that, resin was filtered off and solvent was removed in vacuum. 
After purification pure 5.4 was obtained as a white solid. The excess of sodium 
methoxide used in the reaction allowed final deprotection of the nucleoside derivative 
(Scheme 5.1). Conversion of 5.2 to 5.4 was straightforward and high yielding – 78%.  
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Synthesis of the 2-amino-6-ethoxy-9-(2’-C-methyl-!-D-ribofuranosyl) 5.5 was 
performed using similar procedure as described above, using sodium ethoxide in 
ethanol, at 50 °C for 16 h (Scheme 5.1).4 After purification the compound was 
obtained as a white solid in 84% yield. 
6-Methylamino analogue 5.6 was synthesised in the reaction of 5.2 with 25% 
solution of methylamine in methanol, in the presence of triethylamine.
4,5
  Reaction 
was performed in a sealed tube, at 85 °C for 16 hours (Scheme 5.1). Displacement of 
the chlorine and deprotection were performed in one step, in 90% yield. 
Replacement of the oxygen atom at the 6-position of guanine base by a sulfur 
atom, to produce clinically useful agents is known in the literature.
6
 Therefore, it was 
decided to investigate the influence of thiomethoxy substitution at the 6-position. 
Sodium methanothiolate (15% in H2O) in dimethylformamide (DMF) was used to 
convert 2-amino-6-chloro-9-(2’-C-methyl-!-D-ribofuranosyl)purine to 5.7 (Scheme 
5.1). After being stirred at ambient temperature for 2h, the mixture was diluted with 
water and extracted 3 times with ethyl acetate.
7
 Column chromatography provided 
pure 5.7, in 86% yield. As in the previous reactions, deprotection of the benzoyl-
protecting groups took place under reaction conditions. 
In the first attempt towards 5.8, 3-methoxy-1-propoxide was formed in situ 
from 3-methoxy-1-propanol and sodium hydride (NaH) in dry THF, at 0 °C.8 The 
reaction was allowed to stir for 30 min at ambient temperature before addition of  
2-amino-6-chloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-!-Dribofuranosyl)purine.    
The reaction mixture was stirred for 16 hours at ambient temperature. After that time, 
the reaction was quenched by the addition of Amberlite (H
+
). The resin was filtered 
off and solvents were removed under reduced pressure. Crude mixture was purified 
on silica gel, using CHCl3/MeOH (93:7) as an eluent. Analysis of isolated fractions 
revealed that during the displacement reaction partial deprotection of the nucleoside 
analogue took place. Fractions containing partially deprotected nucleoside were 
combined and submitted for the ammonolysis step. After completion of the reaction it 
was found that, 3-methoxy-1-propoxy substitution was not stable under the conditions 
of the deprotection reaction, and was cleaved off. To avoid unwanted side-products, it 
was decided that the displacement of the chlorine atom with 3-methoxy-1-propoxide 
will be performed on already deprotected 2-amino-6-chloro-9-(2’-C-methyl-!-D-
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ribofuranosyl)purine nucleoside 5.3 instead of 5.2 (Scheme 5.1). After completion of 
the reaction and purification, 5.8 was successfully isolated in 50% yield. 
Treatment of 5.2 with benzylamine or phenylethylamine in refluxing dry 
ethanol, resulted in formation of 5.9 and 5.10, respectively (Scheme 5.1).
9
 In case of 
5.10 additional deprotection step was required as phenylethylamine was not basic 
enough to remove benzoyl-protecting groups. Both nucleosides were obtained in 
excellent yields >90%. 
 
5.2.1 Biological evaluation of 6-C-modified 2’-C-!-methylguanosine analogues. 
 
All newly synthesised compounds were assayed for their ability to inhibit 
HCV RNA replication in subgenomic replicon cells by Inhibitex Inc. The potency and 
toxicity of these compounds is summarised in Table 5.1.  
 
 
ClogP values calculated using ChemOffice ultra 11.0.; EC50: 50% effective concentration or compound 
concentration required to inhibit HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 5.1. Anti-HCV activity and calculated lipophilicity of C-6 substituted 2’-C-!-
methylguanosine analogues.  
 
 As can be seen in Table 5.1, all C6-substituted nucleoside analogues exhibit 
improved ClogP values, comparing to the 2’-C-!-methylguanosine 4.10, with 
compounds 5.9 and 5.10 possessing the most enhanced lipophilicity. Not much 
difference in ClogP values was seen between 6-Cl, -NHCH3 and OCH3. Similar 
values were also predicted for compounds 5.5, 5.7 and 5.8. When anti-HCV activity 
was measured, it was found that the EC50 values do not correlate with compounds 
improved ClogP. In general, all compounds were active at µM range, however none 
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of the newly synthesised analogues was more potent that 4.10. Small substituents e.g. 
6-methoxy 5.4 retain the activity, while the presence of larger groups at C-6 resulted 
in significant decrease in activity, by 8-10-fold (5.10 and 5.9). 
 
5.2.3 Adenosine deaminase assay on 6-C-modified 2’-C-!-methylguanosine 
analogues. 
 
 When this family of C6-modified nucleosides was designed, it was kept in 
mind that they will act as pro-drugs of 2’-C-!-methylguanosine. In order to 
investigate whether C6-substituted analogues can serve as substrates for adenosine 
deaminase, an enzymatic assay in the presence of adenosine deaminase from calf 
intestinal mucosa was performed. 
  Adenosine deaminase (ADA, EC 3.5.4.4) and adenylate deaminase (5’-
adenylic acid deaminase, AMPDA, EC 3.5.4.6) are enzymes that catalyze the 
deaminiation reaction of adenosine and adenosine 5’-monophosphate to the 
corresponding inosine derivatives.
10
 ADA is able to catalyze the deamination of 
structurally distinctive purine nucleosides, provided that 5’-hydroxyl group is present 




44 µM Solutions of the appropriate C-6 substituted nucleosides in phosphate 
buffer (pH 7.4) were prepared. 1 mL of solution was place in a cuvet and a blank 
spectrum was recorded using a UV spectrophotometer (red curve, Figure 5.3). After 
that 30 µL of ADA solution were added and spectra were recorded in 1-minute 
intervals. As can be seen in Figure 5.3, starting material 5.4 with maximum 
absorbance at "max = 280 nm, was easily processed to form a new species (blue curve) 
with "max = 253 nm. It was found that this new species corresponds to the 2’-C-
methylguanosine nucleoside as expected. Full conversion of 5.4 to 4.10 was 
accomplished within 30 min. 




Figure 5.3. Spectral change during ADA-mediated hydrolytic removal of alkyl group from 
5.4. 
 
 Similarly compound 5.5 was investigated for its ability to serve as a substrate 
for the adenosine deaminase mediated cleavage (Figure 5.4).  
 
Figure 5.4. Spectral change during ADA-mediated hydrolytic removal of alkyl group from 
5.5. 
 
Nucleoside analogue 5.5 was found to be suitable substrate for the enzyme, however 
the conversion rate to 4.10 was much lower than in the case of 5.4. Full conversion 
was achieved after further addition of an enzyme (20 µL) and within 8 hours (Figure 
5.4). 
 Compounds 5.6 and 5.7 were also tested in the adenosine deaminase assay, but 
neither of them served as substrates for the enzyme (Figure 5.5).  
 




Figure 5.5. Spectral change during ADA-mediated hydrolytic removal of alkyl group from 
5.6 and 5.7. 
 
 It is not clear whether the corresponding 5’-monophosphate forms of these 
nucleosides could serve as substrates for adenylic acid deaminase or other hydrolytic 
enzymes. AMPDA is not commercially available and therefore more appropriate 
studies have not been conducted. Based on the literature, adenosine deaminase-like 
protein 1 (ADAL1) may be an alternative enzyme responsible for the hydrolytic 
cleavage of C-6 substituted purine 5’-monophosphates.
12
 Studies carried out by 
Murakami et al show that the active site of the enzyme could accommodate modest 
size lipophilic N-6 substitutions of the purine analogues. According to these findings 
ADAL1 could be responsible for the deamination of the 5’-monophosphate of 5.6. 
Furthermore 6-thiomethyl purine analogues similar to 5.7 were found to be slowly 
processed by the enzyme. The difference seen in conversion rate can presumably arise 
from the electronic influence of the thioether on C-6 carbon, reducing its 
electrophilicity and therefore make it less susceptible for the nucleophilic attack by 
the water molecule.  
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Compounds 5.9 and 5.10 bearing benzylamino- and phenylethylamino- substituents in 
C-6 position were not deaminated in ADA assays (data not shown) possibly because 
the side groups are too large to be accommodated in the active site of the enzyme. 
 To further support the requirement of adenosine deaminase mediated 
activation of C-6-modified nucleosides, replicon activity assay in the presence of 
2µM erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) - specific inhibitor of ADA was 
performed on 6-O-methyl-2’-C-methylguanosine 5.4 (Figure 5.6) and evaluated at 
Inhibitex Inc. 
 
Figure 5.6. Effect of EHNA on anti-HCV activity of nucleoside 5.4. 
 
 Data with ADA-specific inhibitor EHNA (light blue curve) clearly suggest 
that the hydrolysis of substitution at C-6 carbon is required for the compound to 
obtain its antiviral activity (dark blue curve). When replicon cells were treated with 
combination of 5.4 and 2 µM EHNA, no or little antiviral effect was observed up to 
10 µM concentration (Figure 5.6). Under the same conditions 5.4 alone exhibited 
more than 50% inhibition.  
 This study provided proof of concept and revealed the potential of O6 and/or 
N6 2-aminopurine nucleosides as anti-HCV agents.  
The aryloxyphosphoramidate approach was applied to 5.3-5.10 in order to investigate 
whether the delivery of their pre-formed and masked monophosphate can enhance 
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5.3 Synthesis of 6-C-modified 2’-C-!-methylguanosine ProTides. 
 
 In the first instance, the phosphoramidate approach was applied to the  
6-methoxy analogue 5.4 (Scheme 5.4). As in the case of 2’-C-!-methylguanosine 
4.10, 2’,3’-protecting procedures were investigated. Several different approaches to 
introduce isopropylidene protection were not successful and the compound proved to 
be unstable in acidic conditions. It was decided to use NMI coupling procedure 















































Reagents and Conditions: i) HClO4, acetone, rt, overnight; ii) a) appropriate phosphorochloridate, 
NMI, dry THF, rt, overnight. 
Scheme 5.2 General synthesis for 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine phosphoramidates using NMI method. 
 
 A small series of 5’-phosphoramidates (2.15, 5.12a – 5.12c) was prepared in 
moderate yield 11-14% (Table 5.2).  
 
 
AA: amino acid; ClogP values calculated using ChemOffice ultra 11.0. 
Table 5.2. Summary of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 
ProTides, their calculated lipophilicity and reaction yields.  
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 At this point it was decided to investigate other coupling conditions in an 
attempt to improve coupling yields. The tBuMgCl coupling method was chosen and 
applied to 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine in order to 
obtain 2.15. Surprisingly during the reaction course, the formation of 3’ and/or 3’,5’ 
disubstituted regioisomeric mixtures was not observed. We hypothesised that methyl 
substitution in 2’!-face position may have an influence, causing steric hindrance 
and/or changing sugar conformation, and therefore enabling reaction to proceed in the 
3’ position. This unexpected result gave us the opportunity to use Gringard reagent-
mediated coupling in order to complete the second series of C6-modified 
phosphoramidates using previously synthesised nucleoside analogues 5.3 – 5.10, with 
higher yields and easier purification step (Scheme 5.3, Table 5.3). All compounds 
































(5.3-5.10) (5.12a-5.19a)  
Reagents and Conditions: i) Naph-L-alanine-2,2-dimethylpropyl phosphorochloridate, tBuMgCl, dry 
THF, rt, overnight. 





Table 5.3. Summary of synthesised ProTides of 6-modified-2’-C-methylguanosine, their 
calculated lipophilicity and isolated yields.  
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All newly synthesised compounds were isolated as roughly equimolar 
mixtures of diastereoisomers at the phosphorus centre, evidenced by 
31
P NMR and 
HPLC. The first two series of C-6 modified nucleoside analogues were evaluated in in 
vitro assay, as inhibitors of HCV replication by Inhibitex Inc. 
 
5.4 Biological evaluation of first series of 6-C-modified 2’-C-!-methylguanosine 
ProTides. 
 
The first set of the new phosphoramidates was evaluated in replicon assay 
against hepatitis C virus, with data being shown in Table 5.4, along with comparator 
data of parent nucleosides 5.3-5.10. 
As noted in Table 5.4, all of the novel L-alanine phosphoramidates were active at 
submicromolar concentrations in the replicon assay, while all parent nucleoside were 
only moderately active. In every case application of ProTide technology resulted in 
significant increase of activity up to ca. 1000-fold (5.14a vs 5.5). In particular the 
most active phosphoramidates were those bearing -Cl, -OMe and -OEt substitutions in 
C-6 position (5.13a, 2.15, 5.12a-c and 5.14a, respectively).  Some of these 
compounds were active at 10 nM levels, making them amongst the most potent 
nucleotides vs. HCV at the time. 2.15 has later emerge as the clinical candidate INX-
08189. ProTides 5.15a-5.17a were equipotent, exhibiting EC50 values of about 0.04 
µM and more than 300-fold improvement comparing to the respective parent 
nucleosides. Phosphoramidates bearing the largest substitutions in C6-position e.g. 
5.18a and 5.19a, lost some activity comparing to 2.15 or 5.14a. This difference can 
arise most probably due to the size restriction at C6, nevertheless these ProTides were 
over 30-fold more potent than the parent nucleoside analogues 5.9 or 5.10, 
respectively. Comparing different esters in the 6-O-methyl-2’-C-!-methylguanosine 
L-alanine series (entries 2.15, 5.12a-c, Table 5.4) it can be clearly seen, that within 
this small family of ProTides, not much of a difference in anti-HCV activity can be 


























AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 5.4. Anti-HCV activity of 6-modified 2’CMeG ProTides. 
  
 All synthesised phosphoramidates exhibited cytotoxicity at µM 
concentrations, however taking in consideration their high potency, the values of the 
therapeutic indexes were in the range of a 1000. In general, the most toxic compounds 
were also the most potent suggesting perhaps that toxicity was arising from the active 
5’-nucleoside triphosphate form or a precursor. 
Given the very good activity of 2-amino-6-methoxy-9-(2’-C-methyl-!-D-
ribofuranosyl) purine and 2-amino-6-ethoxy-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine phosphoramidates, it was decided to further investigate these two families of 
ProTides. 
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5.5 SAR studies of 6-O-methyl and 6-O-ethyl-2’-C-!-methylguanosine ProTides. 
 
 Following the tBuMgCl coupling procedure described in the previous section 
of this Chapter, two series of phosphoramidates were synthesised in order to complete 
the 6OMe and 6OEt2’CMeG families. ProTides were varied at amino acid, ester and 
aryl moieties.  
 
5.5.1 Synthesis and biological evaluation of 6-O-methyl-2’-C-!-methylguanosine 
phosphoramidates. 
 
In the first instance 2-amino-6-methoxy-9-(2’-C-methyl-!-D-ribofuranosyl) 












































Reagents and Conditions: i) appropriate phosphorochloridate, tBuMgCl, dry THF, rt, overnight. 
Scheme 5.4. General method for the synthesis of aryloxyphosphoramidates of 6-O-methyl-2’-
C-methylguanosine using tBuMgCl. 
 
All synthesised ProTides (Scheme 5.4) were routinely isolated as roughly 1:1 
mixtures of phosphate diastereoisomers as evidenced by HPLC and 
31
P NMR signal 
splitting. The only exception was compound 5.12f, which was isolated as a mixture of 
four diastereoisomers, due to the additional variable chiral centre in the ester unit. The 
variation of different amino acids, esters and aryl moieties lead to the compounds 
with a ClogP values between 1.1 and 4.6 (Table 5.5).  
Compounds were evaluated for their inhibitory activity in in vitro replicon 
assay and the corresponding results are reported in Table 5.5. All synthesised 
phosphoramidates exhibited improved EC50 values compared to the parent nucleoside 
5.4. In the L-alanine series, entries 5.12d-k, lengthening, branching and aromatization 
of the ester moiety lead to agents with desired submicromolar activity. The most 
active derivatives were bearing 2,2-dimethylpropyl, propyl, 3,3-dimethyl-1-butyl and 
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S-phenylethyl esters (2.15, 5.12d, 5.12e and 5.12h, respectively, Figure 5.7) showing 





















AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 5.5. Summary of the anti-HCV activity of 6OMe2’CMeG ProTides and their calculated 
ClogP values. 
 
The least active compound amongst the L-alanine analogues were 5.12f, 5.12g 
and 5.12i. The explanation for the relative loss of activity for these compounds may 
be different in each case. For example in the case of 5.12g, the tetrahydrapyranyl L-
alanine ProTide, the value of calculated lipophilicity (ClogP = 1.1) is somewhat lower 
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than that considered as an optimal for passive cellular uptake, and thus perhaps 
resulting in a decrease in activity comparing to 2.15 or 5.12e. One important thing 
that has to be mentioned is that this particular analogue exhibited no cytotoxicity in 
the cell-based assay, and possesses the best therapeutic index (>700). The bulkiness 
and relative stability of 2-indanyl ester (which in some extent may be similar to the t-
butyl ester) can be responsible for the lack of efficient activation of this particular 
phosphoramidate and as a result, reduction of potency of 5.12i is observed. In the case 
of 5.12f, the explanation might be that additional branching of the ester unit may give 
some steric hindrance and thus, processing to the corresponding 5’-monophosphate is 
less effective. 
Looking at the relationship between compounds lipophilicity and in vitro anti-
HCV activity, it can be noticed that compounds with ClogP below 2 and above 4 had 
lower potency than those with ClogP between 2 and 4 (Figure 5.7).  
 
 
Figure 5.7. Potency (1/EC50) and calculated lipophilicity (ClogP) data plot of synthesised 
phosphoramidates 2.15, 5.12a-i. 
 
This range might be considered as an optimal for passive cellular uptake and 
therefore result in enhanced antiviral activity. The only exception were compounds 
5.12f and 5.12i, which had ClogP in the same range, however the EC50 values (0.17 
and 0.4 µM, respectively) were somewhat lower. This difference may arise, as already 
mentioned, from the relative stability of ester groups present in the structure of these 
phosphoramidates. 
When we compare ProTides bearing the same amino acid ester (L-Ala-2,2-
dimethylpropyl) but different aryl moieties, it can be noticed that the aryl unit has an 
impact on the potency of synthesised compounds.  




Figure 5.8. Potency (1/EC50) data plot of L-alanine ProTides bearing different aryl moieties. 
 
Replacement of !-naphthyl unit (2.15, EC50 = 0.01 µM) by phenyl- (5.12j, EC50 = 
0.05 µM) or p-NO2-phenyl- (5.12k, EC50 = 0.38 µM) resulted in 5- to ~40-fold 
decrease in antiviral activity seen in replicon based assay (Figure 5.8). In this set of 
aryl units, p-NO2-phenol is recognized as the best leaving group, however the 
compound with this particular substituted phenol was found to be the least active 
within the L-Ala-2,2-dimethylpropyl family (Table 5.5, Figure 5.8). It may suggest 
that the compound 5.12k is liberating phosphoramidate monoester prior entering the 
cell due to the very good leaving group ability of p-NO2-phenol and therefore 
observed antiviral activity is lower. 
Beside the ester and aryl moiety variation, several analogues with differed 
amino acids were prepared, varying the amino acid unit from L-alanine 2.15, 5.12a-k, 
to L-valine 5.12l-o, L-methionine 5.12p-r and unnatural amino acid D-phenylglycine 
5.12s-u. All synthesised compounds possess improved antiviral activities comparing 
to the parent nucleoside 5.4, with the exemption of compounds bearing D-
phenylglycine as amino acid, which did not exhibit improved potency. These results 
are consistent with the previous findings (see Chapter 4), and confirm that the 
unnatural amino acids may not lead to good substrates for carboxypeptidase-mediated 
activation. "-Branched amino acids like L-valine were less active than the 
corresponding L-alanine derivatives but still kept good antiviral activity, in sub-µM 
range. The most active compound across L-valine family was 5.12o (EC50 = 0.06 
µM), bearing a benzyl ester (Figure 5.9). This particular valine derivative was the 
most active L-valine ProTide synthesised so far. 
 




Figure 5.9. Potency (1/EC50) data ploto of various amino acid esters ProTides of 
6OMe2’CMeG. 
 
Longer amino acids like L-methionine lost ca. 6- to 20-fold activity in regard to the 
corresponding L-alanine analogues.  
 
5.5.2 Enzymatic studies using Carboxypeptidase Y on 6OMe2’CMeG ProTides. 
 
 Described in the following paragraph are the enzymatic assays performed on 
the 6OMe2’CMeG phosphoramidate derivatives reported in the previous section of 
this Chapter, using procedures reported in Chapter 4.  
 
Figure 5.10. Carboxypeptidase Y mediated hydrolysis of 5.12e, followed by 31P NMR. 
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A first experiment was performed with the !-naphthyl L-alanine 3,3-dimethyl-
1-butyl ester 5’-phosphoramidate 5.12e (Figure 5.10). In the blank 
31
P NMR two 
diastereoisomer (ca. 1:1 ratio) signals were observed ("P= 3.92 and 4.10 ppm). Once 
the enzyme was added, the compound was quickly hydrolysed to the intermediate 
(5.20, "P= 4.53 and 4.85 ppm) lacking the ester moiety, which appeared in 1:1 ratio. It 
can be noticed that processing of both diastereoisomers proceeded at the similar rate. 
At the 10-minute time point, a peak corresponding to the final aminoacyl intermediate 
(5.21, "P= 6.94 ppm) was formed (Figure 5.10). The half-life of the compound 5.12e 
is estimated to be less than 5 min.  
Carboxypeptidase assay performed on L-valine derivative 5.12o shows good 
conversion of the parent ProTide (Figure 5.11).  
 
 
Figure 5.11. Carboxypeptidase Y mediated hydrolysis of 5.12o, followed by 31P NMR. 
 
After addition of carboxypeptidase Y, the formation of new peak ("P= 7.38 ppm) 
corresponding to the chemical structure of 5.22 was observed within 17 min. 
Completion of the processing to the aminoacyl intermediated 5.22 was achieved after 
ca. 1.5 h.  
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The biological results reported for these two compounds supported by the enzymatic 
data can be taken as an early indication that the 2-amino-6-methoxy-9-(2’-C-methyl-
!-D-ribofuranosyl)purine ProTides successfully improved the intracellular delivery of 
the eventual 5’-triphosphate pharmacophore of 2’-C-!-methylguanosine. 
 
5.5.3 Synthesis and biological evaluation of 6-O-ethyl-2’-C-!-methylguanosine 
phosphoramidates. 
 
 Further exploration of the 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine ProTides lead to the small series of L-alanine derivatives. 
Compounds were prepared via coupling reaction with different phosphorochloridates 
3.3j-l, in dry THF in the presence of tBuMgCl (Scheme 5.5). All phosphoramidates 
were isolated as roughly equimolar mixtures of diastereoisomers at the phosphate, in 








































(3.3j-l) (5.14b-d)  
Reagents and Conditions: i) appropriate phosphorochloridate, tBuMgCl, dry THF, rt, overnight. 
Scheme 5.5. General method for the synthesis of aryloxyphosphoramidates of 6-O-ethyl-2’-
C-methylguanoosine using tBuMgCl. 
 
6-O-Ethyl-2’-C-!-methylguanosine ProTides were evaluated by Inhibitex Inc. 
against hepatitis C virus in vitro using a replicon assay.  
Again, the phosphoramidate technology allowed us to convert a poorly active 
nucleoside into ProTides with nM activity (Table 5.6). All newly synthesised 
phosphoramidates were 50- to ~900-fold more potent than the parent nucleoside. The 
900-fold boost in activity of L-alanine-2,2-dimethylpropyl derivative 5.14a, is the 
highest one observed so far among all synthesised phosphoramidates of 2’CMeG and 
closely related nucleoside analogues. L-Alanine benzyl ester analogue 5.14b was 
approximately 4-times less potent than the most active 5.14a, nevertheless this 
compound was circa 200-fold more efficient as an inhibitor of viral replication than 
the parent nucleoside analogue 5.5 (Table 5.6, Figure 5.12a).  




AA: Amino acid; EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 5.6. Summary of the anti-HCV activity 6OEt2’CMeG ProTides and their calculated 
ClogP values. 
 
The two phosphoramidates bearing tetrahydropyranyl- 5.14b and S-phenylethyl esters 
5.14d were the least active across this small family of 2-amino-6-O-ethyl-9-(2’-C-
methyl-!-D-ribofuranosyl)purine ProTides, showing circa 8-fold decrease in activity 
comparing to 5.14a (Figure 5.12a).  
 
 
Figure 5.12. a) Potency (1/EC50) data ploto of L-alanine ProTides of 6OEt2’CMeG; b) 
Potency (1/EC50) vs. calculated lipophilicity data ploto of L-alanine ProTides of 
6OEt2’CMeG 
 
 Similarly like in the case of 6OMe2’CMeG ProTides, compounds with 
calculated lipophilicity values in a range between 2 and 4, exhibited the best antiviral 
activity (Figure 5.12b). Of course it has to be remembered that logP is only one of the 
factors that contributes to a successful compound. There are other very important 
features including: the ease of enzymatic activation and ability to release 
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5.5.4 Enzymatic and cell lysate studies on 6OEt2’CMeG ProTides. 
 
To confirm the possible mode of action of these 6OEt2’CMeG 
phosphoramidates, enzymatic assays were performed in order to investigate the 
activation pathway (Figure 5.13 and Figure 5.14).  
 
 
Figure 5.13. Carboxypeptidase Y mediated hydrolysis of 5.14c, followed by 31P NMR. 
 
In the first instance the carboxypeptidase Y assay was performed on naphthyl 
benzylalanine analogue 5.14c (Figure 5.13). During the first 13 min after enzyme 
addition, the starting material 5.14c (!P= 3.62 and 4.11 ppm) was quickly hydrolysed 
to the intermediate lacking ester moiety 5.23 (!P= 4.69 and 4.83 ppm). Notably both 
diastereoisomers were processed with roughly similar efficacy. The estimated half-
life of 5.14c was less than 5 min. The final product of the hydrolysis, achiral 
aminoacyl phosphate 5.24 is represented by a single peak at !P= 6.95 ppm. 
Efficient activation of 5.14c is consistent with the replicon data reported for this 
compound, indicating that carboxypeptidase assay is a useful tool for the in vitro 
probing of the first steps of ProTides activation.  
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  The release of aminoacyl intermediate, the final product of carboxypeptidase 
Y mediate hydrolysis is considered as a first stage of ProTides activation. In order to 
gain its antiviral activity this particular intermediate needs to be hydrolysed to the 5’-
monophosphate, which subsequently could undergo kinase-dependent activation to 
the corresponding 5’-triphosphate. 
The ability of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl)purine 
ProTides to release 5’-monophosphate was investigated in Huh7 cell lysate  and the 
corresponding data are reported in Figure 5.14. 
 
 
* Phosphate peak present in the cell lysate, remains unchanged during the experiment. 
Figure 5.14. Formation of 5’-monophosphate from 5.14d in cell lysate assay, followed by 31P 
NMR. 
 
 Compound 5.14d was incubated in the presence of the Huh7 cell lysate (10
7
 cells) in 
acetone-d6 and Trizma buffer (pH 7.6) at 37 °C. 
31
P NMR spectra were recorded in  
1 h intervals for 11 h. During the first hour of incubation, the appearance of new peak 
at "P= 0.98 ppm was observed. The presence of that species can indicate successful 
liberation of 5.25 from the parent ProTide. In fact, this species has exactly the same 
chemical shift as chemically synthesised 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-
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ribofuranosyl) purine 5’-monophosphate under the same experimental conditions. 
During the hydrolysis the presence of aminoacyl intermediate 5.24 was not observed, 
suggesting that this metabolite is rapidly deaminated resulting in the formation of 
5.25. 
 
5.5.5 ProTides anti-HCV activity studies in the presence of adenosine and 
adenylate deaminase inhibitors. 
 
 As already discussed in the previous sections of this Chapter, the C6-modified 
nucleosides like 5.4 or 5.5 require deaminase mediated cleavage to obtain their full 
antiviral potency. To further investigate these findings specific antiviral assays were 
performed. The anti-HCV potency values of selected ProTides were determined in 
genotype 1b replicon cells, in the presence or absence of 2 µM EHNA or 40 µM 
pentostatin (deoxycofyrmycin, dCF) and evaluated by Inhibitex Inc. The 




Figure 5.15. Effect of EHNA and dCF on activity of 4.13f, 2.15 and 5.14a ProTides. 
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 In the first instance effect of EHNA on activity of naphthyl-L-alanine-2,2-
dimethylpropyl 6-O-methyl-2’-C-methylguanosine 2.15 was investigated. As can be 
seen in Figure 5.15a, EHNA has no effect on antiviral potency of 2.15. This data, with 
adenosine deaminase specific inhibitor suggests that the primary route of activation of 
2.15 involves direct conversion of the phosphoramidate to the corresponding 5’-
monophosphate then di- and triphosphate with negligible contribution of the 
nucleoside metabolite. Influence of pentostatin, a known inhibitor of ADA, AMPDA 
and ADAL1, on antiviral activity of 4.13f, 2.15 and 5.14a is shown in Figure 5.15b 
and c. Each of the ProTides bearing modifications in the C6 position (2.15 and 5.14a), 
loses entirely their anti-HCV activity in the presence of pentostatin, while 4.13f- the 
2’-C-methylguanosine analogue retain its potency. These findings clearly confirm an 
absolute need for the hydrolysis of C-6 substituent in order to be active, and that this 
happens at the nucleotide level. 
  
5.5.6 Effect of 6-O-alkylation on activity of 2’-C-!-methylguanosine 
phosphoramidates. 
 
 In vitro replicon based assay showed that both parent nucleosides 2-amino-6-
methoxy-9-(2’-C-methyl-!-D-ribofuranosyl) purine and 2-amino-6-ethoxy-9-(2’-C-
methyl-!-D-ribofuranosyl) purine displayed similar activity as 2’-C-!-
methylguanosine (Scheme 5.6). With 5.5 being ca. 2-fold less active than 4.10. 
 
 
Scheme 5.6. Comparison of EC50 of 6OEt2’CMeG, 2’CMeG and 6OMe2’CMeG. 
 
The most probable explanation for that difference is fact that both 5.4 and 5.5 require 
additional hydrolytic step before being converted to the corresponding 2’-C-!-
methylguanosine 5’-triphosphate. Lower EC50 value exhibited by the 6-O-ethyl is in 
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accordance with adenosine/adenylate deaminase substrate specificity, which was 
discussed in the section 5.2.3 of this Chapter. 
All three nucleoside analogues were found to be non-toxic in the cell based assay. 
Comparing compounds on the ProTide level it can be noticed that the 
introduction of the 6-methoxy moiety provided 2-5-fold improvement in the potency 
comparing to the corresponding 2’CMeG ProTides (Table 5.7). The analogous 6-
ethoxy phosphoramidates were found to be active against HCV replicon with sub-
micromolar activity, comparable to the 6-methoxy analogues (Table 5.7).  
 
 
Table 5.7.  Comparison betweeanti-HCV activity of analogous ProTides bearing different C-
6 substitutions. 
 
These results confirm the 6-O-alkylation principle of concept. It is suggested 
that the improved lipophilicity of the base unit and application of the ProTide 
technology, can increase both: cellular uptake and metabolic conversion to the active 
2’CMeG 5’-triphosphate, resulting in enhanced anti-HCV inhibitory activity. 
 
5.5.7 Effect of 6-O-alkylation on membrane permeation. 
 
 Effect of increased lipophilicity on cellular uptake was investigated in Caco-2 
studies. The most potent phosphoramidate in the 2-amino-6-methoxy-9-(2’-C-methyl-
!-D-ribofuranosyl) purine family 2.15 was evaluated alongside with 2’-C-!-
methylguanosine analogue 4.13f (Table 5.8).  
Caco-2 permeation studies were performed by Dr M. Gumbleton and Dr M. Smith at 
Cardiff University.  
Permeation was measured as % transport in 80 minutes across Caco-2 cells grown for 
27 days (resistance 600 ohms/cm
2
), measured apical to basal. 




Table 5.8.  Anti-HCV activity, cytotoxicity, calculated lipophilicity and observed Caco-2 
permeation for 4.13f and 2.15. 
 
 From the Caco-2 studies it is clear, that introduction of 6-O-methyl 
modification increased calculated lipophilicity by ca. 6-fold (Table 5.8) comparing to 
the corresponding 2’-C-!-methylguanosine derivative 4.13f. This translates into "5-
fold improvement in membrane transport as measured by Caco-2 permeation. Perhaps 
as a consequence 5-fold improvement in antiviral activity against HCV replicon 1b 
for 2.15 was observed.  
 These data further support the notion that increase of lipophilicity of 
nucleoside analogues and implementation of ProTide technology can enhance cellular 
uptake and result in improved potency. 
 
5.6 Intracellular levels of 2’-C-methylguanosine triphosphate – in vitro studies. 
 
5.6.1 Intracellular levels of 2’-C-!-methylguanosine triphosphate in replicon 1b 
cells – in vitro studies.  
 
 In order to determine whether 6OMe2’CMeG ProTides can be converted 
intracellularly to the 2’-C-methylguanosine TP, replicon 1b cells were incubated in 
the presence of 2.15 at concentrations required to produce 50%, 90% and 2x 90% 
inhibition of viral replication (EC50 = 0.01 µM, EC90 = 0.04 µM and 2x EC90 = 0.08 
µM, respectively). After 6 h of exposure to 2.15, cells were harvested and 
intracellular levels of 2’-C-methylguanosine triphosphate were measured (Table 5.9). 
 




All values are means ± standard deviation from six determinations. 
Table 5.9. Intracellular levels of 2’CMeGTP in replicon cells resulted from the incubation 
with 2.15. 
 
At 0.01 µM 2.15, the concentration of 2’CMeGTP produced in replicon cells was 
0.84 ± 0.36 pmol/1 x 10
6
 cells, what considering the liver cellularity would 
correspond to the 84 pmol/g of liver tissue. Incubation of replicon cells with 0.04 µM 
concentration of 2.15 (1x EC90), resulted in formation of 2.43 ± 0.42 pmol/1 x 10
6
 
cells of intracellular 2’CMeGTP.  
This data would correspond to the 243 pmol/g tissue of 2’-C-methylguanosine 5’-
triphosphate. This amount would be expected to eradicate 90% of viral load in the 
liver tissue.  
                                                              
5.6.2 Intracellular levels of 2’-C-!-methylguanosine triphosphate in human 
hepatocytes – in vitro studies.  
 
Further investigation of triphosphate production was carried out in primary 
human hepatocytes. Studies were performed and evaluated by Inhibitex Inc.  
 ProTides were incubated in primary human hepatocytes at an arbitrary 
concentration of 2 µM. Triphosphate levels were measured over a period of 24 h at 2, 
6, 12 and 24 h time points. Additionally levels of 2’CMeGTP resulting from the 
incubation of 2’-C-methylguanosine 4.10 and 6-O-methyl-2’-C-methylguanosine 5.4 
during 12 h and 24 h were also measured.  
Several structurally different ProTides were chosen for the study, including L-
alanine (2.15, 5.12c, 5.12h) and L-valine (5.12m) derivatives and the corresponding 
results are shown in Figure 5.16. 




Figure 5.16. 24h time course of 2’CMeGTP production in primary human hepatocytes of 
selected ProTides 5.12a, 5.12d, 5.12i, 5.12n and parent nucleosides 4.10 and 5.4. 
 
 Incubation of all phosphoramidates resulted in formation of high amounts of 
triphosphate within 6 h of incubation. In comparison incubation of both nucleoside 
analogues 4.10 and 5.4 resulted in rather poor triphosphate levels. Looking at L-
alanine and L-valine analogues, it can be clearly seen that the latter produce 
significantly less 2’CMeG triphosphate. These data correlate with the ease of 
activation observed for the appropriate L-alanine and L-valine phosphoramidates and 
their EC50 values. The highest levels of 2’-C-!-methylguanosine 5’-triphosphate were 
obtained from the incubation of 2.15, followed by 5.12c and 5.12h.  
 Compound 2.15 was chosen for prolonged (48 h) incubation studies (Figure 
5.17). The data show that L-alanine-2,2-dimethypropyl phosphoramidate can produce 
a substantial amount of 2’-C-methylguanosine triphosphate comparing with the 
nucleoside analogue 4.10. The maximum concentration (Cmax) of TP formed during 
the incubation of 2.15 was ca. 83 pmol/10
6
 cells (twice as much as obtained from the 
corresponding 2’CMeG ProTide 4.13f) and has formed within first 8 h, and then I 
slowly decays.  
On the other hand 2’CMeG was found to slowly build up triphosphate levels, with 
significantly lower and delayed Cmax of around 20 pmol/10
6








EC90: Defined as the amount of intra cellular triphosphate necessary to achieve 90% inhibition in the 
HCV replicon assay. 
Figure 5.17. Levels of 2’CMeGTP produced from ProTide 2.15 and nucleoside 4.10 in 
primary human hepatocytes system over 48h incubation period.  
 
Levels of 5’-triphosphate resulted from the incubation of 2.15 in primary human 
hepatocytes were more than 30-times higher than the concentration required to 
eradicate 90% of the viral load, indicating undeniable potential of 2.15 as an anti-
HCV agents.  
 Based on the exceptional anti-HCV activity of 2.15, improved permeability 
and ability to produce substantial levels of 2’-C-methylguanosine-5’-triphosphate, the 
compound was chosen for the further in vitro and in vivo studies supporting its 
selection and subsequent progression as a clinical candidate. Data regarding 





 In conclusion, a series of novel C6-modified 2’-C-methylguanosine analogues 
has been synthesised. The rational behind the design was to introduce modification 
that could be later on hydrolysed and therefore act as a pro-moiety. It was found that 
at the nucleoside level, adenosine deaminase was able to ‘deaminate’ most of the 
synthesised nucleosides. ADA inhibition studies confirmed absolute need for these 
compounds to be hydrolysed in order to act as inhibitors of viral replication. All 
synthesised nucleoside analogues exhibited improved calculated lipophilicity, 
however their antiviral activities were lower than that corresponding to the 2’-C-
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methylguanosine. To enhance antiviral activity, ProTide technology was applied to all 
synthesised nucleoside analogues. In almost every case, the newly synthesised 
phosphoramidates were more active than the parent nucleoside, often by >30-fold and 
in many cases by 300 to 800-fold. Structure activity relationship was extensively 
studied, including modification in ester, aryl and amino acid moiety. A combination 
of different esters and amino acids resulted in very potent (nM) compounds, suitable 
for further preclinical development. Comparative Caco-2 studies between C6-
modified ProTide and their corresponding 2’-C-methyguanosine analogue, revealed 
that the C6-modified compound was able to cross cell membrane more efficiently 
(enhanced cellular uptake) and as a consequence improved anti-HCV activity was 
seen. Ability of the synthesised ProTides to produce substantial levels of 2’-C-
methylguanosine triphosphate in vitro confirmed their undisputed potential. All 
collected data suggest that ProTides of 6-O-methyl-2’-C-methylguanosine represent a 
very interesting class of compounds for the treatment of HCV infections, with !-
naphthyl-L-alanine-2,2-dimethypropyl ProTide showing the biggest promise. This 
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Identification of INX-189: from bench to the clinical trials. 
 
6.1 Characterisation of INX-08189. 
 
During our ongoing effort to identify new, potent inhibitors of HCV replication, we 
discovered !-naphthyl-L-alanine-2,2-dimethypropyl 6-O-methyl-2’-C-"-methylguanosine 
phosphoramidate 2.15. This compound exhibited extraordinary anti-HCV activity along with 
other desirable properties such as cell permeability and the ability to produce high levels of 
2’-C-"-methylguanosine 5’-triphosphate in primary human hepatocytes. Based on all 
available data, it was decided that compound 2.15 – INX-08189 (INX-189, BMS-094), 
would be advanced in to further preclinical development, supporting its selection as a clinical 
candidate. Much of the work was done by our collaborators, as acknowledged below. 
 
6.2 Biological evaluation and carboxypeptidase Y studies of separated isomers of INX-
189. 
 
Most of the phosphoramidate ProTides are represented by a mixture of 
diastereoisomers at the phosphorus centre. PSI-7977 as already described in Chapter 2, is a 
chirally pure (Sp) isomer of "-D-2’-deoxy-2’-fluoro-2’-C-methyluridine phosphoramidate.  
The reason why only one of the isomers was advanced into clinical trials was significant 
difference in potency between two separated isomers ~100-fold (Table 6.1).1    
 
 
EC90: 90% effective concentration or compound concentration required to inhibit HCV replication by 90%; 
CC90: 90% cytotoxic concentration. 
Table 6.1. Anti-HCV activity and cytotoxicity of PSI7851, PSI7977 and PSI7976 phosphoramidates.1 
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Given the considerable interest in INX-189 it was decided to separate the two 
diastereoisomers. Isomer separation was performed by Chiral Technologies Inc. The absolute 
configuration of each of the two diastereoisomers was determined by vibrational circular 
dichroism (VCD) by BioTools Inc., and later on confirmed by the crystal structure. 
Pure isomers were tested against HCV in replicon assay by Inhibitex Inc. Interestingly the 
two separated isomers shown only 2-fold difference in antiviral potency (Table 6.2).  
 
 
Table 6.2. Data on separated isomers of 5.12a- INX189. 
 
It was hypothesised that this comparable potency may arise from the similar rate of activation 
of both isomers. To investigate the initial cleavage of amino acid ester and subsequent 
liberation of aminoacyl intermediate, carboxypeptidase Y assay was performed (Figure 6.1 
and 6.2) and related data are presented in Table 6.2.  
 
Figure 6.1. Carboxypeptidase Y mediated hydrolysis of INX-189 Sp, followed by 31P NMR. 
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Figure 6.2. Carboxypeptidase Y mediated hydrolysis of INX-189 Rp, followed by 31P NMR. 
 
Data reported in the Figure 6.1 and 6.2 represent 31P MNR spectra recorded every 7 
minutes over 5 hours incubation period with carboxypeptidase Y in acetone-d4 and Trizma 
buffer (pH 7.6). In the case of INX-189 Sp isomer (Figure 6.1), after addition of the enzyme, 
the parent phosphoramidate (!P = 3.76 ppm) is cleaved to the free amino acid carboxylate (!P 
= 4.92 ppm). The final product of the activation is represented by the single peak at 6.95ppm 
and corresponds to the aminoacyl phosphate. The aminoacyl intermediate started to form 
within first 10 min and full conversion of the parent ProTide was achieved within 3 h. The 
half-life for the separated Sp isomer was estimated as ca. 17 min. Looking at carboxypetidase 
Y assay of INX-189 Rp isomer (!P = 4.27 ppm), it can be clearly noticed that the initial 
hydrolysis of the ester moiety proceeds at a slightly slower rate comparing to the INX-189 Sp 
analogue. Interestingly, the free amino acid carboxylate intermediated (!P = 4.82 ppm) which 
has formed, has 31P shift more upfield than the corresponding Sp analogue. Final aminoacyl 
species (!P = 6.95 ppm), started to form within the first 17 min and full conversion of the 
INX-189 Rp derivative was accomplished within ca. 4.5 h. The estimated half-life of the Rp 
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isomer was 20 min. These findings are consistent with the replicon data, showing that the Sp 
isomer, which is processed somewhat faster, is also found to be 2-fold more active. 
Taking in consideration all available data, it was decided not to separate INX-189 to the 
single isomers, and use it for the further evaluation as a diastereomeric mixture.  
 
6.3 Activity of INX-189 against wild type and resistant mutant HCV replicons. 
 
6.3.1 Anti-HCV activity of INX-189 against genotype 1a, 1b and 2a replicon cells. 
 
 Further in vitro evaluation was carried out in comparative replicon assays (Inhibitex 
Inc.), using replicon genotypes 1a, 1b and 2a. INX-189 was found to be a very potent 
inhibitor of all tested HCV genotypes (Table 6.3). 
 
 
Table 6.3. INX-189 potency in wild type replicons. 
 
During 72 h of exposure, the EC50 concentration values for genotype 1a were ranged from 
0.008-0.016 µM (mean 0.012 µM), for genotype 1b: 0.004-0.016 µM (mean 0.010µM) and 
for genotype 2a: 0.0008-0.0010 µM (mean 0.0009 µM). For all tested genotypes INX-189 
maintain its potency in the low nanomolar range. 
To fully define the potency of INX-189, multiple HCV replicon 1b assays were 
performed. The compound was tested in 16-replicates and results are shown in Figure 6.3. 
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Figure 6.3. Potency of INX-189 in the HCV genotype 1b replicon assay. Data represent results 
obtained from 16 replicates. 
 
As shown in Figure 6.3, EC50 and EC90 values were ranging from 0.003-0.024 µM 
and 0.019-0.095 µM, respectively. These data revealed that INX-189 is one of the most 
potent nucleoside based inhibitors of HCV polymerase reported up to date. The summary of 
the replicon activities of INX-189 competitors is reported in Table 6.4. 
 
 
EC90: 90% effective concentration or compound concentration required to inhibit HCV replication by 90%; 
Table 6.4. Summary of the replicon 1b activities of INX-189 competitors.2 
 
6.3.2 Rebound and clearance studies of INX-189. 
 
 In the next step, INX-189 was evaluated y Inhibitex Inc. in a long-term treatment of 
HCV genotype 1b replicon cells. Cells were incubated in the presence of increasing 
concentrations of INX-189 (0- control, 5, 10, 20, 40 and 80 nM) for 14 days. At specified 
time points (5, 8, 10, 12 and 14-days) cells were harvested and replication activity was 
measured as a HCV viral load reduction based on Renilla luciferase gene expression. 
Corresponding data are reported in the Figure 6.4. 
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RLU –Relative luminescence unit. 
Figure 6.4. In vitro clearance of wild-type HCV replicon 1b with increasing concentrations of INX-
189. 
 
As reported in Figure 6.4, treatment of the replicon cells with INX-189 resulted in 
decrease of viral load over time comparing with the control data. When cells were incubated 
with concentrations of INX-189 as low as 5 nM ca. 1 log10 reduction of viral load was 
observed. Incubation with 10 nM of compound, gave more than 2 log10 decrease in HCV 
replication activity at day 14. Culturing in the presence of 20 nM solution of INX-189 
resulted in >5 log10 decline in viral load at day 12. When cells were incubated in the presence 
of 40 nM concentration of INX-189, which corresponds to the EC90- concentration required 
to eradicate 90% of infected cells, HCV replication activity was reduced nearly to the 
baseline. Not much difference was observed when concentration of INX-189 was increased 
to 80 nM (2x EC90) comparing to the 40 nM data.  
In general inhibition of HCV replication was found to be dose dependent up to 40 nM. 
 Additionally at days 5, 10 and 14 treated cells were harvested and subcultured without 
INX-189 but in the presence of G418- specific antibiotic used for the selection of neomycin 
resistant colonies. Any cells that were remaining in the treated cultures and were able to 
express replicon genome would confer resistance to the G418 treatment, as the replicon 
genome contains neomycin resistance gene (Chapter 4). As these secondary cultures grew, 
individual flasks were fixed and stained with crystal violet (Figure 6.5). For the colonies 
where there was no visible growth, flasks were stained after 5-weeks. 
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Figure 6.5. In vitro clearance of wild-type HCV replicon 1b with increasing concentrations of INX-
189 under G418 selection. 
 
As can be seen in Figure 6.5, after 5 days of treatment all treated colonies retain their 
replicating ability regardless the concentrations, although the replication fitness diminished 
with increased concentration of INX-189. After 10 days of culturing, complete eradication of 
replicon expressing cells was achieved with 80 nM (2x EC90) and 40 nM (1x EC90) 
concentrations. During 14-days treatment, complete elimination of replicon expressing cells 
was attained at concentration as low as 20 nM. The ability of INX-189 to clear the replicon 
and prevent the cells from recovering their replication ability at such a low concentration 
(~2x EC50) is striking. In contrast IDX184 (2.14) another 2’-C-methylguanosine 
monophosphate prodrug required a concentration of !2.5 µM to achieve complete clearance 
of replicon expressing cells.3 
 
6.3.3 Activity of INX-189 against resistant mutant strains.  
 
 Emergence of resistance has become a concern for antiviral compounds because it 
may lead to viral breakthrough and treatment failure. In order to evaluate the ability of INX-
189 to select for resistance, selection studies were performed using genotypes 1b and 1a. All 
studies were performed at Inhibitex Inc. 
 Replicon cells were cultured in the presence of increasing concentrations of INX-189 
up to eight times EC50 (80 nM) in the 1b replicon and up to 40 nM (4x EC50) in the 1a 
replicon. All colonies were incubated in the presence of G418 antibiotic. Emergence of 
resistance was monitored at various time points. The establishment of stable INX-189 escape 
mutants required 6 to 9-weeks.  
During selection studies, resistant colonies were isolated and the nucleotide sequence of the 
NS5B genes were determined. Two consistent NS5B mutations were found. In the first 
Karolina Made!a                                                                                                       Chapter Six 
 144
mutation serine 282 codon was replaced by threonine (S282T). This particular S282T 
mutation has been previously identified as a resistant mutant for 2’-C-methylguanosine TP.4 
A second change was alteration of the amino acid in position 585 from isoleucine to 
threonine (I585T). Selection studies carried out in clone 1a resulted in one single mutation in 
position 540; alanine codon was replaced by threonine (A540T). To determine whether these 
amino acid alterations could be sufficient to confer resistance to INX-189 and if they can 
have effect on replication fitness, replicon and transient assays were performed. Additionally 
activity of INX-189 against a replicon carrying resistance to 4’-azidocytidine 2.4 (S96T and 
N142T) was evaluated alongside. All data are reported in Table 6.5. 
 
 
Table 6.5. INX-189 Potency against wild type and transient replicons expressing mutant NS5B. 
 
 Results of the fitness analysis showed that S282T replicon was the most unfit replicon 
(4% of wild-type) followed by the replicon carrying double mutation S282T/I585T (8%), 
comparing to the wild-type. What is striking is that the I585T mutation increased the 
replication efficiency comparing to the wild-type replicon, and most probably this mutation is 
responsible for improved replication fitness of S282T/I585T in comparison with S282T 
replicon. The potency of INX-189 across all mutant strains was retained, with the only 
exception of mutants carrying S282T alteration. In these cases the EC50 values were reduced 
approximately by 10-fold. Regardless of loss of activity by ca. 10-fold, INX-189 could still 
efficiently inhibit HCV replication in S282T mutant replicons with an EC90 values of 0.34 ± 
0.17 µM (Figure 6.6).  








6.4 Intracellular levels of 2’-C-!-methylguanosine triphosphate – in vivo studies.  
 
 Initial studies carried out in replicon 1b cells and primary human hepatocytes revealed 
excellent ability of INX-189 to produce high levels of intracellular 2’CMeG 5’-triphosphate. 
Subsequently, the ability of INX-189 to deliver monophosphate inside the liver cells and 
subsequent formation of 2’CMeGTP after oral administration was investigated in different 
animal models. All studies were performed at Inhibitex Inc.  
 
6.4.1 Intracellular levels of 2’-C-!-methylguanosine triphosphate in rat model.  
 
 INX-189 was evaluated in rat model (Sprangue-Dawley rats) to investigate 
metabolism and pharmacokinetics after oral administration. The compound was formulated in 
95% Capmul MCM and 5% Tween 80, and administrated as oral gavage to male Sprangue-
Dawley rats. 
Rats were orally treated with an ascending dose of INX-189, starting from 3 mg/kg up to 50 
mg/kg of body weight, once daily. After 24 h of treatment, liver samples were harvested and 
levels of 2’-C-methylguanosine TP were analysed using LC-MS/MS tandem spectroscopy 
(Figure 6.7). 
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EC90: 90% effective concentration or compound concentration required to inhibit HCV replication by 90%; 
Figure 6.7. Concentrations of 2’CMeGTP in rat liver following single oral dose of INX-189. 
 
  As reported in Figure 6.7, 24 h post dose, at all tested concentrations, levels of 2’-C-
methylguanosine triphosphate in the rat liver exceeded the EC90 values. It can be seen that 
with the dose as low as 10 mg/kg (97 mg HED) INX-189 was able to produce ca. 2200 pmol 
of intracellular triphosphate per gram of liver tissue. 
During prolonged (7 days) studies, it was observed that liver concentrations of 2’CMeG 5’-
triphosphate exceeded the EC90 soon after dosing, and remained at or above this level for 72 
h and decayed slowly after that time. 
 
6.4.2 Intracellular levels of 2’-C-!-methylguanosine triphosphate in cynomolgus 
monkey model.  
 
 In order to investigate the ability of INX-189, to generate sufficient levels of 2’-C-
methylguanosine triphosphate in the liver of cynomolgus monkey, four animals were orally 
dosed with INX-189 at 25 mg/kg (equivalent of 50 mg/kg in rats). The compound was 
formulated in 5% DMA, 20% Solutol HS, 15-20% PEG 400, 55-60% 50mM sodium acetate, 
pH 4.0, and was administrated as a single oral gavage dose.  
All non-human primate studies were conducted at MPI Research Inc. 
Liver biopsy samples (four to five samples per animal) were collected at 3 h and 8 h post-
dose. Blood/plasma samples were collected from the portal and femoral veins (0.5, 1, 2, 3, 4, 
8, 12 and 24 h post administration) to determined levels of INX-189 being absorbed from the 
gastrointestinal tract and to measure the systemic exposure to INX-189 and 2’CMeG 
nucleoside (Figure 6.8). 




EC90: Defined as the amount of intra cellular triphosphate necessary to achieve 90% inhibition in the HCV 
replicon assay. 
Figure 6.8. Oral pharmacokinetics in nonhuman primates following single oral dose of INX-189. 
 
 According to the data shown in Figure 6.8, the concentration of intact INX-189 was 
measured in portal vein plasma shortly after oral administration (0.5 h). The highest 
concentration of INX-189 was achieved within 1 h and remained detectable for a short period 
of time, approximately 6 - 8 h. INX-189 was not detected in systemic circulation (femoral 
vein samples) at any time point. These data clearly suggest that at this concentration of 
compound (25 mg/kg), INX-189 was efficiently extracted by the liver.  
As reported in Figure 6.8, the mean concentration of the 2’-C-methylguanosine triphosphate, 
at 3 h post administration, was 525 ± 233 pmol/g liver (282 ± 177 ng/g) and increased over 
time (8 h) to 1160 ± 216 pmol/g liver (624 ± 165 ng/g). Comparing to the in vitro data (EC90 
= 234 pmol/g liver, 130.5 ng/g), the EC90 was exceeded by 2.2- and 4.95-fold at the 
respective time points. Since these data represent a triphosphate levels obtained after a single 
dose treatment, multiple dosing would be expected to significantly improve triphosphate liver 
exposure. 
As the measurement of the 2’CMeGTP as an analytical tool is highly limited, the levels of 2’-
C-methylguanosine nucleoside were measured in femoral vein. 2’CMeG is one of the 
metabolites of INX-189 and can be used as a surrogate analyte of 2’CMeGTP to monitor 
pharmacokinetics in HCV patients. The cynomolgus monkey data indicate a linear correlation 
between 2’CMeG AUC24 values and AUC24 of 2’CMeGTP. 
All presented data supported the progression of INX-189 into Phase 1a clinical development. 
Karolina Made!a                                                                                                       Chapter Six 
 148
6.5 Results of the Phase Ia clinical trials of INX-189.  
 
 The aim of the Phase Ia clinical trials was to evaluate the safety profile, tolerability 
and pharmacokinetics in healthy volunteers. Some 42 healthy subjects were enrolled for the 
trial and were evaluated in a single ascending dose, double blind, placebo controlled study. 
During the treatments recipients were orally administered with dose ranging from 3 mg to 
100 mg of INX-189.  
In general INX-189 was well-tolerated at all tested dose levels. During the trial, no drug-
related serious adverse events, frequency or type of adverse events were observed. The 
occurring side events were no different than the ones seen in the placebo group. The most 
common events, which had occurred in more than one subject, were headaches and nasal 
congestions.  
Pharmacokinetic data support once a day, oral dosing. 
Based on all available data, INX-189 was further progressed into Phase Ib clinical 
development. 
 
6.6 Results of the Phase Ib clinical trials of INX-189.  
 
 The Phase Ib trail was carried out on HCV genotype 1 treatment-naïve patients, who 
where received an all-oral regimen of INX-189 and/or RBV against placebo-controlled 
group. 80 Patients were divided into 8 cohorts and randomized 8:2, to receive either INX-189 
in a dose ranging from 9 mg to 100 mg or placebo, once daily for 7-days (Figure 6.9a). One 
cohort was dosed 50 mg on day 1, followed by 9 mg of INX-189 or placebo on days 2-6. 
Additional two cohorts were treated with INX-189 (9 mg or 25 mg) in combination with 
RBV for 7 days (Figure 6.9b). All groups were monitored up to 14 days. 
Karolina Made!a                                                                                                       Chapter Six 
 149 
 
Figure 6.9. Median HCV RNA changes from baseline. a) During treatment with ascending dose of 
INX-189; b) INX-189 + RBV combination study. 
 
 All tested doses of INX-189 resulted in significant decrease of viral replication, based 
on the reduction of HCV RNA levels from baseline. As summarized in Figure 6.9, INX-189 
monotherapy at 100 mg QD for seven days, provided mean 2.54 log10 IU/mL decrease in 
viral RNA, while 200 mg QD produced a highly significant median 4.25 log10 IU/mL 
reduction in HCV viral load. In general INX-189 demonstrated dose dependent effects. 
When ribavirin (RBV) was added to the 25 mg of INX-189, the average drop in HCV RNA 
was ca. 0.5-log greater than monotherapy. This data indicate that INX-189, when dosed once 
daily at 9 mg or 25 mg in combination with ribavirin demonstrates dose-dependent, 
synergistic antiviral effect. 
Additional data from Phase Ib clinical trials revealed that INX-189 was generally well 
tolerated at all tested doses. There were no significant adverse events related to the drug. 
Reported adverse events were mild or moderate in severity, with headache being the most 
common one. In the 25 mg INX-189 + RBV group there was one case of grade 3 laboratory 
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abnormality (decrease in hemoglobin level). There were no discontinuations of treatment due 
to adverse events.  
Upon successful completion of Phase Ib clinical trials, INX-189 entered Phase II clinical 
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New ProTide approach: Cyclic phosphoramidate (oxazaphosporine) based prodrugs of  
6-O-methyl-2’-C-methylguanosine.  
 
7.1 Cyclic phosphoramidates – rational behind the design. 
 
 As already mentioned in previous Chapters, all nucleoside analogues require kinase 
dependent activation to their corresponding 5’-monophosphates in order to be active. 
Considering the fact that usually the first phosphorylation step is recognized as a rate 
limiting1, we decided to investigate new pro-nucleotide approach, in order to deliver 5’-
monophosphates intracellularly.  
 We decided to focus our attention on cyclic phosphoramidate prodrugs. It is known in 
the literature that oxazaphosporine based prodrugs (e.g. cyclophospamide, Scheme 7.1) can 
undergo metabolic activation by hepatic P450-dependent mixed-function oxidases to give the 




























Cyclophosphamide  4-OH Cyclophosphamide
 Phosphoramide mustard  Acrolein  
Figure 7.1. Metabolic activation of cyclophosphamide. 
 
As this strategy depends on cytochrome P450 (highly expressed in the liver) catalyzed 
cleavage, the introduction of oxazaphosphorine moiety as a 5’-monophosphate masking unit, 
could result in liver specific prodrugs with more potent activity, lower systemic exposure and 
consequently lower toxicity. 
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 In this Chapter, an effort to develop a series of oxazaphosphorine prodrugs of 6-O-













R = H or amino acid ester
 
Figure 7.2. General structure of cyclic phosphonamide prodrugs of 6-O-methyl-2’-C-methylgunosine. 
 
7.2 Synthesis of phosphorylating reagents. 
 
 In order to synthesise the family of oxazaphosphorine prodrugs of 6-O-methyl-2’-C-
methylguanosine, the appropriate phosphorylating agents had to be prepared. Our interest 
was focused on the 2-chloro-1,3,2-oxazaphosphinane 2-oxide 7.1 and amino acid derived 













(7.2a) R = CH3(7.2b) R= OCH2C(CH3)3(7.2c) R= OCH2Ph  
Figure 7.3. Chemical structures of phosphorylating agents 7.1 and 7.2a-c. 
 
7.2.1 Synthesis of 2-Chloro-1,3,2-oxazaphosphinane 2-oxide. 
 
 To prepare 7.1, phosphorus oxychloride in dry chloroform (CHCl3) was cooled down 
to -15 °C. A solution of 3-aminopropanol and Et3N in dry CHCl3 was added dropwise with 
stirring to the reaction mixture. Reaction was kept at -10 °C and additional portion of Et3N in 
CHCl3 was added. The reaction mixture was maintained at 0 °C for 18 h. After that time, 
solvents were removed under reduced pressure (at temperature not higher than 35 °C).3 The 
solid residue was extracted with dry acetone and evaporated to dryness. The crude mixture 
was purified on silica gel using ethyl acetate : hexane (1:1) as an eluent and pure product was 
obtained as a white solid in 84% yield (Scheme 7.1).  












Reagents and Conditions: i) Et3N, CHCl3, -15 °C to 0 °C, 18 h. 
Scheme 7.1. Synthesis of 2-chloro-1,3,2-oxazaphosphinane 2-oxide. 
 
7.2.2. Synthesis of amino acid derived cyclic phosphorochloridates. 
 
To synthesise the amino acid derived cyclic phosphonamides, firstly N-alkylation of 
the !-amino group of precursor amino acids was investigated.  
There are a number of different N-alkylation methods of !-amino acids reported in 
the literature, however none of them is general, and without problems. The most common 
method is the alkylation of sulfonamides (usually tosylates) of !-amino acids. Nevertheless 
this method was found to be problematic due to the difficulties in tosylate protecting group 
removal.4 Fukuyama and co-workers reported facile synthesis of mono N-alkylated !-amino 
acids using 2-nitrophenylsulphonamide derivatives.5 We decided to use this protocol in order 
to obtain a family of N-hydroxypropyl !-amino acid esters, which could be subsequently 
used for the synthesis of cyclic phosphorochloridates. 
For the synthesis, enantiomerically pure L-alanine amino acid was chosen. L-alanine 
methyl ester hydrochloride and L-alanine benzyl ester tosylate salt were commercially 
available; L-alanine 2,2-dimethylpropyl ester tosylate salt was prepared according to the 
procedure reported in Chapter 3. 
In the first instance, the amino acid esters salts were protected with a 2-
nitrobenzenesulfonyl group (Scheme 7.2). The appropriate amino acid ester was dissolved in 
dry dichloromethane and Et3N was added dropwise to the stirring solution. The reaction 
mixture was cooled down in an ice/H2O bath and 2-nitrosulfonylbenzyl chloride was added. 
After that, reaction mixture was allowed to warm to ambient temperature and the reaction 
was stirred overnight.5 The resulting solution was washed 3x with water, dried over 
anhydrous Na2SO4 and concentrated. The resultant N-(2-nitrophenylsulfonyl)-L-alanine esters 
7.3a’-c’ were obtained as yellowish oils and were used for the subsequent step without any 
purifications. Compounds were obtained in quantitative yields. 



























(7.3a') R = CH3(7.3b') R= CH2C(CH3)3(7.3c') R= CH2Ph
(7.3a'') R = CH3(7.3b'') R= CH2C(CH3)3(7.3c'') R= CH2Ph
(7.3a) R = CH3(7.3b) R= CH2C(CH3)3(7.3c) R= CH2Ph
X= Cl; R = CH3X= Ts; R= CH2C(CH3)3X= Ts; R= CH2Ph  
Reagents and Conditions: i) 2-nitrobenzenesulfonic chloride, Et3N, CH2Cl2, -5 °C to rt, overnight; ii) Cs2CO3, 
3-bromopropanol, DMF, 60 °C, overnight; iii) K2CO3, PhSH, ACN, rt, overnight. 
Scheme 7.2. Synthesis of N-alkylated amino acid esters 7.3a-c. 
 
Alkylation of 2-nitrophenylsulfonamides 7.3a’-c’ was performed in the presence of 
cesium carbonate in dry dimethylformamide (Scheme 7.2). The reaction mixture was heated 
to 60 °C and 3-bromopropanol was added dropwise with stirring.5,6 The resulting solution 
was heated overnight and after that time was diluted with water and extracted 3x with ethyl 
acetate. The combined organic phases were washed with 3M calcium chloride solution, water 
and brine. After that, the solution was dried over anhydrous Na2SO4 and solvent was 
evaporated. The crude mixture was purified on silica gel using light petroleum : ethyl acetate  
(8:2) as an eluent, to afford componds 7.3a”-c” in moderate yields (25-31%). These yields 
where somewhat lower than those reported for the alkylation of simple amines.5 It can be 
explained by the fact that the presence of the !-ester causes an extra electron withdrawing 
effect and as a consequence the anion of nitrophenylsulfonamide is less nucleophilic, and 
therefore reacts relatively slow with 3-bromopropanol. As the amounts of the N-alkylated 
intermediates were sufficient to progress with the synthesis, optimization of the reaction 
conditions was not investigated. 
The removal of the protecting 2-nitrophenylsulfonyl group was accomplished using 
thiophenol in dry acetonitrile.6 After reaction completion, the reaction mixture was 
concentrated in vacuum and the residue was taken up in diethyl ether. 1M Hydrochloric acid 
was added to the resulting mixture and stirred for 10 min. After that time, the organic layer 
was removed and washed with water. The combined aqueous layers were washed with 
diethyl ether, followed by basification with solid K2CO3. The product was extracted from the 
basic aqueous phase with ethyl acetate. Combined organic phases were dried over Na2SO4, 
evaporated and purified on silica gel, using CHCl3/MeOH (9:1) as an eluent to afford the 
Karolina Made!a                                                                                                   Chapter Seven 
! 157 
substituted free amino alcohols 7.3a-c (Scheme 7.2). Pure compounds were obtained as a 
yellowish oils, in reasonable yields (42-67%). 
Synthesised N-alkylated amino acid esters were used for the cyclisation reaction in 











(7.2a) R = CH3(7.2b) R= CH2C(CH3)3(7.2c) R= CH2Ph
i
 
Reagents and Conditions: i) POCl3, Et3N, CHCl3, -15 °C to 0 °C, 18 h. 
Scheme 7.3. Synthesis of amino acid derived cyclic phosphorochloridates7.2a-c. 
 
 After reaction completion, the solvent was removed under reduced pressure at 35 °C. 
The crude mixture was purified on silica gel using Hexane/AcOEt (7:3) as an eluent. All 
compounds were obtained as clear, colourless oils in good to excellent yields (Table 7.1). 
 
 
Table 7.1. Summary of synthesised cyclic phosphorochloridates 7.1 and 7.3a-c. 
 
 All synthesised compounds were obtained as roughly equimolar mixtures of 
diastereoisomers at phosphorus centre (based on the 31P NMR). In the case of 7.1 overlapping 
of the enantiotopic 31P NMR signals was presumably observed (Table 7.1). 
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7.3 Synthesis of oxazaphosphorine prodrugs of 6-O-methyl-2’-C-methylguanosine. 
 
 In order to synthesise the family of oxazaphosphorine prodrugs of 6-O-methyl-2’-C-
methylguanosine, appropriate coupling conditions had to be investigated. 
 In the first instance tBuMgCl-mediated coupling was considered. Application of the 
same procedure as used for the synthesis of a large family of 6-O-methyl-2’-C-
methylguanosine ProTides (described in Chapter 5), resulted in a complex mixture of 
products, which proved to be very difficult to purify.  
To avoid the formation of unwanted side products, different coupling procedures were 
investigated. The most successful one was a simple coupling reaction in the presence of 
pyridine as a sole solvent/reagent.3 Compounds 7.4a-d were synthesised according to the 
following procedure: To a mixture of 6-O-methyl-2’-C-methylguanosine and appropriate 
cyclic phosphorochloridate under argon atmosphere, dry pyridine was added and reaction 




























R = H or amino acid ester
 
Reagents and Conditions: i) Pyridine, rt, 20 h. 
Scheme 7.3. Synthesis cyclic phosphonamide prodrugs 7.4a-d. 
 
After that time, pyridine was removed under reduced pressure followed by co-evaporation 
with toluene and MeOH. In case of 7.4a, the residue was purified on silica gel using CHCl3 : 
EtOH (0 to 5% gradient) as an eluent. Use of ethanol provided better product separation than 
when more polar MeOH was used. For compounds 7.4b-c, chromatographic purification was 
performed using CHCl3/MeOH (9:1) as an eluent. 
All pure compounds were obtained as white solids in low yields 3-16% (Table 7.2). 
 
Karolina Made!a                                                                                                   Chapter Seven 
! 159 
 
Table 7.2. Summary of synthesised cyclic phosphonamide ProTides 7.4a-d. 
 
 Interestingly only 7.4a was isolated as roughly 1:1 mixture of phosphorus 
diastereoisomers (Table 7.2). After NMR and HPLC analysis of isolated prodrugs 7.4b-d, it 
was found that one of the isomers was greatly predominant comparing to the other one. In all 
cases, main/major isomer peak had more downfield NMR shift. It is clear that during the 
reaction strong stereoselective preference was observed. It has to be noted, that cyclic 
phosphorochloridates used for the coupling reactions were represented by circa equimolar 
mixtures of diastereoisomers (Table 7.1). 
These findings may be useful if stereoselective synthesis of phosphoramidates was of 
interest. 
 
7.4 Putative metabolic activation pathway. 
  
 The suggested mechanism of activation of the cyclic phosphonamide prodrug of 6-O-
methyl-2’-C-methylguanosine 7.4a involves oxidation of carbon adjacent to the nitrogen 
atom (Scheme 7.4). Subsequent hydrolysis of 7.5 afforded the second intermediate 7.6, which 
can undergo facile !-elimination to give intermediate 7.7 and acrolein. It was postulated that 
conversion of phosphoramidate 7.7 to the corresponding 5’-monophosphate 7.8 would occur 
by chemical or enzymatic hydrolysis (Scheme 7.4). Released monophosphate could be then 
deaminated by specific deaminases to give 2’-C-methylguanosine 5’-monophosphate, which 
could be further phosphorylated to the active triphosphate species.  































































d) enzymatic or chemical hydrolysis
(7.5) (7.6)
(7.7)(7.8)  
Scheme 7.4. Suggested mechanism of activation of oxazaphosphorine prodrug 7.4a. 
  
 In the case of the amino acid derived analogues 7.4b-d, a similar route would be 
expected. Based on the work of Lu et al.7 the activation process would start with the 
oxidation of the carbon adjacent to the amide. The following activation pathway would lead 
to the formation of 5’-monophosphate intermediate 7.8 (Scheme 7.5). However it is not clear, 
whether the ester moiety would be cleaved or not, at any stage of the activation process. It is 
possible that the phosphoramidase type enzyme, responsible for the P-N bond cleavage, 
could perform the deamination reaction on the amino acid ester, as long as the ester moiety 










































































Scheme 7.5. Suggested mechanism of activation of oxazaphosphorine prodrug 7.4b. 
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7.4.1 Human liver microsomes assay. 
 
 To probe the suggested mechanism of activation, compound 7.4a was incubated in the 
presence of human liver microsomes (purchased from Sigma).8 Incubation was carried out 
without the presence of NADPH co-factor. The incubation mixture (final volume 600 µL) 
contained: 90 µL of microsomal protein, 235 µL of Tris buffer (pH 7.5) and 7.4a (500 µM 
concentration in Tris buffer, 75 µL) and 200 µL of D2O.  
The reaction was followed by the 31P NMR at 37 °C, for 14 h. Spectra were recorded in 7 min 
intervals with blank spectra of compound 7.4a in the Tris buffer (without microsomes) 
recorded first. 
As can be seen in Figure 7.1, after addition of liver microsomes to the ProTide 7.4a (!P = 
7.08, 7.03 ppm) new species at !P = 2.24 ppm started to form within the first 10-24 min. This 
new species, based on the 31P NMR shift could correspond to the 6-O-methyl-2’-C-
methylguanosine monophosphate 7.8. 
 
 
Figure 7.1. Formation of 5’-monophosphate 7.8 from oxazaphosphorine prodrug 7.4a in liver 
microsomes, followed by 31P NMR. 
Karolina Made!a                                                                                                   Chapter Seven 
!162 
 The processing rate for the compound 7.4a was found to be very slow, with more than 
90% of parent compound remaining after 14 h of incubation. It might be that that the 
enzymes involved in the activation of cyclophosphamide were not fully active in this case or 
the six-membered cyclic phosphoramidate 7.4a was too stable and therefore the release of 
monophosphate was not efficient. Any other 31P NMR signals related to the metabolic 
intermediates 7.5-7.7 were not detected, suggesting that once the parent prodrug is oxidised 
subsequent steps leading to the monophosphate formation are very rapid. These findings can 
imply that the oxidation step is the rate-limiting step during the activation of 
oxazaphosphorine prodrugs. 
 To validate the results obtained from 7.4a, additional assays on compounds 7.4b-d 
should be performed. Furthermore, assays in the presence of NADPH as a co-factor need to 
be considered in order to fully understand the mechanism of activation. 
 
7.5 Biological evaluation of cyclic phosphoramidate prodrugs of 6-O-methyl-2’-C-
methylguanosine. 
 
 All novel oxazaphosphorine prodrugs of 6-O-methyl-2’-C-methylguanosine (7.4a-
7.4d) were evaluated by Inhibitex Inc., against hepatitis C virus in vitro using a replicon 
assay. Corresponding data are reported in Table 7.3. 
 
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 50%; 
CC50: 50% cytotoxic concentration. 
Table 7.3. Anti-HCV activity and calculated lipophilicity of oxazaphosphorine prodrugs 7.4a-d.  
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 As can be seen in Table 7.3, none of the synthesized oxazaphosphorine prodrugs of 6-
O-methyl-2’-C-methylguanosine exhibited anti-HCV activity. The lack of antiviral activity 
indicates that the 5’-monophosphate was not efficiently released from the tested 
oxazaphosphorine prodrugs 7.4a-d. The explanation might be the fact that the Huh7 cell line 
(cell line used for the replicon assay) expresses low levels of CYP enzymes comparing to the 
primary human hepatocytes.9 This feature limits the utility of Huh7 cells for drug metabolism 
studies per se. As the cytochrome P450-mediated oxidation of 1,3,2-oxazaphosphorine ring is 
essential for the activity of this class of compounds, decreased levels of cytochrome P450 
enzymes would result in deficiency of anti-HCV activity.  
It is known that some of the drugs including rifampicin can induce CYP enzymes expression. 
It might be of interest to test compounds 7.4a-d in replicon assay in the presence of 




 In summary, the synthesis and structure activity relationship of a novel class of 
oxazaphosphorine prodrugs of 6-O-methyl-2’-C-methylguanosine was reported. All novel 
compounds were investigated for their ability to inhibit HCV replication in vitro. None of the 
newly synthesised compound exhibited anti-HCV activity in replicon assay. As an 
explanation lack of specific enzymes responsible for the oxidation of the oxazaphosphorine 
ring when tested in the replicon assay was suggested. To fully validate the potential of this 
class of molecules, further testing of these compounds in more appropriate conditions 
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Phosphorodiamidates- phosphate prodrugs. 
 
8.1 Phosphorodiamidate prodrugs. 
 
As already mentioned in Chapter 2, diamidate prodrugs are a group of pronucleotides 
capable of entering the cell by passive cellular uptake.
1
 In the phosphorodiamidate core 
structure, the phosphate group is masked with two amines (including amino acids). 
Considering the structure of phosphorodiamidates two families can be distinguished: 
symmetrical diamidates where the phosphate group is masked with two identical amines and 
asymmetrical diamidates where two distinctive amines are attached to the phosphorus atom 
(Figure 8.1).   
Symmetrical phosphorodiamidates have two main advantages over aryl 
phosphoramidates. The first one relates to the phosphorus stereogenic centre. Since two 
identical masking groups are used to mask the phosphate, it is no longer chiral and issues 
associated with diasteroisomer formation during the synthesis do not exist.  
 
! 
Figure 8.1. General structure of phosphorodiamidate. R, R’=amine or amino acid. 
 
The second advantage relates to the toxicity of synthesised prodrugs. When amino acid esters 
are used as phosphate masking moieties, the by-products of the enzymatic activation consist 
of non-toxic amino acids (at released concentrations). 
The first reported family of nucleoside analogue phosphorodiamidates consisted of a 
series of 5’-phosphorodiamidates of FUdR. Different amines were used as masking units, and 
compounds were evaluated against murine leukaemia L5178Y cell line.
2 
A positive 
correlation between compound activity and the rate of hydrolysis of diamidates was found. 
Karolina Made!a                                                                                                   Chapter Eight 
 166
Phosphorodiamidate [FUdR-5’-P(NH2)2] was found to be the most active against L5178Y 
cell line and the least stable in the hydrolytic assay. The diamidate bearing two morpholine 





Figure 8.2. Structures of FUdR diamidates. Inhibition of L5178 cell growth in vitro and rate of 
hydrolysis to FdU-5’P.  
 
Although in vitro studies proved the concept of intracellular monophosphate delivery, 
this class of phosphorodiamidate prodrugs was not greatly developed. 
Although diamides have existed in the literature for almost 20 years, they have only 
recently emerged as an important class of prodrugs. McGuigan et al. reported application of 
the phosphorodiamidate approach to AZT and FdT.
1,3
 In the case of AZT 5’-diamidates, the 
amino acid derivatives were particularly active comparing to the primary and secondary 
amine derivatives. However, the potency of these compounds was lower than the parent 
nucleoside.
3
 Interestingly, clear correlation between the toxicity of masking units was 
observed. The amino acid derivatives were found to be non-toxic while secondary amine 
analogues possess marked toxicity.
3
 
The initial studies of the phosphorodiamidate technology applied to the PMEA 
analogue 9-[2-(phosphonomethoxy)ethoxy]adenine were unsuccessful. The prodrug was 
prepared as a glycine methyl ester and failed to afford any detectable blood levels of the 
active drug following oral administration to mice.
4
 Recently PMEA diamidates were found to 
exhibit inhibitory activity against orthopoxvirus replication in vitro. These results indicate 




We decided to apply a phoshorodiamidate approach to the 2-amino-6-methoxy-9-(2’-
C-methyl-!-D-ribofuranosyl) purine in order to explore its effect on anti-HCV activity. 
 
Karolina Made!a                                                                                                   Chapter Eight 
 167 
8.2 Synthesis of symmetrical amino acid phosphorodiamidates of 6-O-methyl-2’-C-!-
methylguanosine. 
 
 There are several reported synthetic pathways of phosphorodiamidate synthesis.
1
 In 
our study we decided to adapt the Yoshikawa
6 
procedure to obtain 5’-phosphorylated 
nucleoside analogue using unprotected nucleoside 6-O-methyl-2’-C-!-methylguanosine.  
In one pot reaction, free nucleoside analogue 5.4 (Scheme 8.1) was reacted in 
anhydrous conditions with POCl3 and Et3N in dry THF, to give 5’-phosphorylated 
intermediate 8.1 (Scheme 8.1). The disappearance of the POCl3 
31
P signal and formation of 
the new peak at ~8.00 ppm was followed by the 
31
P NMR. The phosphorylation step was 
found to be critical for the formation of phosphorodiamidates. It was found that the 
intermidiate 8.1 forms within the first 30 min of the reaction time. When reaction time was 
prolonged, degradation/hydrolysis of 8.1 was observed. Due to the relative instability of 8.1, 
the compound was not isolated. The amino acid ester was added to the reaction mixture, 
followed by the addition of dry dichloromethane and triethylamine. The progress of the 
reaction was monitored by the phosphorus NMR.  Appearance of the single peak at ~ 13-17 
ppm (depending on amino acid used for the synthesis (Table 8.1)) indicated formation of the 
product. The overnight reaction followed by the purification on silica gel resulted in a final 












































(5.4) (8.1) (8.2a-u)  
Reagents and Conditions: i) POCl3, Et3N, dry THF, -78 °C to rt, 30 min; ii) Appropriate amino acid ester, Et3N, 
DCM, -78 °C to rt, overnight. 
Scheme 8.1. Synthesis of symmetrical phosphorodiamidates of 6-O-methyl-2’-C-methylguanosine. 
 
In some cases additional extraction with 0.1 M HCl was required in order to remove 
excess of amino acid esters.  
As the structure activity relationship of symmetrical phosphorodiamidates was 
unknown, it was decided to vary amino acids and ester units (Table 8.1). 
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ClogP: calculated lipophilicity, values calculated using ChemOffice Ultra 11.0; *Yields calculated 
over two steps. ** Synthesised by M. Aljarah.7 
Table 8.1 Summary of symmetrical diamidates synthesised, ClogP values, 31P NMR shifts and 
synthetic yields. 
 
 Based on our experience with phosphoramidates of 6-O-methyl-2’-C-
methylguanosine, we decided to investigate L-alanine amino acid first. Different ester units 
including linear, branched, cyclic and aromatic were explored (Table 8.1, entries 8.2a-j). The 
compound 8.2e was prepared as a diamidate analogue of INX-189 in order to compare the 
efficiency of these two prodrug approaches. 
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Although the L-alanine amino acid proved to be strongly preferred in 
phosphoramidate series, it was decided to investigate other amino acids as well and evaluate 
their effect on antiviral potency of 6-O-methyl-2’-C-methylguanosine phosphorodiamidates. 
A series of L-valine (8.2k-m), L-isoleucine (8.2n-q) and L-methionine (8.2r-t) compounds 
was prepared. In order to facilitate comparison compounds were synthesised as 2,2-
dimethylpropyl, cyclohexyl and benzyl esters. Additionally an example of !-alanine 
phosphorodiamidate 8.2u was made with the aim of probing the activation mechanism.  
 The variation of different amino acids and ester moieties lead to the compounds with 
a ClogP values between -0.2 and 7.5 (Table 8.1). It was interesting to see, whether the same 
tendency like in the case of 6-O-methyl-2’-C-methylgusanosine aryloxyphosphoramidates 
would be observed. As described in Chapter 5, the most potent compounds posses ClogP 
values in a range between 2 and 4. Compounds with ClogP values below 2 and above 4 had 
lower potency. 
 
8.3 Biological evaluation of symmetrical diamidates of 6-O-methyl-2’-C-
methylguanosine. 
 
 All novel phosphorodiamidates were evaluated by Inhibitex Inc., for their potential as 
anti-HCV agents in in vitro replicon assay. Related data are reported in Table 8.2. 
 




AA: Amino acid, EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%; CC50: 50% cytotoxic concentration. 
Table 8.2. Summary of the anti-HCV activity of 6OMe2’CMeG phosphorodiamidates, INX-189 and 
parent nucleoside 5.4, and their calculated ClogP values. 
 
Parent nucleoside 5.4 and INX-189 were tested alongside. 
As can be seen in Table 8.2, most of the synthesised phosphorodiamidates were 
significantly more potent than the parent nucleoside 5.4, in low nanomolar range. The most 
active compound across the L-alanine phosphorodiamidate family was 8.2f (3,3-dimethyl-1-
butyl derivative, EC50 = 0.02 µM), followed by 8.2c (L-alanine-O-pentyl, EC50 = 0.03 µM), 
8.2e (L-alanine-O-2,2-dimethylpropyl, EC50 = 0.06 µM) and 8.2g (cyclohexyl analogue, EC50 
= 0.06 µM). These compounds showed 75- to 200-fold enhancement in the antiviral potency 
comparing to the parent nucleoside 5.4. Phosphorodiamidate 8.2f exhibit similar potency as 
INX-189, however 8.2f was ca. 7 times less cytotoxic than INX-189 in replicon assay (71 
µM vs. 7 µM). The diamidate analogue of INX-189, 8.2e was found to be 5-fold less active 
in cell based assay than its aryloxyphosphoramidate analogue but at the same time 
significantly less cycotoxic (CC50 >100 µM vs. 7 µM). Thus, the values of the therapeutic 
indexes for diamidates were in the range of a 3500. This profound lack of toxicity in anti-
HCV assay makes diamidates very interesting compounds for further development. 
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The structure activity relationship of L-alanine phosphorodiamidates revealed that  
n-alkyl ester derivatives where more potent with increasing chain length, thus n-pentyl 8.2c 
(EC50 = 0.03 µM)> n-butyl 8.2b (EC50 = 0.07 µM)> n-propyl 8.2a (EC50 = 0.3 µM). These 
data clearly correlate with calculated lipophilicity for compounds 8.2a-c (Figure 8.3), 
showing that the n-pentyl derivative, which was the most lipophilic, was also the most active.  
 
 
Figure 8.3. Potency (1/EC50) and calculated lipophilicity (ClogP) data plot of synthesised 
phosphoramidates 5.12a-j. 
 
Not much difference in anti-HCV activity between linear and ! or " branched esters 
was found. Hence !-branched 2,2-dimethylpropyl analogue 8.2e possesses similar activity as 
n-butyl 8.2b analogue (EC50 = 0.06 µM vs. 0.07 µM) and activity of "-branched  
3,3-dimethyl-1-butyl 8.2f compound was comparable to n-pentyl 8.2c (EC50 = 0.02 µM vs. 
0.03 µM). Similarly, like in the case of linear esters, longer branched esters possessed 
increased activity comparing to the shorter derivatives, which also correlates with ClogP 
values for these compounds. Sec-butyl-L-alanine phosphoramidate 8.2d was found to be ca. 
7-fold less active than 8.2f (EC50 = 0.15 µM vs. 0.02 µM). 
 In case of cyclic esters, the cyclohexyl compound 8.2g (EC50 = 0.06 µM) was as 
potent as 8.2b or 8.2e. Tetrahydropyranyl analogue 8.2h was found to be the least active 
across the whole synthesised family of phosphorodiamidates. This particular compound was 
found to be less active than the parent nucleoside 5.4 (EC50 = 13.3 µM vs. 4.6 µM, Table 
8.2). The poor activity of 8.2h can be explained by the low ClogP value, suggesting that 
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compound is not getting efficiently inside the cell and thus the intracellular release of the 5’-
monophosphate is greatly limited.  
 Surprisingly L-alanine benzyl ester derivative 8.2i (EC50 = 0.49 µM) was found to be 
less active than most of the n-alkyl ester analogues. This is in contrast with 
aryloxyphosphoramidate data reported in Chapters 4 and 5, where benzyl derivatives were 
amongst the most potent compounds. These findings cannot be explained by the lipophilicity 
of the compound, as it is similar to n-butyl analogue 8.2b (ClogP = 3.9 vs 3.7). The indanyl 
analogue 8.2j exhibited similar activity as 8.2i (EC50 = 0.58 µM vs. EC50 = 0.49 µM). 
 Structure activity relationships of 6-O-methyl-2’-C-methylguanosine diamidates 
bearing different amino acids are presented in Table 8.2, entries 8.2k-u, and Figure 8.4. More 
bulky amino acids were considered as more stable towards enzymatic degradation. All 
compounds in general were less active than L-alanine analogues. Across L-valine series, the 
most potent compound was bearing benzyl ester and was found to be ca. 4-times more potent 
than L-alanine analogue (EC50 = 0.12 µM vs. EC50 = 0.49 µM). These data are in contrast 
with phosphoramidate ProTide results, where L-alanine benzyl ester 4.13i was ca. 10-fold 
more potent than L-valine analogue 4.13m (EC50 = 0.06 µM vs. EC50 = 0.76 µM, 
respectively). Whereas cyclohexyl- and 2,2-dimethylpropyl-L-valine diamidates were 
significantly less active (Figure 8.4). 
 
 
Figure 8.4. Potency (1/EC50) data plot of various amino acid ester diamidates of 6OMe2’CMeG. 
 
 Other !-branched amino acid - L-isolueucine was found to be poorly active, with 
replicon EC50 values similar to the parent nucleoside 5.4. The only compound that exhibited 
submicromolar activity in this family was benzyl derivative 8.2q (EC50 = 0.4 µM), being  
10-fold more potent than the parent nucleoside 5.4. Benzyl analogue was also found to be the 
most active in the L-methionine series 8.2t, EC50 = 0.25 µM. 
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 The !-alanine analogue 8.2u and parent nucleoside 5.4 were found to be equipotent. 
These data clearly confirm that position of carboxyl group in relation to the amine is very 
important for activity. 
 From the SAR studies general conclusions can be made, namely that the small amino 
acids e.g. L-alanine are strongly preferred over longer or branched amino acids. For amino 
acids different than L-alanine, benzyl ester derivatives were found to be the most potent 
(Figure 8.4).  
 Considering the ClogP of synthesised compounds, some consistencies have been 
observed. Compounds that exhibit ClogP values below 3.4 and greater than 5.5, were found 
to be less active than compounds with the calculated lipophilicity in the range of 3.5-5.5 
(Figure 8.3). It is possible that compounds with the high logP values can be too lipophilic to 
cross the cellular membrane and can get trapped in the lipid bilayer, and as a consequence 
low levels of intracellular 5’-triphosphate are generated. This could explain lower antiviral 
potency for L-isoleucine compounds (8.2o-q, Figure 8.3). Solubility may also be an issue in 
biological assays. 
 In general, symmetrical diamidates tested in the replicon assay were found to be less 
toxic than analogous phosphoramidates of 6-O-methyl-2’-C-methylguanosine (refer to 
Chapter 5), with CC50 values greater than 100 µM. However some cellular toxicity for 
compounds bearing different amino acids than L-alanine was observed. For example 
cyclohexyl-L-isoleucine 8.2p and 2,2-dimethylpropyl-L-isoleucine 8.2o compounds were 
found to be toxic at 14 µM and 15 µM concentrations, respectively. Considering the anti-
HCV activity of these compounds, their respective selectivity indexes would be ca. 4 for 8.2p 
and 5 for 8.2o, and would make them one of the most cytotoxic across diamidate series.  
 
8.4 Enzymatic studies of symmetrical phosphorodiamidates of 6-O-methyl-2’-C-
methylguanosine. 
 
 To probe the mechanism of activation of symmetrical phosphorodiamidates of 6-O-
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8.4.1 Putative mechanism of activation of symmetrical diamidates.  
 
 The proposed mechanism of activation of phosphorodiamidate prodrugs would 
involve ester cleavage of one of the masking units (IIa, IIb Scheme 8.2) followed by the 
intramolecular attack of the amino acid carboxylate anion onto the phosphorus with 
subsequent cyclisation (IVa, IVb) and elimination of the second amino acid (V, Scheme 8.2). 
It is not clear if both of the esters are hydrolysed at the same time (III) or only one of them.  
Hydrolysis of the unstable five-membered ring would result in formation of the final 
aminoacyl intermediate (V). The final conversion and release of the monophosphate is 
thought to relay on Hint enzyme. The 5’-monophosphate (VI) could then undergo further 
phosphorylation to the active 5’-triphosphate form. 
 
Scheme 8.2. Putative mechanism of activation of 6OMe2’CMeG phosphorodiamidates. 
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8.4.2 Carboxypeptidase Y studies of symmetrical diamidates.  
  
As already mentioned, the initial step of the activation of diamidates involves an 
enzyme-mediated hydrolysis of the amino acid ester moiety. Thus, to probe the activation 
pathway, an enzymatic assays in the presence of carboxypeptidase Y, an enzyme capable of 
in vitro ester cleavage, were performed.  
 The first assay was conducted on L-alanine benzyl ester derivative 8.2i, according to 
the procedure described in Chapter 4, Section 4.6.! 
In the blank 
31
P spectrum, a single peak at !P =14.08 ppm corresponds to the parent 
phosphorodiamidate. After addition of the enzyme, rapid hydrolysis of the ester units was 
observed, with complete disappearance of the starting material within 30 min (Figure 8.5).  
 
Figure 8.5. Carboxypeptidase Y mediated hydrolysis of 8.2i, followed by 31P NMR, with proposed 
structures. 
 
 The chemical structures depicted in Figure 8.5, represent one of the possible routes 
leading to the formation of aminoacyl derivatives 5.21. The intermediate with 
31
P chemical 
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shift of 14.46 ppm, could correspond to the structure where only one of the ester moieties is 
hydrolysed 8.3, while signal at !P =14.78 ppm to the compound with both ester moieties 
being cleaved 8.4 (Figure 8.5). The compound represented by the structure 8.3 is chiral and 
therefore signals of pro-Rp and pro-Sp isomer would have to overlap to be represented by  
a single peak in the 
31
P NMR. The other possibility is that each of the peaks: !P =14.46 ppm 
and !P =14.78 ppm represents a distinctive structure, where one of the esters is cleaved (8.3a 
and 8.3b, respectively Figure 8.6). In this case the cleavage of both esters does not occur. 
Current data do not discriminate between these possibilities. 
 
 
Figure 8.6. Carboxypeptidase Y mediated hydrolysis of 8.2i, followed by 31P NMR, with proposed 
structures. 
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 The metabolite peak at !P =14.46 ppm builds up for approximately 35 min and then 
diminishes. The metabolite at !P =14.78 ppm starts to form within 6 min after 
carboxypetidase Y addition and remains present for ca. 2 h. 
 In both cases, the cyclisation of 8.3, 8.3a and 8.3b with subsequent elimination of one 
of the amino acids results in the formation of 5.21 (Figure 8.5 and 8.6). The intermediate 5.21 
starts to form within 13 min of incubation. The presence of the peak at 6.94 ppm is consistent 
with the chemical shift of the identical amino acyl intermediate released during enzymatic 
activation of aryloxyphosphoramidates of 6-O-methyl-2’-C-methylguanosine (Chapter 5, 
Section 5.5.2). The half-life of 8.2i was found to be less than 13 min. 
 In the case of the 2,2-dimethylpropyl-L-alanine diamidate 8.2e, subtle differences in 
the processing pattern can be seen (Figure 8.7) 
 
Figure 8.7. Carboxypeptidase Y mediated hydrolysis of 8.2e, followed by 31P NMR, with proposed 
structures. 
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After 10 min of incubation of parent diamidate (!P =14.24 ppm) in the presence of 
carboxypeptidase Y, more downfield peak at !P =14.91 ppm has been observed. This 
particular peak can correspond to the structure of metabolite 8.4 or 8.5. The peak at  
14.91 ppm builds up for approximately 40 min and after that time diminishes with 
simultaneous formation of 5.21 (!P =6.95 ppm). The half-life of 8.2e was found to be ca.  
50 min and within 2 hours the parent diamidate prodrug has been processed to the free diacid 
intermediate. 
It has to be noted that in the case of aryloxyphosphoramidates the carboxypeptidase Y 
assays clearly correlated with replicon EC50 values. However in the case of diamidates 8.2e 
and 8.2i, where 8.2e is ca. 10-fold more potent than 8.2i, the overall rate of carboxypeptidase 
processing for both prodrugs was found to be very similar and therefore do not correlate 
directly with replicon potency. 
 
8.4.3 Huh7 cell lysate studies of symmetrical diamidates.  
 
 In order to investigate the process of 5’-monophosphate release, compound 8.2b was 
incubated in the presence of Huh7 cell lysate.  
 The compound 8.2b was dissolved in D2O and Trizma buffer (pH 7.6) and blank 
31
P 
spectrum was recorded at 37 °C. Then Huh7 cell lysate was added and spectra were recorded 
in 1 h intervals for 14 h at 37 °C. Corresponding data are reported in Figure 8.8. 
As can be seen in Figure 8.8, after 1 h of incubation, parent diamidate 8.2b (!P = 
14.67 ppm) is metabolized to the intermediate represented by the small downfield peak !P = 
15.11 ppm. This particular species can correspond to one of the structures, discussed in the 
earlier paragraph, where ester(s) unit is/are hydrolysed. At the same time, formation of the 
new peak at 7.11 ppm has been observed. This intermediate corresponds to the structure of 
aminoacyl 5.21. After 2 h the 
31
P signal of 5.21 is no longer observed, while a new peak 
emerged at 1.21 ppm. Based on the 
31
P shift the new peak represents 6-O-methyl-2’-C-
methylguanosine 5’-monophosphate 7.8. This was determined by using synthesised 
compound 7.8 as an analytical reference standard (data not shown) under the same 
experimental conditions. This is the first direct observation of nucleoside monophosphate 
production by a diamidate. During the incubation period, the presence of a new, unknown 
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species at ~2.7 ppm has been observed. This compound forms within 1 h after cell lysate 
addition and slowly diminishes over 14 h. 
 
Figure 8.8. Huh7 cell lysate mediated hydrolysis of 8.2b, followed by 31P NMR, with proposed 
structures. * Unknown species. 
  
 Reported data may indicate ease of the monophosphate release from the 
phosphorodiamidate prodrug. Given that the release of the 5’-monophosphate is considered 
to be essential for the antiviral activity (via the 5’-triphosphate formation), these data are 
consistent with replicon EC50 values (Table 8.2).  
 This is the first time where 
31
P NMR of Huh7 cell lysate was used as an ex vivo model 
of phosphorodiamidate activation. 
 
8.5 Synthesis of asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-!-
methylguanosine. 
 
 During carboxypeptidase Y studies reported in Section 8.4.2, it has been proved that 
the metabolic intermediates 8.3, 8.4 or 8.5 can successfully eliminate an amino acid moiety in 
order to give aminoacyl intermediate 5.21. We therefore decide to synthesised a family of 
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mixed diamidates consisted of amino acid and either simple primary or secondary amine, to 
investigate whether the latter ones can serve as a leaving groups. Additionally diamidates 
bearing two different amino acids were considered.  
 This concept was at variance with the biggest advantages of symmetrical diamidates. 
Introduction of the second amino acid will restore chirality on the phosphorus centre and 
further introduction of an amine may have an impact on toxicity of these compounds. 
However, from the SAR point of view, we thought that this is necessary to understand fully 
the nature of new phosphorodiamidate motif.  
 To facilitate comparison, one of the two amines was maintained either as L-alanine-O-
2,2-dimethypropyl ester or L-alanine-O-benzyl ester. 
 
8.5.1 Synthesis of asymmetrical phosphorodiamidates via p-NO2-phenyl route. 
 
 The first synthetic route consisted of coupling reaction between parent nucleoside 6-
O-methyl-2’-C-methylguanosine 5.4 and p-NO2-phenyl-(2,2-dimethylpropoxy-L-alaninyl) 





























































Reagents and Conditions: i) 3.3o, tBuMgCl, dry THF, rt, overnight; ii) L-alanine tert-butyl ester tosylate salt, 
DIPEA, -78 °C to rt, overnight. 
Scheme 8.3. Attempted synthesis of asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-
methylguanosine via p-NO2-phenyl route. 
 
 The p-NO2-phenyl group is considered as a very good leaving group and therefore it 
was suggested that the introduction of the second amino acid ester would proceed via 
nucleophilic attack of the amino group of amino acid on the phosphorus atom with 
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subsequent release of p-NO2-phenol. Reaction was carried out in the presence of L-alanine 
tert-butyl ester tosylate salt, diisopropylethylamine (DIPEA) as a base in dry THF at ambient 
temperature, overnight. After 16 h no product formation was observed. Increase of the 
reaction time did not resulted in product formation. After three days of stirring reaction was 
warmed up to 50 °C and stirring was continued for 24 hours. After that time 
31
P NMR 
indicate presence of several new potential compounds. Crude mixture was purified on silica 
gel using CHCl3/MeOH (0 to 7% gradient). None of the isolated fraction contain desired 
diamidate product. However, reaction provided 3’,5’-cyclic phosphoramidate 8.6 in a low 
yield (Scheme 8.3). 
 Although the p-NO2-phenyl route did not result in a formation of desired 
assymetrical-mixed diamidates, it demonstrates a new and alternative synthetic approach 
towards 3’,5’-cyclic phosphoramidates.  
 
8.5.2 Synthesis of asymmetrical phosphorodiamidates via phosphorodichloridate route. 
 
It was decided to investigate other synthetic pathways in order to obtain mixed 
diamidates. Firstly, the approach via an amino acid chloridate intermediate was considered.  
The L-alanine 2,2-dimethyprpyl/benzyl ester phosphorodichloridates used for the 
synthesis were prepared using the following procedure: Anhydrous Et3N was added dropwise 
at -78 °C to a solution of the appropriate amino acid ester salt and POCl3 in dry DCM. After 
1 h at -78 °C, the reaction mixture was allowed to warm up to ambient temperature and 
formation of the product was followed by the 
31
P NMR. After reaction completion, solvents 
were removed under vacuum and the crude mixture was purified on silica gel using hexane/ 
ethyl acetate (7:3) as an eluent. Pure compounds 8.7a-b were obtained as yellowish oils in 
high yields (Table 8.3).  
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AA: Amino acid. 
Table 8.3. Summary of synthesised L-alanine dichloridates 8.7a-b. 
 
The 6-O-methyl-2’-C-methylguanosine nucleoside 5.4 was coupled with the 
appropriate amino acid ester dichloridate 8.7a-b under standard tBuMgCl coupling 
conditions. After 16 hours second amino acid was added to the reaction mixture, followed by 
the addition of triethylamine at -78 °C. Although the first step of reaction did work (presence 




P NMR), the introduction of second amino acid ester was 
not successful and starting material was recovered. Therefore it was decided to use simple 
amines (butylamine, pentylamine, cyclopropylamine) in the second step, to investigate 
whether the reaction can take place. After purification of crude mixture on silica gel using 
CHCl3/MeOH (0 to 5% gradient) as an eluent, asymmetrical diamidates 8.8a-d were obtained 























































(8.7a-b) (8.8a-d)  
Reagents and Conditions: i) tBuMgCl, dry THF, rt, overnight; ii) appropriate amine, Et3N, -78 °C to rt, 
overnight. 
Scheme 8.4. Synthesis of asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-methylguanosine 
via amino acid ester phosphorodichloridate route. 
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ClogP- calculated lipophilicity, values calculated using ChemOffice Ultra 11.0; *Yields calculated 
over two steps. 
Table 8.4 Summary of asymmetrical diamidates synthesised via phosphorodichloridate route, their 
ClogP values, 31P NMR shifts and synthetic yields. 
 
 Phosphorodiamidates 8.8a-d were isolated as ca. 1:1 mixtures of diastereoisomers at 
the phosphate centre. 
Application of diethylamine did not result in product formation. From these findings, 
it was clear that this reaction pathway is suitable for the introduction of primary amines, but 
not secondary amines or second amino acids. 
  At this point, it was decided to adopt the method used for symmetrical diamidates for 
the requirements of mixed diamidate synthesis.  
 
8.5.3 Synthesis of asymmetrical phosphorodiamidates via POCl3 route. 
 
 The synthesis of asymmetrical phosphorodiamidates with chemistry methodology 
used for the preparation of symmetrical diamidates required stepwise introduction of one 
























































Reagents and Conditions: i) POCl3, Et3N, dry THF, -78 °C to rt, 30 min; ii) Appropriate amine or amino acid 
ester, Et3N, DCM, -78 °C to rt, 3 h; iii) Appropriate amino acid ester, Et3N, DCM, -78 °C to rt, overnight.   
Scheme 8.5. Synthesis of asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-methylguanosine 
via POCl3 route. 
 
The 6-O-methyl-2’-C-methylguanosine nucleoside 5.4 was allowed to react with 
triethylamine and phosphorus oxychloride. Formation of 5’-phosphorylated intermediate was 




P NMR. Subsequently 1 mol equivalent of amino acid ester or amine was 
added to the reaction mixture, followed by the addition of triethylamine. As anticipated, the 
product formed within 3 hours. 
31
P NMR showed the presence of a newly formed peak at  
11-12 ppm (spectra recorded in CDCl3). The second amino acid was added to the reaction 
mixture, followed by the addition of triethylamine. After 16 hours, 
31
P NMR indicated the 
presence of the desired product with !P = 12-16 ppm (spectra recorded in MeOD). Solvents 
were removed under reduced pressure and crude mixture was purified on silica gel using 
CHCl3/MeOH (0 to 5% gradient) as an eluent.  
 
Table 8.5. Summary of asymmetrical diamidates synthesised via modified symmetrical diamidates 
procedure, ClogP values and 31P NMR shifts. 
 
In the case of compounds where a secondary amine was used it was important that the 
amine was introduced first followed by the addition of amino acid.  
The purified asymmetrical phosphorodiamidates (8.8e-h, Table 8.5) were isolated as a 
roughly 1:1 mixture of diastereoisomers at the phosphorus centre, confirmed by the presence 
of two peaks in the 
31
P NMR and HPLC. 
 
8.6 Biological evaluation of asymmetrical diamidates of 6-O-methyl-2’-C-
methylguanosine. 
 
 All synthesised novel asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-"-
methylguanosine were evaluated by Inhibitex Inc., against hepatitis C virus in vitro (Table 
8.6). Additionally 3’,5’-cyclic phosphoramidate 8.6, INX-189 and parent nucleoside 5.4 were 
tested alongside. 
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AA-Amino acid, EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%; CC50: 50% cytotoxic concentration. 
Table 8.6. Summary of the anti-HCV activity of 6OMe2’CMeG asymmetrical phosphorodiamidates, 
3’,5’-cyclic ProTide 8.6, INX-189 and parent nucleoside 5.4, and their calculated ClogP values. 
 
 As can be seen in Table 8.6, in general phosphorodiamidates bearing L-alanine and 
simple amines exhibited moderate to good activity in replicon based assay, with EC50 values 
ranging from 0.1 to 0.9 µM. Compounds were found to be 5- to 40-fold more potent than the 
parent nucleoside 5.4. However, compounds were found to be less active than the 
symmetrical L-alanine-O-2,2-dimethylpropyl phosphorodiamidate 8.2e and ca. 10-100 times 
less potent than INX-189. 
 The most active compounds across the asymmetrical diamidates family were 8.8c 
bearing primary pentylamine as a second masking group, 8.8h L-Ala-O-benzyl 
ester/morpholine and 8.8e mixed amino acid L-Ala-O-2,2-dimethylpropyl/L-Ala-O-benzyl 
diamidate, with EC50 ~ 0.1 µM.  
 Cyclic phosphoramidate 8.6 exhibits moderate activity in in vitro assay (EC50 = 0.85 
µM), being ca. 8-fold less potent than the clinical candidate INX-189. Although the 
compound was approximately 5-times more potent than the parent nucleoside 5.4, it was 
decided that further development of this particular family of cyclic phosphoramidates will not 
be carried out.  
 The least potent compound was 8.8f, a phosphorodiamidate bearing L-Ala-O-2,2-
dimethylpropyl ester and diethylamine as a phosphate masking units. The activity of this 
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particular compound was similar to the one of the parent nucleoside 5.4 (EC50 = 3.7 µM vs. 
EC50 = 4.6 µM, respectively), but almost 400-fold lower than of INX-189 (Table 8.6). 
Calculated ClogP of 8.8m is identical as the one of INX-189 and therefore cannot explain the 
lack of activity. In this case, decrease in replicon potency may be related to the ability of 
diethylamine to act as a leaving group.  
 
 
Figure 8.9. Potency (1/EC50) data plot of diamidates bearing various simple amines. 
 
 Comparing amines between each other, it can be clearly seen (Figure 8.9) that the best 
choice was pentylamine 8.8c followed by the morpholine 8.8e, followed by the butylamine 
8.8a and 8.8b. In general compounds bearing secondary amines were least potent than those 
with primary amines. 
 All synthesised asymmetrical diamidates exhibited no cellular toxicity up to 100 µM 
concentration. 
 In general no clear correlation between activity and calculated lipophilicity was found 
(Table 8.6). It appears that in the case of mixed simple amine diamidates the main feature 
accountable for compounds activity was leaving group ability of introduced amines. To probe 
these assumptions, carboxypeptidase Y-mediated ester cleavage assays were conducted. 
 
8.7 Enzymatic studies of asymmetrical phosphorodiamidates of 6-O-methyl-2’-C-
methylguanosine. 
  
 The first experiment was carried out on L-alanine -O-benzyl/n-butylamine diamidate 
8.8a and corresponding data are presented in Figure 8.9. 
Karolina Made!a                                                                                                   Chapter Eight 
 187 
 Due to the fact that phosphorodiamidate 8.8a is chiral at the phosphorus centre, two 
peaks !P = 16.75 and 16.59 ppm are seen in the blank spectrum (Figure 8.10). Both peaks 
disappear within 120 min with simultaneous appearance of the new species with chemical 
shift of 6.94 ppm. It can be noticed that the diastereoisomer, which is represent by the more 
downfiled 
31
P NMR signal (!P = 16.75) is processed faster. 
The peak corresponding to the aminoacyl intermediate 5.21, started to form within the first  
10 min of incubation with carboxypeptidase Y, and builds up during the course of the 
experiment.  
 During the experiment, no signals corresponding to the species with cleaved ester 
moiety were observed, what could suggest that the ester cleavage followed by the 
spontaneous cyclisation with subsequent release of butylamine is very rapid. The half-life for 
8.8a was found to be ca. 30 min. 
 
 
* Phosphate impurity in Trizma buffer; present in blank and amines unchanged throughout. 
Figure 8.10. Carboxypeptidase Y mediated hydrolysis of 8.8a, followed by 31P NMR, with proposed 
structures. 
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A second experiment was performed on phosphorodiamidate 8.8g (Figure 8.11). In 
the blank experiment, two peaks !P = 15.54 and 15.42 ppm were detected. After enzyme 
addition a new peak at 6.94 ppm started to form within ca. 1 h and grows in magnitude over 
14 h. This intermediate 5.21 is common in all phosphoramidate and phosphorodiamidate 
activation pathways. Interestingly, in this particular case, the enzyme cleaved only one of the 
two diastereoisomers of 8.8g with rapid amine loss following the ester cleavage. The second 





Figure 8.10. Carboxypeptidase Y mediated hydrolysis of 8.8g, followed by 31P NMR, with proposed 
structures. 
 
In summary, it has been shown that a primary amine or secondary amine can also be 
eliminated and act as a leaving group to produce key aminoacyl intermediate 5.21. The data 
obtained from the carboxypeptidase Y assays performed on 8.8a and 8.8g support the notion 
that only one ester cleavage is necessary to initiate the activation process.  
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8.8 Molecular modelling studies. 
 
To understand the difference in the processing rate of the two isomers of 8.8g, 
docking studies were carried out.  
 Molecular modelling studies were performed using the published crystal structure of 
carboxypeptisae Y (protein data bank (PDB) 1YSC).
8,9 
The critical residues involved in the 
ester cleavage are: Ser146- involved in attack on the carbonyl of the ester and two glycine 
residues: Gly52 and Gly53 responsible for the appropriate coordination of the carbonyl 
group.  
 As can be seen in Figure 8.11, in the case of 8.8g-Sp isomer, the stabilization by H-
binding of two glycine residues is notable and the nucleophilic site of Ser146 is also well 
positioned (Figure 8.11). 
 
 
Figure 8.11. Docking studies of Sp and Rp isomers of 8.8g into carboxypeptidase Y active site. 
 
 For the Rp isomer, the carbonyl group is situated a little further away from the Ser146 
and therefore cannot efficiently interact with critical residues. These result support the 
difference in processing rate found for this compound during the enzymatic assay. It would 
be interesting to see whether the anti-HCV activity of separated isomers would differ as it has 
been seen in the case of PSI7977. As separation of diastereoisomers of 8.8g was not possible, 
we were not able to conduct appropriate experiments. 
 On the basis of these differences we assumed that the more downfield species (one 
which was processed faster) in the 
31
P NMR spectra of 8.8g corresponded to the Sp isomer. 
These findings would be in contrast with the data corresponding to the separated isomers of 
INX-189, where more downfield signal was represented by the Rp isomer. 
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8.9 Stability studies of 6-O-methyl-2’-C-methylguanosine symmetrical diamidates. 
 
 Given the very promising data of the new phosphorodiamidate prodrug motif, it was 
interesting to establish some stability outlines prior the animal pharmacokinetic studies.  
Therefore compound 8.2e was incubated in the presence of mouse plasma, dog and human 
serum. Data are showing stability/decomposition of 8.2e followed by the 
31
P NMR over 12 h. 
 As can be seen in Figure 8.12, when parent phosphorodiamidate 8.2e (!P = 14.50 
ppm) was incubated in the presence of mouse plasma at 37 °C, after 25 min only signal 
corresponding to the aminoacyl intermediate 5.21 (7.11 ppm) was observed.  
 
 
Figure 8.12. Stability of 8.2e during the incubation with mouse plasma. 
 
 These data confirmed profound rodent plasma instability of 8.2e, regardless the 
phosphorodiamidate motif. Reported data are consistent with stability data presented for 
aryloxyphosphoramidate ProTides described in Chapter 4, Section 4.8.1. 
 On the other hand when compound was incubated in the presence of either dog or 
human serum at 37 °C, 8.2e was found to be completely stable and remained for the period of 
12 h (Figure 8.13 and 8.14). 
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Figure 8.13. Stability of 8.2e in dog serum. 
 
 
Figure 8.14. Stability of 8.2e in human serum. 
 
The phosphorodiamidate 8.2e seems essentially stable in human serum, certainly for 
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8.10 Intracellular levels of 2’-C-methylguanosine triphospate – in vitro studies. 
 
The initial investigation of 6-O-methyl-2’-C-methylguanosine phosphorodiamidates 
revealed promising means of 2’-C-methylguanosine 5’-monophosphate delivery into cells. In 
order to determine whether synthesised diamidates can be converted intracellularly to the 
active 2’-C-methylguanosine 5’-triphosphate, several diamidates were investigated in 
primary human hepatocytes. Studies were conducted and evaluated at Inhibitex Inc. 
 Phosphorodiamidates were incubated in primary human hepatocytes at arbitrary 
concentration of 10 µM. Triphosphate levels were measured at 2 h, 6 h and 24 h time points 
using LC-MS/MS tandem spectroscopy. Additionally, levels of 2’CMeGTP obtain from the 
incubation of clinical candidate INX-189 were measured alongside. Related data are reported 
in Figure 8.15. 
 
Figure 8.15. Levels of 2’CMeGTP produced from INX-189, 8.8b, 8.8c and 8.8e in primary human 
hepatocytes system over 24 h incubation period. 
 
 As can be seen in Figure 8.15, incubation of all phosphorodiamidates in the presence 
of primary human hepatocytes resulted in the formation of high amounts of 2’-C-
methylguanosine 5’-triphosphate. It can be clearly seen that the diamidate prodrugs were able 
to produce similar levels of the desired 5’-triphosphate as our lead compound INX-189. For 
compounds 8.2b and 8.2c the Cmax of TP was achieved within the first six hours of incubation 
and then slowly decayed. Additionally compound 8.2b exhibit a very similar profile to  
INX-189, with Cmax of ca. 420 pmol/10
6
 cells. Interestingly the phosphorodiamidate analogue 
Karolina Made!a                                                                                                   Chapter Eight 
 193 
of INX-189 – 8.2e was found to build up triphosphate levels up to 24 h and produce the 
highest overal triphosphate AUC across the tested compounds. 
 
8.11 Intracellular levels of 2’-C-methylguanosine triphospate – in vivo studies. 
 
 The ability of phosphorodiamidate 8.2e to deliver monophosphate inside the liver 
cells with subsequent formation of the active 5’-triphosphate species after oral administration 
was investigated in a rat model.  
The rat PK studies were performed by Inhibitex Inc. 
 The compound 8.2e and INX-189 were formulated in 95% Capmul MCM and 5% 
Tween 80, and administrated at 10 mg/kg dose as oral gavage to male Sprague-Dawley rats. 
Liver samples were collected at eight time points (up to 24 h post administration) and 
concentrations of 2’-C-methylguanosine triphosphate were measured by LC-MS/MS tandem 
spectroscopy. The related data are reported in the Figure 8.16. 
 The EC90 value (243 pmol/g liver, 130.5 ng/g liver tissue) used as a reference in this 
study, was determined during the extensive evaluation of INX-189 in the replicon cells, and 
has been described in Chapter 5 and 6. 
 
 
EC90: Defined as the amount of intra cellular triphosphate necessary to achieve 90% inhibition in the HCV 
replicon assay. 
Figure 8.16. 2’CMeGTP levels in livers of rats orally dosed with INX-189 or 8.8e. 
 
  
 It is clear that both of the compounds were able to produce significant levels of 
intracellular triphosphate in the rat liver after oral administration (Figure 8.16). Interestingly, 
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8.2e provide similar levels of the triphosphate as INX-189 greatly exceeding the EC90 value 
by ca. 15-fold and maintained for over 24 h. 
 These data clearly show undisputed potential of the new prodrug motif and promise of 
potential phosphorodiamidate prodrug candidate suitable for the HCV clinical studies.   
 
8.12 In vivo toxicity studies. 
 
 In order to determine the toxicity profile of the most interesting phosphorodiamidates 
(8.8b, c and e) and INX-189, compounds were evaluated in 14-days rat toxicity studies at 
Inhibitex Inc.  
 Compounds were formulated in the standard PO formulation (95% Capmul MCM and 
5% Tween 80) and were orally dosed to male Sprague-Dawley rats at 30 mg/kg once daily 
for 14 days. The body weight was checked daily pre-dosing. All tested groups were checked 
against vehicle group, which was orally dosed with 95% Capmul MCM and 5% Tween 80 
only. Obtained data are presented in Figure 8.17. 
 
!- Necropsied in moribund state, !- Found dead. 
Figure 8.17. 14-Days rat toxicity studies. 
 
Karolina Made!a                                                                                                   Chapter Eight 
 195 
As reported in Figure 8.17, all tested phosphorodiamidates 8.2b, c and e showed 
favourable toxicity profile comparing to the INX-189, with less variation in the body mass 
comparing to the vehicle groups. 
In the case of 8.2e there was one case of mortality and in each treated groups 1 to 2 animals 
were found in moribund condition. Upon necropsy, the moribund animals showed signs of 
gastrointestinal tract toxicity namely haemorrhaging in intestines. Apart from that no other 




 In conclusion, a series of novel 6-O-methyl-2’-C-methylguanosine 
phosphorodiamidates derived from different amino acids and/or simple amines has been 
synthesised. This type of 5’-monophosphate prodrugs as shown in this Chapter, can be 
designed to be achiral or chiral at the phosphate centre if desired. During the extensive 
structure activity relationship studies, compounds exhibiting nM activity against HCV 
replicon assay were identified. In general phosphorodiamidates were not toxic in the cell-
based assay up to 100 µM concentration. This is the first time, when application of a 
phosphorodiamidate approach to the nucleoside analogue is successful. Carboxypeptidase Y 
studies revealed that the cleavage of only one of the ester moieties is essential for the 
efficient activation of diamidates and their potent activity versus the hepatitis C virus. 
Additionally phosphorodiamidates were found to be stable in dog and human serum. All 
tested diamidates showed ability to produce substantial levels of 2’-C-methylguanosine 5’-
triphosphate, similar to the one exhibited by INX-189. Several compounds were advanced 
into the rat PK studies, and it was demonstrated that phosphorodiamidates could provide high 
levels of 2’CMeGTP in vivo in rat livers. 
 The combination of replicon activity with in vitro and in vivo data resulted in the 
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In search of new pharmacophore: C-8 modifications. 
 
9.1 8-C-modified 6-O-methyl-2’-C-!-methylguanosine – the rational behind the design. 
 
 Recently 8-halogenated purine analogues have been recognized as an interesting class 
of biologically active agents. 8-Chloroadenosine (8ClAdo), a dephosphorylated metabolite of 
8-chloro-cyclicAMP has been involved in pre-clinical and clinical studies for the treatment of 
human multiple myeloma, human promyelocytic leukemia and solid tumors.1 8ClAdo is 
cytotoxic to cell lines that are resistant to other drugs and therefore it can constitute as an 
alternative for the treatment of neoplastic diseases.2  
Although, the effect of the C8-modified purine nucleosides has been well studied in 
the field of anti-cancer agentslittle is known about the antiviral activity of these type of 
molecules.  
To address the effect of C8 steric bulk on the anti-HCV activity, family of analogues 
of 6-O-methyl-2’-C-methylguanosine that contained halogens of increasing size (chlorine, 
bromine and iodine) at the C8-position was synthesised. 
Introduction of a substituent in C-8 position (in contrast to the most of the 
modifications in C-2 or C-6 position) preserves the pairing with pyrimidines and the ability to 
form nucleic acid duplexes in which the substituent would point out to the major groove and 
thus modulate the interactions with proteins.4 
 
9.2 Synthesis of 8-C-halo-6-modified-2’-C-!-methylguanosine nucleoside analogues. 
 
9.2.1 Synthesis of 8-C-bromo-6-O-methyl-2’-C-!-methylguanosine. 
 
 The synthesis of 8-C-bromo-2’-deoxyguanosine from 2’-deoxyguanosine in the 
presence of N-bromosuccinamide in water has been reported for the first time by Gannett and 
Sura in 1993.5 We decided to investigate this procedure in order to synthesise 8-C-bromo-6-
O-methyl-2’-C-methylguanosine. The trial reaction in the exact conditions as described by 
Gannett et al. did not result in product formation. The main issue was the solubility of the 
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starting material. Examination of different solvent systems, provided the best results. When 
dry methanol was used as a sole solvent and 1 mol equivalent of N-bromosuccinamide (NBS) 
as brominating agent, at ambient temperature for 4 hours (Scheme 9.1), after purification on 
silica gel, using CHCl3 : MeOH (0 to 4% gradient) as an eluent, pure compound was obtained 






















Reagents and Conditions: i) NBS, dry MeOH, rt, 4 h. 
Scheme 9.1. Synthesis of 8-C-bromo-6-O-methyl-2’-C-methylguanosine. 
   
9.2.2 Synthesis of 8-C-chloro-6-O-methyl-2’-C-!-methylguanosine. 
 
There are several reported methods for chlorination at the C8-position of purines, 
including reaction with benzoyl chloride (BzCl) and m-chlorobenzoic acid (mCPBA).6 
Although this method was very successful in the preparation of 8-chloroadenosine, it proved 
to be not effective with the guanosine analogue (Table 9.1). Application of the 8-bromo 
analogue methodology, using N-chlorosuccinamide (NCS) did not provide the desired 
product. Increase of the reaction time and temperature had no impact on the product 
formation (Table 9.1).  
 
 
Table 9.1. Attempts (reagents and conditions) to synthesise 8-C-chloro-6-O-methyl-2’-C-
methylguanosine. 
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After several unsuccessful attempts, the procedure reported by Hamm et al. was 
investigated.7 Thus, 6-O-methyl-2’-C-methylguansine 5.4 was reacted with NCS in dry THF 





















Reagents and Conditions: i) NCS, dry THF, 35 °C, 16 h. 
Scheme 9.2. Synthesis of 8-C-bromo-6-O-methyl-2’-C-methylguanosine. 
 
After purification on silica gel, using CHCl3 : MeOH (0 to 4% gradient) as an eluent, 
pure compound was obtained as a white solid in an excellent 85% yield.  
 
9.2.3 Synthesis of 8-C-iodo-6-O-methyl-2’-C-!-methylguanosine. 
 
 In the first attempt to synthesise 8-C-iodo-6-O-methyl-2’-C-methylguanosine, 
reaction was carried out in dry methanol, in the presence of N-iodosuccinamide (NIS) at 
ambient temperature. However the reaction resulted in a complex mixture of potential 
products, which proved to be difficult to isolate.  
Lipkin et al. reported successful iodination of guanine in dimethyl sulfoxide.8 A 
drawback of this protocol is the use of DMSO and troublesome isolation of the product from 
the high boiling-point solvent and from unreacted starting material. Since the iodination 
procedure was similar to the well established route to the 8-C-chloro-6-O-methyl-2’-C-






















Reagents and Conditions: i) NIS, dry THF, 35 °C, 3 days. 
Scheme 9.3. Synthesis of 8-C-iodo-6-O-methyl-2’-C-methylguanosine. 
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 The extension of reaction time to 3-days, resulted in formation of the desired product, 
which after purification was obtained as a yellowish solid in 51% yield.  
 
 The introduction of the halogen atom onto C8-position can be easily recognized by a 
chemical shift of the C-8 carbon atom (Figure 9.1 and 9.2).  
In the parent nucleoside 5.4, the C-8 carbon is represented by a single negative signal at 
139.35 ppm in the 13C PENDANT spectrum (Figure 9.1).  
 
 
Figure 9.1. The 13C PENDANT spectrum of 6-O-methyl-2’-C-methylguanosine. 
 
Introduction of bromine atom resulted in the appearance of more upfield positive 
signal at !C = 125.57 ppm (Figure 9.2a). Replacement of C8-H by the chlorine atom gave 13C 
peak at 136.59 ppm (Figure 9.2b) with only ca. 2 ppm difference comparing to the parent 
nucleoside 5.4. From all halogens introduced onto C-8 position, the biggest effect was 
observed for the iodine atom. The peak of C-8 observed for 9.3 was shifted ca. 40 ppm more 
upfield comparing to the starting material 5.4, resulting in a positive signal at !C = 99.27 
ppm. 
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Figure 9.2. 13C PENDANT spectra of a) 9.1; b) 9.2; c) 9.3. 
 
The upfield trend in the 13C chemical shift, observed for the compounds 9.2 and 9.3, 
is caused by the bromine and iodine atom, and is called the ‘heavy atom effect’.  This is 
attributed to the increased diamagnetic shielding caused by the large number of electrons 
introduced by heavy atoms.9 




Table 9.2. Summary of C8-modified nucleoside analogues synthesised, reaction yields, C8 13C 
PENDANT NMR shifts and calculated lipophilicity. 
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9.2.4 Biological evaluation of 8-C-halo-6-modified-2’-C-!-methylguanosine nucleoside 
analogues. 
 
 All novel C8-modified analogues of 6-O-methyl-2’-C-methylguanosine were 
evaluated for their anti-HCV activity using in vitro replicon assay by Inhibitex Inc (Table 
9.3). 
 
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 50%; 
CC50: 50% cytotoxic concentration. 
Table 9.3. Biological activity and calculated lipophilicity of C-8 modified analogues of 6-O-methyl-
2’-C-methylguanosine. 
 
  As can be seen in Table 9.3, the analogues bearing the bromo- and chloro- 
substituents in the C8-position (9.1 and 9.2, respectively), were found to be completely 
inactive in the replicon assay EC50 > 100 µM. On the other hand C8-iodo analogue 9.3 was 
found to be as potent as 6-O-methyl-2’-C-methylguanosine 5.4 (EC50 = 6.0 µM vs. 4.6 µM). 
This result was somewhat surprising as none of the smaller size halogens provided any 
biological activity. These results evidently indicate the importance of the iodine substitution 
in C8-position however it was not clear whether this particular halogen is a part of a new 
pharmacophore or is being metabolized on one of the steps during activation to the 
triphosphate species. 
 The phosphoramidate technology was applied to the nucleoside analogues 9.1-9.3 in 
order to investigate whether their in vitro anti-HCV activity can be enhanced. Synthesis and 
biological evaluation of aryloxyphosphoramidates of 9.1-9.3 will be described in Section 9.3. 
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9.2.5 Adenosine deaminase assay on 8-C-iodo-6-O-methyl-2’-C-!-methylguanosine. 
 
 In order to investigate whether the 8-C-iodo-6-O-methyl-2’-C-methylguanosine can 
serve as a suitable substrate for the adenosine deaminase mediated hydrolysis; enzymatic 
assay in the presence of ADA was conducted, according to the procedure described in 
Chapter 5, Section 5.2.3. 
 
 
Figure 9.3. Spectral change during ADA-mediated hydrolytic removal of alkyl group from 9.3. 
 
 As can be seen in Figure 9.3, nucleoside analogue 9.3 was found to be completely 
stable during 16 h course of the experiment, showing that 9.3 cannot serve as a substrate for 
ADA. The presence of the iodine in the C8-position prevents the enzyme mediated hydrolysis 
of the C6 alkyl substituent. This profound lack of activity may be related to the conformation 
of the nucleoside. It is very likely that the C8-iodo analogue can preferentially adopt syn 
conformation, wherein the nucleobase is positioned over the ribose sugar. This conformation, 
which is in contrast to the anti conformation of ordinary purine nucleosides, arises because 
the steric bulk of the iodine precludes its residence over the ribose ring.  
 Substrate specificity of AMPDA suggests that the 8-C-iodo-6-O-methyl-2’-C-
methylguanosine 5’-monophosphate could not serve as a suitable substrate for the enzyme 
mediated hydrolysis of the C6-substituent. However it is not clear, whether ADAL1 could 
accept the presence of the bulky substituent in the C-8 position of the modified nucleoside 
and perform hydrolytic cleavage of the methoxy moiety in order to obtain C6-keto analogue. 
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9.3 Synthesis of 8-C-halo-6-O-modified-2’-C-!-methylguanosine prodrugs. 
 
9.3.1 Synthesis of a first series of 8-C-halo-6-O-modified-2’-C-!-methylguanosine 
prodrugs. 
 
 The aryloxyphosphoramidate approach was applied to the 8-C-modified-6-O-methyl-
2’-C-methylguanosine analogues 9.1-9.3 in order to investigate the influence of ProTide 
technology on anti-HCV activity of these nucleoside analogues. To facilitate the comparison 
all compounds were prepared as "-naphthyl-L-alanine analogues bearing two different esters: 
2,2-dimethylpropy and benzyl, and also as "-naphthyl-L-valine-O-benzyl derivatives. 
 All compounds were synthesised using tBuMgCl mediated coupling reaction, 




































(3.3e, 3.3i, 3.3k) (9.4a-c, X = Br 
 9.5a-c, X = Cl
 9.6a-c, X = I)
X
+
(9.1, X = Br 
 9.2, X = Cl
 9.3, X = I)  
Reagents and Conditions: i) tBuMgCl, dry THF, rt, 16 h. 
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AA-amino acid, ClogP values calculated using ChemOffice ultra 11.0. 
Table 9.4. Summary of a first series of 8-C-modified-6-O-methyl-2’-C-methylguanosine ProTides, 
their calculated lipophilicity and reaction yields. 
 
 All novel ProTides were obtained as white solids in moderate to good yields  
(13-27%). Compounds were isolated as roughly 1:1 mixtures of phosphate diastereoisomers 
as evidenced by 31P NMR and HPLC. 
 From the synthetic point of view, it was of interest to investigate whether the 
introduction of the halogen atom would be possible at the ProTide level. To probe this, 
aryloxyphosphoramidate 5.12a was dissolved in dry methanol and treated with 1 mol 





























(5.12a) (9.4a)  
Reagents and Conditions: i) NBS, dry MeOH, rt, 4 h. 
Scheme 9.5. Synthesis of aryloxyphosphoramidates of 8-C-modified-6-O-methyl-2’-C-
methylguanosine. 
 
The bromination reaction was clean and resulted in a formation of 9.4a in excellent 
94% yield during four hours reaction course. Comparing two possible routes of synthesis of 
8-C-bromo modified ProTides it was noticed that the second route (bromination on the 
ProTide level) was slightly better in terms of overall yield (25% vs. 20%). Not much 
difference in terms of purification between two synthetic pathways was observed. 
However when 5.12a was treated with either N-chlorosuccinamide or  
N-iodosuccinamide in reaction conditions described above, no product formation was 
observed.  
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Additionally we decided to investigate the effect of phosphorodiamidate motif on the 
anti-HCV activity of the 8-modified nucleosides 9.1-9.3. In the first attempt 































(8.2e) (9.7a)  
Reagents and Conditions: i) NBS, dry MeOH, rt, 6 h. 
Scheme 9.6. Synthesis of phosphorodiamidate 9.7a via direct NBS bromination. 
 
The pure compound 9.7a was obtained in 50% yield after purification on silica gel, 
using CHCl3 : MeOH (97:3) as an eluent. Similar attempt performed with NCS or NIS did 
not result in product formation. In order to obtain 8-C-chloro- and 8-C-iodo 
phosphorodiamidate analogues of 9.7a, synthetic procedure used for the synthesis of 6-O-





































(9.2, X = Cl
 9.3, X = I)
(9.8a, X = Cl
9.9a, X = I)
X X X
(9.8', X = Cl
9.9', X = I)  
Reagents and Conditions: i) POCl3, Et3N, dry THF, -78 °C to rt, 30 min; ii) L-alanine-O-2,2-dimethylpropyl 
ester x pTSA, Et3N, DCM, -78 °C to rt, overnight. 
Scheme 9.7. Synthesis of symmetrical phosphorodiamidates of 9.2 and 9.3 via POCl3 route. 
 
After column chromatography, compounds 9.8a and 9.9a were obtain as white solids 
in 26% and 10% yield, respectively (Table 9.5). 
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AA-amino acid, ClogP values calculated using ChemOffice ultra 11.0. 
Table 9.5. Summary of a first series of 8-C-modified-6-O-methyl-2’-C-methylguanosine diamidates, 
their calculated lipophilicity and reaction yields. 
 
At this point it was clear that only 8-C-bromo analogues could be synthesised via 
NBS-mediated direct bromination of either phosphoramidate or phosphorodiamidate 
prodrugs, synthesis of 8-C-chloro or 8-C-iodo analogues required coupling reactions of C8-
modified nucleosides with the appropriate phosphorochloridates or POCl3 (followed by the 
addition of amino acid ester). 
 
9.3.2 Biological evaluation of a first series of 8-C-halo-6-O-modified-2’-C-!-
methylguanosine prodrugs. 
 
 All newly synthesised prodrugs of 8-C-halo-6-O-modified-2’-C-methylguanosine 
analogues were evaluated for their ability to inhibit viral replication in in vitro replicon assay 
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AA: Amino acid, EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%; CC50: 50% cytotoxic concentration. 
Table 9.6. Summary of the anti-HCV activity of 8-C-modified 6OMe2’CMeG phosphoramidates and 
diamidates, parent nucleosides 9.1-9.3, INX-189, and their calculated ClogP values. 
 
 As can be seen in Table 9.6, in the case of 8-C-bromo (9.4a-c, 9.7a) and 8-C-chloro 
(9.5a-c, 9.8a) analogues the application of aryloxyphosphoramidate or phosphorodiamidate 
technology did not improve the anti-HCV activity of the corresponding parent nucleosides 
9.1 and 9.2, respectively. The explanation for this lack of activity might be that these 
nucleoside analogues are not capable to interact with the viral polymerase and therefore 
cannot cause inhibition of viral replication or that one or more steps in the putative activation 
mechanism is blocked. On the other hand, all analogues bearing C8-iodo modification exhibit 
in vitro anti-HCV activity in submicromolar range. Application of the 
aryloxyphosphoramidate or diamidate technology resulted in enhancement of antiviral 
activity up to 300-fold. The most potent derivative across this set of compounds was 9.6a 
(EC50 = 0.02 µM), with activity comparable to that of the clinical candidate INX-189 (EC50 = 
0.01 µM).  
It has been noticed that the L-alanine derivative 9.6b was ca. 8-times more active than 
the corresponding L-valine analogue 9.6c (EC50 = 0.04 µM vs. EC50 = 0.30 µM, 
respectively). This observation is in agreement with the previous data obtain for 2’CMeG and 
6OMe2’CMeG ProTides (Chapter 4 and 5), showing superior role of L-alanine over L-valine. 
Additionally it was found that aryloxyphosphoramidate produgs were slightly more potent 
than the analogous diamidates (9.6a vs. 9.9a, EC50 = 0.02 µM vs. EC50 = 0.13 µM, 
respectively). 
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In general compounds 8-C-iodo-6-O-methyl-2’-C-methylguanosine prodrugs were 
found to exhibit some toxicity in the cell-based assay (at µM level), however their high 
potency still leads to the therapeutic index values in the 1000 range. 
Given the extremely high potency of the 9.6a derivative we decided to vary the 
ProTide and diamidate motives on 8-C-iodo-6-O-methyl-2’-C-methylguanosine. 
 
9.3.3 SAR studies of a second series of 8-C-iodo-6-O-modified-2’-C-!-methylguanosine 
prodrugs. 
 
 The second family of 8-C-iodo-6-O-methyl-2’-C-methylguanosine prodrugs was 
obtained following the procedures as in Scheme 9.4 and 9.7, but varying the 
phosphorochloridate and/or amino acid esters. All synthesised compounds (except diamidate 
prodrugs) were isolated as roughly 1:1 diastereomeric mixtures at the phosphorus centre, in 
moderate to good yields (14-30 % for phosphoramidates and 23-40% for diamidates). 
Compounds were evaluated for their inhibitory activity in replicon based assay 
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AA: Amino acid, EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%; CC50: 50% cytotoxic concentration. 
Table 9.7. Summary of the anti-HCV activity of 8-C-iodo-6OMe2’CMeG phosphoramidates and 
diamidates, parent nucleoside 9.3, INX-189, and their calculated ClogP values. 
  
All synthesised prodrugs displayed improved EC50 values comparing to the parent 
nucleoside 9.3. In the L-alanine series, entries 9.6d-l, different types of aliphatic 9.6d-f, 
cyclic 9.6g-j and aromatic esters 9.6k were investigated. Amongst this family the most active 
compound was 9.6d (!-naphthyl-L-alanine-O-propyl analogue) with EC50 value of 0.0074 
µM, showing more than 800-fold enhancement in the inhibition of the viral replication 
comparing to the parent nucleoside 9.3 (Table 9.7).  
Not much difference in anti-HCV activity between L-alanine compounds bearing 
straight aliphatic, cyclic or aromatic esters was observed. All of these compounds exhibited 
the antiviral activity in ca. 10-20 nM range. Somewhat surprising result (EC50 = 0.018 µM, 
Table 9.7) was obtained for compound 9.6j. In the previous families of ProTides, the 
tetrahydropyranyl derivative was always less active than the corresponding cyclohexyl 
analogue (EC50 = 0.17 µM vs. 0.03 µM for 5.12h and 5.12c, respectively, Chapter 5). As a 
factor responsible for that loss of activity we suggested relatively low ClogP value of the 
THP compound. In the case of 9.6j introduction of the iodine atom in the C8-position 
resulted in the increase of the lipophilicity (ClogP = 1.1 for non-iodinated 5.12h and 1.9 for 
9.6j) and most probably in enhanced cellular uptake and subsequently in the greater potency. 
The introduction of L-methionine, entries 9.6m-n, provided compounds with submicromolar 
activity (EC50 = 0.07 µM and EC50 = 0.034 µM, respectively, Table 9.7), however no 
improvement over corresponding L-alanine derivatives was observed, confirming the superior 
role of L-alanine in the ProTide motif.  
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The variation of the aryl unit, replacement of !-naphthyl (9.6a, EC50 = 0.02 µM, 
Table 9.7) by phenyl (9.6l, EC50 = 0.03 µM, Table 9.7) did not result in noticeable difference 
in the replicon assay, showing that the 8-C-iodo-6-O-methyl-2’-C-methylguanosine 
nucleoside analogue do not greatly distinguish between L-alanine esters or aromatic units. 
The replicon activities for eleven different L-alanine ProTides ranged from 0.01 µM to 0.04 
µM (regardless the L-alanine ester or aromatic moiety used), only 2- to 4-fold, which is 
similar to the variability in the replicon assay. 
Looking at diamidate series (Table 9.6 entry 9.9a, Table 9.7 entries 9.9b-d) it can be 
seen that the most active compounds were bearing L-alanine-O-benzyl ester (9.9d, EC50 = 
0.046 µM, Table 9.7), followed by L-alanine-O-3,3-dimethyl-1-butyl ester (9.9c, EC50 = 
0.072 µM, Table 9.7). Compounds 9.9a and 9.9b, were found to be equipotent (EC50 = 0.13 
µM), and at the same time the least active across the whole family of synthesised prodrugs, 
although still more than 40-fold potent than the parent nucleoside 9.3. 
 
9.3.4 Enzymatic studies in the presence of carboxypeptidase Y. 
 
 To probe the mechanism of activation of newly synthesised prodrugs of 8-C-iodo-6-
O-methyl-2’-C-methylguanosine carboxypeptidase assays were performed (Figure 9.4 and 
9.5) according to the procedure described in Chapter 4, Section 4.6. 
In the first instance carboxypeptidase Y assay was performed on !-naphthyl 
propylalanine analogue 9.6d (Figure 9.4). In the blank experiments two peaks at "P = 3.80 
and 3.18 ppm corresponding to the two diastereoisomers of 9.6d are present. During the first 
7 min after enzyme addition, new peak at "P = 4.82 ppm started to form and continued to be 
present for ca. 50 min. This intermediate corresponds to the compounds with the chemical 
structure 9.10. Notably one of the diastereoisomers represented by the more downfield peak, 
was processed slightly faster. The half-life of 9.6d was found to be 35 min. In comparison the 
half-life of INX-189 was ca. 20 min.  
The final product of the hydrolysis, represented by the single peak at "P = 7.37 ppm, 
corresponds to the aminoacyl intermediate represented by the chemical structure 9.11. The 
full conversion of the parent ProTide was achieved within ca. 4 h. 
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Figure 9.4. Carboxypeptidase Y mediated hydrolysis of 9.6d, followed by 31P NMR. 
  
Efficient activation of 9.6d is consistent with its exceptional replicon anti-HCV 
activity (Table 9.7). 
 Similarly, carboxypeptidase Y assay performed on L-alanine benzyl diamidate 
derivative 9.9d, showed good conversion of the parent diamidate (Figure 9.5). 
In the blank experiment 9.9d has a 31P NMR shift of 13.86 ppm (Figure 9.5). After 10 
minutes of enzyme addition, a small downfield metabolite peak is observed at 14.28 ppm, 
which is consistent with cleavage of the benzyl ester moieties. The peak at 14.28 ppm builds 
up for approximately 50 min and after that time slowly diminishes with the concurrent 
formation of a new peak at 7.37 ppm. This intermediate starts to form within the first 17 min 
and grows in the magnitude over the course of the experiment. The peak at 7.37 ppm 
corresponds to the aminoacyl metabolite 9.11. The half-life of 9.9d was found to be less than 
20 min. 
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Figure 9.5. Carboxypeptidase Y mediated hydrolysis of 9.9d, followed by 31P NMR. 
 
9.3.5 Synthesis of metabolic intermediate 9.11. 
 
 In order to verify chemical structure of aminoacyl metabolite 9.11 formed during 
carboxypeptidase Y assay, synthesis of 9.11 was performed (Scheme 9.8). We were 
interested to see, whether the iodine atom is not being lost/metabolised during the initial steps 
of produg activation. To investigate that, UV spectra of 9.11 obtain during enzymatic and 
chemical hydrolysis and also non-iodinated analogue 5.21 from enzymatic assay were 
compared. The presence of the iodine in C8-position would result in noticeable shift of !max 
value comparing to the non-iodinated compound. 
 Synthesis of the diacid intermediate 9.11 involved hydrolysis of the previously 
prepared phosphoramidate 9.6e (Scheme 9.8) in a 1:1 mixture of triethylamine and water. 
The reaction mixture was stirred at 40 °C for 6 days and after that time purified on silica gel, 
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Reagents and Conditions: i) Et3N : H2O (1:1), 40 °C, 6 days. 
Scheme 9.8. Synthesis of 8-C-iodo-6-O-methyl-2’-C-methylguanosine aminoacyl intermediate 9.11. 
 
The structure of compound 9.11 was confirmed by NMR analysis and mass 
spectrometry. 
With analytical marker 9.11 in hand, UV spectra comparison was performed (Figure 9.6). 
 
 
Figure 9.6. UV spectra comparison of metabolic intermediates 9.11 and 5.21. 
 
 It is clear from Figure 9.6, that metabolic intermediate 9.11 obtained during 
enzymatic hydrolysis and one prepared synthetically share the same base structure, indicated 
by the same value of !max = 288 nm (red and brown curve). Non-iodinated analogue 5.21 
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shows maximum absorbance at !max = 280 nm. These data evidently show that in the 
presence of carboxypeptidase Y mediated hydrolysis of an ester unit the C8-iodo substituent 
stays intact. 
 
9.4 Synthesis of a second series of 8-modified nucleosides. 
 
 Encouraged by the results obtained for the C8-iodo nucleoside we decided to replace 
the C8-iodo atom by methyl-, thiomethyl-, methoxy- and phenyl- groups to mimic the iodine 
electronically and/or sterically and to investigate the influence on the antiviral potency. 
 
9.4.1 Synthesis of 8-C-methyl-6-O-methyl-2’-C-"-methylguanosine. 
 
Application of cross-coupling reactions in the synthesis of purines and nucleosides 
began in late 80’s. At the beginning only rather scattered applications of reactions of 
halopurines with arylmagnesium halides, alkylcuprates and alkenylstannanes were reported.10 
Introduction of various carbon chains onto the C-8 carbon atom of the naturally occurring 
purine nucleosides was mainly achieved via application of radical reactions or C-lithiation.11 
These methods however do not provide satisfactory regioselectivity and yields.  
Although the cross-coupling of Grignard reagents with aryl halides proved to be very 
successful in synthetic organic chemistry, however the application to the 8-bromopurine was 
inefficient.12 Hirota et al. reported the cross-coupling reaction of protected 8-bromoadenosine 
with trialkylaluminums in the presence of palladium catalyst in good yields.13 Thus, 
following the procedure, 8-C-methyl-6-O-methyl-2’-C-methylguanosine was synthesised in 






















Reagents and Conditions: i) a) HMDS, (NH4)2SO4, 1,4-dioxane, 3 h, reflux; then b)Al(Me3)3, Pd(PPh3)4, THF, 
70 °C; b) NH4Cl, MeOH, reflux, 3 h. 
Scheme 9.9. Synthesis of 8-C-methyl-6-O-methyl-2’-C-methylguanosine 9.13. 
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 The conversion of the 8-C-bromo-6-O-methyl-2’-C-methylguanosine was performed 
according to the slightly modified procedure: A mixture of 8-bromo nucleoside analogue was 
refluxed for 3 h in 1,4-dioxane, in the presence of excess of HMDS and a catalytic amount of 
ammonium sulfate, under an argon atmosphere. After solvents removal, the residue was 
dissolved in dry THF and tetrakis palladium triphenylphosphine was added, followed by the 
addition of trimethylaluminum solution. The reaction mixture was refluxed for 18 h. 
Removal of trimethylsislyl protecting groups was achieved in the presence of ammonium 
chloride in methanol. After column chromatography on silica gel, using CHCl3 : MeOH (0 to 
5%, gradient) as an eluent, pure compound was obtained as a yellowish solid in overall 72% 
yield.  
 
9.4.2 Synthesis of 8-C-phenyl-6-O-methyl-2’-C-!-methylguanosine. 
 
 Although palladium catalysed cross-coupling reactions are widely used to obtain C-
modified nucleosides, there are only few examples of palladium-catalysed syntheses of 8-
arylpurine nucleosides. A Suzuki coupling of 8-halopurines and appropriate arylboronic acids 
was investigated. The typical Suzuki cross-coupling reaction is carried out under anhydrous 
conditions in nonpolar solvent with protected nucleoside to increase its lipophilicity. The 
necessary protection/deprotection ads additional two steps to the synthetic scheme and might 
cause decrease in overall reaction yield. 
Western et al. reported efficient synthesis of 8-aryl-2’-deoxyguanosine in an aqueous 
solvent from unprotected halonucleoside in the presence of palladium catalyst and water-
soluble phosphine ligand.14 It was decided to adopt this procedure in order to synthesise 8-C-






















Reagents and Conditions: i) Pd(OAc)2, TPPTS, Na2CO3, phenylboronic acid, H2O : ACN (2:1), 80 °C, 4 h. 
Scheme 9.10. Synthesis of 8-C-phenyl-6-O-methyl-2’-C-methylguanosine 9.14. 
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The desired 8-aryl nucleoside analogue 9.14 was obtained in a single step reaction 
from unprotected 8-C-bromo-6-O-methyl-2’-C-methylguanosine 9.1. Reaction was carried 
out in degassed water : acetonitrile mixture (2:1) in the presence of palladium acetate 
(Pd(OAc)2) and 3,3!,3!!-phosphinidynetris(benzenesulfonic acid) trisodium salt (TPPTS) as a 
ligand under argon atmosphere, at 80 °C for 4 h. Degassing of the solvent system was found 
to be crucial for the good conversion of the starting material. After work-up and 
recrystallisation from water, pure 9.14 was obtained as a white fine powder, in very good 
75% yield. 
 
9.4.3 Synthesis of 8-C-thiomethyl-6-O-methyl-2’-C-!-methylguanosine. 
 
 Compounds bearing 8C-thiomethyl substituent was synthesised according to the 
procedure described for the 6-Cl displacement reactions described in detail in Chapter 5, 





















Reagents and Conditions: i) NaSMe (15% in H2O), DMF, rt, 2 h. 
Scheme 9.11. Synthesis of 8-C-thiomethyl-6-O-methyl-2’-C-methylguanosine 9.15. 
 
 In the case of nucleoside analogue 9.15, better results in terms of starting material 
conversion and ease of purification, were obtained when sodium methanethiolate was added 
portion wise over a period of 2 h. 
After purification on silica gel, using CHCl3/MeOH (0 to 5% in gradient) as an eluent, pure 
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9.4.4 Biological evaluation of a second series of 8-modified 6-O-methyl-2’-C-!-
methylguanosine nucleoside analogues. 
 
 All newly synthesised nucleoside analogues 9.13-9.15 were investigated for their 
ability to inhibit HCV replication in in vitro cell-based assay by Inhibitex Inc.  
The corresponding data are reported in Table 9.8. 
 
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 50%; 
CC50: 50% cytotoxic concentration. 
Table 9.8. Summary of the anti-HCV activity of a second series of 8-C-modified-6OMe2’CMeG 
nucleoside analogues. 
 
 As can be seen in Table 9.8, all C8-modified nucleoside analogues possess increased 
ClogP values comparing to the 6-O-methyl-2’-C-methylguanosine with no modification at 
C8-position. The lowest ClogP value was reported for 9.13 C8-methyl analogue (ClogP =  
-0.4) and the highest for 9.14 bearing C8-phenyl alteration (ClogP = 1.4). 
 From the replicon data it can be noticed that none of the newly synthesised analogues 
of 8-C-iodo-6-O-methyl-2’-C-methylguanosine exhibit significant anti-HCV activity. 
Compounds bearing simple methyl- 9.13 and thiomethyl- 9.15 substituents at C8-position 
were found to be completely inactive in replicon assay. In parallel experiments analogue with 
8-C-phenyl modification was exhibiting low anti-HCV activity, with EC50 values in a range 
of 50 µM.  
 All synthesised nucleoside analogues did not display any toxicity up to 100 µM in 
replicon assay. 
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 It was decided to apply ProTide technology to the second series of 8C-modifed 
nucleoside analogues in order to investigate potential improvement of antiviral activity of 
these compounds. 
 
9.5 SAR of a second series of 8-modified 6-O-methyl-2’-C-!-methylguanosine ProTides. 
 
 A small series of 5’-phosphoramidates (9.17a-9.19a) was prepared using tBuMgCl-
mediated coupling conditions, in moderate yield 7-23% (Scheme 9.12, Table 9.9). To 




























Reagents and Conditions: i) Naph-L-alanine-O-2,2-dimethypropyl phosphorochloridate, tBuMgCl, dry THF, rt, 
overnight. 
Scheme 9.11. Generalprocedure for the synthesis of a second series of 8-C-modified-6-O-methyl-2’-
C-methylguanosine ProTides using tBuMgCl. 
 
 After column chromatography, pure compounds 9.17a-9.19a were obtained as 
equimolar mixtures of phosphate diastereoisomers as evidenced by 31P NMR and HPLC. 
 All newly synthesised compounds were assayed for their ability to inhibit HCV RNA 
replication in subgenomic replicon cells by Inhibitex Inc. The potency and toxicity of these 
compounds are summarised in Table 9.9. The INX-189 and 9.6a- 8C-iodo analogue were 
evaluated alongside and were used as a references. 
 Considering the lipophilicity, all synthesised analogues have ClogP values in a range 
of 3.5-5.5 (Table 9.9), which is considered as an optimal for the passive cellular uptake.  
As noted in Table 9.9, phosphoramidate 9.17a (8C-methyl) was poorly active against HCV 
replicon cells. Its EC50 value was found to be greater than 30 µM; at the same time the 
compound did not display any cellular toxicity up to 100 µM concentration. The C8-
thiomethyl derivative 9.19a exhibited improved potency comparing to the parent nucleoside 
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9.15 (EC50 = 13 µM vs. EC50 >100 µM, respectively), however this activity was more than a 
1000-fold lower than the one of clinical candidate INX-189 (EC50 = 0.01 µM). Additionally 
some toxicity (CC50 = 39 µM) related to 9.19a was observed. 
 
 
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 50%; 
CC50: 50% cytotoxic concentration. 
Table 9.9. Summary of the anti-HCV activity of a second series of 8-C-modified-6OMe2’CMeG 
ProTides, their calculated lipophilicity values and isolated yields. 
 
 The most interesting compound across the family was 8-C-phenyl derivative 9.18a, 
exhibiting anti-HCV activity in low micromolar range (EC50 = 3.6 µM). This is the only 
example (except the 8-C-iodo series) of 8-modified ProTide displaying inhibitory activity 
below 5 µM concentration. This particular compound is a proof of concept example where 
application of ProTide technology allowing to convert a very poorly active nucleoside 9.14 
(EC50 = 58 µM) into compound with low micromolar activity. 
 Although the activity of 9.18a is greatly decreased comparing to the activity of INX-
189, the family of novel 8-C-phenyl analogues can become a starting point in the design and 
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9.6 Understanding the 8-C-iodo phenomena. Analysis of hepatocyte metabolites of 8-C-
iodo-6-O-methyl-2’-C-methylguanosine ProTides. 
 
 Several novel 8-C-modified-6-O-methyl-2’-C-methylguanosine nucleoside analogues 
were designed and synthesised, and ProTide technology was applied to each one. Across 
seven different modifications only 8-C-iodo derivatives exhibited potency comparable to that 
of clinical candidate INX-189. From all experiments performed it was clear that the presence 
of iodine is essential for the activity.  
 In order to understand the phenomenon of the iodine substituent, the following 
metabolic pathway was suggested (Figure 9.7).  
 
 
Figure 9.7. Suggested metabolic pathway of 8-C-iodo-6-O-methyl-2’-C-methylguanosine ProTides. 
 
The activation of the 8-C-iodo ProTide could involve ‘traditional’ conversion to the 
8-C-iodo-6-O-methyl-2’-C-methylguanosine 5’-monophosphate 9.20. At this point it is not 
clear whether the 9.20 could serve as a substrate for adenylate deaminase or any other 
deaminating enzyme to give 8-C-iodo-2’-C-methylguanosine-5’-monophosphate 9.21 which 
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could undergo further phosphorylation to the active 8-C-iodo-2’-C-methylguanosine-5’-
triphosphate 9.22. An experiment performed in the presence of ADA (Section 9.2.5) shown 
that 8-C-iodo-6-O-methyl-2’-C-methylguanosine 9.3 (parent nucleoside) is not susceptible 
substrate for the enzyme. Taking in consideration substrate specificity of adenylate 
deaminase it is possible that this enzyme could not be responsible for the hydrolysis of C6-
substituent. Also due to the fact that there are many different type of deaminases able to 
deaminate adenosine monophosphate, this particular metabolic pathway cannot be excluded. 
On the other hand it was considered that the monophosphate 9.20 could undergo a 
deiodination reaction. We wondered if it may be mediated by iodotyrosine dehalogenase I 
(iodotyrosine deiodinase, IYD, EC 1.22.1.1). This enzyme is responsible for iodide salvage, 
catalysing deiodination of mono- and diiodotyrosine- halogenated by-products of thyroid 
hormone production. It has been reported that deiodination occurs predominantly in the liver 
microsomes and is mediated by NADPH. Molecular modelling studies15 (data not shown) 
suggest good fitting of 9.20 in the active site of IYD. After deiodination 9.23 could undergo 
ADA-mediated hydrolysis to form 9.24 and consequently after phosphorylation to the active 
2’-C-methylguanosine-5’-triphosphate species 9.25. The deiodination step could explain the 
specific activity of 8-C-iodo nucleoside and related prodrugs comparing to any other C8-
modified analogues. 
To probe the suggested metabolic pathway of 8-C-iodo prodrugs, the analysis of 
metabolites produced during incubation of 8-iodinated ProTides in the presence of primary 
human hepatocytes was performed. Experiments were conducted by Inhibitex Inc. 
ProTides 9.6a and INX-189 were incubated in primary human hepatocytes at an 
arbitrary concentration of 10 µM over a period of 24 h. ProTide uptake was measured in cell 
supernatant (Figure 9.8) and metabolic products were measured intracellularly at 0.5 h, 1h, 2 
h, 4 h, 6 h, 8 h and 24 h time points (Figure 9.9). 
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No cells control. 
Figure 9.8. Cellular uptake of INX-189 and 9.6a during incubation with primary human hepatocyts. 
 
 Data reported in Figure 9.8 clearly show rapid cellular uptake of both ProTides. In the 
case of INX-189 no traces of prodrug in cell supernate were detected after 6 h of incubation. 
In comparison 9.6a was found to be delivered faster inside the cell, within ca. 4 h. This 
difference can arise from improved lipophilicity of 9.6a compared to INX-189 (ClogP = 4.1 
vs. 3.3, respectively).  
In the next instance intracellular levels of metabolite formed during incubation with 
primary hepatocytes were measured (Figure 9.9). 
 
 
Figure 9.9. Intracellular metabolites produced from 9.6a and INX-189 during incubation in the 
presence of primary human hepatocytes. 
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 Results obtained from the analysis of hepatocyte intracellular fractions (Figure 9.9) 
clearly show, that there has been no difference between the levels of individual metabolites 
including the active 2’CMeG 5’-triphosphate produced from the incubation of either 9.6a or 
INX-189 with primary human hepatocytes. These data are consistent with biological activity 
observed for these compounds. Furthermore no traces of 8-C-iodo analogues of any of the 
metabolites were detected.  
These results are somewhat surprising, as the iodo substituent did not display any 
profound instability, however it is obvious that the 8-C-iodo comes off very quickly (once in 
the presence of biological media), apparently before the cleavage of the phosphoramidate 
amino acid ester.  
Data reported in Figure 9.9 explain the high replicon activity of 8-C-iodo derivatives 
comparing to any other 8-C-modified analogues and make clear that the introduced 8-C-iodo 




 To summarise, a series of novel 8-C-modified-6-O-methyl-2’-C-methylguanosine 
nucleoside analogues and their aryloxyphosphoramidate, and diamidate prodrugs has been 
synthesised. During biological evaluation it was found, that only analogues bearing 8-C-iodo 
substituent displayed anti-HCV inhibitory activity. Structure activity relationships were 
extensively studied, including modification in the ester, aryl and amino acid moieties. A 
combination of various esters and amino acids resulted in very potent compounds displaying 
nanomolar activity, suitable for further development. 
 Evaluation of a second family of 8-C-modified nucleosides and ProTides designed to 
mimic the 8-C-iodo sterically and/or electronically showed that only 8-C-phenyl derivative 
exhibit some potential, however these compounds were ca. 200-fold less potent than the 
corresponding iodo analogues and ca. 400-times less active than the clinical candidate INX-
189.  
 To understand the phenomenon of the 8-C-iodo substituent, metabolite analyses of 
intermediates formed during incubation of appropriate ProTides with primary human 
hepatocytes were conducted. Obtained data revealed that the 8-C-iodo substituent act as a 
promoiety with eventual liberation of 2’CMeGTP, as with the clinical candidate INX-189.  
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New family: C-2 modifications. 
 
10.1 2-C-modified-2’-C-!-methylguanosine – the rational behind the design. 
 
 It has been reported in the literature, that the 2C-N atom of guanine is susceptible to 
modifications by various potential carcinogens including formaldehyde, acetaldehyde and 
oxidation products of structurally distinctive aromatic hydrocarbons. Some of these 2C-N 
adducts were found to exhibit mutagenic properties by generating G to T transversion. The 
activity of C2-N substituted nucleoside analogues is based partly on their ability to mimic the 
base-pairing capacity of guanosine 5’-triphosphate. Furthermore it has been suggested, that 
the bulky group on 2C-N atom of guanine can cause strong interference with polymerisation 
reaction, leading to misincorporation and blockage of replicative DNA polymerases, most 
probably at or before the phosphodiester bond formation.
1-4
 
Several different substitutions in the C2-position of the purine base were investigated 
and docking studies using HCV polymerase model were performed by Brancale and  
Zonta.
5a-b
 Molecular modelling studies confirmed important role of the C2-nitrogen in 
hydrogen bond formation during base pairing. Consequently modifications which do not 
affect hydrogen bonding capabilities of the C2-nitrogen were well tolerated (even bearing 
bulky substituents) in the active site of the RdRp. 
We decided to synthesise various C2-modified analogues of 2’-C-!-methylguanosine 
and investigate their influence on HCV replication. 
 
10.2 Synthesis of 2C-modified derivatives – 2C-benzylamine analogue. 
 
In the first instance we have focused our attention on modifications that would 
preserve the ability of the C2-group to form hydrogen bonding during base pairing. 
Molecular modelling studies suggested 2-C-benzylamine-2’-C-!-methylguanosine as an 
analogue that would fit the best in the active site of the RdRp (Figure 10.1).
5a
 




Figure 10.1. Docking results of the 2-C-benzyl-2’-C-methylguanosine in the active site of RdRp.5a 
 
10.2.1 Synthesis of 2-C-benzylamine-2’-C-!-methylguanosine via diazotization-
halogenationreaction. 
 
 One of the reported routes towards 2-C-modified purine analogues involves 
diazotization/bromo dediazoniation reaction followed by nucleophilic displacement of the 
halogen atom. It was decided to adopt the procedure described by Trivedi
6
 in order to 




















































Reagents and Condition: i) Et3N, DMAP, Ac2O, ACN, rt, 4 h; ii) i-pentyl nitrite, CHBr3, 95 °C, 3 h; 
iii) PhCH2NH2, EtOH, reflux, 16 h; iv) NH3/MeOH, 0 C to rt, 16 h. 
Scheme 10.1. Synthesis of 2-C-benzylamine-2’-C-methylguanosine via diazotization-halogenation 
reaction. 
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In the first step, 2’-C-methylguanosine 4.10 was fully protected with acetyl groups in 
90% yield. Halogenation of 2’-C-methylguanosine 2’,3’,5’-triacetate 10.1 was performed in 
bromoform in the presence of isopentyl nitrite. After column chromatography pure 
compound 10.2 was obtained as a yellowish solid in 35% yield. The nucleophilic 
displacement with benzylamine in refluxing ethanol provided 10.3 in 33% yield. The final 
deprotection of acetyl protecting groups was accomplished using methanolic ammonia. After 
purification on silica gel using CHCl3 : MeOH (8:2) as eluent, pure 2-C-benzylamine-2’-C-
mehylguanosine (10.4) was obtain in 74% yield. 
 As the overall yield of the reaction was lower than 8%, we decided to investigate 
different synthetic pathways in order to obtain 10.4 in more satisfactory yield. 
 
10.2.2 Synthesis of 2-C-benzylamine-2’- C-!-methylguanosine via convergent method. 
 
In order to obtain 10.4 in better yield, Vorbruggen coupling reaction of 1,2,3,5-tetra-
O-benzoyl-2-C-methyl-D-ribofuranose (4.5) and commercially available  
2-bromohypoxathine (10.5) was investigated.  
The coupling reaction was carried out in dry acetonitrile in the presence of DBU and 
TMS-triflate at 65 °C for 6-8 h (Scheme 10.2).  After column chromatography, pure 10.6 was 
isolated as a yellowish solid in 78% yield. The introduction of benzylamine functionality was 
carried out using conditions described in the previous section and resulted in formation of 















































Reagents and Condition: i) DBU, TMSOTf, dry ACN, 65 °C, 6-8 h; ii) PhCH2NH2, EtOH, reflux,  
16 h; iii) NH3/MeOH, 0 C to rt, 16 h. 
Scheme 10.2. Synthesis of 2-C-benzylamine-2’-C-methylguanosine using convergent approach. 
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Subsequent deprotection step in methanolic ammonia followed by column chromatography, 
provided pure 10.4 in good yield (73%). 
 The new synthetic route resulted not only in improved overall yield (25% vs. 8%) but 
also involved fewer steps and reaction mixtures were easier to purify. 
 
10.2.2.1 Synthesis of ProTides of 2-C-benzylamine analogues – first attempt. 
 
 With 10.4 in hand, direct coupling of nucleoside analogue and !-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) phosphorochloridate was performed. In the first attempt, the 
general tBuMgCl mediated procedure (used for the synthesis of 6-O-methyl-2’-C-
methylguanosine) was applied (Scheme 10.3, Table 10.1, Entry 1). During 16 h course of the 
reaction, no product formation was observed as evidenced by TLC analysis. After column 
chromatography only starting material was recovered.  
After failure of the first attempt two additional reactions were set up. Firstly, reaction was 
carried out in elevated temperature at 35 °C (Table 10.1, Entry 2) and secondly 5 mol 
equivalents of phosphorochloridate were used (Table 10.1, Entry 3). As can be seen in Table 
10.1. none of the described attempts resulted in product formation. Alteration of the reaction 
solvent was investigated in order to enhance solubility of the starting material 10.4. The 
reaction was carried out in the mixture of THF and pyridine, and in the presence of NMI 
(Table 10.1, Entry 4) as an activator. The NMI-mediated coupling was applied instead of the 








































Reagents and Condition: For reagents and conditions refer to Table 10.1. 
Scheme 10.3. Attempted synthesis of 2-C-benzylamine-2’-C-methylguanosine ProTide. 
 




Table 10.1. Reagents and conditions of Scheme 10.3. 
 
The reaction was carried out at ambient temperature over 16 h. During that time no 
product formation was observed. It was decided to use pyridine as a sole solvent for the 
reaction (Table 10.1, Entries 5 and 6), however no improvement either at ambient or elevated 
(35 °C) temperature was observed. 
Due to the low solubility of 2-C-benzylamine-2’-C-methylguanosine in THF and 
pyridine, it was decided to investigate a nucleoside protection strategy. 
 
10.2.2.2 2’,3’-protection of 2-C-benzylamine-2’-C-methylguanosine. 
 
 To overcome solubility problems and to enhance 5’-phosphorylation, 2’,3’-diol 
protection was investigated. As the method used for the preparation of 2’,3’-isopropylidene-
2’-C-methylguanosine was very successful (Chapter 4, Section 4.3), it was decided to apply 
the same reaction conditions to 2-C-benzylamine-2’-C-methylguanosine (Scheme 10.4, Table 


























Reagents and Condition: For reagents and conditions refer to Table 10.2. 
Scheme 10.4. Attempted synthesis of 2’,3’-isopropylidene protected 2-C-benzylamine-2’-C-
methylguanosine. 
 




Table 10.2. Reagents and conditions of Scheme 10.4. 
 
 As can be seen in Table 10.2, reaction carried out in acetone and in the presence of 
catalytic amount of perchloric acid, did not result in product formation. The TLC analysis of 
the reaction mixture indicated that mostly starting material 10.4 was present plus some 
decomposition products. Reduction of the reaction time with elevated temperature (Table 
10.2, Entry 2) gave mainly decomposition (base line product) of the starting material 10.4. 
The replacement of the acid catalyst by pTSA (Table 10.2, Entry 3) gave similar results as 
the first trial. The two subsequent reaction attempts (Table 10.2, Entry 4 and 5) carried out in 
the presence of acetone and 2,2-dimethoxypropane and catalytic amounts of pTSA, either at 
ambient temperature or at 35 °C, did not result in product formation. Change of the solvent 
from acetone to DMF also did not provide the desired product. 
  All attempts clearly suggest a relative instability of the starting material 10.4 during 
the reaction course. Due to the fact that direct coupling of unprotected nucleoside 10.4 and 
phosphorochloridate species was unsuccessful, and furthermore 2’,3’-diol protection did not 
provide the desired product, it was decided to investigate a different route towards 2-C-
benzylamine-2’-C-methylguanosine ProTides. 
 
10.2.3 Synthesis of 2-C-benzylamine-6-O-methyl-2’-C-!-methylguanosine via 
halogenation reaction. 
 
 During the synthesis of 6-O-methyl-2’-C-methylguanosine and related ProTides, it 
has been noticed that the introduction of the 6-O-methyl modification resulted in enhanced 
solubility of the parent nucleoside comparing to the unmodified 2’-C-methylguanosine 4.10. 
The coupling reaction of nucleoside analogue 5.4 did not require 2’,3’-protection and 
proceeded in good yields. We wondered whether the same effect would be observed in the 
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case of 2-C-benzylamine-2’-C-methylguanosine 10.4, and therefore we decided to investigate 
the synthesis of 6-O-modified 2-C-benzylamine-2’-C-methylguanosine analogue. 
 The synthesis involved full protection of 6-O-methyl-2’-C-methylguanosine with 
acetyl protecting groups (Scheme 10.5). The 2’,3’,5’-protected nucleoside analogue 10.10 
















































(10.12)(10.13 X= OCH3, Y=NHCH2Ph
 10.14 X=NHCH2Ph, Y=Cl
 10.15  X=Y=NHCH2Ph)  
Reagents and Condition: i) Et3N, DMAP, Ac2O, ACN, rt, 16 h; ii) AcCl, Bu4NNO2, DCM, -5 °C to 0 
°C, 15 min; iii) NH3/MeOH, 0 C to rt, 16 h; iv) PhCH2NH2, EtOH, reflux, 16 h. 
Scheme 10.5. Synthesis of 2-C-benzylamine-6-O-methyl-2’-C-methylguanosine. 
 
As the introduction of C-2 bromo modification was low yielding, we decided to 
investigate a different approach. The attention was focused on C-2 chlorination reaction, as 




The reaction was performed according to the procedure described by Janeba et al.
7
 
Thus, 10.10 was reacted with acetyl chloride in the presence of tetrabutylammonium nitrite in 
dry dichloromethane. After work up and column chromatography, pure 10.11 was obtain in 
62% yield (Scheme 10.5). Methanolic ammonia mediated deprotection reaction resulted in 
formation of 10.12 in excellent yield (90%). Introduction of benzylamine functionality was 
performed in refluxing ethanol in the presence of benzylamine for 16 h. The resulting mixture 
consisted of three different products. During the reaction course partial displacement of 6-O-
methyl group was observed. The major and the least lipophilic product was the desired 2-C-
benzylamine-6-O-methyl-2’-C-methylguanosine 10.13. The other two products were 
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identified as 2-C-chloro-6-C-benzylamine-2’-C-methylguanosine 10.14 and 10.15 bearing 
benzylamine in both C2- and C6-positions (Scheme 10.5). 
Although the reaction resulted in formation of desired 10.13, due to the low reaction 
yield and very difficult purification of the last step, further optimization of the reaction 
conditions or an alternative route towards 10.13 would have to be investigated. 
Reductive amination procedures or Buchwald type chemistry may be considered as an option. 
 
10.2.4 Synthesis of ProTides of 2-C-benzylamine analogues. 
 
 In order to synthesise !-naphthyl-L-alaninyl-O-2,2-dimethylpropyl phosphoramidate 
of 10.13, the tBuMgCl-mediated coupling was applied.  
The nucleoside analogue 10.13 was dissolved in dry THF and reacted with 3.3e in the 
presence of the Grignard reagent. During the reaction course, formation of only one product 
was observed, as evidenced by the TLC analysis. After column chromatography on silica gel, 
using CHCl3/MeOH (0 to 3% gradient) as eluent, pure 10.16a was obtained as a white solid 
in 19% yield (Scheme 10.6). 
At this point we decided to investigate, whether it would be possible to cleave the C6 
methyl ether in order to obtain 2-C-benzylamine-2’-C-methylguanosine ProTide. 
In the first instance the procedure reported by Moreau et al.
8
























































Reagents and Condition: i) tBuMgCl, dry THF, rt, 16 h; ii) TMSCl, NaI, dry ACN, rt, 3 h. 
Scheme 10.6. Synthesis of 2-C-benzylamine-6-O-methyl-2’-C-methylguanosine and 2-C-
benzylamine-2’-C-methylguanosine ProTides. 
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 The cleavage of the C6 methyl ether was performed in dry acetonitrile in the presence 
of trimethylsilyl chloride (TMSCl) and sodium iodide (NaI), at ambient temperature. After  
3 h of reaction course, TLC analysis revealed the presence of a new, more polar species. 
After purification using preparative TLC, pure 10.17a was obtained as a white solid, in 29% 
yield. 
 Biological evaluation of 10.16a and 10.17a will be reported and discussed in Section 
10.6. 
 
10.3 Synthesis of 2C-modified analogues – 2-C-thiophenyl analogues. 
 
At the same time we where also interested in the preparation of 2-C-thiophenyl-2’-C-
methylguanosine and its derivatives in order to investigate whether the presence of the 
hydrogen bond donor in the C2-position is crucial for the appropriate interaction in RdRp 
active site. 
In the first instance the possibility of direct introduction of thiophenyl functionality at 
the C2-position was investigated (Scheme 10.7). 
Reaction of 2-amino-6-chloro-9-(2’-C-methyl-!-D-ribofuranosyl)purine 5.2 with 
diphenyldisulfide and isopentyl nitrite in refluxing acetonitrile was carried out. Purification 
on silica gel, using CHCl3 : MeOH (98:2) as eluent provided 10.17 contaminated with some 









































Reagents and Condition: i) diphenyldisulfide, isopentyl nitrite, dry ACN, reflux, 3 h; ii) 
NaOMe/MeOH, 0 C to rt, 16 h; iii) TMSCl, NaI, dry ACN, reflux 4 h. 
Scheme 10.7. Synthesis of 2-C-thiophenyl-6-O-methyl-2’-C-methylguanosine and 2-C-thiophenyl-2’-
C-methylguanosine. 
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 The crude 10.17 was submitted for the displacement and deprotection reaction using 
excess of sodium methoxide in methanol. After column chromatography, pure 10.18 was 
obtained in 44% yield (over 2 steps) as a white solid. Subsequent cleavage of the methyl 
ether in the presence of TMSCl and NaI, provided C6-keto analogue 10.19 in 42% yield. 
  Both 2-C-thiophenyl analogues 10.18 and 10.19 were submitted for the 
phosphoramidate coupling reaction. 
 
10.3.1 Synthesis of ProTides of 2-C-thiophenyl analogues. 
 
 The coupling reactions were performed in dry THF using tBuMgCl coupling method. 
To facilitate comparison, both compounds were prepared as !-naphthyl-L-alanine-O-2,2-



































 10.21a, X=OH)  
Reagents and Condition: i) tBuMgCl, dry THF, rt, 16 h. 
Scheme 10.8. Synthesis of ProTides of 2-C-thiophenyl analogues 10.18 and 10.19. 
 
 The newly synthesised compounds were isolated as roughly equimolar mixtures of 
diastereoisomers at the phosphorus centre, evidenced by 
31
P NMR and HPLC. 
Phosphoramidates 10.20a and 10.21a alongside with parent nucleosides 10.18 and 10.19 
were submitted for the biological evaluation. The corresponding results will be reported and 
discussed in Section 10.6. 
 
10.4 Synthesis of 2C-modified analogues – 2-C-thiobenzyl analogues. 
 
In the next step, the exact sulphur-containing analogue of 2-C-benzylamine-2’-C-
methylguanosine was prepared (Scheme 10.9). 
 










































Reagents and Condition: i) dibenzyldisulfide, isopentyl nitrite, dry ACN, reflux, 3 h; ii) 
NaOMe/MeOH, 0 C to rt, 16 h; iii) TMSCl, NaI, dry ACN, reflux 4 h. 
Scheme 10.9. Synthesis of 2-C-benzylamine-2’-C-methylguanosine. 
 
 Compounds 10.24 and 10.25 were prepared in analogous sequence as 2C-thiophenyl 
derivatives, using dibenzyldisulfide as a donor of thiobenzyl functionality (Scheme 10.9).  
The 2-C-thiobenzyl-6-O-methyl-2’-C-methylguanosine 10.24 was obtained in 34% over two 
steps, and its guanine analogue 10.25 in 47% yield after the cleavage of the C6 methyl ether 
(Scheme 10.9). 
The 2-C-thiobenzyl-6-O-methyl-2’-C-methylguanosine 10.24 was used in the 
subsequent phosphorylation reaction in order to obtain corresponding ProTide. 
Both parent nucleosides 10.24 and 10.25 were evaluated against HCV in in vitro 
replicon assay, related data will be discussed in Section 10.6. 
 
10.4.1 Synthesis of ProTides of 2-C-thiobenzyl analogues. 
 
The coupling reaction was performed using the tBuMgCl-mediated method. To 
facilitate comparison, the compound was prepared as the !-naphthyl-L-alanine-O-2,2-
dimethylpropyl analogue 10.25a (Scheme 10.10). 



















































Reagents and Condition: i) tBuMgCl, dry THF, rt, 16 h; ii) TMSCl, NaI, dry ACN, rt, 2 h. 
Scheme 10.10. Synthesis 2-C-thiobenzyl ProTides of 10.25a and 10.26a. 
 
 As the procedure used for the cleavage of the methyl ether was found to be successful 
on the ProTide level, compound 10.26a was prepared from 10.25a by treatment with TMSCl 
and NaI. After purification on preparative TLC, pure 10.26a was obtained in 34% yield. 
The newly synthesised compounds were isolated as roughly 1:1 mixtures of 
diastereoisomers at the phosphate, evidenced by 
31
P NMR and HPLC. 
Phosphoramidates 10.25a and 10.26a were evaluated for their anti-HCV activity in 
cell-based replicon assay. The corresponding data will be reported and discussed in Section 
10.6. 
 
10.5 Synthesis of ProTides of other 2-C-modified analogues. 
 
 During the synthetic pathway towards 2-C-benzylamine-6-O-methyl-2’-C-
methylguanosine 10.13, a synthetic intermediate bearing chlorine in C2-position 10.11 was 
found to be of interest. It was decided to deprotect 10.12 and to apply the ProTide approach 
in order to investigate the influence of the C2-chloro substituent on the anti-HCV activity.  
The deprotection reaction, carried out in methanolic ammonia, provided 2-C-chloro-
6-O-methyl-2’-C-methylguanosine 10.12 in excellent 90% yield (Scheme 10.11). After 
coupling with !-naphthyl-(2,2-dimethylpropoxy-L-alaninyl) phosphorochloridate 3.3e, 
10.27a was obtained in 19% yield (Scheme 10.11). Due to the low amount of 10.27a the 
attempt of cleaving C6 methyl ether was not performed. 












































































Reagents and Condition: i) NH3/MeOH, 0 °C to rt, 16 h; ii) tBuMgCl, dry THF, rt, 16 h; iii) 
NaOMe/MeOH, 0 °C to rt, 3 days; iv) TMSCl, NaI, dry ACN, rt, 3 h. 
Scheme 10.11. Synthesis of 2-C-benzylamine-2’-C-methylguanosine. 
 
 It was also interesting to see, whether the substitution of C2-chloro with a methoxy 
moiety will have an impact on biological activity. The displacement-deprotection reaction 
was carried out in an excess of sodium methoxide in methanol (Scheme 10.11). The best 
results were obtained using 6 mol equivalents of sodium methoxide added portionwise over 3 
days reaction course. Because the desired product and C2-chloro analogue have exactly the 
same Rf on TLC, the progress of the reaction was monitored by NMR. Small samples were 
collected from the reaction mixture and after work up with Amberlite H
+
, proton NMR 
spectra were recorded. After full conversion of 10.10, as evidenced by proton NMR, 
purification was performed and 10.28 was obtained in 86% yield (Scheme 10.11). 
The coupling reaction with the appropriate phosphorochloridate 3.3e gave 10.29a in 
17% yield (Scheme 10.11). Subsequent reaction of C6 methyl ether cleavage performed in 
the presence of TMSCl and NaI, provided C6-modified xanthosine type derivative 10.30a in 
47% (Scheme 10.11). 
All synthesised phosphoramidates 10.27a, 10.29a and 10.30a were isolated as a 
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10.6 Biological evaluation of 2-C-modified analogues and corresponding ProTides. 
 
 All newly synthesised C2-modified nucleosides and corresponding 
aryloxyphosphoramidates were evaluated in in vitro HCV replicon assay by Inhibitex Inc., 
(Table 10.3). 2’-C-methylguanosine 4.10, 6-O-methyl-2’-C-methylguanosine 5.4 and clinical 























AA: Amino acid; ClogP values calculated using ChemOffice Ultra 11.0; EC50: 50% effective concentration or 
compound concentration required to inhibit HCV replication by 50%; CC50: 50% cytotoxic concentration. 
Table 10.3. Summary of ant-HCV activity of C2-modified nucleoside analogues and their 
corresponding ProTides. 
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As can be seen in Table 10.3, most of the parent nucleosides bearing modifications at 
C6- and C2-position at the same time were completely inactive in the replicon based assay 
(Entries 10.12, 10.13, 10.18, 10.29, EC50 > 100 µM). The only exception was compound 
10.23 – 2-C-thiobenzyl-6-O-methyl-2’-C-methylguanosine analogue which displayed some 
anti-HCV activity at 40 µM concentration. Compounds, which were modified only at the C2-
position, were found to exhibit poor to moderate activity in cell based assay (10.24, EC50 = 
35 µM). The anti-HCV activity of 2-C-bezylamin-6-O-methyl-2’-C-methylguanosine 10.4 
was found to be >10 µM. All parent nucleosides were non-toxic in the replicon assay up to 
100 µM concentration. 
Looking at compounds at the ProTide level, it can be clearly noticed that the 
application of aryloxyphosphoramidate technology to the inactive or poorly active parent 
nucleosides resulted in compounds with anti-HCV activity in low micromolar and 
submicromolar range. The least active compound across the whole family was 2-C-
benzylamine-6-O-methyl-2’-C-methylguanosine ProTide 10.16a, which activity was greater 
than 40 µM. In contrast its C6-keto analogue 10.8a displayed EC50 value of 4.9 µM, being 
>10-times more potent that 10.16a but at the same time ca. 500-fold less potent than the 
clinical candidate INX-189. This result was somewhat disappointing as the compound 
showed the best fit in the active site of RdRp (according to the molecular modelling). It 
would be of interest to synthesise analogues bearing different substituents on the benzyl ring 
to see whether the anti-HCV activity can be improved. The compound was non-toxic up to 
100 µM concentration. No clear correlation between ClogP values and anti-HCV activity was 
found. 
Compounds 10.20a (2-C-thiophenyl-6-O-methyl-2’-C-methylguanosine ProTide) and 
10.25a (2-C-thiobenzyl-6-O-methyl-2’-C-methylguanosine ProTide) were found to exhibit 
similar activity EC50 = 13 and 12 µM, respectively. Both compounds displayed some toxicity 
in the replicon assay (CC50 = 25 and 16 µM, respectively). Considering the anti-HCV activity 
of these compounds, their selectivity indexes would be ca. 2 for 10.20a and 1 for 10.25a, and 
would make them one of the most toxic across reported series of ProTides. Interestingly, their 
C6-keto analogues 10.21a and 10.26a were found to be much more potent (EC50 = 1.4 and 
0.73 µM, respectively) and considerably less toxic (CC50 > 100 and = 58 µM, respectively). 
The compound 10.26a with an EC50 value of 0.07 µM was found to be the most active 
across the whole family, being ca. 50-times more potent than the parent nucleoside 10.24, 
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and ca. 70-times less active than the clinical candidate INX-189. High potency of these 
compounds proved, that the presence of the hydrogen bond donor functionality at the C2-
position is not crucial for the anti-HCV activity. Furthermore these compounds exhibited 
much improved HCV inhibitory activity comparing to the compound bearing amino group in 
the C2 (EC50 = 4.9 µM vs. 0.73 µM, for 10.8a and 10.26a, respectively). 
The compound 10.27a bearing C6-methoxy and C2-chloro substituents was active at 
2 µM concentration, while its analogue possessing methoxy functionality in both C6- and C2-
position was poorly active EC50 = 58 µM. Interestingly, xanthosine type analogue 10.30a 
displayed anti-HCV activity at 0.8 µM concentration, being as potent as 10.26a (EC50 = 0.73 
µM), and non-toxic up to 100 µM concentration. 
Reported results clearly indicate that presence of modifications at both C6- and C2- 
position greatly decreases anti-HCV activity of synthesised ProTides. The most probable 
explanation is that the active compounds require C6-keto functionality in order to display 
HCV inhibitory activity. The presence of the C2-substituents may prevent ADA-mediated 
hydrolysis of C6-modifications and as a result lower or no antiviral activity has been 
observed. To support this theory ADA assays on parent nucleosides 10.18 and 10.28 were 
peformed (Figure 10.1). 
Experiments were performed according to the procedure described in Chapter 5, 
Section 5.2.3. As can be seen in Figure 10.1, compounds 10.18 and 10.28 were found not to 
be suitable substrates for adenosine deaminase. No spectral change (shift in !max) was 
observed during 10 h of experiment (Figure 10.1). 
 
Figure 10.1. Spectral change during ADA-mediated hydrolytic removal of alkyl group from 10.18 
and 10.28. 
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The obtained results may to some extent explain lack of activity (or significantly 




 In summary, a series of novel 2-C-modified-6-O-methyl-2’-C-methylguanosine and 
2-C-modified-2’-C-methylguanosine analogues and their aryloxyphosphoramidates has been 
synthesised. During biological evaluation it was found that compounds bearing modifications 
in C6- and C2-position were significantly less active than their corresponding C6-keto 
analogues. These findings were supported by the ADA-mediated hydrolytic assays.  
The best results were obtained for 2-C-thiophenyl (10.21a), 2-C-thiobenzyl (10.26a) 
and xanthosine (10.30a) analogues.  
Given the importance of finding a new pharmacophore for the anti-HCV drug 
development and promising biological results obtained, further work should be carried out in 
order to discover the full potential of these new promising family of compounds, particularly 
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11.1 Main conclusions and perspectives. 
 
 Each project was concluded in the appropriate section of each Chapter. In the 
following the main conclusions are summarised. 
  Design, synthesis and biological evaluation of 2’-C-methylguanosine ProTides 
resulted in almost every case in greatly improve anti-HCV activity comparing to the 
parent nucleoside, often by 10-30-fold and sometimes up to 1000-fold. Extensive 
structure activity relationships studies resulted in very potent compounds, suitable for 
further preclinical development. Compounds were found to be stable in different 
media including human plasma. Intestinal and liver S9 stability data, followed by the 
experiments in simulated gastric and intestinal fluids gave an indication that oral 
administration would be feasible. 
 Further development of ProTides bearing modification in the base unit of the 
nucleoside analogue, resulted in identification of the 6-O-methyl-2’-C-
methylguanosine !-naphthyl-L-alanine-O-2,2-dimethypropyl ProTide showing the 
biggest promise. This particular compound was further progressed into clinical 
development as INX-189. INX-189 is currently in the phase IIa clinical development.!
 In an effort to obtain achiral prodrugs of 6-O-methyl-2’-C-methylguanosine, a 
new phosphorodiamidate approach was investigated. As a result compounds 
exhibiting nM activity in HCV replicon assay were identified. This is the first time, 
when application of a phosphorodiamidate approach to the nucleoside analogue was 
successful and lead to the suitable candidates for an INX-189 back up programme. 
 Additionally, a novel family of oxazaphosphorine type prodrugs of 6-O-
methyl-2’-C-methylguanosine was reported. Compounds were found to be not active 
in the replicon based assay, however their mode of action is based on cytochrome 
P450-mediated oxidation and therefore to fully validate the potential of this class of 
molecules, further testing in more appropriate conditions (presence of CYP inducing 
agents) is required. 
 A series of novel 8-C-modified-6-O-methyl-2’-C-methylguanosine nucleoside 
analogues and their aryloxyphosphoramidate, and diamidate prodrugs has been 
synthesised, resulting in identification of 8-C-iodo substituted analogues as a new 
promising anti-HCV agents with nanomolar activity. Further biological evaluation 
Karolina Made!a                                                                                     Chapter Eleven 
!
!"#$!
revealed that the 8-C-iodo substituent act as a promoiety with eventual release of 2’-
C-methylguanosine monophosphate.  
 During the design, synthesis and biological evaluation of novel 2-C-modified-
6-O-methyl-2’-C-methylguanosine and 2-C-modified-2’-C-methylguanosine 
analogues and their corresponding ProTides, 2-C- thiophenyl, 2-C-thiobenzyl and 
xanthosine analogues were identified as new interesting anti-HCV agents. Given the 
importance of finding new a pharmacophore for the anti-HCV drug development and 
promising biological results obtained, further work on this particular family of 











12.1 General Experimental Details. 
 
Glassware 
 All glassware was dried in the oven at 130 °C for several hours and allowed to cool 
down. 
 
Solvents and Reagents  
All solvents and reagents commercially available were used without any further 
purification. 
 The following solvents were purchased as anhydrous: aceton, acetonitrile (ACN), 
chloroform (CHCl3), dichloromethane (DCM), diethyl ether (Et2O), N,N-
dimethylformamide (DMF), ethanol (EtOH), methanol (MeOH), pyridine, 
tetrahydrofuran (THF). 
 
Thin Layer Chromatography 
The reactions were analysed by Thin Layer Chromatography (TLC).  Aluminium 
backed TLC plates, precoated with silica gel (60 F254, 0.2 mm) were purchased from 
Merck Kieselgel. Separated components were visualized using ultra violet light (245 
and 366 nm). 
Praparative TLC plates (20 x 20 cm, 500-2000 µM) were also purchased from Merck. 
 
 Column Chromatography (CC) 
Column chromatography was performed using normal phase Silica gel 35-70 µ, 60A 
(Fluka/Fisher) as a stationery phase. Glass columns were slurry packed in the 
appropriate eluent under gravity. Samples were applied as concentrated solutions in 
the same eluent, or pre absorbed onto silica gel. The fractions containing the product 
were analyzed by TLC, and then combined together and the solvent removed under 
vacuum. 
 
Karolina Made!a                                                                                     Chapter Twelve  
 252
Nuclear Magnetic Resonance (NMR) 
1H, 13C, 31P spectra were recorded on a Brucker Avance 500 spectrometer (500, 125, 
202 MHz, respectively), at 25 °C. 31P NMRs are reported in units of ! relative to 85% 
phosphoric acid as the external standard.Spectra were calibrated to the residual peak 
of the deuterated solvent. In 1H NMR, 13C NMR, 31P NMR shifts are given in parts 
per million (ppm) and rounded to two decimal places. 
The following abbreviations are used in the NMR signals assignment: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet). 
Coupling constants (J) are measured in Hertz and rounded to one decimal place. 
Unless otherwise stated, coupling constants are three-bond couplings between two 
hydrogen atoms. Other couplings are marked with a subscript, according to the type 
of coupling e.g.: 2JC-O-P (two bond coupling between carbon and phosphorus). 
 
High Performance Liquid Chromatography (HPLC) 
Analytical and semi-preparative experiments were carried out on a Varian ProStar 
(LC Work Station - Varian ProStar 335LC detector, Varian fraction collector - model 
701, ProStar 201 delivery system, using Varian Pursuit XRs 5C18 (150 x 4.6 mm) as 
an analytical column and Varian Puruit XRs 5C18 (150 x 21.2 mm) as semi-
preparative column. Used software was Galaxie Chromatography Data System. 
Elution were performed using: 
- Mobile phase water/ acetonitrile in gradient (H2O/ACN:  0% to 100% of ACN 
in 30 minutes) – System 1. 
- Mobile phase water/ methanol in gradient (H2O/MeOH:  0% to 100% of ACN 
in 30 minutes) – System 2. 
 
Mass Spectrometry (MS) 
High (HRMS) and low resolution mass spectrometry was performed as a service by 
Cardiff University, using electrospray. 
 
Elemental analysis (CHN) 








Carboxypeptidase Y Assay 
5mg of appropriate phosphoramidate was dissolved in 200 µl of deuterated acetone 
and 400 µl of TRIZMA buffer (pH 7.6) was added. A 31P-NMR was conducted at this 
stage as a reference (t= 0). To this mixture 0.3mg of Carboxypeptidase Y (purchased 
from SIGMA, > 50unit/mg, EC 3.4.16.1) dissolved in 200µl of TRIZMA buffer was 
added. 31P-NMR of the reaction mixture was carried out every 7 minutes for 14 hours, 
at room temperature. 
 
Adenosine Deaminase Assay 
Stock solutions of appropriate nucleoside analogue were dissolved in phosphate 
buffer (pH 7.5, 0.05M) to a final concentration of 44 µM. To a solution of adenosine 
deaminase from calf intestinal mucosa (solution in 50% glycerol, 0.01M potassium 
phosphate, pH 6.0, Sigma-Aldrich) phosphate buffer (pH 7.5, 0.05M) was added to a 
final volume of 2.0 ml.  
For each assay, 1ml of 44 µM solution of the appropriate nucleoside analogue was 
placed in a 1cm UV cuvet, at 25 C, and UV spectrum was recorded over the range 
400 to 220 nm. A portion of enzyme solution (30 to 200 µM) waas added, and spectra 
were recorded in 1 min intervals for 30 min, and after that time in 10 or 30 min 
intervals for 8 h. 
 
Cell Lysate Assay 
The cell lysate experiments were performed using Huh7 human hepatoma cells (107 
cells) lasate, which was added and incubated with the appropriate 
aryloxyphosphoramidate or phosphorodiamidate in deuterated solvent (D2O or d6-
acetone) at 37 °C. 31P NMR spectra were recorded every hour for 14 hours. 
Blank experiment (ProTide in deuterated solvent) was recorder prior lysate addition. 
 
Human liver microsomes assay 
Appropriate cyclic phosphoramidate was incubated in the presence of human liver 
microsomes (purchased from Sigma). Incubation was carried out without the presence 
of NADPH co-factor. The incubation mixture (final volume of 600 µL) contained: 90 
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µL of microsomal protein, 235 µL of Tris buffer (pH 7.5) and appropriate cyclic 
phosphoramidate (500 µM concentration in Tris buffer, 75 µL) and 200 µL of D2O.  
The reaction was followed by the 31P NMR at 37 °C, for 14 h. Spectra were recorded 
in 7 min intervals with blank spectra of compound. The blank spectrum was recorded 
in the Tris buffer prior the microsomes addition. 
 
Biological Testing 
Biological testings (unless stated otherwise) were performed by John Vernachio’s 
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12.2 Standard Procedures. 
 
Standard procedure 1: Preparation of phosphorodichloridate species. 
 
Phosphorus oxychloride (1.0 mol equivalents) and the appropriate naphhol (1.0 mol 
equivalent) were stirred in anhydrous diethyl ether. Anhydrous triethylamine was 
added (1.0 mol equivalent) at -78 oC and after 25 minutes, the solution was allowed to 
warm to ambient temperature. Progress of the reaction was monitored by the 31P 
NMR. After reaction completion, triethylamine hydrochloride salts were filtered off 
and the solvent was removed under reduce pressure to give a clear pale yellow oil. 
 
Standard procedure 2a: Preparation of amino acid ester hydrochloride salts. 
 
To a stirred solution of appropriate alcohol (15,0 mol equivalents) at 0 °C under argon 
atmosphere, thionyl chloride (2,0 mol equivalents) was added. The reaction mixture 
was stirred at 0 °C for 30 minutes and after that time slowly allowed to warm to 
ambient temperature. The appropriate amino acid (1,0 mol equivalent) was added and 
the mixture was heated at 70 °C overnight. After that time, solvents were removed 
under vacuum (the last traces of solvents were removed by co-evaporation). Pure 
product was obtained by precipitation from diethyl ether, as a white solid of 
hydrochloride salt. 
 
Standard procedure 2b: Preparation of amino acid ester sulfonate salts. 
 
To the amino acid (1 mol equivalent) in toluene, was added: appropriate alcohol (5 to 
15 mol equivalents) and para-toluene sulfonic acid (1.1 mol equivalents). The 
mixture was heated at reflux overnight using Dean-Stark apparatus. After that time 
solvents were removed under reduce pressure. The amino acid ester was then 
precipitated either from diethyl ether or ethyl acetate (0 oC). Pure product was 
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Standard procedure 2c: Preparation of Boc amino acid esters. 
 
To the Boc-protected amino acid (1 equiv.) in DCM (20 ml/g of amino acid) the 
alcohol (1.2 to 2 equiv.), DCC (1 equiv.) and DMAP (0.1 equiv.) were added at room 
temperature. After being stirred overnight, the solvent was removed under reduce 
pressure and the residue was purified on silica gel (Hexane/AcOEt 9:1) to afford the 
pure Boc-amino acid ester. 
 
Standard procedure 2d: Boc amino acid deprotection. 
 
To the Boc-amino ester (1 eq) in AcOEt (35ml/g of Boc-amino ester), pTSA (1 eq) 
was added. The mixture was stirred for 2 hours at 65 oC and the solvent was removed 
under reduce pressure to afford the pure amino ester pTSA salt. The latter can 
crystallise in AcOEt at 0 oC or from MeOH/Et2O. 
 
Standard procedure 3: Preparation of phosphorochloridate species. 
 
Aryl phosphorodichloridate (1 mol equivalents) and the appropriate amino acid ester 
(1 mol equivalent) were suspended in anhydrous dichloromethane. Anhydrous 
triethylamine (2 mol equivalents) was added dropwise at -78 oC and after one hour, 
the reaction was left to rise to room temperature and stirred for 2 to 4 hours. The 
formation of phosphorochloridate was monitored by 31P NMR. The solvent was 
removed under vacuum and the crude residue was purified by a quick column 
chromatography on silica gel (Hexane/EtOAc 1:1). 
 
Standard procedure 4: Preparation of 2’,3’-isopropylidene protected 2’-C-
methylguanosine ProTides. 
 
2’,3’-O,O-isopropylidene-2’-C-!-methylguanosine (1 mol equivalent) was dissolved 
in anhydrous THF, solution of tBuMgCl (1M in THF, 2 mol equivalent) was added 
dropwise and stirred for 20 min. Appropriate phosphorochloridate (2 mol equivalent) 
in anhydrous THF was added very slowly to the reaction mixture. The reaction was 
stirred overnight at room temperature under argon atmosphere. After that time solvent 
was removed under reduced pressure. The foamy residue was purified by column 
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chromatography in a gradient (CHCl3/MeOH 98:2 to CHCl3/MeOH 92:8) to afford 
the pure desired product. 
 
Standard procedure 5: Deprotection of 2’,3’-isopropylidene protected 2’-C-
methylguanosine ProTides. 
 
The protected phosphoramidate was dissolved in a 60% acetic acid in water (~10ml / 
200 mg) and heated at 95 oC overnight. The solvent was then removed under reduced 
pressure. Residue was purified by column chromatography using as an eluent 
CHCl3/MeOH (9:1), to give the desired product as a white solid. 
 
Standard procedure 6: Preparation of aryloxyphosphoramidates (NMI method). 
 
To the solution/suspension of appropriate nucleoside analogue (1 mol equivalent) in 
dry THF, phosphorochloridate (3 mol equivalent) in THF was added, followed by the 
addition of N-methylimidazole (5 mol equivalent) under argon atmosphere. The 
reaction mixture was stirred overnight at ambient temperature and after that time, the 
solvent was removed under reduce pressure. To remove the residues of Nmethyl-
imidazole, the crude phosphoramidate was dissolved in chloroform (or 
dichloromethane) and washed 3 times with hydrochloric acid (HCl 0.1N). The organic 
layer was then dried over sodium sulfate and evaporated to dryness under reduce 
pressure. The residue was then purified on silica gel using CHCl3/MeOH (0 to 5%, 
gradient) as an eluent, to give the pure phosphoramidate as a white solid.  
 
Standard procedure 7: Preparation of aryloxyphosphoramidates (tBuMgCl 
method). 
 
To the solution/suspension of appropriate nucleoside analogue (1 mol equivalent) in 
dry THF, solution of tBuMgCl (1M in THF, 2 mol equivalents) was added dropwise 
and stirred for 30 min. The appropriate phosphorochloridate (2 mol equivalents) in 
anhydrous THF (1M solution) was added very slowly to the reaction mixture. The 
reaction was stirred overnight at ambient temperature under argon atmosphere. After 
that time solvent was removed under reduced pressure. The foamy residue was 
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purified by column chromatography in a gradient (CHCl3 to CHCl3/MeOH 95:5) to 
afford the pure desired product. 
 
Standard procedure 8: Preparation of 5’-cyclic phosphoramidates. 
 
2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine (1 mol equivalent) was 
dissolved in anhydrous pyridine and appropriate cyclic phosphorochloridate (1 mol 
equivalent) in anhydrous pyridine (1M solution) was added very slowly to the 
reaction mixture. The reaction was stirred overnight at room temperature under argon 
atmosphere. After that time solvent was removed under reduced pressure. The foamy 
residue was purified by column chromatography using in CHCl3/MeOH or 
CHCl3/MeOH as eluent, afford the pure desired product. 
 
Standard procedure 9: Preparation of N-(2-nitrophenylsulfonyl)-amino acid esters. 
 
2-Nitrosulfonylbenzyl chloride (1.0 mol equivalent) was added to an ice-cold solution 
of the appropriate amino acaid ester salt (1.0 mol equivalent) and triethylamine (2.3 
mol equivalent) in dry DCM (70ml/10.0 mmol). The mixture was allowed to warm to 
ambient temperature and stirred overnight. The resulting solution was washed with 
water (3x), dried over anhydrous MgSO4 and concentrated in vacuo. The resulting N-
(2-nitrophenylsulfonyl)-amino acid ester was used without further purification. 
  
Standard procedure 10: Preparation of N-(3-hydroxypropyl)-N-(2-
nitrophenylsulfonyl)-amino acid esters. 
 
Cesium carbonate (1.0 mol equivalent) was added to a solution of the N-(2-
nitrophenylsulfonyl)-amino acid ester (1.0 mol equivalent) in DMF (45 ml/10 mmol). 
The reaction mixture was heated to 60 °C and then 3-bromopropan-1-ol (1,5 mol 
equivalent) was added dropwice with stirring. The reaction mixture was stirred 
overnight at 60 °C. After that time, the mixture was diluted with water and extracted 
3x with ethyl acetate. The combined organic phases were dried over anhydrous 
Na2SO4 and concentrated. The resulting N-(3-hydroxypropyl)-N-(2-
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nitrophenylsulfonyl)-amino acid ester was purified by column chromatography using 
EtOAc/petroleum ether (8:2) as en eluent.  
 
Standard procedure 11: Preparation of N-(3-hydroxypropyl)-amino acid esters. 
 
Potassium carbonate was added to a solution of the resulting N-(3-hydroxypropyl)-N-
(2-nitrophenylsulfonyl)-amino acid ester (1.0 mol equivalent) and thiophenol (1.1 mol 
equivalent) in dry acetonitrile (15 ml/10 mmol). The reaction mixture was stirred at 
ambient temperature overnight. After that time the reaction mixture was concentrated 
under reduced pressure and the residue was taken up in diethyl ether. Hydrochloric 
acid solution (1N) was added and the mixture was stirred for 10 min (till all salts are 
dissolved). The organic layer was removed and washed with water. The combined 
aqeous layers were washed with diethyl ether followed by basification with solid 
K2CO3 (3.25 mol equivalent). The product was extracted with DCM or EtOAc several 
times. Organic phases were combined, dried over Na2SO4, evaporated to dryness and 
purified on silica gel, using CHCl3/MeOH (9:1) as an eluent.. 
 
Standard procedure 12: Preparation of cyclic phosphorochloridates. 
 
N-(3-hydroxypropyl)-amino acid ester (1.0 mol equivalent) was dissolved in dry 
CHCl3 (0.5 ml/2.5 mmol) and Et3N (1.0 mol equivalent) was added. POCl3 (1.0 mol 
equivalent) was dissolved inn dry CHCl3 (2.5 ml/2.5 mmol) and the solution was 
cooled to -15 °C. A solution of amino acid was added dropwise to the POCl3 mixture, 
followed by the addition of further quantity of Et3N (1.0 mol equivalent) in dry CHCl3 
(0.5 ml/ 2.5 mmol). The temperature was kept below 0 C all the time, and the reaction 
mixture was stirred at 0 C for 18 hours. After that time solvent was removed under 
reduced pressure at 35 C. The crude mixture was purified on silica gel (flash 
chromatography), using EtOAc/hexane (7:3) as an eluent. 
 
Standard procedure 13a: Preparation of symmetrical phosphorodiamidates.  
 
To a suspension of the nucleoside (1.0 mol equivalent) in dry tetrahydrofuran, 
triethylamine (1.0 mol equivalent) was added. After stirring for 30 min at ambient 
temperature, phosphorus oxychloride (1.0 mol equivalent) was added dropwise at -78 
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°C. The reaction mixture was stirred for 30 min at -78 °C and then allowed to warm to 
ambient temperature over 30 min (Progress of the reaction was followed by 31P 
NMR). After reaction completion, anhydrous dichloromethane was added, followed 
by amino acid ester (3-5 mol equivalent) and triethylamine (6-10 mol equivalent) at -
78 °C. After stirring at rambient temperature for 16-20 h, the reaction mixture was 
evaporated to dryness. The resulting residue was purified by silica gel column 
chromatography using as eluent a gradient of methanol in dichloromethane. 
Standard procedure 13b: Preparation of asymmetrical phosphorodiamidates (POCl3 
route). 
 
To a suspension of the nucleoside (1.0 mol equivalent) in dry tetrahydrofuran, 
triethylamine (1.0 mol equivalent) was added. After stirring for 30 min at ambient 
temperature, phosphorus oxychloride (1.0 mol equivalent) was added dropwise at -78 
°C. The reaction mixture was stirred for 30 min at -78 °C then allowed to warm to 
ambient temperature and stirred for additional 30 min. Reaction progress was 
monitored by 31P NMR. After reaction completion, dry dichloromethane was added, 
followed by amino acid ester or amine (1 mol equivalent) and triethylamine (2 or 1 
mol equivalent, respectively) at -78 °C. Reaction was warmed to ambient temperature 
and monitored by 31P NMR. When NMR indicated completion of the reaction (no 
starting material, presence of mono-substituted product) 2nd amino acid ester or 
amine (5 mol equivalent) was added followed by the addition of triethylamine (10 or 
5 mol equivalent, respectively) at -78°C. After stirring at ambient temperature for 16-
20 h, reaction mixture was evaporated to dryness. The resulting residue was purified 
by silica gel column chromatography using as eluent a gradient of methanol in 
chloroform. 
Standard procedure 13c: Preparation of asymmetrical phosphorodiamidates (amino 
acid dichloridate route). 
 
To a suspension of the nucleoside (1.0 mol equivalent) in dry tetrahydrofuran, 
triethylamine (1.0 equivalent) was added. After stirring for 30 min at ambient 
temperature amino acid ester dichloridate (2.0 mol equivalent) was added. After 
stirring at ambient temperature for 20 h, primary amine was added (5.0 mol 
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equivalent) followed by the addition of triethylamine (5.0 mol equivalent) at -78 °C. 
After stirring at ambient temperature for 16-20 h, the reaction mixture was evaporated 
to dryness. The resulting residue was purified by silica gel column chromatography 
using as eluent a gradient of methanol in chloroform.  
Standard procedure 14: C6-Methyl ether cleavage. 
 
To a solution of appropriate ProTide (1 mol equivalent) in dry ACN, sodium iodide 
(1.1 mol equivalent), followed by trimethylsilyl chloride (1.1 mol equivalent) was 
added. Reaction mixture was stirred at ambient temperature (unless otherwise stated) 
and monitored by TLC. After reaction completion, the reaction mixture was poured 
into saturated solution of sodium bicarbonate and extracted 3 times with 
dichloromethane. The organic layers were combined, dried over Na2SO4 and 
evaporated to dryness. Crude mixture was purified using preparative TLC, with 
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12.3 Experimental section - Chapter Three. 
 
Synthesis of !-naphthyl phosphorodichloridate (3.1a). 
 
Prepared according to the Standard Procedure 1, from: !-naphthol 
(5.00g, 34.7 mmol), phosphorus oxychloride (3.23 ml, 34.7 
mmol) and triethylamine (4.84 ml, 34.7 mmol) in 25 ml of dry 
diethyl ether. Product was obtained as thick, yellow oil (8.10g, 90%). 
 
31P NMR (202 MHz, CDCl3) ! 3.69. 
1H NMR (500 MHz, CDCl3) ! 8.11 (d, J= 8.4 Hz, 1H. H8), 7.89 (d, J= 7.5 Hz, 1H, 
H5), 7.81 (d, J= 8.3 Hz, 1H, H4), 7.65 – 7.54 (m, 3H, H2, H6, H7), 7.45 (t, J= 8.0 Hz, 
1H, H3). 
 
Synthesis of "-naphthyl phosphorodichloridate (3.1b). 
 
Prepared according to the Standard Procedure 1, from:  
"-naphthol (5.00g, 34.7 mmol), phosphorus oxychloride (3.23 
ml, 34.7 mmol) and triethylamine (4.84 ml, 34.7 mmol) in  
25 ml of dry diethyl ether. Product was obtained as thick, yellow oil (7,95g, 88%). 
 
31P NMR (202 MHz, CDCl3) ! 2.71. 
1H NMR (500 MHz, CDCl3) ! 7.87- 7.78 (m, 2H, H4, H5-naph), 7.72 (s, 1H, H8-
naph), 7.53- 7.45 (m, 2H, H7, H6-naph), 7.39- 7.35 (m, 2H, H1, H3-naph). 
 
Synthesis of p-NO2-phenyl phosphorodichloridate (3.1c). 
 
Prepared according to the Standard Procedure 1, from:  
p-NO2-phenol (1.60g, 11.50 mmol), phosphorus 
oxychloride (1.07 ml, 11.50 mmol) and triethylamine (1.60 
ml, 11.50 mmol) in 10 ml of dry diethyl ether. Product was obtained as thick, yellow 
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31P NMR (202 MHz, CDCl3) ! 3.54. 
1H NMR (500 MHz, CDCl3) ! 8.35 (d, J=9.00 Hz, 2H, H3 and H5 Ph), 7.54-7.50 (m, 
2H, H2 and H6 Ph). 
 
Synthesis of L-alanine isopropyl ester hydrochloride salt (3.2a). 
 
Prepared according to the Standard Procedure 2a, from: L-alanine 
(5.00g, 56.0 mmol), thionyl chloride (8.20ml, 112.0 mmol) in 65 
ml of isopropanol. The product was obtained as a white solid 
(8.0g, 85%). 
 
1H NMR (500 MHz, MeOD) ! 5.18- 5.04 (m, 1H, CH(CH3)2), 4.05 (q, J= 7.5 Hz, 1H, 
CHCH3), 1.56 (d, J= 7.5 Hz, 3H, CHCH3), 1.36, 1.31 (2d, J= 6.5 Hz, 6H, CH(CH3)2). 
 
 Synthesis of L-alanine n-propyl ester hydrochloride salt (3.2b). 
 
Prepared according to the standard procedure 2a, from:  
L-alanine (3.00g, 33.67 mmol), thionyl chloride (4.91ml, 67.00 
mmol) and n-propanol (40 ml, 0.51 mol). The product was 
obtained as a white solid (4.90g, 87%). 
 
1H NMR (500 MHz, CDCl3) ! 8.85 (bs, 3H, NH3+), 4.26- 4.18 (m, 3H, OCH2CH2CH3 
and CHCH3), 1.75- 1.71 (m, 5H, CHCH3 and OCH2CH2CH3), 0.97 (t, J= 4.6 Hz, 3H, 
OCH2CH2CH3). 
 
Synthesis of L-alanine cyclohexyl ester hydrochloride salt (3.2c). 
 
Prepared according to the standard procedure 2a, from L-alanine 
(5.00g, 56.0 mmol) thionyl chloride (8.20 ml, 5.60 mmol) and 
cyclohexanol (90g, 0.90 mol). Product was obtained as a white 














Karolina Made!a                                                                                     Chapter Twelve  
 265 
1H NMR (500 MHz, CDCl3) ! 8.76 (bs, 3H, NH3), 4.91–4.79 (m, 1H, CH ester), 4.22 
(q, J= 7.5 Hz, 1H, CHCH3), 1.86-1.73 (m, 7H, 2x CH2 ester and CHCH3), 1.56-1.46 
(m, 4H, 2x CH2 ester), 1.42 – 1.23 (m, 2H, CH2 ester). 
 
Synthesis of L-methionine isopropyl ester hydrochloride salt (3.2d). 
 
Prepared according to the Standard Procedure 2a, from:  
L-methionine (5.00g, 33.51 mmol), thionyl chloride (4.9 ml, 67.01 
mmol) and isopropanol (40 ml, 0.50 mol). Product was obtained as a 
white solid (7.61g, 98%). 
 
1H NMR (500 MHz, DMSO) ! 8.54 (s, 3H, NH3+), 5.06-4.98 (m, 1H, OCH(CH3)2), 
4.05 (t, J= 6.0 Hz, 1H, CHCH2CH2SCH3) 2.66 (dt, J= 7.5 Hz, J= 15.0 Hz, 1H, 
CHCH2CH2SCH3), 2.54 (dt, J= 7.5 Hz, J= 15.0, 1H, CHCH2CH2SCH), 2.09–2.03 (m, 
2H, CHCH2CH2SCH3), 2.07 (s, 3H, CHCH2CH2SCH3), 1.27 (d, J= 3.5 Hz, 3H, 
OCH(CH3)2), 1.25 (d, J= 3.5 Hz, 3H, OCH(CH3)2). 
 
Synthesis of D-phenylglycine propyl ester hydrochloride salt (3.2e). 
 
Prepared according to the Standard Procedure 2a, from:  
D-phenylglycine (3.00g, 19.84 mmol), thionyl chloride (2.88 
ml, 39.69 mmol) and n-propanol (22 ml, 0.30 mol). Product was 
obtained as a white solid (4.54, 100%). 
 
1H NMR (500 MHz, DMSO) ! 9.16 (s, 3H, NH3+), 7.54-7.56 (m, 5H, CHPh), 5.23 (s, 
1H, CHPh), 4.11 (t, J=7.5 Hz, 2H, OCH2CH2CH3), 1.56-1.49 (m, 2H, 
OCH2CH2CH3), 0.74 (t, J=7.5 Hz, 3H, OCH2CH2CH3). 
 
Synthesis of D-phenylglycine cyclohexyl ester hydrochloride salt (3.2f). 
 
Prepared according to the Standard Procedure 2a, from:  
D-phenylglycine (5.00g, 33.08 mmol), thionyl chloride (4.90 
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was obtained as a white solid (8.85, 99%). 
 
1H NMR (500 MHz, DMSO) ! 9.17 (s, 3H, NH3+), 7.53-7.45 (m, 5H, CHPh), 5.18 (s, 
1H, CHPh), 4.81-4.79 (m, 1H, OCH ester), 1.77-1.72 (m, 1H, CH2 ester), 1.60-1.46 
(m, 1H, CH2 ester), 1.32-1.24 (m, 4H, 2x CH2 ester), 1.22-1.16 (m, 4H, 2x CH2 ester). 
 
Synthesis of L-alanine 2,2-dimethylpropyl ester p-toluene sulfonate salt (3.2g). 
 
Prepared according to the standard procedure 2b, 
from: L-alanine (8.00g, 89.8 mmol) neopentyl 
alcohol (40g, 45.4 mol), pTSA (18.96g, 98.9 mmol) 
in 120 ml of toluene. The product was obtained as a 
white powder (28g, 97%). 
 
1H NMR (500 MHz, DMSO) ! 8.29 (bs, 3H, NH3+), 7.49 (d, J= 8.0 Hz, 2H, Ts), 7.12 
(d, J= 8.0, 2H. Ts), 4.16 (q, J= 7.2 Hz, 1H, CHCH3), 3.95, 3.82 (AB, JAB = 10.5 Hz, 
2H, OCH2C(CH3)3), 2.30 (s, 3H, CH3 Ts), 1.43 (d, J= 7.2 Hz, 3H, CHCH3), 0.94 (s, 
9H, OCH2C(CH3)3). 
 
Synthesis of L-methionine 2,2-dimethylpropyl ester p-toluene sulfonate salt 
(3.2h). 
 
Prepared according to the standard procedure 2b, 
from: L-methionine (3.0g, 20.00 mmol), neopentyl 
alcohol (17.63g, 0.20 mol) and pTSA (9.48g, 22.00 
mmol) in 60ml of toluene. The product was obtained 
as a white powder (7.20g, 91%). 
 
1H NMR (500 MHz, MeOD) ! 7.73 (d, J= 8.5 Hz, 2H, Ts), 7.26 (d, J= 8.5 Hz, 2H, 
Ts), 4.27 (t, J= 6.5 Hz, 1H, CHCH2CH2SCH3), 3.98, 3.85 (AB, JAB = 10.5 Hz, 2H, 
OCH2C(CH3)3), 2.69, 2.68 (2x t, J= 7.0 Hz, 2H, CHCH2CH2SCH3), 2.39 (s, 3H, CH3 
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Synthesis of Boc-L-alanine 3,3-dimethyl-1-butyl ester (3.2i’). 
 
Prepared according to the standard procedure 2c, 
from: Boc-L-alanine (5.00g, 26.43 mmol),  
3,3-dimethyl-1-butanol (5.00 ml, 39.64 mmol), DCC 
(5.45g, 26.43 mmol), DMAP (0.32g, 2.64 mmol) in 100ml of DCM. The product was 
obtained as clear oil (6.32g, 87%). 
 
1H NMR (500 MHz, CDCl3) ! 5.06 (bs, 1H, NH), 4.34- 4.27 (m, 1H, CHCH3), 4.23-
4.18 (m, 2H, OCH2CH2C(CH3)3), 1.59 (t, J= 7.0 Hz, 2H, OCH2CH2C(CH3)3), 1.46 (s, 
9H, 3x CH3 Boc), 1.39 (d, J= 7.0 Hz, 3H, CHCH3), 0.96 (s, 9H, OCH2CH2C(CH3)3). 
 
Synthesis of L-alanine 3,3-dimethyl-1-butyl ester p-toluene sulfonate salt (3.2i). 
 
Prepared according to the standard procedure 2d, 
from: Boc-L-alanine 3,3-dimethyl-1-butyl ester 
(6.32g, 23.12 mmol) and pTSA (4.40g, 23.12 
mmol) in 220 ml of AcOEt. The product was 
obtained as a white solid (5.35g, 67%). 
 
1H NMR (500 MHz, CDCl3) ! 8.22 (bs, 3H, NH3+), 7.79 (d, J= 9.3 Hz, 2H, Ts), 7.17 
(d, J= 9.3 Hz, 2H, Ts), 4.19- 4.06 (m, 2H, OCH2CH2C(CH3)3), 3.99-3.94 (m, 1H, 
CHCH3), 2.37 (s, 3H, CH3 Ts), 1.52-1.44 (m, 5H, OCH2CH2C(CH3)3 and CHCH3), 
0.90 (s, 9H, s, OCH2CH2C(CH3)3). 
 
Synthesis of Boc-L-alanine 3,3-dimethyl-2-butyl ester (3.2j’). 
 
Prepared according to the standard procedure 2c, from: 
Boc-L-alanine (5.00g, 26.43 mmol), 3,3-dimethyl-2-
butanol (4.32 ml, 34.35 mmol), DCC (5.45g, 26.43 
mmol), DMAP (0.32g, 2.64 mmol) in 100ml of DCM. The product was obtained as 
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1H NMR (500 MHz, CDCl3) ! 5.09 (bs, 1H, NH), 4.75-4.70 (m, 1H, 
CH(CH3)C(CH3)3), 4.33-4.25 (m, 1H, CHCH3), 1.45, 1.44 (2x s, 3x CH3 Boc), 1.41-
1.36 (m, 3H, CHCH3), 1.17- 1.13 (m, 3H, CH(CH3)C(CH3)3), 0.92, 0.91 (2x s, 9H, 
CH(CH3)C(CH3)3). 
 
Synthesis of L-alanine 3,3-dimethyl-2-butyl ester p-toluene sulfonate salt (3.2j). 
 
Prepared according to the standard procedure 2d, 
from: Boc-L-alanine 3,3-dimethyl-2-butyl ester 
(6.53g, 23.89 mmol) and pTSA (4.54g, 23.89 mmol) 
in 230 ml of AcOEt. The product was obtained as a 
white solid (5.52g, 67%). 
 
1H NMR (500 MHz, CDCl3) ! 8.23 (bs, 3H, NH3+), 7.79 (d, J= 8.0 Hz, 2H, Ts), 7.15 
(d, J= 8.0 Hz, 2H, Ts), 4.71, 4.70 (2x q, J= 6.5 Hz, 1H, CHCH3), 4.03-3.96 (m, 1H, 
CH(CH3)C(CH3)3), 2.36 (s, 1H, CH3 Ts), 1.48, 1.46 (2x d, J= 6.5 Hz, 3H, CHCH3) 
1.10, 1.08 (2x d, J= 6.5 Hz, 3H, CH(CH3)C(CH3)3), 0.87, 0.85 (2x s, 9H, 
CH(CH3)C(CH3)3). 
 
Synthesis of Boc-L-alanine 2-indanolyl ester (3.2k’). 
Prepared according to the standard procedure 2c, 
from: Boc-L-alanine (5.00g, 26.43 mmol), 2-indanol 
(5.32g, 39.64 mmol), DCC (5.45g, 26.43 mmol), 
DMAP (0.32g, 2.64 mmol) in 100ml of DCM. The 
product was obtained as clear oil (7.20g, 89%). 
 
1H NMR (500 MHz, CDCl3) ! 7.24- 7.20 (m, 4H, Ar), 5.63- 5.59 (m, 1H, OCH ester), 
5.03 (bs, 1H, NH), 4.28-4.26 (m, 1H, CHCH3), 3.38 (dd, J= 7.00 Hz, J= 17.0 Hz, 2H, 
2x CHA ester), 3.07 (d, J= 17.0 Hz, 2H, 2 x CHB1 ester), 3.01 (d, J= 17.0 Hz, 2H, 2 x 
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Synthesis of L-alanine 2-indanyl ester p-toluene sulfonate salt (3.2k). 
 
Prepared according to the standard procedure 
2d, from: Boc-L-alanine 2-indanyl ester (7.20g, 
23.58 mmol) and pTSA (4.50g, 23.58 mmol) in 
250 ml of AcOEt. The product was obtained as a 
white solid (6.97g, 78%). 
 
1H NMR (500 MHz, CDCl3) ! 8.21 (bs, 3H, NH3+), 7.76 (d, 2H, 2x CH Ts), 7.17- 
7.11 (m, 6H, 2x CH Tos, 4x CH Ar), 5.52-5.48 (m, 1H, CH ester), 3.96- 3.91 (m, 1H, 
CHCH3), 3.25, 3.20 (2x dd, J= 7.00 Hz, J= 17.0 Hz, 2H, 2x CHA ester), 2.96 (d, J= 
17.0 Hz, 2H, 2x CHB ester), 3.01 (2x d, J= 17.0 Hz, 2H, 2 x CHB ester), 2.34 (s, 3H, 
CH3 Tos), 1.40 (d, J= 7.0 Hz, 3H, CH3). 
 
Synthesis of Boc-L-methionine cyclohexyl ester (3.2l’). 
 
Prepared according to the standard procedure 2c, from: 
Boc-L-methionine (5.00g, 20.05 mmol), cyclohexanol 
(2.70 ml, 26.07 mmol), DCC (4.14g, 20.05 mmol), 
DMAP (0.24g, 2.01 mmol) in 100ml of DCM. The 
product was obtained as clear oil (5.90g, 87%). 
 
1H NMR (500 MHz, CDCl3) ! 5.15 (bs, 1H, NH), 4.81-4.72 (m, 1H, OCH ester), 
4.47-4.41 (m, 1H, CHCH2CH2SCH3), 2.56-2.49 (m, 2H, CHCH2CH2SCH3), 2.20-2.12 
(m, 1H, 1 of CHCH2CH2SCH3), 2.08 (s, 3H, CHCH2CH2SCH3), 1.99- 1.92 (m, 1H, 1 
of CHCH2CH2SCH3), 1.77-1.72 (m, 1H, CH2 ester), 1.62-1.48 (m, 1H, CH2 ester), 
1.43 (s, 9H, 3x CH3 Boc), 1.32-1.24 (m, 4H, 2x CH2 ester), 1.22-1.16 (m, 4H, 2x CH2 
ester). 
 
Synthesis of L-methionine cyclohexyl ester p-toluene sulfonate salt (3.2l). 
 
Prepared according to the standard procedure 2d, 
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17.38 mmol) and pTSA (3.31g, 17.38 mmol) in 205 ml of AcOEt. The product was 
obtained as a white solid (5.50g, 77%). 
 
1H NMR (500 MHz, CDCl3) ! 8.37 (bs, 3H, NH3+), 7.77 (d, J= 8.5 Hz, 2H, Ts), 7.13 
(d, J= 8.5 Hz, 2H, Ts), 4.83-4.77 (m, 1H, OCH ester), 4.12-4.02 (m, 1H, 
CHCH2CH2SCH3), 2.61-2.57, 2.54-2.49 (2m, 2H, CHCH2CH2SCH3), 2.34 (s, 3H, 
CH3 Ts), 2.18-2.09 (m, 2H, CHCH2CH2SCH3), 1.98 (s, 3H, CHCH2CH2SCH3), 1.81-
1.72 (m, 2H, CH2 ester), 1.69-1.61 (m, 2H, CH2 ester), 1.42-1.21 (m, 6H, 3x CH2 
ester). 
 
Synthesis of Boc-L-methionine benzyl ester (3.2m’). 
 
Prepared according to the standard procedure 2c, 
from: Boc-L-methionine (5.00g, 20.05 mmol), benzyl 
alcohol (2.70 ml, 26.07 mmol), DCC (4.14g, 20.05 
mmol), DMAP (0.24g, 2.01 mmol) in 100ml of DCM. 
The product was obtained as clear oil (5.90g, 87%). 
 
1H NMR (500 MHz, CDCl3) ! 7.39-7.35 (m, 5H, OCH2Ph), 5.23, 5.17 (AB, JAB= 
12.0 Hz, 2H, OCH2Ph), 5.15 (bs, 1H, NH), 4.47- 4.41 (m, 1H, CHCH2CH2SCH3), 
2.52-2.49 (m, 2H, CHCH2CH2SCH3), 2.20-2.12 (m, 1H, CHCH2CH2SCH3), 2.06 (s, 
3H, CHCH2CH2SCH3), 1.99- 1.92 (m, 1H, CHCH2CH2SCH3), 1.90 (s, 3H, 
CHCH2CH2SCH3), 1.45 (s, 9H, 3x CH3 Boc). 
 
Synthesis of L-methionine benzyl ester p-toluene sulfonate salt (3.2m). 
 
Prepared according to the standard procedure 2d, 
from: Boc-L-methionine benzyl ester (5.90g, 
17.38 mmol) and pTSA (3.31g, 17.38 mmol) in 
205 ml of AcOEt. The product was obtained as a 
white solid (5.50g, 77%). 
 
1H NMR (500 MHz, CDCl3) ! 8.39 (bs, 3H, NH3+), 7.77 (d, J= 8.5 Hz, 2H, Ts), 7.32-
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2H, OCH2Ph), 4.20- 4.17 (m, 1H, CHCH2CH2SCH3), 2.55-2.52 (dt, J= 7.0 Hz, J= 
14.5 Hz, 1H, CHCH2CH2SCH3), 2.43 (dt, J= 8.0 Hz, J= 14.5 Hz, 1H, 
CHCH2CH2SCH3), 2.34 (s, 3H, CH3 Ts), 2.21- 2.12 (m, 2H, CHCH2CH2SCH3), 1.87 
(s, 3H, CHCH2CH2SCH3). 
 
Synthesis of Boc-L-methionine S-phenylethyl ester (3.2n’). 
 
Prepared according to the standard procedure 2c, 
from: Boc-L-methionine (5.00 g, 20.05 mmol),  
S-phenylethanol (3.15 ml, 26.07 mmol), DCC (4.14 g, 
20.05 mmol), DMAP (0.24g, 2.01 mmol) in 100 ml of 
DCM. The product was obtained as clear oil (6.50 g, 92%). 
 
1H NMR (500 MHz, CDCl3) ! 7.37- 7.30 (m, 5H, OCH(CH3)Ph), 5.94 (q, J= 7.0 Hz, 
1H, OCH(CH3)Ph), 4.47- 4.41 (m, 1H, CHCH2CH2SCH3), 2.47- 2.42, 2.38- 2.32 (2x 
m, 2H, CHCH2CH2SCH3), 2.11-2.06 (m, 1H, CHCH2CH2SCH3), 2.01 (s, 3H, 
CHCH2CH2SCH3), 1.93- 1.85 (m, 1H, CHCH2CH2SCH3),  1.59 (d, J= 7.00 Hz, 3H, 
OCH(CH3)Ph), 1.00 (s, 9H, 3x CH3 Boc). 
 
Synthesis of L-methionine S-phenylethyl ester p-toluene sulfonate salt (3.2n). 
 
Prepared according to the standard procedure 2d, 
from: Boc-L-methionine S-phenylethyl ester (6.50 
g, 18.49 mmol) and pTSA (3.52 g, 18.49 mmol) 
in 230 ml of AcOEt. The product was obtained as 
a white solid (4.67 g, 59%). 
 
1H NMR (500 MHz, CDCl3) ! 8.34 (bs, 3H, NH3+), 7.75 (d, J= 8.0 Hz, 2H, Ts), 7.33-
7.32 (m, 5H, OCH(CH3)Ph), 7.12 (d, J= 8.0 Hz, 2H, Ts), 5.90 (q, J= 6.5 Hz, 1H, 
OCH(CH3)Ph), 4.20- 4.16 (m, 1H, CHCH2CH2SCH3), 2.45 (dt, J= 8.0 Hz, J= 14.5 
Hz, 1H, CHCH2CH2SCH3), 2.35 (s, 3H, CH3 Ts), 2.30 (dt, J= 7.0 Hz, J= 14.5 Hz, 1H, 
CHCH2CH2SCH3), 2.10- 2.06 (m, 2H, CHCH2CH2SCH3), 1.83 (s, 3H, 
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Synthesis of Boc-L-isoleucine cyclohexyl ester (3.2o’). 
 
Prepared according to the standard procedure 2c, from: 
Boc-L-isoleucine (5.00g, 21.62 mmol), cyclohexanol 
(3.38 ml, 32.43 mmol), DCC (4.46 g, 21.62 mmol), 
DMAP (0.26 g, 2.16 mmol) in 100 ml of DCM. The 
product was obtained as clear oil (7.20 g, 100%). 
 
1H NMR (500 MHz, CDCl3) ! 5.07 (bs, 1H, NH), 4.82-4.74 (m, 1H, OCH ester), 
4.27-4.22 (m, 1H, CHCH(CH3)CH2CH3), 1.91-1.12 (m, 3H, CHCH(CH3)CH2CH3 and 
CH2 ester), 1.77-1.72 (m, 2H, CH2 ester), 1.48 (s, 9H, 3x CH3 Boc), 1.47-1.17 (m, 8H, 
3x CH2 ester and CHCH(CH3)CH2CH3), 0.99-0.87 (m, 6H, CHCH(CH3)CH2CH3 and 
CHCH(CH3)CH2CH3). 
 
Synthesis of L-isoleucine cyclohexyl ester p-toluene sulfonate salt (3.2o). 
  
Prepared according to the standard procedure 2d, 
from: Boc-L-isoleucine cyclohexyl ester (7.20 g, 
21.62 mmol) and pTSA (4.37 g, 21.62 mmol) in 250 
ml of AcOEt. The product was obtained as a white 
solid (4.70 g, 53%). 
 
1H NMR (500 MHz, CDCl3) ! 8.17 (bs, 1H, NH3+), 7.78 (d, J= 8.0 Hz, 2H, Ts), 7.13 
(d, J= 8.0 Hz, 2H, Ts), 4.84-4.77 (m, 1H, OCH ester), 3.98-3.91 (m, 1H, 
CHCH(CH3)CH2CH3), 2.35 (s, 3H, CH3 Ts), 2.01-1.97 (m, 1H, 
CHCH(CH3)CH2CH3), 1.87-1.85 (m, 2H, CH2 ester), 1.77-1.72 (m, 2H, CH2 ester), 
1.456-1.21 (m, 8H, 3x CH2 ester and CHCH(CH3)CH2CH3), 0.92 (d, J= 6.5 Hz, 3H, 
CHCH(CH3)CH2CH3), 0.73 (t, J= 7.5 Hz, CHCH(CH3)CH2CH3). 
 
Synthesis of Boc-L-isoleucine 2,2-dimethylpropyl ester (3.2p’). 
 
Prepared according to the standard procedure 2c, from: 
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dimethylpropanol (2.68 ml, 32.43 mmol), DCC (4.46 g, 21.62 mmol), DMAP (0.26 g, 
2.16 mmol) in 100 ml of DCM. The product was obtained as clear oil (7.14 g, 100%). 
 
1H NMR (500 MHz, CDCl3) ! 5.06 (bs, 1H, NH), 4.43-4.37 (m, 1H, 
CHCH(CH3)CH2CH3), 3.76, 3.62 (AB, JAB=12.0 Hz, OCH2C(CH3)3), 1.91-1.89 (m, 
1H, CHCH(CH3)CH2CH3), 1.49 (s, 9H, 3x CH3 Boc), 1.27-1.18 (m, 2H, 
CHCH(CH3)CH2CH3), 0.99-0.87 (m, 6H, CHCH(CH3)CH2CH3 and 
CHCH(CH3)CH2CH3). 
 
Synthesis of L-isoleucine 2,2-dimethylpropyl ester p-toluene sulfonate salt (3.2p). 
  
Prepared according to the standard procedure 2d, 
from: Boc-L-isoleucine 2,2-dimethylpropyl ester 
(7.14 g, 23.68 mmol) and pTSA (4.51 g, 23.68 
mmol) in 250 ml of AcOEt. The product was 
obtained as a white solid (4.10 g, 46%). 
 
1H NMR (500 MHz, CDCl3) ! 8.21 (bs, 1H, NH3+), 7.79 (d, J= 8.0 Hz, 2H, Ts), 7.13 
(d, J= 8.0 Hz, 2H, Ts), 4.08-3.99 (m, 1H, CHCH(CH3)CH2CH3), 3.81, 3.77 (AB, 
JAB=12.0 Hz, OCH2C(CH3)3), 2.34 (s, 3H, CH3 Ts), 2.04-1.98 (m, 1H, 
CHCH(CH3)CH2CH3), 1.46-1.41, 1.32-1.79 (2m, 2H, CHCH(CH3)CH2CH3), 0.92 (d, 
J= 6.5 Hz, 3H, CHCH(CH3)CH2CH3), 0.90 (s, 9H, OCH2C(CH3)3), 0.74 (t, J= 7.5 Hz, 
CHCH(CH3)CH2CH3). 
 
Synthesis of Boc-D-phenylglycine benzyl ester (3.2r’). 
 
 Prepared according to the standard procedure 2c, 
from: Boc-D-phenylglycine (1.5 g, 0.74 mmol), 
benzyl alcohol (0.97 ml, 0.96 mmol), DCC (1.49 g, 
0.74 mmol), DMAP (0.09 g, 0.07 mmol) in 35 ml of 
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1H NMR (500 MHz, CDCl3) ! 7.38-7.21 (m, 10H, CHPh and OCH2Ph), 5.58 (bs, 1H, 
NH), 5.41 (bs, 1H, CHPh), 5.19 (s, 2H, OCH2Ph), 1.46 (s, 9H, 3x CH3 Boc). 
 
Synthesis of D-phenylglycine benzyl ester p-toluene sulfonate salt (3.2r). 
  
Prepared according to the standard procedure 2d, 
from: Boc-D -phenylglycine benzyl ester (2.10 g, 
0.71 mmol) and pTSA (1.34 g, 0.71 mmol) in 75 
ml of AcOEt. The product was obtained as a 
white solid (1.78 g, 61%). 
 
1H NMR (500 MHz, CDCl3) ! 8.22 (bs, 1H, NH3+), 7.50-7.47 (m, 7H, CHPh and 
OCH2Ph), 7.36-7.33 (m, 3H, OCH2Ph and Ts), 7.25-7.23 (m, 2H, OCH2Ph), 7.11 (d, 
J= 7.5 Hz, 2H, Ts), 5.40 (s, 1H, CHPh), 5.28, 5.22 (AB, JAB= 12.5 Hz, 2H, OCH2Ph), 
2.30 (s, 3H, Ts). 
 
Synthesis of !-naphthyl-(methoxy-L-alaninyl) phosphorochloridate (3.3a). 
 
Prepared to the Standard Procedure 3, from L-alanine 
methyl ester chydrochloride salt: (1.00g, 7.16 mmol),   
!-naphthyl phosphorodichloridate (1.87g, 7.16 mmol) 
and  Et3N (3.99 ml, 14.32 mmol) in 15 ml of dry DCM. Product was obtained as a 
pale, yellow, thick oil (1.21g, 52%).  
 
31P NMR (202 MHz, CDCl3) ! 8.19, 7.92. 
1H NMR (500 MHz, CDCl3) ! 8.12, 8.10 (2d, J= 7.5 Hz, 1H, H8-Naph), 7.90 (d, J= 
7.5 Hz, 1H, H5-Naph), 7.76 (d, J= 8.0 Hz, 1H, H4-Naph), 7.68 – 7.55 (m, 3H, H7, H6, 
H2-Naph), 7.46 (t, J= 8.0 Hz, 1H, H3-Naph), 4.52, 4.45 (2bs, 1H, NH), 4.36- 4.30 (m, 
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Synthesis of !-naphthyl-(isopropoxy-L-alaninyl) phosphorochloridate (3.3b). 
 
Prepared according to the Standard Procedure 3, from: 
!-naphthyl (2.70g, 10.33 mmol), L-alanine isopropyl 
ester hydrochloride salt (1.40g, 10.33 mmol), and 
Et3N (2.88 ml, 20.65 mmol) in 15 ml of dry DCM. Product was obtained as a pale, 
yellow, thick oil (1.10g, 30%). 
 
31P NMR (202 MHz, CDCl3) ! 8.29, 7.97. 
1H NMR (500 MHz, CDCl3) ! ! 8.12, 8.11 (2x d, J= 8.0 Hz, 1H, H8-Naph), 7.91- 
7.89 (m, 1H, H5-Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.64–7.56 (m, 3H, H7, H6, 
H2-Naph), 7.47, 7.46 (2t, J= 8.0 Hz, 1H, H3-Naph), 5.17- 5.06 (m, 1H, OCH(CH3)2), 
4.46- 4.31 (m, 1H NH), 4.30 – 4.23 (m, 1H, CHCH3), 1.57, 1.55 (2d, J= 7.0 Hz, 3H, 
CHCH3), 1.33 (d, J= 6.0 Hz, 3H, OCH(CH3)2), 1.29 (d, J = 6.0, 3H, OCH(CH3)2). 
 
Synthesis of !-naphthyl-(n-propoxy-L-alaninyl) phosphorochloridate (3.3c) 
 
Prepared according to the Standard Procedure 3, 
from: L-alanine n-propyl ester hydrochloride salt 
(2.00g, 11.93 mmol), !-naphthyl 
phosphorodichloridate (3.11g, 11.93 mmol) and 
Et3N (3.32 ml, 23.86 mmol) in 30 ml of dry DCM. The product was obtained as a 
clear, yellow, thick oil (3.50g, 82%). 
 
31P NMR (202 MHz, CDCl3) ! 8.29, 8.04 
1H NMR (500 MHz, CDCl3) ! 8.13 – 8.04 (m, 1H, H8-Naph), 7.89, 7.88 (2d, J= 7.5 
Hz, 1H, H5-Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64–7.55 (m, 3H, H7, H6, H2-
Naph), 7.45 (t, J= 8.0 Hz, 1H, H3-Naph), 4.51, 4.25 (2bs, 1H, NH), 4.28–4.27 (m, 1H, 
CHCH3), 4.15, 4.14 (2q, J= 7.0 Hz, 2H, OCH2CH2CH3), 1.76-1.65 (m, 2H, 
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Synthesis of !-naphthyl-(t-butoxy-L-alaninyl) phosphorochloridate (3.3d). 
 
Prepared according to the Standard Procedure 3 from: 
L-alanine t-butyl ester hydrochloride salt (1.00g, 5.50 
mmol), !-naphthyl phosphorodichloridate (1.43g, 
5.50 mmol) and Et3N (1.53 ml, 11.00 mmol) in 15 ml 
of dry DCM. Product was obtained as a pale, yellow, thick oil (1.48g, 69%). 
 
31P NMR (202 MHz, CDCl3) ! 8.43, 8.11. 
1H NMR (500 MHz, CDCl3) ! 8.13, 8.10 (2d, J= 8.0 Hz, 1H, H8-Naph), 7.89 (d, J= 
8.3 Hz 1H, H5-Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64–7.55 (m, 3H, H7, H6, 
H2-Naph), 7.46 (t, J= 7.5 Hz, 1H, H3-Naph), 4.53- 4.41 (m, 1H NH), 4.23– 4.16 (m, 
1H, CHCH3), 1.55, 1.53 (2d, J= 7.0 Hz, 3H, CHCH3), 1.53, 1.49 (2s, 9H, CH(CH3)3). 
 
Synthesis of !-naphthyl-(2,2-dimethylpropoxy-L-alaninyl) phosphorochloridate 
(3.3e). 
 
Prepared according to the Standard Procedure 3, 
from: L-alanine 2,2-dimethylpropyl ester tosylate salt 
(5.00g, 15.09 mmol), !-naphthyl 
phosphorodichloridate (3.94g, 15.09 mmol) and Et3N (4.20 ml, 30.17 mmol) in 66 ml 
of dry DCM. The product was obtained as clear, yellow, thick oil (5.70g, 99%). 
 
31P NMR (202 MHz, CDCl3) ! 8.21, 7.90. 
1H NMR (500 MHz, CDCl3) ! 8.10 (d, J= 7.5 Hz 1H, H8-Naph), 7.90-7.88 (m, 1H, 
H5-Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64 – 7.55 (m, 3H, H6, H7, H2-Naph), 
7.45, 7.44 (2t, J= 8.0 Hz, 1H, H3- Naph), 4.60- 4.49 (m, 1H, NH), 4.40– 4.30 (m, 1H, 
CHCH3), 3.97, 3.93, 3.89, 3.83 (2AB, JAB= 10.5 Hz 2H, OCH2C(CH3)3), 1.61, 1.58 
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Synthesis of !-naphthyl-(3,3-dimethyl-1-butoxy-L-alaninyl) phosphorochloridate 
(3.3f). 
 
Prepared according to the Standard Procedure 3, 
from: L-alanine 3,3-dimethyl-1-butyl ester 
tosylate salt (2.00g, 5.79 mmol), !-naphthyl 
phosphorodichloridate (1.51g, 5.79 mmol) and Et3N (1.61 ml, 11.58 mmol) in 30 ml 
of dry DCM. The product was obtained as clear, yellow, thick oil (2.10g, 91%). 
 
31P NMR (202 MHz, CDCl3) ! 8.46, 8.02. 
1H NMR (500 MHz, CDCl3) ! 8.11, 8.09 (2d, J= 7.5 Hz 1H, H8-Naph), 7.90-7.89 (m, 
1H, H5-Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.64 – 7.55 (m, 3H, H6, H7, H2-
Naph), 7.46 (t, J= 7.5 Hz, 1H, H3- Naph), 4.56- 4.45 (m, 1H, NH), 4.32- 4.26 (m, 2H, 
OCH2CH2C(CH3)3), 4.25– 4.21 (m, 1H, CHCH3),1.64- 1.60 (m, 2H, 
OCH2CH2C(CH3)3), 1.58, 1.55(2d, J= 7.0 Hz, CHCH3),  0.98, 0.96 (2s, 9H, 
OCH2CH2C(CH3)3). 
 
Synthesis of !-naphthyl-(3,3-dimethyl-2-butoxy-L-alaninyl) phosphorochloridate 
(3.3g). 
Prepared according to the Standard Procedure 3, 
from: L-alanine 3,3-dimethyl-2-butyl ester tosylate 
salt (2.00g, 5.79 mmol), !-naphthyl 
phosphorodichloridate (1.51g, 5.79 mmol) and Et3N 
(1.61 ml, 11.58 mmol) in 30 ml of dry DCM. The product was obtained as clear, 
yellow, thick oil (2.20g, 96%). 
 
31P NMR (202 MHz, CDCl3) ! 8.30, 8.24, 7.98, 7.95. 
1H NMR (500 MHz, CDCl3) ! 8.12, 8.10 (2d, J= 6.5 Hz 1H, H8-Naph), 7.91- 7.88 (m, 
1H, H5-Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64–7.55 (m, 3H, H6, H7, H2-
Naph), 7.46 (t, J= 8.0 Hz, 1H, H3- Naph), 4.84- 4.77 (m, 1H, OCH(CH3)C(CH3)3), 
4.57- 4.42 (m, 1H, NH), 4.36– 4.25 (m, 1H, CHCH3), 1.60, 1.58, 1.57, 1.56 (4d, J= 
7.0 Hz, 3H, CHCH3), 1.22, 1.20, 1.18, 1.17 (4d, J= 6.5 Hz, 3H, OCH(CH3)C(CH3)3),  
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Synthesis of !-naphthyl-(cyclopentoxy-L-alaninyl) phosphorochloridate (3.3h). 
 
Prepared according to the Standard Procedure 3, 
 from: L-alanine cyclopentyl ester tosylate salt 
(4.00g, 12.14 mmol), !-naphthyl 
phosphorodichloridate (3.17g, 12.14 mmol) and Et3N (1.60 ml, 24.28 mmol) in 66 ml 
of dry DCM. Product was obtained as a yellow, clear, thick oil (3.01g, 65%).  
 
31P NMR (202 MHz, CDCl3) ! 8.38, 8.13. 
1H NMR (500 MHz, CDCl3) ! 8.13- 8.09 (m, 1H, H8-Naph), 7.95- 7.88 (m, 1H, H5-
Naph), 7.74 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64- 7.54 (m, 3H, H7, H6, H2-Naph), 7.50- 
7.40 (m, 1H, H3-Naph), 5.30-5.28, 5.25-5.23 (2m, 1H, OCH ester), 4.63-4.57 (m, 1H, 
NH), 4.28-4.25 (m, 1H, CHCH3), 1.94-1.85 (m, 2H, CH2 ester), 1.79-1.69 (m, 4H, 2 x 
CH2 ester), 1.66-1.59 (m, 2H, CH2 ester), 1.57, 1.54 (2d, J= 7.0 Hz, 3H, CHCH3). 
 
Synthesis of !-naphthyl-(cyclohexoxy-L-alaninyl) phosphorochloridate (3.3i). 
 
Prepared according to the Standard Procedure 3, 
from: L-alanine cyclohexyl ester hydrochloride salt 
(5g, 24.07 mmol), !-naphthyl 
phosphorodichloridate (6.28g, 24.07 mmol) and Et3N (3.35 ml, 48.14 mmol) in 100 
ml of dry DCM. Product was obtained as yellow, clear, thick oil (8.72g, 92%).  
 
31P NMR (202 MHz, CDCl3) ! 8.29, 7.92. 
1H NMR (500 MHz, CDCl3) ! 8.11, 8.10 (2d, J= 6.5 Hz, 1H, H8-Naph), 7.91-7.89 (m, 
1H, H5-Naph), 7.76 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64-7.55 (m, 3H, H7, H6, H2-
Naph), 7.47, 7.46 (2t, J= 8.0 Hz, 1H, H3-Naph), 4.92-4.84 (m, 1H, OCH ester), 4.45- 
4.25 (m, 2H, NH and CHCH3), 1.92-1.85 (m, 2H, CH2 ester), 1.79-1.73 (m, 2H, CH2 
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Synthesis of !-naphthyl-(tetrahydropyranoxy-L-alanine) phosphorochloridate 
(3.3j). 
 
Prepared according to the standard procedure 3, 
from: L-alanine tetrahydropyranyl ester tosylate 
salt (1.00g, 2.90 mmol), !-naphthyl 
phosphorodichloridate (0.76g, 2.90 mmol) and Et3N (0.80 ml, 5.79 mmol) in 30 ml of 
dry DCM. The product was obtained as yellow, thick oil in (0.84g, 70%). 
 
31P NMR (202 MHz, CDCl3) ! 8.19, 8.00. 
1H NMR (500 MHz, CDCl3) ! 8.11, 8.08 (2d, J = 8.00 Hz, 1H, H8-Naph), 7.91, 7.89 
(2d, J = 8.50 Hz, 1H, H5-Naph), 7.72, 7.66 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.61-7.51 
(m, 3H, H7, H6, H2,), 7.47 (t, J = 8.00 Hz, 1H, H3-Naph), 5.12-4.99 (m, 1H, OCH 
ester), 4.57 (bs, 1H, NH), 4.31-4.22 (m, 1H, CHCH3), 3.98-3.80 (m, 2H, CH2 ester), 
3.53 – 3.45 (m, 2H, CH2 ester), 1.97-1.88 (m, 2H, CH2 ester), 1.71-1.62 (m, 2H, CH2 
ester), 1.54, 1.51 (2d, J = 7.00 Hz, 3H, CHCH3). 
 
Synthesis of !-naphthyl-(benzoxy-L-alaninyl) phosphorochloridate (3.3k). 
 
Prepared accordingto the Standard Procedure 3, 
from L-alanine benzyl ester tosylate salt (10.00g, 
28.46 mmol), !-naphthyl phosphorodichloridate 
(7.43g, 28.46 mmol) and Et 3N (7.92 ml, 56.91 
mmol) in 200 ml of dry DCM). The product was obtained as clear, yellow, thick oil 
(9.80g, 85%). 
 
31P NMR (202 MHz, CDCl3) ! 8.16, 7.92. 
1H NMR (500 MHz, CDCl3) ! 8.10- 8.08 (m, 1H, H8-Naph), 7.91- 7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.60-7.58 (m, 3H, H6, H7, H2-Naph), 7.45, 
7.44 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.40-7.36 (m, 5H, OCH2Ph), 5.26-5.17 (m, 2H, 
OCH2Ph), 4.60-4.48, 4.53-4.49 (2m, 1H, NH), 4.41-4.34 (m, 1H, CHCH3), 1.59, 1.57 
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Synthesis of !-naphthyl-(S-phenylethoxy-L-alanine) phosphorochloridate (3.3l). 
 
Prepared according to the Standard Procedure 3, 
from: L-alnine S-phenylethyl ester tosylate salt 
(7.70g, 21.07 mmol), !-naphthyl 
phosphorodichloridate (5.50g, 21.07 mmol), Et3N (3.80 ml, 42.13 mmol) in 80 ml of 
rdy DCM. Product was obtained as yellow, thick oil (6.00g, 68%). 
 
31P NMR (202 MHz, CDCl3) ! 8.22, 7.94. 
1H NMR (500 MHz, CDCl3) ! 8.10 (d, J= 7.5 Hz, 1H, H8-Naph), 7.91- 7.89 (m, 1H, 
H5-Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.64-7.56 (m, 3H, H7, H6, H2-Naph), 
7.48 – 7.42 (m, 1H, H3-Naph), 7.39-7.36 (m, 5H, OCH(CH3)Ph), 5.98, 5.94 (2q, J= 
7.0 Hz, 1H, OCH(CH3)Ph), 4.48-4.41 (m, 1H, NH), 4.39-4.32 (m, 1H, CHCH3), 1.63, 
1.59 (2 d, J= 7.0 Hz, 3H, OCH(CH3)Ph), 1.54, 1.51 (2d, J= 7.0 Hz, 3H, CHCH3). 
 
Synthesis of !-naphthyl-(2-indanoxy-L-alaninyl) phosphorochloridate (3.3m). 
 
Prepared according to the Standard Procedure 3, 
from: L-alnine 2-indanyl ester tosylate salt 
(2.00g, 5.30 mmol), !-naphthyl 
phosphorodichloridate (1.38g, 5.30 mmol), 
Et3N (1.48 ml, 10.60 mmol) in 15 ml of rdy DCM. Product was obtained as yellow, 
thick oil (1.48g, 65%). 
 
31P NMR (202 MHz, CDCl3) ! 8.16, 7.90. 
1H NMR (500 MHz, CDCl3) ! 8.08-8.05 (m, 1H, H8-Naph), 7.90-7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.62-.52 (m, 3H, H7, H6, H2-Naph), 7.45, 
7.44 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.29- 7.20 (m, 4H, 4x CH Ar ester), 5.68-5.65, 
5.63-5.59 (2m, 1H, OCH ester), 4.51, 4.25 (2bs, 1H, NH), 4.31-4.22 (m, 1H, CHCH3), 
3.42- 3.32 (m, 2H, CH2 ester), 3.11- 3.00 (m, 2H, CH2 ester), 1.54, 1.52 (2d, J= 7.0 
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Synthesis of phenyl-(2,2-dimethylpropoxy-L-alaninyl) phosphorochloridate 
(3.3n). 
 
Prepared according to the Standard Procedure 3, 
from: L-alanine 2,2-dimethylpropyl ester tosylate 
salt (1.50g, 6.03 mmol), phenyl phosphorodichloridate (0.90 ml, 6.03 mmol) and Et3N 
(1.68 ml, 12.06 mmol) in 66 ml of dry DCM. The product was obtained as clear, thick 
oil (1.91g, 95%). 
 
31P NMR (202 MHz, CDCl3) ! 8.02, 7.73. 
1H NMR (500 MHz, CDCl3) ! 7.40- 7.23 (m, 5H, Ph), 4.53- 4.43 (m, 1H, NH), 4.30– 
4.18 (m, 1H, CHCH3), 3.94, 3.92, 3.88, 3.85 (2AB, JAB= 10.5 Hz, 2H, 
OCH2C(CH3)3), 1.56, 1.55 (2d, J= 5.5 Hz, 3H, CHCH3), 0.98, 0.97 (2s, 9H, 
OCH2C(CH3)3). 
 
Synthesis of p-nitrophenyl-(2,2-dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3o). 
 
Prepared according to the Standard Procedure 
3, from: L-alanine 2,2-dimethylpropyl ester 
tosylate salt (2.00g, 10.22 mmol), p-NO2-phenyl phosphorodichloridate (2.62 g, 10.22 
mmol) and Et3N (2.85 ml, 20.43 mmol) in 66 ml of dry DCM. After reaction 
completion, solvent was removed under reduced pressure and residue was taken up in 
EtOAc and the resulting salts were filtered off. After evaporation, the product was 
obtained as clear, thick oil (3.2 g) and was used immediately for subsequent step 
without further purification. 
 
31P NMR (202 MHz, CDCl3) ! 8.10. 
 
Synthesis of !-naphthyl-(benzoxy-dimethylglicynyl) phosphorochloridate (2.3p). 
 
Prepared according to the Standard Procedure 3, 
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6.03 mmol), !-naphthyl phosphorodichloridate (0.90 ml, 6.03 mmol) and Et3N (1.68 
ml, 12.06 mmol) in 66 ml of dry DCM. The product was obtained as clear, thick oil 
(1.91g, 95%). 
 
31P NMR (202 MHz, CDCl3) ! 5.86. 
1H NMR (500 MHz, CDCl3) ! 8.13 (d, J= 7.0 Hz, 1H, H8-Naph), 7.88 (d, J= 7.0 Hz 
1H, H5-Naph), 7.74 (d, J= 8.0 Hz, 1H, H4-Naph), 7.58 – 7.55 (m, 3H, H7, H6, H2-
Naph), 7.44 (t, J= 8.0 Hz, 1H, H3-Naph), 7.39 – 7.36 (m, 5H, OCH2Ph), 5.25 (s, 2H, 
OCH2Ph), 4.90 (bs, 1H, NH), 1.80 (s, 3H, C(CH3)2), 1.75 (s, 3H, C(CH3)2). 
 
Synthesis of !-naphthyl-(methoxy-L-valinyl) phosphorochlori-date (3.3r). 
 
Prepared according to the standard procedure 3, from:  
L-valine methyl ester hydrochloride salt (2.00g, 11.93 
mmol), !-naphthyl phosphorodichloridate (0.77g, 11.93 
mmol) and Et3N (4.11 ml, 23.85 mmol) in 20 ml of dry 
DCM.Compound was obtained as a clear, yellow, thick oil (2.63g, 62%). 
 
31P NMR (202 MHz, CDCl3) ! 10.02, 9.56. 
1H NMR (500 MHz, CDCl3) ! 8.12, 8.10 (2d, J = 7.50 Hz, 1H, H8-Naph), 7.88 (d, J = 
8.00 Hz, 1H, H5-Naph), 7.74 (d, J = 8.00 Hz, 1H, H4-Naph), 7.65-7.52 (m, 3H, H7, 
H6, H2-Naph), 7.50, 7.45 (2t, J = 8.00 Hz, 1H, H3-Naph), 4.59 (bs, 1H, NH), 4.09-
4.06 (m, 1H, CHCH(CH3)2), 3.81, 3.76 (2s, 3H, OCH3), 2.25 – 2.18 (m, 1H, 
CHCH(CH3)2), 1.06, 1.03 (2d, J = 6.50 Hz, 3H, CHCH(CH3)2), 0.99, 0.96 (2d, J = 
6.50 Hz, 3H, CHCH(CH3)2). 
 
Synthesis of !-naphthyl-(2,2-dimethylpropoxy-L-valinyl) phosphorochlori-date 
(3.3s). 
 
Prepared according to the Standard Procedure 3, 
from: L-valine neopentyl tosylate salt (2.00g, 5.56 
mmol), !-naphthyl phosphorodichloridate (1.45g, 
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ml of dry DCM. Product was obtained as pale, thick oil (1.75 g, 76%). 
 
31P NMR (202 MHz, CDCl3) ! 9.84, 9.34. 
1H NMR (500 MHz, CDCl3) ! 8.13 – 8.11 (m, 1H, H8-Naph), 7.90- 7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.60- 7.55 (m, 3H, H7, H6, H2-Naph), 7.45 
(t, J= 8.0 Hz, 1H, H3-Naph), 4.42- 4.35 (m, 1H, NH), 4.17 – 4.11 (m, 1H, 
CHCH(CH3)2), 3.94- 3.86 (m, 2H, OCH2C(CH3)3), 2.28- 2.19 (m, 1H, CHCH(CH3)2), 
1.09, 1.06 (2d, J= 7.0 Hz, 3H, CHCH(CH3)2), 1.02, 0.99 (2d, J= 7.0 Hz, 3H, 
CHCH(CH3)2), 1.00, 0.98 (2s, 9H, OCH2C(CH3)3).  
 
Synthesis of !-naphthyl-(benzoxy-L-valinyl) phosphorochloridate (3.3t). 
 
Prepared according to the Standard Procedure 3, 
from: L-valine benzyl ester tosylate salt (1.50 g, 
3.95 mmol), !-naphthyl phosphorodichloridate 
(1.03g, 3.95 mmol), Et3N (0.71 ml, 7.55 mmol) 
in 30 ml of dry DCM. Product was obtained as yellow, thick oil (1.23g, 72%). 
 
31P NMR (202 MHz, CDCl3) ! 9.78, 9.29. 
1H NMR (500 MHz, CDCl3) ! 8.12-8.10 (m, 1H, H8-Naph), 7.90-7.88 (m, 1H, H5-
Naph), 7.76-7.74 (m, 1H, H4-Naph), 7.65- 7.54 (m, 3H, H7, H6, H2-Naph), 7.45 (t, J= 
8.0 Hz, 1H, H3-Naph), 7.42-7.32 (m, 5H, OCH2Ph), 5.22-5.19 (m, 2H, OCH2Ph), 
4.17–4.11 (m, 2H, NH and CHCH(CH3)2), 2.28- 2.19 (m, 1H, CHCH(CH3)2), 1.05, 
1.02 (2d, J= 7.0 Hz, 3H, CHCH(CH3)2), 1.01, 0.98 (2d, J= 7.0 Hz, 3H, 
CHCH(CH3)2).  
 
Synthesis of "-naphthyl-(benzoxy-L-valinyl) phosphorochloridate (3.3u). 
 
Prepared according to the Standard 
Procedure 3, from: L-valine benzyl ester 
tosylate salt (1.50 g, 3.95 mmol), !-
naphthyl phosphorodichloridate (1.03g, 3.95 mmol), Et3N (0.71 ml, 7.55 mmol) in 30 
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31P NMR (202 MHz, CDCl3) ! 9.71, 9.18. 
1H NMR (500 MHz, CDCl3) ! 7.86–7.75 (m, 4H, H4, H5, H8, H7- Naph), 7.56–7.47 
(m, 2H, H6, H1-Naph) 7.40-7.33 (m, 6H, H3-Naph and OCH2Ph), 5.24–5.21 (m, 2H, 
OCH2Ph), 4.64- 4.59 (m, 1H, NH), 4.11- 4.03 (m, 1H, CHCH(CH3)2), 2.29–2.16 (m, 
1H, CHCH(CH3)2), 1.07, 1.04 (2d, J= 7.0 Hz, 3H, CHCH(CH3)2), 0.97, 0.95 (2d, J= 
7.0 Hz, 3H, CHCH(CH3)2). 
 
Synthesis of !-naphthyl-(benzoxy-D-valinyl) phosphorochloridate (3.3v). 
 
Prepared according to the Standard Procedure 3, 
from: D-valine benzyl ester tosylate salt (1.50 g, 
3.95 mmol), !-naphthyl phosphorodichloridate 
(1.03g, 3.95 mmol), Et3N (0.71 ml, 7.55 mmol) in 
30 ml of dry DCM. Product was obtained as yellow, thick oil (1.70g, 99%). 
 
31P NMR (202 MHz, CDCl3) ! 9.71, 9.30 
1H NMR (500 MHz, CDCl3) ! 8.11- 8.08 (m, 1H, H8-Naph), 7.91- 7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 8.0 Hz, 1H, H4-Naph), 7.64- 7.54 (m, 3H, H7, H6, H2-Naph), 7.45 
(t, J= 7.5 Hz, 1H, H5-Naph), 7.40 – 7.33 (m, 5H, OCH2Ph), 5.23, 5.17 (AB, JAB= 11.5 
Hz, 2H, OCH2Ph), 4.38- 4.31 (m, 1H, NH), 4.17- 4.10 (m, 1H, CHCH(CH3)2), 2.26- 
2.18 (m, 1H, CHCH(CH3)2), 1.05, 1.02 (2d, J= 7.0 Hz, 3H, CHCH(CH3)2), 0.96, 0.93 
(2d, J= 7.0 Hz, 3H, CHCH(CH3)2). 
 
Synthesis of !-naphthyl-(p-chloro-benzoxy-L-valinyl) phosphorochloridate 
(3.3w). 
 
Prepared according to the Standard Procedure 3, 
from: L-valine o-chlorobenzyl ester tosylate salt 
(9.95g, 24.04 mmol) !-naphthyl 
phosphorodichloridate (6.27g, 24.04 ml), Et3N 
(6.77 ml, 48.07 mmol) in 135 ml of dry DCM. Product was obtained as yellow, thick 
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31P NMR (202 MHz, CDCl3) ! 9.72, 9.24. 
1H NMR (500 MHz, CDCl3) ! 8.09- 8.08 (m, 1H, H8-Naph), 7.90-7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 8.5 Hz, 1H, H4-Naph), 7.58-7.30 (m, 8H, H7-, H6-, H3-, H2-Naph, 
and OCH2Ph), 5.35- 5.25 (m, 2H, OCH2Ph), 4.30- 4.22 (m, 1H, NH), 4.18- 4.11 (m, 
1H, CHCH(CH3)2), 2.27-2.20 (m, 1H, CHCH(CH3)2), 1.07, 1.04 (2d, J= 8.0 Hz 6H, 
CHCH(CH3)2), 0.98, 0.94 (2d, J= 7.0 Hz 6H, CHCH(CH3)2). 
 
Synthesis of !-naphthyl-(isopropoxy-L-methionine) phosphorochloridate (3.3x). 
 
Prepared according to the Standard Procedure 3, from: 
L-methionine isopropyl ester chydrochloride salt (1.50 
g, 6.59 mmol), !-naphthyl phosphorodichloridate 
(1.72g, 6.59 mmol) and Et3N (1.19 ml, 13.17 mmol) 
in 50 ml of dry DCM. Product obtained as a white 
solid (1.84g, 67%). 
 
31P NMR (202 MHz, CDCl3) ! 8.88, 8.80. 
1H NMR (500 MHz, CDCl3) ! 8.15–8.12 (m, 1H, H8-Naph), 7.89 (d, J=7.0 Hz, 1H, 
H5-Naph), 7.75 (d, J= 7.0 Hz, 1H, H4-Naph), 7.65- 7.54 (m, 3H, H7, H6, H2-Naph), 
7.45 (t, J= 7.5 Hz, 1H, H3-Naph), 5.16- 5.07 (m, 1H, OCH(CH3)2), 4.73- 4.68 (m, 1H, 
NH), 4.38- 4.31 (m, 1H, CHCH2CH2SCH3), 2.66- 2.54 (m, 2H, CHCH2CH2SCH3), 
2.23- 2.10 (m, 2H, CHCH2CH2SCH3), 2.08, 2.06 (2s, CHCH2CH2SCH3), 1.32, 1.31 
(2d, J= 7.0 Hz, 3H, OCH(CH3)2), 1.29, 1.28 (2d, J= 8.5 Hz, 3H, OCH(CH3)2). 
 
Synthesis of !-naphthyl-(2,2-dimethylpropoxy-L-methioninyl) 
phosphorochloridate (3.3y). 
 
Prepared according to the Standard Procedure 3, 
from: L-methionine neopentyl ester tosylate salt 
(2.00 g, 5.11 mmol), !-naphthyl 
phosphorodichloridate (1.30 g, 5.11 mmol) and 
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Product obtained as a white solid (0.92g, 41%). 
 
31P NMR (202 MHz, CDCl3) ! 8.92, 8.74. 
1H NMR (500 MHz, CDCl3) ! 8.15–8.11 (m, 1H, H8-Naph), 7.87 (d, J= 8.2 Hz, 1H, 
H5-Naph), 7.73 (d, J = 8.85, 1H, H4-Naph), 7.67– .52 (m, 3H, H7, H6, H2-Naph), 7.43 
(t, J = 8.0, 1H, H3-Naph), 4.97 (bs, 1H, NH), 4.48–4.41 (m, 1H, CHCH2CH2SCH3), 
3.93, 3.90, 3.89, 3.86 (2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3)  2.65–2.58 (m, 2H, ), 
2.25– 2.07 (m, 5H, CHCH2CH2SCH3 and CHCH2CH2SCH3), 0.99, 0.96 (2s, 9H, 
OCH2C(CH3)3). 
 
Synthesis of !-naphthyl-(2,2-dimethylpropoxy-L-methioninyl) 
phosphorochloridate (3.3z). 
 
Prepared according to the standard procedure 3, 
from: L-methionine benzyl ester tosylate salt 
(2.00 g, 4.70 mmol), !-naphthyl 
phosphorodichloridate (1.23 g, 4.70 mmol) and 
Et3N (1.31 ml, 9.40 mmol) in 30 ml of dry DCM. 
Compound was obtained as clear, yellow, thick oil (1.67g, 74%). 
 
31P NMR (202 MHz, CDCl3) ! 8.72, 8.63. 
1H NMR (500 MHz, CDCl3) ! 8.13-8.08 (m, 1H, H8-Naph), 7.90-7.88 (m, 1H, H5-
Naph), 7.75 (d, J= 9.00 Hz, 1H, H4-Naph), 7.64–7.54 (m, 3H, H7, H6, H2-Naph), 7.44 
(t, J= 8.20 Hz, 1H, H3-Naph), 7.35-7.31 (m, 5H, OCH2Ph), 5.25, 5.22 (AB, JAB= 8.50 
Hz, 2H, OCH2Ph), 4.75-4.69 (m, 1H, NH), 4.48 – 4.41 (m, 1H, CHCH2CH2SCH3), 
2.62 – 2.52 (m, 2H, CHCH2CH2SCH3), 2.18– 1.96 (m, 2H, CHCH2CH2SCH3), 2.03, 
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Synthesis of !-naphthyl-(S-phenylethoxy-L-methioninyl) phosphorochloridate 
(3.3za). 
  
Prepared according to the standard procedure 3, 
from: L-methionine S-phenylethyl ester the tosylate 
salt (2.00 g, 4.70 mmol), !-naphthyl 
phosphorodichloridate (1.23 g, 4.70 mmol) and 
Et3N (1.31 ml, 9.40 mmol) in 30 ml of dry DCM. Compound was obtaine as clear, 
thick oil (1.67g, 74%). 
 
31P NMR (202 MHz, CDCl3) ! 8.64, 8.59 
1H NMR (500 MHz, CDCl3) ! 8.12, 8.10 (2d, J = 8.00 Hz, 1H, H8-Naph), 7.91-7.88 
(m, 1H, H5-Naph), 7.76 (d, J = 8.50 Hz, 1H, H4-Naph), 7.65 – 7.55 (m, 3H, H7, H6, 
H2-Naph), 7.46, 7.45 (2t, J= 8.00 Hz, 1H, H3-Naph), 7.40-7.31 (m, 5H, 
OCH(CH3)Ph), 6.00, 5.97 (2q, J= 7.50 Hz, 1H, OCH(CH3)Ph), 4.58-4.47 (m, 1H, 
NH), 4.47 – 4.40 (m, 1H, CHCH2CH2SCH3), 2.55–2.34 (m, 2H, CHCH2CH2SCH3), 
2.18– 1.96 (m, 5H, CHCH2CH2SCH3 and CHCH2CH2SCH3), 1.64, 1.60 (2d, J = 7.50 
Hz, 3H, OCH(CH3)Ph). 
 
Synthesis of !-naphthyl-(propoxy-D-phenylglicynyl) phosphorochloridate 
(3.3zb). 
 
Prepared according to the standard procedure 3, 
from: D-phenylglycine propyl ester hydrochloride 
salt (2.00g, 8.71 mmol), !-naphthyl 
phosphorodichloridate (2.27, 8.71 mmol) and Et3N 
(2.42 ml, 17.41 mmol) in 20 ml of dry DCM. 
Compound was obtained as clear, yellow, thick (2.15g, 59%). 
 
31P NMR (202 MHz, CDCl3) ! 7.72, 7.52. 
1H NMR (500 MHz, CDCl3) ! 8.06 – 8.04 (m, 1H, H8-Naph), 7.87, 7.81 (2d, J = 6.00 
Hz, 1H, H5-Naph), 7.81, 7.67 (2d, J = 8.0 Hz, 1H, H4-Naph), 7.57–7.44 (m, 4H, H7, 
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1H, CHPh), 4.15 (q, J= 7.00 Hz, 2H, OCH2CH2CH3), 1.65-1.59 (m, 2H, 
OCH2CH2CH3), 0.84 (t, J = 7.00 Hz, 3H, OCH2CH2CH3). 
 
Synthesis of !-naphthyl-(cyclohexoxy-D-phenylglicynyl) phosphorochloridate 
(3.3zc). 
 
Prepared according to the standard procedure 3, 
from: D-phenylglycine cyclohexyl ester 
hydrochloride salt (2.00g, 7.41 mmol), !-naphthyl 
phosphorodichloridate (1.94g, 7.41 mmol) and Et3N 
(2.06 ml, 14.83 mmol) in 15 ml of dry DCM. 
Compound was obtained as yellow, thick oil yield (2.75g, 60%). 
 
31P NMR (202 MHz, CDCl3) ! 7.82, 7.64. 
1H NMR (500 MHz, CDCl3) ! 8.05, 7.88 (2d, J = 8.00 Hz, 1H, H8-Naph), 7.87 (d, J = 
8.50 Hz, 1H, H5-Naph), 7.72, 7.66 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.58- 7.45 (m, 4H, 
H7, H6, H2, H3-Naph), 7.40–7.37 (m, 5H, CHPh), 5.38–5.31 (m, 1H, NH), 5.25–5.17 
(m, 1H, CHPh), 4.89–4.85 (m, 1H, OCH ester), 1.88–1.67 (m, 2H, CH2 ester), 1.56-
1.48 (m, 2H, CH2 ester), 1.46-1.33 (m, 6H, 3 x CH2 ester). 
 
Synthesis of !-naphthyl-(benzoxy-D-phenylglicynyl) phosphorochloridate (3.3zd). 
Prepared according to the standard procedure 3, 
from: D-phenylglycine benzyl ester tosylate salt 
(1.50g, 3.63 mmol), !-naphthyl 
phosphorodichloridate (0.95g, 3.63 mmol) and 
Et3N (1.01 ml, 7.26 mmol) in 20 ml of dry DCM. 
Compound was obtained as clear, yellow, thick oil (1.21g, 72%). 
 
31P NMR (202 MHz, CDCl3) ! 7.60, 7.42. 
1H NMR (500 MHz, CDCl3) ! 8.11–8.01 (m, 1H, H8-Naph), 7.87, 7.81 (2d, J = 8.5 
Hz, 1H, H5-Naph), 7.72, 7.67 (2d, J = 8.0 Hz, 1H, H4-Naph), 7.58–7.48 (m, 3H, H7, 
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12.4 Experimental section - Chapter Four. 
 
Synthesis of 1,3,5-tri-O-benzoyl-D-2-ketoribofuranose (4.2). 
 
To a solution of Dess-Martine periodinane (7.13 g, 16.8 
mmol) in anhydrous DCM (50 ml), was added 1,3,5-tri-O-
benzoyl-D-ribofuranose (5.0 g, 11.2 mmol) at 0 °C. The 
mixture was allowed to warm up to ambient temperature and stirred for 16 h. The 
solvent was reduced under reduced pressure and the residu was triturated with diethyl 
ether (100 ml). The solid was filtered through MgSO4 pad. The solvent was stirred 
with an equal volume of the Na2S2O3  (12.5 g) solution of a saturated NaHCO3. The 
otganic layer was separated, washed with brine and dried over anhydrous MgSO4. The 
solvents was evaporated in vacuo and product was isolated as white foam. (4.57 g, 
89%). 
 
1H NMR (500 MHz, CDC13) ! 8.35-8.15 (m, 6H, Bz), 7.56-7.44 (m, 3H, Bz), 7.41-
7.31 (m, 6H, Bz), 6.15 (s, lH, H1), 5.80 (d, J= 8.8 Hz, 1H, H3), 4.98-4.87 (m, lH, H4), 
4.82-4.66 (m, 2H, H5). 
13C NMR (126 MHz, CDC13) ! 201.31 (C2), 166.02 (C=O, Bz), 165.57 (C=O, Bz), 
165.20 (C=O, Bz), 134, 11, 133.95, 133.37, 130.56, 130.37, 129.80, 128.67, 128.55, 
128.32 (C and CH, Bz), 91.45 (C1), 78.18 (C3), 72.05 (C4), 64.20 (C5). 
 
Synthesis of 1,3,5-Tri-O-benzoyl-2-C-methyl-D-ribofuranose (4.3). 
 
TiCl4 (4.2 ml, 38.72 mmol) 
was added dropwise to 
anhydrous diethyl ether (120 
ml) at -78 °C, followed by the addition of 3M solution of MeMgBr in diethyl ether 
(12.90 ml, 38.72 mmol). The reaction mixture was allowed to warm up to -10 °C and 
a solution of 1,3,5-tri-O-benzoyl-D-2-ketoribofuranose (4.2, 4.50 g, 9.68 mmol) in 
diethyl ether (13 ml). After 3 h, the reaction was quenched with 60 ml of water. The 
water layer was separted and extracted with diethyl ether (3x 50 ml). The combined 
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mixture was purified on silica gel, using hexane/ethyl acetate 5:2 then 5:3 as eluent. 
The collected producted consisted of a mixture of two species 4.3 and 4.4 (4.0g, 
75%). 
 
Synthesis of 2,3,5-Tri-O-benzoyl-2-C-methyl- D-ribofuranose (4.4) is reported after 
the synthesis of 4.7, using 4.7 as a starting material. 
 
Synthesis of 1,2,3,5-Tetra-O-benzoyl-2-C-methyl-D-ribofuranose (4.5). 
 
To a cold solution (5 °C) of 4.3 and 4.4 (11.3 g, 23.6 
mmol), 4-dimethylaminopyridine (290 mg, 2.36 mmol) 
and triethylamine (16.4 ml, 117.9 mmol) in anhydrous 
tetrahydrofuran (120ml), benzoyl chloride (5.5 ml, 47.1 mmol) was added dropwise. 
The reaction mixture was stirred under nitrogen, at room temperature overnight. The 
reaction was quenched with ice-cold water (200 ml) and saturated aqueous solution of 
sodium bicarbonate. Tetrahydrofuran was removed under vacuum and the mixture 
was extracted with ethyl acetate (3x 50 ml). The organic layers were combined, 
washed with water and brine. Mixture was dried over anhydrous sodium sulfate. 
Solvent was removed under reduced pressure to give thick oil. This crude product was 
stirred with 200 ml of tert-butyl methyl ether for 5 minutes. Heptane (200 ml) and 
water (4.1 ml) were added and stirring was continued for two hours at room 
temperature. Solids were collected by vacuum filtration and filter cake was washed 
with mixture of heptane/tert-butyl methyl ether (1:1, 200 ml) and tert-butyl methyl 
ether (80 ml). Solid was dried in vacuum, to gave 6.75 g (63%) of desired product, as 
a white solid. 
 
1H NMR (500 MHz, CDCl3) ! 8.18 – 8.10 (m, 4H, Bz), 8.09–8.05 (m, 2H, Bz), 7.95 – 
7.89 (m, 2H, Bz), 7.65-7.62 (m, 3H, Bz), 7.54–7.45 (m, 7H, Bz), 7.18-7.10 (m, 2H, 
Bz), 7.09, 7.08 (2s, 1H, H), 5.97-5.94 (m, 1H, H3), 4.85–4.78 (m, 1H, H4), 4.72-4.59 
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Synthesis of 2,3,5-tri-O-benzoyl-2-C-methyl-D-ribonolactone (4.7). 
 
A mixture of 2-C-methyl-D-ribono-1,4-lactone 4.6 (6.0 g, 37 
mmol), 4-dimethylaminopyridine (0.90 g, 7.44 mmol) and 
triethylamine (69.5 ml, 500 mmol.) in 1,2-dimethoxyethane 
(100 ml) was stirred at 25 °C under argon atmosphere for 30 minutes. Reaction 
mixture was cooled down to 5 °C, and benzoyl chloride (19.32 ml, 166.46 mmol) was 
added dropwise. The mixture was stirred at room temperature for 2 hours. Ice-cold 
water (100 ml) was added to quenched the reaction. Stirring was continued for 30 
minutes. The formed white solids were collected by vacuum filtration and washed 
with cold water. Crude product was stirred with tert-butyl methyl ether (120 ml) at 
room temperature for 30 minutes, and then filtered, filter cake washed with tert-butyl 
methyl ether (2x 20 ml) and dried in vacuum to give 13.0 g (74% yield) of compound 
as a white solid. Compound was used for further synthesis without any purification. 
 
1H NMR (500 MHz, CDC13) ! 8.07-8.05 (m, 2H, Bz), 7.96-7.94 (m, 2H, Bz), 7.76-
7.74 (m, 2H, Bz), 7.61-7.57 (m, lH, Bz), 7.45 (m, 4H, Bz), 7.36-7.33 (m, 2H, Bz), 
7.21-7.18 (m, 2H, Bz), 5.51 (d, lHn H3), 5.21-5.18 (m, lH, H4), 4.82-4.66 (m, 2H, H5), 
1.95 (s, 3H, 2’CCH3). 
 
Synthesis of 2,3,5-Tri-O-benzoyl-2-C-methyl- D-ribofuranose (4.4). 
 
Red-A1 (65wt.% in toluene, 19.2 ml, 63 mmol.) in 
anhydrous toluene (19 ml) was stirred at 0 °C under argon 
atmosphere. A mixture of anhydrous ethanol (3.65 ml, 59.86 mmol) in anhydrous 
toluene (15.4 ml) was added dropwise to t he Red-Al solution. The resulting mixture 
was stirred at 0 °C for 15 minutes. Prepared that way reagent was added to a pre- 
cooled (-5 °C) solution of 2,3,5-tri-O-benzoyl-2-C-methyl-D-ribonolactone 3.7 (13.6 
g, 28.6 mmol) in anhydrous toluene (96 ml) over a period of 15 minutes. The reaction 
mixture was stirred at -5 °C for 40 minutes. After that time, reaction was quenched by 
addition of acetone (1.9 ml), water (140 ml) and 1 N HCl (140 ml) at 0 °C. After that 
reaction mixture was allowed to warm to room temperature. 1 N HCl (~100 ml) was 
added to rich pH 2-3. The mixture was extracted with ethyl acetate (3x 200 ml). 
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sodium sulphate. Solvent was removed under reduced give desired product in 
quantitative yield (~14 g). Product was used for subsequent step without further 
purifications. 
 
Synthesis of N2-Acetyl-2’,3’,5’-tri-O-benzoyl-2’-C-!-methylguanosine (4.9). 
 
A suspension of N2-acetylguanine 4.8 (2.00 g, 10.35 
mmol) in dry pyridine (10 ml), and 1,1,1,3,3,3-
hexamethyldisilazane (35 ml), was heated at reflux 
for 5 to 8 hours, to obtain a clear solution. Solvents 
were removed and dried carefully under high 
vacuum and maintained under argon. To the flask containing persilylated N2-
acetylguanosine (10.35 mmol) was added p-xylene (100 ml) and 1,2,3,5-tetra-O-
benzoyl-2-C-!-methylribofuranose 4.5 (2 g, 3.44 mmol). To the resulting mixture was 
added trimethylsilyl triflate (1.88 ml, 10.35 mmol) slowly with vigorous stirring at 
room temperature. After the reaction mixture was stirred under an argon atmosphere 
at 140-150 °C (reflux) for 6 h. The reaction mixture was cooled to room temperature 
and quenched with saturated aqueous sodium bicarbonate. The organic layer was 
separated, and the aqueous layer was extracted with dichloromethane (3x 150 ml). 
The organic layers were combined and dried over a magnesium sulfate. The 
magnesium sulfate was filtered off, and the solvent was removed under vacuum. The 
pure compound was obtained as a white precipitate from the mixture of chloroform 
and methanol (70% yield). 
 
1H NMR (500 MHz, CDCl3) 12.04 (s, 1H, NH), 11.21 (s, 1H, NHAc), 8.17-7.23 (m, 
16H, Bz), 6.69 (s, 1H, H1’), 5.97 (d, 1H, J= 8.5 Hz, H3’), 4.93-4.81 (m, 3H, H4’ and 
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Synthesis of 2’-C- !–methylguanosine (4.10). 
 
N-2-Acetyl-2’,3’,5’-tri-O-benzoyl-2’-C-!-methyl 
guanosine 3.9 (1.00 g, 1.53 mmol) in methanol (20 ml) 
was saturated with ammonia for 30 min at -5 to -10 °C, 
then sealed and stirred at room temperature for 16 to 20 
h. The solvent was removed by evaporation under vacuum. The residue was then 
dissolved in a small volume of hot methanol and precipitated by addition of 
chloroform. The solid was filtered off, washed with chloroform and dried to yield the 
deprotected nucleoside (90-100%). 
 
1H NMR (500 MHz, DMSO) ! 10.52 (bs, 1H, NH), 8.38 (s, 1H, H8), 6.52 (bs, 2H, 
NH2), 5.73 (s, 1H, H1’), 5.24 (d, 1H, J= 6.7 Hz, 3’OH), 5.16 (t, 1H, J= 4.9 Hz, 5’OH), 
5.03 (s, 1H, 2’OH), 4.01-3.96 (m, 1H, H3’), 3.85-3.79 (m, 2H, H4’ and H5’a), 3.79-3.72 
(m, 1H, H5’b), 0.81 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, DMSO) ! 156.70 (C6), 153.67 (C2), 150.74 (C4), 135.11 (C8), 
116.32 (C5), 90.10 (C1’), 82.33 (C3’), 78.50 (C2’), 71.63 (C4’), 59.44 (C5’), 20.02 
(2’CCH3). 
HRMS calculated for C11H15N5O5Na: 320.0986; found 320.0972. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!-methylguanosine (4.11). 
 
To a solution of 2’-C-"-methylguanosine 4.10 (1.50 g, 
5.04 mmol) in anhydrous acetone (90 ml), at room 
temperature, perchloric acid (0.85 ml) was added 
dropwise and stirred overnight. Then, a saturated 
solution of NH4OH was added dropwise to reach 
neutral pH. The solvent was removed under reduced 
pressure and the resulting solid was purified by column chromatography 
(CHCl3/MeOH, 8:2), to yield the protected nucleoside 4.11 (1.61 g, 93%). 
 
1H NMR (500 MHz, DMSO) ! 10.61 (br s, 1H, NH), 7.92 (s, 1H, H8), 6.48 (bs, 2H, 
NH2), 6.01 (s, 1H, H1’), 5.21 (t, 1H, J= 5.0 Hz, 5’OH), 4.58 (d, J= 2.7 Hz, 1H, H3’), 
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(s, 3H, CH3 isopropylidene), 1.16 (s, 3H, 2’CCH3). 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-phenyl-
(benzoxy-L-alaninyl)] phosphate (4.12a). 
 
 Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(4.11, 200 mg, 0.59 mmol), phenyl-
(benzoxy-L-alaninyl) phosphorochloridate 
(3.3a, 419 mg, 1.18 mmol) tBuMgCl (1.18 
ml, 1.18 mmol) in 3 ml of dry THF. The 
crude mixture was purified by column 
chromatography, using CHCl3/MeOH (2 to 8% gradient) as en eluent, to give a pure 
product 4.12a as a white foam (115 mg, 30%). 
 
31P NMR (202 MHz, MeOD) " 4.63, 4.37. 
1H NMR (500 MHz, MeOD) " 7.87, 7.85 (2s, 1H, H8), 7.36-7.34 (m, 5H, OCH2Ph 
and/or Ph), 7.32-7.28 (m, 5H, OCH2Ph and/or Ph), 6.05, 6.03 (2s, 1H, H1’), 5.17-5.12 
(m, 2H, OCH2Ph), 4.55-4.52 (m, 2H, H3’ and H5’a), 4.47-4.38 (m, 2H, H5’b and H4’), 
4.10-4.09 (m, 1H, CHCH3), 1.61, 1.53, 1.39, 1.37 (4s, 3H, CH3 isopropylidene), 1.33, 
1.27 (2d, J= 7.0 Hz, 3H, CHCH3), 1.03, 1.00 (2s, 3H, 2’CCH3).!
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-phenyl-(benzoxy-L-alaninyl)] 
phosphate (4.13a). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!-methylguanosine 5’-
O-[#-naphthyl-(methoxy-L-alaninyl)] 
phosphate (4.12a, 115 mg, 0.177 mmol) in 
10 ml of 60% CH3COOH in water at 90 °C 
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by column chromatography, using CHCl3/MeOH (9:1) as an eluent, to give a pure 
product 4.13a as a white solid (68 mg, 62%). 
 
31P NMR (202 MHz, MeOD) ! 4.09, 3.93. 
1H NMR (500 MHz, MeOD) ! 7.99, 7.95 (2s, 1H, H8), 7.32-7.23 (m, 10H, OCH2Ph 
and Ph), 5.95, 5.93 (2s, 1H, H1’), 5.14-5.09 (m, 2H, OCH2Ph), 4.55-4.42 (m, 2H, H3’ 
and H5’a), 4.23-4.17 (m, 2H, H5’b and H4’), 4.07-4.01 (m, 1H, CHCH3), 1.35, 1.33 (2d, 
J=7.0 Hz, 3H, CHCH3), 1.00, 0.97 (2s, 3H, 2’CCH3).!
13C NMR (126 MHz, MeOD) ! 174.83, 174.64 (2d, 3J C-C-N-P = 4.6 Hz, C=O), 159.50, 
159.49 (C6), 155.34, 155.29 (C2), 152.65, 152.64 (C4), 152.16, 152.10 (ipso Ph), 
137.48, 137.41 (C8), 137.19, 137.16 (ipso OCH2Ph), 131.16, 130.95, 130.82, 130.78, 
129.90, 129.65, 129.59, 129.57, 129.31, 129.27, 129.18, 126.17, 121.52, 121.51 (Ph 
and OCH2Ph), 118.05, 117.94 (C5), 93.10, 92.78 (C1’), 82.13, 81.96 (2d, 3JC-C-O-P = 
8.3 Hz, C4’), 80.08, 80.01 (C2’), 74.60, 74.11 (C3’), 68.02, 67.98 (OCH2Ph), 67.52, 
66.61 (2d, 2JC-O-P = 5.0 Hz, C5’), 51.76, 51.62 (CHCH3), 21.02 (2’CCH3), 20.66, 
20.43 (2d, 2JC-O-P = 5.0 Hz CHCH3). 
HPLC (System 1) tR= 17.05, 17.25 min. 
MS (ES+) m/z: 637.18 (M+Na+, 100%). 
HRMS calculated for C27H31N6O9PNa: 637.1788; found. 637.1813. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(methoxy-L-alaninyl)] phosphate (4.12b). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 300 mg, 0.889 mmol), #-naphthyl-
(methoxy-L-alaninyl) phosphorochloridate 
(3.3a, 582 mg, 1.78 mmol in 1M solution in THF) tBuMgCl (1.78 ml, 1.78 mmol) in 
3 ml of dry THF. The crude mixture was purified by column chromatography, using  
CHCl3/MeOH (2 to 8% gradient) as en eluent, to give a pure product 4.12b as a white 
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31P NMR (202 MHz, MeOD) ! 4.49, 4.40. 
1H NMR (500 MHz, MeOD) ! 8.17 (t, J = 8.0 Hz, 1H, H8-Naph), 7.87-7.65 (m, 2H, 
H5-Naph and H8), 7.71-7.69 (m, 1H, H4-Naph), 7.58–7.48 (m, 3H, H7, H6, H2-Naph), 
7.43-7.41 (m, 1H, H3-Naph), 6.08, 6.07 (2s, 1H, H1’), 4.54-4.50 (m, 2H, H3’ and H5’a), 
4.48-4.36 (m, 2H, H5’b and H4’), 4.10-4.09 (m, 1H, CHCH3), 3.61 (s, 3H, OCH3), 1.59, 
1.55, 1.39, 1.36 (4s, 3H, CH3 isopropylidene), 1.03, 1.00 (2s, 3H, 2’CCH3).!
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(methoxy-L-alaninyl)] 
phosphate (4.13b). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-"-methylguanosine 
5’-O-[#-naphthyl-(methoxy-L-alaninyl)] 
phosphate (4.12b, 178 mg, 0.283 mmol) in 
10 ml of 60% CH3COOH in water at 90 
°C overnight. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (9:1) as an eluent, to give a pure product 4.13b as a white solid (93 mg, 
55%). 
 
31P NMR (202 MHz, MeOD) ! 4.38, 4.25. 
1H NMR (500 MHz, MeOD) ! 8.18 (m, 1H, H8-Naph), 7.93-7.83 (m, 2H, H5-Naph 
and H8), 7.69-7.64 (m, 1H, H4-Naph), 7.56-7.49 (m, 3H, H7, H6, H2-Naph), 7.42-7.38 
(m, 1H, H3-Naph), 5.94, 5.93 (2s, 1H, H1’), 4.57-4.51 (m, 2H, H5’), 4.29-4.23 (m, 2H, 
H3’ and H4’), 4.10-3.98 (m, 1H, CHCH3), 3.56, 3.54 (2s, 3H, OCH3), 1.31-1.28 (m, 
3H, CHCH3), 1.01, 0.99 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.62 (d, 3J C-C-N-P = 4.6 Hz, C=O), 174.41 (d, 3J C-C-
N-P = 5.6 Hz, C=O), 159.57, 159.55 (C6), 155.30, 155.27 (C2), 152.67, 152.66 (C4), 
148.01, 147.97 (2d, 2J C-O-P = 2.8 Hz, ipso Naph), 137.99, 137.79 (C8), 136.27, 136.24 
(C10-Naph) 128.85, 128.80 (CH-Naph), 127.90, 127.85 (C9-Naph), 127.75, 127.47, 
126.51, 126.49, 125.97, 125.94, 122.80, 122.75 (CH-Naph), 118.05 (C5), 116.22, 
116.16 (2d, 3JC-C-O-P = 3.3 Hz, C2-Naph), 93.25, 93.15 (C1’), 82.24 (d, 3JC-C-O-P = 7.9, 













Karolina Made!a                                                                                     Chapter Twelve  
 297 
67.59 (2d, 2JC-O-P = 5.0 Hz, C5’), 61.97, 61.92 (OCH3), 51.87, 51.79 (CHCH3), 21.96, 
21.89 (2’CCH3), 20.73, 20.47 (2d, 3J C-C-N-P = 6.3 Hz, CHCH3). 
HPLC (System 1) tR= 14.67, 15.04 min. 
HRMS calculated for C25H29N6O9PNa: 611.1627; found. 611.1632. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-
naphthyl-(isopropoxy-L-alaninyl)] phosphate (4.12c). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
(4.11, 200 mg, 0.593 mmol), "-naphthyl 
(isopropoxy-L-alaninyl) 
phosphorochloridate (3.3b, 422mg, 1.19 
mmol) tBuMgCl (1.19 ml, 1.19 mmol) in 
3 ml of dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (2 to 8%, gradient) as en eluent, to give a pure product 4.12c as a white 
foam (202 mg, 52%). 
 
31P NMR (202 MHz, CDCl3) # 4.49, 4.46. 
1H NMR (500 MHz, MeOD) # 8.21, 8.17 (2d, J= 8.0 Hz, 1H, H8-naph) 7.95-7.79 (m, 
2H, H5-Naph and H8), 7.75-7.70 (m, 1H, H4-Naph), 7.58-7.52 (m, 3H, H7, H6, H2-
Naph), 7.48-7.41 (m, 1H, H3-Naph), 6.09, 6.08 (2s, 1H, H1’), 4.99-4.92 (m, 1H, 
OCH(CH3)2), 4.63-4.52 (m, 2H, H3’,H5’a), 4.46-4.40 (m, 2H, H5’b, H4’), 4.05-4.01 (m, 
1H, CHCH3), 1.61, 1.59 (2s, 3H, CH3 isopropylidene), 1.42, 1.40 (2d, J= 6.0 Hz, 3H, 
CHCH3), 1.37, 1.35 (2s, 3H, CH3 isopropylidene), 1.25, 1.23 (2d, J= 2.0 Hz, 3H, 
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Synthesis of 2’-C-!-methylguanosine 5’-O-["-naphthyl-(isopropoxy-L-alaninyl)] 
phosphate (4.13c). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
5’-O-["-naphthyl-(isopropoxy-L-
alaninyl)] phosphate (4.12c, 202 mg, 
0.308 mmol) in 10 ml of 60% CH3COOH 
in water at 90 °C overnight. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (9:1) as an eluent, to give a pure product 4.13c 
as a white solid (100 mg, 53%). 
 
31P NMR (202 MHz, MeOD) # 4.39, 4.26. 
1H NMR (500 MHz, MeOD) # 8.20-8.17 (m, 1H, H8-Naph), 7.89-7.84 (m, 2H, H8,  
H5-Naph), 7.69, 7.67 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.54- 7.48 (m, 3H, H7, H6, H2-
Naph), 7.41, 7.38 (2t, J= 8.0 Hz, 1H, H3-Naph), 5.95, 5.94 (2s, 1H, H1’), 5.10-4.99 
(m, 1H, OCH(CH3)2), 4.67-4.57 (m, 2H, H5’), 4.31-4.21 (m, 2H, H3’, H4’), 4.04-4.94 
(m, 1H, CHCH3) 1.28 (m, 3H, CHCH3), 1.15-1.11 (m, 6H, OCH(CH3)2), 1.01 and 
0.98 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) # 174.61 (d, 3J C-C-N-P = 4.6 Hz, C=O), 174.38 (d, 3J C-C-
N-P = 5.6 Hz, C=O), 159.52, 159.49 (C6), 155.29, 155.26 (C2), 152.65, 152.64 (C4), 
148.01, 147.96 (ipso Naph), 137.95, 137.73 (C8), 136.27, 136.24 (C10-Naph) 128.85, 
128.80 (CH-Naph), 127.90, 127.85 (2d, 3JC-C-O-P = 1.5 Hz, C9-Naph), 127.75 127.47 
126.51, 126.47 125.97, 125.93, 122.82, 122.77 (CH-Naph), 118.06 (C5), 116.22, 
116.15 (2d, 3JC-C-O-P = 3.2 Hz, C2-Naph), 93.25, 93.17 (C1’), 82.23 (d, 3JC-C-O-P = 7.9 
Hz, C4’), 82.14 (d, 3JC-C-O-P = 8.7 Hz, C4’), 80.03, 79.98 (C2’), 74.79, 74.59 (C3’), 
70.20, 70.18 (OCH(CH3)2), 67.94 (d, 2JC-O-P = 5.2 Hz, C5’), 67.58 (d, 2JC-O-P = 4.6 Hz, 
C5’), 51.87, 51.79 (CHCH3), 30.76 (OCH(CH3)2), 21.96, 21.89 (2’CCH3), 20.73, 
20.58 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3). 
HPLC (System 1) tR= 14.71, 15.07 min. 
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Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-
naphthyl-(tert-butoxy-L-alaninyl)] phosphate (4.12d). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
(4.11, 200 mg, 0.593 mmol), "-naphthyl 
(tert-butoxy-L-alaninyl) 
phosphorochloridate (3.3d, 436 mg, 1.19 
mmol) tBuMgCl (1.19 ml, 1.19 mmol) in 3 ml of dry THF. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en 
eluent, to give a pure product 4.12d as a white foam (170 mg, 43%). 
 
31P NMR (202 MHz, CDCl3) # 4.63, 4.52. 
1H NMR (500 MHz, MeOD) # 8.22-8.17 (m, 1H, H8-naph) 7.94-7.87 (m, 2H, H5-
Naph and H8), 7.76-7.70 (m, 1H, H4-Naph), 7.59-7.52 (m, 3H, H7, H6, H2-Naph), 
7.48-7.41 (m, 1H, H3-Naph), 6.09, 6.07 (2s, 1H, H1’), 4.62, 4.58 (2d, J= 3.5 Hz, 1H, 
H3’), 4.55-4.52 (m, 1H, H5’a), 4.47-4.40 (m, 2H, H5’b, H4’), 4.05-4.01 (m, 1H, 
CHCH3), 1.61, 1.58 (2s, 3H, CH3 isopropylidene), 1.43. 1.41 (2s, 9H, OC(CH3)3), 
1.35, 1.34 (2d, J= 6.0 Hz, 3H, CHCH3), 1.37, 1.35 (2s, 3H, CH3 isopropylidene), 1.02, 
0.99 (2s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!-methylguanosine 5’-O-["-naphthyl-(tert-butoxy-L-alaninyl)] 
phosphate (4.13d). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
5’-O-["-naphthyl-(tert-butoxy-L-alaninyl)] 
phosphate (4.12d, 170 mg, 0.253 mmol) in 
10 ml of 60% CH3COOH in water at 90 
°C overnight. The crude mixture was purified by column chromatography, using 
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31P NMR (202 MHz, CDCl3) ! 4.51, 4.28. 
1H NMR (500 MHz, MeOD) ! 8.21-8.18 (m, 1H, H8-naph) 7.88-7.84 (m, 2H, H5-
Naph and H8), 7.71-7.66 (m, 1H, H4-Naph), 7.53-7.47 (m, 3H, H7, H6, H2-Naph), 
7.42-7.37 (m, 1H, H3-Naph), 5.93 (s, 1H, H1’), 4.63-4.57 (m, 2H, H5’), 4.31-4.22 (m, 
2H, H3’ and H4’), 3.94-3.88 (m, 1H, CHCH3), 1.37, 1.34 (2s, 9H, OC(CH3)3), 1.30, 
1.29 (2d, J= 7.5 Hz, 3H, CHCH3), 1.01, 0.98 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.60, 174.35 (C=O), 159.49, 159.41 (C6), 155.29, 
155.26 (C2), 152.66, 152.65 (C4), 148.00, 147.95 (ipso Naph), 137.95, 137.77 (C8), 
136.27, 136.24 (C10-Naph) 128.85, 128.80 (CH-Naph), 127.93, 127.87 (C9-Naph), 
127.74, 127.45, 126.50, 126.44, 125.94, 125.88, 122.80, (CH-Naph), 118.10 (C5), 
116.21, 116.08 (2d, 3JC-C-O-P = 3.2, C2-Naph), 93.30, 93.20 (C1’), 82.68, 82.64 
(OC(CH3)3), 82.23, 82.12 (2d, 3JC-C-O-P = 7.9 Hz, C4’), 79.98, 79.95 (C2’), 74.79, 
74.58 (C3’), 67.90, 67.54 (C5’), 52.30 (CHCH3), 28.19, 28.14 (OC(CH3)3), 20.88, 
2.84 (2’CCH3), 20.62, 20.57 (CHCH3). 
HPLC (System 1) tR= 15.63, 15.87 min. 
HRMS calculated for C28H35N6O9P: 630.2278; found 630.2215. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(butoxy-L-alaninyl)] phosphate (4.12e).  
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 250 mg, 0.741 mmol), #-naphthyl-
(butoxy-L-alaninyl) phosphorochloridate 
(3.3d, 0.548mg, 1.48 mmol), tBuMgCl 
(1.48 ml, 1.48 mmol) in 3 ml of dry THF. 
Crude mixture was purified by column chromatography, using CHCl3/MeOH (2 to 
8%, gradient) as en eluent, to give a pure product 4.12e as white foam (200 mg, 42%). 
 
31P NMR (202 MHz, MeOD) ! 4.48, 4.46. 
1H NMR (500 MHz, MeOD) ! 8.21, 8.16 (2d, J= 9.00 MHz, 1H, H8-Naph), 7.92–7.88 
(m, 1H, H5-Naph), 7.80-7.71 (m, 2H, H4-Naph and H8), 7.60– .52 (m, 3H, H7, H6, H2-
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H5’a), 4.47-4.39 (m, 2H, H5’b, H4’), 4.10-4.01 (m, 3H, CHCH3 and 
OCH2CH2CH2CH3), 1.61, 1.59 (2s, 3H, CH3 isopropylidene), 1.57–1.53 (m, 2H m, 
2H, OCH2CH2CH2CH3), 1.40-1.32 (m, 8H, CHCH3, CH3 isopropylidene, and 
OCH2CH2CH2CH3), 1.04, 1.01 (2s, 3H, 2’CCH3), 0.89, 0.87 (2t, J= 8.5 Hz, 3H, 
OCH2CH2CH2CH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(butoxy-L-alaninyl)] 
phosphat (4.13e). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-naphthyl-(butoxy-L-alaninyl)] 
phosphate (4.12e, 200 mg, 0.298 mmol) in 
10 ml of 60% CH3COOH in water at 90 
°C overnight. Crude mixture was purified 
by column chromatography, using CHCl3/MeOH (9:1) as an eluent, to give a pure 
product 4.13e as a white solid (62 mg, 30%). 
 
31P NMR (202 MHz, MeOD) # 4.37, 4.20. 
1H NMR (500 MHz, MeOD) # 8.20-8.16 (m, 1H, H8-Naph), 7.90–7.88 (2s, 1H, H8), 
7.87-7.83(m, 1H, H5-Naph), 7.70-7.65 (m, 1H, H4-Naph), 7.53–7.47 (m, 3H, H7, H6, 
H2-Naph), 7.41-7.36 (m, 1H, H3-Naph), 5.95, 5.94 (2s, 1H, H1’), 4.67-4.57 (m, 2H, 
H5’), 4.30- 4.22 (m, 2H, H3’, H4’), 4.07- 4.00 (m, 1H, CHCH3)  3.98- 3.96 (m, 2H, 
OCH2CH2CH2CH3), 1.50–1.43 (m, 2H m, 2H, OCH2CH2CH2CH3), 1.32-1.27 (m, 3H: 
CHCH3, OCH2CH2CH2CH3), 1.00, 0.98 (2s, 3H, 2’CCH3), 0.87-0.83 (m, 3H, 
OCH2CH2CH2CH3). 
13C NMR (126 MHz, MeOD) # 175.10 (d, 3J C-C-N-P = 4.5 Hz, C=O), 174.87 (d, 3J C-C-
N-P = 5.6 Hz, C=O ester), 159.49, 159.47 (C6), 155.30, 155.26 (C2), 152.64 (C4), 
148.01, 147.96 (2d, J = 2.9 Hz, ipso Naph), 137.90, 137.71 (C8), 136.28, 136.24 
(C10-Naph), 128.85, 128.79, 127.91, 127.85 (C9-Naph), 127.47, 126.51, 126.46, 
125.95, 125.91, 122.81, 122.76 (CH-Naph), 118.05 (C5), 116.21, 116.10 (2d, 3JC-C-O-P 
= 3.2 Hz, C2-Naph), 93.24, 93.16 (C1’), 82.21, 82.10 (2d, 3JC-C-O-P = 8.6 Hz, C4’), 
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66.16 (OCH2CH2CH2CH3), 51.76, 51.72 (CHCH3), 31.65, 31.62 (OCH2CH2CH2CH3), 
20.71, 20.47 (2d, 3J C-C-N-P = 6.3 Hz, CHCH3), 20.38 (2’CCH3), 20.03 
(OCH2CH2CH2CH3), 14.02, 14.00 (OCH2CH2CH2CH3) 
HPLC (System 1) tR=16.27, 16.88 min. 
HRMS calculated for C28H35N6O9PNa: 653.2101; found 653.2095. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(2,2-dimethylpropoxy-L-alaninyl)] phosphate (4.12f). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-isopropylidene-
2’-C-!-methylguanosine (4.11, 1.50 g, 4.45 
mmol), "-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 3.40 g, 
8.89 mmol), tBuMgCl (8.89 ml, 8.89 mmol, 
1M solution in THF) in 15 ml of dry THF. 
The crude mixture was purified by column chromatography, using CHCl3/MeOH (2 
to 8%, gradient) as an eluent, to give a pure product 4.12f as white foam (1.73g, 
57%). 
 
31P NMR (202 MHz, MeOD) # 4.51, 4.47. 
1H NMR (500 MHz, MeOD) # 8.21-8.15 (m, 1H, H8-Naph), 7.91- 7,67 (m, 1H, H5-
Naph), 7.79- 7.70 (m, 2H, H4-Naph and H8), 7.58-7.51 (m, 3H, H7, H6, H2-Naph), 
7.47- 7.41 (m, 1H, H3-Naph), 6.09, 6.07 (2s, 1H, H1’), 4.67- 4.53 (m, 2H, H3’, H5’a), 
4.45- 4.39 (m, 2H, H5’b, H4’), 4.14- 4,10 (m, 1H, CHCH3), 3.83, 3.81, 3.77, 3.75 
(2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3),1.61, 1.58 (2s, 3H, CH3 isopropylidene), 
1.41-1.39 (m, 6H, CH3 isopropylidene, CHCH3), 1.03, 1.00 (2s, 3H, 2’CCH3), 0.89, 
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Synthesis of 2’-C-! –methylguanosine 5’-O-["-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl)] phosphate (4.13f). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-Naphthyl-(2,2dimethylpropoxy-L-
alaninyl)] phosphate (4.12f, 1.73 g, 2.53 
mmol) in 100 ml of 60% CH3COOH in 
water at 90 °C overnight. Crude mixture 
was purified by column chromatography, using CHCl3/MeOH (9:1) as an eluent, to 
give a pure product 4.13f as a white solid (100mg, 53%). 
 
31P NMR (202 MHz, MeOD) # 4.33, 4.25. 
1H NMR (500 MHz, MeOD) # 8.20- 8.17 (m, 1H, H8-Naph), 7.89- 7,85 (m, 2H, H5 
naph and H8), 7.71- 7.67 (m, 1H, H4-Naph), 7.54 – 7.47 (m, 3H, H7, H6, H2-Naph), 
7.43- 7.37 (m, 1H, H3-Naph), 5,93 (s, 1H, H1’), 4.67- 4.53 (m, 2H, H5’), 4.28- 4.20 (m, 
2H, H3’ and H4’), 4.11- 4,03 (m, 1H, CHCH3), 3.76, 3.74, 3.65, 3.62 (2AB, JAB= 10.5 
Hz, 2H, OCH2C(CH3)3),1.36- 1.33 (m, 3H, CHCH3), 1.00, 0,98 (2s, 3H, 2’CCH3), 
0.88, 0.87 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) # 175.05 (d, 3J C-C-N-P = 4.6, C=O), 174.80 (d, 3J C-C-N-P = 
5.6, C=O), 159.52, 159.49 (C6), 155.39, 155.35 (C2), 152.65 (C4), 148.01, 147.95 (d, 
2JC-O-P = 3.3, ipso Naph), 137.91, 137.72 (C8), 136.30, 136.26 (C10-Naph), 128.85, 
128.79 (CH-Naph), 127.90, 127.85 (C9-Naph), 127.75, 127.74, 127.48, 127.47, 
126.51, 126.45, 125.97, 125.93, 122.81, 122.76  (CH-Naph), 118.05 (C5), 116.23, 
116.16 (2d, 3JC-C-O-P = 3.2, C2-Naph), 93.26, 93.18 (C1’), 82.23, 82.12 (2d, 3JC-C-O-P = 
7.5, C4’), 80.00, 79.94 (C2’), 75.38, 75.36 (OCH2C(CH3)3), 74.81, 74.60 (C3’), 
68.05, 67.63 (2d, 2JC-O-P = 5.0, C5’), 51.80, 51.73 (CHCH3), 32.26, 32.23 
(OCH2C(CH3)3), 31.31 (CHCH3), 26.73, 26.70 (OCH2C(CH3)3), 20.86, 20.81 
(2’CCH3). 
HPLC (System 1) tR= 16.87, 17.13 min. 
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Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(cyclohexoxy-L-alaninyl)] phosphate (4.12g). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
(4.11, 474 mg, 1.40 mmol), "-naphthyl-
(cyclohexoxy-L-alaninyl) 
phosphorochloridate (3.3h, 1.11 g, 2.81 
mmol), tBuMgCl (2.81 ml, 2.81 mmol) in 
6 ml of dry THF. Crude mixture was purified by column chromatography 
CHCl3/MeOH (2 to 8%, gradient) to give a pure product 4.12g as white foam (980 
mg, 100%). 
 
31P NMR (202 MHz, MeOD) # 4.49, 4.48. 
1H NMR (500 MHz, MeOD) # 8.20-8.18 (m, 1H, H8-Naph), 7.92-7.86 (m, 2H, H5-
Naph and H8), 7.75-7.68 (m, 1H, H4-Naph), 7.58-7.51 (m, 3H, H7, H6, H2-Naph), 
7.48- 7.43 (m, 1H, H3-Naph), 6.09, 6.07 (2s, 1H, H1’), 4.73-4.69 (m, 2H, H3’, H5’a), 
4.60- 4.39 (m, 3H, H5’b, H4’, OCH ester ), 4.07-4.03 (m, 1H, CHCH3), 1.77-1.68 (m, 
4H, 2x CH2 ester), 1.39-1.36 (m, 15H, 2x CH3 isopropylidene, CHCH3, 3x CH2 ester), 
1.04, 1.00 (2s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(cyclohexoxy-L-alaninyl)] 
phosphate (4.13g). 
 
Prepared according t the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-naphthyl-(cyclohexoxy-L-
alaninyl)] phosphate (4.12g, 980 mg, 1.40 
mmol) in 30 ml of 60% CH3COOH in 
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mixture was purified by column chromatography, using CHCl3/MeOH (9:1) as en 
eluent, to give a pure product 4.13g as a white solid (285 mg, 31%). 
31P NMR (202 MHz, MeOD) ! 4.39, 4.22. 
1H NMR (500 MHz, MeOD) ! 8.19-8.16 (m, 1H, H8-Naph), 7.90-7.80 (m, 2H, H5-
Naph and H8), 7.67-7.63 (m, 1H, H4-Naph), 7.53-7.46 (m, 3H, H7, H6, H2-Naph), 
7.40-7.34 (m, 1H, H3-Naph), 5.95 (s, 1H, H1’), 4.68- 4.59 (m, 3H, H5’, OCH ester), 
4.31-4.24 (m, 2H, H3’, H4’), 4.05-3.97 (m, 1H, CHCH3), 1.71-1.61 (m, 4H, CH2 ester), 
1.35-1.20 (m, 9H, CHCH3, 3x CH2 ester), 1.00, 0.98 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.27, 174.22 (C=O), 159.40 (C6), 155.29 (C2), 
152.64, 152.61 (C4), 148.04, 147.98 (ipso Naph), 137.86, 137.68 (C8), 136.31, 
136.27 (C10-Naph), 128.84, 128.78 (CH-Naph), 127.92, 127.85 (C9-Naph), 127.74, 
127.46, 126.51, 126.44, 125.95, 125.88, 122.82, 122.76 (CH-Naph), 118.09 (C5), 
116.20, 116.10 (2d, 3JC-C-O-P = 3.2 Hz, C2-Naph), 93.28, 93.18 (C1’), 82.23, 82.10 
(2d, 3JC-C-O-P = 8.5 Hz, C4’), 79.98, 79.95 (C2’), 79.47 (OCH ester), 74.79, 74.58 
(C3’), 67.99, 67.56 (2d, 2JC-O-P = 5.0 Hz, C5’), 51.87, 51.80 (CHCH3), 32.37, 32.29, 
26.36, 24.57 (CH2 ester), 20.74 (d, 3J C-C-N-P = 6.2 Hz, CHCH3), 20.51 (d, 3J C-C-N-P = 
7.5, CHCH3), 20.35, 20.32 (2’CCH3). 
HPLC (System 1) tR= 17.36, 17.54 min. 
HRMS calculated for C30H37N6O9PNa: 679.2257; found 679.2267. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(1-methoxy-2-propoxy-L-alaninyl)] phosphate (4.12h). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"-methylguanosine 
(4.11, 250 mg, 0.741 mmol), #-naphthyl-
(1-methoxy-2-propoxy-L-alaninyl) 
phosphorochloridate (572 mg, 1.48 
mmol), tBuMgCl (1.48 ml, 1.48 mmol) in 4 ml of dry THF. Crude mixture was 
purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en 
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31P NMR (202 MHz, MeOD) ! 4.52, 4.45, 4.44. 
1H NMR (500 MHz, MeOD) ! 8.20-8.17 (m, J= 7.50 Hz, 1H, H8-Naph), 7.90, 7.89, 
7.87, 7.86 (4s, 1H, H8), 7.78-7.70 (m, 2H, H5-Naph, H4-Naph), 7.59-7.52 (m, 3H, H7, 
H6, H2-Naph), 7.46-7.43 (m, 1H, H3-Naph), 6.09, 6.08, 6.07 (3s, 1H, H1’), 5.08-5.02 
(m, 1H, OCH(CH3)CH2OCH3), 4.63-4.51 (m, 2H, H3’ and H5’a), 4.47–4.38 (m, 2H, 
H5’b and H4’), 4.11–4.05 (m, 1H, CHCH3), 3.41–3.37 (m, 2H, OCH(CH3)CH2OCH3), 
3.32, 3.31, 3.30, 3.29 (4s, 3H, OCH(CH3)CH2OCH3), 1.61, 1.58 (2 s, 3H, 
isopropylidene) 1.39, 1.37 (2d, J= 7.5 Hz, 3H, CHCH3), 1.37, 1.36 (2 s, 3H, 
isopropylidene), 1.19-1.14 (m, 3H, OCH(CH3)CH2OCH3), 1.03, 0.99 (2s, 3H, 
2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(1-methoxy-2-propoxy-L-
alaninyl)] phosphate (4.13h). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[#-naphthyl-(1-methoxy-2-propoxy-
L-alaninyl)] phosphate (4.12h, 273 mg, 
0.398 mmol) in 10 ml of 60% CH3COOH 
in water at 90 °C overnight. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (9:1) as en 
eluent, to give a pure product 4.13h as a white solid (70.1 mg, 27%). 
 
31P NMR (202 MHz, MeOD) ! 4.35, 4.32, 4.28. 
1H NMR (500 MHz, MeOD) ! 8.20-8.17 (m, 1H, H8-Naph), 7.90, 7.87 (2s, 1H, H8), 
7.86–7.83 (m, 1H, H5-Naph), 7.68-7.63 (m, 1H, H4-Naph), 7.54-7.47 (m, 3H, H7, H6, 
H2-Naph), 7.40-7.35 (m, 1H, H3-Naph), 5.95, 5.94 (2s, 1H, H1’), 5.00-4.92 (m, 1H, 
OCH(CH3)CH2OCH3), 4.67-4.58 (m, 2H, H5’), 4.31-4.23 (m, 2H, H3’ and H4’), 4.06-
3.99 (m, 1H, CHCH3), 3.34-3.33 (m, 2H, OCH(CH3)CH2OCH3), 3.27-3.26 (m, 3H, 
OCH(CH3)CH2OCH3), 1.32, 1.31 (2d, J= 7.5 Hz, 3H, CHCH3), 1.13-1.09 (m, 3H, 
OCH(CH3)CH2OCH3), 1.00, 0.98 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.42, 174.32 (2d, 3J C-C-N-P = 6.7 Hz, C=O), 159.49, 














Karolina Made!a                                                                                     Chapter Twelve  
 307 
Naph), 137.95, 137.72 (C8), 136.27, 136.24 (C10-Naph), 128.85, 128.80 (CH-Naph), 
127.90, 127.85 (C9-Naph), 127.76, 127.49, 126.53, 126.48, 125.95, 122.86, 122.84, 
122.77 (CH-Naph), 118.05 (C5), 116.22, 166.16 (2d, 3JC-C-O-P= 3.8 Hz, C2-Naph), 
93.24, 93.16 (C1’), 82.21, 82.12 (2d, 3JC-C-O-P= 8.8 Hz, C4’), 80.01, 79.96 (C2’), 
75.88, 75.74, 75.70 (OCH(CH3)CH2OCH3), 74.80, 74.57 (C3’), 71.73, 71.72, 71.64, 
71.59 (OCH(CH3)CH2OCH3), 67.94, 67.53 (2d, 2JC-O-P= 3.8 Hz, C5’), 59.38, 59.35, 
59.33, 59.30 (OCH(CH3)CH2OCH3), 51.80, 51.78 (CHCH3), 20.71, 20.49 (2d, 3J C-C-
N-P= 6.3 Hz, CHCH3), 20.40, 20.38 (2’CCH3), 16.65, 16.61, 16.58, 16.57 
(OCH(CH3)CH2OCH3). 
HPLC (System 1) tR= 13.77, 14.23, 14.37 min. 
HRMS calculated for C28H35N6O10PNa: 669.2019; found 669.2027. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(benzoxy-L-alaninyl)] phosphate (4.12i). 
  
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
(4.11, 200 mg, 0.592 mmol), "-naphthyl-
(benzoxy-L-alaninyl) phosphorochloridate 
(513 mg, 1.18 mmol), tBuMgCl (1.18 ml, 
1.18 mmol) in 4 ml of dry THF. Crude 
mixture was purified by column chromatography, using CHCl3/MeOH (2 to 8%, 
gradient) as en eluent, to give a pure product 4.12i as white foam (210 mg, 50%). 
 
31P NMR (202 MHz, MeOD) # 4.54, 4.38. 
1H NMR (500 MHz, MeOD) # 8.22–8.12 (m, 1H, H8-Naph), 7.94–7.85 (m, 2H, H5- 
Naph and H8), 7.79– .69 (m, 2H, H5- and H4- Naph), 7.59–7.48 (m, 3H, H7, H6, H2- 
Naph), 7.43-7.41 (m, 1H, H3- Naph), 7.33-7.29 (m, 5H, OCH2Ph), 6.08, 6.06 (2s, 1H, 
H1’), 5.16–5.08 (m, 2H, OCH2Ph), 4.60, 4.52 (2d, J = 3.3 Hz, 1H, H3’), 4.53– 4.39 (m, 
2H, H5’), 4.36–4.31 (m, 1H, H4’), 4.18–4.09 (m, 1H, CHCH3), 1.60, 1.58 (2s, 3H, CH3 
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Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(benzoxy-L-alaninyl)] 
phosphate (4.13i). 
 
 Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-naphthyl-(1-methoxy-2-propoxy-
L-alaninyl)] phosphate (4.12i, 210 mg, 
0.298 mmol) in 10 ml of 60% CH3COOH 
in water at 90 °C overnight. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (9:1) as en 
eluent, to give a pure product 4.13i as a white solid (78 mg, 39%). 
 
31P NMR (202 MHz, MeOD) # 4.27, 4.26. 
1H NMR (500 MHz, MeOD) # 8.19-8.17 (m, 1H, H8-Naph), 7.87–7.80 (m, 2H, H5- 
Naph and H8), 7.67-7.64 (m, 1H, H4-Naph), 7.53–7.42 (m, 3H, H7, H6, H2- Naph), 
7.37-7.35 (m, 1H, H3-Naph), 7.30–7.21 (m, 5H, OCH2Ph), 5.95, 9.94 (2s, 1H, H1’), 
5.07–4.93 (m, 2H, OCH2Ph), 4.64-4.51 (m, 2H, H3’ and H5’a), 4.32-4.19 (m, 2H, H4’ 
and H5’b), 4.15-4.04 (m, 1H, CHCH3), 1.32-1.28 (m, 3H, CHCH3), 0.99, 0.97 (2s, 3H, 
2’CCH3). 
HPLC (System 1) tR= 16.11, 16.43 min. 
MS (ES+) m/z: 687.19 (M+Na+, 100%). 
HRMS calculated for C31H33N6O10PNa: 687.1953, found: 687.1922.  
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(R,S-phenylethoxy-L-alaninyl)] phosphate (4.12j). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(250mg, 0.741 mmol), "-naphthyl-(R,S-
phenylethoxy-L-alaninyl) 
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tBuMgCl (1.48 ml, 1.48 mmol) in 4 ml of dry THF. Crude mixture was purified by 
column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en eluent, to give 
a pure product 4.12j as white foam (310 mg, 58%). 
 
31P NMR (202 MHz, MeOD) ! 4.52,4.45, 4.42. 
1H NMR (500 MHz, MeOD) ! 8.21-8.12 (m, 1H, H8-Naph), 7.91-7.88 (m, 1H, H5-
Naph), 7.78-7.69 (m, 2H, H4-Naph, H8), 7.58-7.49 (m, 4H, H7, H6, H3, H2-Naph), 
7.42–7.34 (m, 5H, OCH(CH3)Ph), 6.08, 6.06, 6.05, 6.03 (4s, 1H, H1’), 5.88-5.83 (m, 
1H, OCH(CH3)Ph), 4.58-4.47 (m, 2H, H3’, H5’a), 4.42- 4.24 (m, 2H, H5’b, H4’), 4.15- 
4.08 (m, 1H, CHCH3), 1.52-1.48 (m, 3H, OCH(CH3)Ph), 1.44-1.33 (m, 9, CHCH3, 2x 
CH3 isopropylidene), 1.01, 0.99, 0.98, 0.93 (4s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-Naphthyl-(R,S-phenylethoxy -L-
alaninyl)] phosphate (4.13j). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[#-naphthyl-(R,S-phenylethoxy-L-
alaninyl)] phosphate (4.12j, 310 mg, 0.431 
mmol) in 10 ml of 60% CH3COOH in 
water at 90 °C overnight. The crude 
mixture was purified by column 
chromatography, using CHCl3/MeOH (9:1) as en eluent, to give a pure product 4.13j 
as a white solid (78.6 mg, 27%). 
 
31P NMR (202 MHz, MeOD) ! 4.37,4.32, 4.29, 4.16. 
1H NMR (500 MHz, MeOD) ! 8.20-8.13 (m, 1H, H8-Naph), 7.91- 7.79 (m, 2H, H5-
Naph and H8), 7.68-7.62 (m, 1H, H4-Naph), 7.54–7.17 (m, 9H, H7, H6, H3, H2-Naph 
and OCH(CH3)Ph), 5.96, 5.95, 5.93, 5.92 (4s, 1H, H1’), 5.78-5.67 (m, 1H, 
OCH(CH3)Ph), 4.65-4.53 (m, 2H, H5’), 4.30-4.20 (m, 2H, H3’, H4’), 4.12–4.04 (m, 1H, 
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13C NMR (126 MHz, MeOD) ! 174.29 , 174.02 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 159.54, 
159.51 (C6), 155.28, 155.26 (C2), 152.66, 152.64 (C4), 147.96, 147.90 (2d, 2JC-O-P = 
2.5 Hz, ipso Naph), 142.88, 142.82, 142.63, 142.61 (ipso OCH(CH3)Ph), 137.93, 
137.88, 137.69 (C8), 136.26, 136.23, 136.20 (C10-Naph), 129.54, 129.52, 129.51, 
128.96, 128.87, 128.84, 128.78 (OCH(CH3)Ph and CH-Naph), 127.89, 127.85 (Naph-
C9), 127.78, 127.76, 127.52, 127.50, 127.04, 126.99, 126.53, 126.46, 125.97, 122.84, 
122.75 (OCH(CH3)Ph and CH-Naph), 118.02 (C5), 116.29, 116.19 (2d, 3JC-C-O-P = 
3.7, C2-Naph), 93.22, 93.16, 93.10 (C1’), 82.24, 82.10 (2d, 3J C-C-N-P = 8.8 Hz, C4’), 
80.04, 80.03, 79.98 (C2’), 74.85, 74.79, 74.74, 74.69 (C3’), 74.50 (OCH(CH3)Ph), 
68.01, 67.94, (2d, 2JC-O-P = 5.0 Hz, C5’), 51.97, 51.94, 51.78, 51.73 (CHCH3), 22.71, 
22.61, 22.54, 22.47 (OCH(CH3)Ph), 20.72, 20.59, 20.50, 20.45 (4d, 3J C-C-N-P = 6.3 Hz, 
CHCH3), 20.44 (2’CCH3). 
HPLC (System 1) tR=17.11, 17.67, 17.77, 17.96 min. 
HRMS calculated for C32H35N6O9PNa: 701.2101; found 701.2102. 
CHN calculated for C32H35N6O9P x H2O: C55.17, H5.35, N 12.06; found. C 55.24, H 
5.27, N 11.57,  
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(S-phenylethoxy -L-alaninyl)] phosphate (4.12k). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 12 g, 35.57 mmol), 1.5 eq of #-
naphthyl-(S-phenylethoxy-L-alaninyl) 
phosphorochloridate (3.3l, 22.29 g, 53.36 
mmol), tBuMgCl (71.14 ml, 71.14 mmol) 
in 150 ml of dry THF. The crude mixture 
was purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as 
en eluent, to give a pure product 4.12k as white foam (20g, 78%). 
 
31P NMR (202 MHz, MeOD) ! 4.54, 4.45.  
1H NMR (500 MHz, MeOD) ! 8.21-8.12 (m, 1H, H8-Naph), 7.91-7.88 (m, 1H, H5-
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7.42-7.34 (m, 5H, OCH(CH3)Ph), 6.08, 6.06, (2s, 1H, H1’), 5.88-5.83 (m, 1H, 
OCH(CH3)Ph), 4.58-4.47(m, 2H, H3’, H5a’), 4.42- 4.24 (m, 2H, H5’b, H4’), 4.15-4.08 
(m, 1H, CHCH3), 1.52-1.48 (m, 3H, OCH(CH3)Ph), 1.44-1.33 (m, 9, CHCH3, 2x CH3 
isopropylidene), 0.99, 0.98, (2s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-naphthyl-(S-phenylethoxy-L-
alaninyl)] phosphate (4.13k). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!-methylguanosine 
5’-O-["-naphthyl-(S-phenylethoxy-L-
alaninyl)] phosphate (4.12k, 20 g, 27.84 
mmol) in 500 ml of 60% CH3COOH in 
water at 90 °C overnight. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (9:1), to give a 
pure product 4.13k as a white solid (4.05 g, 21%). 
 
31P NMR (202 MHz, MeOD) # 4.34, 4.29. 
1H NMR (500 MHz, MeOD) # 8.20-8.13 (m, 1H, H8-Naph), 7.91-7.79 (m, 2H, H5-
Naph and H8), 7.68-7.62 (m, 1H, H4-Naph), 7.54-7.17 (m, 9H, H7, H6, H3, H2-Naph 
and OCH(CH3)Ph), 5.95, 5.93, (2s, 1H, H1’), 5.78-5.67 (m, 1H, OCH(CH3)Ph), 4.65- 
4.53 (m, 2H, H5’), 4.30-4.20 (m, 2H, H3’, H4’), 4.12-4.04 (m, 1H, CHCH3), 1.42-1.33 
(m, 6H, OCH(CH3)Ph and CHCH3), 0.99, 0.98 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) # 174.24 (d, 3J C-C-N-P = 4.5, C=O), 174.99 (d, 3J C-C-N-P 
= 5.7, C=O), 159.50, 159.49 (C6), 155.30, 155.26 (C2), 152.68 (C4), 147.99, 147.93 
(2d, 2J C-O-P = 2.5 Hz, ipso Naph), 142.87, 142.82 (ipso OCH(CH3)Ph), 137.95, 
137.70 (C8), 136.27, 136.24, (C10-Naph) 129.53, 128.94, 128.92, 128.87, 128.82 
(CH-Naph, OCH(CH3)Ph), 127.89, 127.84 (C9-Naph), 127.77, 127.51, 127.04, 
127.01, 126.52, 126.48, 125.99, 125.95, 122.83, 122.76 (CH-Naph, OCH(CH3)Ph), 
118.06 (C5), 116.27, 116.19 (2d, 3JC-C-O-P = 3.1 Hz, C2-Naph), 93.25, 93.12 (C1’), 
82.24, 82.10 (2d, 3JC-C-O-P = 8.5 Hz, C4’), 80.02, 79.96 (C2’), 74.85, 74.79 (C3’), 
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(CHCH3), 22.65, 22.55 (OCH(CH3)Ph), 20.54, 2.40 (2d, 3J C-C-N-P = 6.0 Hz, CHCH3), 
20.35, 2.31 (2’CCH3). 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-naphthyl-
(benzoxy-L-alaninyl)] phosphate (4.12l). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–
methylguanosine (4.11, 250 mg, 0.741 
mmol), !-naphthyl-(benzoxy-L-
alaninyl) phosphorochloridate (598 mg, 
1.48 mmol) tBuMgCl (1.48 ml, 1.48 
mmol) in 6 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (2 to 8%, 
gradient) as en eluent, to give a pure product 4.12l as white foam (212.5 mg, 41%). 
 
31P NMR (202 MHz, MeOD) " 4.32, 4.22. 
1H NMR (500 MHz, MeOD) " 7.89-7.81 (m, 4H, CH-Naph), 7.75 (s, 1H, H8), 7.53-
7.44 (m, 3H, CH-Naph), 7.32-7.29 (m, 5H, OCH2Ph), 6.12, 6.10 (2s, 1H, H1’), 5.14- 
5.08 (m, 2H, OCH2Ph), 4.67, 4.60 (2d, J = 3.5 Hz, 1H, H3’), 4.54-4.30 (m, 3H, H5’, 
H4’), 4.15-4.08 (m, 1H, CHCH3), 1.60, 1.58 (2s, 3H, CH3 isopropylidene), 1.39 – 1.36 
(m, 6H, CH3 isopropylidene and CHCH3), 1.15, 1.05 (2s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(benzoxy-L-alaninyl)] 
phosphate (4.13l). 
 
Prepared according to the Standard 
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ml of 60% CH3COOH in water at 90 °C overnight. The crude mixture was purified by 
column chromatography, using CHCl3/MeOH (9:1), to give a pure product 4.13l as a 
white solid (53 mg, 26%). 
 
31P NMR (202 MHz, MeOD) ! 4.19, 4.16. 
1H NMR (500 MHz, MeOD) ! 7.88-7.81 (m, 3H, CH-Naph), 7.76-7.72 (m, 2H, H8), 
7.48-7.37 (m, 3H, CH-Naph), 7.29-7.23 (m, 5H, OCH2Ph), 5.93 (s, 1H, H1’), 5.10-
5.00 (m, 2H, OCH2Ph), 4.57-4.50 (m, 2H, H5’), 4.24-4.05 (m, 3H, H3’, H4’, CHCH3), 
1.36, 1.33 (2d, J= 7.5 Hz, 3H, CHCH3), 0.99, 0.91 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.78, 174.66 (C=O), 159.42 (C6), 155.31, (C2), 
149.70, 149.65 (C4), 137.18, 137.14 (ipso OCH2Ph), 135.28 (ipso Naph), 132.40 (C9-
Naph), 130.91, 130.85 (C10-Naph), 130.60, 129.81, 129.68, 129.61, 129.54, 129.51, 
129.25, 129.22, 129.22, 129.21, 129.13, 128.77, 128.53, 128.51, 127.80, 127.79, 
126.58, 121.49, 121.45 (CH-Naph and OCH2Ph), 117.90 (C5), 117.86, 117.82 (CH-
Naph), 93.13, 93.05 (C1’), 82.10, 81.95 (2d, 3JC-C-O-P = 8.5 Hz, C4’), 80.05, 79.98 
(C2’), 74.55, 74.02 (C3’), 67.94, 67.88 (OCH2Ph), 67.56 (d, 2JC-O-P = 6.8 Hz, C5’) , 
67.68 (d, 2JC-O-P = 4.7 Hz, C5’), 51.76, 51.67 (CHCH3), 20.55, 20.35 (2d, 3JC-C-N-P = 
7.0 Hz, CHCH3), 20.27, 20.23 (2’CCH3). 
HPLC (System 1) tR= 15.89, 16.32 min. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(benzoxy-L-valinyl)] phosphate (4.12m). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 250 mg, 0.741 mmol), #-
naphthyl-(benzoxy-L-valinyl) 
phosphorochloridate (3.3t, 640mg, 1.48 
mmol), tBuMgCl (1.48 ml, 1.48 mmol) 
in 4 ml of dry THF. The crude mixture 
was purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as 













Karolina Made!a                                                                                     Chapter Twelve  
 314
 
31P NMR (202 MHz, MeOD) ! 5.44, 5.30. 
1H NMR (500 MHz, MeOD) ! 8.20-8.17 (m, 1H, H8-Naph), 7.92-7.87 (m, 1H, H5-
Naph), 7.76 (s, 1H, H8), 7.74–7.70 (m, 1H, H4-Naph), 7.56–7.52 (m, 3H, H7, H6, H2-
Naph), 7.45-7.39 (m, 1H, H3-Naph), 7.34–7.28 (m, 5H, OCH2Ph), 6.07, 6.06 (2s, 1H, 
H1’), 5.15-4.99 (m, 2H, OCH2Ph), 4.62-4.52 (m, 1H, H3’, H5’a), 4.44-4.31 (m, 2H, 
H5’b, H4’), 3.87-3.77 (m, 1H, CHCH(CH3)2), 2.12–2.01 (m, 1H, CHCH(CH3)2), 1.60, 
1.58, 1.39, 1.38 (4s, 6H, 2x CH3 isopropylidene), 1.03, 0.94 (2s, 3H, 2’CCH3), 0.90 – 
0.85 (m, 6H, CHCH(CH3)2). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(benzoxy-L-valinyl)] 
phosphate (4.13m). 
 
Prepared according to the Standard 
Procedure 5 from: 2’, 3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[#-naphthyl-(benzoxy-L-valinyl)] 
phosphate (4.12m, 225 mg, 0.307 mmol) 
in 10 ml of 60% CH3COOH in water at  
90 °C overnight. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (9:1), to give a pure product 
4.13m as a white solid (47.8 mg, 24%). 
 
31P NMR (202 MHz, MeOD) !  5.13, 4.98. 
1H NMR (500 MHz, MeOD) ! 8.18 (d, 1H, J= 8.0 MHz, H8 naph), 7.88-7.84 (m, 2H, 
H5-Naph and H8), 7.71-7.67 (m, 1H, H4-Naph), 7.55–7.49 (m, 3H, H7, H6, H2-Naph), 
7.39-7.35 (m, 1H, H3-Naph), 7.28–7.26 (m, 5H, OCH2Ph), 5,92, 5.91 (2s, 1H, H1’) 
5.05- 4.92 (m, 2H, OCH2Ph), 4.58-4.54 (m, 2H, H5’), 4.29-4.19 (m, 2H, H3’, H4’) 
3.81-3.76 (m, 1H, CHCH(CH3)2), 2.05–1.94 (m, 1H, CHCH(CH3)2), 1.01, 0.96 (2s, 
3H, 2’CCH3), 0.85-0.79 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 174.05, 173.78 (2d, 3J C-C-N-P = 3.0 Hz, C=O), 159.50, 
159.48 (C6), 155.28, 155.25 (C2), 152.63 (C4), 148.02, 147.97 (ipso Naph), 138.02, 
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129.50, 129.49, 129.44, 129.30, 128.84, 128.78 (CH-Naph and OCH2Ph), 127.90, 
127.85 (2d, 3JC-C-O-P = 2.5 Hz, Naph-C9), 127.76, 127.74, 127.48, 126.53, 126.52, 
126.45, 126.44, 125.94, 122.87, 122.83 (CH-Naph and OCH2Ph), 118.11 (C5), 
116.25, 116.18 (2d, 3JC-C-O-P = 3.0 Hz, C2-Naph), 93.35, 93.21 (C1’), 82.32, 82.16 
(2d, 3JC-C-O-P = 7.5 Hz, C4’), 79.97, 79.94 (C2’), 74.85, 74.66 (C3’), 68.30, 67.84 (2d, 
2JC-O-P = 5.0 Hz, C5’), 67.78, 67.73 (OCH2Ph), 62.05, 62.02 (CHCH(CH3)2), 33.31, 
33.19 (2d, 3JC-C-N-P = 7.5 Hz, CHCH(CH3)2), 20.43, 19.48 (2’CCH3), 18.39, 18.26 
(CHCH(CH3)2). 
HPLC (System 1) tR= 18.85, 19.28 min. 
HRMS calculated for C33H37N6O9PNa: 715.2257; found 715.2236. 
CHN calculated for C33H37N6O9P + 1.0 H2O: C 55.77, H 5.53, N 11.83; found: C 
55.39, H 5.37, N, 11.83. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(benzoxy-D-valinyl)] phosphate (4.12n). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(4.11, 250 mg, 0.741 mmol), "-naphthyl-
(benzoxy-D-valinyl) phosphorochloridate 
(3.2v, 640 mg, 1.48 mmol), tBuMgCl 
(1.48 ml, 1.48 mmol) in 4 ml of dry THF. 
The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en eluent, to give a pure 
product 4.12n as white foam (331mg, 61%). 
 
31P NMR (202 MHz, MeOD) # 5.71, 5.09. 
1H NMR (500 MHz, MeOD) # 8.23-8.21, 8.16-8.14 (2m, 1H, H8 naph), 7.90-7.87 (m, 
1H, H5 naph), 7.75, 7.74 (2s, 1H, H8), 7.72- 7.67 (m, 1H, H4-Naph), 7.56–7.52 (m, 
3H, H7, H6, H2-Naph), 7.45, 7.36 (2d, J= 8.0 Hz, 1H, H3-Naph), 7.30–7.26 (m, 5H, 
OCH2Ph), 6.05, 6.04 (s, 1H, H1’) 5.14-5.02 (m, 2H, OCH2Ph), 4.59-4.33 (m, 4H, H3’, 
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1.57 (2s, 3H, CH3 isopropylidene), 1.38, 1.36 (2s, 3H, CH3 isopropylidene), 1.00, 
0.96 (2s, 3H, 2’CCH3), 0.90-0.85 (m, 6H, CHCH(CH3)2). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(benzoxy-D-valinyl)] 
phosphate (4.13n). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-naphthyl-(benzoxy-D-valinyl)] 
phosphate (4.12n, 331 mg, 0.451 mmol) in 
20 ml of 60% CH3COOH in water at  
90 °C overnight. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (9:1), to give a pure product 
4.13n as a white solid (147.5 mg, 47%). 
 
31P NMR (202 MHz, MeOD) # 5.71, 5.09. 
1H NMR (500 MHz, MeOD) # 8.20-8.18 (m, 1H, H8 naph), 7.90, 7.88 (2s, 1H, H8), 
7.83- 7.78 (m, 1H, H5-Naph), 7.65, 7.61 (2d, J=8.5 Hz, 1H, H4-Naph), 7.53–7.44 (m, 
3H, H7, H6, H2-Naph), 7.37-7.30 (m, 1H, H3-Naph), 7.23–7.18 (m, 5H, OCH2Ph), 
5.96, 5.93 (2s, 1H, H1’) 5.08-4.99 (m, 2H, OCH2Ph), 4.62-4.57 (m, 2H, H5’), 4.34- 
4.23 (m, 2H, H3’, H4’), 3.81, 3.76 (2d, J= 6.0 Hz, 1H, CHCH(CH3)2), 2.00–1.92 (m, 
1H, CHCH(CH3)2), 1.00, 0.96 (2s, 3H, 2’CCH3), 0.80- 0.74 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) # 174.16, 137.97 (2d, 3J C-C-N-P = 2.5 Hz, C=O), 159.58 
(C6), 155.29, 155.25 (C2), 152.63 (C4), 148.01, 147.94 (ipso Naph), 138.13, 137.72 
(C8), 137.01, 136.92 (OCH2Ph), 136.25, 136.22 (C10-Naph), 129.51, 129.48, 129.32, 
129.24, 128.84 (CH-Naph and OCH2Ph), 127.94, 127.89 (C9-Naph), 127.80, 127.77 
127.63, 127.49, 126.51, 126.49, 126.06, 125.92, 122.92, 122.78 (CH-Naph and 
OCH2Ph), 118.08 (C5), 116.46, 116.00 (2d, 3JC-C-O-P = 3.0 Hz, C2-Naph), 93.26, 
93.10 (C1’), 82.27, 82.13 (2d, 3JC-C-O-P = 8.5 Hz, C4’), 80.02 (C2’), 74.79, 74.47 
(C3’), 67.93, 67.91 (OCH2Ph), 67.55, 67.49 (2d, 2JC-O-P = 4.5 Hz, C5’), 61.91 
(CHCH(CH3)2), 33.28, 33.14 (2d, 3JC-C-N-P = 7.5 Hz, CHCH(CH3)2), 20.50, 20.48 
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HPLC (System 1) tR= 17.11, 17.71 min. 
HRMS calculated for C33H37N6O9PNa: 715.2244; found 715.2257. 
CHN calculated for C33H37N6O9P + 1.0 H2O: C 55.77, H 5.53, N 11.83; found: C 
55.95, H 5.44, N 11.49. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-naphthyl-
(benzoxy-L-valinyl)] phosphate (4.12o). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–
methylguanosine (4.11, 250 mg, 
0.741 mmol), !-naphthyl-(benzoxy-L-
valinyl) phosphorochloridate (3.3u, 
640 mg, 1.48 mmol), tBuMgCl (1.48 
ml, 1.48 mmol) in 4 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (2 to 5%, gradient) as en eluent, to give a pure 
product 4.12o as white foam (234 mg, 43%). 
 
31P NMR (202 MHz, MeOD) " 5.07, 5.05. 
1H NMR (500 MHz, MeOD) " 7.88–7.80 (m, 3H, Naph), 7.74, 7.71 (2s, 1H, H8) 7.51-
7.44 (m, 2H, Naph), 7.39-7.34 (m, 2H, Naph), 7.33-7.27 (m, 5H, OCH2Ph), 6.10, 6.09 
(2s, 1H, H1’), 5.15, 5.11, 5.02, 4.97 (2AB, JAB= 10.0 Hz, 2H, OCH2Ph) 4.67- 4.52 (m, 
2H, H3’, H5’a), 4.44-4.38 (m, 2H, H5’b, H4’), 3.85-3.75 (m, 1H, CHCH(CH3)2), 2.12- 
2.01 (m, 1H, CHCH(CH3)2), 1.59, 1.57, 1.36, 1.35 (4s, 6H, 2x CH3 isopropylidene), 
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Prepared according to the Standard 




(4.12o, 234 mg, 0.319 mmol) in 10 ml 
of 60% CH3COOH in water at 90 °C overnight. The crude mixture was purified by 
column chromatography, using CHCl3/MeOH (9:1), to give a pure product 4.13o as a 
white solid (32.8 mg, 15%). 
 
31P NMR (202 MHz, MeOD) " 5.03, 4.90. 
1H NMR (500 MHz, MeOD) " 7.87-7.81 (m, 3H, CH-Naph), 7.77- 7.70 (m, 2H, CH-
Naph and H8), 7.53-7.49 (m, 3H, CH-Naph), 7.30-7.20 (m, 5H, OCH2Ph), 5.92, 5.91 
(2s, 1H, H1’), 5.09, 5.05, 4.94, 4.88 (2AB, JAB= 12.0 Hz, OCH2Ph), 4.60-4.47 (m, 2H, 
H5’), 4.30-4.09 (m, 2H, H3’, H4’), 3.81-3.76 (m, 1H, CHCH(CH3)2), 2.06 – 1.99 (m, 
1H, CHCH(CH3)2), 1.00, 0.99 (2s, 3H, 2’CCH3), 0.89-0.82 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) " 174.01, 173.79 (2d, 3J C-C-N-P = 2.8 Hz, C=O), 159.42, 
159.40 (C6), 155.30, 155.28 (C2), 149.80, 149.74 (C4), 149.71, 149.66 (ipso Naph), 
137.85, 137.56 (C8), 137.15, 137.03 (ipso OCH2Ph), 135.30, 135.26 (C9-Naph), 
132.40, 132.38 (C10-Naph), 130.89, 130.84, 129.53, 129.52, 129.47, 129.41, 129.31, 
129.27, 128.77, 128.74, 128.54, 128.48, 127.77, 126.55, 121.52 (CH-Naph and 
OCH2Ph), 118.03 (C5), 117.88, 117.85 (CH-Naph), 93.18, 92.91 (C1’), 82.21, 82.04 
(2d, 3JC-C-O-P = 8.5 Hz, C4’), 79.99, 79.96 (C2’), 74.65, 74.23 (C3’), 67.90, 87.86 (2d, 
2JC-O-P = 5.0 Hz, C5’), 67.86, 67.76 (OCH2Ph), 62.07, 61.99 (CHCH(CH3)2), 33.31 
(2d, 3JC-C-N-P = 7.5 Hz, CHCH(CH3)2), 20.32, 20.27 (2’CCH3), 19.52, 19.47, 18.38, 
18.21 (CHCH(CH3)2). 
HPLC (System 1) tR= 17.28, 17.92 min. 














Karolina Made!a                                                                                     Chapter Twelve  
 319 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(o-chloro-benzoxy-L-valinyl)] phosphate (4.12p). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(4.11, 250 mg, 0.741 mmol), !-naphthyl-
(o-chloro-benzoxy-L-valinyl) 
phosphorochloridate (691 mg, 1.48 
mmol), tBuMgCl (1.48 ml, 1.48 mmol) in 
4 ml of dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (2 to 8%, gradient) as en eluent, to give a pure product 4.12p as white 
foam (367 mg, 51%). 
 
31P NMR (202 MHz, MeOD) " 5.34, 5.23. 
1H NMR (500 MHz, MeOD) " 8.19-8.16 (m, 1H, H8-Naph), 7.88-7.83 (m, 1H, H5-
Naph), 7.76, 7.73 (2s, 1H, H8), 7.72-7.67 (m, 1H, H4-Naph), 7.56-7.52 (m, 3H, H7, 
H6, H2-naph), 7.43-7.19 (m, 6H, H3-Naph and OCH2Ph), 6.05, 6.04 (2s, 1H, H1’), 
5.20, 5.17, 5.13, 5.11 (2AB, JAB= 10.5 Hz, 2H, OCH2Ph), 4.62-4.53 (m, 2H, H3’ and 
H5’a), 4.48–4.36 (m, 2H, H5’b and H4’), 3.88, 3.82 (2d, J= 6.0 Hz, CHCH(CH3)2), 2.15 
–2.02 (m, 1H, CHCH(CH3)2) 1.57, 1.38 (2s, 6H, 2x CH3 isopropylidene) 1.04, 0.96 
(2s, 3H, 2’CCH3), 0.91, 0.88 (2d, J = 7.5 Hz, 6H, CHCH(CH3)2). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(o-chloro-benzoxy-L-
valinyl)] phosphate (4.13p). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 5’-
O-[!-naphthyl-(o-chloro-benzoxy-L-
valinyl)] phosphate (4.12p, 367 mg, 0.478 
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at 90 °C overnight. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (9:1), to give a pure product 4.13p as a white solid (112.4 mg, 32%). 
 
31P NMR (202 MHz, MeOD) ! 5.10, 4.91. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16 (m, 1H, H8-Naph), 7.89-7.84 (m, 2H, H8 and 
H5-Naph), 7.69, 7.67 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.53-7.18 (m, 8H, H7, H6, H2, H3-
Naph and OCH2Ph), 5.92, 5.91 (2s, 1H, H1’), 5.13-4.98 (m, 2H, OCH2Ph), 4.59- 4.56 
(m, 2H, H5’), 4.31-4.19 (m, 2H, H3’ and H4’), 3.83, 3.80 (2d, J= 6.0 Hz, 
CHCH(CH3)2),  2.07-1.99 (m, 4H, CHCH(CH3)2 and 2’CCH3), 0.87-0.82 (m, 6H, 
CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 173.85, 173.61 (C=O), 159.45 (C6), 155.25 (C2), 
152.58 (C4), 148.00, 147.93 (ipso Naph), 137.98, 137.76 (C8), 136.26, 136.21 (C10-
Naph), 134.67 (ipso OCH2(o-Cl)Ph), 134.45 (C-Cl OCH2(o-Cl)Ph), 131.54, 131.50, 
130.92, 130.44, 128.83, 128.76, 128.15 (OCH2(o-Cl)Ph and CH-Naph), 127.86 (C9-
Naph), 127.73, 127.46, 126.50, 126.42, 125.93, 122.83, 122.80 (OCH2(o-Cl)Ph and 
CH-Naph), 118.12, 118.10 (C5), 116.17 (C2-Naph), 93.35, 93.22 (C1’), 82.30, 82.15 
(2d, 3JC-C-O-P = 8.5 Hz, C4’), 79.93 (C2’), 74.83, 74.64 (C3’), 68.31 (d, 2JC-O-P = 3.5 
Hz, C5’), 67.74 (d, 2JC-O-P = 4.2 Hz, C5’), 65.10 (OCH2(o-Cl)Ph), 62.08, 62.02 
(CHCH(CH3)2), 33.24, 33.07 (d, 3JC-C-N-P = 5.0 Hz, CHCH(CH3)2), 20.39, 2.38 
(2’CCH3), 19.50, 19.36, 18.37, 18.24 (CHCH(CH3)2). 
HPLC (System 1) tR= 18.75, 19.01 min. 
HRMS calculated for C33H37N6O9PClNa: 749.1868; found 749.1879. 
CHN calculated for C33H37N6O9PCl + 1.0 H2O: C 53.19, H 5.14, N 11.28; found: C 
53.20, H 4.90, N 11.04. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(m-chloro-benzoxy-L-valinyl)] phosphate (4.12r). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
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phosphorochloridate (691 mg, 1.48 mmol), tBuMgCl (1.48 ml, 1.48 mmol) in 4 ml of 
dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (2 to 8%, gradient), to give a pure product 4.12r as white foam (288 
mg, 51%). 
 
31P NMR (202 MHz, MeOD) ! 5.27, 5.11, 4.92, 4.87. 
1H NMR (500 MHz, MeOD) ! 8.19-8.13 (m, 1H, H8-Naph), 7.89-7.84 (m, 1H, H5-
Naph), 7.75-7.66 (m, 2H, H8 and H4-Naph), 7.54-7.50 (m, 3H, H7, H6, H2-Naph), 
7.43-7.31 (m, 2H, H3-Naph and OCH2(m-Cl)Ph), 7.26-7.21 (m, 3H, OCH2(m-Cl)Ph), 
6.05, 6.04 (2s, 1H, H1’), 5.10-5.02 (m, 2H, OCH2(m-Cl)Ph), 4.61-4.35 (m, 4H, H5’, 
H4’ and H3’), 3.88-3.79 (m, 1H, CHCH(CH3)2), 2.13-2.01 (m, 1H, CHCH(CH3)2), 
1.59, 1.57, 1.38, 1.37 (4s, 6H, 2x CH3 isopropylidene) 1.04, 0.99, 0.95, 0.96 (4s, 3H, 
2’CCH3), 0.92-0.86 (m, 6H, CHCH(CH3)2). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(m-chloro-benzoxy-L-
valinyl)] phosphate (4.13r). 
 
Prepared according t the Standard 
Procedure 5 from: 2’, 3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[!-naphthyl-(m-chloro-benzoxy-L-
valinyl)] phosphate (4.12r, 288 mg, 0.375 
mmol) in 20 ml of 60% CH3COOH in 
water at 90 °C overnight. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (9:1), to give a 
pure product 4.13r as a white solid (97mg, 36%). 
 
31P NMR (202 MHz, MeOD) ! 5.27, 5.11, 4.92, 4.87. 
1H NMR (500 MHz, MeOD) ! 8.19-8.15 (m, 1H, H8-Naph), 7.83–7.77 (m, 1H, H5-
Naph), 7.66, 7.64, 7.62, 7.60 (4s, 1H, H8), 7.53–7.50 (m, 1H, H4-Naph), 7.47–7.10 
(m, 8H, H7, H6, H2, H3-Naph, OCH2(m-Cl)Ph), 5.95, 5.94, 5.93, 5.92 (4s, 1H, H1’), 
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and H4’), 3.83- 3.75 (m, 1H, CHCH(CH3)2), 2.03 – 1.93 (m, 1H, CHCH(CH3)2), 1.00, 
0.96, 0.95 (3s, 3H, 2’CCH3), 0.84–0.75 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 174.04, 173.95 (2d, 3J C-C-N-P = 2.5 Hz, C=O), 173.86, 
173.70 (2d, 3J C-C-N-P = 2.7 Hz, C=O), 159.60, 159.57 (C6), 155.30, 155.26 (C2), 
152.62, 152.60 (C4), 147.96, 147.94 (2d, 2J C-O-P = 7.0 Hz, ipso Naph), 139.26, 
139.23, 139.16 (C-Cl OCH2(m-Cl)Ph), 138.10, 138.00, 137.78, 137.67 (C8), 136.23, 
136.20, 136.18 (C10-Naph), 135.28, 135.25 (ipso OCH2(m-Cl)Ph), 131.06, 131.04, 
129.30, 129.28, 129.26, 129.25, 129.19, 129.08, 128.85, 128.84, 128.78 (CH-Naph 
and OCH2(m-Cl)Ph), 127.88 (C9-Naph), 127.80, 127.76, 127.65, 127.62, 127.55, 
127.50, 127.44, 126.52, 126.46, 126.06, 125.95, 122.89, 122.84, 122.80, 122.76 (CH-
Naph and OCH2(m-Cl)Ph), 118.10 (C5), 116.46 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 
116.24 (d, 3JC-C-O-P = 4.0 Hz, C2-Naph), 116.21 (d, 3JC-C-O-P = 3.3 Hz, C2-Naph), 
116.02 (d, 3JC-C-O-P = 3.0 Hz, C2-Naph), 93.30, 93.18, 93.08 (C1’), 82.26, 82.16, 
82.10, 80.00 (4d, 3JC-C-O-P = 5.0 Hz, C4’), 79.97 (C2’), 74.85, 74.79, 74.66, 74.43 
(C3’), 67.97, 67.74, 67.68, 67.51 (4d, 2JC-O-P = 5.0 Hz, C5’), 66.98, 66.95, 66.90, 
66.86 (OCH2(m-Cl)Ph), 62.02, 61.98, 61.89 (CHCH(CH3)2), 33.28, 33.23, 33.15, 
33.08 (4d, 3JC-C-O-P = 2.5 Hz, CHCH(CH3)2), 20.50 (2’CCH3), 19.55, 19.42, 18.43, 
18.40, (CHCH(CH3)2). 
HPLC (System 1) tR= 18.91, 19.15, 19.31 min.   
HRMS calculated for C33H37N6O9PClNa: 749.1868; found 749.1881. 
CHN calculated for C33H37N6O9PCl + 1.0 H2O: C 53.19, H 5.14, N 11.28; found C 
53.25, H. 5.28, N 11.25.  
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(o-methyl-benzoxy-L-valinyl)] phosphate (4.12s). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 250 mg, 0.741 mmol), !-naphthyl-
(o-methyl-benzoxy-L-valinyl) 
phosphorochloridate (618 mg, 1.48 
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4 ml of dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (2 to 8%, gradient), to give a pure product as white foam (172 mg, 
31%). 
 
31P NMR (202 MHz, MeOD) ! 5.11, 4.97. 
1H NMR (500 MHz, MeOD) ! 8.19–8.15 (m, 1H, H8-Naph), 7.89–7.85 (m, 1H, H5-
Naph), 7.75-7.68 (m, 2H, H8 and H4-Naph), 7.54–7.51 (m, 3H, H7, H6, H2-Naph), 
7.43- 7.37 (m, 1H, H3-Naph), 7.20–7.09 (4H, OCH2(o-CH3)Ph), 6.06, 6.05 (2s, 1H, 
H1’), 5.16- .08 (m, 2H, OCH2(o-CH3)Ph), 4.60, 4.50 (2d, J=3.5 Hz, 1H, H3’), 4.42– 
4.28 (m, 3H, H5’ and H4’), 3.85, 3.78 (2d, J=6.5 Hz, 1H, CHCH(CH3)2), 2.31 (s, 3H, 
OCH2(o-CH3)Ph), 2.11–2.00 (m, 1H, CHCH(CH3)2), 1.59, 1.57, 1.38, 1.37 (4s, 6H, 2 
x CH3 isopropylidene) 1.02, 0.94 (2s, 3H, 2’CCH3), 0.89–0.85 (m, 6H, 
CHCH(CH3)2). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-[!-naphthyl-(o-methyl-benzoxy-L-
valinyl)] phosphate (4.13s). 
 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[!-Naphthyl-(o-methyl-benzoxy-L-
valinyl)] phosphate (4.12s, 172 mg, 0.230 
mmol) in 10 ml of 60% CH3COOH in 
water at 90 °C overnight. The crude mixture was purified by column chromatography, 
using CHCl3/MeOH (9:1), to give a pure product 4.13s as a white solid (90 mg, 55%). 
 
31P NMR (202 MHz, MeOD) ! 5.11, 4.97. 
1H NMR (500 MHz, MeOD) ! 8.17 (d, J= 8.0 Hz, 1H, H8-Naph), 7.85, 7.83 (2s, 1H, 
H8), 7.81 (d, 1H, J= 7.5 Hz, H5-Naph), 7.66, 7.63 (2d, J= 8.00 Hz, 1H, H4-Naph), 
7.52–7.44 (m, 3H, H7, H6, H2-Naph), 7.36-7.32 (m, 1H, H3-Naph), 7.20–7.14 (m, 2H, 
OCH2(o-CH3)Ph) 7.11–7.05 (m, 2H, OCH2(o-CH3)Ph), 5.93, 5.92 (2s, 1H, H1’), 5.06- 
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H4’), 3.79, 3.76 (2d, J= 6.0 Hz, 1H, CHCH(CH3)2), 2.24, 2.23 (2s, 3H, OCH2(o-
CH3)Ph), 2.05–1.92 (m, 1H, CHCH(CH3)2), 1.00, 0.95 (2s, 3H, 2’CCH3), 0.83–0.77 
(m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 174.06 (d, 3J C-C-N-P = 2.7 Hz, C=O), 173.81 (d, 3J C-C-
N-P = 3.1 Hz, C=O), 159.49, 159.46 (C6), 155.25, 155.21 (C2), 152.59 (C4), 148.01, 
147.96 (ipso Naph), 138.22 (C-CH3 OCH2(o-CH3)Ph), 138.01, 137.77 (C8), 136.26, 
136.21 (C10-Naph), 134.84, 134.82 (ipso OCH2(o-CH3)Ph), 131.25, 130.63, 130.60, 
129.65, 129.64, 128.83, 128.76 (CH-Naph and OCH2(o-CH3)Ph), 127.89, 127.84 (C9-
Naph), 127.74, 127.46, 126.97, 126.52, 126.43, 125.92, 122.87, 122.82 (CH-Naph 
and OCH2(o-CH3)Ph), 118.12, 118.10 (C5), 116.23 (d, 3JC-C-O-P = 2.6 Hz, C2-Naph), 
116.15 (d, 3JC-C-O-P = 3.1 Hz, C2-Naph), 93.33, 93.20 (C1’), 82.30 (d, 3JC-C-O-P = 7.9 
Hz, C4’), 82.15 (d, 3JC-C-O-P = 8.3 Hz, C4’), 79.96, 79.93 (C2’), 74.84, 74.64 (C3’), 
68.29, 67.70 (2d, 2JC-O-P = 5.0 Hz, C5’), 66.23 (OCH2(o-CH3)Ph), 62.09 
(CHCH(CH3)2), 33.30 (d, 3JC-C-N-P = 7.0 Hz, CHCH(CH3)2), 33.10 (d, 3JC-C-N-P = 7.4 
Hz, CHCH(CH3)2), 20.42, 19.48 (2’CCH3), 18.38, 18.24 (OCH2(o-CH3)Ph).  
HPLC (System 1) tR= 18.59, 18.75 min. 
HRMS C34H39N6O9PClNa:  found 729.2407, calc. 729.2414 
CHN calculated for C34H39N6O9PCl + 1.0 H2O: C56.75, H5.70, N11.60; found: C 
56.33, H 5.82, N 11.20. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(benzoxy-dimethylglicinyl)] phosphate (4.12t). 
 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
(4.11, 250 mg, 0.741 mmol), #-Naphthyl-
(benzoxy-dimethylglicinyl) 
phosphorochloridate (3.3p, 619 mg, 1.48 
mmol), tBuMgCl (1.48 ml, 1.48 mmol) in 
4 ml of dry THF. The crude mixture was purified by column chromatography, using 
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31P NMR (202 MHz, CDCl3) ! 2.75, 2.28. 
1H NMR (500 MHz, CDCl3) ! 8.19–8.11 (m, 1H, H8-Naph), 7.84– .68 (m, 2H, H5-
Naph and H8), 7.58–7.43 (m, 4H, H4, H7, H6, H2-Naph), 7.41–7.38 (m, 1H, H3-Naph), 
7.33 – 7.29 (m, 5H, OCH2Ph), 6.25 (bs, 1H, NH), 6.00 (s, 1H, H1’), 5.19–5.13 (m, 2H, 
CH2 ester), 4.80–4.68 (m, 2H, H3’ and H5’a), 4.39–4.30 (m, 2H, H5’b and H4’), 1.65–
1.57 (m, 9H, CH3 isopropylidene and C(CH3)2), 1.39 (s, 3H, CH3 isopropylidene), 
1.16 (s, 3H, 2’CCH3). 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(benzoxy-dimethylglicinyl)] phosphate (4.12t). 
 
Prepared according to the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-"–methylguanosine 
5’-O-[#-naphthyl-(benzoxy-
dimethylglicinyl)] phosphate (4.12t, 140 
mg, 0.292 mmol) in 10 ml of 60% 
CH3COOH in water at 90 °C overnight. 
The crude mixture was purified by column chromatography CHCl3/MeOH (9:1) to 
give a pure product 4.13t as a white solid (51 mg, 39%). 
 
31P NMR (202 MHz, MeOD) ! 2.75, 2.62. 
1H NMR (500 MHz, MeOD) ! 8.20-8.18 (m, 1H, H8-Naph), 7.87 – 7.82 (m, 2H, H5-
Naph and H8), 7.68 - 7.63 (m, 1H, H4-Naph), 7.53–7.35 (m, 3H, H7, H6, H2-Naph), 
7.32–7.26 (m, 5H, OCH2Ph), 5.94, 5.90 (2s, 1H, H1’), 5.14, 5.11, 5.08, 5.05 (2AB, J= 
10.5 Hz, 2H, OCH2Ph), 4.60–4.49 (m, 2H, H5’), 4.28–4.18 (m, 2H, H3’ and H4’), 1.52- 
1.49 (m, 6H, C(CH3)2), 1.00, 0.96 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 176.58, 176.54 (2d, 3J C-C-N-P = 3.8 Hz, C=O), 159.45, 
159.43 (C6), 155.29, 155.23 (C2), 152.65, 152.61 (C4), 148.07, 148.01 (2d, 2JC-O-P = 
4.2 Hz, ipso Naph), 137.96, 137.90 (C8), 137.27, 137.25 (ipso OCH2Ph), 136.26, 
136.22 (C10-Naph), 129.57, 129.56, 129.25, 129.20, 128.82, 128.78 (CH-Naph and 
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125.79, 123.01 (CH-Naph and OCH2Ph), 118.04 (C5), 116.38, 116.27 (2d, 3JC-C-O-P = 
3.1 Hz, C2-Naph), 93.19 (C1’), 82.24, 82.12 (2d, 3JC-C-O-P = 8.5 Hz, C4’), 80.02, 
79.96 (C2’), 74.72, 74.61 (C3’), 68.30, 68.26 (OCH2Ph), 67.77, 67.56 (2d, 2JC-O-P = 
5.0 Hz, C5’), 58.23, 58.15, (2d, 2JC-N-P = 3.7 Hz, C(CH3)2), 30.48, 27.82, 27.68, 27.65 
(4d, 3JC-C-N-P = 5.0 Hz, C(CH3)2), 20.46 (2’CCH3). 
HPLC (System 1) tR= 16.83, 17.16 min. 
HRMS calculated for C32H35N6O9PClNa: 701.2101; found 701.2097. 
 
Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-[!-
naphthyl-(benzoxy-L-isolucinyl)] phosphate (4.12u). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(4.11, 200 mg, 0.593 mmol), !-naphthyl-
(benzoxy-L-isoleucinyl) 
phosphorochloridate (264 mg, 1.18 
mmol), tBuMgCl (1.18 ml, 1.18 mmol) in 
4 ml of dry THF. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en 
eluent, to give a pure product 4.12u as white foam (205 mg, 50%). 
 
31P NMR (202 MHz, MeOD) "  5.27, 5,08. 
1H NMR (500 MHz, MeOD) " 8.19-8.16 (m, 1H, H8-Naph), 7.88–7.84 (m, 1H, H5-
Naph), 7.77, 7.73 (2s, 1H, H8) 7.73-7.67 (m, 1H, H4-Naph), 7.55–7.50 (m, 3H, H7, H6, 
H2-Naph), 7.43-7.37 (m, 1H, H3-Naph), 7.33–7.27 (m, 5H, OCH2Ph), 6.06, 6.05 (2s, 
1H, H1’), 5.14–5.01 (m, 2H, OCH2Ph), 4.60-4.42 (m, 2H, H3’, H5’a), 4.39- .31(m, 2H, 
H5’b, H4’) 3.92–3.85 (m, 1H, CHCH(CH3)CH2CH3), 1.81-1.73 (m, 1H, 
CHCH(CH3)CH2CH3), 1.64-1.63 (m, 2H, CHCH(CH3)CH2CH3), 1.59, 1.57 (2s, 3H, 
CH3 isopropylidene), 1.38, 1.37 (2s, 3H, CH3 isopropylidene), 1.03, 0.96 (2s, 3H, 
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Prepared according t the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-[!-naphthyl-(benzoxy-L-leucinyl)] 
phosphate (4.12u, 205 mg, 0.274 mmol) in 
10 ml of 60% CH3COOH in water at 90 °C overnight. The crude mixture was purified 
by column chromatography, using CHCl3/MeOH (9:1) as en eluent, to give a pure 
product 4.13u as a white solid (27 mg, 14%). 
 
31P NMR (202 MHz, MeOD) "  4.99, 4.90. 
1H NMR (500 MHz, MeOD) " 8.18 (d, J= 7.0 Hz, 1H, H8-Naph), 7.90–7.87 (m, 1H, 
H5-Naph), 7.84, 7.83 (2s, 1H, H8) 7.71- 7.67 (m, 1H, H4-Naph), 7.55–7.49 (m, 3H, 
H7, H6, H2-Naph), 7.40-7.35 (m, 1H, H3-Naph), 7.28–7.27 (m, 5H, OCH2Ph), 5.02 (s, 
1H, H1’), 5.06–4.91 (m, 2H, OCH2Ph), 4.57-4.55 (m, 2H, H5’), 4.29-4.20 (m, 2H, H3’, 
H4’) 3.87–3.83 (m, 1H, CHCH(CH3)CH2CH3), 1.74-1.69 (m, 1H, 
CHCH(CH3)CH2CH3), 1.42-1.36 (m, 1H, CHCH(CH3)CH2CH3), 1.09-1.03 (m, 1H, 
CHCH(CH3)CH2CH3), 1.00, 0.97 (2s, 3H, 2’CCH3), 0.81-0.74 (m, 6H, 3H, 
CHCH(CH3)CH2CH3 and CHCH(CH3)CH2CH3). 
HPLC (System 1) tR= 18.23 min. 
HRMS calculated for C34H39N6O9PNa: 729.2497; found 729.2453. 
CHN calculated for C34H39N6O9PCl + 0.75H2O: C 56.7, H 5.67, N 11.67; found: C 
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Synthesis of 2’,3’-O,O-isopropylidene-2’-C-!–methylguanosine 5’-O-["-naphthyl-
(isopropoxy-L-methioninyl)] phosphate (4.12v). 
 
Prepared according to the Standard 
Procedure 4 from: 2’3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
(4.11, 250 mg, 0.741 mmol), "-naphthyl-
(isopropoxy-L-methioninyl) 
phosphorochloridate (3.3x, 422 mg, 1.48 
mmol) tBuMgCl (1.48 ml, 1.48 mmol) in 3 ml of dry THF. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (2 to 8%, gradient) as en 
eluent, to give a pure product 4.12v  as a white foam (314.2 mg, 59%). 
 
31P NMR (202 MHz, MeOD) # 4.80, 4.71. 
1H NMR (500 MHz, MeOD) # 8.24–8.16 (m, 1H, H8-Naph), 7.89-7.87 (m, 1H, H5-
Naph), 7.87, 7.82 (s, 1H, H8), 7.74-7.70 (m, 1H, H4-Naph), 7.59–7.51 (m, 3H, H7, H6, 
H2-Naph), 7.47-7.40 (m, 1H, H3-Naph), 6,10, 6.07 (2s, 1H, H1’), 5.00–4.94 (m, 1H, 
OCH(CH3)2), 4.63-4.39 (m, 4H, H3’, H5’, H4’), 4.15- 4.09 (m, 1H, CHCH2CH2SCH3), 
2.51–2.38 (m, 2H, CHCH2CH2SCH3), 2.05- 1.90 (m, 5H, CHCH2CH2SCH3 and 
CHCH2CH2SCH3), 1.61, 1.58 (2s, 3H, CH3 isopropylidene), 1.40, 1.39 (2s, 3H, CH3 
isopropylidene), 1.22-1.18 (m, 6H, OCH(CH3)2), 1.05, 1.02 (2s, 3H, 2’CCH3). 
 
Synthesis of 2’-C-!–methylguanosine 5’-O-["-Nnaphthyl-(isopropoxy-L-
methioninyl)] phosphate (4.13v). 
 
Prepared according t the Standard 
Procedure 5 from: 2’,3’-O,O-
isopropylidene-2’-C-!–methylguanosine 
5’-O-["-Naphthyl-(isopropoxy-L-
methioninyl)] phosphate (296.6mg, 0.414 
mmol) in 20 ml of 60%CH3COOH in 
water at 90°C overnight. The crude mixture was purified by column chromatography, 
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31P NMR (202 MHz, MeOD) ! 4.60, 4.57 
1H NMR (500 MHz, MeOD) ! 8.21–8.17 (m, 1H, H8-Naph), 7.93, 7.91 (2s, 1H, H8), 
7.85-7.80 (m, 1H, H5-Naph), 7.68-7.64 (m, 1H, H4-Naph), 7.55–7.46 (m, 3H, H7, H6, 
H2-Naph), 7.40-7.34 (m, 1H, H3-Naph), 5.96, 5.95 (2s, 1H, H1’), 4.90–4.85 (m, 1H, 
OCH(CH3)2), 4.71-4.59(m, 2H, H5’), 4.36- 4.24 (m, 2H, H3’, H4’), 4.10-4.03 (m, 1H, 
CHCH2CH2SCH3), 2.45–2.29   (m, 2H, CHCH2CH2SCH3), 1.96- 1.80 (m, 5H, 
CHCH2CH2SCH3 and CHCH2CH2SCH3), 1.15-1.11 (m, 6H, OCH(CH3)2), 1.02, 0.98 
(2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 173.99 (d, 3J C-C-N-P = 3.3, C=O), 173.70 (d, 3J C-C-N-P 
= 4.0 Hz, C=O), 159.56 (C6), 155.30, 155.26 (C2), 152.67 (C4), 148.00, 147.95 (2d, 
2J C-O-P = 7.0 Hz, ipso Naph), 138.02, 137.81 (C8), 136.28, 136.23 (C10-Naph), 
128.87, 128.84 (CH-Naph), 127.88, 127.87 (C9-Naph), 127.79, 127.54, 127.50, 
126.52, 125.98, 122.87, 122.83 (CH-Naph), 118.08 (C5), 116.29, 116.13 (2d, 3JC-C-O-P 
= 3.0 Hz, C2-Naph), 93.27, 93.19 (C1’), 82.28, 82.16 (2d, 3JC-C-O-P = 8.0 Hz, C4’), 
80.06, 80.02 (C2’), 74.76, 74.64 (C3’), 70.42, 70.39 (OCH(CH3)2), 68.12, 67.74 (2d, 
2JC-O-P = 5.0 Hz, C5’), 55.32, 55.23 (CHCH2CH2SCH3), 34.46 (d, 3JC-C-N-P = 6.6 Hz, 
CHCH2CH2SCH3), 34.23 (d, 3JC-C-N-P = 7.4 Hz, CHCH2CH2SCH3), 30.94, 30.87 
(CHCH2CH2SCH3), 21.98, 21.96 (OCH(CH3)2), 20.48 (2’CCH3), 15.24, 15.21 
(CHCH2CH2SCH3) 
HPLC (System 1) tR= 16.15, 16.45 min. 
HRMS calculated for C29H37N6O9PSNa: 699.1978; found. 699.1951.  
CHN calculated for C29H37N6O9PS + 1.0 H2O: C 50.14, H 5.66, N 12.10; found. C 
50.07, H 5.41, N 11.86. 
 
Synthesis of 2’-C-!–methylguanosine 5’-(L-alaninyl) phosphate diammonium salt 
(4.15). 
 
135 mg of 4.13g was dissolved in a mixture 
of water and triethylamine (1:1, 10.0 ml) and 
heated at 35 °C and stirred overnight. After 
that time TLC analysis indicated no traces of 
starting material. The reaction mixture was 
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propanol/water/ammonia (8:1:1) as an eluent. The pure compound was obtained as a 
white solid (63 mg, 62%). 
 
31P NMR (202 MHz, D2O) ! 7.20. 
1H NMR (500 MHz, D2O) ! 8.12 (s, 1H, H8), 5.83 (s, 1H, H1’), 4.19-4.07 (m, 4H, H5’, 
H4’ and H3’), 3.57 (q, J= 7.5 Hz, 1H, CHCH3), 1.24 (d, J= 7.5 Hz, 3H, CHCH3), 0.89 
(s, 3H, 2’CCH3). 
13C NMR (500 MHz, D2O) ! 182.68 (C=O), 158.79 (C6), 153.76 (C2), 151.00 (C4), 
137.11 (C8), 115.93 (C5), 90.57 (C1’), 80.90 (d, 3JC-C-O-P = 8.3 Hz, C4’), 79.34 (C2’), 
71.94 (3’), 62.50 (d, 2JC-O-P = 3.7 Hz, C5’), 52.31 (CHCH3), 21.27 (d, 3JC-C-O-P = 3.7 
Hz, CHCH3), 18.81 (2’CCH3). 
HPLC (System 1) tR= 1.83 min. 
MS (ES-) m/z: 446.11 (M, 100%).  
HRMS calculated for C14H20N6O9P: 447.1029; found. 447.1011.  
 
Synthesis of 2’-C-!–methylguanosine 5’-(L-valinyl) phosphate diammonium salt 
(4.16). 
 
147 mg of 4.13m was dissolved in a mixture 
of water and triethylamine (1:1, 10.0 ml) and 
heated at 35 °C and stirred overnight. After 
that time TLC analysis indicated no traces of 
starting material. The reaction mixture was 
evaporated to dryness and purified on silica gel, using a mixture of i-
propanol/water/ammonia (8:1:1) as an eluent. The pure compound was obtained as a 
white solid (69 mg, 63%). 
 
31P NMR (202 MHz, D2O) ! 7.51. 
1H NMR (500 MHz, D2O) ! 8.07 (s, 1H, H8), 5.82 (s, 1H, H1’), 4.17-4.02 (m, 4H, H5’, 
H4’ and H3’), 3.48 (d, J= 7.0 Hz, 1H, CHCH(CH3)2), 1.72-1.86 (m, 1H, 
CHCH(CH3)2), 0.94 (s, 3H, 2’CCH3), 0.87, 0.85 (2d, J= 6.0 Hz, 5H, CHCH(CH3)2). 
13C NMR (500 MHz, D2O) ! 181.43 (C=O), 158.90 (C6), 153.87 (C2), 152.01 (C4), 
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71.87 (3’), 62.36 (d, 2JC-O-P = 5.0 Hz, C5’), 48.89 (CHCH(CH3)2), 32.00 (d, 3JC-C-O-P = 
7.5 Hz, CHCH(CH3)2), 18.83, 18.62 (CHCH(CH3)2), 17.57 (2’CCH3). 
HPLC (System 1) tR= 1.85 min. 
MS (ES-) m: 474.15 (M-H+, 100%).  
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12.5 Experimental section - Chapter Five. 
 
Synthesis of 2-amino-6-chloro-9-(2’-C-methyl-2,3,5-tri-O-benzoyl-!-D-
ribofuranosyl) purine (5.2). 
 
To a pre-cooled (0 oC) suspension of 1,2,3,5-tetra-O-
benzoyl-2-C-methyl-!-D-ribofuranose (10.0 g, 17.22 
mmol), 2-amino-6-chloropurine (3.2 g, 18.87 mmol), 
and 1,8-diazabicycl[5.4.0]undec-7-ene (DBU) (7.7 ml, 
51 mmol) in anhydrous acetonitrile (200 ml) 
trimethysilyl triflate (12.5 ml, 68.8 mmol) was added dropwise. The reaction mixture 
was heated at 65oC for 4 to 6 hours, allowed to cool down to room temperature, 
poured into saturated aqueous sodium bicarbonate (300 ml), and extracted with 
dichloromethane (3x 150 ml). The combined organic phase was dried over sodium 
sulfate and evaporated under reduced pressure. The residue was precipitated from 
dichloromethane and methanol. Precipitate was filtered and washed with methanol, to 
give the desired compound (8.5 g, 79 %) as a white solid. 
 
1H NMR (500 MHz, CDCl3) ! 8.17-8.14 (m, 2H, Bn), 8.03–7.98 (m, 4H, Bn), 8.02 (s, 
1H, H8), 7.65–7.60 (m, 1H, Bn), 7.58-7.45 (m, 3H, Bn), 7.41-7.36 (m, 4H, Bn), 6.65 
(s, 1H, H1’), 6.40 (d, J= 6.5 Hz, 1H, H3’), 5.31 (s, 2H, NH2), 5.08-4.82 (m, 2H, H5’), 
4.78- 4.75 (m, 1H, H4’), 1.60 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, CDCl3) ! 166.31 (C=O), 165.38 (C=O), 165.32 (C=O), 159.13 
(C2), 152.87 (C6), 152.06 (C4), 141.42 (C8), 133.77, 133.69, 133.28, 129.90, 129.82 
(CH Bn), 129.78 (ipso Bn), 129.70 (CH Bn), 129.41 (ipso Bn), 128.78 (ipso Bn), 
128.61, 128.50, 128.41 (CH Bn), 126.00 (C5), 88.84 (C1’), 85.68 (C2’), 79.43 (C4’), 
76.07 (C3’), 63.57 (C5’), 17.77 (2’CCH3). 
 
Synthesis of 2-amino-6-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.3). 
 
2-amino-6-chloro-9-(2’-C-methyl-2,3,5-tri-O-benzoyl-
!-D-ribofuranosyl) purine (5.2, 2.00 g, 3.18 mmol) was 
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cooled down to 0 °C. After that solution was saturated with ammonia and 
immediately sealed. Reaction mixture was allowed to warm to ambient temperature 
and reaction mixture was stirred overnight. After that time solvents were evaporated 
under reduced pressure and crude mixture was purified on silica gel, using 
CHCl3/MeOH (9:1) as eluent. Pure compound 5.3 was obtained as white solid (0.92 
mg, 90%). 
 
1H NMR (500 MHz, DMSO) ! 8.19 (s, 1H, H8), 7.00 (bs, 2H, NH2), 5.85 (s, 1H, H1’), 
5.27 (d, J= 7.0 Hz, 1H, 3’OH), 5.19 (t, J= 5.0 Hz, 1H, 5’OH), 5.17 (s, 1H, 2’OH), 
4.02 (dd, J= 9.0 Hz, J= 7.0 Hz 1H, H3’), 3.91-3.81 (m, 2H, H4’ and H5’a), 3.71- 3.68 
(m, 1H, H5’b), 0.83 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, DMSO) ! 159.84 (C2), 153.56 (C6), 149.51 (C4), 140.64 (C8), 
123.22 (C5), 90.42 (C1’), 82.59 (C4’), 78.52 (C2’), 71.63 (C3’), 59.34 (C5’), 19.91 
(2’CCH3). 
HPLC (System 1) tR = 9.01 min. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.4). 
 
To a suspension of 2-amino-6-chloro-9-(2’-C-methyl-
2,3,5-tri-O-benzoyl-!-D-ribofuranosyl)purine (5.2, 3.0 
g, 4.78 mmol) in anhydrous methanol (36 ml) at 0 oC 
NaOMe in methanol (5.4 ml, 25% w/w) was added. 
The mixture was stirred at room temperature for 24 
hours then quenched by addition of amberlite (H+). The 
mixture was then filtrated and solvent was removed under reduced pressure. The 
residue was purified by silica gel chromatography (CHCl3/MeOH, 85:15) to give the 
pure compound 5.4 (1.125g, 76 %) as a white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.26 (s, 1H, H8), 5.99 (s, 1H, H1’), 4.24 (d, J= 9.0 Hz, 
1H, H3’), 4.09 (s, 3H, 6OCH3), 4.05-4.02 (m, 2H, H4’ and H5’a), 3.87-3.83 (m, 1H, 
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13C NMR (126 MHz, MeOD) ! 162.75 (C6), 161.86 (C2), 154.50 (C4), 139.35 (C8), 
115.36 (C5), 93.00 (C1’), 84.15 (C4'), 80.34 (C2’), 73.57 (C3’), 61.17 (C5’), 54.25 
(6OCH3), 20.35 (2’CCH3). 
HPLC (System 1) tR = 8.73 min. 
HRMS calculated for C12H17N5O5 Na: 334.1127, found 334.1125 
CHN calculated for C12H17N5O5+ 0.75 H2O: C 44.37, H 5.74, N 21.56; found: C 
44.24, H 5.49, N 21.13. 
 
Synthesis of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.5). 
 
To a suspension of 2-amino-6-chloro-9-(2’-C-methyl-
2,3,5-tri-O-benzoyl-!-D-ribofuranosyl)purine (5.2, 2.0 
g, 3.19 mmol) in anhydrous ethanol (24 ml) at 0 oC, 
NaOEt in ethanol (1.95 g in 4.9 ml, 9 mol equivalents) 
was added. The mixture was stirred at 50 oC for 5 
hours, cooled down to room temperature, filtrated and 
neutralised by addition of amberlite (H+). The mixture was then filtrated and solvent 
was removed under reduced pressure. The residue was purified by silica gel 
chromatography (CHCl3/MeOH, 85:15) to give the pure compound (0.87 g, 84 %) as 
a white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.25 (s, 1H, H8), 5.99 (s, 1H, H1’), 4.56 (q, J= 7.1 Hz, 
2H, 6OCH2CH3), 4.24 (d, J= 9.1 Hz, 1H, H3’), 4.05-4.02 (m, 2H, H4’ and H5’), 3.87-
3.85 (m, 1H, H5’), 1.46 (t, J= 7.1 Hz, 3H, 6OCH2CH3), 0.96 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 162.42 (C6), 161.84 (C2), 154.53 (C4), 139.39 (C8), 
115.65 (C5), 93.32 (C1’), 82.98 (C4'), 80.05 (C2’), 73.97 (C3’), 64.25 (6OCH2CH3), 
61.15 (C5’), 20.35 (2’CCH3), 14.92(6OCH2CH3). 
HPLC (System 1) tR = 10.55 min.  
MS (TOF AP+) m/z: 326.15 (MH+, 100%).  
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Synthesis of 2-amino-6-N-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.6). 
 
To a suspension of 2-amino-6-chloro-9-(2’-C-methyl-
2,3,5-tri-O-benzoyl-!-D-ribofuranosyl)purine (5.2, 
0.50 g, 0.80 mmol) in anhydrous methanol (10 ml) in 
sealed tube, was added methyl amine (4 ml, 4.8 mmol) 
and triethylamine (0.57 ml, 4.8 mmol). The reaction 
mixture was stirred at 85 oC overnight. After cooling to room temperature, solvents 
were evaporated and filtrated and the residue was purified by silica gel 
chromatography (CHCl3/MeOH, 9:1) to give the pure compound 5.6 (0.20 g, 90 %) as 
a white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.06 (s, 1H, H8), 5.95 (s, 1H, H1’), 4.25 (d, J= 9.0 Hz, 
1H, H3’), 4.05-4.02 (m, 2H, H4’ and H5’a), 3.87-3.83 (m, 1H, H5’b), 3.69 (s, 3H, 
6NCH3), 0.96 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 161.83(C6), 160.97 (C2), 152.71 (C4), 139.41 (C8), 
119.42 (C5), 93.27 (C1’), 84.17 (C4'), 80.31 (C2’), 73.59 (C3’), 62.27 (C5’), 27.78 
(6NCH3), 20.37 (2’CCH3). 
HPLC (System 1) tR = 7.99 min. 
HRMS calculated for C12H18N6O4 Na: 333.1378, found 333.1325 
 
Synthesis of 2-amino-6-N-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.7). 
 
To a solustion of 2-amino-6-chloro-9-(2’-C-methyl-
2,3,5-tri-O-benzoyl-!-D-ribofuranosyl)purine (5.2, 
2.00 g, 3.19 mmol) in dry DMF (30 ml) was aqueous 
solution of sodium methanethiolate (1.24 g in 6 ml of 
H2O, 19.15 mmol. The reaction mixture was stirred at 
ambient temperature for 2 h, after that time mixture 
was diluted with water (50 ml) and extracted 3x with EtOAc (3x 20 ml). Combined 
organic fractions were dried over anhydrous MgSO4 and evaporated to dryness under 
reduced pressure. The residue was purified by silica gel chromatography 
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1H NMR (500 MHz, MeOD) ! 8.32 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.22 (d, J= 9.0 Hz, 
1H, H3’), 4.06-4.02 (m, 2H, H4’ and H5’a), 3.89-3.88 (m, 1H, H5’b), 2.63 (s, 3H, 
6SCH3), 0.97 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 164.08 (C6), 163.30 (C2), 151.14 (C4), 140.00 (C8), 
125.46 (C5), 92.85 (C1’), 84.20 (C4'), 80.33 (C2’), 73.56 (C3’), 61.15 (C5’), 20.35 
(2’CCH3), 11.47 (6SCH3). 
HPLC (System 1) tR = 9.96 min. 
HRMS calculated for C12H17N5O4S Na: 350.0968, found 350.0945. 
 
Synthesis of 2-amino-6-O-(3-methoxypropyl)-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (5.8). 
 
To a solution of 3-methoxy-1-propanol (ml, 1.17 
mmol) in dry THF (10 ml), sodium hydride (1.17 
mmol) was added at 0 °C. Reaction was allowed 
to warm to ambient temperature and was stirred 
for 30 min, after that time a solution of 2-amino-6-
chloro-9-(2’-C-methyl-!-D-ribofuranosyl) purine (5.3, 0.12 g, 0.38 mmol) in dry THF 
(10 ml) was added dropwise. The reaction mixture was stirred at ambient temperature 
for 8h. After that time reaction was neutralised by the addition of amberlite (H+). The 
mixture was then filtrated and solvent was removed under reduced pressure. The 
residue was purified by silica gel chromatography (CHCl3/MeOH, 85:15) to give the 
pure compound 5.8 (73 mg, 50 %) as a white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.27 (s, 1H, H8), 6.01 (s, 1H, H1’), 4.57 (t, J= 6.5 Hz, 
2H, 6OCH2CH2CH2OCH3), 4.24 (d, J= 9.0 Hz, 1H, H3’), 4.08-4.02 (m, 2H, H4’ and 
H5’a), 3.89-3.86 (m, 1H, H5’b), 3.61 (t, J= 6.5 Hz, 2H, 6OCH2CH2CH2OCH3),  3.37 (s, 
3H, 6OCH2CH2CH2OCH3), 2.13-2.08 (m, 2H, 6OCH2CH2CH2OCH3), 0.96 (s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) ! 162.40 (C6), 161.84 (C2), 154.60 (C4), 139.35 (C8), 
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(6OCH2CH2CH2OCH3), 61.16 (6OCH2CH2CH2OCH3), 61.16 (C5’), 58.91 
(6OCH2CH2CH2OCH3), 30.23 (6OCH2CH2CH2OCH3), 20.35 (2’CCH3). 
HPLC (System 1) tR = 10.42 min.  
HRMS Calculated for C15H23N5O6Na 392.1574; found: 392.1512. 
 
Synthesis of 2-amino-6-NH-(benzyl)-9-(2’-C-methyl-2,3,5-tri-O-benzoyl-!-D-
ribofuranosyl) purine (5.9). 
 
To a suspension of 2-amino-6-chloro-9-(2’-C-
methyl-2,3,5-tri-O-benzoyl-!-D-ribofuranosyl)purine 
(5.2, 1.0 g, 1.60 mmol) in anhydrous ethanol (100 
ml), at room temperature, benzylamine (1.75 ml, 10 
equiv.) was added. The mixture was stirred under 
reflux overnight, cooled down to room temperature 
and ethanol was removed under reduced pressure. The residue was then precipitated 
from CHCl3/MeOH to give the pure compound 5.9 (0.57 g, 91 %) as a white solid. 
 
1H NMR (500 MHz, DMSO) ! 8.03 (s, 1H, H8), 7.36 (d, J= 7.5 Hz, 2H, 6NHCH2Ph), 
7.30 (t, J= 7.5 Hz, 2H, 6NHCH2Ph), 7.21 (t, J= 7.5 Hz, 1H, 6NHCH2Ph), 5.86 (s, 2H, 
NH2), 5.80 (s, 1H, H1’), 5.18-5.14 (m, 2H, 3’OH and 5’OH), 5.01 (s, 1H, 2’OH), 4.68-
4.62 (m, 2H, 6NHCH2Ph), 4.02 (d, J= 8.1 Hz, 1H, H3’), 3.88-3.85 (m, 2H, H4’ and 
H5’a), 3.75–3.58 (m, 1H, H5’b), 0.81 (s, 3H, CH3). 
HPLC (System 1) tR = 12.61 min.  





To a suspension of 2-amino-6-chloro-9-(2-C-
methyl-2,3,5-tri-O-benzoyl-!-D-
ribofuranosyl)purine (1.00 g, 1.60 mmol) in 
anhydrous ethanol (100 ml), at room temperature, 
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mmol). The mixture was stirred under reflux overnight, cooled down to room 
temperature. Ethanol was removed under reduced pressure. The residue was then 
precipitated from CHCl3/MeOH to give the pure compound 5.10' (0.626 g, 55 %) as a 
white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.12 (d, J = 7.2 Hz, 2H, Bz), 8.03 (d, J = 7.2 Hz, 2H, 
Bz), 7.96 (d, J = 7.3 Hz, 2H, Bz), 7.90 (s, 1H, H8), 7.65 (t, J = 7.5 Hz, 1H, Bz), 7.58 – 
7.52 (m, 2H, Bz), 7.53 (t, J = 7.8 Hz, 2H, Bz), 7.43 (t, J = 7.8 Hz, 2H, Bz), 7.39 (t, J = 
7.8 Hz, 2H, Bz), 7.35-7.26 (m, 5H, 6NHCH2CH2Ph), 6.65 (s, 1H, H1’), 6.28 (d, J = 
6.00Hz, 1H, H3’), 5.05-5.02 (m, 1H, H5’a), 4.84 – 4.67 (m, 3H, H5’b, H4’), 3.95–3.89 
(m, 2H, 6NHCH2CH2Ph), 3.01 (t, J = 7.0 Hz, 2H, 6NHCH2CH2Ph) 1.65 (s, 3H, 
2’CCH3). 
 
Synthesis of 2-amino-6-NH-(phenylethyl)-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (5.10). 
 
To a solution of protected nucleoside 5.10’ (0.628 
g, 0.88 mmol) in anhydrous methanol (10 ml) at 
room temperature was added sodium methoxide 
(0.15 g, 2.82 mmol). After being stirred for 2 
hours, the solvent was removed under reduced 
pressure and the residue chromatographied on 
silica gel (CHCl3/MeOH, 92:8) to yield the pure unprotected nucleoside (0.332 g, 94 
%) as a white solid. 
 
1H NMR (500 MHz, MeOD) ! 8.20 (s, 1H, H8), 7.32 – 7.19 (m, 5H, 6NHCH2CH2Ph), 
5.96 (s, 1H, H1’), 4.29 (d, J = 8.0 Hz, 1H, H3’), 4.13–4.05 (m, 3H, H4’ and H5’a), 3.95 – 
3.85 (m, 2H, 6NHCH2CH2Ph), 3.04 (t, J = 7.0 Hz, 2H, 6NHCH2CH2Ph) 0.97 (s, 3H, 
2’CCH3). 
HPLC  (System 1) tR = 13.55 min.  
HRMS calculated for C19H24N6O4Na: 423.1757; found 423.1763 
CHN calculated for C19H24N6O4 + 3.5 H2O: C 49.24, H 6.74, N 18.13; found: C 
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Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (2.15, INX-189). 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 584 mg, 1.88 mmol), !-naphthyl-
(2,2-dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 2.16 g, 5.63 
mmol), NMI (0.74 ml, 9.38 mmol) in 15 ml of dry THF. Crude mixture was purified 
by column chromatography, using CHCl3/MeOH (0 to 5%, gradient). To give a pure 
product 2.15 as white foam (139 mg, 11%). 
 
31P NMR (202 MHz, MeOD) " 4.33, 4.29. 
1H NMR (500 MHz, MeOD) " 8.19-8.15 (m, 1H, H8-naph), 7.98, 7.96 (2s, 1H, H8), 
7.86-7.82 (m, 1H, H5-Naph), 7.68, 7.65 (2d, J= 7.0 Hz, 1H, H4-Naph), 7.53–7.44 (m, 
3H, H2, H7, H6-Naph), 7.39, 7.37 (2t, J= 8.0 Hz, 1H, H3-Naph), 6.01, 6.00 (2s, 1H, 
H1’), 4.67-4.64 (m, 2H, H5’), 4.63-4.59 (m, 2H, H3’, H4’), 4.09–4.05 (m, 1H, CHCH3), 
4.04 (s, 3H, 6OCH3), 3.75, 3.72, 3.64, 3.58 (2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 
1.33 (d, J= 7.5 Hz, 3H, CHCH3), 0.98, 0.96 (2s, 3H, 2’CCH3),  0.85, 0.84 (2s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) " 175.06, 174.80 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.73 
(C6), 161.86 (C2), 154.55, 154.51 (C4), 148.00, 147.95 (d, 2JC-O-P = 3.8 Hz, ipso 
Naph), 139.36, 139.08 (C8), 136.27, 136.25 (C10-Naph), 128.86, 128.80 (CH-Naph), 
127.88, 127.73 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.48, 126.53, 126.49, 125.97, 
122.81, 122.76 (CH-Naph), 116.24, 116.22 (C2-Naph), 116.19, 115.63 (C5), 93.34, 
93.18 (C1’), 82.32, 82.16 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.99, 79.95 (C2’), 75.52, 
75.37 (OCH2C(CH3)3), 74.95, 74.70 (C3’), 68.11, 67.62 (2d, 2JC-O-P = 5.0 Hz, C5’), 
54.28, 54.07 (6OCH3), 51.79, 51.71 (C"CH3), 32.26, 32.22 (OCH2C(CH3)3), 26.74, 
26.71 (OCH2C(CH3)3), 20.89, 20.69 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.39, 20.35 
(2’CCH3). 
HPLC ( System 1) tR = 20.95, 21.48 min 
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Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-
O-[!-naphthyl-(cyclopentoxy-L-alaninyl)] phosphate (5.12a). 
 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(5.4, 2’-C-methyl-!-D-ribofuranosyl) 
purine (250 mg, 0.80 mmol), !-naphthyl-
(cyclopentoxy-L-alaninyl) 
phosphorochloridate (3.3h, 920 mg, 2.40 
mmol), NMI (0.47 ml, 4.02 mmol) in 5 ml of dry THF. Crude mixture was purified by 
column chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure 
product 5.12a, as white foam (75 mg, 14%). 
 
31P NMR (202 MHz, MeOD) " 4.36, 4.20. 
1H NMR (500 MHz, MeOD) " 8.19- 8.15 (m, 1H, H8-naph), 7.98, 7.96 (2s, 1H, H8), 
7.86–7.82 (m, 1H, H5-Naph), 7.68, 7.65 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53–7.44 (m, 
3H, H2, H7, H6-Naph), 7.39, 7.37 (2t, J= 8.0 Hz,1H, H3-Naph), 6.02, 6.00 (2s, 1H, 
H1’), 5.00-4.97 (m, 1H, OCH ester), 4.66- 4.58 (m, 2H, H5’), 4.37- 4.24 (m, 2H, H3’, 
H4’), 4.04 (s, 3H, 6OCH3), 4.01- 3.93 (m, 1H, CHCH3), 1.78- 1.69 (m, 2H, CH2 ester), 
1.60- 1.47 (m, 6H, 3x CH2 ester), 1.28 (d, J= 7.0 Hz, 3H, CHCH3), 0.98, 0.96 (2s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 174.87, 174.62 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.73 
(C6), 161.86 (C2), 154.55, 154.50 (C4), 148.01, 147.95 (d, 2JC-O-P = 3.8 Hz, ipso 
Naph), 139.38, 139.08 (C8), 136.27, 136.24 (C10-Naph), 128.86, 128.81 (CH-Naph), 
127.86, 127.78 (2d, 3JC-C-O-P = 5.0 Hz, C9-Naph),127.73, 127.47, 126.52, 126.48, 
125.96, 125.93, 122.78, 122.74 (CH-Naph), 116.21, 116.13 (2d, 3JC-C-O-P = 3.8 Hz, 
C2-Naph), 115.63, 115.60 (C5), 93.37, 93.19 (C1’), 82.31, 82.16 (2d, 3JC-C-O-P = 8.8 
Hz, C4’), 80.00, 79.96 (C2’), 79.52, 79.50 (OCH ester), 74.95, 74.71 (C3’), 68.06, 
67.59 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.30, 54.29 (6OCH3), 51.81, 51.75 (CHCH3) 33.52, 
33.39 (CH2 ester), 24.60, 24.58 (CH2 ester), 20.67, 20.63 (2d, 3JC-C-N-P = 6.3 Hz, 
CHCH3), 20.44, 20.36 (2’CCH3). 
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MS (ES+) m/z: 657.24 (MH+, 100%) 
HRMS calculated for C30H39N6O9PNa: 681.2457; found 681.2472. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(cyclohexoxy-L-alaninyl)] phosphate (5.12d). 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(980mg, 3.15 mmol), !-naphthyl-
(cyclohexoxy-L-alaninyl) 
phosphorochloridate (3.3i, 3.82 g, 9.44 
mmol), NMI (1.25 ml, 15.74 mmol) in 5 ml of dry THF. Crude mixture was purified 
by column chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure 
product 5.12b as white foam (730 mg, 14%). 
 
31P NMR (202 MHz, MeOD) " 4.34, 4.26. 
1H NMR (500 MHz, MeOD) " 8.19-8.15 (m, 1H, H8-naph), 7.98, 7.96 (2s, 1H, H8), 
7.84-7.82 (m, 1H, H5-Naph), 7.67, 7.65 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53-7.44 (m, 
3H, H2, H7, H6-Naph), 7.41-7.36 (m, 1H, H3-Naph), 6.02, 6.00 (2s, 1H, H1’), 4.69- 
4.60 (m, 3H, CH ester and H5’), 4.35- 4.29 (m, 2H, H3’, H4’), 4.04 (s, 3H, 6OCH3), 
4.00 (q, J= 7.8 Hz, 1H, CHCH3), 1.69- 1.60 (m, 4H, 2x CH2 ester), 1.31- 1.19 (m, 9H, 
3x CH2 ester and CHCH3), 0.98, 0.96 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 174.51, 174.25 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.72 
(C6), 161.86 (C2), 154.55, 154.50 (C4), 148.03, 148.01 (d, 2JC-O-P = 3.8 Hz, ipso 
Naph), 139.33, 139.05 (C8), 136.28, 136.25 (C10-Naph), 128.85, 128.79 (CH-Naph), 
127.88, 127.73 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.46, 126.82, 126.53, 126.48, 
125.95, 125.91, 122.81, 122.76, 122.27 (CH-Naph), 116.21, 116.12 (2d, 3JC-C-O-P = 
3.8 Hz, C2-Naph), 115.62, 115.59 (C5), 93.35, 93.17 (C1’), 82.31, 82.15 (2d, 3JC-C-O-P 
= 8.8 Hz, C4’), 79.99, 79.96 (C2’), 74.94, 74.92 (CH ester), 74.95, 74.71 (C3’), 68.05, 
67.56 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.29 (6OCH3), 51.85, 51.79 (C" Ala), 32.35, 32.39 
(CH2 ester), 26.35 (CH2 ester), 24.57 (CH2 ester), 20.81, 20.60 (2d, 3JC-C-N-P = 6.3 Hz, 
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HPLC (System 1) tR = 21.28, 21.83 min. 
MS (ES+) m/z: 671.26 (MH+, 100%).  
HRMS calculated for C31H40N6O9P1: 671.2594, found 671.2584. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-
O-[!-naphthyl-(benzoxy -L-alaninyl)] phosphate (4.4e). 
 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 150 mg, 0.482 mmol), !-naphthyl-
(benzoxy-L-alaninyl) phosphorochloridate 
(3.3k, 584 mg, 1.44 mmol), NMI (0.19 ml, 
2.41 mmol) in 5 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (0 to 5%, 
gradient), to give a pure product as white foam (5.12c, 45 mg, 14%). 
 
31P NMR (202 MHz, MeOD) " 4.27, 4.26. 
1H NMR (500 MHz, MeOD) " 8.17, 8.15 (2d, J= 7.5 Hz, 1H, H8-Naph), 7.97, 7.93 
(2s, 1H, H8), 7.89–7.85 (m, 1H, H5-Naph), 7.69, 7.67 (2d, J= 8.5 Hz, 1H, H4-Naph), 
7.54–7.44 (m, 3H, H2, H7, H6-Naph), 7.37, 7.36 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.28– 
7.23 (m, 5H, OCH2Ph), 5.99, 5.98 (2s, 1H, H1’), 5.06- 4.95 (m, 2H, OCH2Ph), 4.61– 
4.56 (m, 2H, H5’), 4.34, 4.27 (2d, J= 9.0 Hz, 1H, H3’), 4.25- 4.21 (m, 1H, H4’), 4.10 – 
4.06 (m, 1H, CHCH3), 4.04, 4.03 (2s, 3H, 6OCH3), 1.30, 1.29 (2d, J= 7.0 Hz, 
CHCH3), 0.98, 0.95 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 174.85 (d, 3J C-C-N-P = 4.4, C=O), 174.62 (d, 3J C-C-N-P 
= 5.5, C=O), 162.74 (C6), 161.83 (C2), 154.56, 154.51 (C4), 147.99, 147.86 (2d, 2JC-
O-P = 1.9 Hz, ipso Naph), 139.31, 139.04 (C8), 137.08 (ipso OCH2Ph), 136.24, 136.22 
(C10-Naph), 129.54, 129.26, 129.25, 129.17, 129.12, 128.87, 128.83 (CH-Naph and 
OCH2Ph), 127.90, 17.85 (2d, 3JC-C-O-P = 4.1, C9-Naph), 127.77 (CH-Naph), 127.53, 
126.56, 126.53, 126.00, 122.83, 122.76 (CH-Naph and OCH2Ph), 116.28, 116.27 
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Hz, C4’), 80.03, 79.99 (C2’), 79.53 (6OCH3), 74.96, 74.64 (C3’), 68.03 (d, 2JC-O-P = 
4.7 Hz, C5’), 67.98, 67.96 (OCH2Ph), 67.48, 67.12 (2d, 2JC-O-P = 5.0 Hz, C5’), 51.84, 
51.75 (CHCH3), 20.87 (d, 3JC-C-N-P = 6.1 Hz, CHCH3), 20.68 (d, 3JC-C-N-P = 4.6, 
CHCH3), 20.36, 20.33 (2’CCH3). 
HPLC (System 1) tR = 18.51, 18.92 min. 
MS (ES+) m/z: 701.21 (MNa+, 100%).  
HRMS calculated for C32H35N6O9P1Na: 701.2101, found 701.2119. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(propoxy-L-alaninyl)] phosphate (5.12d). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.803 mmol), !-naphthyl-
(propoxy-L-alaninyl) phosphorochloridate 
(3.3c, 571 mg, 1.60 mmol), tBuMgCl 
(1.61 ml, 1.61 mmol) in 5 ml of dry THF. 
The crude mixture was purified by column chromatography, using CHCl3/MeOH (0 
to 5%, gradient), to give a pure product 5.12d as white foam (163 mg, 32%). 
 
31P NMR (202 MHz, MeOD) " 4.33, 4.22. 
1H NMR (500 MHz, MeOD) " 8.19–8.15 (m, 1H, H8-naph), 7.99, 7.97 (2s, 1H, H8), 
7.90- 7.82 (m, 1H, H5-Naph), 7.68, 7.65 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.54–7.45 (m, 
3H, H2, H7, H6-Naph), 7.38, 7.36 (2t, J= 8.0 Hz, 1H, H3-Naph), 6.04, 6.03 (2s, 1H, 
H1’), 4.70- 4.61 (m, 2H, H5’), 4.37- 4.26 (m, 2H, H3’, H4’), 4.10- 4.04 (m, 1H, 
CHCH3), 4.03 (s, 3H, 6OCH3),  3.95 – 3.84 (m, 2H, OCH2CH2CH3), 1.53- 1.45 (m, 
2H, OCH2CH2CH3), 1.31 (d, J= 7.0 Hz, 3H, CHCH3), 0.99, 0.97 (2s, 3H, 2’CCH3), 
0.82 (t, J= 7.5 Hz, 3H, OCH2CH2CH3). 
13C NMR (126 MHz, MeOD) " 175.13, 174.89 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.75 
(C6), 161.84 (C2), 156.56, 154.52 (C4), 148.02, 147.96 (2d, 2JC-O-P = 3.0 Hz, ipso 
Naph), 139.33, 139.07 (C8), 136.25, 136.22 (C10-Naph), 128.86, 128.82, (CH-Naph), 
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125.95, 122.81, 122.76 (CH-Naph), 116.24, 116.17 (2d, 3JC-C-O-P = 4.5 Hz, C2-Naph), 
115.67, 115.66 (C5), 93.32, 93.17 (C1’), 82.30, 82.16 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 
80.04, 80.01 (C2’), 74.94, 74.71 (C3’), 68.00 (OCH2CH2CH3), 67.87, 67.54 (d, 2JC-O-P 
= 5.0 Hz, C5’), 54.36 (6OCH3), 51.77, 51.17 (C!C!3), 20.84, 20.62 (2d, 3JC-C-N-P = 
6.3 Hz, CHCH3), 20.46, 20.44 (2’CCH3), 10.67, 10.65 (OCH2CH2CH3). 
HPLC (System 1) tR = 18.51, 18.95 min. 
HPLC (System 2) tR = 24.63, 25.49 min. 
MS (ES+) m/z: 653.20 (MNa+, 100%).  
HRMS calculated for C30H36N6O9P1Na: 653.2101, found 653.2073. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(3,3-dimethyl-1-butoxy-L-alaninyl)] phosphate (5.12e). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-"-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.803 mmol), !-naphthyl-
(3,3-dimethyl-1-butoxy-L-alaninyl) 
phosphorochloridate (3.3f, 640 mg, 1.60 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 
5 ml of dry THF. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (95:5), to give a pure product 5.12e, as white foam (190 mg, 35%). 
 
31P NMR (202 MHz, MeOD) " 4.33, 4.29. 
1H NMR (500 MHz, MeOD) " 8.20- 8.16 (m, 1H, H8-naph), 8.00, 7.98 (2s, 1H, H8), 
7.85- 7.81 (m, 1H, H5-Naph), 7.66, 7.64 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.54– 7.45 (m, 
3H, H2, H7, H6-Naph), 7.39, 7.37 (2t, J= 8.0 Hz, 1H, H3-Naph), 6.04, 6.03 (2s, 1H, 
H1’), 4.71- 4.61 (m, 1H, H5’), 4.36- 4.27 (m, 1H, H3’, H4’), 4.03 (s, 3H, 6OCH3), 4.02 
– 3.91 (m, 2H, CHCH3 and OCH2CH2C(CH3)3), 1.39-1.29 (m, 5H, CHCH3 and 
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13C NMR (126 MHz, MeOD) ! 175.06, 174.80 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.73 
(C6), 161.86 (C2), 154.55, 154.51 (C4), 148.00, 147.95 (d, 2JC-O-P = 3.8 Hz, ipso 
Naph), 139.36, 139.08 (C8), 136.27, 136.25 (C10-Naph), 128.86, 128.80 (CH-Naph), 
127.88, 127.73 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.78, 127.76, 127.51, 126.51, 
125.53, 125.98, 125.93, 122.83, 122.79 (CH-Naph), 116.22, 116.09 (2d, 3JC-C-O-P = 
3.8 Hz, C2-Naph), 115.67 (C5), 93.30, 93.16 (C1’), 82.29, 82.15 (2d, 3JC-C-O-P = 8.8 
Hz, C4’), 80.06, 80.03 (C2’), 74.90, 74.67 (C3’), 67.97, 67.50 (2d, 2JC-O-P = 5.0 Hz, 
C5’), 64.01, 63.99 (OCH2CH2C(CH3)3), 54.37, 54.35 (6OCH3), 51.74, 51.71 
(CHCH3), 42.67, 42.60 (OCH2CH2C(CH3)3), 30.08, 30.00 (OCH2CH2C(CH3)3), 
20.73, 20.52 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.46, 20.44 (2’CCH3). 
HPLC (System 1) tR = 22.03, 22.49 min 
MS (ES+) m/z: 695.27 (MNa+, 100%).  
HRMS calculated for C31H42N6O9P1: 673.2751, found 673.2752. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(3,3-dimethyl-2-butoxy-L-alaninyl)] phosphate (5.12f). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-
9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (5.4, 250 mg, 0.80 mmol), "-
naphthyl-(3,3-dimethyl-2-butoxy-L-
alaninyl) phosphorochloridate (3.3g, 
960mg, 1.60 mmol), tBuMgCl (1.61 ml, 
1.61 mmol) in 5 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (95:5), to give a pure product 5.12f as a white 
foam (195 mg, 36%). 
 
31P NMR (202 MHz, CDCl3) ! 4.33, 4.29. 
1H NMR (500 MHz, MeOD) ! 8.19- 8.15 (m, 1H, H8-naph), 7.99, 7.98, 7.96 (3s, 1H, 
H8), 7.86- 7.80 (m, 1H, H5-Naph), 7.67- 7.63 (m, 1H, H4-Naph), 7.53 – 7.46 (m, 3H, 
H2, H7, H6-Naph), 7.39- 7.34 (m, 1H, H3-Naph), 6.01, 6.00 (2s, 1H, H1’), 4.69- 4.57 
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1H, H!), 4.03 (s, 3H, 6OCH3), 1.33, 1.31 (2d, J= 7.0 Hz, 3H, CHCH3), 1.05- 0.98 (m, 
3H, OCH(CH3)C(CH3)3) 0.95, 0.94, 0.91 (3s, 3H, 2’CCH3),  0.84, 0.83, 0.80, 0.79 
(4s, 9H, OCH(CH3)C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.06, 174.80 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.73 
(C6), 161.86 (C2), 154.55, 154.51 (C4), 148.00, 147.95 (d, 2JC-O-P = 3.8 Hz, ipso 
Naph), 139.36, 139.08 (C8), 136.27, 136.25 (C10-Naph), 128.86, 128.80 (CH-Naph), 
127.88, 127.73 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.48, 126.55, 126.49, 125.98, 
122.84, 122.79 (CH-Naph), 116.28, 116.23 (C2-Naph), 116.20, 115.68 (C5), 93.35, 
93.19 (C1’), 82.32, 82.17 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.16, 80.07 
(OCH(CH3)C(CH3)3), 80.01, 79.98 (C2’), 75.52, 75.37 (OCH(CH3)C(CH3)3), 75.00, 
74.75 (C3’), 68.09 (d, 2JC-O-P = 5.0 Hz, C5’), 67.66 (C5’), 54.28 (6OCH3), 51.94, 
51.87 (d, 2JC-N-P = 7.5 Hz, CHCH3), 35.16, 35.14, 35.07, 35.03 (OCH(CH3)C(CH3)3), 
21.05, 20.69 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.39, 20.35 (2’CCH3), 15.27, 15.19, 
15.13, 15.07 (OCH(CH3)C(CH3)3). 
HPLC (System 1) tR= 21.73 min. 
HPLC (System 2) tR= 28.21, 28.91 min. 
MS (ES+) m/z: 695.26 (MNa+, 100%).  
HRMS calculated for C31H42N6O9P1Na: 695.2570, found 695.2551. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(tetrahydropyroxy-L-alaninyl)] phosphate (5.12g). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-"-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), "-naphthyl-
(tetrahydropyroxy-L-alaninyl) 
phosphorochloridate (3.3j, 640 mg, 1.60 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 
5 ml of dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (95:5), to give a pure product 5.12g as a white foam (142 mg, 26%). 
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1H NMR (500 MHz, MeOD) ! 8.19- 8.16 (m, 1H, H8-naph), 7.99, 7.96 (2s, 1H, H8), 
7.87– 7.82 (m, 1H, H5-Naph), 7.68, 7.66 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.58 – 7.45 
(m, 3H, H2, H7, H6-Naph), 7.40, 7.38  (2t, J= 8.0 Hz,1H, H3-Naph), 6.02, 6.00 (2s, 
1H, H1’), 4.81- 4.73 (m, 1H, OCH ester), 4.69- 4.58 (m, 2H, H5’), 4.36- 4.24 (m, 2H, 
H3’, H4’), 4.07- 3.99 (m, 1H, CHCH3), 4.05, 4.04 (2s, 3H, 6OCH3), 3.80- 3.73 (m, 2H, 
CH2 ester ), 3.47- 3.39 (m, 2H, CH2 ester), 1.79- 1.70 (m, 2H, CH2 ester), 1.54- 1.44 
(m, 2H, CH2 ester), 1.32, 1.30 (2d, J= 6.5 Hz, 3H, CHCH3), 0.98, 0.97 (2s, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.31, 174.07 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.73 
(C6), 161.89, 161.87 (C2), 154.58, 154.53 (C4), 148.00, 147.96 (ipso Naph), 139.39, 
139.11 (C8), 136.28, 136.25 (C10-Naph), 128.85, 128.79 (CH-Naph), 127.86, 127.77 
(2d, 3JC-C-O-P = 5.0 Hz, C9-Naph), 127.49, 127.25, 126.97, 126.69, 126.54, 126.51, 
125.98, 125.92, 122.79, 122.74 (CH-Naph), 116.24, 116.12 (2d, 3JC-C-O-P = 3.8 Hz, 
C2-Naph), 115.61 (C5), 93.37, 93.20 (C1’), 82.34, 82.16 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 
79.99, 79.95 (C2’), 74.96, 74.73 (OCH ester), 71.33 (C3’), 68.14, 67.65 (2d, 2JC-O-P = 
5.0 Hz, C5’), 66.04, 66.02 (CH2O ester), 54.29 (6OCH3), 51.85, 51.76 (CHCH3), 
32.52, 32.48 (CH2 ester), 20.67, 20.50 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.35, 20.31 
(2’CCH3). 
HPLC (System 1) tR= 16.72, 17.08 min. 
HPLC (System 2) tR= 22.55, 23.49 min. 
MS (ES+) m/z: 695.22 (MNa+, 100%).  
HRMS calculated for C30H37N6O10P1Na: 695.2207, found 695.2217. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(S-phenylethoxy-L-alaninyl)] phosphate (5.12h). 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 1.50 g, 4.82 mmol), "-naphthyl-
(benzoxy-L-alaninyl) phosphorochloridate 
(3.2l, 6.04 g, 14.46 mmol), tBuMgCl (9.64 
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crude mixture was purified by column chromatography, using CHCl3/MeOH (0 to 
5%, gradient), to give a pure product 5.12h as a white foam (571mg, 17%). 
 
31P NMR (202 MHz, MeOD) ! 4.30, 4.27. 
1H NMR (500 MHz, MeOD) ! 8.20- 8.16 (m, 1H, H8-Naph), 7.98, 7.94 (2s, 1H, H8), 
7.92- 7.85 (m, 1H, H5-Naph), 7.71, 7.68 (2d, J= 8.0 Hz, 1H), 7.54 – 7.46 (m, 3H, H2, 
H7, H6-Naph), 7.40, 7.39 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.30- 7.22 (m, 5H, 
OCH(CH3)Ph), 6.00, 5.99 (2s, 1H, H1’), 5.74, 5.68 (2q, J= 7.0 Hz, 1H, 
OCH(CH3)Ph), 4.62– 4.55 (m, 1H, H5’), 4.33, 4.29 (2d, J= 9.0 Hz, 1H, H3’), 4.26- 
4.21 (m, 1H, H4’), 4.07- 4.01 (m, 1H, CHCH3), 4.05, 4.04 (2s, 3H, 6OCH3), 1.40, 1.41 
(2d, J= 6.0 Hz, 3H, OCH(CH3)Ph), 1.26, 1.24 (2d, J= 7.0 Hz, 3H, CHCH3), 0.98, 0.96 
(2s, 3H, 2’CCH3). 
HPLC  (System 1) tR= 20.87, 21.39 min. 
MS (ES+) m/z: 693.25 (MH+, 100%).  
HRMS calculated for C33H38N6O9P1: 693.2438, found 693.2468. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(2-indanoxy-L-alaninyl)] phosphate (5.12i). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), "-naphthyl-(2-
indanoxy-L-alaninyl) phosphorochloridate 
(3.3m, 690 mg, 1.60 mmol), tBuMgCl 
(1.61 ml, 1.61 mmol) in 5 ml of dry THF. 
The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (95:5), to give a pure product 5.12i as white 
foam (255.4 mg, 45%). 
 
31P NMR (202 MHz, MeOD) ! 4.26, 4.25. 
1H NMR (500 MHz, MeOD) ! 8.17 – 8.10 (m, 1H, H8-Naph), 7.95, 7.93 (2s, 1H, H8) 
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7.42 (m, 3H, H7, H6, H2-Naph), 7.37- 7.33 (m, 1H, H3-Naph), 7.15- 7.08 (m, 4H, Ar 
ester), 6.00 (s, 1H, H1’), 5.34- 5.31 (m, 1H, OCH ester), 4.59 – 4.51 (m, 2H, H5’), 4.33 
– 4.21 (m, 2H, H3’ and H4’), 4.02, 4.01 (2s, 3H, 6OCH3), 3.98- 3.95 (m, 1H, CHCH3), 
3.20-3.01 (m, 2H, CH2 ester), 2.85- 2.78 (m, 2H, CH2 ester), 1.26, 1.25 (2d, J= 7.00 
Hz, 3H, CHCH3), 0.97, 0.94 (2s, 3H, 2’-CH3). 
13C NMR (126 MHz, MeOD) ! 174.97, 174.73 (d, 3J C-C-N-P = 3.8, C=O), 162.73 (C6), 
161.83 (C2), 154.53, 154.48 (C4), 147.97, 147.91 (d, 2JC-O-P = 3.8 Hz, ipso Naph), 
141.52, 141.48, 141.36, 141.35, 139.28, 138.97, 136.24, 136.22, 128.87, 128.83, 
127.88, 127.82, 127.81, 127.77, 127.52, 126.55, 126.51, 125.99, 125.60, 125.57, 
125.52, 122.81, 122.75 (Naph, C9-Naph, 2 ipso Ar ester and 4x CH Ar), 116.24, 
16.22 (d, 3JC-C-O-P = 3.8 Hz, C2-Naph), 115.67, 115.65 (C5), 93.32, 93.11 (C1’), 
82.28, 82.08 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.98, 79.96 (C2’), 77.73, 77.69 (OCH 
ester), 74.91, 74.57 (C3’), 67.97, 67.34 (2d, 2JC-O-P = 5.0, C5’), 54.36, 54.34 (6OCH3), 
51.82, 51.71 (CHCH3), 40.49, 40.44, 40.33, 40.25 (CH2 ester), 20.63, 20.49 (CHCH3), 
20.4, 20.3 (2’CCH3),  
HPLC (System 1) tR= 20.81, 21.28 min. 
HPLC (System 2) tR= 27.75, 28.16 min 
MS (ES+) m/z: 727.23 (MNa+, 100%).  
HRMS calculated for C34H38N6O9P1: 705.2438, found 705.2468. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[phenyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.12j). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), phenyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3n, 650 mg, 1.60 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 5 ml of dry THF. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (95:5), to give a pure 
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31P NMR (202 MHz, MeOD) ! 4.04, 3.89. 
1H NMR (500 MHz, MeOD) ! 7.96, 7.95 (2s, 1H, H8), 7.36–7.32 (m, 2H, Ph), 7.28 – 
7.26 (m, 2H, Ph), 7.19 – 7.15 (m, 1H, Ph), 6.03, 6.00 (2s, 1H, H1’), 4.63- 4.50 (m, 1H, 
H5’), 4.30- 4.20 (m, 1H, H3’, H4’), 4.07, 4.06 (2s, 3H, 6OCH3), 4.03 – 4.06 (m, 1H, 
CHCH3), 3.83, 3.80, 3.72, 3.66 (2AB, JAB = 10.50 Hz, 2H, OCH2C(CH3)3), 1.36, 1.35 
(2d, J = 7.50 Hz, 3H, CHCH3), 0.99, 0.96 (2s, 3H, 2’CCH3),  0.91, 0.88 (2s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.07, 174.85 (2d, 3J C-C-N-P = 5.00 Hz, C=O), 162.75 
(C6), 161.93, 161.89 (C2), 154.63 (C4), 152.21, 152.15 (d, 2JC-O-P = 3.80 Hz, ipso 
Ph), 139.26, 138.92 (C8), 130.28, 130.78, 126.15, 121.50, 121.47 (Ph), 115.59, 
115.47 (C5), 93.24, 92.91 (C1’), 82.23, 82.03 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 80.04, 
19.97 (C2’), 75.42, 75.39 (OCH2C(CH3)3), 74.77, 74.28 (C3’), 67.71, 66.80 (2d, 2JC-O-
P = 5.00 Hz, C5’), 54.29 (6OCH3), 51.73, 51.60 (CHCH3), 32.32, 32.25 
(OCH2C(CH3)3), 26.77, 26.73 (OCH2C(CH3)3), 20.86, 20.65 (2d, 3JC-C-N-P = 6.3 Hz, 
CHCH3), 20.33 (2’CCH3). 
HPLC (System 1) tR= 19.71, 20.16 min. 
MS (ES+) m/z: 609.23 (MH+, 100%).  
HRMS calculated for C26H38N6O9P1: 609.2438; found 609.2443. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[p-NO2-phenol-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.12k). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 500 mg, 
1.61 mmol), p-NO2-phenyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3o, 1.22 g, 3.21 mmol), tBuMgCl (3.22 ml, 3.22 mmol) in 10 
ml of dry THF. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (95:5), to give a pure product 5.12k as a white foam (370 mg, 35%). 
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1H NMR (500 MHz, MeOD) ! 8.21 (2d, J= 9.2 Hz, 2H, H3 and H5-Ph) 7.93, 7.92 (2s, 
1H, H8), 7.46, 7.45 (2d, J= 9.2 Hz, 2H, H2 and H6-Ph), 5.99, 5.96 (2s, 1H, H1’), 4.62 - 
4.56 (m, 2H, H5’), 4.36- 4.21 (m, 2H, H3’, H4’), 4.07, 4.06 (2s, 3H, 6OCH3), 4.05- 4.01 
(m, 1H, CHCH3), 3.83, 3.79, 3.74, 3.65 (2AB, J= 10.5 Hz, 2H, OCH2C(CH3)3), 1.39 
(d, J= 7.5 Hz, CHCH3), 0.99, 0.97 (2s, 3H, 2’CCH3), 0.91, 0.89 (2s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.87, 174.72 (2d, 3JC-C-N-P = 3.8 Hz, C=O), 162.74, 
162.72 (C6), 161.87, 161.84 (C2), 157.05, 157.00 (ipso Ph) 154.50, 154.44 
(C4),145.98 (C4-Ph), 139.32, 139.01 (C8), 126.54, 126.53 (C3 and C5-Ph), 122.22, 
122.18 (C2 and C6-Ph), 115.61, 115.57 (C5), 93.33, 93.13 (C1’), 82.13, 81.98 (2d, 3JC-
C-O-P = 7.6 Hz, C4’), 80.05, 79.98 (C2’), 75.48, 75.28 (OCH2C(CH3)3), 74.89, 74.54 
(C3’), 68.17, 67.54 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.31, 54.29 (6OCH3), 51.64 
(CHCH3), 32.34, 32.28 (OCH2C(CH3)3), 26.81, 26.77, 26.74 (OCH2C(CH3)3), 20.80, 
20.61 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.42, 20.29 (2’CCH3). 
HPLC (System 1) tR= 20.31, 20.16 min. 
MS (ES+) m/z: 676.21 (MNa+, 100%).  
HRMS calculated for C26H37N7O11P1: 654.2289; found 654.2313. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(methoxy-L-valinyl)] phosphate (5.12l). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), "-naphthyl-
(methoxy-L-valinyl) phosphorochloridate 
(3.3r, 670 mg, 1.61 mmol), tBuMgCl (1.60 ml, 1.61 mmol) in 5 ml of dry THF. The 
crude mixture was purified by column chromatography, using CHCl3/MeOH (95:5), 
to give a pure product 5.12l as a white foam (78.4 mg, 15%). 
 













Karolina Made!a                                                                                     Chapter Twelve  
 353 
1H NMR (500 MHz, MeOD) ! 8.19 – 8.15 (m, 1H, H8-Naph), 8.00 (s, 1H, H8), 7.90- 
7.82 (m, 1H, H5-Naph), 7.68, 7.65 (2d, J= 7.7 Hz, 1H, H4-Naph), 7.57–7.43 (m, 3H, 
H7, H6, H2-Naph), 7.40-7.34 (m, 1H, H3-Naph), 6.01, 6.00 (2s, 1H, H1’), 4.64- 4.61 
(m, 2H, H5’), 4.41- 4.26 (m, 2H, H3’ and H4’), 4.04 (s, 3H, 6OCH3),  3.76 – 3.72 (m, 
1H, CHCH(CH3)2), 3.53, 3.50 (2s, 3H, OCH3), 2.03- 1.92 (m, 1H, CHCH(CH3)2), 
1.00, 0.96 (2s, 3H, 2’CCH3), 0.88- 0.79 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 174.74, 174.41 (2d, 3J C-C-N-P = 2.5 Hz, C=O), 162.64 
(C6), 161.88, 161.87 (C2), 154.39 (C4), 148.03, 147.97 (ipso Naph), 139.33, 139.07 
(C8), 136.27, 136.22 (C10-Naph), 128.81, 128.75, 128.52, 127.87, 127.82, 127.74, 
127.70, 127.41, 126.56, 126.50, 126.43, 125.90, 122.79 (Naph), 116.16, 116.14 (C2-
Naph), 115.38, 115.30 (C5), 93.47, 93.33 (C1’), 82.37, 82.23 (2d, 3JC-C-O-P = 8.8 Hz, 
C4’), 79.93, 79.91 (C2’), 74.88, 74.75 (C3’), 68.18, 67,70 (d, 2JC-O-P = 6.3 Hz, C5’), 
61.97, 61.92 (OCH3 ester) 54.31, 54.29 (6OCH3), 52.43, 52.39, 52.03 (CHCH(CH3)2), 
33.27, 33.03 (2d, 3JC-C-N-P = 8.8 Hz, CHCH(CH3)2), 20.35, 20.32 (2’CCH3), 19.45, 
19.42, 18.45, 18.39 (CHCH(CH3)2). 
HPLC (System 1) tR= 18.28 min. 
MS (ES+) m/z: 631.23 (MH+, 100%).  
HRMS calculated for C28H36N6O9P1: 631.2281; found 631.2252. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(2,2dimethylpropoxy-L-valinyl)] phosphate (5.12m). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 150 mg, 0.48 mmol), "-naphthyl-
(methoxy-L-valinyl) phosphorochloridate 
(3.3s, 393 mg, 0.97 mmol), tBuMgCl 
(0.97 ml, 0.97 mmol) in 5 ml of dry THF. 
The crude mixture was purified by column chromatography, using CHCl3/MeOH 
(97:3), to give a pure product 5.12m as a white foam (46 mg, 14%). 
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1H NMR (500 MHz, MeOD) ! 8.19–8.15 (m, 1H, H8-Naph), 8.02 (s, 1H, H8) 7.88- 
7.82 (m, 1H, H5-Naph), 7.68, 7.65 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.52–7.43 (m, 3H, 
H7, H6, H2-Naph), 7.39, 7.36 (2t, 1H, J= 8.0 Hz, H3-Naph ), 6.00, 5.99 (2s, 1H, H1’), 
4.64- 4.60 (m, 2H, H5’), 4.37- 4.24 (m, 2H, H3’ and H4’), 4.05 (s, 3H, 6OCH3),  3.82 – 
3.75 (m, 1H, CHCH(CH3)2), 3.91–3.81 (m, 2H, OCH2C(CH3)3), 2.08- .95 (m, 1H, 
CHCH(CH3)2), 0.99, 0.96 (2s, 3H, 2’CCH3), 0.89- 0.83 (m, 15H, CHCH(CH3)2 and 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.34, 174.09 (2d, 3J C-C-N-P = 2.5 Hz, C=O), 162.59, 
162.55 (C6), 161.91, 161.88 (C2), 154.26 (C4), 148.02, 147.97 (ipso Naph), 139.36, 
139.07 (C8), 136.29, 136.23 (C10-Naph), 128.83, 128.76 (CH-Naph), 127.86, 127.71 
(2d, 3JC-C-O-P = 8.8 Hz, C9-Naph), 127.42, 126.51, 126.44, 125.90, 122.83, 122.81 
(CH-Naph), 116.19, 116.13 (2d, 3JC-C-O-P = 3.8 Hz, C2-Naph), 115.15, 115.00 (C5), 
93.55, 93.40 (C1’), 82.46, 82.31 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.91, 79.88 (C2’), 
75.50, 75.48 (OCH2C(CH3)3), 74.94, 74.81 (C3’), 68.34, 67.88 (2d, 2JC-O-P = 5.0 Hz, 
C5’), 62.05 (6OCH3) 54.36, 54.33 (CHCH(CH3)2), 33.31, 33.11 (2d, 3JC-C-N-P = 8.8 
Hz, CHCH(CH3)2), 32.05, 32.00 (OCH2C(CH3)3), 26.80, 26.78, 26.74 
(OCH2C(CH3)3), 20.34, 20.31 (2’CCH3), 18.32, 18.20 (CHCH(CH3)2). 
HPLC (System 1) tR= 21.32 min. 
HPLC (System 2) tR= 29.16, 29.75 min. 
MS (ES+) m/z: 687.29 (MH+, 100%).  
HRMS calculated for C32H44N6O9P1: 687.2907 found 687.2888 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(cyclohexoxy-L-valinyl)] phosphate (5.12n). 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 150 mg, 0.482 mmol), "-naphthyl-
(cyclohexoxy-L-valinyl) 
phosphorochloridate (633 mg, 1.44 mmol, 
1M solution in THF), NMI (0.19 ml, 2.41 













Karolina Made!a                                                                                     Chapter Twelve  
 355 
chromatography, using CHCl3/MeOH (97:7) as eluent, to give a pure product 5.12o as 
a white foam (45 mg, 11%). 
 
31P NMR (202 MHz, MeOD) ! 5.15, 4.91. 
1H NMR (500 MHz, MeOD) ! 8.21–8.14 (m, 1H, H8-Naph), 7.96, 7.94 (s, 1H, H8), 
7.89–7.82 (m, 1H, H5-Naph), 7.69, 7.65 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.55–7.42 (m, 
3H, H7, H6, H2-Naph), 7.42–7.33 (m, 1H, H3-Naph), 5.99 (s, 1H, H1’), 4.66–4.54 (m, 
3H, OCH ester, H5’), 4.39–4.22 (m, 2H, H3’ and H4’), 4.05, 4.04 (2s, 3H, 6OCH3), 
3.75–3.68 (m, 1H, CHCH(CH3)2), 2.06–1.93 (m, 1H, CHCH(CH3)2), 1.70–1.57 (m, 
4H, 2x CH2 ester), 1.39–1.15 (m, 6H, 3x CH2 ester), 0.99, 0.95 (s, 3H, 2’CCH3), 0.89 
– 0.82 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) ! 173.67 (d, 3J C-C-N-P = 2.8 Hz, C=O), 173.39 (d, 3J C-C-
N-P = 3.4 Hz, C=O), 162.73 (C6), 161.89, 161.86 (C2), 154.53, 154.49 (C4), 148.06, 
148.00 (2d, 2JC-O-P = 1.6, ipso Naph), 139.44, 139.15 (C8), 136.30, 136.25 (C10-
Naph), 128.81, 128.75 (CH-Naph), 127.88, 127.86 (2d, 3JC-C-O-P = 6.5 Hz, Naph-C9), 
127.72, 127.67, 127.39, 126.49, 126.42, 125.85, 122.85, 122.83 (CH-Naph), 116.12, 
116.07 (2d, 3JC-C-O-P = 3.2, C2-Naph), 115.67, 115.62 (C5), 93.48, 93.29 (C1’), 82.41, 
82.22 (2d, 3JC-C-O-P = 8.0 Hz, C4’), 79.89 (C2’), 74.98, 74.93 (C3’), 74.86, 74.81 
(OCH ester), 68.36, 67.82 (2d, 2JC-O-P = 5.5 Hz, C5’), 62.05, 62.01 (CHCH(CH3)2), 
54.23, 54.22 (6OCH3), 33.34 (d, 3JC-C-N-P = 6.9 Hz, CHCH(CH3)2), 33.16, (d, 3JC-C-N-P 
= 7.4, CHCH(CH3)2), 32.46, 32.39 (CH2 ester), 26.35 (CH2 ester), 24.62, 24.58 (CH2 
ester), 20.32, 20.28 (2’CCH3), 19.46, 19.46, 19.44 (CHCH(CH3)2), 18.35, 18.23 
(CHCH(CH3)2). 
HPLC (System 1) tR= 21.61, 22.11 min. 
MS (ES+) m/z: 721.27 (MNa+, 100%).  









Karolina Made!a                                                                                     Chapter Twelve  
 356
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(benzoxy-L-valinyl)] phosphate (5.12o). 
 
Prepared according to the Standard 
Procedure 6 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(benzoxy-L-valinyl) phosphorochloridate 
(3.3t, 1.04 g, 2.41 mmol), NMI (0.32 ml, 
4.02 mmol) in 5 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (97:3) as 
eluent to give a pure product 5.12p as a white foam (170 mg, 30%). 
 
31P NMR (202 MHz, MeOD) "  5.08, 5.00. 
1H NMR (500 MHz, MeOD) " 8.17- 8.15 (m, 1H, H8-Naph), 7.98, 7.96 (2s, 1H, H8), 
7.86- 7.82 (m, 1H, H5-Naph), 7.68- 7.64 (m, 1H, H4-Naph), 7.52–7.41 (m, 3H, H7, H6, 
H2-Naph), 7.37, 7.36 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.25–7.21 (m, 5H, OCH2Ph), 
5.03, 4.93 (AB, JAB= 12.0 Hz, 2H, OCH2Ph), 4.61 - 4.58 (m, 2H, H5’), 4.34, 4.27 (2d, 
J= 9.0 Hz, 1H, H3’), 4.25- 4.21 (m, 1H, H4’), 4.04, 4.03 (2s, 1H, 6OCH3), 3.81- 3.76 
(m, 1H, CHCH(CH3)2), 2.04 – 1.91 (m, 1H, CHCH(CH3)2), 0.98, 0.94 (2s, 3H, 
2’CCH3), 0.82- 0.78 (m, 6H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) " 174.04, 173.78 (2d, 3J C-C-N-P = 2.5 Hz, C=O), 162.64 
(C6), 161.85 (C2), 154.38 (C4), 148.02, 147.97 (ipso Naph), 139.37, 139.05 (C8), 
137.11, 137.08 (ipso OCH2Ph), 137.06 (C10-Naph), 136.23, 129.48, 129.43, 129.40, 
129.28, 128.82, 128.76, 127.90, 127.85, 127.74, 127.70, 127.44, 127.24, 126.76, 
126.63, 126.51, 126.44, 126.34, 125.92, 124.02, 123.53, 122.85, 122.81 (Naph, 
OCH2Ph), 116.15, 116.16 (2d, 3JC-C-O-P = 3.8 Hz, C2-Naph), 115.40, 115.31 (C5), 
93.50, 93.28 (C1’), 82.41, 82.21 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.91, 79.88 (C2’), 
74.95, 74.71 (C3’), 68.32, 68.28 (OCH2Ph), 67.81, 67.65 (2d, 2JC-O-P = 5.0 Hz, C5’), 
62.02, 61.96 (6OCH3) 54.32, 54.28 (CHCH(CH3)2), 33.31, 33.11 (2d, 3JC-C-N-P = 8.8 
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HPLC tR= 21.64 min. 
MS (ES+) m/z: 707.26 (MH+, 100%).  
HRMS calculated for C34H40N6O9P1: 707.2594; found 707.2572. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(2,2-dimethylpropoxy-L-methioninyl)] phosphate (5.12p). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(2,2-dimethylpropoxy-L-methioninyl) 
phosphorochloridate (3.3y, 713 mg, 1.61 
mmol, 1M solution in THF), tBuMgCl 
(1.61 ml, 1.61 mmol) in 5 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure product 
5.12p as a white foam (214 mg, 37%). 
 
31P NMR (202 MHz, MeOD) " 4.50, 4.44. 
1H NMR (500 MHz, MeOD) " 8.23 – 8.16 (m, 1H, H8-Naph), 7.99, 7.97 (2s, 1H, H8) 
7.88 – 7.8. (m, 1H, H5-Naph), 7.69, 7.66 (2d, J = 8.6 Hz, 1H, H4-Naph), 7.55 – 7.45 
(m, 3H, H7, H6, H2-Naph), 7.41, 7.37 (2t, J = 8.0 Hz, 1H, H3-Naph), 6.01, 6.00 (2s, 
1H, H1’), 4.72 – 4.59 (m, 2H, H5’), 4.35 – 4.23 (m, 2H, H3’ and H4’), 4.18- 4.13 (m, 
1H, CHCH2CH2SCH3), 4.05, 4.04 (2s, 3H, 6OCH3), 3.75, 3.71, 3.66, 3.62 (2AB, JAB= 
10.0 Hz, 2H, OCH2C(CH3)3), 2.47-2.38, 2.32-2.29 (2m, 2H, CHCH2CH2SCH3), 2.02-
1.81 (m, 5H, CHCH2CH2SCH3 and CHCH2CH2SCH3), 0.98, 0.97 (2s, 3H, 2’CCH3), 
0.88, 0.85 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) " 174.52, 174.28 (d, 3J C-C-N-P = 3.8, C=O), 162.7 (C6), 
161.93, 161.87 (C2), 154.57, 154.51 (C4), 148.00, 147.95 (2d, 2JC-O-P = 6.3 Hz, ipso 
Naph), 139.41, 139.29 (C8), 136.31, 136.25 (C10-Naph), 128.94, 128.87 (CH-Naph), 
127.95 (d, 3JC-C-O-P = 3.8 Hz, C9-Naph), 127.88 (d, 3JC-C-O-P = 5.0 Hz, C9-Naph), 
127.72, 127.63, 127.55, 126.51, 126.09, 122.89 (CH-Naph), 116.32 (d, 3JC-C-O-P = 3.8, 
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(C1’), 82.34 (d, 3JC-C-O-P = 7.5, C4’), 82.22 (d, 3JC-C-O-P = 8.8, C4’), 80.00, 79.95 
(C2’), 75.63 (OCH2C(CH3)3), 74.9, 74.8 (C3’), 68.27, 67.82 (2d, 2JC-O-P = 5.0 Hz, 
C5’), 55.27, 55.19 (CHCH2CH2SCH3), 54.21, 54.09 (OCCH3), 34.52, 34.35 (2d, 3JC-C-
N-P = 6.3 Hz, CHCH2CH2SCH3), 32.21, 32.17 (OCH2C(CH3)3), 31.02, 30.94 
(CHCH2CH2SCH3), 26.91, 28.82, 28.75 (OCH2C(CH3)3) 20.42, 20.38 (2’CCH3), 
15.22, 15.16 (CHCH2CH2SCH3). 
HPLC (System 1) tR= 24.36 min. 
HPLC (System 1) tR= 27.89, 28.76 min. 
MS (ES+) m/z: 719.26 (MH+, 100%).  
HRMS calculated for C32H44N6O9P1: 719.2628; found 719.2645. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(benzoxy-L-methioninyl)] phosphate (5.12q). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(benzoxy-L-methioninyl) 
phosphorochloridate (3.3z, 742 mg, 1.61 
mmol, 1M solution in THF), tBuMgCl 
(1.61 ml, 1.61 mmol) in 5 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure product 
5.12p as a white foam (246 mg, 42%). 
 
31P NMR (202 MHz, MeOD) " 4.54, 4.42 
1H NMR (500 MHz, MeOD) " 8.19, 8.16 ( 2d, J = 7.8 Hz, 1H, H8-Naph), 7.98, 7.94 
(2s, 1H, H8) 7.86, 7.84 (2d, J = 9.0 Hz, 1H, H5-Naph), 7.68, 7.66 (2d, J= 8.2 Hz, 1H, 
H4-Naph), 7.53–7.44 (m, 3H, H7, H6, H2-Naph), 7.36, 7.35 (2t, J= 8.0 Hz, 1H, H3-
Naph), 7.26-7.25 (m, 5H, OCH2Ph), 6.00, 5.99 (2s, 1H, H1’), 5.08–4.95 (m, 2H, 
OCH2Ph), 4.66–4.58 (m, 2H, H5’), 4.35, 4.29 (2d, J= 9.0 Hz, 1H, H3’), 4.26–4.22 (m, 
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(m, 2H, CHCH2CH2SCH3), 1.98-1.77 (m, 5H, CHCH2CH2SCH3 and 
CHCH2CH2SCH3), 0.98, 0.96 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.21, 173.89 (2d, 3J C-C-N-P = 3.8 Hz, C=O), 162.72 
(C6), 161.85 (C2), 154.56, 154.51 (C4), 148.00, 147.94 (ipso Naph), 139.34, 139.09 
(C8), 137.08, 137.06 (ipso OCH2Ph), 136.28, 136.25 (C10-Naph), 129.53, 129.36, 
129.31, 128.85, 128.83 (Naph, OCH2Ph), 127.89 (d, 3JC-C-O-P = 3.8 Hz, C9-Naph), 
127.80 (d, 3JC-C-O-P = 5.0 Hz, C9-Naph), 127.54, 127.52, 126.52, 126.03, 125.97, 
122.86, 122.82 (Naph, OCH2Ph), 116. 35, 116.25 (d, 3JC-C-O-P = 3.8 Hz, C2-Naph), 
116.15 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 115.64, 115.60 (C5), 93.35, 93.16 (C1’), 
82.32, 82.13 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.98, 79.93 (C2’), 74.91, 74.63 (C3’), 
68.17 (d, 2JC-O-P = 5.0 Hz, C5’),  68.04 (d, 2JC-O-P = 6.25 Hz, C5’), 67.59, 67.55 
(OCH2Ph), 55.23, 55.11 (CHCH2CH2SCH3), 54.26 (6OCH3), 34.35 (d, 3JC-C-N-P = 
6.25 Hz, CHCH2CH2SCH3), 34.13 (d, 3JC-C-N-P = 7.5 Hz, CHCH2CH2SCH3), 30.74, 
30.72 (CHCH2CH2SCH3), 20.36 (2’CCH3), 15.13, 15.09 (CHCH2CH2SCH3). 
HPLC tR= 19.13, 19.59 min. 
MS (ES+) m/z: 761.20 (MNa+, 100%).  
HRMS calculated for C34H39N6O9P1Na: 761.2135; found 761.2097. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(S-phenylethoxy-L-methioninyl)] phosphate (5.12r). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), "-naphthyl-(S-
phenylethoxy-L-methioninyl) 
phosphorochloridate (3.3za, 768 mg, 1.61 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 5 ml of dry THF. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (97:3), to give a pure 
product 5.12r as a white foam (226 mg, 37%). 
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1H NMR (500 MHz, MeOD) ! 8.22–8.17 (m, 1H, H8-Naph), 7.99, 7.96 (2s, 1H, H8) 
7.86 – 7.82 (m, 1H, H5-Naph), 7.67, 7.65 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.55–7.46 
(m, 3H, H7, H6, H2-Naph), 7.37, 7.35 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.29-7.26 (m, 5H, 
OCH(CH3)Ph), 6.03, 6.01 (2s, 1H, H1’), 5.77, 5.69 (2q, J= 5.0 Hz, OCH(CH3)Ph), 
4.68–4.54 (m, 2H, H5’), 4.35, 4.31 (2d, J= 9.0 Hz, 1H, H3’), 4.28–4.23 (m, 1H, H4’), 
4.16-4.12 (m, 1H, CHCH2CH2SCH3), 4.04, 4.03 (2s, 3H, 6OCH3), 2.33-2.11 (m, 1H, 
CHCH2CH2SCH3), 1.93-1.86, 1.80-1.72 (2m, 2H, CHCH2CH2SCH3), 1.82, 1.81 (2s, 
3H, CHCH2CH2SCH3), 1.40, 1.39 (2d, J= 5.0 Hz, 3H, OCH(CH3)Ph), 0.98, 0.97 (2s, 
3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 173.63, 173.33 (2d, 3J C-C-N-P = 3.8 Hz, C=O), 162.75 
(C6), 161.87 (C2), 154.58, 154.54 (C4), 147.98, 147.95 (2d, 2JC-O-P = 6.3 Hz, ipso 
Naph), 139.42, 139.12 (C8), 137.68 (ipso OCH(CH3)Ph), 136.29, 136.25 (C10-Naph), 
129.68, 129.57, 129.55, 129.08, 128.88, 128.86, (CH-Naph, OCH(CH3)Ph), 127.89 
(d, 3JC-C-O-P = 3.8 Hz, naph-C9), 127.79 (d, 3JC-C-O-P = 3.8 Hz, C9-Naph), 127.55, 
127.53, 127.25, 126.53, 126.00, 122.86, 122.83 (CH-Naph, OCH(CH3)Ph), 116. 27, 
116.25 (C2-Naph), 115.67, 115.62 (C5), 93.37, 93.17 (C1’), 82.36 (d, 3JC-C-O-P = 7.5 
Hz, C4’), 82.15 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.00, 79.94 (C2’), 75.03, 74.96 (C3’), 
74.92, 74.70 (OCH(CH3)Ph), 68.26, 67.66 (2d, 2JC-O-P = 6.25 Hz, C5’), 55.20, 55.12 
(CHCH2CH2SCH3), 55.02, 54.32 (6OCH3), 34.34, 34.17 (2d, 3JC-C-N-P = 7.5 Hz, 
CHCH2CH2SCH3), 30.65, 30.61 (CHCH2CH2SCH3), 22.47, 22.41 (OCH(CH3)Ph) 
20.40, 20.38 (2’CCH3), 15.13, 15.11 (CHCH2CH2SCH3). 
HPLC tR= 20.87, 21.35 min. 
MS (ES+) m/z: 775.23 (MNa+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(propoxy-D-phenylglycinyl)] phosphate (5.12s). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(propoxy-D-phenylglycinyl) 
phosphorochloridate (3.3zb, 670 mg, 1.61 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.12s was obtained as a white foam (395 mg of 71%). 
31P NMR (202 MHz, MeOD) " 4.38, 3.68. 
1H NMR (500 MHz, MeOD) " 8.00–7.96 (m, 2H, H8-Naph and H8), 7.84, 7.81 (2d, J 
= 8.0 Hz, 1H, H5-Naph), 7.65, 7.62 (2d, J = 8.5 Hz, 1H, H4-Naph), 7.50–7.37 (m, 3H, 
H2, H7, H6-Naph), 7.31–7.30 (m, 1H, H3-Naph), 7.28–7.18 (m, 5H, CHPh), 6.01, 5.99 
(2s, 1H, H1’), 5.05, 5.01 (2d, J = 9.0 Hz, 1H, CHPh), 4.66-4.53 (m, 2H, H5’), 4.36, 
4.29 (2d, J = 9.0 Hz , 1H, H3’), 4.27-4.20 (m, 1H, H4’), 4.06 (s, 3H, 6OCH3),  3.98–
3.88 (m, 2H, OCH2CH2CH3), 1.49 - 1.39 (m, 2H, OCH2CH2CH3), 0.98, 0.97 (2s, 3H, 
2’CCH3), 0.71, 0.69 (2t, J = 7.5 Hz, 3H, OCH2CH2CH3). 
13C NMR (126 MHz, MeOD) " 173.05, 172.75 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.77, 
162.70 (C6), 161.91, 161.85 (C2), 154.65, 154.50 (C4), 147.89, 147.84 (ipso Naph), 
139.45, 139.09 (C8), 139.29 (d, 3J C-C-N-P = 6.30 Hz, CHPh), 139.20 (d, 3J C-C-N-P = 5.0 
Hz, ipso CHPh),  136.23, 136.20 (C10-Naph), 129.61, 129.19, 128.72, 128.69, 
128.16, 128.14, (CH-Naph and CHPh), 127.86, 127.76 (2d, 3JC-C-O-P = 6.3 Hz, C9-
Naph), 127.67, 127.43, 127.37, 126.40, 126.34, 125.93, 125.89, 122.82, 122.76 (CH-
Naph and CHPh), 116.25, 115.95 (2d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 115.64, 115.56 
(C5), 93.40, 93.08 (C1’), 82.32 (d, 3JC-C-O-P = 7.6 Hz, C4’), 82.00 (d, 3JC-C-O-P = 8.8 
Hz, C4’), 79.97, 79.93 (C2’), 74.96, 74.60 (C3’), 68.24 (d, 2JC-O-P = 2.5 Hz, C5’), 
68.15 (d, 2JC-O-P = 5.0 Hz, C5’), 67.29, 67.25 (OCH2CH2CH3), 59.93, 59.73 (d, 2JC-N-P 
= 5.0 Hz, C5’, CHPh), 54.27, 54.22 (6OCH3), 22.80, 22.77 (OCH2CH2CH3), 20.33, 
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HPLC  (System 1) tR= 16.91 min 
MS (ES+) m/z: 715.23 (MNa+, 100%).  
HRMS calculated for C33H38N6O9P1: 693.2438; found 693.2463. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(cyclohexoxy-D-phenylglycinyl)] phosphate (5.12t). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(propoxy-D-phenylglycinyl) 
phosphorochloridate (3.3zc, 735 mg, 1.61 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.12t was obtained as a white foam (360 mg of 61%). 
31P NMR (202 MHz, MeOD) " 4.41, 3.70. 
1H NMR (500 MHz, MeOD) " 8.00–7.95 (m, 2H, H8-naph and H8), 7.83, 7.80 (2d, J 
= 8.0 Hz 1H, H5-Naph), 7.64, 7.62 (2d, J = 8.0 Hz, 1H, H4-Naph), 7.50-7.38 (m, 3H, 
H2, H7, H6-Naph), 7.33 - 7.18 (m, 6H, H3-Naph and CHPh), 6.02, 5.99 (2s, 1H, H1’), 
5.03, 4.99 (2d, J = 9.0 Hz, 1H, CHPh), 4.67-4.55 (m, 3H, OCH ester and H5’), 4.36- 
4.27 (m, 2H, H3’, H4’), 4.06 (s, 3H, 6OCH3), 1.68-1.49 (m, 4H, 2x CH2 ester), 1.40–
1.28 (m, 4H, 2x CH2 ester), 1.18–1.13 (m, 2H, CH2 ester), 0.97, 0.97 (2s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 172.40, 172.09 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.70, 
162.70 (C6), 161.91, 161.84 (C2), 154.65, 154.51 (C4), 147.90, 147.86 (ipso Naph), 
139.44, 139.03 (C8), 139.33, 139.29 (ipso CHPh), 136.24, 136.21 (C10-Naph), 
129.79, 129.60, 129.15, 128.74, 128.70, 128.16, 128.14 (CH-Naph and CHPh), 
127.86, 127.77 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.67, 127.44, 127.37, 126.42, 
126.35, 125.93, 125.89, 122.84, 122.77 (CH-Naph and CHPh), 116.24, 115.94 (2d, 
3JC-C-O-P = 3.8 Hz, C2-Naph), 115.65, 115.57 (C5), 93.39, 93.05 (C1’), 82.32, 81.98 
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74.78 (C3’), 68.16, 67.25 (2d, 2JC-O-P = 5.0 Hz, C5’), 60.02, 59.83 (d, 2JC-N-P = 3.5 Hz, 
CHPh), 54.30, 54.24 (6OCH3), 32.37, 32.23, 32.19, 32.00 (CH2 ester), 26.37, 26.29 
(CH2 ester), 24.29, 24.21 (CH2 ester), 20.36, 20.30 (2’CCH3) 
HPLC (System 1) tR= 18.40 min. 
MS (ES+) m/z: 755.26 (MNa+, 100%).  
HRMS calculated for C36H42N6O9P1Na: 755.2570; found 755.2576. 
 
Synthesis of 2-amino-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(benzoxy-D-phenylglycinyl)] phosphate (5.12u). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-methyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 250 mg, 0.80 mmol), !-naphthyl-
(benzoxy-D-phenylglycinyl) 
phosphorochloridate (3.3zd, 735 mg, 1.61 
mmol), tBuMgCl (1.61 ml, 1.61 mmol) in 
5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.12u was obtained as a white foam (360 mg of 48%). 
31P NMR (202 MHz, MeOD) " 4.37, 3.65. 
1H NMR (500 MHz, MeOD) " 8.02, 7.99 (2d, J= 7.5 Hz, 1H, H8-Naph), 7.95, 7.94 
(2s, 1H, H8) 7.83, 7.81 (2d, J= 8.5 Hz, 1H, H5-Naph), 7.65, 7.62 (2d, J= 8.0 Hz, 1H, 
H4-Naph), 7.49–7.06 (m, 14H, H7, H6, H2, H3-Naph, OCH2Ph and CHPh), 5.99, 5.98 
(2s, 1H, H1’), 5.15 – 5.04 (m, 2H, OCH2Ph), 5.00, 4.97 (2d, J= 5.0 Hz, 1H, CHPh), 
4.65–4.51 (m, 2H, H5’), 4.35- 4.21 (m, 2H, H3’ and H4’), 4.05, 4.04 (2s, 3H, 6OCH3), 
0.97, 0.95 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 172.81, 172.55 (2d, 3JC-C-N-P = 6.3 Hz, C=O), 162.75, 
162.71 (C6), 161.81 (C2), 154.59, 154.49 (C4), 147.87, 147.82 (ipso Naph), 139.44, 
139.98 (C8), 138.90 (CHPh), 136.82, 136.76 (C10-Naph), 136.18 (OCH2Ph), 129.85, 
129.69, 129.47, 129.41, 129.30, 129.16, 129.14, 128.98, 128.89, 128.83, 128.75, 
128.26, 127.84, 127.78, 127.71, 127.52, 127.43, 126.45, 126.40, 126.00, 125.96, 
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116.03 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 115.72, 115.65 (C5), 93.38, 93.06 (C1’), 
82.32 (d, 3JC-C-O-P = 7.5 Hz, C4’), 81.98 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.02 (C2’), 
75.00, 74.56 (C3’), 68.24 (d, 2JC-O-P = 5.0 Hz, C5’),  68.15 (d, 2JC-O-P = 6.3 Hz, C5’), 
67.24 (OCH2Ph), 60.00, 59.79 (CHPh), 54.38 (6OCH3), 20.48 (2’CCH3). 
HPLC (System 1) tR= 19.49, 19.89 min. 
MS (ES+) m/z: 763.21 (MNa+, 100%).  
HRMS calculated for C37H38N6O9P1Na: 741.2438; found 741.2465. 
 
Synthesis of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.14a). 
  
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-ethyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.5, 250 mg, 0.77 mmol), !-naphthyl-
(2,2-dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 589 mg, 1.54 
mmol), tBuMgCl (1.54 ml, 1.54 mmol) in 5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.14a was obtained as a white foam (145 mg of 28%). 
31P NMR (202 MHz, MeOD) " 4.28, 4.21. 
1H NMR (500 MHz, MeOD) " 8.20-8.14 (m, 1H, H8-Naph), 7.96, 7.94 (2s, 1H, H8), 
7.89–7.84 (m, 1H, H5-Naph), 7.71-7.68 (m, 1H, H4-Naph), 7.58–7.46 (m, 3H, H7, H6, 
H2-Naph), 7.43-7.36 (m, 1H, H4-Naph), 5.99, 5.98 (2s, 1H, H1’), 4.65- 4.55 (m, 2H, 
H5’), 4.53, 4.51 (2q, J=6.70, 2H, 6OCH2CH3), 4.35- 4.22 (m, 2H, H3’ and H4’), 4.08-
3.99 (m, 1H, CHCH3), 3.78-3.67 (m, 2H, OCH2C(CH3)3), 1.44 (t, J=7.20 Hz, 3H, 
6OCH2CH3 ), 1.33, 1.31 (2d, J=6.35 Hz, 3H, CHCH3), 0.98, 0.97 (2s 3H, 2’CCH3), 
0.88, 0.86 (OCH2C(CH3)3) 
HPLC  (System 1) tR= 22.92, 23.16 min 
MS (ES+) m/z: 695.26 (MNa+, 100%).  
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Synthesis of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(tetrahydropyroxy-L-alaninyl)] phosphate (5.14b). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-ethyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.5, 250 mg, 0.77 mmol), !-naphthyl-
(tetrahydropyroxy-L-alaninyl) 
phosphorochloridate (3.3j, 612 mg, 1.54 
mmol), tBuMgCl (1.54 ml, 1.54 mmol) in 5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.14b was obtained as a white foam (72 mg of 14%). 
31P NMR (202 MHz, MeOD) " 4.26, 4.12. 
1H NMR (500 MHz, MeOD) " 8.20-8.15 (m, 1H, H8-Naph), 8.00, 7.98 (2s, 1H, H8), 
7.89– 7.81 (m, 1H, H5-Naph), 7.71-7.67 (m, 1H, H4-Naph), 7.58–7.45 (m, 3H, H7, H6, 
H2-Naph), 7.43- 7.37 (m, 1H, H4-Naph), 6.00, 5.99 (2s, 1H, H1’), 4.81-4.73 (m, 1H, 
OCH ester), 4.65- 4.55 (m, 2H, H5’), 4.53 (q, J= 6.7 Hz, 2H, 6OCH2CH3), 4.35-4.22 
(m, 2H, H3’ and H4’), 4.08-3.99 (m, 1H, CHCH3), 3.80-3.75 (m, 2H, CH2 ester), 3.48-
3.37 (m, 2H, CH2 ester), 1.80-1.69 (m, 2H, CH2 ester), 1.54-1.49 (m, 2H, CH2 ester), 
1.44 (t, J= 7.2 Hz, 3H, 6OCH2CH3 ), 1.32, 1.30 (2d, J= 6.4 Hz, 3H, CHCH3), 0.98, 
0.97 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) "  174.08 (C=O), 162.33 (C6), 161.90 (C2), 154.85 
(C4), 148.02, 147.96 (ipso Naph), 139.39, 139.11 (C8), 136.30, 136.26 (C10-Naph), 
128.85, 128.80, (Naph), 127.77, 127.73 (C9-Naph), 127.48, 127.45, 127.20, 126.77, 
126.55, 126.52, 125.97, 125.90, 123.86, 123.73, 123.59, 123.46, 122.78, 122.73 
(Naph), 116.23, 116.11 (2d, 3JC-C-O-P = 3.8 Hz, C2-Naph), 115.38 (C5), 93.41, 93.26 
(C1’), 83.36, 82.19 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.95, 79.91 (C2’), 74.92, 74.71 
(OCH ester), 71.30 (C3’), 68.12, 67.67 (2d, 2JC-O-P = 5.0 Hz, C5’), 66.06, 66.04 (2x 
CH2O ester), 63.65, 63.62 (6OCH2CH3), 51.80, 51.74 (CHCH3), 32.52, 32.48 (2x CH2 
ester), 20.61, 20.43 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.30, 20.26 (2’CCH3), 14.85 
(6OCH2CH3). 
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HPLC (System 2) tR= 24.23, 24.77 min. 
MS (ES+) m/z: 687.25 (MH+, 100%).  
HRMS calculated for C34H40N6O9P1: 687.2571; found 687.2549. 
 
Synthesis of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(benzoxy-L-alaninyl)] phosphate (5.14c). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-ethyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.5, 250 mg, 0.77 mmol), !-naphthyl-
(benzoxy-L-alaninyl) phosphorochloridate 
(3.3k, 622 mg, 1.54 mmol), tBuMgCl 
(1.54 ml, 1.54 mmol) in 5 ml of dry THF. 
After silica gel column chromatography, using CHCl3/MeOH (0 to 5%, gradient) as 
eluent, pure product 5.14c was obtained as a white foam (68.7 mg of 13%). 
31P NMR (202 MHz, MeOD) " 4.31, 4.26. 
1H NMR (500 MHz, MeOD) " 8.17-8.15 (m, 1H, H8-Naph), 7.96, 7.92 (2s, 1H, H8), 
7.85, 7.84 (2d, 1H, J= 8.0 Hz, H5-Naph), 7.67, 7.66 (2d, J= 8.0 Hz, 1H, H4-Naph), 
7.51–7.43 (m, 3H, H2, H7, H6-Naph), 7.36, 7.35 (2t, J= 8.0 Hz, 1H, H3-Naph), 7.27–
7.22 (m, 5H, OCH2Ph), 6.00, 5.99 (2s, 1H, H1’), 5.05- 4.95 (m, 2H, OCH2Ph), 4.61–
4.57 (m, 2H, H5’), 4.51, 4.50 (2q, J= 7.0 Hz, 2H, 6OCH2CH3) 4.34, 4.27 (2d, J= 9.0 
Hz, 1H, H3’), 4.25-4.22 (m, 1H, H4’), 4.12–4.05 (m, 1H, CHCH3), 1.42, 1.41 (2t, J= 
7.0 Hz, 3H, 6OCH2CH3), 1.30, 1.28 (2d, J= 7.5 Hz, CHCH3), 0.98, 0.95 (2s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 174.80, 174.61 (d, 3J C-C-N-P = 5.0 Hz, C=O), 162.39, 
162.38 (C6), 161.85 (C2), 154.58, 154.52 (C4), 147.98 (ipso Naph), 139.26, 138.98 
(C8), 137.13 (ipso OCH2Ph), 136.26, 136.24 (C10-Naph), 129.51, 129.22, 129.15, 
129.11, 128.93, 128.79 (Naph, OCH2Ph), 127.91, 127.88 (2d, 3JC-C-O-P = 6.3 Hz, C9-
Naph), 127.74, 127.72, 127.48, 126.51, 126.48, 125.95, 122.83, 122.75 (Naph, 
OCH2Ph),116.25, 116.23 (C2-Naph), 115.64, 115.62 (C5), 93.32, 93.14 (C1’), 82.29, 
82.11 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.96, 79.92 (C2’), 74.94, 74.62 (C3’), 68.02, 
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51.81, 51.72 (CHCH3), 20.59, 20.54, 20.39 (CHCH3), 20.36, 20.34 (2’CCH3), 14.89, 
14.88 (6OCH2CH3). 
HPLC (System 1) tR= 22.25, 22.73 min 
MS (ES+) m/z: 693.25 (MH+, 100%).  
HRMS calculated for C33H38N6O9P1: 693.2438, found 693.2452. 
 
Synthesis of 2-amino-6-O-ethyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-O-
[!-naphthyl-(S-phenylethoxy-L-alaninyl)] phosphate (5.14d). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-ethyl-9-
(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.5, 250 mg, 0.77 mmol), !-naphthyl-(S-
phenylethoxy-L-alaninyl) 
phosphorochloridate (3.3l, 678 mg, 1.54 
mmol), tBuMgCl (1.54 ml, 1.54 mmol) in 5 ml of dry THF. After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as eluent, pure product 
5.14d was obtained as a white foam (120 mg of 22%). 
31P NMR (202 MHz, MeOD) " 4.32, 4.29. 
1H NMR (500 MHz, MeOD) " 8.19- 8.16 (m, 1H, H8-Naph), 8.05, 8.01 (2s, 1H, H8), 
7.84- 7.78 (m, 1H, H5-Naph), 7.65, 7.63 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.55–7.45 (m, 
3H, H2, H7, H6-Naph), 7.38-7.32 (m, 1H, H3-Naph), 7.27-7.19 (m, 5H, 
OCH(CH3)Ph), 6.02, 6.01 (2s, 1H, H1’), 5.73, 5.69 (2q, J= 6.5 Hz, 1H, 
OCH(CH3)Ph), 4.67–4.56 (m, 1H, H5’), 4.49 (q, J= 7.0 Hz, 2H, 6OCH2CH3), 4.32- 
4.22 (m, 2H, H3’ and H4’), 4.10- 4.03 (m, 1H, CHCH3), 1.41-1.37 (m, 6H, 6OCH2CH3 
and OCH(CH3)Ph), 1.28, 1.25 (2d, J= 8.0 Hz, 3H, CHCH3), 0.98, 0.96 (2s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 174.26, 174.00 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.24, 
162.21 (C6), 161.82, 161.75 (C2), 154.25 (C4), 147.99, 147.97, 147.92 (ipso Naph), 
142.84, 142.80 (ipso OCH(CH3)Ph), 139.19, 138.88 (C8), 136.23, 136.21 (2d, 3JC-C-O-
P = 3.7 Hz, C10-Naph), 129.74, 129.55, 129.51, 128.97, 128.88, 128.84, 128.63 













Karolina Made!a                                                                                     Chapter Twelve  
 368
127.50, 127.31, 127.15, 127.02, 126.98, 126.79, 126.72, 126.55, 126.52, 126.38, 
126.01, 125.99, 124.22, 123.49, 122.81, 122.75 (Naph and OCH(CH3)Ph),116.30, 
116.24 (2d, 3JC-C-O-P = 3.7 Hz, C2-Naph), 115.06, 114.94 (C5), 93.38, 93.22 (C1’), 
82.39, 82.24 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 80.00, 79.94 (C2’), 74.91, 74.86, 74.77, 
74.64, 74.50 (C3’ and OCH(CH3)Ph), 68.01, 67.53 (2d, 2JC-O-P = 5.0 Hz, C5’), 63.86, 
63.81 (6OCH2CH3), 51.91, 51.82 (CHCH3), 22.66, 22.60 (OCH(CH3)Ph), 20.60, 
20.55 (CHCH3), 20.41, 20.35 (2’CCH3), 14.92 (6OCH2CH3). 
HPLC (System 1) tR= 22.41, 22.93 min 
HPLC (System 2) tR= 28.28, 28.89 min 
MS (ES+) m/z: 707.26 (MH+, 100%).  
HRMS calculated for C34H40N6O9P1: 707.2594, found 707.2560. 
 
Synthesis of 2-amino-6-O-(3-methoxypropyl)-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.17a). 
  
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-O-(3-
methoxypropyl)-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.8, 40 mg, 
0.11 mmol), !-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 83 mg, 0.22 mmol), tBuMgCl (0.22 ml, 0.22 mmol) in 2 
ml of dry THF. After silica gel column chromatography, using CHCl3/MeOH (0 to 
5%, gradient) as eluent, pure product 5.14d was obtained as a white foam (19 mg of 
25%). 
31P NMR (202 MHz, MeOD) " 4.28, 4.21. 
1H NMR (500 MHz, MeOD) " 8.19-8.15 (m, 1H, H8-naph), 7.98, 7.95 (2s, 1H, H8), 
7.89–7.85 (m, 1H, H8 and H5-naph), 7.70, 7.68 (2d, J= 8.5 Hz, 1H, H4-naph), 7.54–
7.45 (m, 3H, H7, H6, H2-naph), 7.42–7.37 (m, 1H, H3-naph), 6.00, 5.98 (2s, 1H, H1’), 
4.65–4.57 (m, 2H, H5’), 4.55 (t, J= 6.3 Hz, 2H, 6OCH2CH2CH2OCH3), 4.35–4.22 (m, 
2H, H3’ and H4’), 4.11–4.03 (m, 1H, CHCH3), 3.78–3.58 (m, 4H, OCH2C(CH3)3 and 
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6OCH2CH2CH2OCH3), 1.33, 1.32 (2d, J= 7.0 Hz, 3H, CHCH3), 0.98, 0.97 (2s, 3H, 
2’CCH3), 0.87, 0.86 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.80, 174.76 (C=O), 162.72, 162.37 (C6), 161.84 
(C2), 156.64, 154.60 (C4), 147.98 (ipso Naph), 139.40, 139.12 (C8), 136.30, 136.28 
(C10-Naph), 128.82, 128.77 (CH-Naph), 127.89, 127.71 (2d, d, 3JC-C-O-P = 5.0 Hz, 
C9-Naph), 127.52, 127.50, 126.53, 126.49, 125.98, 122.82, 122.75 (CH-Naph), 
116.21, 116.17 (C2-naph), 115.56 (C5), 93.37, 93.22 (C1’), 82.33, 82.17 (d, 3JC-C-O-P 
= 7.5 Hz, C4’), 79.96, 79.90 (C2’), 75.34 (OCH2C(CH3)3), 74.95, 74.71 (C3’), 70.32 
(6OCH2CH2CH2OCH3), 67.83, 67.27 (2d, 2JC-O-P = 5.0 Hz, C5’), 64.72 
(6OCH2CH2CH2OCH3), 58.92 (6OCH2CH2CH2OCH3)51.79, 51.73 (CHCH3), 32.24, 
32.21 (OCH2C(CH3)3), 30.24 (6OCH2CH2CH2OCH3), 26.68, 26.67 (OCH2C(CH3)3), 
20.79, 20.58 (2d, 3JC-C-N-P = 6.20 Hz, CHCH3), 20.29, 20.27 (2’CCH3). 
HPLC  tR= 19.15, 19.48 min.  
MS (ES+) m/z: 717.30 (MH+, 100%).  
HRMS calculated for C33H46N6O10P1: 717.3013, found 717.3004. 
 
Synthesis of 2-amino-6-NH-benzyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 5’-
O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.18a). 
 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-NH-
benzyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.9, 150 mg, 0.39 
mmol), "-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 303 mg, 0.79 mmol), tBuMgCl (0.79 ml, 0.79 mmol) in 5 
ml of dry THF. After silica gel column chromatography, using CHCl3/MeOH (0 to 
5%, gradient) as eluent, pure product 5.18a was obtained as a white foam (33 mg of 
11%). 
31P NMR (202 MHz, MeOD) ! 4.43, 4.23. 
1H NMR (500 MHz, MeOD) ! 8.19–8.17 (m, 1H, H8-naph), 7.87 (s, 1H, H8), 7.86- 
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Naph), 7.46- 7.36 (m, 3H, H3-Naph and 6NHCH2Ph), 7.32- 7.29 (m, 2H, 
6NHCH2Ph), 7.25- 7.22 (m, 1H, 6NHCH2Ph), 5.98, 5.97 (2s, 1H, H1’), 4.75- 4.72 (m, 
2H, 6NHCH2Ph), 4.68- 4.57 (m, 2H, H5’), 4.30- 4.23 (m, 2H, H3’ and H3’), 4.10–4.03 
(m, 1H, CHCH3), 3.76, 3.71, 3.63, 3.59 (2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 
1.32, 1.30 (2d, J = 7.4 Hz, 1H, CHCH3), 0.99, 0.98 (2s, 3H, 2’CCH3), 0.85, 0.84 (2s, 
9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.06 (d, 3J C-C-N-P = 4.7, C=O), 174.82 (d, 3J C-C-N-P 
= 5.8, C=O), 162.15 (C6), 156.46 (C4), 148.02, 147.96 (d, 2JC-O-P = 2.0, ipso Naph), 
140.61 (ipso 6NHCH2Ph), 137.17, 136.87 (C8), 136.30 (C10-Naph), 129.53, 129.52, 
128.86, 128.80, 128.65, 128.64, 128.15 (CH-Naph and 6NHCH2Ph), 127.91, 127.86 
(2d, 3JC-C-O-P = 2.5, C9-Naph), 127.77, 127.75 (CH-Naph), 127.50, 127.49, 126.53, 
126.47, 125.97, 122.81, 122.74 (CH-Naph, 6NHCH2Ph), 116.20 (d, 3JC-C-O-P = 3.3 
Hz, C2-Naph), 116.17 (d, 3JC-C-O-P = 4.5 Hz, C2-Naph), 114.78, 114.75 (C5), 92.98, 
92.79 (C1’), 82.13, 81.98 (2d, 3JC-C-O-P = 8.3 Hz, C4’), 79.98, 79.90 (C2’), 75.37, 
75.35 (OCH2C(CH3)3), 74.82, 74.51 (C3’), 67.87, 67.29 (2d, 2JC-O-P = 5.2 Hz, C5’), 
51.78 (CHCH3), 44.91 (6NHCH2Ph), 32.24, 32.21 (OCH2C(CH3)3), 26.70, 26.69 
(OCH2C(CH3)3), 20.84, 20.62 (2d, 3JC-C-N-P = 6.2 Hz, CHCH3), 20.38, 20.35 
(2’CCH3). 
HPLC tR= 22.41, 22.93 min 
MS (ES+) m/z: 733.30 (MH+, 100%).  
HRMS calculated for C36H45N7O8P1: 733.3057, found 733.3041. 
CHN calculated for C36H45N7O8P1 + 0.75 H2O: C 57.86, H 6.14, N 13.12; found: C 
57.90, H 5.98, N 13.01. 
 
Synthesis of 2-amino-6-NH-phenylethyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (5.19a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-amino-6-NH-
phenylethyl-9-(2’-C-methyl-!-D-
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phosphorochloridate (3.3e, 367 mg, 1.01 mmol), tBuMgCl (1.01 ml, 1.01 mmol) in 5 
ml of dry THF. After silica gel column chromatography, using CHCl3/MeOH (0 to 
5%, gradient) as eluent, pure product 5.18a was obtained as a white foam (247 mg of 
24%). 
 
31P NMR (202 MHz, MeOD) ! 4.25. 
1H NMR (500 MHz, MeOD) ! 8.19, 8.16 (2d, J= 8.5 Hz, 1H, H8-naph), 7.87–7.81 (m, 
2H, H8 and H5-naph), 7.69, 7.67 (2d, J= 8.5 Hz, 1H, H4-naph), 7.54–7.47 (m, 3H, H7, 
H6, H2-naph), 7.42–7.37 (m, 1H, H3-naph), 7.27–7.16 (m, 5H, NHCH2CH2Ph), 5.98, 
5.97 (2s, 1H, H1’), 4.69–4.58 (m, 2H, H5’), 4.27–4.22 (m, 2H, H3’ and H4’), 4.11–4.03 
(m, 1H, CHCH3), 3.78–3.58 (m, 4H, OCH2C(CH3)3 and NHCH2CH2Ph), 2.94 (t, J= 
7.7 Hz, 2H, NHCH2CH2Ph), 1.33, 1.32 (2d, J= 7.0 Hz, 3H, CHCH3), 0.98, 0.96 (2s, 
3H, 2’CCH3), 0.86, 0.84 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.06 (d, 3J C-C-N-P = 4.7, C=O), 174.83 (d, 3J C-C-N-P 
= 5.8, C=O), 162.12 (C6), 156.51 (C4), 148.01 (ipso Naph), 140.69 (ipso 
NHCH2CH2Ph), 137.04, 136.76 (C8), 136.30, 136.28 (C10-Naph), 129.91, 129.50, 
128.87, 128.82 (CH-Naph and NHCH2CH2Ph), 127.93, 127.76 (C9-Naph), 127.52, 
127.50, 127.31, 126.53, 126.49, 125.98, 122.82, 122.75 (CH-Naph and 
NHCH2CH2Ph), 116.22, 116.20 (C2-naph), 114.81 (C5), 92.95, 92.77 (C1’), 82.11 (d, 
3JC-C-O-P = 7.7 Hz, C4’), 81.97 (d, 3JC-C-O-P = 8.5, C4’), 79.98, 79.91 (C2’), 75.38, 
75.36 (OCH2C(CH3)3), 74.80, 74.49 (C3’), 67.83, 67.27 (2d, 2JC-O-P = 5.0 Hz, C5’), 
51.79, 51.73 (CHCH3), 44.52 (NHCH2CH2Ph), 36.82 (OCH2C(CH3)3), 32.26, 32.23 
(NHCH2CH2Ph), 26.72, 26.71 (OCH2C(CH3)3), 20.87 (d, 3JC-C-N-P = 6.20 Hz, 
CHCH3), 20.64 (d, 3JC-C-N-P = 7.70 Hz, CHCH3), 20.39, 20.37 (2’CCH3). 
HPLC  tR= 22.75, 22.93 min.  
MS (ES+) m/z: 748.34 (MH+, 100%).  
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12.6 Experimental section – Chapter Seven. 
 
Synthesis of 2-chloro-1,3,2-oxazaphosphinane-2-oxide (7.1). 
 
POCl3 (4.58 ml, 49.14 mmol) in 40 ml of dry CHCl3 was cooled down to 
-15 °C. A solution of 3-aminopropan-1-ol (3.79 ml, 49.14 mmol) in dry 
CHCl3  (10 ml), containing Et3N (7.00 ml, 50.00 mmol) was added dropwise with 
stirring to the mixture which was kept at -10 °C, followed by the addition of further 
quantity (7 ml, 50.00 mmol) of Et3N in dry CHCl3 (10 ml). The reaction mixture was 
stirred at 0 °C for 18 h. After that time, solvent was removed under reduced pressure 
at 35 °C. The solid residue was extracted with dry acetone (4x 20 ml), and evaporated 
to dryness. The crude mixture was purified on sílica gel (flash chromatography), using 
EtOAc/Hexane (1:1) as eluent. Desired compound 7.1 was obteind as a white solid 
(6.50 g, 84%). 
 
31P NMR (202 MHz, CDCl3) ! 9.22. 
1H NMR (500 MHz, CDCl3) ! 4.57- 4.47 (m, 2H, OCH2CH2CH2NH), 4.07 (s, 1H, 
NH), 3.46- 3.36 (m, 2H, OCH2CH2CH2NH), 2.25- 2.16, 1.80- 1.76 (2m, 2H, 
OCH2CH2CH2NH). 
 
Synthesis of N-(2-nitrophenylsulphonyl)-L-alanine methyl ester (7.3a). 
 
Prepared according to the Standard Procedure 9, starting 
from: L-alanine methyl ester hydrochloride (5.00 g, 35.82 
mmol), Et3N (11.47 ml, 82.38 mmol) and 2-
nitrobenzenesulfonyl chloride (7.94 g, 35.82 mmol) in dry DCM (250 ml). After work 
up, the pure compound 7.3a was obtained as a yellow oil (10.36 g, 100%). 
 
1H NMR (500 MHz, MeOD) ! 8.09-8.07 (m, 1H, H3-Ar), 7.92- 7.90 (m, 1H, H6 Ar), 
7.77- 7.73 (m, 1H, H4 and H5 Ar), 5.99 (bs, 1H, NH), 4.24 (q, J= 7.00 Hz, 1H, 
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Synthesis of N-(2-nitrophenylsulphonyl)-L-alanine 2,2-dimethylpropyl ester 
(7.3b). 
Prepared according to the Standard Procedure 9, 
starting from: L-alanine 2,2-dimethylpropyl ester 
hydrochloride (8.00 g, 15.09 mmol), Et3N (4.83 ml, 
34.70 mmol) and 2-nitrobenzenesulfonyl chloride (3.34 
g, 15.09 mmol) in dry DCM (400 ml). After work up, the pure compound 7.3b was 
obtained as a yellow oil (7.64 g, 92%). 
 
1H NMR (500 MHz, CDCl3) ! 8.11- 8.09 (m, 1H, H3-Ar), 7.94- 7.92 (m, 1H, H4-Ar), 
7.76- 7.72 (m, 2H, H5-Ar and H4-Ar), 4.29 (q, J= 7.5 Hz, 1H, CHCH3), 3.68, 3.65 
(AB, JAB= 12.00 Hz, 2H, OCH2C(CH3)3), 1.53 (d, J= 7.5 Hz, 3H, CHCH3), 0.87 (s, 
9H, OCH2C(CH3)3). 
 
Synthesis of N-(2-nitrophenylsulphonyl)-L-alanine benzyl ester (7.3c). 
 
Prepared according to the Standard Procedure 9, 
starting from: L-alanine benzyl ester hydrochloride 
(5.00 g, 14.23 mmol), Et3N (4.55 ml, 32.72 mmol) 
and 2-nitrobenzenesulfonyl chloride (3.15 g, 14.23 mmol) in dry DCM (250 ml). 
After work up, the pure compound 7.3c was obtained as a yellow oil (5.80 g, 100%). 
 
1H NMR (500 MHz, CDCl3) ! 8.03 (d, J= 8.0 Hz, 1H, H3-Ar), 7.84 (d, J= 6.5 Hz, 1H, 
H4- Ar), 7.69-7.62 (m, 2H, H5- Ar and H4- Ar), 7.36-7.20 (m, 5H, OCH2Ph), 4.98, 
4.95 (AB, JAB= 8.5 Hz, 2H, OCH2Ph), 4.33 (q, J= 7.0 Hz, 1H, CHCH3), 1.52 (d, J= 
7.0 Hz, 3H, CHCH3). 
 
Synthesis of N-(3-hydroxypropyl)-N-(2-nitrophenylsulphonyl)-L-alanine methyl 
ester (7.3a’). 
 
Prepared according to the Standard Procedure 10, starting 
from: N-(2-nitrophenylsulphonyl)-L-alanine methyl ester 
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35.94 mmol) and 3-bromopropanol (4.71 ml, 53.91 mmol) in dry DMF (160 ml). 
After work up and column chromatography using EtOAc/petroleum ether (8:2) as an 
eluent, the pure compound 7.3a’ was obtained as a yellow oil (4.15 g, 31%). 
 
1H NMR (500 MHz, MeOD) ! 8.12 (d, J= 9.5 Hz, 1H, H3-Ar), 7.84-7.79 (m, 2H, H5 
and H6 Ar), 7.75- 7.74 (m, 1H, H4 Ar), 4.76 (q, J= 7.5 Hz, 1H, CHCH3), 3.61- 3.54 
(m, 6H, OCH3, NCH2aCH2CH2OH and NCH2CH2CH2OH), 3.35-3.28 (m, 1H, 
NCH2bCH2CH2OH), 1.96- 1.82 (m, 2H, NCH2CH2CH2OH), 1.53 (d, J= 7.5 Hz, 3H, 
CHCH3). 
 
Synthesis of N-(3-hydroxypropyl)-N-(2-nitrophenylsulphonyl)-L-alanine 2,2-
dimethylpropyl ester (7.3b’). 
  
Prepared according to the Standard Procedure 10, 
starting from: N-(2-nitrophenylsulphonyl)-L-alanine 
2,2-dimethylpropyl ester (7.3b, 7.64 g, 22.18 mmol), 
cesium carbonate (7.23 g, 22.18 mmol) and 3-
bromopropanol (2.90 ml, 33.28 mmol) in dry DMF 
(150 ml). After work up and column chromatography using EtOAc/petroleum ether 
(8:2) as an eluent, the pure compound 7.3b’ was obtained as a yellow oil (2.17 g, 
29%). 
 
1H NMR (500 MHz, CDCl3) ! 8.06 (d, J= 7.0 Hz, 1H, H3-Ar), 7.70-7.67 (m, 2H, H6 
and H5 Ar), 7.60-7.59 (m, 1H, H4- Ar), 4.81 (q, J=7.5 Hz, 1H, CHCH3), 3.78-3.64 (m, 
4H, OCH2C(CH3)3 and NCH2CH2CH2OH), 3.60-3.55 (m, 1H, NCH2aCH2CH2OH), 
3.93-3.33 (m, 1H, 1 of NCH2bCH2CH2OH), 1.90-1.83 (m, 2H, NCH2CH2CH2OH), 
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Synthesis of N-(3-hydroxypropyl)-N-(2-nitrophenylsulphonyl)-L-alanine 2,2-
dimethylpropyl ester (7.3c’). 
 
Prepared according to the Standard Procedure 10, 
starting from: N-(2-nitrophenylsulphonyl)-L-alanine 
benzyl ester (7.3c, 5.80 g, 18.16 mmol), cesium 
carbonate (5.92 g, 18.16 mmol) 3-bromopropanol 
(2.38 ml, 27.24 mmol) and in dry DMF (80 ml). After work up and column 
chromatography using EtOAc/petroleum ether (8:2) as an eluent, the pure compound 
7.3c’ was obtained as a yellow oil (1.92 g, 25%). 
 
1H NMR (500 MHz, MeOD) ! 8.05 (d, J= 8.0 Hz, 1H, H3-Ar), 7.72-7.62 (m, 3H, H4, 
H5 and H6 Ar), 7.33-7.25 (m, 5H, OCH2Ph), 5.05, 5.00 (AB, JAB= 11.50 Hz, 2H, 
OCH2Ph), 4.11 (q, J= 7.5 Hz, 1H, CHCH3), 3.61-3.53 (m, 3H, NCH2CH2CH2OH and 
NCH2aCH2CH2OH), 3.32-3.27 (m, 1H, NCH2bCH2CH2OH), 1.94- 1.83 (m, 2H, 
NCH2CH2CH2OH), 1.55 (d, J= 7.5 Hz, 3H, CHCH3). 
 
Synthesis of N-(3-hydroxypropyl)- L-alanine methyl ester (7.3a”). 
 
Prepared according to the Standard Procedure 11, starting 
from: N-(3-hydroxypropyl)-N-(2-nitrophenylsulphonyl)-L-
alanine methyl ester (7.3a’, 3.85 g, 11.12 mmol), potasium 
carbonate (4.98 g, 36.13 mmol) and thiophenol (1.25 ml, 27.24 mmol) in dry ACN 
(60 ml). After work up and column chromatography using CHCl3/MeOH (9:1) as an 
eluent, the pure compound 7.3a” was obtained as a yellowish oil (0.76 g, 42%). 
 
1H NMR (500 MHz, CDCl3) ! 3.74 (t, J= 5.5 Hz, 2H, NCH2CH2CH2OH), 3.70 (s, 3H, 
OCH3), 3.35 (q, J= 7.0 Hz, 1H, CHCH3), 3.02 (bs, 1H, NH), 2.88-2.83 (m, 1H, 
NHCH2aCH2CH2OH), 2.65-2.60 (m, 1H, NHCH2bCH2CH2OH), 1.68-1.64 (m, 2H, 
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Synthesis of N-(3-hydroxypropyl)- L-alanine 2,2-dimethylpropyl ester (7.3b”). 
 
Prepared according to the Standard Procedure 11, 
starting from: N-(3-hydroxypropyl)-N-(2-
nitrophenylsulphonyl)-L-alanine 2,2-dimethylpropyl ester (7.3b’, 2.17 g, 6.30 mmol), 
potasium carbonate (2.83 g, 20.51 mmol) and thiophenol (0.71 ml, 6.93 mmol) in dry 
ACN (60 ml). After work up and column chromatography using CHCl3/MeOH (9:1) 
as an eluent, the pure compound 7.3b” was obtained as a yellowish oil (0.91 g, 66%). 
 
1H NMR (500 MHz, CDCl3) ! 3.80, 3.78 (AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 
3.73 (t, J= 5.5 Hz, 2H, NHCH2CH2CH2OH), 3.35 (q, J=7.0 Hz, 1H, CHCH3), 3.00 
(bs, 1H, NH), 2.89-2.83, 2.65-2.60 (2m, 2H, NHCH2CH2CH2OH), 1.68-1.63 (m, 2H, 
NHCH2CH2CH2OH), 1.28 (d, J=7.0 Hz, 3H, CHCH3), 0.91 (s, 9H, OCH2C(CH3)3). 
 
Synthesis of N-(3-hydroxypropyl)- L-alanine benzyl ester (7.3c”). 
 
Prepared according to the Standard Procedure 11, 
starting from: N-(3-hydroxypropyl)-N-(2-
nitrophenylsulphonyl)-L-alanine benzyl ester 
(7.3c’, 1.92 g, 4.54 mmol), potasium carbonate (2.04 g, 14.77 mmol) and thiophenol 
(0.51 ml, 5.00 mmol) in dry ACN (60 ml). After work up and column 
chromatography using CHCl3/MeOH (9:1) as an eluent, the pure compound 7.3c” was 
obtained as a yellowish oil (0.72 g, 67%). 
 
1H NMR (500 MHz, CDCl3) ! 7.39-7.32 (m, 5H, OCH2Ph), 5.19, 5.15 (AB, JAB=12.5 
Hz, 2H, OCH2Ph), 3.77 (t, J= 5.5 Hz, 2H, NHCH2CH2CH2OH), 3.42 (q, J=7.0 Hz, 
1H, CHCH3), 2.95 (bs, 1H, NH), 2.91-2.87 (m, 1H, NHCH2aCH2CH2OH), 2.68-2.64 
(m, 1H, NHCH2bCH2CH2OH), 1.71-1.66 (m, 2H, NHCH2CH2CH2OH), 1.32 (d, J=7.0 
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Synthesis of (2S)-methyl 2-(2-chloro-2-oxido-1,3,2-oxazaphosphinan-3-
yl)propanoate (7.2a). 
 
 Prepared according to the Standard Procedure 12, starting from: N-(3-
hydroxypropyl)- L-alanine methyl ester (7.3a”, 0.40 g, 2.48 mmol) and 
Et3N (0.35 ml, 2.48 mmol) in dry CHCl3 (2.5 ml). POCl3 (0.23 ml, 2.48 
mmol) was dissolved in dry CHCl3 (0.5 ml) and the reaction mixture 
was cooled down to -15 °C.  A solution of N-(3-hydroxypropyl)- L-alanine methyl 
ester waas added dropwise to the POCl3 solution, followed by the addition of further 
quantity of Et3N (0.35 ml, 2.48 mmol) in dry CHCl3 (0.5 ml). The reaction mixture 
was stirred at 0 °C for 18 h. After purification on sílica gel (flash chromatography), 
using EtOAc/Hexane (1:1) as eluent, the compound 7.2a was obteind as a clear, 
colorless oil (0.52 g, 87%). 
 
31P NMR (202 MHz, CDCl3) ! 9.27, 8.62. 
1H NMR (500 MHz, CDCl3) ! 4.69-4.57 (m, 1H, CHCH3), 4.55- 4.38 (m, 2H, 
NCH2CH2CH2O), 3.73 (s, 3H, OCH3), 3.47-3.16 (m, 2H, NCH2CH2CH2O), 2.42- 
2.40, 2.21- 2.07 (2m, 1H, NCH2CH2aCH2O), 1.91-1.80 (m, 1H, NCH2CH2bCH2O), 
1.46, 1.45 (2d, J= 7.0 Hz, 3H, CHCH3). 
 
(2S)-neopentyl 2-(2-chloro-2-oxido-1,3,2-oxazaphosphinan-3-yl) propanoate 
(7.2b) 
  
Prepared according to the Standard Procedure 12, starting from: N-(3-
hydroxypropyl)- L-alanine 2,2-dimethylpropyl ester (7.3b”, 0.40 g, 1.84 
mmol) and Et3N (0.25 ml, 1.84 mmol) in dry CHCl3 (1.84 ml). POCl3 
(0.17 ml, 1.84 mmol) was dissolved in dry CHCl3 (0.37 ml) and the 
reaction mixture was cooled down to -15 °C.  A solution of N-(3-
hydroxypropyl)- L-alanine 2,2-dimethylpropyl ester waas added dropwise to the 
POCl3 solution, followed by the addition of further quantity of Et3N (0.25 ml, 1.84 
mmol) in dry CHCl3 (0.37 ml). The reaction mixture was stirred at 0 °C for 18 h. 
After purification on sílica gel (flash chromatography), using EtOAc/Hexane (1:1) as 
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31P NMR (202 MHz, CDCl3) ! 9.04, 8.62. 
1H NMR (500 MHz, CDCl3) ! 4.71-4.61 (m, 1H, CHCH3), 4.55-4.42 (m, 2H, 
NCH2CH2CH2O), 3.88-3.79 (m, 2H, OCH2C(CH3)3), 3.49-3.28 (m, 2H, 
NCH2CH2CH2O), 2.41-2.34, 2.18-2.09, 1.89-1.83 (3m, 2H, NCH2CH2CH2O), 1.47, 
1.45 (2d, J= 7.5 Hz, 3H, CHCH3), 0.97, 0.96 (2s, 9H, OCH2C(CH3)3). 
 
Synthesis of (2S)-benzyl 2-(2-chloro-2-oxido-1,3,2-oxazaphosphinan-3-yl) 
propanoate (7.2c). 
 
 Prepared according to the Standard Procedure 12, starting from: N-(3-
hydroxypropyl)- L-alanine benzyl ester (7.3c”, 0.35 g, 1.47 mmol) and 
Et3N (0.21 ml, 1.47 mmol) in dry CHCl3 (1.47 ml). POCl3 (0.14 ml, 
1.47 mmol) was dissolved in dry CHCl3 (0.30 ml) and the reaction 
mixture was cooled down to -15 °C.  A solution of N-(3-
hydroxypropyl)- L-alanine benzyl ester waas added dropwise to the 
POCl3 solution, followed by the addition of further quantity of Et3N (0.21 ml, 1.47 
mmol) in dry CHCl3 (0.30 ml). The reaction mixture was stirred at 0 °C for 18 h. 
After purification on sílica gel (flash chromatography), using EtOAc/Hexane (1:1) as 
eluent, the compound 7.2c was obteind as a clear, colorless oil (0.42 g, 90%). 
 
31P NMR (202 MHz, CDCl3) ! 9.15, 8.61 
1H NMR (500 MHz, CDCl3) ! 7.37-7.32 (m, 5H, OCH2Ph), 5.20-5.11 (m, 2H, 
OCH2Ph), 4.69-4.60 (m, 1H, CHCH3), 4.48-4.37 (m, 2H, NCH2CH2CH2O), 3.34-3.14 
(m, 2H, NCH2CH2CH2O), 2.25-2.18, 2.12-2.07, 1.84-1.74 (3m, 1H, NCH2CH2CH2O), 
1.44, 1.42 (2d, J= 7.5 Hz, 3H, CHCH3). 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
1”,3”,2”-oxazaphosphacyclohex-2”-oxide (7.4a). 
 
Prepared according to the Standard Procedure 8, 
starting from: 2-amino-6-O-methyl-9-(2’-C-
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oxide (7.1, 399 mg, 2.57 mmol), in 10 ml of dry pyridine. The crude mixture was 
purified by column chromatography, using CHCl3/EtOH (0 to 5%, gradient), to give a 
pure product as white foam (7.4a, 87 mg, 16%). 
 
31P NMR (202 MHz, MeOD) ! 5.50, 5.46 
1H NMR (500 MHz, MeOD) ! 8.06, 8.05 (2s, 1, H8), 6.04, 6.03 (2s, 1H, H1’), 4.45- 
4.31 (m, 4H, H5’ and OCH2CH2CH2NH), 4.29- 4.22 (m, 2H, H3’ and H4’), 4.07 (s, 3H, 
6OCH3), 3.29- 3.23 (m, 2H, OCH2CH2CH2NH), 2.01- 1.4 (m, 1H, 
OCH2CH2CH2NH), 1.70- 1.67 (m, 1H, OCH2CH2CH2NH), 1.01, 1.00 (2s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) ! 162.73 (C6), 161.97 (C2), 154.66 (C4), 138.80, 
138.75 (C8), 115.37 (C5), 92.84, 92.79 (C1’), 82.15, 82.09 (C4’), 80.16, 80.14 (C2’), 
74.28, 74.20 (C3’), 71.38, 71.31 (2d, 2JC-O-P= 6.3 Hz, OCH2CH2CH2NH), 65.64, 
65.60 (2d, 2JC-O-P= 5.0 Hz, C5’), 54.29 (6OCH3), 42.30 (d, 2JC-N-P= 11.3 Hz, 
OCH2CH2CH2NH), 42.24 (d, 2JC-N-P= 2.50 Hz, OCH2CH2CH2NH), 27.38, 27.32 (2d, 
2JC-C-O-P= 7.55 Hz, OCH2CH2CH2NH), 20.28 (2’CCH3). 
HPLC (System 1) tR= 5.72, 6.04 min. 
MS (EI+) m/z: 431.13 (MH+, 100%).  
HRMS calculated for C15H29N6O7P1: 430.1366, found 430.1361. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O- 
(2S)-methyl 2-(2-oxido-1,3,2-oxazaphosphinan-3-yl)propanoate (7.4b). 
 
Prepared according to the Standard Procedure 8, 
starting from: 2-amino-6-O-methyl-9-(2’-C-
methyl-!-D-ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), (2S)-methyl 2-(2-chloro-2-oxido-
1,3,2-oxazaphosphinan-3-yl)propanoate (7.2a, 
310 mg, 0.96 mmol), in 7 ml of dry pyridine. The crude mixture was purified by 
column chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure 
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31P NMR (202 MHz, MeOD) ! 4.62, 4.48. 
1H NMR (500 MHz, MeOD) ! 8.02 (s, 1H, H8), 6.01, 6.00 (2s, 3H, H1’), 4.40- 4.22 
(m, 7H, H3’, H4’, H5’, CHCH3 and OCH2CH2CH2N), 4.07 (s, 3H, 6OCH3), 3.74, 3.73 
(2s, 3H, OCH3), 3.30-3.21 (m, 2H, OCH2CH2CH2N), 2.24-2.15 (m, 1H, 
OCH2CH2aCH2N), 1.84-1.81 (m, 1H, OCH2CH2CH2N), 1.42 (d, J= 7.5 Hz, CHCH3), 
1.01 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174, 23, 174.18 (C=O), 162.76 (C6), 161.99 (C2), 
154.60 (C4), 138.93 (C8), 115.51 (C5), 93.04 (C1’), 82.17, 82.10 (C4’), 80.05 (C2’), 
71.08, 71.03 (OCH2CH2CH2N), 66.33, 66.29 (C5’), 54.23 (6OCH3), 52.79 (CHCH3), 
52.79, 52.73 (OCH3 ester), 44.22, 43.80 (OCH2CH2CH2N), 27.12, 27.07 
(OCH2CH2CH2N), 20.24 (2’CCH3), 16.07, 16.05 (CHCH3).  
HPLC (System 1) tR = 8.17 min. 
MS (EI+) m/z: 516.71 (MH+, 100%).  
HRMS calculated for C19H29N6O7P1: 516.1734, found 516.1739. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O- 
(2S)-neopentyl 2-(2-oxido-1,3,2-oxazaphosphinan-3-yl)propanoate (7.4c). 
 
Prepared according to the Standard Procedure 8, 
starting from: 2-amino-6-O-methyl-9-(2’-C-
methyl-!-D-ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), (2S)-neopentyl 2-(2-chloro-2-
oxido-1,3,2-oxazaphosphinan-3-yl)propanoate 
(7.2b, 410 mg, 0.96 mmol), in 7 ml of dry 
pyridine. The crude mixture was purified by column chromatography, using 
CHCl3/MeOH (0 to 5%, gradient), to give a pure product as white foam (7.4c, 15.5 
mg, 3%). 
 
31P NMR (202 MHz, MeOD) ! 4.46. 
1H NMR (500 MHz, MeOD) ! 8.03 (s, 1H, H8), 6.01 (s, 1H, H1’), 4.45-4.30 (m, 6H, 
H3’, H5’, CHCH3 and OCH2CH2CH2N), 4.24-4.22 (m, 1H, H4’), 4.08 (s, 3H, 6OCH3), 
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OCH2CH2CH2N), 2.24-2.15, 1.85-1.82 (2m, 2H, OCH2CH2CH2N), 1.44 (d, J=7.5 Hz, 
3H, CHCH3), 1.01 (s, 3H, 2’CCH3), 0.98 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 173.73 (C=O), 162.76 (C6), 162.01 (C2), 154.55 
(C4), 138.94 (C8), 115.52 (C5), 93.06 (C1’), 82.16 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.04 
(C2’), 75.51 (OCH2C(CH3)3), 74.43 (C3’), 70.99 (d, 2JC-O-P = 7.6 Hz, 
OCH2CH2CH2N), 66.36 (d, 2JC-N-P= 6.3 Hz, C5’), 55.33 (d, 2JC-N-P = 5.5 Hz, CHCH3), 
54.20 (6OCH3), 44.08 (OCH2CH2CH2N), 32.29 (OCH2C(CH3)3), 27.11 (d, 3JC-C-N-
P/C-C-O-P = 5.50 Hz, OCH2CH2CH2N), 26.78 (OCH2C(CH3)3), 20.23 (2’CCH3), 
16.04 (CHCH3).  
HPLC (System 1) tR = 13.11 min. 
MS (EI+) m/z: 572.24 (MH+, 100%).  
HRMS calculated for C23H37N6O7P1: 572.2360, found 572.2352. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O- 
(2S)-benzyl 2-(2-oxido-1,3,2-oxazaphosphinan-3-yl)propanoate (7.4c). 
 
 Prepared according to the Standard Procedure 8, 
starting from: 2-amino-6-O-methyl-9-(2’-C-
methyl-!-D-ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), (2S)-benzyl 2-(2-chloro-2-oxido-
1,3,2-oxazaphosphinan-3-yl)propanoate (7.2c, 367 
mg, 0.96 mmol), in 7 ml of dry pyridine. The 
crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give a pure product as 
white foam (7.4c, 34 mg, 6%). 
 
31P NMR (202 MHz, MeOD) ! 9.15, 8.61. 
1H NMR (500 MHz, MeOD) ! 8.00 (s, 1H, H8), 7.40-7.32 (m, 5H, OCH2Ph), 6.00 (s, 
1H, H1’), 5.21, 5.16 (AB, JAB=12.5 Hz, 2H, OCH2Ph), 4.46-4.41 (m, 1H, CHCH3), 
4.38-4.29 (m, 5H, H3’, H5’, and OCH2CH2CH2N), 4.23-4.22 (m, 1H, H4’), 4.06 (s, 3H, 
6OCH3), 3.29-3.17 (m, 2H, OCH2CH2CH2N), 2.10-2.03, 1.76-1.74 (m, 2H, 
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13C NMR (126 MHz, MeOD) ! 173.46 (d, 3JC-C-N-P = 6.3 Hz, C=O), 162.75 (C6), 
161.98 (C2), 154.59 (C4), 138.91 (C8), 137.29 (ipso OCH2Ph), 129.61, 129.50, 
129.37 (OCH2Ph), 115.52 (C5), 93.05 (C1’), 82.14 (d, 3JC-C-O-P = 7.6 Hz, C4’), 80.05 
(C2’), 74.42 (C3’), 71.02 (d, 2JC-O-P = 6.29 Hz, OCH2CH2CH2N), 67.99 (OCH2Ph), 
66.35 (d, 2JC-N-P = 6.3 Hz, C5’), 55.49 (d, 2JC-N-P=3.77 Hz, CHCH3), 54.24 (6OCH3), 
44.15 (OCH2CH2CH2N), 27.01 (d, 3J C-C-N-P = 6.2 Hz, OCH2CH2CH2N), 20.25 
(2’CCH3), 16.00 (CHCH3).  
HPLC (System 1) tR = 13.09 min.  
MS (TOF ES+) m/z: 592.21 (MH+, 100%);  
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12.7 Experimental section – Chapter Eight. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(butoxy-L-alaninyl) phosphate (8.2b) 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 0.80 
mmol), POCl3 (0.07 ml, 0.80 mmol), 
Et3N (0.11 ml, 0.80 mmol), L-alanine butyl ester hydrochloride salt (0.43 g, 2.41 
mmol), Et3N (0.67 ml, 4.82 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The 
crude mixture was purified by column chromatography in gradient (CHCl3/MeOH 0 
to 5%), to give a pure product 8.2b as a white foam (75 mg, 14%). 
 
31P NMR (202 MHz, MeOD) " 14.02. 
1H NMR (500 MHz, MeOD) " 7.99 (s, 1H, H8), 6.01 (s, 1H, H1’), 4.40-4.37 (m, 2H, 
H5’), 4.29 (d, J= 9.0 Hz, 1H, H3’), 4.21- 4.19 (m, 1H, H4’), 4.15- 4.01 (m, 7H, 6OCH3 
and 2x OCH2CH2CH2CH3), 3.94 (q, J=8.0 Hz, 2H, 2x CHCH3), 1.63- 1.56 (m, 4 H, 
2x OCH2CH2CH2CH3 ester), 1.41- 1.34 (m, 10H, 2x OCH2CH2CH2CH3 and 2x 
CHCH3), 1.00 (s, 3H, 2’CCH3), 0.93 (t, J= 7.5 Hz, 6H, 2x OCH2CH2CH2CH3). 
13C NMR (126 MHz, MeOD) " 175.72, 175.65 (2d, 3JC-C-N-P= 6.30 Hz, C=O), 162.74 
(C6), 161.91 (C2), 154.60 (C4), 139.30 (C8), 115.55 (C5), 93.14 (C1’), 82.35 (d, 3JC-
C-O-P = 8.8 Hz, C4’), 80.06 (C2’), 74.81 (C3’), 66.22 (d, 2JC-O-P = 5.0 Hz, C5’), 66.13 
(OCH2CH2CH2CH3), 66.11 (OCH2CH2CH2CH3 ester), 54.26 (6OCH3), 51.06 (d, 2JC-
N-P = 10.0 Hz, 2x CHCH3), 31.75 (2x OCH2CH2CH2CH3 ester), 21.03, 20.86 (2d, 3JC-
C-N-P= 5.0 Hz, 2x CHCH3), 20.33 (2’CCH3), 20.13 (2x OCH2CH2CH2CH3), 14.07, 
14.06 (2x OCH2CH2CH2CH3). 
HPLC (System 1) tR= 15.23 min. 
MS (ES+) m/z: 668.28 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(pentoxy-L-alaninyl) phosphate (8.2c). 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 mmol), L-
alanine pentyl ester hydrochloride salt (0.79 g, 4.02 mmol), Et3N (0.67 ml, 4.82 
mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude mixture was purified 
by column chromatography in gradient (CHCl3/MeOH 0 to 5%), to give a pure 
product 8.2c as a white foam (260 mg, 40%). 
 
31P NMR (202 MHz, MeOD) " 14.05. 
1H NMR (500 MHz, MeOD) " 8.00 (s, 1H, H8), 6.03 (s, 1H, H1’), 4.44-4.35 (m, 2H, 
H5’), 4.29 (d, J= 8.5 Hz, 1H, H3’), 4.22- 4.13 (m, 1H, H4’), 4.13- 3.93 (m, 9H, 6OCH3, 
2x OCH2CH2CH2CH2CH3 and 2x CHCH3), 1.62-1.59 (m, 4H, 2x 
OCH2CH2CH2CH2CH3), 1.38- 1.31 (m, 14H, 2x OCH2CH2CH2CH2CH3, 2x 
OCH2CH2CH2CH2CH3 and 2x CHCH3), 1.00 (s, 3H, 2’CCH3), 0.89 (t, J= 5.0 Hz, 6H, 
2x OCH2CH2CH2CH2CH3). 
13C NMR (126 MHz, MeOD) " 175.72, 175.67 (2d, 3JC-C-N-P= 6.30 Hz, C=O), 162.75 
(C6), 161.92 (C2), 154.61 (C4), 139.26 (C8), 115.56 (C5), 93.07 (C1’), 82.34 (d, 3JC-
C-O-P = 7.5 Hz, C4’), 80.11 (C2’), 74.81 (C3’), 66.43 (d, 2JC-O-P = 2.52 Hz, C5’), 66.25, 
66.22 (2x OCH2CH2CH2CH2CH3 ester), 54.34 (6OCH3), 51.16 (d, 2JC-N-P= 11.3 Hz, 
CHCH3), 51.07 (d, 2JC-N-P = 10.0 Hz, CHCH3), 29.39 (2x OCH2CH2CH2CH2CH3 
ester), 29.16 (2x OCH2CH2CH2CH2CH3 ester), 23.38 (2x OCH2CH2CH2CH2CH3 
ester), 21.12, 21.01 (2d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.43 (2’CCH3), 14.07, 14.42 (2x 
OCH2CH2CH2CH2CH3). 
HPLC tR = 18.68 min. 
MS (ES+) m/z: 674.32 (M+H+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(R,S-2-butoxy-L-alaninyl) phosphate (8.2d). 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 mmol), L-
alanine R,S-2-butyl ester hydrochloride salt (0.73 g, 4.02 mmol), Et3N (0.67 ml, 4.82 
mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude mixture was purified 
by column chromatography in gradient (CHCl3/MeOH 0 to 5%), to give a pure 
product 8.2d as a white foam (90 mg, 17%). 
 
31P NMR (202 MHz, MeOD) 14.05. 
1H NMR (500 MHz, MeOD) 7.99 (s, 1H, H8), 6.00 (s, 1H, H1'), 4.80- 4.78 (m, 2H, 2x 
OCH(CH3)CH2CH3), 4.41- 4.39 (m, 2H, H5'), 4.30 (d, J= 8.5 Hz, 1H, H3'), 4.21- 4.20 
(m, 1H, H4'), 4.07 (s, 3H, 6OCH3), 3.92-3.90 (m, 2H, 2x CHCH3), 1.63- 1.51 (m, 4H, 
2x OCH(CH3)CH2CH3), 1.37- 1.33 (m, 6H, 2x CHCH3), 1.24- 1.17 (m, 6H, 2x 
OCH(CH3)CH2CH3), 1.00 (s, 3H, 2'CCH3), 0.89 (t, J= 6.0 Hz, 2x 
OCH(CH3)CH2CH3). 
13C-NMR (126 MHz, MeOD) 175.30, 175.16 (2d, 3JC-C-N-P= 3.8 Hz, C=O), 162.74 
(C6), 161.89 (C2), 154.58 (C4), 139.37 (C8), 115.58 (C5), 93.19 (C1'), 82.38, 82.36 
(d, 3JC-C-O-P= 7.6 Hz, C4'), 80,06 (C2'), 74.91 (C3'), 74.59, 74.55 
(OCH(CH3)CH2CH3), 66.40 (d, 2JC-O-P= 3.8 Hz, C5'), 54.27 (6OCH3), 51.19 (d, 2JC-N-
P= 7.6 Hz, CHCH3), 51.14 (d, 2JC-N-P= 8.8 Hz, CHCH3), 29.78, 29.74 
(OCH(CH3)CH2CH3), 21.17 (d, 3JC-C-N-P= 6.2 Hz, CHCH3), 21.04 (d, 3JC-C-N-P= 2.50 
Hz, CHCH3), 21.01 (CHCH3), 20.91(d, 3JC-C-N-P= 5.25 Hz, CHCH3), 20.89 (2'CCH3), 
19.76, 19.61 (OCH(CH3)CH2CH3), 10.05 (OCH(CH3)CH2CH3). 
HPLC tR = 15.12 min. 
MS (ES+) m/z: 668.28 (M+Na+, 100%). 
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(2,2-dimethylpropoxy-L-alaninyl) phosphate (8.2e). 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 1.00g, 
3.18 mmol), POCl3 (0.28 ml, 3.18 
mmol), Et3N (0.43 ml, 3.18 mmol), 
L-alanine 2,2-dimethylpropyl ester 
tosylate salt (3.2g, 5.30 g, 16.05 mmol), Et3N (2.68 ml, 32.10 mmol) in 40 ml of 1:1 
mixture of dry THF and DCM. The crude mixture was purified by column 
chromatography in gradient (CHCl3/MeOH 0 to 5%), to give a pure product 8.2e as a 
white foam (640 mg, 30%). 
 
31P NMR (202 MHz, MeOD) ! 14.01. 
1H NMR (500 MHz, MeOD) ! 7.98 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.41-4.37 (m, 2H, 
H5’), 4.28 (d, 1H, J=9.0 Hz, H3’), 4.22-4.16 (m, 1H, H4’), 4.07 (s, 3H, 6OCH3), 4.05–
3.93 (m, 2H, 2x CHCH3), 3.86, 3.84, 3.82, 3.79 (2AB, JAB= 10.0 Hz, 2H, 2x 
OCH2C(CH3)3), 1.40, 1.36 (2d, 6H, J=7.5 Hz, 2x CHCH3), 0.99 (s, 3H, 2CCH3), 0.95, 
0.94 (2s, 18H, 2x OCH2C(CH3)3). 
13C-NMR (126 MHz, MeOD) 175.30 (2d, 3JC-C-N-P= 3.8 Hz, C=O), 162.74 (C6), 
161.90 (C2), 154.57 (C4), 139.37 (C8), 115.60 (C5), 93.20 (C1'), 82.37 (d, 3JC-C-O-P= 
7.6 Hz, C4'), 80,06 (C2'), 75.72, 75.64 (2x OCH2C(CH3)3), 74.89 (C3'), 74.59, 74.55 
(OCH(CH3)CH2CH3), 66.38 (d, 2JC-O-P= 3.8 Hz, C5'), 54.30 (6OCH3), 51.20, 51.17 
(2d, 2JC-N-P= 7.6 Hz, CHCH3), 32.14, 32.09 (2x OCH2C(CH3)3, 27.08, 26.98 (2x 
OCH2C(CH3)3), 21.15 (d, 3JC-C-N-P= 6.0 Hz, CHCH3), 21.05 (d, 3JC-C-N-P= 5.3 Hz, 
CHCH3), 20.90 (2'CCH3). 
HPLC (System 1) tR= 16.95 min. 
HPLC (System 2) tR= 27.95 min.  
MS (ES+) m/z: 673.32 (M+H+, 100%). 
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(3,3-dimethylbutoxy-L-alaninyl) phosphate (8.2f). 
 
Prepared according to the standard 
procedure 13a from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 mmol), 
L-alanine 3,3-dimethylbutyl ester 
tosylate salt (3.2i, 0.83 g, 2.41 mmol), Et3N (0.67 ml, 4.82 mmol) in 10 ml of 1:1 
mixture of dry THF and DCM. Crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 5% gradient), to give a pure product8.2f  
as a white foam (52 mg, 9%). 
 
31P NMR (202 MHz, MeOD) " 14.03. 
1H NMR (500 MHz, MeOD) " 7.99 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.42-4.36 (m, 2H, 
H5’), 4.28 (d, J= 9.0 Hz, 1H, H3’), 4.23- 4.09 (m, 5H, H4’ and 2x OCH2CH2C(CH3)3), 
4.07 (s, 3H, 6OCH3), 3.92 (q, J=7.0 Hz, 2H, 2x CHCH3), 1.60 (t, J= 7.0 Hz, 4H, 2x 
OCH2CH2C(CH3)3), 1.37 (d, J= 7.0 Hz, 6H, 2x CHCH3), 0.99 (s, 3H, 2’CCH3), 0.97 
(s, 9H, OCH2CH2C(CH3)3), 0.94 (s, 9H, OCH2CH2C(CH3)3). 
13C NMR (126 MHz, MeOD) " 175.67, 175.59 (2d, 3J C-C-N-P= 6.3 Hz, C=O), 162.74 
(C6), 161.91 (C2), 154.61 (C4), 139.24 (C8), 115.58 (C5), 93.13 (C1’), 82.35 (d, 3JC-
C-O-P = 8.8 Hz, C4’), 80.06 (C2’), 74.75 (C3’), 66.22 (d, 2JC-O-P = 5.0 Hz, C5’), 66.96 
(OCH2CH2C(CH3)3), 66.94 (OCH2CH2C(CH3)3), 54.24 (6OCH3), 51.07 (d, 2JC-N-P = 
10.0 Hz, 2x CHCH3), 42.85 (OCH2CH2C(CH3)3),  42.83 (OCH2CH2C(CH3)3), 30.59 
(OCH2CH2C(CH3)3), 30.55 (OCH2CH2C(CH3)3), 30.03 (2x OCH2CH2C(CH3)3), 
20.96 (d, 3JC-C-N-P= 6.3 Hz, CHCH3),  20.79 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.34 
(2’CCH3). 
HPLC (System 1) tR= 20.12 min.  
MS (ES+) m/z: 724.35 (M+Na+, 100%). 
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(3,3-dimethylbutoxy-L-alaninyl) phosphate (8.2h). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 
mmol), L-alanine tetrahydropyranyl ester tosylate salt (0.83g, 2.41 mmol), Et3N (0.67 
ml, 4.82 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude mixture was 
purified by column chromatography, using CHCl3/MeOH (0 to 5%, gradient), to give 
a pure product 8.2h as a white foam (75 mg, 14%). 
 
31P NMR (202 MHz, MeOD) " 13.94. 
1H NMR (500 MHz, MeOD) " 7.99 (s, 1H, H8), 5.99 (s, 1H, H1’), 4.94- 4.83 (m, 2H, 
2x OCH ester), 4.39-4.38 (m, 2H, H5’), 4.28 (d, J= 9.0 Hz, 1H, H3’), 4.21- 4.18 (m, 
1H, H4’), 4.07 (s, 3H, 6OCH3), 3.99- 3.83 (m, 6H, 2x CHCH3 and 4x OCH2a ester), 
3.56- 3.45 (m, 4H, 4x OCH2b ester), 1.93- 1.83 (m, 4 H, 4x OCH2c ester), 1.69- 1.59 
(m, 4 H, 4x OCH2d ester), 1.38 (d, J= 7.0 Hz, 3H, CHCH3), 1.36 (d, J= 7.0 Hz, 3H, 
CHCH3), 0.99 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 175.00, 174.92 (2d, 3JC-C-N-P= 5.0 Hz, C=O), 162.75 
(C6), 161.94 (C2), 154.63 (C4), 139.36 (C8), 115.54 (C5), 93.14 (C1’), 82.41 (d, 3JC-
C-O-P= 8.8 Hz, C4’), 80.03 (C2’), 74.89 (C3’), 71.27 (OCH ester), 71.23 (OCH ester), 
66.47 (d, 2JC-O-P = 5.0 Hz, C5’), 66.18 (4x OCH2 ester), 54.29 (6OCH3), 51.15 (d, 2JC-
N-P = 6.3 Hz, 2x CHCH3), 32.64 (4x CH2 ester), 20.98 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 
20.79 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.31 (2’CCH3). 
HPLC (System 1) tR= 9.57 min.  
MS (ES+) m/z: 724.27 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(indanyl-L-alaninyl) phosphate (8.2j). 
Prepared according to the 
standard procedure 13a, from: 
2-amino-6-O-methyl-9-(2’-C-
methyl-!-D-ribofuranosyl) 
purine (5.4, 250 mg, 0.80 
mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 
mmol), L-alanine 2-indanyl 
ester tosylate salt (3.2k, 0.91 g, 2.41 mmol), Et3N (0.67 ml, 4.82 mmol) in 10 ml of 
1:1 mixture of dry THF and DCM. The crude mixture was purified by column 
chromatography using CHCl3/MeOH (0 to 5%, gradient). Additional extraction from 
water using DCM was performed to remove remaining amino acid ester salt. The pure 
product  8.2j was obtained as a white foam (52 mg, 9%). 
 
31P NMR (202 MHz, MeOD) " 13.94. 
1H NMR (500 MHz, MeOD) " 7.95 (s, 1H, H8), 7.19-7.10 (m, 8H, 8 x CH-Ar), 5.99 
(s, 1H, H1’), 5.49- 5.46 (m, 1H, OCH ester), 5.42- 5.40 (m, 1H, OCH ester), 4.34-4.25 
(m, 3H, H5’ and H3’), 4.16- 4.14 (m, 1H, H4’), 4.03 (s, 3H, 6OCH3), 3.83 (q, J=7.0 Hz, 
2H, 2x CHCH3), 3.28-3.16 (m, 4H, 2x CH2 ester), 3.01- 2.90 (m, 4H, 2x CH2 ester), 
1.25 (d, J= 7.0 Hz, 3H, CHCH3), 1.24 (d, J= 7.0 Hz, 3H, CHCH3), 0.98 (s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 175.53, 175.48 (2d, 3JC-C-N-P= 5.0 Hz, C=O), 162.73 
(C6), 161.89 (C2), 154.57 (C4), 141.59, 141.51, 141.47 (C-Ar), 139.30 (C8), 127.84, 
125.59 (CH-Ar), 115.58 (C5), 93.13 (C1’), 82.35 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.04 
(C2’), 77.70 (OCH ester), 77.67 (OCH ester), 74.81 (C3’), 66.28 (d, 2JC-O-P= 5.0 Hz, 
C5’), 54.29 (6OCH3), 51.11 (d, 2JC-N-P = 10.0 Hz, 2x CHCH3), 40.42, 40.36 (CH2 
ester), 20.76 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.62 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 
20.38 (2’CCH3). 
HPLC (System 1) tR= 17.88 min. 
MS (ES+) m/z: 788.28 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(2,2-dimethylpropyl-L-valinyl) phosphate (8.2k). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), 
L-valine 2,2-dimethylpropyl ester 
tosylate salt (1.98 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture 
of dry THF and DCM. The crude mixture was purified by column chromatography 
using CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM 
was performed to remove remaining amino acid ester salt. The pure product 8.2k was 
obtained as a white foam (42 mg, 6%). 
 
31P NMR (202 MHz, MeOD) ! 15.16. 
1H NMR (500 MHz, MeOD) ! 7.99 (s, 1H, H8), 5.99 (s, 1H, H1’), 4.41-4.35 (m, 2H, 
H5’), 4.33 (d, J= 9.0 Hz, 1H, H3’), 4.20- 4.17 (m, 1H, H4’), 4.09 (s, 3H, 6OCH3), 3.87-
3.68 (m,6H, 2x CHCH(CH3)2 and 2x OCH2C(CH3)3), 2.11-1.98 (m, 2H, 2x 
CHCH(CH3)2), 0.99, 0.98 (2s, 3H, 2’CCH3), 0.95, 0.94 (2s, 18H, 2x OCH2C(CH3)3), 
0.89- 0.83 (m, 12H, 2x CHCH(CH3). 
13C NMR (126 MHz, MeOD) ! 174.87, 174.80 (2d, 3J C-C-N-P = 2.5 Hz, 2x C=O), 
162.77 (C6), 161.92 (C2), 154.54 (C4), 139.49 (C8), 115.68 (C5), 93.35 (C1’), 82.55 
(d, 3JC-C-O-P = 8.8 Hz, C4’), 79.92 (C2’), 75.65 (OCH2C(CH3)3),  75.58 
(OCH2C(CH3)3), 75.03 (C3’), 67.11 (d, 2JC-O-P = 5.0 Hz, C5’), 61.09 (CHCH(CH3)2),   
61.03 (CHCH(CH3)2),  54.24 (6OCH3), 33.23 (d, 3JC-C-N-P = 6.3 Hz, 2x CHCH(CH3)2), 
32.14 (2x OCH2C(CH3)3),  32.08 (2x OCH2C(CH3)3), 26.89 (2x OCH2C(CH3)3), 
20.32 (2’CCH3), 18.09 (CHCH(CH3)2), 18.07 (CHCH(CH3)2). 
HPLC(System 1) tR = 22.15 min.  
MS (ES+) m/z: 752.37 (M+Na+, 100%). 
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(cyclohexoxy-L-valinyl) phosphate (8.2l). 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 mmol), 
L-valine cyclohexyl ester 
hydrochloride salt (0.57 g, 2.41 mmol), Et3N (0.67 ml, 4.82 mmol) in 10 ml of 1:1 
mixture of dry THF and DCM. The crude mixture was purified by column 
chromatography using CHCl3/MeOH (0 to 5%, gradient). Additional extraction from 
water using DCM was performed to remove remaining amino acid ester salt. The pure 
product 8.2l was obtained as a white foam (32 mg, 5%). 
 
31P NMR (202 MHz, MeOD) " 15.28. 
1H NMR (500 MHz, MeOD) " 7.96 (s, 1H, H8), 5.98 (s, 1H, H1’), 4.81-4.76 (m, 2H, 
2x OCH ester), 4.41-4.35 (m, 2H, H5’), 4.33 (d, J= 9.0 Hz, 1H, H3’), 4.20- 4.17 (m, 
1H, H4’), 4.07 (s, 3H, 6OCH3), 3.66-3.63 (m, 2H, 2x CHCH(CH3)2), 2.07-1.98 (m, 
2H, 2x CHCH(CH3)2), 1.85- 1.80 (m, 4H, 2x CH2 ester), 1.75- 1.71 (m, 4H, 2x CH2 
ester), 1.55- 1.29 (m, 12H, 6x CH2 ester), 1.00 (s, 3H, 2’CCH3), 0.95 (d, J= 6.5 Hz, 
3H, CHCH(CH3)2), 0.90 (d, J= 6.5 Hz, 3H, CHCH(CH3)2), 0.89 (d, J= 6.5 Hz, 3H, 
CHCH(CH3)2), 0.82 (d, J= 6.5 Hz, 3H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD-d4) " 174.12 (d, 3JC-C-N-P= 5.0 Hz, C=O), 162.77 (C6), 
161.94 (C2), 154.56 (C4), 139.47 (C8), 115.66 (C5), 93.34 (C1’), 82.55 (d, 3J C-C-O-P = 
6.3 Hz, C4’), 79.91 (C2’), 75.02 (C3’), 74.86 (OCH ester), 74.84 (OCH ester), 67.06 
(d, 2J C-O-P = 5.0 Hz, C5’), 61.04 (d, 2JC-N-P = 4.5 Hz, 2x CHCH(CH3)2), 54.22 
(6OCH3), 33.21 (2x CHCH(CH3)2), 32.60 (CH2 ester), 26.43 (CH2 ester), 26.40 (CH2 
ester), 24.68 (CH2 ester), 24.64 (CH2 ester), 20.27 (2’CCH3), 19.48 (CHCH(CH3)2), 
19.37 (CHCH(CH3)2), 18.08 (CHCH(CH3)2), 18.02 (CHCH(CH3)2). 
HPLC (System 1) tR= 22.99 min.  
MS  (ES+) m/z: 776.40 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(benzoxy-L-valinyl) phosphate (8.2m). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (250 mg, 
0.80 mmol), POCl3 (0.07 ml, 0.80 
mmol), Et3N (0.11 ml, 0.80 mmol), 
L-valine benzyl ester tosylate salt 
(0.91 g, 2.41 mmol), Et3N (0.67 ml, 4.82 mmol) in 10 ml of 1:1 mixture of dry THF 
and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2m was 
obtained as a white foam (64 mg, 10%). 
 
31P NMR (202 MHz, MeOD) " 15.11. 
1H NMR (500 MHz, MeOD) " 7.94 (s, 1H, H8), 7.34-7.25 (m, 10H, 2x OCH2Ph), 
5.98 (s, 1H, H1’), 5.19- 5.06 (m, 4H, 2x OCH2Ph), 4.40-4.34 (m, 2H, H5’ and H3’), 
4.20- 4.18 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 3.72-3.68 (m, 2H, 2x CHCH(CH3)2), 
2.02-1.94 (m, 2H, 2x CHCH(CH3)2), 0.99 (s, 3H, 2’CCH3), 0.87 (d, J= 7.0 Hz, 3H, 
CHCH(CH3)2), 0.84 (d, J= 7.0 Hz, 3H, CHCH(CH3)2), 0.79(d, J= 7.0 Hz, 3H, 
CHCH(CH3)2), 0.77 (d, J= 7.0 Hz, 3H, CHCH(CH3)2). 
13C NMR (126 MHz, MeOD) " 174.53 (C=O), 162.75 (C6), 161.90 (C2), 154.54 
(C4), 139.46 (C8), 137.21 (ipso OCH2Ph), 137.14 (ipso OCH2Ph), 129.61, 129.59, 
129.58, 129.55, 129.41, 129.36 (2x OCH2Ph), 115.68 (C5), 93.29 (C1’), 82.49 (d, 3JC-
C-O-P = 8.8 Hz, C4’), 79.94 (C2’), 74.97 (C3’), 67.93 (2x CH2Ph), 66.89 (d, 2JC-O-P = 
5.0 Hz, C5’), 61.09 (d, 2JC-N-P = 4.5 Hz, 2x CHCH(CH3)2), 54.27 (6OCH3), 33.20 (d, 
3J C-C-N-P =6.3 Hz, 2x CHCH(CH3)2), 20.37 (2’CCH3), 19.50 (CHCH(CH3)2), 19.42 
(CHCH(CH3)2), 18.17 (CHCH(CH3)2), 18.12 (CHCH(CH3)2). 
HPLC(System 1) tR= 19.63 min.  
MS (ES+) m/z: 770.33 (M+H+, 100%).  
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Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(methoxy-L-isoleucinyl) phosphate (8.2n). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-methyl-
9-(2’-C-methyl-!-D-ribofuranosyl) purine 
(5.4, 300 mg, 0.96 mmol), POCl3 (0.09 ml, 
0.96 mmol), Et3N (0.13 ml, 0.96 mmol), L-
leucine methyl ester hydrochloride salt 
(1.15 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture of dry THF 
and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2n was 
obtained as a white foam (135 mg, 22%). 
 
31P NMR (202 MHz, MeOD) " 14.88. 
1H NMR (500 MHz, MeOD) " 8.01 (s, 1H, H8), 5.99 (s, 1H, H1’), 4.47-4.38 (m, 2H, 
H5’), 4.34 (d, J= 9.0 Hz, 1H, H3’), 4.20- 4.18 (m, 1H, H4’), 4.07 (s, 3H, 6OCH3), 3.87-
3.83 (m, 2H, 2x CHCH(CH3)CH2CH3), 3.72, 3.70 (2s, 6H, OCH3 ester), 1.74-1.69 (m, 
2H, 2x CHCH(CH3)CH2CH3), 1.44-1.36 and  (m, 2H, CHCH(CH3)CH2CH3), 1.09-
1.03 (m, 2H, CHCH(CH3)CH2CH3), 1.00 (s, 3H, 2’CCH3), 0.91 (d, J= 6.5 Hz, 3H, 
CHCH(CH3)CH2CH3), 0.89 (d, J= 6.5 Hz, 3H, CHCH(CH3)CH2CH3), 0.84 (t, J= 7.5 
Hz, 3H, CHCH(CH3)CH2CH3), 0.82 (t, J= 7.5 Hz, 3H, CHCH(CH3)CH2CH3). 
13C NMR (126 MHz, MeOD) " 175.17 (d, 3JC-C-N-P= 3.8 Hz, 2x C=O), 162.74 (C6), 
161.91 (C2), 154.46 (C4), 139.40 (C8), 115.44 (C5), 93.27 (C1’), 82.51 (d, 3J C-C-O-P = 
7.5 Hz, C4’), 79.97 (C2’), 74.87 (C3’), 66.72 (d, 2J C-O-P = 5.0 Hz, C5’), 60.02 (d, 2JC-
N-P = 4.5 Hz, CHCH(CH3)CH2CH3),  60.00 (d, 2JC-N-P = 4.5 Hz, 
CHCH(CH3)CH2CH3), 54.37 (6OCH3), 52.54, 52.51 (2x OCH3 ester), 33.21 (d, 3J C-C-
N-P = 3.8 Hz CHCH(CH3)CH2CH3), 33.19 (d, 3J C-C-N-P = 7.5 Hz 
CHCH(CH3)CH2CH3), 26.10 (CHCH(CH3)CH2CH3), 26.08 (CHCH(CH3)CH2CH3), 
20.41 (2’CCH3), 15.91 (CHCH(CH3)CH2CH3), 15.83 (CHCH(CH3)CH2CH3), 11.93 
(CHCH(CH3)CH2CH3). 
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MS (ES+) m/z: 668.28 (M+Na+, 100%).  
HRMS C26H44N7O10Na1P1 calculated: 668.2785 found: 668.2759. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(2,2-dimethylpropoxy-L-isoleucinyl) phosphate (8.2o). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), 
L-leucine 2,2-dimethylpropyl ester tosylate salt (3.2p, 1.80 g, 4.82 mmol), Et3N (1.34 
ml, 9.63 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude mixture was 
purified by column chromatography using CHCl3/MeOH (0 to 5%, gradient). 
Additional extraction from water using DCM was performed to remove remaining 
amino acid ester salt. The pure product 8.2o was obtained as a white foam (210 mg, 
29%). 
 
31P NMR (202 MHz, MeOD) " 14.93. 
1H NMR (500 MHz, MeOD-d4) " 7.96 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.41-4.40 (m, 
2H, H5’), 4.34 (d, J= 8.5 Hz, 1H, H3’), 4.21- 4.20 (m, 1H, H4’), 4.07 (s, 3H, 6OCH3), 
3.84-3.72 (m, 6H, 2x OCH2C(CH3)3 and 2x CHCH(CH3)CH2CH3), 1.81-1.78 (m, 2H, 
2x CHCH(CH3)CH2CH3), 1.46-1.41, 1.39-1.33 (2m, 2H, CHCH(CH3)CH2CH3), 1.16-
1.11, 1.07-1.04 (2m, 2H, CHCH(CH3)CH2CH3), 1.00 (s, 3H, 2’CCH3), 0.95, 0.94 (2s, 
2x OCH2C(CH3)3), 0.91 (d, J= 6.5 Hz, 3H, CHCH(CH3)CH2CH3), 0.88 (d, J= 6.5 Hz, 
3H, CHCH(CH3)CH2CH3), 0.83 (t, J= 7.5 Hz, 3H, CHCH(CH3)CH2CH3), 0.81 (t, J= 
7.5 Hz, 3H, CHCH(CH3)CH2CH3). 
13C NMR (126 MHz, MeOD-d4) " 174.79, 174.72  (2d, 3JC-C-N-P= 3.8 Hz, 2x C=O), 
162.79 (C6), 161.90 (C2), 154.58 (C4), 139.46 (C8), 115.70 (C5), 93.28 (C1’), 82.56 
(d, 3J C-C-O-P = 6.3 Hz, C4’), 79.97 (C2’), 75.72, 75.64 (2x OCH2C(CH3)3), 74.98 
(C3’), 67.00 (d, 2J C-O-P = 5.0 Hz, C5’), 60.17 (CHCH(CH3)CH2CH3),  60.07 
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(CHCH(CH3)CH2CH3), 32.14 (OCH2C(CH3)3),  32.09 (OCH2C(CH3)3), 27.08 
(OCH2C(CH3)3), 26.98 (OCH2C(CH3)3), 26.04 (2x CHCH(CH3)CH2CH3), 20.43 
(2’CCH3), 16.14 (CHCH(CH3)CH2CH3), 16.03 (CHCH(CH3)CH2CH3), 12.13 
(CHCH(CH3)CH2CH3), 12.09 (CHCH(CH3)CH2CH3). 
HPLC (System 1) tR= 24.55 min.  
MS (ES+) m/z: 780.40 (M+Na+, 100%).  
HRMS C34H61N7O10P1 calculated: 758.4218 found: 758.4196. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(cyclohexoxy-L-isoleucinyl) phosphate (8.2p). 
 
Prepared according to the standard 
procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), 
L-leucine cyclohexyl ester tosylate 
salt (3.2o, 1.86 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture of 
dry THF and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2p was 
obtained as a white foam (140 mg, 19%). 
 
31P NMR (202 MHz, MeOD) " 15.04. 
1H NMR (500 MHz, MeOD) " 7.97 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.80-4.74 (m, 2H, 
2x OCH ester), 4.43-4.39 (m, 2H, H5’), 4.33 (d, J= 9.0 Hz, 1H, H3’), 4.22- 4.19 (m, 
1H, H4’), 4.07 (s, 3H, 6OCH3), 3.74-3.73 (m, 2H, 2x CHCH(CH3)CH2CH3), 1.82- 
1.80 (m, 4H, 2x CH2 ester), 1.75- 1.70 (m, 6H, 2x CH2 ester and 2x 
CHCH(CH3)CH2CH3), 1.55- 1.29 (m, 14H, 6x CH2 ester and CHCH(CH3)CH2CH3), 
1.15-1.02 (m, 2H, CHCH(CH3)CH2CH3), 1.00 (s, 3H, 2’CCH3), 0.91 (d, J= 6.5 Hz, 
3H, CHCH(CH3)CH2CH3), 0.88 (d, J= 6.5 Hz, 3H, CHCH(CH3)CH2CH3), 0.85 (d, J= 
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13C NMR (126 MHz, MeOD) ! 174.05 (d, 3JC-C-N-P= 3.8 Hz, C=O), 174.03 (d, 3JC-C-N-
P= 3.8 Hz, C=O), 162.79 (C6), 161.91 (C2), 154.59 (C4), 139.44 (C8), 115.69 (C5), 
93.26 (C1’), 82.54 (d, 3J C-C-O-P = 7.5 Hz, C4’), 79.97 (C2’), 74.98 (C3’), 74.82 (2x 
OCH ester), 66.11 (d, 2J C-O-P = 5.0 Hz, C5’), 60.02 (2x CHCH(CH3)CH2CH3), 54.33 
(6OCH3), 40.30 (4x CH2 ester), 32.64 (d, 3J C-C-N-P = 3.8 Hz, CHCH(CH3)CH2CH3), 
32.60 (d, 3J C-C-N-P = 7.5 Hz, CHCH(CH3)CH2CH3), 26.47 (CH2 ester), 26.44 (CH2 
ester), 26.09 (2x CHCH(CH3)CH2CH3), 24.69 (CH2 ester), 24.67 (CH2 ester), 20.42 
(2’CCH3), 16.01 (CHCH(CH3)CH2CH3),  15.91 (CHCH(CH3)CH2CH3), 12.14 
(CHCH(CH3)CH2CH3),  12.08 (CHCH(CH3)CH2CH3). 
HPLC (System 1) tR= 25.45 min. 
MS (ES+) m/z: 804.41 (M+Na+, 100%);  
HRMS C36H61N7O10P1 calculated: 782.4218 found: 782.4234 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-"-D-ribofuranosyl) purine 5’-O-
bis(benzoxy-L-isoleucinyl) phosphate (8.2q). 
  
Prepared according to the 
Standard Procedure 13a, from: 2-
amino-6-O-methyl-9-(2’-C-
methyl-"-D-ribofuranosyl) purine 
(5.4, 300 mg, 0.96 mmol), POCl3 
(0.09 ml, 0.96 mmol), Et3N (0.13 
ml, 0.96 mmol), L-leucine benzyl 
ester tosylate salt (1.89 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 
mixture of dry THF and DCM. The crude mixture was purified by column 
chromatography using CHCl3/MeOH (0 to 5%, gradient). Additional extraction from 
water using DCM was performed to remove remaining amino acid ester salt. The pure 
product 8.2q was obtained as a white foam (200 mg, 16%). 
 
31P NMR (202 MHz, MeOD) ! 14.93. 
1H NMR (500 MHz, MeOD) ! 7.92 (s, 1H, H8), 7.42-7.28 (m, 10H, 2x OCH2Ph), 
5.99 (s, 1H, H1’), 5.21-5.18 (m, 4H, 2x OCH2Ph), 4.43-4.40 (m, 2H, H5’), 4.37 (d, J= 
8.5 Hz, 1H, H3’), 4.19- 4.15 (m, 1H, H4’), 4.03 (s, 3H, 6OCH3), 3.74-3.73 (m, 2H, 2x 
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2H, CHCH(CH3)CH2CH3), 1.15-1.02 (m, 2H, CHCH(CH3)CH2CH3), 1.00 (s, 3H, 
2’CCH3), 0.83-0.69 (m, 12H, 2x CHCH(CH3)CH2CH3 and 2x CHCH(CH3)CH2CH3). 
13C NMR (126 MHz, MeOD) ! 174.47 (2x C=O), 162.77 (C6), 161.90 (C2), 154.58 
(C4), 139.42 (C8), 137.19 (ipso OCH2Ph), 137.12 (ipso OCH2Ph), 129.93, 129.59, 
129.42, 129.39 (2x OCH2Ph), 115.68 (C5), 93.22 (C1’), 82.49 (d, 3J C-C-O-P = 7.5 Hz, 
C4’), 79.95 (C2’), 74.91 (C3’), 67.91 (OCH2Ph), 67.75 (OCH2Ph), 66.77 (d, 2J C-O-P = 
5.0 Hz, C5’), 60.19 (CHCH(CH3)CH2CH3), 60.10 (CHCH(CH3)CH2CH3), 54.31 
(6OCH3), 40.16 (d, 3J C-C-N-P = 3.8 Hz, CHCH(CH3)CH2CH3), 40.11 (d, 3J C-C-N-P = 
3.8 Hz, CHCH(CH3)CH2CH3), 25.96 (CHCH(CH3)CH2CH3),  25.92 
(CHCH(CH3)CH2CH3), 20.42 (2’CCH3), 15.87(CHCH(CH3)CH2CH3), 15.74 
(CHCH(CH3)CH2CH3), 11.95 (CHCH(CH3)CH2CH3),11.92 (CHCH(CH3)CH2CH3). 
HPLC (System 1) tR= 20.88 min. 
MS (ES+) m/z: 820.34 (M+Na+, 100%).  
HRMS C38H52N7O10Na1P1 calculated: 820.3411 found: 820.3378. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-"-D-ribofuranosyl) purine 5’-O-
bis(cyclohexoxy-L-methioninyl) phosphate (8.2s). 
  
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-"-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), L-
methionine cyclohexyl ester tosylate 
salt (3.2l, 1.94 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture of 
dry THF and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2s was 
obtained as a white foam (160 mg, 20%). 
 
31P NMR (202 MHz, MeOD) ! 14.26. 
1H NMR (500 MHz, MeOD) ! 8.07 (s, 1H, H8), 6.00 (s, 1H, H1’), 4.79-4.74 (m, 1H, 
OCH ester), 4.73-4.70 (m, 1H, OCH ester), 4.45-4.36 (m, 2H, H5’), 4.30 (d, 1H, J= 
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8.5 Hz, H3’), 4.23-4.20 (m, 1H, H4’), 4.08 (s, 3H, 6OCH3), 4.02-3.97 (m, 2H, 2x 
CHCH2CH2SCH3), 2.61-2.48 (m, 4H, 2x CHCH2CH2SCH3), 2.07, 2.05 (2s, 6H, 2x 
CHCH2CH2SCH3), 2.02-1.87 (m, 4H, 2x CHCH2CH2SCH3), 1.86- 1.79 (m, 4H, 2x 
CH2 ester), 1.73- 1.71 (m, 4H, 2x CH2 ester), 1.47- 1.30 (m, 12H, 6x CH2 ester), 1.01 
(s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.30, 174.21 (2d, 3J C-C-N-P = 5.3 Hz, 2x C=O), 
162.66 (C6), 161.987 (C2), 154.19 (C4), 139.34 (C8), 115.05 (C5), 93.33 (C1’), 82.61 
(d, 3JC-C-O-P = 6.5 Hz, C4’), 80.03 (C2’), 75.07 (OCH ester), 75.02 (OCH ester), 74.84 
(C3’), 66.74 (d, 2J C-O-P = 5.3 Hz, C5’), 54.87 (CHCH2CH2SCH3), 54.79 
(CHCH2CH2SCH3), 54.41 (6OCH3), 34.67 (d, 3J C-C-N-P = 2.6 Hz, CHCH2CH2SCH3), 
34.62 (d, 3J C-C-N-P = 2.6 Hz, CHCH2CH2SCH3), 32.53 (CH2 ester), 30.95 
(CHCH2CH2SCH3), 30.87 (CHCH2CH2SCH3), 26.47 (CH2 ester), 26.44 (CH2 ester), 
24.71 (CH2 ester), 24.68 (CH2 ester), 20.33 (2’CCH3), 15.29 (CHCH2CH2SCH3), 
15.23 (CHCH2CH2SCH3). 
HPLC (System 1) tR= 21.60 min.  
MS (ES+) m/z: 840.32 (M+Na+, 100%).  
HRMS C34H57N7O10P1S2 calculated: 818.3346 found: 818.3359. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(benzoxy-L-methioninyl) phosphate (8.2t). 
  
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), L-
methionine benzyl ester tosylate salt 
(3.2m, 1.94 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture of dry 
THF and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2t was 
obtained as a white foam (130 mg, 16%). 
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31P NMR (202 MHz, MeOD) ! 14.11. 
1H NMR (500 MHz, MeOD) ! 7.95 (s, 1H, H8), 7.36-7.30 (2x OCH2Ph) 5.97 (s, 1H, 
H1’), 5.19-5.05 (m, 2x OCH2Ph), 4.41-4.31 (m, 2H, H5’ and H3’), 4.19-4.17 (m, 1H, 
H4’), 4.04 (s, 3H, 6OCH3), 4.07-4.03 (m, 2H, 2x CHCH2CH2SCH3), 2.51-2.39 (m, 
4H, 2x CHCH2CH2SCH3), 1.99 (s, 3H, CHCH2CH2SCH3), 1.95 (s, 3H, 
CHCH2CH2SCH3), 1.90-1.80 (m, 4H, 2x CHCH2CH2SCH3), 1.00 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 173.78 (d, 3J C-C-N-P = 4.8 Hz, C=O), 173.75 (d, 3J C-C-
N-P = 4.8 Hz, C=O), 161.91 (C6), 161.04 (C2), 153.73 (C4), 138.55 (C8), 136.39 (ipso 
OCH2Ph), 136.35 (ipso OCH2Ph), 128.77, 128.66, 128.63, 128.56, 128.53 (2x 
OCH2Ph), 114.79 (C5), 92.37 (C1’), 81.59 (d, 3JC-C-O-P = 7.3 Hz, C4’), 79.20 (C2’), 
74.00 (C3’), 67.25 (d, 2J C-O-P = 6.3 Hz, C5’), 65.81 (OCH2Ph), 65.77 (OCH2Ph), 
53.87 (CHCH2CH2SCH3), 53.72 (CHCH2CH2SCH3), 53.42 (6OCH3), 33.62 
(CHCH2CH2SCH3), 33.57 (CHCH2CH2SCH3), 29.98 (CHCH2CH2SCH3), 29.93 
(CHCH2CH2SCH3), 19.50 (2’CCH3), 14.36 (CHCH2CH2SCH3), 14.30 
(CHCH2CH2SCH3). 
HPLC (System 1) tR= 19.05 min.  
MS (ES+) m/z: 856.25 (M+Na+, 100%).  
HRMS C34H57N7O10P1S2 calculated: 834.2720 found: 834.2692. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
bis(benzoxy-!-alaninyl) phosphate (8.2t). 
 
 Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (5.4, 300 mg, 
0.96 mmol), POCl3 (0.09 ml, 0.96 
mmol), Et3N (0.13 ml, 0.96 mmol), 
!-alanine benzyl ester tosylate salt 
(1.69 g, 4.82 mmol), Et3N (1.34 ml, 9.63 mmol) in 10 ml of 1:1 mixture of dry THF 
and DCM. The crude mixture was purified by column chromatography using 
CHCl3/MeOH (0 to 5%, gradient). Additional extraction from water using DCM was 
performed to remove remaining amino acid ester salt. The pure product 8.2t was 
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obtained as a white foam (170 mg, 25%). 
 
31P NMR (202 MHz, MeOD) ! 17.45. 
1H NMR (500 MHz, MeOD) ! 8.00 (s, 1H, H8), 7.32-7.25 (m, 10H, 2x OCH2Ph), 
6.00 (s, 1H, H1’), 5.08-5.06 (m, 4H, 2x OCH2Ph), 4.33-4.26 (m, 3H, H5’ and H3’), 
4.20- 4.17 (m, 1H, H4’), 4.03 (s, 3H, 6OCH3), 3.21-3.15 (m, 4H, 2x NHCH2CH2), 
2.56 (t, J= 6.7 Hz, 2H, NHCH2CH2), 2.55 (t, J= 6.7 Hz, 2H, NHCH2CH2), 0.97 (s, 
3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 173.42 (C=O), 162.72 (C6), 161.89 (C2), 154.63 
(C4), 139.10 (C8), 137.52 (2x ipso OCH2Ph), 129.87, 129.55, 129.21, 129.18 (2x 
OCH2Ph), 115.53 (C5), 92.96 (C1’), 82.28 (d, 3JC-C-O-P = 8.8 Hz, C4’), 79.51 (C2’), 
74.44 (C3’), 67.33 (2x OCH2Ph), 65.48 (d, 2JC-O-P = 5.0 Hz, C5’), 54.29 (6OCH3), 
38.10 (d, 3J C-C-N-P =5.0 Hz, NHCH2CH2), 37.99 (d, 3J C-C-N-P =3.8 Hz, NHCH2CH2), 
37.38 (NHCH2CH2), 37.34 (NHCH2CH2), 20.36 (2’CCH3). 
HPLC (System 1) tR=16.12 min. 
MS (ES+) m/z: 736.32 (M+Na+, 100%).  
HRMS C3H41N7O10P1 calculated: 714.2653 found: 714.2623. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-"-D-ribofuranosyl) purine 5’,3’-
O- (2,2-dimethylpropoxy-L-alaninyl) cyclic phosphate (8.6). 
 
200 mg of 5.12l (0.31 mmol) was 
dissolved in 5 ml of dry THF. L-
alanine butyl ester hydrochloride salt 
(166 mg, 0.92 mmol) was added 
followed by the addition of 5 ml of 
DCM. The reaction mixture was 
cooled down to -78 °C and DIPEA (0.32 ml, 1.84 mmol) was added, The reaction 
mixture was stirred for 20 min at -78 °C and after that time was allowed to warm to 
ambient temperature. When after 24 h, TLC analysis showed no product formation, 
reaction was heated up to 50 C and the reaction mixture was stirred for additional 24 
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silca gel, using CHCl/MeOH (0 to 5%, gradient) as en eluent, to provide pure 8.6 as a 
White solid (22 mg, 14%). 
 
31P NMR (202 MHz, MeOD) ! 7.56, 5.54. 
1H NMR (500 MHz, MeOD) ! 7.93, 7.92 (2s, 1H, H8), 5.95, 5.94 (2s, 1H, H1’), 4.71-
4.64 (m, 1H, H3’), 4.63-4.51 (m, 1H, H3’, H5’a), 4.35-4.30 (m, 1H, H5’b), 4.08, 4.07 
(2s, 3H, 6OCH3), 4.05–4.00 (m, 1H, CHCH3), 3.95, 3.91, 3.86, 3.77 (2AB, JAB= 10.5 
Hz, 2H, OCH2C(CH3)3), 1.51, 1.46 (2d, J= 7.5 Hz, 3H, CHCH3), 1.15, 1.10 (2s, 3H, 
2’CCH3),  1.00, 0.99 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.66, 175.02 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 162.82 
(C6), 161.97, 161.90 (C2), 154.32 (C4), 140.30, 140.28 (C8), 115.96 (C5), 93.38, 
93.22 (C1’), 82.85, 81.90 (C4’), 78.36 (d, 3JC-C-O-P = 8.8 Hz, C2’), 78.21 (d, 3JC-C-O-P = 
7.6 Hz, C2’), 75.68, 75.47 (OCH2C(CH3)3), 73.54, 72.67 (2d, 2JC-O-P = 8.8 Hz, C3’), 
70.73 (d, 2JC-O-P = 8.8 Hz, C5’), 70.21 (d, 2JC-O-P = 7.6 Hz, C5’), 54.21, 54.18 
(6OCH3), 50.85 (C!CH3), 32.40 (OCH2C(CH3)3), 26.81, 26.73 (OCH2C(CH3)3), 
20.63 (d, 3JC-C-N-P = 5.0 Hz, CHCH3), 20.45 (d, 3JC-C-N-P = 6.3 Hz, CHCH3), 19.94, 
19.74 (2’CCH3). 
HPLC  (System 1) tR = 13.96 min. 
MS (ES+) m/z: 515.20 (M+Na+, 100%). 
HRMS calculated for C20H32N6O8PNa: 515.2019; found 515.1998. 
 
Synthesis of 2,2-dimethylpropoxy-L-alaninyl phoshorodichloridate (8.7a). 
 
To a solution of L-alanine 2,2-dimethylpropyl ester tosylate salt (3.2g, 
2.5 g, 7.54 mmol) and POCl3 (0.69 ml, 7.54 mmol) in dry DCM (50 ml), 
Et3N (1.92 ml, 15.08 mmol) was added at -78 °C. The reaction mixture 
was stirred at -78 °C for 1 h and after that time was allowed to warm to 
ambient temperature and was stirred for additional 1.5 h. After that time 
solvent was removed in vacuum and the crude was dissolved in diethyl ether (30 ml) 
and salts were filtered off. The solvent was evaporated and the product 8.7b was 
obtained as clear oil (1.77 g, 83%).  
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1H NMR (500 MHz, CDCl3) 4.96 (bs, 1H, NH), 4.29–4.16 (m, 1H, CHCH3), 3.97, 
3.95, 3.91, 3.88 (2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 1.56, 1.55 (2d, J= 5.5 Hz, 
3H, CHCH3), 0.98, 0.97 (2s, 9H, OCH2C(CH3)3). 
 
Synthesis of benzoxy-L-alaninyl phoshorodichloridate (8.7b). 
 
 To a solution of L-alanine benzyl ester tosylate salt (2.5 g, 7.11 
mmol) and POCl3 (0.65 ml, 7.54 mmol) in dry DCM (50 ml), Et3N 
(1.81 ml, 14.22 mmol) was added at -78 °C. The reaction mixture was 
stirred at -78 °C for 1 h and after that time was allowed to warm to 
ambient temperature and was stirred for additional 1.5 h. After that 
time solvent was removed in vacuum and the crude was dissolved in 
diethyl ether (30 ml) and salts were filtered off. The solvent was evaporated and the 
product 8.7b was obtained as clear oil (1.68 g, 80%).  
 
31P NMR (202 MHz, CDCl3) ! 12.77. 
1H NMR (500 MHz, CDCl3) ! 7.44-7.37 (m, 5H, OCH2Ph), 5.27 (s, 2H, OCH2Ph), 
4.95 (bs, 1H, NH), 4.27- 4.21 (m, 1H, CHCH3),  1.55 (d, J= 7.0 Hz, 3H, CHCH3). 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
butylamine-(benzoxy-L-alaninyl) phosphate (8.8a). 
 
Prepared according to the Standard 
Procedure 13c: In a first step, a 
suspension of 6-O-methyl-2’-C-
methylguanosine (5.4, 200 mg, 0.64 
mmol) in anhydrous tetrahydrofuran (5 
mL) was allowed to react with 
triethylamine (0.11 ml, 0.771 mmol) and 
L-alaninyl benzyl ester phosphorodichloridate (8.7b, 380 mg, 1.29 mmole). 
Butylamine (0.32 ml, 3.21mmole) and triethylamine (0.45 ml, 3.21 mmol) were 
added. After silica gel column chromatography, using CHCl3/MeOH as en eluent, the 
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31P NMR (202 MHz, MeOD) ! 16.25, 16.09. 
1H NMR (500 MHz, MeOD) ! 7.99, 7.98 (2s, 1H, H8), 5.99, 5.98 (2s, 1H, H1'), 4.35- 
4.34 (m, 2H, H5') 4.27 (d, J=9.0 Hz, 1H, H3'), 4.19- 4.17 (m, 1H, H4'), 4.07 (s, 3H, 
6OCH3), 3.91- 3.79 (m, 1H, CHCH3), 3.83, 3.70 (AB, JAB= 12.0 Hz, 2H, 
OCH2C(CH3)3), 2.92- 2.87 (m, 2H, NHCH2CH2CH2CH3), 1.47-1.43 (m, 2H, 
NHCH2CH2CH2CH3), 1.37 (d, J=7.5 Hz, 3H, CHCH3), 1.33- 1.29 (m, 2H, 
NHCH2CH2CH2CH3), 0.99, 0.98 (2s, 3H, 2'CCH3), 0.94, 0.93 (2s, 9H, 
OCH2C(CH3)3), 0.89 (t, J= 7.5 Hz, 3H, NHCH2CH2CH2CH3). 
HPLC (System 1) tR = 13.79 min. 
MS (EI+) m/z: 607.25 (M+H+, 100%).  
HRMS C26H38N7O8P1 Calculated: 607.2520 found: 607.2504. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-"-D-ribofuranosyl) purine 5’-O-
butylamine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8b). 
 
Prepared according to the Standard 
Procedure 13c: In a first step, a suspension 
of 6-O-methyl-2’-C-methylguanosine (5.4, 
200 mg, 0.64 mmol) in anhydrous 
tetrahydrofuran (5 mL) was allowed to 
react with triethylamine (0.11 ml, 0.771 
mmol) and L-alaninyl 2,2-dimethylpropyl ester phosphorodichloridate (8.7a, 355 mg, 
1.29 mmole). Butylamine (0.32 ml, 3.21mmole) and triethylamine (0.45 ml, 3.21 
mmol) were added. After silica gel column chromatography, using CHCl3/MeOH as 
en eluent, the pure 8.8b was obtained as an off white solid (11 mg, 3%). 
 
31P NMR (202 MHz, MeOD) ! 16.25, 16.09. 
1H NMR (500 MHz, MeOD) ! 7.99, 7.98 (2 s, 1H, H8), 5.99, 5.98 (2s, 1H, H1'), 4.35- 
4.34 (m, 2H, H5') 4.27 (d, J= 9.0 Hz, 1H, H3'), 4.19- 4.17 (m, 1H, H4'), 4.07 (s, 3H, 
6OCH3), 3.91- 3.79 (m, 1H, CHCH3), 3.83, 3.70 (AB, JAB= 12.0 Hz, 2H, 
OCH2C(CH3)3), 2.92- 2.87 (m, 2H, NHCH2CH2CH2CH3), 1.47- 1.43 (m, 2H, 
NHCH2CH2CH2CH3), 1.37 (d, J= 7.5 Hz, 3H, CHCH3), 1.33- 1.29 (m, 2H, 
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NHCH2CH2CH2CH3), 0.99, 0.98 (2 s, 3H, 2’CCH3), 0.94, 0.93 (2s, 9H, 
OCH2C(CH3)3), 0.89 (t, J= 7.5 Hz, 3H, NHCH2CH2CH2CH3). 
HPLC (System 1) tR = 14.71 min. 
MS (EI+) m/z: 587.28 (M+H+, 100%).  
HRMS C24H42N7O8P1 Calculated: 587.2833 found: 587.2813. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
pentylamine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8c). 
 
Prepared according to the Standard 
Procedure 13c: In a first step, a 
suspension of 6-O-methyl-2’-C-
methylguanosine (5.4, 200 mg, 0.64 
mmol) in anhydrous tetrahydrofuran (5 
mL) was allowed to react with 
triethylamine (0.11 ml, 0.771 mmol) and L-alaninyl 2,2-dimethylpropyl ester 
phosphorodichloridate (8.7a, 355 mg, 1.29 mmole). Pentylamine (0.56 ml, 
3.21mmole) and triethylamine (0.45 ml, 3.21 mmol) were added. After silica gel 
column chromatography, using CHCl3/MeOH as en eluent, the pure 8.8c was obtained 
as an off white solid (14 mg, 3%). 
 
31P NMR (202 MHz, MeOD) " 16.28, 16.12. 
1H NMR (500 MHz, MeOD) " 8.02, 8.01 (2 s, 1H, H8), 6.00, 5.99 (2 s, 1H, H1'), 4.36- 
4.33 (m, 2H, H5') 4.29, 4.28 (2d, J= 9.0 Hz, 1H, H3'), 4.20- 4.17 (m, 1H, H4'), 4.07 (s, 
3H, 6OCH3), 3.94-3.90 (m, 1H, CHCH3), 3.87, 3.83, 3.75, 3.70 (2AB, JAB= 10.5 Hz, 
2H, OCH2C(CH3)3), 2.90- 2.85 (m, 2H, NHCH2CH2CH2CH2CH3), 1.50-1.43 (m, 2H, 
NHCH2CH2CH2CH2CH3), 1.39, 1.37 (2d, J= 6.0 Hz, 3H, CHCH3), 1.31-1.21 (m, 4H, 
NHCH2CH2CH2CH2CH3 and NH-CH2CH2CH2CH2CH3), 0.99, 0.98 (2s, 3H, 2'CCH3), 
0.94, 0.93 (2s, 9H, OCH2C(CH3)3), 0.87-85 (m, 3H, NHCH2CH2CH2CH2CH3). 
13C NMR (127 MHz, MeOH-d4) " 175.75, 175.68 (C=O), 162.72 (C6), 161.92 (C2), 
154.61, 154.57 (C4), 139.25, 139.11 (C8), 115.43 (C5), 93.05, 92.94 (C1’), 82.41, 
82.34 (2d, 3JC-C-O-P=8.8 Hz, C4’), 80.08, 80.04 (C2’), 75.34, 75.31 (OCH2C(CH3)3), 
74.60, 74.37 (C3’), 65.90, 65.49 (2d, 2JC-O-P=5.0 Hz, C5’), 54.21 (6OCH3), 51.27, 
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51.16 (CHCH3), 42.06 (NHCH2CH2CH2CH2CH3), 32.76 (d, 3JC-C-N-P=5.0 Hz 
NHCH2CH2CH2CH2CH3), 32.72 (d, 3JC-C-N-P=6.3 Hz NHCH2CH2CH2CH2CH3), 32.27 
(OCH2C(CH3)3), 30.11, 30.08 (NHCH2CH2CH2CH2CH3), 26.74, 26.72 
(OCH2C(CH3)3), 23.46 (NHCH2CH2CH2CH2CH3), 21.19 (d, 3JC-C-N-P=6.3 Hz, 
CHCH3), 21.96 (d, 3JC-C-N-P=6.3 Hz, CHCH3), 20.24 (2’CCH3), 14.40 
(NHCH2CH2CH2CH2CH3). 
HPLC (System 1) tR = 17.11 min.  
MS (EI+) m/z: 624.34 (MNa+, 100%).  
HRMS C25H45N7O8P1 Calculated: 602.3067 found: 602.3057. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
cyclopropylamine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8d). 
 
Prepared according to the Standard 
Procedure 13c: In a first step, a suspension 
of 6-O-methyl-2’-C-methylguanosine (5.4, 
200 mg, 0.64 mmol) in anhydrous 
tetrahydrofuran (5 mL) was allowed to react 
with triethylamine (0.11 ml, 0.771 mmol) 
and L-alaninyl 2,2-dimethylpropyl ester phosphorodichloridate (8.7a, 355 mg, 1.29 
mmole). Cyclopropylamine (0.33 ml, 3.21mmole) and triethylamine (0.45 ml, 3.21 
mmol) were added. After silica gel column chromatography, using CHCl3/MeOH as 
en eluent, the pure 8.8d was obtained as an off white solid (14 mg, 3%). 
 
31P NMR (202 MHz, MeOD) " 16.03, 15.77. 
1H NMR (500 MHz, MeOD) " 8.04, 8.03 (2s, 1H, H8), 6.01, 5.99 (2s, 1H, H1'), 4.42- 
4.31 (m, 2H, H5') 4.29-4.25 (m, 1H, H3'), 4.20-4.17 (m, 1H, H4'), 4.08, 4.07 (2s, 3H, 
6OCH3), 3.97- 3.92 (m, 1H, CHCH3), 3.87, 3.82, 3.75, 3.68 (2AB, JAB= 10.5 Hz, 2H, 
OCH2C(CH3)3), 2.41-2.36 (m, 1H, NHCH cyclopropylamine), 1.39 (d, J=6.5 Hz, 3H, 
CHCH3), 1.38 (d, J=6.5 Hz, 3H, CHCH3), 0.99, 0.98 (2s, 3H, 2'CCH3), 0.94, 0.92 (2s, 
9H, OCH2C(CH3)3 ester), 0.58-52 (m, 4H, 2x CH2 cyclopropylamine). 
13C NMR (127 MHz, MeOD) " 175.70, 175.67 (C=O), 162.71 (C6), 161.99 (C2), 
154.62, 154.56 (C4), 139.24, 139.00 (C8), 115.42, 115.33 (C5), 93.07, 92.82 (C1’), 
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82.40, 82.24 (2d, 3JC-C-O-P=8.8 Hz, C4’), 80.10, 80.04 (C2’), 75.35, 75.30 
(OCH2C(CH3)3). 74.56, 74.23 (C3’), 65.86, 65.23 (2d, 2JC-O-P=5.0Hz, C5’), 54.20 
(6OCH3), 51.30, 51.14 (CHCH3), 32.26 (OCH2C(CH3)3), 26.73, 26.70 
(OCH2C(CH3)3), 23.46 (NHCH cyclopropylamine), 21.23, 20.99 (2d, 3JC-C-N-P=6.3 
Hz, CHCH3), 20.23 (2’CCH3), 7.46, 7.26 (2x CH2 cyclopropylamine). 
HPLC (System 1) tR = 13.17 min.  
MS (EI+) m/z: 594.29 (MNa+, 100%).  
HRMS C23H39N7O8P1 Calculated: 572.2587 found: 572.2598. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
(2,2-dimethylpropoxy-L-alaninyl)-(benzoxy-L-alaninyl) phosphate (8.8e). 
 
 Prepared according to the Standard 
Procedure 13b: In the first step, a 
suspenssion of 6-O-methyl-2’-C-
methylguanosine (5.4, 250 mg, 0.80 
mmol) in anhydrous tetrahydrofuran 
(5 ml) was allowed to react with 
triethylamine (0.11 ml, 0.80 mmol) 
and phosphorus oxychloride (0.07 ml, 0.80 mmol). In the second step, L-alanine 
benzyl ester tosylate salt (282 mg, 0.80 mmol) and triethylamine (0.11 ml, 0.80 
mmol) were added, followed by the addition of anhydrous dichloromethane (4 mL). 
In the third step, L-alanine 2,2-dimethylpropyl ester tosylate salt (3.2g, 1.33g, 4.02 
mmol) and triethylamine (1.12 mL, 8.03 mmol) were added.  After silica gel column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient), the pure compound 8.8e 
was obtained as an off white solid (25 mg, 4%). 
 
31P NMR (202 MHz, MeOD) 13.98, 13.94. 
1H NMR (500 MHz, MeOD) 7.97, 7.96 (2s, 1H, H8), 7.36-7.30 (m, 5H, OCH2Ph), 
5.98, 5.97 (2s, 1H, H1'), 5.18- 5.09 (m, 2H, OCH2Ph), 4.39- 4.33 (m, 2H, H5'), 4.28 
(2d, J= 8.00 Hz, 1H, H3'), 4.20- 4.16 (m, 1H, H4'), 4.06, 4.05 (2s, 3H, 6OCH3), 4.02- 
3.94 (m, 2H, 2x CHCH3), 3.84, 3.82, 3.72, 3.67 (2AB, JAB= 10.50 Hz, 2H, 
CH2C(CH3)3), 1.39- 1.32 (m, 6H, 2x CHCH3), 0.97 (s, 3H, 2’CCH3), 0.93, 0.91 (2s, 
9H, CH2C(CH3)3). 
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13C NMR (126 MHz, MeOD) 175.54, 175.43, 175.39 (C=O), 162.73, 162.71 (C6), 
161.93, 161.89 (C2), 154.57, 154.55 (C4), 139.32, 139.08 (C8), 137.39 (ipso 
OCH2Ph), 129.55, 129.35, 129.25, 129.23, 129.20, 129.16, 128.27, 128.00 
(OCH2Ph), 116.19, 115.54 (C5), 93.34, 93.18 (C1’), 82.39, 82.33 (C4’), 80.01, 79.99 
(C2’), 75.34, 75.04 (CH2C(CH3)3), 74.84, 74.82 (C3’), 67.88, 67.85 (OCH2Ph), 67.86 
(d, 2JC-O-P= 3.75 Hz, C5’), 66.36 (d, 2JC-O-P= 5.50 Hz, C5’), 54.18, 54.01 (6OCH3), 
49.69, 49.64, 49.52, 49.46 (2x CHCH3), 32.28, 32.25 (CH2C(CH3)3), 26.74, 26.71 
(CH2C(CH3)3), 21.07, 20.90, 20.79, 20.66 (4d, 3JC-C-N-P= 6.25 Hz, 2x CHCH3), 20.39, 
20.25 (2’CCH3). 
HPLC (System 1) tR = 16.11, 16.80 min.  
MS (ES+) m/z: 716.28 (M+Na+, 100%).  
HRMS C30H44N7O10P1 calculated: 694.2966 found: 694.2956. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
diethylamine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8f). 
 
 Prepared according to the Standard 
Procedure 13b: In the first step, a 
suspenssion of 6-O-methyl-2’-C-
methylguanosine (5.4, 300 mg, 0.96 mmol) 
in anhydrous tetrahydrofuran (5 ml) was 
allowed to react with triethylamine (0.16 ml, 
0.96 mmol) and phosphorus oxychloride 
(0.11 ml, 0.96 mmol). In the second step, diethylamine (0.10 ml, 0.96 mmol) and 
triethylamine (0.13 ml, 0.96 mmol) were added. In the third step, L-alanine 2,2-
dimethylpropyl ester tosylate salt (3.2g, 1.56g, 4.82 mmol) and triethylamine (1.34 
mL, 9.64 mmol) were added followed by the addition of anhydrous dichloromethane 
(4 mL). After silica gel column chromatography, using CHCl3/MeOH (0 to 5%, 
gradient), the pure compound 8.8f was obtained as a white solid (15 mg, 3%). 
 
31P NMR (202 MHz, MeOD) " 16.76, 16.68. 
1H NMR (500 MHz, MeOD) " 7.99, 7.95 (2s, 1H, H8), 5.99, 5.97 (2s, 1H, H1'), 4.41- 
4.28 (m, 3H, H5' and H3'), 4.21- 4.17 (m, 1H, H4'), 4.08 (s, 3H, 6OCH3), 3.91- 3.79 (m, 
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3H, CHCH3 and OCH2C(CH3)3), 3.18- 3.11 (m, 4H, NHCH(CH2CH3)CH2CH3), 2.40-
2.37 (m, 1H, NHCH(CH2CH3)CH2CH3), 1.40 (d, J= 7.5 Hz, 3H, CHCH3), 1.11 (t, J= 
7.0 Hz, 6H, NHCH(CH2CH3)CH2CH3), 0.99 (s, 3H, 2’CCH3), 0.96, 0.93 (2s, 9H, 
OCH2C(CH3)3). 
HPLC (System 1) tR = 11.68 min.  
MS (EI+) m/z: 587.28 (MH+, 100%).  
HRMS C24H42N7O8P1 Calculated: 587.2833 found: 587.2813. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-!-D-ribofuranosyl) purine 5’-O-
pyrrolidine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8g). 
 
 Prepared according to the Standard 
Procedure 13b: In the first step, a 
suspenssion of 6-O-methyl-2’-C-
methylguanosine (5.4, 250 mg, 0.80 mmol) 
in anhydrous tetrahydrofuran (5 ml) was 
allowed to react with triethylamine (0.11 
ml, 0.80 mmol) and phosphorus oxychloride (0.07 ml, 0.80 mmol). In the second step, 
pyrrolidine (0.07 ml, 0.80 mmol) and triethylamine (0.11 ml, 0.80 mmol) were added. 
In the third step, L-alanine 2,2-dimethylpropyl ester tosylate salt (3.2g, 1.33 g, 4.02 
mmol) and triethylamine (1.12 mL, 8.03 mmol) were added followed by the addition 
of anhydrous dichloromethane (4 mL). After silica gel column chromatography, using 
CHCl3/MeOH (0 to 5%, gradient), the pure compound 8.8g was obtained as a white 
solid (38 mg, 8%). 
 
31P NMR (202 MHz, MeOD) " 14.54, 14.42. 
1H NMR (500 MHz, MeOD) " 8.01, 7.99 (2s, 1H, H8), 6.00, 5.99 (2s, 1H, H1'), 4.38- 
4.35 (m, 2H, H5'), 4.31- 4.28 (m, 1H, H3'), 4.21- 4.19 (m, 1H, H4'), 4.08, 4.07 (2s, 3H, 
6OCH3), 3.93- 3.91 (m, 1H, CHCH3), 3.88- 3.71 (m, 2H, OCH2C(CH3)3), 3.22-3.19 
(m, 4H, 2x NCH2 pyrrolidine), 1.87- 1.75 (m, 4H, 2x CH2 pyrrolidine), 1.40, 1.37 (2d, 
J= 7.0 Hz, 3H, CHCH3), 1.00, 0.99 (2s, 3H, 2’CCH3), 0.95, 0.92 (2s, 9H, 
OCH2C(CH3)3). 
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13C NMR (126 MHz, MeOD) ! 175.71, 175.67 (C=O), 162.75, 162.73 (C6), 161.93 
(C2), 154.56, 154.52 (C4), 139.16 (C8), 116.19, 115.57 (C5), 93.32, 93.16 (C1’), 
82.44, 82.40 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.09, 80.03 (C2’), 75.34, 75.29 
(OCH2C(CH3)3), 74.64, 74.60 (C3’), 65.86 (d, 2JC-O-P = 8.80 Hz, C5’), 65.80 (d, 2JC-O-
P = 5.0 Hz, C5’), 54.24 (6OCH3), 51.14, 51.02 (CHCH3), 47.84 (d, 2JC-N-P = 3.8 Hz, 
NCH2 pyrrolidine), 47.84 (d, 2JC-N-P=3.8 Hz, NCH2 pyrrolidine), 32.33 
(OCH2C(CH3)3), 27.34, 27.27 (2d, 3JC-C-N-P= 5.0 Hz, 2x CH2 pyrrolidine), 26.78, 
26.74 (OCH2C(CH3)3), 21.20, 21.04 (2d, 3JC-C-N-P= 6.29 Hz, CHCH3), 20.32. 20.26 
(2’CCH3). 
HPLC (System 1)  tR = 13.41 min.  
MS (EI+) m/z: 585.27 (MH+, 100%).  
HRMS C24H40N7O8P1 Calculated: 585.2676 found: 585.2662. 
 
Synthesis of 2-amino-6-O-methyl-9-(2-C-methyl-"-D-ribofuranosyl) purine 5’-O-
morpholine-(2,2-dimethylpropyl-L-alaninyl) phosphate (8.8h). 
  
Prepared according to the Standard 
Procedure 13b: In the first step, a 
suspenssion of 6-O-methyl-2’-C-
methylguanosine (5.4, 250 mg, 0.80 mmol) 
in anhydrous tetrahydrofuran (5 ml) was 
allowed to react with triethylamine (0.11 ml, 
0.80 mmol) and phosphorus oxychloride 
(0.07 ml, 0.80 mmol). In the second step, morpholine (0.08 ml, 0.80 mmol) and 
triethylamine (0.11 ml, 0.80 mmol) were added. In the third step, L-alanine benzyl 
ester tosylate salt (1.35 g, 4.02 mmol) and triethylamine (1.12 mL, 8.03 mmol) were 
added followed by the addition of anhydrous dichloromethane (4 mL). After silica gel 
column chromatography, using CHCl3/MeOH (0 to 5%, gradient), the pure compound 
8.8g was obtained as a white solid (108 mg, 22%). 
 
31P NMR (202 MHz, MeOD) 14.65, 14.30. 
1H NMR (500 MHz, MeOD) 7.96, 7.95 (2s, 1H, H8), 7.37-7.30 (m, 5H, OCH2Ph), 
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4.22-4.18 (m, 1H, H4’), 4.07, 4.06 (2s, 3H, 6OCH3), 3.96-3.82 (m, 1H, CHCH3), 3.52-
3.79 (m, 4H, 2x O(CH2)2), 3.11-3.08 (m, 4H, 2x N(CH2)2), 1.38, 1.33 (2d, J=7.5 Hz, 
3H, CHCH3), 1.01, 1.00 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) 175.38, 175.34 (2d, 3JC-C-N-P= 3.8 Hz, C=O), 162.79, 
162.75 (C6), 161.91 (C2), 154.52, 154.47 (C4), 139.40, 139.31 (C8), 137.31 (ipso 
OCH2Ph), 129.60, 129.57, 129.47, 129.38, 129.32 (OCH2Ph), 115.71, 115.60 (C5), 
93.46, 93.30 (C1’), 82.39, 82.33 (2d, 3JC-C-O-P= 3.8 Hz, C4’), 80.04 (C2’), 74.98, 
74.82 (C3’), 68.05 (d, 2JC-O-P= 3.8 Hz, C5’), 67.97 (d, 2JC-O-P= 5.0 Hz, C5’), 66.53, 
66.49 (OCH2Ph and O(CH2)2), 54.23 (6OCH3), 51.24, 50.99 (CHCH3), 45.74 
(N(CH2)2), 20.79 (d, 3JC-C-N-P= 5.0 Hz, CHCH3), 20.55 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 
20.29, 20.23 (2’CCH3). 
HPLC (System 1) tR = 11.29, 11.60 min.  
MS (ES+) m/z: 644.22 (M+Na+, 100%).  
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ribofuranosyl)purine (5.4, 1.50 g, 4.82 mmol) was 
suspended in dry MeOH (50 ml) and NBS (1.03 g, 4.82 
mmol) was added. The mixture was stirred at room 
temperature for 4 h. After that time, solution was 
concentrated and the resulting solid was purified by 
silica gel chromatography using 1-4% (gradient) of MeOH in CHCl3 to yield 1.65 g 
(88% yield) of the desired product 9.1. 
1H NMR (500 MHz, MeOD) " 6.04 (s, 1H, H1’), 4.60 (d, J= 8.0 Hz, 1H, H3’), 4.09- 
4.05 (m, 2H, H4’ and H5’a), 4.04 (s, 3H, 6OCH3), 3.98 (dd, J= 4.0 Hz, J= 12.5 Hz, 1H, 
H5’b), 1.01 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 161.89 (C6), 161.18 (C2), 154.45 (C4), 125.57 (C8), 
116.37 (C5), 96.70 (C1’), 84.40 (C4'), 80.38 (C2’), 74.34 (C3’), 62.27 (C5’), 54.66 
(6OCH3), 21.23 (2’CCH3). 
HPLC (System 1) tR= 7.37 min. 
MS (AP+) m/z: 390.04 (M+H+, 100%). 





ribofuranosyl)purine (5.4, 250 mg, 0.80 mmol) was 
suspended in dry THF (10 ml) and NCS (110 mg, 0.80 
mmol) was added. The mixture was warmed to 35 oC 
and stirred in the dark for overnight. After that time, 
solution was concentrated and the resulting solid was 
purified by silica gel chromatography using 1-4% (gradient) of MeOH in CHCl3 to 
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1H NMR (500 MHz, MeOD) ! 6.03 (s, 1H, H1’), 4.58 (d, J= 8.0 Hz, 1H, H3’), 4.09- 
4.04 (m, 2H, H4’ and H5’a), 4.05 (s, 3H, 6OCH3), 3.97 (dd, J= 4.0 Hz, J= 11.0 Hz, 1H, 
H5’b), 1.03 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 162.02(C6), 161.30(C2), 154.35 (C4), 136.59 (C8), 
114.52 (C5), 95.55 (C1’), 84.29 (C4'), 80.31 (C2’), 74.42 (C3’), 62.35 (C5’), 54.55 
(6OCH3), 21.03 (2’CCH3). 
HPLC (System 1) tR= 7.63 min. 
MS (AP+) m/z: 346.09 (M+H+, 100%). 






ribofuranosyl)purine (5.4, 1.50 g, 4.82 mmol) was 
suspended in dry THF (40 ml) and NIS (1.10 g, 4.82 
mmol) was added. The mixture was warmed to 35 oC 
and stirred in the dark for 3 days. After that time, 
solution was concentrated and the resulting solid was 
purified by silica gel chromatography using 1-4% (gradient) of MeOH in CHCl3 to 
yield 1.01 g (51% yield) of the desired product 9.3. 
1H NMR (500 MHz, MeOD) ! 6.00 (s, 1H, H1’), 4.64 (d, J= 9.0 Hz, 1H, H3’), 4.07- 
3.98 (m, 3H, H4’ and H5’), 4.05 (s, 3H, 6OCH3), 1.01 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 161.70 (C6), 161.08 (C2), 154.28 (C4), 119.18 (C5), 
99.27 (C8), 98.71 (C1’), 84.39 (C4'), 80.31 (C2’), 74.52 (C3’), 62.40 (C5’), 54.41 
(6OCH3), 21.25 (2’CCH3). 
HPLC (System 1) tR = 7.65  min.  
MS (AP+) m/z: 438.03 (M+H+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-bromo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (9.4a). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-bromo-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.1, 160 mg, 0.41 
mmol), tBuMgCl (0.81 ml, 0.81 mmol), 
and "-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 270 mg, 0.81 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.4a was obtained as an off white solid (70 mg, 23% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.15, 3.71. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 8.01-8.00 (2m, 1H, H8-Naph), 7.83-7.81, 
7.75-7.73 (2m, 1H, H5- Naph), 7.63, 7.64 (2d, J= 8.0 Hz, 1H, H4- Naph), 7.50–7.41 
(m, 3H, H2, H7, H6- Naph), 7.36, 7.27 (2t, J= 8.0 Hz, 1H, H3- Naph), 6.05, 6.04 (2s, 
1H, H1’), 4.86- 4.82 (m, 2H, H3’and H5’a), 4.67- 4.57 (m, 1H, H5’b), 4.35- 4.27 (m, 1H, 
H4’), 4.08 – 4.01 (m, 1H, CHCH3), 4.00, 3.96 (2s, 3H, 6OCH3), 3.75, 3.72, 3.64, 3.58 
(2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 1.33, 1.27 (2d, J= 7.0 Hz, 3H, CHCH3), 
1.05, 1.04 (2s, 3H, 2’CCH3),  0.84, 0.82 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.05, 174.77 (2d, 3J C-C-N-P = 6.3 Hz, C=O), 161.58, 
161.49 (C6), 161.40, 161.27 (C2), 154.83, 154.75 (C4), 148.03, 147.96 (2d, 2JC-O-P = 
7.5 Hz, ipso Naph), 136.23, 136.09 (C10-Naph), 128.79, 128.63 (CH-Naph), 127.82, 
127.71 (2d, 3JC-C-O-P = 7.5 Hz, C9-Naph), 127.53, 127.38, 127.12, 126.44, 126.43, 
125.82 (CH-Naph), 125.71 (C8), 125.59, 122.81, 122.69 (CH-Naph), 116.26, 116.23 
(2d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 115.90, 115.87 (C5), 95.88 (C1’), 83.42 (d, 3JC-C-O-P 
= 6.3 Hz, C4’), 83.24 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.19, 80.17 (C2’), 76.03, 75.93 
(C3’), 75.34, 75.29 (OCH2C(CH3)3), 69.51, 69.39 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.29, 
54.27 (6OCH3), 51.66, 51.60 (CHCH3), 32.24 (OCH2C(CH3)3), 26.72, 26.71 
(OCH2C(CH3)3), 20.82 (d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.69 (d, 3JC-C-N-P = 7.5 Hz, 
CHCH3), 20.56, 20.51 (2’CCH3). 
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MS (ES+) m/z: 737.16 (M+H+, 100%).  
HRMS C30H39N6O9P1Br Calculated: 737.1700 found: 737.1683. 
 
Synthesis of 2-amino-6-O-methyl-8-C-bromo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-alaninyl)] phosphate (9.4b). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-bromo-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.1, 250 mg, 0.64 
mmol), tBuMgCl (1.28 ml, 1.28 mmol), 
and "-naphthyl-(benzoxy-L-alaninyl) 
phosphorochloridate (3.3k, 517 mg, 1.28 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.4b was obtained as an off white solid (63 
mg, 13% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.17, 3.75. 
1H NMR (500 MHz, MeOD) ! 8.15, 7.99 (2d, 1H, J= 8.0 Hz, H8-Naph), 7.83, 7.76 
(2d, 1H, J= 8.0 Hz, H5- Naph), 7.64, 7.54 (2d, J= 8.0 Hz, 1H, H4- Naph), 7.50–7.41 
(m, 3H, H2, H7, H6- Naph), 7.37-7.32 (m, 1H, H3- Naph), 7.27-7.22 (m, 5H, 
OCH2Ph), 6.04, 6.02 (2s, 1H, H1’), 5.20-4.99 (m, 2H, OCH2Ph), 4.92- 4.86 (m, 2H, 
H3’and H5’a), 4.63- 4.56(m, 1H, H5’b), 4.32- 4.24 (m, 1H, H4’), 4.10–4.03 (m, 1H, 
CHCH3), 3.97, 3.96 (2s, 3H, 6OCH3), 1.33, 1.30 (2d, J= 7.0 Hz, 3H, CHCH3), 1.05, 
1.04 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.80, 174.63 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.57, 
161.50 (C6), 161.38, 161.27 (C2), 154.82, 154.76 (C4), 148.03, 147.96 (2d, 2JC-O-P = 
7.5 Hz, ipso Naph), 137.41, 137.12 (ipso OCH2Ph), 136.20, 136.07 (C10-Naph), 
129.61, 129.51, 129.38, 129.34, 129.28, 129.21, 129.07, 128.78, 128.64, 128.29, 
128.02, 127.90, 127.85, 127.80, 127.75, 127.68, 127.56, 127.39, 127.15, 126.45, 
126.36 (CH-Naph and OCH2Ph), 126.31, 125.71 (C8), 125.73, 125.62 (CH-Naph), 
122.81, 122.72 (C5), 116.28 (d, 2JC-C-O-P = 3.8 Hz, C2-Naph), 115.94 (d, 2JC-C-O-P = 
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80.19 (C2’), 76.05, 76.00 (C3’), 69.43, 69.34 (2d, 2JC-O-P = 5.0 Hz, C5’), 67.85, 
67.77(OCH2Ph), 54.30, 54.29 (6OCH3), 51.67, 51.62 (CHCH3), 20.56, 20.45 (2d, 3JC-
C-N-P = 6.3 Hz, CHCH3), 20.19 (2’CCH3). 
HPLC (System 1) tR = 19.76, 20.35 min. 
MS (ES+) m/z: 805.12 (M+H+, 100%).  
HRMS C32H35N6O9P1Br1 Calculated: 805.1248 found: 805.1241.  
 
Synthesis of 2-amino-6-O-methyl-8-C-bromo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-valinyl)] phosphate (9.4c). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-bromo-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.1, 250 mg, 0.64 
mmol), tBuMgCl (1.28 ml, 1.28 mmol), 
and "-naphthyl-(benzoxy-L-valinyl) 
phosphorochloridate (3.3t, 553 mg, 1.28 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.4b was obtained as an off white solid (131 
mg, 26% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.94, 4.37. 
1H NMR (500 MHz, MeOD) ! 8.14, 7.98 (2d, 1H, J= 7.5 Hz, H8-Naph), 7.83-7.80, 
7.73-7.72 (2m, 1H, H5-Naph), 7.63, 7.52 (2d, J= 7.5 Hz, 1H, H4- Naph), 7.50-7.40 
(m, 3H, H2, H7, H6- Naph), 7.34-7.26 (m, 1H, H3- Naph), 7.25-7.21 (m, 5H, 
OCH2Ph), 6.04, 6.02 (2s, 1H, H1’), 4.97-4.88 (m, 2H, OCH2Ph), 4.85-4.78 (m, 2H, 
H3’and H5’a), 4.63- 4.59 (m, 1H, H5’b), 4.33-4.27 (m, 1H, H4’), 3.97, 3.95 (2s, 3H, 
6OCH3), 3.80-3.72 (m, 1H, CHCH(CH3)2), 2.00-1.1.94, 1.91-1.84 (2m, 1H, 
CHCH(CH3)2), 1.06, 1.03 (2s, 3H, 2’CCH3), 0.79, 0.73 (2d, J= 6.5 Hz, 3H, 
CHCH(CH3)2), 0.77, 0.72 (2d, J= 6.0 Hz, 3H, CHCH(CH3)2).  
13C NMR (126 MHz, MeOD) ! 173.98 (d, 3J C-C-N-P = 3.7 Hz, C=O),  173.81 (d, 3J C-C-
N-P = 2.5 Hz, C=O), 161.58, 161.48 (C6), 161.38, 161.24 (C2), 154.81, 154.74 (C4), 
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136.04 (C10-Naph), 129.63, 129.50, 129.44, 129.40, 129.31, 129.29, 128.79, 128.62, 
127.90, 127.85 127.77, 127.69, 127.54, 127.40, 127.10, 126.47 (CH-Naph and 
OCH2Ph), 125.86, 125.80 (C8), 125.72, 125.59, 122.86, 122.75 (CH-Naph), 116.30, 
116.28 (C5), 116.18 (d, 2JC-C-O-P = 3.8 Hz, C2-Naph), 115.91 (d, 2JC-C-O-P = 2.5 Hz, 
C2-Naph), 95.87, 95.83 (C1’), 83.53, 83.27 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.19, 80.14 
(C2’), 76.05, 75.94 (C3’), 69.64, 69.57 (2d, 2JC-O-P = 5.0 Hz, C5’), 67.78 (OCH2Ph), 
61.88, 61.79 (CHCH(CH3)2), 54.35, 54.33 (6OCH3), 33.34, 33.20 (2d, 3JC-C-N-P = 7.5 
Hz, CHCH(CH3)2), 20.61, 20.54 (2’CCH3), 19.48, 19.35, 18.31, 18.24 
(CHCH(CH3)2). 
HPLC (System 1) tR = 21.80, 22.32 min. 
MS (AP+) m/z: 785.17 (M+H+, 100%). 
HRMS C34H39N6O9P1Br1 Calculated: 785.1700 found: 785.1720.                                            
 
Synthesis of 2-amino-6-O-methyl-8-C-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (9.5a). 
  
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.2, 160 mg, 0.41 
mmol), tBuMgCl (0.81 ml, 0.81 mmol), 
and "-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 270 mg, 0.81 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.5a was obtained as an off white solid (70 mg, 23% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.16, 3.74. 
1H NMR (500 MHz, MeOD) ! 8.17-8.16, 8.02-8.00 (2m, 1H, H8-Naph), 7.86- 7.85, 
7.78-7.76 (2m, 1H, H5-Naph), 7.67, 7.56 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53–7.36 (m, 
3H, H2, H7, H6-Naph), 7.35-7.27 (m, 1H, H3-Naph), 6.02, 6.01 (2s, 1H, H1’), 4.88- 
4.80 (m, 2H, H3’and H5’a), 4.63- 4.53 (m, 1H, H5’b), 4.32- 4.24 (m, 1H, H4’), 4.08– 
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10.5 Hz, 2H, OCH2C(CH3)3), 1.33, 1.27 (2d, J= 7.0 Hz, 3H, CHCH3), 1.06, 1.05 (2s, 
3H, 2’CCH3),  0.86, 0.84 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.76 (2d, 3J C-C-N-P = 6.3 Hz, C=O), 161.70, 161.61 
(C6), 161.50, 161.38 (C2), 154.68, 154.61 (C4), 148.06, 147.96 (2d, 2JC-O-P = 7.5 Hz, 
ipso Naph), 136.65, 136.58 (C8), 136.23, 136.09 (C10-Naph), 128.79, 128.64 (CH-
Naph), 127.89, 127.78 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.68, 127.53, 127.37, 
127.12, 126.45, 126.34, 125.83, 125.60, 122.81, 122.70 (CH-Naph), 116.25 (d, 3JC-C-
O-P = 3.8 Hz, C2-Naph), 115.89 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 114.38 (C5), 94.67 
(C1’), 83.39 (d, 3JC-C-O-P = 7.5 Hz, C4’), 83.20 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.13 
(C2’), 75.99, 75.90 (C3’), 75.34, 75.30 (OCH2C(CH3)3), 69.45, 69.33 (2d, 2JC-O-P = 
5.0 Hz, C5’), 54.30, 54.28 (6OCH3), 51.66, 51.60 (CHCH3), 32.24, 32.23 
(OCH2C(CH3)3), 26.72, 26.69 (OCH2C(CH3)3), 20.83, 20.70 (2d, 3JC-C-N-P = 6.3 Hz, 
CHCH3), 20.48, 20.43 (2’CCH3). 
HPLC (System 1) tR= 20.89, 21.72 min. 
MS (ES+) m/z: 713.19 (MH+, 100%).  
HRMS C32H35N6O9P1Cl1 Calculated: 713.1892 found: 713.1911. 
 
Synthesis of 2-amino-6-O-methyl-8-C-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-alaninyl)] phosphate (9.5b). 
  
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.2, 250 mg, 0.64 
mmol), tBuMgCl (1.28 ml, 1.28 mmol), 
and "-naphthyl-(benzoxy-L-alaninyl) 
phosphorochloridate (3.3k, 517 mg, 1.28 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.5b was obtained as an off white solid (83 
mg, 16% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.17, 3.79. 
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(2d, 1H, J= 8.0 Hz, H5- Naph), 7.71, 7.60 (2d, J= 8.0 Hz, 1H, H4- Naph), 7.55–7.40 
(m, 3H, H2, H7, H6- Naph), 7.41-7.28 (m, 1H, H3- Naph), 7.25-7.21 (m, 5H, 
OCH2Ph), 6.02, 6.00 (2s, 1H, H1’), 5.04-4.95 (m, 2H, OCH2Ph), 4.90- 4.78 (m, 2H, 
H3’and H5’a), 4.62- 4.56 (m, 1H, H5’b), 4.33- 4.25 (m, 1H, H4’), 4.11–4.05 (m, 1H, 
CHCH3), 3.95, 3.94 (2s, 3H, 6OCH3), 1.37, 1.28 (2d, J= 7.0 Hz, 3H, CHCH3), 1.04, 
1.03 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.84, 174.63 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.69, 
161.62 (C6), 161.45, 161.35 (C2), 154.68, 154.63 (C4), 148.01 (d, 2JC-O-P = 7.5 Hz, 
ipso Naph), 147.95 (d, 2JC-O-P = 6.3 Hz, ipso Naph), 137.08, 137.05 (ipso OCH2Ph), 
136.70, 136.62 (C8), 136.19, 136.07 (C10-Naph), 129.62, 129.53, 129.40, 129.35, 
129.27, 129.23, 129.09, 128.81, 128.68 (CH-Naph and OCH2Ph), 127.87, 127.77 (2d, 
3JC-C-O-P = 3.8 Hz, C9-Naph), 127.70, 127.58, 127.42, 127.18, 126.48, 126.39, 125.86, 
125.67 (CH-Naph and OCH2Ph), 122.81, 122.73 (C5), 116.31 (d, 3JC-C-O-P = 3.8 Hz, 
C2-Naph), 115.97 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 94.65 (C1’), 83.35, 83.15 (2d, 3JC-
C-O-P = 7.5 Hz, C4’), 80.17 (C2’), 76.02, 75.99 (C3’), 69.42, 69.30 (2d, 2JC-O-P = 5.0 
Hz, C5’), 67.89, 67.77 (OCH2Ph), 54.37 (6OCH3), 51.68, 51.63 (CHCH3), 20.60, 
20.55 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.34 (2’CCH3). 
HPLC (System 1) tR = 19.87, 20.48 min. 
MS (ES+) m/z: 713.19 (M+H+, 100%).  
HRMS C32H35N6O9P1Cl1 Calculated: 713.1911 found: 713.1892.  
 
Synthesis of 2-amino-6-O-methyl-8-C-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-valinyl)] phosphate (9.5c). 
  
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.2, 250 mg, 0.64 
mmol), tBuMgCl (1.28 ml, 1.28 mmol), 
and "-naphthyl-(benzoxy-L-valinyl) 
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mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.5c was obtained as an off white solid (90 
mg, 17% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.93, 3.39. 
1H NMR (500 MHz, MeOD) ! 8.16, 8.02 (2d, 1H, J= 7.5 Hz, H8-Naph), 7.85-7.82, 
7.74-7.72 (m, 1H, H5- Naph), 7.61, 7.54 (2d, J= 7.5 Hz, 1H, H4- Naph), 7.50-7.40 (m, 
3H, H2, H7, H6- Naph), 7.36-7.30 (m, 1H, H3- Naph), 7.26-7.21 (m, 5H, OCH2Ph), 
6.00, 5.99 (2s, 1H, H1’), 4.98-4.87 (m, 2H, OCH2Ph), 4.85-4.79 (m, 2H, H3’ and H5’a), 
4.64- 4.62 (m, 1H, H5’b), 4.37-4.30 (m, 1H, H4’), 3.99, 3.96 (2s, 3H, 6OCH3), 3.81-
3.73 (m, 1H, CHCH(CH3)2), 2.07-1.86 (m, 1H, CHCH(CH3)2), 1.07, 1.05 (2s, 3H, 
2’CCH3), 0.82, 0.73 (2d, J= 6.5 Hz, 3H, CHCH(CH3)2), 0.79, 0.72 (2d, J= 6.0 Hz, 
3H, CHCH(CH3)2).  
13C NMR (126 MHz, MeOD) ! 173.99 (d, 3J C-C-N-P = 3.7 Hz, C=O),  173.84 (d, 3J C-C-
N-P = 2.5 Hz, C=O), 161.70, 161.61 (C6), 161.46, 161.32(C2), 154.64, 154.59 (C4), 
148.06, 147.97 (2d, 2JC-O-P = 7.5 Hz, ipso Naph), 136.97, 136.93 (ipso OCH2Ph), 
136.71, 136.61 (C8), 136.20, 136.05 (C10-Naph), 129.50, 129.43, 129.41, 129.32, 
129.31, 128.80, 128.63 (CH-Naph and OCH2Ph), 127.87, 127.74, (2d, 3JC-C-O-P = 3.8 
Hz, C9-Naph), 127.55, 127.40, 127.12, 126.48, 126.34, 125.82, 125.61, 122.87, 
122.76 (CH-Naph and OCH2Ph), 122.87, 122.76 (C5), 116.17 (d, 2JC-C-O-P = 2.5 Hz, 
C2-Naph), 115.90 (d, 2JC-C-O-P = 3.7 Hz, C2-Naph), 94.63, 94.58 (C1’), 83.46, 83.19 
(2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.14, 80.10 (C2’), 75.99, 75.89 (C3’), 69.57, 69.48 (2d, 
2JC-O-P = 5.0 Hz, C5’), 67.81 (OCH2Ph), 61.87, 61.78 (CHCH(CH3)2), 54.39, 54.37 
(6OCH3), 33.35 (d, 3JC-C-N-P = 6.3 Hz, CHCH(CH3)2), 33.20 (d, 3JC-C-N-P = 7.5 Hz, 
CHCH(CH3)2), 20.85, 20.50 (2’CCH3), 19.51, 19.38, 18.31, 18.25 (CHCH(CH3)2) 
HPLC (System 1) tR = 21.84, 22.31 min. 
MS (ES+) m/z: 741.22 (M+H+, 100%). 
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (9.6a). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 100 mg, 0.23 
mmol), tBuMgCl (0.46 ml, 0.46 mmol), 
and "-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 152 mg, 0.46 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.6a was obtained as an off white solid (46 mg, 27% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.18, 3.68. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16, 7.99-7.97 (2m, 1H, H8-Naph), 7.87- 7.85, 
7.77-7.76 (2m, 1H, H5-Naph), 7.67, 7.56 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53 – 7.37 
(m, 3H, H2, H7, H6-Naph), 7.34-7.26 (m, 1H, H3-Naph), 5.97, 5.96 (2s, 1H, H1’), 
4.89-4.82 (m, 2H, H3’and H5’a), 4.62- 4.53 (m, 1H, H5’b), 4.32- 4.23 (m, 1H, H4’), 
4.08–3.99 (m, 1H, CHCH3), 4.01, 3.97 (2s, 3H, 6OCH3), 3.75, 3.72, 3.64, 3.58 (2AB, 
JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 1.32, 1.25 (2d, J= 7.0 Hz, 3H, CHCH3), 1.03, 1.02 
(2s, 3H, 2’CCH3),  0.87, 0.84 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.04 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.77 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.35, 161.27 (C6), 161.20, 161.06 (C2), 154.53, 154.45 (C4), 
148.04, 147.97 (2d, 2JC-O-P = 7.5 Hz, ipso Naph), 136.23, 136.09 (C10-Naph), 128.78, 
128.62 (CH-Naph), 127.89, 127.77 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.68, 127.53, 
127.38, 127.14, 126.46, 126.33, 125.82, 125.59, 122.83, 122.68 (CH-Naph), 119.16, 
119.12 (C5), 115.89, 115.86 (C2-Naph), 99.72 (C8), 98.04 (C1’), 83.36, 83.21 (2d, 
3JC-C-O-P = 7.5 Hz, C4’), 80.24, 80.21 (C2’), 76.12, 76.02 (C3’), 75.34, 75.28 
(OCH2C(CH3)3), 69.60, 69.44 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.22, 54.20 (6OCH3), 
51.66, 51.60 (CHCH3), 32.25 (OCH2C(CH3)3), 26.73 (OCH2C(CH3)3), 20.81 (d, 3JC-C-
N-P = 6.3 Hz, CHCH3), 20.70 (d, 3JC-C-N-P = 5.0 Hz, CHCH3), 20.66 (2’CCH3). 
HPLC (System 1) tR = 20.23, 21.23 min. 
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HRMS C30H39N6O9P1I1 Calculated: 785.1546 found: 785.1561. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-alaninyl)] phosphate (9.6b). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(benzoxy-L-alaninyl) 
phosphorochloridate (3.3k, 550 mg, 1.37 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.6b was obtained as an off white solid (70 
mg, 13% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.17, 3.69. 
1H NMR (500 MHz, MeOD) ! 8.15, 7.98 (2d, 1H, J= 8.0 Hz, H8-Naph), 7.87, 7.78 
(2d, 1H, J= 8.0 Hz, H5- Naph), 7.67, 7.56 (2d, J= 8.0 Hz, 1H, H4- Naph), 7.53–7.41 
(m, 3H, H2, H7, H6- Naph), 7.39-7.26 (m, 1H, H3- Naph), 7.28-7.23 (m, 5H, 
OCH2Ph), 5.97, 5.96 (2s, 1H, H1’), 5.00-4.91 (m, 2H, OCH2Ph), 4.90- 4.78 (m, 2H, 
H3’and H5’a), 4.60- 4.54 (m, 1H, H5’b), 4.29- 4.22 (m, 1H, H4’), 4.08–4.02 (m, 1H, 
CHCH3), 3.98, 3.97 (2s, 3H, 6OCH3), 1.30, 1.24 (2d, J= 7.0 Hz, 3H, CHCH3), 1.03, 
1.02 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.79, 174.60 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.34, 
161.27 (C6), 161.20, 161.07 (C2), 154.50, 154.44 (C4), 148.01, 147.95 (2d, 2JC-O-P = 
7.5 Hz, ipso Naph), 137.15, 137.12 (ipso OCH2Ph), 136.21, 136.07 (C10-Naph), 
129.50, 129.36, 129.33, 129.28, 129.19, 129.09, 129.07, 128.75, 128.60, 128.27, 
128.01, 127.91, 127.86, 127.80, 127.75, 127.65, 127.53, 127.37, 127.13, 126.43, 
126.31, 125.80, 125.58, 122.82, 122.70 (CH-Naph and OCH2Ph), 119.14, 119.09 
(C5), 116.28 (d, 2JC-C-O-P = 3.8 Hz, C2-Naph), 115.90 (d, 2JC-C-O-P = 2.5 Hz, C2-
Naph), 99.75, 99.72 (C8), 98.04 (C1’), 83.33, 83.16 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 
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67.82, 67.76 (OCH2Ph), 54.18, 54.16 (6OCH3), 51.64, 51.61 (CHCH3), 20.66, 20.45 
(2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.10, 20.05 (2’CCH3). 
HPLC (System 1) tR = 19.76, 20.35 min. 
MS (ES+) m/z: 805.12 (MH+, 100%).  
HRMS C32H35N6O9P1I1 Calculated: 805.1248 found: 805.1241.  
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-valinyl)] phosphate (9.6c). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(benzoxy-L-valinyl) 
phosphorochloridate (3.3t, 592 mg, 1.37 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.6c was obtained as an off white solid (129 
mg, 23% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.97, 4.37. 
1H NMR (500 MHz, MeOD) ! 8.14, 7.98 (2d, 1H, J= 7.5 Hz, H8-Naph), 7.82-7.80, 
7.73-7.71 (2m, 1H, H5- Naph), 7.62, 7.51 (2d, J= 7.5 Hz, 1H, H4- Naph), 7.48-7.38 
(m, 3H, H2, H7, H6- Naph), 7.35-7.29 (m, 1H, H3- Naph), 7.24-7.19 (m, 5H, 
OCH2Ph), 6.01, 5.99 (2s, 1H, H1’), 4.97-4.88 (m, 2H, OCH2Ph), 4.85-4.79 (m, 2H, 
H3’and H5’a), 4.64- 4.61 (m, 1H, H5’b), 4.33-4.28 (m, 1H, H4’), 3.97, 3.94 (2s, 3H, 
6OCH3), 3.80-3.72 (m, 1H, CHCH(CH3)2), 2.04-1.83 (m, 1H, CHCH(CH3)2), 1.04, 
1.02 (2s, 3H, 2’CCH3), 0.79, 0.70 (2d, J= 6.5 Hz, 3H, CHCH(CH3)2), 0.77, 0.74 (2d, 
J= 6.0 Hz, 3H, CHCH(CH3)2).  
13C NMR (126 MHz, MeOD) ! 174.02 (d, 3J C-C-N-P = 3.7 Hz, C=O),  173.84 (d, 3J C-C-
N-P = 2.5 Hz, C=O), 161.38, 161.28 (C6), 161.20, 161.16 (C2), 154.53, 154.47 (C4), 
148.04, 147.96 (2d, 2JC-O-P = 7.5 Hz, ipso Naph), 136.97, 136.93 (ipso OCH2Ph), 
136.18, 136.03 (C10-Naph), 129.86, 129.73, 129.67, 129.64, 129.62, 129.54, 129.48, 
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126.52, 126.37, 125.85, 125.64, 122.89, 122.76 (CH-Naph and OCH2Ph), 119.27, 
119.24 (C5), 116.22 (d, 2JC-C-O-P = 3.8 Hz, C2-Naph), 115.95 (d, 2JC-C-O-P = 2.5 Hz, 
C2-Naph), 99.83, 99.66 (C8), 97.99 (C1’), 83.50, 83.24 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 
80.30, 80.24 (C2’), 76.16, 76.04 (C3’), 69.72, 69.40 (2d, 2JC-O-P = 5.0 Hz, C5’), 
67.84, 67.76 (OCH2Ph), 61.85, 61.76 (CHCH(CH3)2), 54.39, 54.37 (6OCH3), 33.36 
(d, 3JC-C-N-P = 6.3 Hz, CHCH(CH3)2), 33.23 (d, 3JC-C-N-P = 7.5 Hz, CHCH(CH3)2), 
20.90, 20.81 (2’CCH3), 19.42, 19.37, 18.36, 18.31 (CHCH(CH3)2) 
HPLC (System 1) tR = 21.65, 22.11 min. 
MS (ES+) m/z: 833.15 (MH+, 100%). 
HRMS C34H39N6O9P1I1 Calculated: 833.1561 found: 833.1540.                                            
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(n-propyl-L-alaninyl)] phosphate (9.6d). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(n-propoxy-L-alaninyl) 
phosphorochloridate (3.3c, 488 mg, 1.37 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.6d was obtained as an off white solid (100 
mg, 17% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.22, 3.37. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 8.00-7.98 (2m, 1H, H8-Naph), 7.84-7.83, 
7.76-7.75 (2m, 1H, H5- Naph), 7.64, 7.55 (2d, J= 8.0 Hz, 1H, H4- Naph), 7.51–7.36 
(m, 3H, H2, H7, H6- Naph), 7.33-7.26 (m, 1H, H3- Naph), 5.99, 5.98 (2s, 1H, H1’), 
4.91-4.84 (m, 2H, H3’and H5’a), 4.64-4.56 (m, 1H, H5’b), 4.32-4.26 (m, 1H, H4’), 4.04–
3.97 (m, 1H, CHCH3), 4.00, 3.96 (2s, 3H, 6OCH3), 3.91-3.79 (m, 2H, 
OCH2CH2CH3), 1.52-1.45 (m, 2H, OCH2CH2CH3), 1.29, 1.23 (2d, J= 7.0 Hz, 3H, 
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13C NMR (126 MHz, MeOD) ! 175.12, 174.84 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.37, 
161.28 (C6), 161.18, 161.06 (C2), 154.53, 154.47 (C4), 148.04 (d, 2JC-O-P = 7.5 Hz, 
ipso Naph), 147.98 (d, 2JC-O-P = 8.8 Hz, ipso Naph), 136.20, 136.07 (C10-Naph), 
128.79, 128.64 (CH-Naph), 127.89 (d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.76 (d, 3JC-C-
O-P = 7.5 Hz, C9-Naph), 127.69, 127.56, 127.38, 127.14, 126.46, 126.35, 125.82, 
125.59, 122.83, 122.69 (CH-Naph), 119.19, 119.14 (C5), 116.24, 115.87 (2d, 3JC-C-O-P 
= 2.5 Hz, C2-Naph), 99.76, 99.65 (C8), 98.04 (C1’), 83.35 (d, 3JC-C-O-P = 7.5 Hz, 
C4’), 83.20 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.26, 80.25 (C2’), 76.15, 76.08 (C3’), 69.54, 
69.41 (2d, 2JC-O-P = 5.0 Hz, C5’), 67.86, 67.85 (OCH2CH2CH3 ester), 54.29, 54.26 
(6OCH3), 51.61, 51.58 (CHCH3), 22.90, 22.88 (OCH2CH2CH3 ester), 20.78, 20.73 
(2’CCH3), 20.66, 20.61 (CHCH3), 10.65 (OCH2CH2CH3 ester). 
HPLC (System 1) tR = 17.48, 18.29 min. 
MS (ES+) m/z: 757.12 (MH+, 100%).  
HRMS C28H35N6O9P1I1 Calculated: 757.1248 found: 757.1229. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(n-butyl-L-alaninyl)] phosphate (9.6e). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(n-butoxy-L-alaninyl) 
phosphorochloridate (510 mg, 1.37 mmol) 
in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH (0 to 
3%, gradient), the pure compound 9.6e was obtained as an off white solid (150 mg, 
28% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.26, 3.68. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 7.99-7.97 (2m, 1H, H8-Naph), 7.85-7.83, 
7.76-7.75 (2m, 1H, H5-Naph), 7.64, 7.55 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.51–7.35 
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4.91- 4.81 (m, 2H, H3’and H5’a), 4.65- 4.56 (m, 1H, H5’b), 4.34- 4.26 (m, 1H, H4’), 
4.03–3.99 (m, 1H, CHCH3), 4.00, 3.96 (2s, 3H, 6OCH3), 3.92-3.83 (m, 2H, 
OCH2CH2CH2CH3), 1.46-1.39 (m, 2H, OCH2CH2CH2CH3), 1.30-1.23 (m, 5H, 
OCH2CH2CH2CH3 and CHCH3), 1.03 (s, 3H, 2’CCH3),  0.84, 0.83 (2t, J= 7.5 Hz, 
3H, OCH2CH2CH3). 
13C NMR (126 MHz, MeOD) ! 175.12 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.85 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.33, 161.25 (C6), 161.19, 161.06 (C2), 154.50, 154.44 (C4), 
148.03 (d, 2JC-O-P = 7.5 Hz, ipso Naph), 147.97 (d, 2JC-O-P = 8.8 Hz, ipso Naph), 
136.19, 136.05 (C10-Naph), 128.81, 128.65 (CH-Naph), 127.87 (d, 3JC-C-O-P = 6.3 Hz, 
C9-Naph), 127.73 (d, 3JC-C-O-P = 7.5 Hz, C9-Naph), 127.57, 127.40, 127.16, 126.49, 
126.37, 125.83, 125.59, 122.83, 122.69 (CH-Naph), 119.13, 119.09 (C5), 116.25, 
115.83 (2d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 99.87, 99.76 (C8), 98.03 (C1’), 83.35, 
83.20 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.25 (C2’), 76.14, 76.07 (C3’), 69.54, 69.40 (2d, 
2JC-O-P = 5.0 Hz, C5’), 66.12, 65.99 (OCH2CH2CH2CH3 ester), 54.31, 54.28 (6OCH3), 
51.60, 51.58 (CHCH3), 31.65, 31.60 (OCH2CH2CH2CH3), 22.90, 22.88 
(OCH2CH2CH2CH3), 20.80 (2’CCH3), 20.74, 20.63 (2d, 3JC-C-N-P = 7.5 Hz, CHCH3), 
14.14, 14.12 (OCH2CH2CH2CH3 ester). 
HPLC (System 1) tR = 18.92, 19.65 min. 
MS (ES+) m/z: 771.14 (MH+, 100%).  
HRMS C29H37N6O9P1I1 Calculated: 771.1404 found: 771.1400. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(n-propyl-L-alaninyl)] phosphate (9.6f). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(n-pentoxy-L-alaninyl) 
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in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH (0 to 
3%, gradient), the pure compound 9.6f was obtained as an off white solid (120 mg, 
22% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.27, 3.68. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 8.00-7.98 (2m, 1H, H8-Naph), 7.85- 7.83, 
7.76-7.75 (2m, 1H, H5-Naph), 7.65, 7.55 (2d, J= 8.5 Hz, 1H, H4-Naph) 7.51 – 7.35 
(m, 3H, H2, H7, H6-Naph), 7.34-7.26 (m, 1H, H3-Naph), 5.99, 5.98 (2s, 1H, H1’), 
4.87-4.81 (m, 2H, H3’and H5’a), 4.65-4.56 (m, 1H, H5’b), 4.34-4.26 (m, 1H, H4’), 4.04–
3.97 (m, 1H, CHCH3), 4.00, 3.96 (2s, 3H, 6OCH3), 3.92-3.81 (m, 2H, 
OCH2CH2CH2CH2CH3), 1.47-1.41 (m, 2H, OCH2CH2CH2CH2CH3), 1.29, 1.23 (2d, 
J= 7.0 Hz, 3H, CHCH3), 1.21-1.16 (m, 4H, OCH2CH2CH2CH2CH3 and 
OCH2CH2CH2CH2CH3), 1.03 (s, 3H, 2’CCH3),  0.83, 0.82 (2t, J= 7.5 Hz, 3H, 
OCH2CH2CH2CH2CH3). 
13C NMR (126 MHz, MeOD) ! 175.12, 174.86 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.33, 
161.25 (C6), 161.20, 161.07 (C2), 154.51, 154.44 (C4), 148.03 (d, 2JC-O-P = 7.5 Hz, 
ipso Naph), 147.97 (d, 2JC-O-P = 8.8 Hz, ipso Naph), 136.19, 136.05 (C10-Naph), 
128.81, 128.65 (CH-Naph), 127.87 (d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.74 (d, 3JC-C-
O-P = 8.8 Hz, C9-Naph), 127.57, 127.40, 127.15, 126.49, 126.37, 125.83, 125.59, 
122.84, 122.70 (CH-Naph), 119.12, 119.08 (C5), 116.25, 115.83 (2d, 3JC-C-O-P = 2.5 
Hz, C2-Naph), 99.86, 99.77 (C8), 98.03 (C1’), 83.35, 83.20 (2d, 3JC-C-O-P = 7.5 Hz, 
C4’), 80.25 (C2’), 76.14, 76.08 (C3’), 69.55 (d, 2JC-O-P = 6.3 Hz, C5’), 69.40 (d, 2JC-O-
P = 5.0 Hz, C5’), 66.39, 66.31 (OCH2CH2CH2CH2CH3), 54.30, 54.27 (6OCH3), 
51.60, 51.58 (CHCH3), 29.28, 29.23 (OCH2CH2CH2CH2CH3), 29.06, 29.05 
(OCH2CH2CH2CH2CH3), 23.36, 23.34 (OCH2CH2CH2CH2CH3), 20.79, 20.74 
(2’CCH3), 20.70, 20.62(2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 14.40 
(OCH2CH2CH2CH2CH3). 
HPLC (System 1) tR = 20.51, 21.31 min. 
MS (ES+) m/z: 785.16 (MH+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(cyclobutoxy-L-alaninyl)] phosphate (9.6g). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(cyclobutoxy-L-alaninyl) 
phosphorochloridate (510 mg, 1.37 mmol) in 5 mL of  THF. After silica gel column 
chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure compound 9.6g 
was obtained as an off white solid (79 mg, 15% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.21, 3.63. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16, 7.99-7.98 (2m, 1H, H8-Naph), 7.87- 7.85, 
7.78-7.77 (2m, 1H, H5-Naph), 7.67, 7.57 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53– 7.36 
(m, 3H, H2, H7, H6-Naph), 7.35-7.27 (m, 1H, H3-Naph), 5.98, 5.97 (2s, 1H, H1’), 
4.90- 4.80 (m, 2H, H3’and H5’a), 4.77-4.70 (m, 1H, OCH ester), 4.63- 4.54 (m, 1H, 
H5’b), 4.32- 4.24 (m, 1H, H4’), 4.01, 3.97 (2s, 3H, 6OCH3), 3.96 – 3.92 (m, 1H, 
CHCH3), 2.21-2.16 (m, 2H, 2x CH2a’ ester), 1.92-1.83 (m, 2H, 2x CH2a’’ ester), 1.73- 
1.66 (m, 1H, CH2b ester), 1.61- 1.51 (m, 1H, CH2b ester), 1.29, 1.23 (2d, J= 7.0 Hz, 
3H, CHCH3), 1.03, 1.02 (2s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.37 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.14 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.36, 161.27 (C6), 161.21, 161.07 (C2), 154.52, 154.45 (C4), 
148.07, 148.01 (ipso Naph), 136.22, 136.08 (C10-Naph), 128.78, 128.62 (CH-Naph), 
127.92, 128.87 (C9-Naph), 127.78, 127.68, 127.55, 127.37, 127.11, 126.44, 126.33, 
125.80, 125.55, 122.83, 122.70 (CH-Naph), 119.15, 119.11 (C5), 116.23, 115.79 (2d, 
3JC-C-O-P = 2.5 Hz, C2-Naph), 99.76 (C8), 98.05 (C1’), 83.34 (d, 3JC-C-O-P = 7.5 Hz, 
C4’), 83.20 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.24, 80.21 (C2’), 76.12, 76.05 (C3’), 70.96, 
70.95 (OCH ester), 69.53, 69.42 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.23, 54.19 (6OCH3), 
51.47, 51.44 (CHCH3), 31.07, 30.92 (CH2 ester), 20.72, 20.67 (2’CCH3), 20.55, 20.44 
(2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 14.23, 14.21 (CH2 ester). 
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MS (ES+) m/z: 769.12 (MH+, 100%).  
HRMS C29H35N6O9P1I1 Calculated: 769.1248 found: 769.1222. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(cyclopentoxy-L-alaninyl)] phosphate (9.6h). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(cyclopropoxy-L-
alaninyl) phosphorochloridate (3.3h, 520 mg, 1.37 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.6h was obtained as an off white solid (80 mg, 15% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.25, 3.67. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 7.98-7.97 (2m, 1H, H8-Naph), 7.87- 7.85, 
7.78-7.76 (2m, 1H, H5-Naph), 7.67, 7.56 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.53– 7.36 
(m, 3H, H2, H7, H6-Naph), 7.35-7.27 (m, 1H, H3-Naph), 5.97, 5.96 (2s, 1H, H1’), 4.97- 
4.92 (m, 1H, OCH ester), 4.90- 4.79 (m, 2H, H3’ and H5’a), 4.62- 4.54 (m, 1H, H5’b), 
4.31- 4.23 (m, 1H, H4’), 4.01, 3.97 (2s, 3H, 6OCH3), 3.95– 3.89 (m, 1H, H" Ala), 
1.75- 1.70 (m, 2H, CH2), 1.62- 1.59 (m, 6H, 3x CH2 ester), 1.28, 1.20 (2d, J= 7.0 Hz, 
3H, CHCH3), 1.03, 1.02 (2 x s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.88, 174.61 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.37, 
161.28 (C6), 161.18, 161.04 (C2), 154.54, 154.47 (C4), 148.04 (d, 2JC-O-P = 7.5 Hz, 
ipso Naph),  147.96 (d, 2JC-O-P = 6.3 Hz, ipso Naph), 136.20, 136.06 (C10-Naph), 
128.82, 128.66 (CH-Naph), 127.88, 128.74 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.58, 
127.40, 127.25, 127.16, 126.48, 126.36, 125.85, 125.62, 122.82, 122.68 (CH-Naph), 
119.21, 119.17 (C5), 116.26 (d, 3JC-C-O-P = 3.4 Hz, C2-Naph), 115.85 (d, 3JC-C-O-P = 
2.5 Hz, C2-Naph), 99.79, 99.66 (C8), 98.03, 97.84 (C1’), 83.36 (d, 3JC-C-O-P = 7.5 Hz, 
C4’), 83.22 (d, 3JC-C-O-P = 8.8 Hz, C4’), 80.28, 80.26 (C2’), 79.52, 79.48 (OCH ester), 
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54.33, 54.30 (6OCH3), 51.69, 51.63 (CHCH3) 33.53, 33.43 (2x CH2 ester), 24.64, 
24.60 (2x CH2 ester), 20.83, 20.79 (2’CCH3), 20.68, 20.60 (2d, 3JC-C-N-P = 6.3 Hz, 
CHCH3). 
HPLC (System 1) tR = 18.99, 19.81 min. 
MS (TOF ES+) m/z: 783.14 (MH+, 100%).  
HRMS C30H37N6O9P1I1 Calculated: 783.1404 found: 783.1382. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(cyclohexoxy-L-alaninyl)] phosphate (9.6i). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(cyclohexoxy-L-alaninyl) 
phosphorochloridate (3.3i, 550 mg, 1.37 mmol) in 5 mL of  THF. After silica gel 
column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure compound 
9.6i was obtained as an off white solid (75 mg, 14% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.23, 3.66. 
1H NMR (500 MHz, MeOD) ! 8.17-8.15, 7.99-7.98 (2m, 1H, H8-Naph), 7.86-7.84, 
7.77-7.76 (2m, 1H, H5-Naph), 7.66, 7.56 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.52–7.36 (m, 
3H, H2, H7, H6-Naph), 7.35-7.27 (m, 1H, H3-Naph), 5.98, 5.97 (2s, 1H, H1’), 4.90- 
4.81 (m, 2H, H3’ and H5’a), 4.63- 4.51 (m, 2H, H5’b and OCH ester), 4.32- 4.24 (m, 1H, 
H4’), 4.00, 3.97 (2s, 3H, 6OCH3), 3.99– 3.91 (m, 1H, CHCH3), 1.68- 1.63 (m, 4H, 2x 
CH2 ester), 1.48- 1.47 (m, 1H, 1 of CH2 ester), 1.34- 1.26 (m, 7H, 1 of CH2 and 3x 
CH2 ester), 1.29, 1.22 (2d, J= 7.0 Hz, 3H, CHCH3), 1.03 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOH-d4) ! 174.50 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.24 (d, 3J 
C-C-N-P = 6.3 Hz, C=O), 161.36, 161.27 (C6), 161.20, 161.06 (C2), 154.53, 154.46 
(C4), 148.06 (d, 2JC-O-P = 7.5 Hz, ipso Naph),  147.99 (d, 2JC-O-P = 8.8 Hz, ipso Naph), 
136.23, 136.09 (C10-Naph), 128.79, 128.62 (CH-Naph), 127.90, 128.76 (2d, 3JC-C-O-P 
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122.70 (CH-Naph), 119.16, 119.11 (C5), 116.23, 115.80 (2d, 3JC-C-O-P = 3.4 Hz, C2-
Naph), 99.73, 99.65 (C8), 98.04 (C1’), 83.37, 83.21 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 
80.24 (C2’), 76.12, 76.05 (C3’), 74.88 (OCH ester), 69.56, 69.43 (2d, 2JC-O-P = 5.0 
Hz, C5’), 54.24, 54.22 (6OCH3), 51.74, 51.71 (CHCH3) 32.32, 32.27 (2CH2 ester), 
26.37 (2CH2 ester), 24.55 (CH2 ester), 20.73, 20.69 (2’CCH3), 20.72, 20.62 (2d, 3JC-C-
N-P = 6.3 Hz, CHCH3). 
HPLC (System 1) tR = 20.35, 21.16 min. 
MS (ES+) m/z: 819.14 (MNa+, 100%).  
HRMS C31H38N6O9P1I1Na1 Calculated: 819.1380 found: 819.1390. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(tetrahydropyroxy-L-alaninyl)] phosphate (9.6j). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(tetrahydropyroxy-L-
alaninyl) phosphorochloridate (3.3i, 550 mg, 1.37 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.6j was obtained as an off white solid (150 mg, 27% yield). 
31P NMR (202 MHz, MeOD) ! 4.17, 3.61. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16, 7.99-7.98 (2m, 1H, H8-Naph), 7.86- 7.84, 
7.77-7.76 (2m, 1H, H5-Naph), 7.66, 7.56 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.52– 7.36 
(m, 3H, H2, H7, H6-Naph), 7.33-7.27 (m, 1H, H3-Naph), 5.98, 5.97 (2s, 1H, H1’), 4.90- 
4.84 (m, 2H, H3’and H5’a), 4.77- 4.68 (m, 1H, OCH ester) 4.63- 4.51 (m, 1H, H5’b), 
4.32- 4.24 (m, 1H, H4’), 4.03– 3.95 (m, 1H, CHCH3), 4.01, 3.97 (2s, 3H, 6OCH3), 
3.80- 3.74 (m, 2H, OCH2 ester), 3.47- 3.40 (m, 2H, OCH2 ester), 1.77- 1.69 (m, 2H, 
OCHCH2 ester), 1.52- 1.43 (m, 2H, OCHCH2 ester), 1.30, 1.23 (2d, J= 6.5 Hz, 3H, 
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13C NMR (126 MHz, MeOD) ! 174.30 (d, 3J C-C-N-P = 4.3 Hz, C=O), 174.06 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.37, 161.29 (C6), 161.21, 161.06 (C2), 154.55, 154.46 (C4), 
148.03 (d, 2JC-O-P = 7.5 Hz, ipso Naph),  147.97 (d, 2JC-O-P = 8.8 Hz, ipso Naph), 
136.23, 136.08 (C10-Naph), 128.82, 128.65 (CH-Naph), 127.89 (d, 3JC-C-O-P = 6.3 Hz, 
C9-Naph), 127.74 (d, 3JC-C-O-P = 5.0 Hz, C9-Naph),127.58, 127.41, 127.15, 126.49, 
126.37, 125.85, 125.59, 122.81, 122.67 (CH-Naph), 119.19, 119.13 (C5), 116.27, 
115.82 (2d, 3JC-C-O-P = 3.4 Hz, C2-Naph), 99.78, 99.66 (C8), 98.05 (C1’), 83.40 (d, 
3JC-C-O-P = 6.3 Hz, C4’), 83.23 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.24, 80.22 (C2’), 76.13, 
76.04 (C3’), 71.25, 71.22 (OCH ester), 69.59 (d, 2JC-O-P = 6.3 Hz, C5’), 69.44 (d, 2JC-
O-P = 5.0 Hz, C5’), 66.07, 66.01, 65.99 (O(CH2)2 ester), 54.28, 54.24 (6OCH3), 51.70, 
51.66 (CHCH3) 32.50, 32.44, 32.41 (OCH(CH2)2 ester), 20.75, 20.71 (2’CCH3), 
20.63, 20.55 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3). 
HPLC (Sstem 1) tR = 14.91, 15.71 min. 
MS (ES+) m/z: 799.13 (MH+, 100%).  
HRMS C30H37N6O10P1I1 Calculated: 799.1354 found: 799.1349. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,4-di-fluorobenzoxy-L-alaninyl)] phosphate (9.6k). 
 
 Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(2,4-di-F-benzoxy-L-
alaninyl) phosphorochloridate (603 mg, 
1.37 mmol) in 5 mL of  THF. After silica 
gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
compound 9.6k was obtained as an off white solid (120 mg, 20% yield). 
31P NMR (202 MHz, MeOD) ! 4.16, 3.81. 
1H NMR (500 MHz, MeOD) ! 8.14- 8.12, 7.97- 7.96 (2m, 1H, H8-Naph), 7.85- 7.83, 
7.75- 7.74 (2m, 1H, H5-Naph), 7.64, 7.54 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.50– 7.33 
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6.78 (m, 2H, OCH2-2,4-F-Ph), 5.96, 5.91 (2s, 1H, H1’), 5.04-4.95 (m, 2H, OCH2-2,4-
F-Ph), 4.85- 4.76 (m, 2H, H3’and H5’a), 4.64- 4.55 (m, 1H, H5’b), 4.28- 4.22 (m, 1H, 
H4’), 4.08 – 4.02 (m, 1H, CHCH3), 4.00, 3.99 (2s, 3H, 6OCH3), 1.30, 1.24 (2d, J= 7.0 
Hz, 3H, CHCH3), 1.01 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.62, 174.43 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 159.50 
(d, JC-F = 248.5 Hz, OCH2-2,4-F-Ph), 164.42 (d, JC-F = 243.7 Hz, OCH2-2,4-F-Ph), 
162.46 (d, JC-F = 246.7 Hz, OCH2-2,4-F-Ph), 162.33 (d, JC-F = 251.2 Hz, OCH2-2,4-
F-Ph),  161.46, 161.42 (C6), 161.29, 161.25 (C2), 154.50, 154.44 (C4), 148.00, 
147.90 (2d, 2JC-O-P = 7.5 Hz, ipso Naph), 136.19, 136.01 (C10-Naph), 133.08, 
133.05(2d, 3JC-F = 7.1 Hz, OCH2-2,4-F-Ph), 128.78, 128.61 (CH-Naph), 127.85 (d, 
3JC-C-O-P = 6.3 Hz, C9-Naph), 127.72 (d, 3JC-C-O-P = 5.0 Hz, C9-Naph), 127.55, 127.38, 
127.11, 126.43, 126.32, 125.85, 125.64, 122.78, 122.68 (CH-Naph), 120.51-120.43 
(m, ipso OCH2-2,4-F-Ph), 118.80, 118.77 (C5), 116.28 (d, 2JC-C-O-P = 3.8 Hz, C2-
Naph), 116.02 (d, 2JC-C-O-P = 2.5 Hz, C2-Naph), 112.35, 112.32 (2d, 2JC-F = 21.0 Hz, 
OCH2-2,4-F-Ph),  104.75, 104.55 (2d, 2JC-F = 25.2 Hz, OCH2-2,4-F-Ph), 99.75, 99.72 
(C8), 98.05 (C1’), 83.37, 83.21 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.18 (C2’), 76.04, 
76.00 (C3’), 69.48, 69.34 (2d, 2JC-O-P = 5.0 Hz, C5’), 61.18, 61.16 (OCH2-2,4-F-Ph), 
54.52, 54.42 (6OCH3), 51.61, 51.58 (CHCH3), 20.79, 20.70 (2’CCH3), 20.40 (d, 3JC-C-
N-P = 5.0 Hz, CHCH3), 20.36 (d, 3JC-C-N-P = 6.3 Hz, CHCH3). 
19F NMR (470 MHz, MeOD) ! -111.14, -113.69, 115.43, -117.41. 
HPLC (System 1) tR = 19.29, 20.31 min. 
MS (ES+) m/z: 863.08 (MNa+, 100%).  
HRMS C32H32N6O9F2Na1P1I1 Calculated: 863.0879 found: 863.0838. 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(isopropoxy-L-methioninyl)] phosphate (9.6m). 
  
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (9.3, 300 mg, 0.67 mmol), tBuMgCl 
(1.37 ml, 1.37 mmol), and phenyl-(benzoxy-
L-alaninyl) phosphorochloridate (3.3n, 463 
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CHCl3/MeOH (0 to 3%, gradient), the pure compound 9.6m was obtained as an off 
white solid (54 mg, 11% yield). 
 
31P NMR (202 MHz, MeOD) ! 3.79, 3.62. 
1H NMR (500 MHz, MeOD) ! 7.34-7.31 (m 1H, Ph), 7.27-7.21 (m, 2H, Ph), 7.18-
7.10 (m, 2H, Ph), 5.98, 5.96 (2s, 1H, H1’), 4.91-4.72 (m, 2H, H3’and H5’a), 4.60- 4.47 
(m, 1H, H5’b), 4.28- 4.20 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 4.00–3.94 (m, 1H, 
CHCH3), 3.89, 3.86, 3.74, 3.68 (2AB, JAB= 12.0 Hz, 2H, OCH2C(CH3)3), 1.37, 1.23 
(2d, J= 7.0 Hz, 3H, CHCH3), 1.06, 1.04 (2s, 3H, 2’CCH3),  0.97, 0.92 (2s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.10 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.82 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.42, 161.25 (C6), 161.22 (C2), 154.58 (C4), 152.19, 152.14 
(ipso Ph), 130.66, 130.58, 126.01, 125.94, 121.51, 121.47, 121.43 (CH-Ph), 119.13 
(C5), 99.82 (C8), 98.07, 98.04 (C1’), 83.33, 83.10 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.22, 
80.18 (C2’), 76.16, 76.01 (C3’), 75.27, 75.25 (OCH2C(CH3)3), 69.29, 69.22 (2d, 2JC-
O-P = 5.0 Hz, C5’), 54.26 (6OCH3), 51.55, 51.47 (CHCH3), 32.33, 32.27 
(OCH2C(CH3)3), 26.78 (OCH2C(CH3)3), 20.72 (d, 3JC-C-N-P = 5.0 Hz, CHCH3), 20.67 
(d, 3JC-C-N-P = 7.5 Hz, CHCH3), 20.36 (2’CCH3). 
HPLC (System 1) tR = 18.27 min. 
MS (ES+) m/z: 757.12 (M+Na+, 100%).  
HRMS C26H37N6O9P1I1Na Calculated: 757.1224 found: 757.1248. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(isopropoxy-L-methioninyl)] phosphate (9.6m). 
 
 Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
mmol), tBuMgCl (1.37 ml, 1.37 mmol), 
and "-naphthyl-(isopropoxy-L-
methioninyl) phosphorochloridate (3.3x, 570 mg, 1.37 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 3%, gradient), the pure 
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31P NMR (202 MHz, MeOD) ! 4.38, 3.92. 
1H NMR (500 MHz, MeOD) ! 8.20-8.18, 8.00-7.99 (2m, 1H, H8-Naph), 7.87- 7.85, 
7.78-7.76 (2m, 1H, H5-Naph), 7.67, 7.56 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.53– 7.38 
(m, 3H, H2, H7, H6-Naph), 7.35-7.26 (m, 1H, H3-Naph), 5.98, 5.97 (2s, 1H, H1’), 4.91-
4.78 (m, 4H, H3’and H5’a and OCH(CH3)2), 4.63-4.56 (m, 1H, H5’b), 4.31, 4.25 (2td, 
J=8.5, 2.5 Hz, 1H, H4’), 4.05-3.98 (m, 1H, CHCH2CH2SCH3), 4.01, 3.97 (2s, 3H, 
6OCH3), 2.37-2.33 (m, 2H, CHCH2CH2SCH3), 1.94, 1.92 (2s, 3H, CHCH2CH2SCH3), 
1.91-1.73 (m, 2H, CHCH2CH2SCH3), 1.14-1.10 (m, 6H, OCH(CH3)2), 1.03, 1.02 (s, 
3H, 2’CCH3).  
13C NMR (126 MHz, MeOD) ! 173.83, 173.64 (C=O), 161.37, 161.26 (C6), 161.18, 
161.04 (C2), 154.51, 154.44 (C4), 148.05 (d, 2JC-O-P= 7.5 Hz, ipso Naph),  147.92 (d, 
2JC-O-P= 6.3 Hz, ipso Naph), 136.24, 136.08 (C10-Naph), 128.79, 128.64,  (CH Naph), 
127.86 (d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.74 (d, 3JC-C-O-P = 5.0 Hz, C9-Naph), 
127.57, 127.39, 127.16, 126.45, 126.32, 125.81, 125.62, 122.89, 122.75 (CH Naph), 
119.16 (C5), 116.11, 116.88 (2d, 3JC-C-O-P= 2.5 Hz, C2-Naph), 99.80 (C8), 98.02 
(C1’), 83.36, 83.16 (2d, 3JC-C-O-P= 7.5 Hz, C4’), 80.26, 80.20 (C2’), 76.14, 76.02 
(C3’), 70.36, 70.34 (OCH(CH3)2), 69.66 (d, 2JC-O-P= 5.0 Hz, C5’), 69.62 (d, 2JC-O-P = 
6.3 Hz, C5’), 55.12 (CHCH2CH2SCH3), 54.26, 54.21 (6OCH3), 34.56 (d, 3JC-C-N-P= 
6.3 Hz, CHCH2CH2SCH3), 34.39 (d, 3JC-C-N-P= 7.5 Hz, CHCH2CH2SCH3), 30.82, 
30.79 (CHCH2CH2SCH3), 22.02, 21.91 (OCH(CH3)2),  20.75, 30.68 (2’CCH3), 15.26, 
15.23 (CHCH2CH2SCH3). 
MS (ES+) m/z: 617.12 (MH+, 100%).  
HRMS C30H39N6O9P1S1I1 Calculated: 617.1257 found: 617.1248. 
 
Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(benzoxy-L-methioninyl)] phosphate (9.6n). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.3, 300 mg, 0.67 
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and !-naphthyl-(benzoxy-L-methioninyl) phosphorochloridate (3.3z, 640 mg, 1.37 
mmol) in 5 mL of  THF. After silica gel column chromatography using CHCl3/MeOH 
(0 to 3%, gradient), the pure compound 9.6m was obtained as an off white solid (180 
mg, 14% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.17, 3.61. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16, 8.00-7.99 (2m, 1H, H8-Naph), 7.85- 7.83, 
7.76-7.75 (2m, 1H, H5-Naph), 7.64, 7.55 (2d, J= 8.5 Hz, 1H, H4-Naph), 7.50– 7.41 
(m, 3H, H2, H7, H6-Naph), 7.36-7.29 (m, 1H, H3-Naph), 7.26- 7.23 (m, 5H, OCH2Ph), 
5.99, 5.98 (2s, 1H, H1’), 5.03- 4.87 (m, 2H, OCH2Ph), 4.85- 4.80 (m, 2H, H3’ and 
H5’a), 4.65- 4.57 (m, 1H, H5’b), 4.34- 4.24 (m, 1H, H4’), 4.16- 4.68 (m, 1H, 
CHCH2CH2SCH3), 3.98, 3.95 (2s, 3H, 6OCH3), 2.28 (t, J= 7.0 Hz, 2H, 
CHCH2CH2SCH3), 1.89- 1.75 (m, 2H, CHCH2CH2SCH3), 1.86, 1.83 (2s, 3H, 
CHCH2CH2SCH3) 1.03 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 174.04, 173.86 (2d, 3J C-C-N-P = 5.0 Hz, C=O), 161.37, 
161.26 (C6), 161.17, 161.03 (C2), 154.53, 154.45 (C4), 148.01 (d, 2JC-O-P = 7.5 Hz, 
ipso Naph),  147.93 (d, 2JC-O-P = 6.3 Hz, ipso Naph), 137.05, 137.01 (ipso OCH2Ph), 
136.22, 136.06 (C10-Naph), 129.67, 129.56, 129.54, 129.34, 129.32, 129.28, 128.81, 
128.66 (CH-Naph and OCH2Ph), 127.85 (d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.75 (d, 
3JC-C-O-P = 5.0 Hz, C9-Naph), 127.60, 127.45, 127.23, 126.48, 126.37, 125.86, 125.68, 
122.89, 122.75 (CH-Naph), 119.19, 119.14 (C5), 116.19 (d, 3JC-C-O-P = 3.8 Hz, C2-
Naph), 115.98 (d, 3JC-C-O-P = 2.5 Hz, C2-Naph), 99.79 (C8), 98.02 (C1’), 83.37, 83.15 
(2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.27, 80.22 (C2’), 76.14, 76.05 (C3’), 69.64 (d, 2JC-O-P 
= 6.3 Hz, C5’), 69.59 (d, 2JC-O-P = 5.0 Hz, C5’), 67.99 (OCH2Ph), 55.02 
(CHCH2CH2SCH3), 54.29, 54.25 (6OCH3), 34.44 (d, 3JC-C-N-P = 6.3 Hz, 
CHCH2CH2SCH3), 34.33 (d, 3JC-C-N-P = 7.5 Hz, CHCH2CH2SCH3), 30.68 
(CHCH2CH2SCH320.79, 20.72 (2’CCH3), 15.22 (CHCH2CH2SCH3). 
HPLC (system 1) tR = 19.93, 20.75 min. 
MS (ES+) m/z: 865.13 (MH+, 100%).  
HRMS C304H39N6O10P1S1I1 Calculated: 865.1282 found: 865.1256. 
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Synthesis of 2-amino-6-O-methyl-8-C-bromo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(2,2-dimethylpropoxy-L-alaninyl) phosphate (9.7a). 
 
 8.2e (200 mg, 0.30 mmol) was 
dissolved in MeOH (10 ml) and NBS 
(53 mg, 0.30 mmol) was added. The 
mixture was stirred at room 
temperature for 18 h. After that time, 
solution was concentrated and the 
resulting solid was purified by silica gel chromatography using 1-4% (gradient) of 
MeOH in CHCl3 to yield the desired product 9.7a as a white solid (56 mg, 25% 
yield). 
31P NMR (202 MHz, MeOD) ! 13.87. 
1H NMR (500 MHz, MeOD) ! 6.04 (s, 1H, H1'), 4.91-4.80 (m, 2H, H3’), 4.63- 4.58 
(m, 1H, H5’a), 4.41- 4.37 (m, 1H, H5’b), 4.22- 4.18 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 
3.97-3.88 (m, 2H, 2x CHCH3), 3.77, 3.76, 3.66, 3.60 (2AB, JAB= 10.5 Hz, 4H, 2x 
OCH2C(CH3)3), 1.38 (d, J= 7.0 Hz, 3H, CHCH3), 1.25 (d, J= 7.0 Hz, 3H, CHCH3), 
1.06 (s, 3H, 2’CCH3), 0.96 (s, 9H, OCH2C(CH3)3), 0.91 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.72 (d, 3JC-C-N-P = 5.0 Hz, C=O), 175.53 (d, 3JC-C-N-
P = 7.5 Hz, C=O), 161.63 (C6), 161.47 (C2), 154.94 (C4), 125.83 (C8), 116.23 (C5), 
95.86 (C1’), 83.40 (d, 3JC-C-O-P = 6.3 Hz, C4’), 80.24 (C2’), 76.00 (C3’), 75.34, 75.29 
(OCH2C(CH3)3), 67.61 (d, 2JC-O-P = 5.0 Hz, C5’), 54.30 (6OCH3), 51.05 (CHCH3), 
50.91 (CHCH3), 32.34 (OCH2C(CH3)3), 32.27 (OCH2C(CH3)3), 26.84 
(OCH2C(CH3)3), 26.78 (OCH2C(CH3)3), 21.07 (d, 3JC-C-N-P = 5.0 Hz, CHCH3), 21.01 
(d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.60 (2’CCH3). 
HPLC (System 1) tR = 20.67 min. 
MS (ES+) m/z: 754.24 (M+NH+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-chloro-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(2,2-dimethylpropoxy-L-alaninyl) phosphate (9.8a). 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-8-C-chloro-9-(2’-C-methyl-
!-D-ribofuranosyl) purine (9.2, 300 
mg, 0.87 mmol), POCl3 (0.28 ml, 
0.87 mmol), Et3N (0.12 ml, 0.87 
mmol), L-alanine 2,2-dimethylpropyl ester tosylate salt (3.2g, 1.44 g, 4.36 mmol), 
Et3N (1.20 ml, 8.72 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude 
mixture was purified by column chromatography in gradient (CHCl3/MeOH 0 to 5%), 
to give a pure product 9.8a as a white foam (160 mg, 26%). 
 
31P NMR (202 MHz, MeOD) ! 13.87. 
1H NMR (500 MHz, MeOD) ! 6.03 (s, 1H, H1'), 4.78- 4.76 (m, 2H, H3’), 4.62- 4.57 
(m, 1H, H5’a), 4.43- 4.38 (m, 1H, H5’b), 4.23- 4.19 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 
3.99-3.93 (m, 1H, CHCH3), 3.92-3.87 (m, 1H, CHCH3), 3.79, 3.78, 3.68, 3.61 (2AB, 
JAB= 10.5 Hz, 4H, 2x OCH2C(CH3)3), 1.38 (d, J= 7.0 Hz, 3H, CHCH3), 1.25 (d, J= 
7.0 Hz, 3H, CHCH3), 1.07 (s, 3H, 2’CCH3), 0.95 (s, 9H, OCH2C(CH3)3), 0.90 (s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.71 (d, 3J C-C-N-P = 6.3 Hz, C=O), 175.53 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.78 (C6), 161.48 (C2), 154.66 (C4), 136.71 (C8), 114.40 
(C5), 94.63 (C1’), 83.40 (d, 3JC-C-O-P = 6.3 Hz, C4’), 80.22 (C2’), 75.96 (C3’), 75.36, 
75.31 (CH2 ester), 67.55 (d, 2JC-O-P = 5.0 Hz, C5’), 54.42 (6OCH3), 51.06 (CHCH3), 
50.91 (CHCH3), 32.36 (OCH2C(CH3)3), 32.29 (OCH2C(CH3)3),  26.88 
(OCH2C(CH3)3), 26.82 (OCH2C(CH3)3), 21.15 (d, 3JC-C-N-P = 6.3 Hz, CHCH3), 21.08 
(d, 3JC-C-N-P = 6.3 Hz, OCH2C(CH3)3), 20.61 (2’CCH3). 
HPLC (System 1) tR = 20.67 min. 
MS (ES+) m/z: 708.29 (M+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(2,2-dimethylpropoxy-L-alaninyl) phosphate (9.9a). 
  
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-8-C-iodo-9-(2’-C-methyl-!-
D-ribofuranosyl) purine (9.3, 300 
mg, 0.69 mmol), POCl3 (0.06 ml, 
0.69 mmol), Et3N (0.09 ml, 0.69 
mmol), L-alanine 2,2-dimethylpropyl ester tosylate salt (3.2g, 1.14 g, 3.43 mmol), 
Et3N (0.96 ml, 6.86 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude 
mixture was purified by column chromatography in gradient (CHCl3/MeOH 0 to 5%), 
to give a pure product 9.9a as a white foam (50 mg, 10%). 
 
31P NMR (202 MHz, MeOD) 13.89. 
1H NMR (500 MHz, MeOD) 5.98 (s, 1H, H1'), 4.91- 4.83 (m, 2H, H3’), 4.63- 4.57 (m, 
1H, H5’a), 4.42- 4.38 (m, 1H, H5’b), 4.21- 4.18 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 
3.97-3.90 (m, 2H, CHCH3), 3.78, 3.75, 3.67, 3.61 (2AB, JAB= 10.5 Hz, 4H, 2x 
OCH2C(CH3)3), 1.38 (d, J= 7.0 Hz, 3H, CHCH3), 1.24 (d, J= 7.0 Hz, 3H, CHCH3), 
1.04 (s, 3H, 2’CCH3), 0.96 (s, 9H, OCH2C(CH3)3), 0.91 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.74 (d, 3J C-C-N-P = 5.0 Hz, C=O), 175.55 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.40 (C6), 161.27 (C2), 154.64 (C4), 119.12 (C5), 99.76 (C8), 
98.00 (C1’), 83.35 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.29 (C2’), 76.07 (C3’), 75.35, 75.29 
(2x OCH2C(CH3)3), 67.66 (d, 2JC-O-P = 5.0 Hz, C5’), 54.24 (6OCH3), 51.05 (CHCH3), 
50.92 (CHCH3), 32.36 (OCH2C(CH3)3), 32.29 (OCH2C(CH3)3),  26.87 
(OCH2C(CH3)3), 26.80 (OCH2C(CH3)3), 21.07 (CHCH3), 21.03 (CHCH3), 20.78 
(2’CCH3) 
HPLC (System 1) tR = 15.12 min. 
MS (ES+) m/z: 800.22 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(3,3-dimethyl-1-butoxy-L-alaninyl) phosphate (9.9b). 
 
Prepared according to the 
Standard Procedure 13a, from: 2-
amino-6-O-methyl-8-C-iodo-9-
(2’-C-methyl-!-D-ribofuranosyl) 
purine (9.3, 300 mg, 0.69 mmol), 
POCl3 (0.06 ml, 0.69 mmol), 
Et3N (0.09 ml, 0.69 mmol), L-alanine 3,3-dimethyl-1-butyl ester tosylate salt (3.2i, 
1.14 g, 3.43 mmol), Et3N (0.96 ml, 6.86 mmol) in 10 ml of 1:1 mixture of dry THF 
and DCM. The crude mixture was purified by column chromatography in gradient 
(CHCl3/MeOH 0 to 5%), to give a pure product 9.9b as a white foam (130 mg, 23%). 
 
31P NMR (202 MHz, MeOD) 13.96. 
1H NMR (500 MHz, MeOD) 5.98 (s, 1H, H1'), 4.89- 4.81 (m, 2H, H3’), 4.63- 4.57 (m, 
1H, H5’a), 4.41-4.37 (m, 1H, H5’b), 4.21-4.09 (m, 5H, H4’ and 2x OCH2CH2C(CH3)3), 
4.04 (s, 3H, 6OCH3), 3.92-3.86 (m, 1H, CHCH3), 3.85-3.80 (m, 1H, CHCH3), 1.57 (t, 
J= 7.0 Hz, 2H, OCH2CH2C(CH3)3), 1.52 (t, J= 7.0 Hz, 2H, OCH2CH2C(CH3)3), 1.34 
(d, J= 7.0 Hz, 3H, CHCH3), 1.20 (d, J= 7.0 Hz, 3H, CHCH3), 1.03 (s, 3H, 2’CCH3), 
0.97 (s, 9H, OCH2CH2C(CH3)3), 0.94 (s, 9H, OCH2CH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.74 (d, 3J C-C-N-P = 5.0 Hz, C=O), 175.56 (d, 3J C-C-
N-P = 5.0 Hz, C=O), 161.44 (C6), 161.17 (C2), 154.58 (C4), 119.13 (C5), 99.72 (C8), 
97.98 (C1’), 83.33 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.34 (C2’), 76.13 (C3’), 67.57 (d, 2JC-
O-P = 5.0 Hz, C5’), 63.95 (OCH2CH2C(CH3)3), 63.89 (OCH2CH2C(CH3)3), 54.23 
(6OCH3), 51.03 (CHCH3), 50.91 (CHCH3), 42.87 (OCH2CH2C(CH3)3), 30.63 
(OCH2CH2C(CH3)3), 30.61 (OCH2CH2C(CH3)3),  30.13 (OCH2CH2C(CH3)3), 30.11 
(OCH2CH2C(CH3)3), 20.90 (CHCH3), 20.85 (CHCH3), 20.62 (2’CCH3). 
HPLC (System 1) tR = 22.51 min. 
MS (ES+) m/z: 828.25 (M+Na+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(cyclohexoxy-L-alaninyl) phosphate (9.9c). 
 
Prepared according to the Standard 
Procedure 13a, from: 2-amino-6-O-
methyl-8-C-iodo-9-(2’-C-methyl-!-
D-ribofuranosyl) purine (9.3, 300 
mg, 0.69 mmol), POCl3 (0.06 ml, 
0.69 mmol), Et3N (0.09 ml, 0.69 
mmol), L-alanine cyclohexyl ester hydrochloride salt (3.2c, 0.72 g, 3.43 mmol), Et3N 
(0.96 ml, 6.86 mmol) in 10 ml of 1:1 mixture of dry THF and DCM. The crude 
mixture was purified by column chromatography in gradient (CHCl3/MeOH 0 to 5%), 
to give a pure product 9.9c as a white foam (191 mg, 34%). 
 
31P NMR (202 MHz, MeOD) 13.97. 
1H NMR (500 MHz, MeOD) 5.98 (s, 1H, H1'), 4.91-82 (m, 2H, H3’), 4.72-4.67 (m, 
1H, OCH ester), 4.63- 4.57 (m, 2H, H5’a and OCH ester), 4.42- 4.38 (m, 1H, H5’b), 
4.22- 4.18 (m, 1H, H4’), 4.04 (s, 3H, 6OCH3), 3.87 (q, J= 7.0 Hz, 1H, CHCH3), 3.82 
(q, J= 7.0 Hz, 1H, CHCH3), 1.84-1.69 (m, 8H, 4xCH2 ester), 1.41-1.29 (m, 12H, 
6xCH2 ester), 1.34 (d, J= 7.0 Hz, 3H, CHCH3), 1.21 (d, J= 7.0 Hz, 3H, CHCH3), 1.04 
(s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 175.23 (d, 3J C-C-N-P = 6.3Hz, C=O), 174.96 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.40 (C6), 161.20 (C2), 154.58 (C4), 119.09 (C5), 99.82 (C8), 
97.98 (C1’), 83.39 (d, 3JC-C-O-P = 7.5 Hz, C4’), 80.31 (C2’), 76.05 (C3’), 74.80 (OCH 
ester), 74.69 (OCH ester), 67.62 (d, 2JC-O-P = 5.0 Hz, C5’), 54.34 (6OCH3), 51.13 
(CHCH3), 50.94 (CHCH3), 26.47 (CH2 ester), 26.44 (CH2 ester), 24.71 (CH2 ester), 
24.68 (CH2 ester), 21.07 (CHCH3), 21.03 (CHCH3), 20.78 (2’CCH3) 
HPLC (System 1) tR = 20.91 min 
MS (ES+) m/z: 824.23 (M+H+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-iodo-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-bis(benzyl-L-alaninyl) phosphate (9.9d). 
 
Prepared according to the 
Standard Procedure 13a, from: 2-
amino-6-O-methyl-8-C-iodo-9-
(2’-C-methyl-!-D-ribofuranosyl) 
purine (9.3, 300 mg, 0.69 mmol), 
POCl3 (0.06 ml, 0.69 mmol), 
Et3N (0.09 ml, 0.69 mmol), L-
alanine benzyl ester tosylate salt (1.21 g, 3.43 mmol), Et3N (0.96 ml, 6.86 mmol) in 
10 ml of 1:1 mixture of dry THF and DCM. The crude mixture was purified by 
column chromatography in gradient (CHCl3/MeOH 0 to 5%), to give a pure product 
9.9d as a white foam (230 mg, 40%). 
31P NMR (202 MHz, MeOD) ! 13.86. 
1H NMR (500 MHz, MeOD) !  7.35-7.23 (m, 10H, 2Ph), 6.01 (2s, 1H, H1’), 5.09, 
5.05, 4.94, 4.88 (2AB, JAB= 12.0 Hz, 2H, CH2 ester), 4.88- 4.85 (m, 1H, H3’), 4.59- 
4.56 (m, 1H, H5’a), 4.47- 4.43 (m, 1H, H5’b), 4.25- 4.21 (m, 1H, H4’), 4.01 – 3.88 (m, 
2H, 2xH", Ala), 3.99 (s, 3H, 6OCH3), 1.31 (d, J= 7.0 Hz, 3H, CH3 Ala), 1.20 (d, J= 
7.5 Hz, 3H, CH3 Ala), 1.04 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 175.55 (d, 3J C-C-N-P = 5.0 Hz, C=O ester), 175.44 (d, 
3J C-C-N-P = 5.0 Hz, C=O ester), 161.44 (C6), 161.15 (C2), 154.52 (C4), 137.28, 
137.19 (ipso Ph), 129.99, 129.67, 129.64, 129.44, 129.36, 129.27, 128.35, 128.07 (C- 
Ph), 119.17 (C5), 99.89 (C8), 97.98 (C1’), 83.35 (d, 3JC-C-O-P = 6.3 Hz, C4’), 80.39 
(C2’), 76.16 (C3’), 67.93 (d, 2JC-O-P = 5.0 Hz, C5’), 67.60, 67.57 (CH2 ester), 54.49 
(6OCH3), 51.09, 51.01 (2C" Ala), 21.28 (2’CCH3), 20.93 (d, 3JC-C-N-P = 5.0 Hz, CH3 
Ala), 20.84 (d, 3JC-C-N-P = 5.0 Hz, CH3 Ala) 
HPLC tR = 18.60 min 
MS (ES+) m/z: 862.22 (M+Na+, 100%).  

























9.1 (1.00 g, 2.56 mmol) in an excess of HMDS (40 ml) 
in the presence of 1,4-dioxane (15 ml) and a catalytic 
amount of (NH4)2SO4 was refluxed for 3-4 h (TLC 
shows completion of reaction) under argon 
atmosphere. After that time solvents were removed 
under reduced pressure. The reaction mixture was dissolved in dry THF (20 ml) and 
Tetrakis (0.44 g, 0.38 mmol) was added followed by the addition of AlMe3 (2.67 ml, 
5.16 mmol). The reaction mixture was stirred at reflux for 18 h. After that time, 
solvent was removed under vacuum and the residue was dissolved in MeOH and 
NH4Cl (0.80 g, 14.95 mmol) was added. The reaction mixture was stirred at reflux for 
2 h. After that time solvent was evaporated under reduced pressure and the crude 
mixture was purified on silica gel, using CHCl3/MeOH (0 to 5%, gradient) as an 
eluent, to give pure 9.13 (0.60 g, 72%) as a white solid. 
 
1H NMR (500 MHz, DMSO) ! 6.69 (bs, 2H, NH2), 5.75 (s, 1H, H1’), 5.12 (s, 1H, 
2’OH), 5.08 (t, J= 5.0 Hz, 1H, 5’OH), 4.99 (d, J= 7.0 Hz, 1H, 3’OH), 4.47-4.29 (m, 
1H, H3’), 3.93 (s, 3H, 6OCH3), 3.89-3.87 (m, 1H, H4’), 3.77- 3.68 (m, 2H, H5’), 2.43 
(s, 3H, 8CCH3), 0.83 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, DMSO) ! 162.93 (C-6), 161.35 (C-2), 155.00 (C-4), 151.59 (C-
8), 131.49, 131.06 (CH Ph), 130.53 (ipso Ph), 130.05 (CH Ph), 115.53 (C-5), 95.27 
(C-1’), 84.16 (C-4’), 80.30 (C-2’), 74.78 (C-3’), 62.74 (C-5’), 54.30 (6OCH3), 21.39 
(2’CCH3). 
HPLC (System 1) tR= 5.68 min.  
HPLC (System 2) tR=10.96 min.  
MS (ES+) m/z: 326.15 (M+H+, 100%);  


















Palladium acetate (4.2 mg, 2.5mol%), TPPTS (30.5 
mg, 6.5mol%), sodium carbonate (164 mg, 1.54 mol), 
9.1 (300 mg, 0.77 mmol) and phenylboronic acid 
(140.5 mg, 1.15 mmol) were placed in a round bottom 
flask under nitrogen. Degassed mixture of H2O:ACN 
(2:1) was added and the reaction mixture was heated at 80 °C for 4 h. After that time, 
the reaction mixture was diluted with water and pH was adjusted to 6-7 with 10% 
aqueous HCl. The reaction mixture was then heated to dissolve precipitaded solids 
and then allowe to cool down to 0 °C and stand at 0 °C for 16 h. After that time pure 
product was filtered off and dried in air. The pure product was obtained as a white 
solid (220 mg, 74%). 
 
1H NMR (500 MHz, MeOD) 7.68-7.66 (m, 2H, Ph), 7.60-7.58 (m, 3H, Ph), 5.96 (s, 
1H, H1’), 4.80 (d, J=8.5 Hz, 1H, H3’), 4.09 (s, 3H, 6OCH3), 4.02-3.94 (m, 3H, H4’ and 
H5’), 1.15(s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 159.90 (C6), 158.79 (C2), 154.04 (C4), 146.73 (C8), 
112.84 (C5), 92.57 (C1’), 82.95 (C4’), 79.10 (C2’), 73.51 (C3’), 61.13 (C5’), 53.10 
(6OCH3), 20.61 (2’CCH3), 15.01 (8CCH3). 
HPLC (System 1) tR= 9.92 min.  
HPLC (System 2) tR=16.80 min. 
MS (ES+) m/z: 388.16 (M+H+, 100%).  





To a solustion of 2-amino-6-O-methyl-8-C-bromo-9-(2’-
C-methyl-"-D-ribofuranosyl)purine (9.1, 0.40 g, 1.03 
mmol) in dry DMF (30 ml) was aqueous solution of 
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mmol. The reaction mixture was stirred at ambient temperature for 2 h, after that time 
mixture was diluted with water (50 ml) and extracted 3x with EtOAc (3x 20 ml). 
Combined organic fractions were dried over anhydrous MgSO4 and evaporated to 
dryness under reduced pressure. The residue was purified by silica gel 
chromatography (CHCl3/MeOH, 95:5) to give the pure compound 9.15 (0.38 g, 98%) 
as a white solid. 
 
1H NMR (500 MHz, MeOD) 5.97 (s, 1H, H1’), 4.54 (d, J=8.5 Hz, 1H, H3’), 4.07-3.97 
(m, 3H, H4’ and H5’), 4.04 (s, 3H, 6OCH3), 2.71 (s, 3H, 8CSCH3), 0.99 (s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) ! 161.27 (C6), 160.52 (C2), 155.51 (C4), 149.86 (C8), 
116.37 (C5), 95.13 (C1’), 84.21 (C4’), 80.34 (C2’), 74.746 (C3’), 62.31 (C5’), 54.38 
(6OCH3), 20.98 (2’CCH3), 9.28 (8CSCH3). 
HPLC (System 1) tR= 8.00 min.  
HPLC (System 2) tR=14.75 min. 
MS (ES+) m/z: 358.12 (M+H+, 100%).  
HRMS C13H20N5O5S calculated: 358.1185 found: 358.1186. 
 
Synthesis of 2-amino-6-O-methyl-8-C-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (9.17a). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-methyl-9-(2’-C-methyl-"-D-
ribofuranosyl) purine (9.13, 200 mg, 0.54 
mmol), tBuMgCl (1.07 ml, 1.07mmol), 
and #-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 356 
mg, 1.07 mmol) in 5 mL of  THF. After silica gel column chromatography using 
CHCl3/MeOH (0 to 7%, gradient), the pure compound 9.17a was obtained as an off 
white solid (50 mg, 14% yield). 
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1H NMR (500 MHz, MeOD) ! 8.17-8.15, 8.04-8.02 (2m, 1H, H8-Naph), 7.87-7.85, 
7.80-7.78 (2m, 1H, H5-Naph), 7.67, 7.58 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.52–7.44 
(m, 3H, H2, H7, H6-Naph), 7.34-7.28 (m, 1H, H3-Naph), 5.84 (2s, 1H, H1’), 4.82-4.77 
(m, 2H, H3’and H5’a), 4.65- 4.54 (m, 1H, H5’b), 4.30-4.23 (m, 1H, H4’), 4.08–4.03 (m, 
1H, CHCH3), 4.00, 3.99 (2s, 3H, 6OCH3), 3.74, 3.71, 3.63, 3.57 (2AB, JAB= 10.5 Hz, 
2H, OCH2C(CH3)3), 2.53 (s, 3H, 8CCH3), 1.32, 1.25 (2d, J= 7.0 Hz, 3H, CHCH3), 
1.01 (2s, 3H, 2’CCH3),  0.86, 0.84 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.04 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.74 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.77, 161.73 (C6), 161.07, 160.99 (C2), 155.07 (C4), 149.14, 
149.10 (C8), 148.02, 147.96 (ipso Naph), 136.25, 136.15 (C10-Naph), 128.80, 128.67 
(CH-Naph), 127.86, 127.82 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.68, 127.55, 
127.36, 127.18, 126.47, 127.37, 125.82, 125.65 (CH-Naph), 122.81, 122.73 (C5), 
116.25, 115.94 (2d, 3JC-C-O-P = 3.3 Hz, C2-Naph), 114.30 (CH-Naph), 94.23, 94.19 
(C1’), 83.06, 82.85 (2d, 3JC-C-O-P = 7.5 Hz, C4’), 80.07 (C2’), 76.02, 75.97 (C3’), 
75.33, 75.28 (OCH2C(CH3)3), 69.37, 69.33 (C5’), 54.01 (6OCH3), 51.66, 51.62 
(CHCH3), 32.22, 32.27 (OCH2C(CH3)3), 26.70, 26.67 (OCH2C(CH3)3), 20.81 (d, 3JC-
C-N-P = 6.3 Hz, CHCH3), 20.69 (d, 3JC-C-N-P = 7.5 Hz, CHCH3), 20.63, 20.54 
(2’CCH3), 14.77, 14.69 (8CCH3). 
HPLC (System 1) tR = 18.60, 19.17 min. 
MS (ES+) m/z: 673.28 (M+H+, 100%).  
HRMS C31H42N6O9P1 Calculated: 673.2751 found: 673.2782. 
 
Synthesis of 2-amino-6-O-methyl-8-C-phenyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (9.18a). 
  
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-
methyl-8-C-phenyl-9-(2’-C-methyl-!-
D-ribofuranosyl) purine (9.14, 250 
mg, 0.65 mmol), tBuMgCl (1.29 ml, 
1.29 mmol), and "-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) phosphorochloridate (3.3e, 427 mg, 1.29 mmol) in 5 mL 
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gradient), the pure compound 9.18a was obtained as an off white solid (35 mg, 7% 
yield). 
 
31P NMR (202 MHz, MeOD) ! 4.11, 3.64. 
1H NMR (500 MHz, MeOD) ! 8.15, 8.02 (2d, J=8.0 Hz, 1H, H8-Naph), 7.84, 7.79 
(2d, J=8.0 Hz, 1H, H5-Naph), 7.67-7.64 (m, 3H, CH Ph and H4-Naph), 7.60-7.58 (m, 
3H, CH Ph), 7.51-7.43 (m, 3H, H7, H6, H2-Naph), 7.38-7.27 (m, 1H, H3-Naph), 5.93, 
5.91 (2s, 1H, H1’), 5.03 (d, J=8.0 Hz, 1H, H3’), 4.80-4.72, 4.64-4.53 (2m, 2H, H5’), 
4.23, 4.17 (2td, J=8.5, 2.5 Hz, 1H, H4’), 4.06-3.98 (m, 1H, CHCH3), 3.92, 3.89 (2s, 
3H, 6OCH3), 3.73, 3.69, 3.61, 3.58 (2AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 1.28, 
1.24 (2d, J=7.0 Hz, 3H, CHCH3), 1.18, 1.17 (2s, 3H, 2’CCH3), 0.85, 0.83 (2s, 9H, 
OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.02 (3JC-C-N-P= 5.0 Hz, C=O), 174.75 (3JC-C-N-P= 
6.3 Hz, C=O), 162.54 (C6), 161.35, 161.28 (C2), 155.14 (C4), 151.67, 151.63 (C8), 
148.00, 147.95 (ipso Naph), 136.22, 136.14 (C10-Naph), 131.43, 131.12, 131.10 (CH 
Ph), 130.67, 130.05 (ipso Ph), 128.76, 128.68 (CH-Naph), 127.84, 127.79 (C9-Naph), 
127.65, 127.57, 127.34, 127.23, 126.43, 126.37, 125.80, 125.66, 122.81, 122.70 (CH 
Naph), 116.24 (d, 3JC-C-O-P= 3.8 Hz, C2-Naph), 115.97 (d, 3JC-C-O-P= 2.5 Hz, C2-
Naph), 115.52, 115.46 (C5), 94.76, 94.70 (C1’), 83.10 (d, 3JC-C-O-P= 6.3 Hz, 4’), 82.95 
(d, 3JC-C-O-P= 7.5 Hz, C4’), 80.21, 80.19 (C2’), 76.14, 76.01 (C3’), 75.32 
(OCH2C(CH3)3), 69.74 (d, 3JC-C-O-P= 6.3 Hz, C5’),  69.63 (d, 3JC-C-O-P= 5.0 Hz, C5’), 
54.21, 54.13 (6OCH3), 51.64, 51.58 (CHCH3), 32.24 (OCH2C(CH3)3), 26.71, 26.66 
(OCH2C(CH3)3), 20.86 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.68 (d, 3JC-C-N-P= 7.5 Hz, 
CHCH3), 20.27, 20.23 (2’CCH3). 
HPLC (System 1) tR= 21.37, 22.12 min.  
HPLC (System 2) tR= 27.55, 28.55 min.  
MS (TOF ES+) m/z: 735.29 (M+H+, 100%).  
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Synthesis of 2-amino-6-O-methyl-8-C-thiomethyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] 
phosphate (9.18a). 
 
Prepared according to the Starndard 
Procedure 7: from 2-amino-6-O-methyl-8-
C-methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (9.15, 300 mg, 0.84 
mmol), tBuMgCl (1.67 ml, 1.67mmol), 
and "-naphthyl-(2,2-dimethylpropoxy-L-
alaninyl) phosphorochloridate (3.3e, 556 mg, 1.67 mmol) in 5 mL of  THF. After 
silica gel column chromatography using CHCl3/MeOH (0 to 7%, gradient), the pure 
compound 9.17a was obtained as an off white solid (139 mg, 23% yield). 
 
31P NMR (202 MHz, MeOD) ! 4.18, 3.68. 
1H NMR (500 MHz, MeOD) ! 8.19-8.17, 8.06-8.04 (2m, 1H, H8-Naph), 7.87- 7.82, 
7.77-7.76 (2m, 1H, H5-Naph), 7.67, 7.56 (2d, J= 8.0 Hz, 1H, H4-Naph), 7.53–7.42(m, 
3H, H2, H7, H6-Naph), 7.38-7.27 (m, 1H, H3-Naph), 5.99, 5.96 (2s, 1H, H1’), 4.89-
4.64 (m, 2H, H3’ and H5’a), 4.60- 4.56 (m, 1H, H5’b), 4.32-4.25 (m, 1H, H4’), 4.10–
4.03 (m, 1H, CHCH3), 4.01, 3.99 (2s, 3H, 6OCH3), 3.73, 3.70, 3.62, 3.56 (2AB, JAB= 
10.5 Hz, 2H, OCH2C(CH3)3), 2.68, 2.66 (2s, 3H, 8CSCH3), 1.32, 1.26 (2d, J= 7.0 Hz, 
3H, CHCH3), 1.03 (2s, 3H, 2’CCH3),  0.84, 0.82 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.05 (d, 3J C-C-N-P = 5.0 Hz, C=O), 174.79 (d, 3J C-C-
N-P = 6.3 Hz, C=O), 161.00, 160.93 (C6), 161.78, 160.68 (C2), 155.99 (C4), 149.71 
(C8), 148.04, 147.96 (ipso Naph), 136.23, 136.13 (C10-Naph), 128.83, 128.70, 
127.93 (CH-Naph), 127.86, 127.80 (2d, 3JC-C-O-P = 6.3 Hz, C9-Naph), 127.78, 127.72, 
127.60, 127.43, 127.23, 126.53, 126.43, 125.87, 125.68 (CH-Naph), 122.86, 122.76 
(C5), 116.29, 115.96 (2d, 3JC-C-O-P = 3.3 Hz, C2-Naph), 94.35 (C1’), 83.11, 82.89 (2d, 
3JC-C-O-P = 7.5 Hz, C4’), 80.14 (C2’), 76.15, 76.07 (C3’), 75.36, 75.31 
(OCH2C(CH3)3), 69.35, 69.31 (C5’), 54.25 (6OCH3), 51.68, 51.63 (CHCH3), 32.27, 
32.24 (OCH2C(CH3)3), 26.70, 26.67 (OCH2C(CH3)3), 20.92 (d, 3JC-C-N-P = 6.3 Hz, 
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HPLC (System 1) tR = 20.13, 21.05 min. 
MS (ES+) m/z: 727.23 (M+Na+, 100%).  
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12.9 Experimental section – Chapter Ten. 
 
Synthesis of 2’-C-methylguanosine 2’,3’,5’-tri-O-acetate (10.1). 
 
2’-C-methylguanosine (4.10, 2.00 g, 6.73 mmol) was 
suspended in dry aacetonitrile (100 ml) and Et3N 
(3.65 ml, 26.24 mmol) and DMAP (0.08 g, 0.67 
mmol) were added under argon, followed by the 
dropwise addition of acetic anhydride (2.29 ml, 24.22 
mmol). The reaction mixture was stirred at ambient temperature for 4 h. After that 
time reaction was concentrated to 1/3 volume and solids were filtered off washed with 
diethyl ether and dried. The pure compound 10.1 was obtaine as a white solid (2.57 g, 
90%). 
 
1H NMR (500 MHz, DMSO) ! 10.74 (bs, 1H, NH), 7.85 (s, 1H, H8), 6.56 (bs, 2H, 
NH2), 6.16 (s, 1H, H1’), 5.45 (d, J=5.5 Hz, 1H, H3’), 4.44-4.27 (m, 3H, H4’ and H5’), 
2.09 (s, 3H, CH3 acetyl), 2.07 (s, 3H, CH3 acetyl), 2.06 (s, 3H, CH3 acetyl), 1.42 (s, 
3H, 2’CCH3). 
 
Synthesis of 2-bromo-2’-C-methylxanthosine 2’,3’,5’-tri-O-acetate (10.2). 
 
 
2’-C-methylguanosine 2’,3’,5’-tri-O-acetate (10.1, 1.50 
g, 3.54 mmol), isopenyl nitrite (9.48 ml, 70.86 mmol) 
and bromoform (63 ml) were heated at 95 °C for 3 h. 
After that time volatiles were evaporated under reduced 
pressure and the residue was purified on silica gel using EtOAc/MeOH (0 to 5%, 
gradient) as an eluent, to give pure product 10.2 as yellowish solid (0.60 g, 35%). 
 
1H NMR (500 MHz, DMSO) ! 13.42 (bs, 1H, NH), 8.18 (s, 1H, H8), 6.35 (s, 1H, H1’), 
5.51 (d, J=7.5 Hz, 1H, H3’), 4.47-4.32 (m, 3H, H4’ and H5’), 2.08 (s, 3H, CH3 acetyl), 



















Karolina Made!a                                                                                     Chapter Twelve  
 452
Synthesis of 2-NH-benzyl-2’-C-methylguanosine 2’,3’,5’-tri-O-acetate (10.3). 
 
To a solution of 2-bromo-2’C-
methylxanthosine 2’,3’,5’-tri-O-acetate (10.2, 
0.35 g, 0.74 mmol) in dry ethanol (5 ml), 
benzylamine (0.53 ml, 4.74 mmol) was added 
and the reaction mixture was refluxed at 95 °C 
for 16 h. After that time solvent was evaporated and crude residue was absorbed onto 
silica and purified on silica gel, using CHCl3/MeOH (0 to 3%, gradient) as an eluent. 
The pure compound 10.3 was obtaind as a yellowish solid (125 mg, 33%). 
 
1H NMR (500 MHz, DMSO) ! 10.68 (bs, 1H, NH), 7.79 (s, 1H, H8), 7.36-7.25 (m, 
5H, NHCH2Ph), 6.69 (t, J= 6.0 Hz, 1H, NHCH2Ph), 6.28 (s, 1H, H1’), 5.73 (d, J=8.0 
Hz, 1H, H3’), 4.62-4.50 (m, 2H, NHCH2Ph), 4.30-4.24 (m, 3H, H4’ and H5’), 2.11 (s, 
3H, CH3 acetyl), 2.06 (s, 3H, CH3 acetyl), 2.00 (s, 3H, CH3 acetyl), 1.36 (s, 3H, 
2’CCH3). 
 
Synthesis of 2-NH-benzyl-2’-C-methylguanosine (10.4). 
 
2-NH-benzyl-2’-C-methylguanosine 2’,3’,5’-
tri-O-acetate (10.3, 125 mg, 0.24 mmol) was 
suspended in dry methanol (10 ml) in sealed 
tube and cooled down to 0 °C. After that 
solution was saturated with ammonia and 
immediately sealed. Reaction mixture was allowed to warm to ambient temperature 
and reaction mixture was stirred overnight. After that time solvents were evaporated 
under reduced pressure and crude mixture was purified on silica gel, using 
CHCl3/MeOH (8:2) as eluent. Pure compound 10.4 was obtained as white solid (70 
mg, 74%). 
 
1H NMR (500 MHz, DMSO) ! 10.57 (bs, 1H, NH), 8.07 (s, 1H, H8), 7.40 (d, J= 7.5 
Hz, 2H, NHCH2Ph), 7.35 (t, J= 7.5 Hz, 2H, NHCH2Ph), 7.26 (t, J= 7.5 Hz, 1H, 
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1H, 3’OH), 5.09-5.07 (m, 3H, 5’OH and 2’OH), 4.50 (d, J= 5.5 Hz, 2H, NHCH2Ph), 
3.99 (d, J=8.0 Hz, 1H, H3’), 3.88-3.79 (m, 3H, H4’ and H5’a), 3.66-3.64 (m, 1H, H5’b), 
0.79 (s, 3H,  2’CCH3). 
13C NMR (126 MHz, DMSO) 156.71 (C6), 152.37 (C2), 150.20 (C4), 138.98 (ipso 
NHCH2Ph), 128.35 (NHCH2Ph), 127.82 (NHCH2Ph), 127.02 (NHCH2Ph), 116.63 
(C5), 90.37 (C1’), 82.41 (C4’), 78.48 (C2’), 71.69 (C3’), 59.54 (C5’), 44.05 
(NHCH2Ph), 19.86 (2’CCH3). 
HPLC (System 1) tR= 7.79 min. 
MS (ES+) m/z: 388.16 (M+H+, 100%).  
HRMS C18H21N5O5 Calculated: 387.1578 found: 387.1522. 
 
Synthesis of 2-bromo-2’-C-methylxanthosine 2’,3’,5’-tri-O-benzoate (10.6). 
 
To a precooled (0 °C) solution of tetra-O-benzoyl-2’-C-
methyl-!-D-ribofuranose (1.00g, 1.72 mmol), 2-
bromohypoxanthine (0.41 g, 1.89 mmol) and DBU 
(0.77 ml, 5.10 mmol) in anhydrous acetonitrile (20 ml) 
under argon atmosphere, trimethylsilyl triflate (1.25 ml, 
6.88 mmol) was added dropwise. The reaction mixture was heated at 65 °C for 8 h. 
After that time reaction mixture was allowed to cool down to ambient temperature 
and poured into saturated solution of sodium bicarbonate (150 ml), and extracted with 
DCM (3x 100 ml). The combined organic phases were dried over Na2SO4 and 
evaporated in vacuo. The residue was purified on silica gel, using CHCl3/MeOH (0 to 
4%, gradient) as en eluent, to give pure product 10.6 as a yellowish solid (0.91 g, 
78%). 
 
1H NMR (500 MHz, CDCl3) ! 8.21-8.17 (m, 4H, Bn), 8.05 (s, 1H, H8), 8.03–7.99 (m, 
2H, Bn), 7.66–7.62 (m, 1H, Bn), 7.58-7.49 (m, 3H, Bn), 7.41-7.36 (m, 4H, Bn), 6.65 
(s, 1H, H1’), 5.95 (d, J= 6.5 Hz, 1H, H3’), 5.01-4.96 (m, 2H, H5’), 4.72- 4.68 (m, 1H, 
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Synthesis of 2-NH-benzyl-2’-C-methylguanosine 2’,3’,5’-tri-O-benzoate (10.7). 
 
To a solution of 2-bromo-2’C-
methylxanthosine 2’,3’,5’-tri-O-benzoate 
(10.6, 0.50 g, 0.74 mmol) in dry ethanol (5 
ml), benzylamine (0.53 ml, 4.74 mmol) was 
added and the reaction mixture was refluxed at 
95 °C for 16 h. After that time solvent was evaporated and crude residue was 
absorbed onto silica and purified on silica gel, using CHCl3/MeOH (0 to 3%, 
gradient) as an eluent. The pure compound 10.7 was obtaind as a yellowish solid (225 
mg, 43%). 
 
1H NMR (500 MHz, CDCl3) ! 8.23-8.20 (m, 2H, Bn), 8.07 (s, 1H, H8), 8.05–7.98 (m, 
4H, Bn), 7.68–7.64 (m, 2H, Bn), 7.61-7.57 (m, 2H, Bn), 7.53-7.38 (m, 9H, Bn and 
NHCH2Ph), 6.62 (s, 1H, H1’), 5.97 (d, J= 6.5 Hz, 1H, H3’), 5.32-5.27 (m, 2H, 
NHCH2Ph), 5.02-4.97 (m, 2H, H5’), 4.72- 4.68 (m, 1H, H4’), 1.60 (s, 3H, 2’CCH3). 
 




ribofuranosyl) purine (5.4, 2.00 g, 6.42 mmol) was 
suspended in dry aacetonitrile (100 ml) and Et3N 
(3.49 ml, 25.06 mmol) and DMAP (0.078 g, 0.64 
mmol) were added under argon, followed by the 
dropwise addition of acetic anhydride (2.18 ml, 23.13 mmol). The reaction mixture 
was stirred at ambient temperature for 16 h. After that time reaction was concentrated 
to 1/3 volume and solids were filtered off washed with diethyl ether and dried. The 
pure compound 10.10 was obtaine as a white solid (1.85g, 66%). 
 
1H NMR (500 MHz, CDCl3) ! 7.75 (s, 1H, H8), 6.35 (bs, 2H, NH2), 6.16 (s, 1H, H1’), 
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H5’a), 4.44-4.35 (m, 3H, H4’ and H5’b), 4.09 (s, 3H, 6OCH3), 2.18 (s, 3H, CH3 acetyl), 
2.16 (s, 3H, CH3 acetyl), 2.12 (s, 3H, CH3 acetyl), 1.42 (s, 3H, 2’CCH3). 
 
Synthesis of 2-chloro-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 
2’,3’,5’-tri-O-acetate (10.11). 
 
A solution of acetyl chloride (0.44 ml, 8.83 mmol) in dry 
DCM (22 ml) under argon atmospgere was chilled in 
NaCl/ice/H2O bath for 15 min. Tetratbutylammonium 
nitrite (0.33 g, 1.14 mmol) was dissolved in dry DCM (4 
ml) and this solution was added dropwise to the cold, 
stirred solution of AcCl/DCM. A solution of 10.10 (0.50 g, 1.14 mmol) in dry DCM 
(2 ml) was added dropwise to the cold solution and stirring was continued for 5 min. 
After completion of the reaction (as indicated by the TLC analysis), the reaction 
mixture was added dropwise at a rapid rate to a cold (ice/H2O bath) vigorously stirred 
mixture of saturated NaHCO3/H2O/DCM. The layers were separated and the organic 
phase was dried over Na2SO4. Volatiles were evaporated and the residue was purified 
on silica gel, using CHCl3/MeOH (0 to 2%, gradient) as an eluent. The pure product 
10.11 was obtained as a white solid (0.32 g, 62%). 
 
1H NMR (500 MHz, DMSO) ! 8.56 (s, 1H, H8), 6.47 (s, 1H, H1’), 5.56 (d, J=6.5 Hz, 
1H, H3’), 4.45-4.33 (m, 3H, H4’ and H5’), 4.13 (s, 3H, 6OCH3), 2.13 (s, 3H, CH3 
acetyl), 2.10 (s, 3H, CH3 acetyl), 2.06 (s, 3H, CH3 acetyl), 1.36 (s, 3H, 2’CCH3). 
 
Synthesis of 2-chloro-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 
(10.12). 
2-chloro-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine 2’,3’,5’-tri-O-acetate (10.10, 220 mg, 0.48 mmol) 
was suspended in dry methanol (15 ml) in sealed tube 
and cooled down to 0 °C. After that solution was 
saturated with ammonia and immediately sealed. 
Reaction mixture was allowed to warm to ambient 
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evaporated under reduced pressure and crude mixture was purified on silica gel, using 
CHCl3/MeOH (9:1) as eluent. Pure compound 10.12 was obtained as white solid (143 
mg, 90%). 
 
1H NMR (500 MHz, MeOD) ! 8.27 (s, 1H, H8), 6.11 (s, 1H, H1’), 4.27 (d, J= 9.0 Hz, 
1H, H3’), 4.23 (s, 3H, 6OCH3), 4.12-4.03 (m, 2H, H4’ and H5’a), 3.91-3.89 (m, 1H, 
H5’b), 0.96 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 162.61 (C6), 154.40 (C2), 153.83 (C4), 143.54 (C8), 
121.15 (C5), 93.30 (C1’), 84.55 (C4'), 80.33 (C2’), 73.32 (C3’), 61.00 (C5’), 55.69 
(6OCH3), 20.18 (2’CCH3). 
HPLC (System 1) tR = 7.35 min. 
HPLC (System 2) tR = 11.82 min. 
MS (ES+) m/z: 331.07 (M+H+, 100%).  
 
Synthesis of 2-NH-benzyl-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 
(10.13). 
 
To a solution of 2-chloro-6-O-methyl-9-(2’-C-
methyl-!-D-ribofuranosyl) purine (10.12, 0.50 
g, 1.33 mmol) in dry ethanol (5 ml), 
benzylamine (0.73 ml, 6.66 mmol) was added 
and the reaction mixture was refluxed at 95 °C 
for 16 h. After that time solvent was evaporated 
and crude residue was absorbed onto silica and purified on silica gel, using 
CHCl3/MeOH (0 to 3%, gradient) as an eluent. The pure compound 10.13 was obtaind 
as a yellowish solid (50 mg, 9%). 
 
1H NMR (500 MHz, MeOD) ! 8.30 (s, 1H, H8), 7.38 (d, J= 7.5 Hz, 2H, NHCH2Ph), 
7.28 (t, J= 7.5 Hz, 2H, NHCH2Ph), 7.19 (d, J= 7.5 Hz, 1H, NHCH2Ph), 6.03 (s, 1H, 
H1’), 4.61 (d, J= 4.0 Hz, 2H, NHCH2Ph), 4.23 (d, J= 9.0 Hz, 1H, H3’), 4.06-3.98(m, 
2H, H4’ and H5’a), 4.02 (s, 3H, 6OCH3), 3.85 (dd, J= 4.0 Hz, J= 11.0 Hz, 1H, H5’b), 
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13C NMR (126 MHz, MeOD) ! 162.42 (C6), 160.91 (C2), 154.67 (C4), 141.62 (ipso 
NHCH2Ph), 139.19 (C8), 129.37, 128.54, 127.81 (NHCH2Ph), 115.17 (C5), 92.79 
(C1’), 84.13 (C4'), 80.37 (C2’), 73.67 (C3’), 61.35 (C5’), 54.14 (6OCH3), 20.27 
(2’CCH3). 
HPLC (System 1) tR = 7.35 min. 
HPLC (System 2) tR = 11.82 min. 
MS (ES+) m/z: 402.17 (M+H+, 100%).  
 
Synthesis of 2-NH-benzyl-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) purine 
5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (10.16a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-NH-benzyl-6-
O-methyl-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (10.13, 100 
mg, 0.25 mmol), "-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 190 
mg, 0.50 mmol), and tBuMgCl (0.50 ml, 0.50 mmol) in 3 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (0 to 5%, 
gradient) as en eluent. To give a pure product 10.16a as white foam (36 mg, 19%). 
 
31P NMR (202 MHz, MeOD) ! 4.09, 3.95. 
1H NMR (500 MHz, MeOD) ! 8.19-8.16 (m, 1H, H8-naph), 7.96, 7.95 (2s, 1H, H8), 
7.93-7.87 (m, 1H, H5-Naph), 7.67-7.64 (m, 1H, H4-Naph), 7.55–7.47 (m, 3H, H2, H7, 
H6-Naph), 7.42-7.19 (m, 6H, H3-Naph and NHCH2Ph), 5.99, 5.98 (2s, 1H, H1’), 4.62-
4.51 (m, 4H, H5’ and NHCH2Ph), 4.42-4.27 (m, 2H, H3’, H4’), 4.04–3.99 (m, 1H, 
CHCH3), 4.01 (s, 3H, 6OCH3), 3.74, 3.71, 3.63, 3.57 (2AB, JAB= 10.5 Hz, 2H, 
OCH2C(CH3)3), 1.34 (d, J= 7.5 Hz, 3H, CHCH3), 0.97, 0.95 (2s, 3H, 2’CCH3),  0.84, 
0.82 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.00, 174.78 (2d, 3J C-C-N-P = 6.3 Hz, C=O), 162.46 
(C6), 160.89 (C2), 154.45 (C4), 148.00, 147.96 (d, 2JC-O-P = 3.8 Hz, ipso Naph), 
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129.59, 129.49, 129.42, 129.39, 129.37, 128.83, 128.77, 128.65, 128.46, 128.40, 
128.32, 128.15 (CH-Naph and NHCH2Ph), 127.86, 127.82 (2d, 3JC-C-O-P = 6.3 Hz, C9-
Naph), 127.73, 127.69, 127.44, 127.41, 126.49, 126.46, 125.92, 125.89, 122.77, 
122.74 (CH-Naph), 116.20, 116.21 (C2-Naph), 115.62 (C5), 93.60, 93.04 (C1’), 
82.31, 82.17 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.97, 79.90 (C2’), 75.33, 75.21 
(OCH2C(CH3)3), 74.97, 74.76 (C3’), 68.39, 67.97 (2d, 2JC-O-P = 5.0 Hz, C5’), 54.12 
(6OCH3), 51.73, 51.66 (C!CH3), 46.56, 46.50 ((NHCH2Ph), 32.31, 32.23 
(OCH2C(CH3)3), 26.74, 26.71 (OCH2C(CH3)3), 20.81 (d, 3JC-C-N-P = 6.3 Hz, CHCH3),  
20.62 (d, 3JC-C-N-P = 7.5 Hz, CHCH3), 20.42, 20.20 (2’CCH3). 
HPLC ( System 1) tR = 22.95, 23.48 min. 
HRMS calculated for C37H45N6O9PNa: 771.2987; found 771.2965. 
 
Synthesis of 2-NH-benzyl-2’-C-methylguanosine 5’-O-[!-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl)] phosphate (10.8a). 
 
 
Prepared according to the Standard 
Procedure 14, from: 10.16a (36 mg, 
0.048 mmol) was dissolved in dry 
acetonitrile (3 ml) under argon 
atmosphere and NaI (8.6 mg, 0.058 
mmol) was added, followed by the 
addition of trimethylsilyl chloride (0.007 ml, 0.058 mmol). The reaction mixture was 
stirred at ambient temperature for 4 h. After work up, the residue was purified by 
preparative TLC, using CHCl3/MeOH (96:4) as an eluent. The pure compound 10.8a 
was obtained as off white solid (10.2 mg, 29%). 
 
31P NMR (202 MHz, MeOD) ! 4.08, 3.99. 
1H NMR (500 MHz, MeOD) ! 8.18-8.16 (m, 1H, H8-naph), 7.91-7.85 (m, 2H, H5-
Naph and H8), 7.71, 7.68 (2d, J= 7.0 Hz, 1H, H4-Naph), 7.57–7.43(m, 3H, H2, H7, H6-
Naph), 7.39-7.23 (m, 6H, H3-Naph and NHCH2Ph), 5.57 (s, 1H, H1’), 4.59-4.47 (m, 
4H, H5’ and NHCH2Ph), 4.28-4.21 (m, 2H, H3’, H4’), 4.04–3.99 (m, 1H, CHCH3), 
3.75, 3.72, 3.64, 3.58 (2AB, JAB= 10.5 Hz, 2H, OCH2C(CH3)3), 1.39, 1.33 (2d, J= 7.5 
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13C NMR (126 MHz, MeOD) ! 174.97, 174.95 (C=O), 159.40 (C6), 159.22 (C2), 
153.92 (C4), 147.87, 147.58 (ipso Naph), 141.20, 140.73 (ipso NHCH2Ph), 139.74 
(C8), 136.26, 136.24 (C10-Naph), 129.69, 129.65, 129.40, 129.37, 128.85, 128.78, 
128.74, 128.43, 128.40 (CH-Naph and NHCH2Ph), 127.89, 127.83 (2d, 3JC-C-O-P = 6.3 
Hz, C9-Naph), 127.74, 127.69, 127.46, 126.49, 126.46, 125.92, 125.89, 122.77, 
122.74 (CH-Naph), 118.10 (C5), 116.16, 116.13 (C2-Naph), 93.36 (C1’), 82.04, 
81.98 (2d, 3JC-C-O-P = 8.8 Hz, C4’), 79.95, 79.89 (C2’), 75.35, 75.32 (OCH2C(CH3)3), 
74.69, 74.46 (C3’), 68.20, 67.70 (2d, 2JC-O-P = 5.0 Hz, C5’), 51.78, 51.68 (C!CH3), 
46.11, 46.07 ((NHCH2Ph), 32.25 (OCH2C(CH3)3), 26.69 (OCH2C(CH3)3), 20.82, 
20.59 (2d, 3JC-C-N-P = 6.3 Hz, CHCH3), 20.29 (2’CCH3). 
HPLC ( System 1) tR = 18.71, 19.03 min. 
HRMS calculated for C36H44N6O9P: 734.2852; found 734.2837. 
 
Synthesis of 2-C-thiophenyl-6-C-chloro-9-(2’-C-methyl-"-D-ribofuranosyl) 
purine 2’,3’,5’-tri-O-benzoate (10.17). 
 
A mixture of 2-amino-6-chloro-9-(2-C-methyl-
2,3,5-tri-O-benzoyl-"-D-ribofuranosyl)purine 
(5.2, 1.00 g, 1.61 mmol), diphenyl disulfide (1.76 
g, 8.04 mmol) and isopentyl nitrite (2.13 ml, 
16.17 mmol) was suspended in dry acetonitrile 
under argon atmosphere and refluxed at 100 °C, for 3 h. After that time solvent was 
evaporated and the resudiue was purified by flash chromatography, using 
CHCl3/MeOH (98:2) as en eluent. Isolated fractions (1.30 g) containing the desired 
product were contaminated with some impurities related to isopentyl nitrite, having 
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Synthesis of 2-C-thiophenyl-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (10.18). 
 
To a solution of 2-C-thiophenyl-6-C-chloro-9-(2’-
C-methyl-2,3,5-tri-O-benzoyl-!-D-
ribofuranosyl)purine (10.17, 1.30 g, 1.80 mmol) in 
anhydrous methanol (10 ml) at 0 oC, NaOMe (0.59 
g,  10.82 mmol) was added. The mixture was 
stirred at room temperature for 16 hours and then quenched by addition of amberlite 
(H+). The mixture was then filtrated and solvent was removed under reduced pressure. 
The residue was purified by silica gel chromatography (CHCl3/MeOH, 96:4) to give 
the pure compound 10.18 (287 mg, 44%) as a white solid. 
 
1H NMR (500 MHz, MeOD) " 8.58 (s, 1H, H8), 7.67-7.65 (m, 2H, SPh), 7.47-7.45 
(m, 3H, SPh), 6.00 (s, 1H, H1’), 4.10 (d, J=8.0 Hz, 1H, H3’), 4.04-4.01 (m, 1H, H4’), 
3.95-3.93 (m, 1H, H5’a), 3.88 (s, 3H, 6OCH3), 3.80-3.77 (m, 1H, H5’b), 0.93 (s, 3H, 
2’CCH3). 
13C NMR (126 MHz, MeOD) " 166.69 (C6), 161.42 (C2), 153.64 (C4), 142.30 (C8), 
136.69 (CH SPh), 131.51 (ipso SPh), 130.30, 130.12 (CH SPh), 119.68 (C5), 93.32 
(C1’), 84.40 (C4’), 80.24 (C2’), 73.54 (C3’), 61.43 (C5’), 54.76 (6OCH3), 20.23 
(2’CCH3). 
HPLC ( System 1) tR = 13.44 min. 
HRMS calculated for C18H20N4O5SNa: 427.1149; found 427.1136 
 
Synthesis of 2-C-thiophenyl-2’-C-methylguanosine (10.19). 
  
2-C-thiophenyl-6-C-chloro-9-(2’-C-methyl-!-D-
ribofuranosyl) purine (10.18, 270 mg, 0.67 mmol) 
was dissolved in dry acetonitrile (10 ml) under 
argon atmosphere and NaI (109 mg, 0.73 mmol) 
was added, followed by the addition of 
trimethylsilyl chloride (0.09 ml, 0.73 mmol). The reaction mixture was stirred at 
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temperature and poured into saturated solution of sodium bicarbonate (50 ml) and 
extracted with DCM (3x 10ml). The combined organic phases were dried over 
Na2SO4 and evaporated to dryness. The residue was purified by column 
chromatography using CHCl3/MeOH (9:1) as an eluent. The pure compound 10.19 
was obtained as off white solid (110 mg, 42%). 
 
1H NMR (500 MHz, MeOD) ! 8.39 (s, 1H, H8), 7.66-7.42 (m, 2H, SPh), 7.47-7.45 
(m, 3H, SPh), 6.00 (s, 1H, H1’), 3.93 (app bs, 2H, H3’ and H4’), 3.87-3.67 (m, 2H, 
H5’), 0.86 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 159.23 (C6), 158.83 (C2), 149.85 (C4), 140.02 (C8), 
136.68, 131.38, 130.76 (CH SPh), 128.27 (ipso SPh), 122.68 (C5), 93.12 (C1’), 84.25 
(C4’), 80.16 (C2’), 73.38 (C3’), 61.46 (C5’), 20.19 (2’CCH3). 
HPLC ( System 1) tR = 9.18 min. 
HRMS calculated for C17H18N4O5S: 390.1077; found 390.1051 
 
Synthesis of 2-C-thiophenyl-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (10.20a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-C-thiophenyl-6-
O-methyl-9-(2’-C-methyl-"-D-
ribofuranosyl) purine (10.18, 250 mg, 
0.62 mmol), !-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 409 mg, 
1.24 mmol), and tBuMgCl (1.24 ml, 1.24 mmol) in 5 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (0 to 5%, 
gradient) as en eluent. To give a pure product 10.20a as white foam (97 mg, 21%). 
 
31P NMR (202 MHz, MeOD) ! 3.76, 3.38. 
1H NMR (500 MHz, MeOD) ! 8.23, 8.21 (2s, 1H, H8), 8.15, 7.98 (2d, J=8.5 Hz, 1H, 
H8-Naph), 7.86, 7.82 (2d, J=8.0 Hz, 1H, H5-Naph), 7.67-7.62 (m, 2H, H4-Naph and 
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5.95, 5.93 (2s, 1H, H1’), 4.36-4.22 (m, 2H, H5’), 4.20-4.10 (m, 1H, H4’), 4.03-3.98 (m, 
2H, H3’ and CHCH3), 3.92, 3.89 (2s, 3H, 6OCH3), 3.72, 3.67, 3.58, 3.56 (2AB, 
JAB=10.5 Hz, 2H, OCH2C(CH3)3), 1.31, 1.30 (2d, J=7.5 Hz, 3H, CHCH3), 0.96, 0.94 
(2s, 3H, 2’CCH3), 0.85, 0.84 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.89, 174.69 (C=O), 167.05, 166.96 (C6), 161.46, 
161.43 (C2), 153.15 (C4), 147.96 (d, 2JC-O-P= 7.5 Hz, ipso Naph), 147.89 (d, 2JC-O-P= 
6.3 Hz, ipso Naph), 143.14, 142.92 (C8), 136.95, 136.84 (CH SPh), 136.23, 136.19 
(C10-Naph), 131.05 (ipso SPh), 130.58, 130.46, 130.35 (CH SPh), 128.82, 128.73 
(CH Naph), 127.78, 127.70 (C9-Naph), 127.59, 127.40, 127.24, 126.41, 125.81, 
125.71, 122.75, 122.63 (CH Naph), 120.31 (C5), 116.13 (d, 3JC-C-O-P= 3.8 Hz, C2-
Naph), 115.86 (d, 3JC-C-O-P= 2.5 Hz, C2-Naph), 94.66 (C1’), 82.58 (d, 3JC-C-O-P= 7.5 
Hz, C4’), 82.52 (d, 3JC-C-O-P= 8.8 Hz, C4’), 79.81, 79.72 (C2’), 75.29 (OCH2C(CH3)3), 
74.93, 74.88 (C3’), 68.89, 68.62 (C5’), 54.79, 54.76 (6OCH3), 51.70, 51.60 (CHCH3), 
32.22 (OCH2C(CH3)3), 26.67 (OCH2C(CH3)3), 20.86 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 
20.66 (d, 3JC-C-N-P= 7.5 Hz, CHCH3), 20.27, 20.23 (2’CCH3). 
HPLC ( System 1) tR = 24.96, 25.57 min. 
HRMS calculated for C36H42N5O9PS: 751.2471; found 751.2470 
 
Synthesis of 2-C-thiophenyl-2’-C-methylguanosine 5’-O-[!-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl)] phosphate (10.21a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-C-thiophenyl-2’-
C-methylguanosine (10.19, 110 mg, 
0.28 mmol), !-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 187 mg, 
0.56 mmol), and tBuMgCl (0.56 ml, 
0.56 mmol) in 3 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 3%, gradient) as en eluent. To give the 
pure product 10.20a as white foam (45 mg, 21%). 
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1H NMR (500 MHz, MeOD) ! 8.18-8.16, 8.04-8.03 (2m, 1H, H8-Naph), 8.01, 7.91 
(2s, 1H, H8), 7.89-7.84 (m, 1H, H5-Naph), 7.69-7.65 (m, 3H, H4-Naph and SPh), 
7.56-7.45 (m, 6H, H7, H6, H2-Naph and SPh), 7.37-7.33 (m, 1H, H3-Naph), 5.75, 5.74 
(2s, 1H, H1’), 4.06-3.97 (m, 4H, H5’, H4’ and H3’), 3.76-3.70, 3.61-3.56 (2m, 3H, 
OCH2C(CH3)3 and CHCH3), 1.33, 1.32 (2d, J=7.0 Hz, 3H, CHCH3), 0.92, 0.90 (2s, 
3H, 2’CCH3), 0.87, 0.86 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 174.70, 174.42 (C=O), 166.12, 165.68 (C6), 162.07, 
161.55 (C2), 157.26, 157.00 (C4), 148.43, 147.99 (ipso Naph), 141.11, 141.08 (C8), 
137.16, 137.00 (CH SPh), 136.25 (C10-Naph), 132.40 (ipso SPh), 131.75, 131.65, 
131.16, 131.09, 128.87, 128.80 (CH Naph and CH SPh), 127.78, 127.70 (C9-Naph), 
127.43, 127.27, 126.39, 125.86, 125.76, 122.72, 122.68 (CH Naph), 116.14, 116.11 
(C2-Naph), 114.34 (C5), 94.85 (C1’), 82.29, 82.23 (C4’), 79.50 (C2’), 75.30 
(OCH2C(CH3)3), 74.70, 74.63 (C3’), 69.17, 69.14 (C5’), 54.79, 54.76 (6OCH3), 
51.72, 51.57 (CHCH3), 32.26 (OCH2C(CH3)3), 26.71, 26.69 (OCH2C(CH3)3), 20.83 
(d, 3JC-C-N-P= 5.0 Hz, CHCH3), 20.63 (d, 3JC-C-N-P= 7.5 Hz, CHCH3), 20.27 (2’CCH3). 
HPLC ( System 1) tR = 20.71, 21.03 min. 
HRMS calculated for C35H45N5O9PSNa: 760.2254; found 760.2261. 
 
Synthesis of 2-C-thiobenzyl-6-C-chloro-9-(2’-C-methyl-"-D-ribofuranosyl) purine 
2’,3’,5’-tri-O-benzoate (10.22). 
 
 A mixture of 2-amino-6-chloro-9-(2-C-
methyl-2,3,5-tri-O-benzoyl-"-D-
ribofuranosyl)purine (5.2, 1.00 g, 1.61 mmol), 
dibenzyl disulfide (1.98 g, 8.04 mmol) and 
isopentyl nitrite (2.13 ml, 16.17 mmol) was 
suspended in dry acetonitrile under argon atmosphere and refluxed at 100 °C, for 3 h. 
After that time solvent was evaporated and the resudiue was purified by flash 
chromatography, using CHCl3/MeOH (98:2) as en eluent. Isolated fractions (0.70 g) 
containing the desired product were contaminated with some impurities related to 
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Synthesis of 2-C-thiobenzyl-6-O-methyl-9-(2’-C-methyl-!-D-ribofuranosyl) 
purine (10.23). 
 
To a solution of 2-C-thiophenyl-6-C-chloro-9-
(2’-C-methyl-2,3,5-tri-O-benzoyl-!-D-
ribofuranosyl)purine (10.22, 0.70 g, 0.95 
mmol) in anhydrous methanol (10 ml) at 0 oC, 
NaOMe (0.26 g,  5.71 mmol) was added. The 
mixture was stirred at room temperature for 16 hours and then quenched by addition 
of amberlite (H+). The mixture was then filtrated and solvent was removed under 
reduced pressure. The residue was purified by silica gel chromatography 
(CHCl3/MeOH, 96:4) to give the pure compound 10.23 (220 mg, 33%) as a white 
solid. 
 
1H NMR (500 MHz, MeOD) " 8.64 (s, 1H, H8), 7.49-7.48 (m, 2H, SCH2Ph), 7.32-
7.29 (m, 2H, SCH2Ph), 7.23-7.20 (m, 1H, SCH2Ph), 6.18 (s, 1H, H1’), 4.49, 4.45 (AB, 
J= 10.0 Hz, 2H, SCH2Ph), 4.21 (d, J=9.0 Hz, H3’), 4.12 (s, 3H, 6OCH3), 4.10-4.04 (m, 
2H, H4’ and H5’a), 3.90-3.87 (m, 1H, H5’b), 0.93 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) " 166.55 (C6), 161.48 (C2), 153.58 (C4), 141.65 (C8), 
139.35 (ipso SCH2Ph), 130.09, 139.51, 128.11 (CH SCH2Ph), 119.19 (C5), 92.91 
(C1’), 84.32 (C4’), 80.43 (C2’), 73.32 (C3’), 60.97 (C5’), 55.00 (6OCH3), 36.58 
(SCH2Ph), 20.30 (2’CCH3). 
HPLC ( System 1) tR = 14.12 min. 
HRMS calculated for C19H22N4O5S: 418.1321; found 418.1317. 
 
Synthesis of 2-C-thiobenzyl-2’-C-methylguanosine (10.24). 
  
2-C-thiobenzyl-6-C-chloro-9-(2’-C-methyl-!-
D-ribofuranosyl) purine (10.23, 400 mg, 0.96 
mmol) was dissolved in dry acetonitrile (20 ml) 
under argon atmosphere and NaI (160 mg, 1.05 
mmol) was added, followed by the addition of 
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reflux for 4 h. After that time reaction mixture was allowed to cool to room 
temperature and poured into saturated solution of sodium bicarbonate (50 ml) and 
extracted with DCM (3x 10ml). The combined organic phases were dried over 
Na2SO4 and evaporated to dryness. The residue was purified by column 
chromatography using CHCl3/MeOH (9:1) as an eluent. The pure compound 10.19 
was obtained as off white solid (202 mg, 52%). 
 
1H NMR (500 MHz, MeOD) ! 8.69 (s, 1H, H8), 7.49 (d, J= 7.5 Hz, 2H, SCH2Ph), 
7.33 (t, J= 7.5 Hz, 2H, SCH2Ph), 7.23 (d, J= 7.5 Hz, 1H, SCH2Ph), 6.12 (s, 1H, H1’), 
4.52, 4.48 (AB, J= 10.0 Hz, 2H, SCH2Ph), 4.18 (d, J=9.0 Hz, H3’), 4.10-4.02 (m, 2H, 
H4’ and H5’a), 3.89-3.87 (m, 1H, H5’b), 0.92 (s, 3H, 2’CCH3). 
13C NMR (126 MHz, MeOD) ! 159.98 (C6), 159.16 (C2), 149.98 (C4), 139.19 (C8), 
138.09 (ipso SCH2Ph), 130.38, 129.70, 128.58 (CH SCH2Ph), 121.96 (C5), 92.62 
(C1’), 84.24 (C4’), 80.52 (C2’), 73.19 (C3’), 60.81 (C5’), 36.06 (SCH2Ph), 20.39 
(2’CCH3). 
HPLC ( System 1) tR = 11.20 min. 
 
Synthesis of 2-C-thiobenzyl-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) 
purine 5’-O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (10.25a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-C-thiobenzyl-
6-O-methyl-9-(2’-C-methyl-"-D-
ribofuranosyl) purine (10.23, 220 
mg, 0.53 mmol), !-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 350 
mg, 1.05 mmol), and tBuMgCl (1.05 ml, 1.05 mmol) in 5 ml of dry THF. The crude 
mixture was purified by column chromatography, using CHCl3/MeOH (0 to 5%, 
gradient) as en eluent. To give a pure product 10.25a as white foam (102 mg, 25%). 
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1H NMR (500 MHz, MeOD) ! 8.26, 8.24 (2s, 1H, H8), 8.18-8.13 (m, 1H, H8-Naph), 
7.84-7.90 (m, 1H, H5-Naph), 7.68-7.61 (m, 2H, H4-Naph), 7.56-7.40 (m, 5H, H7, H6, 
H2-Naph and SCH2Ph), 7.36-7.32 (m, 1H, H3-Naph), 7.29-7.17 (m, 3H, SCH2Ph), 
6.17, 6.16 (2s, 1H, H1’), 4.67-4.58 (m, 2H, H5’), 4.46-4.25 (m, 4H, H4’, H3’ and 
SCH2Ph), 4.11-4.04 (m, 1H, CHCH3), 4.07, 4.06 (2s, 3H, 6OCH3), 3.74, 3.71, 3.61, 
3.57 (2AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 1.34, 1.32 (2d, J=7.0 Hz, 3H, CHCH3), 
0.95, 0.93 (2s, 3H, 2’CCH3), 0.84, 0.82 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.02, 174.79 (2d, 3JC-C-O-P=5.0 Hz, C=O), 166.60, 
166.59 (C6), 161.49 (C2), 153.41, 153.40 (C4), 147.99 (d, 2JC-O-P= 7.5 Hz, ipso 
Naph), 147.94 (d, 2JC-O-P= 6.3 Hz, ipso Naph), 141.84, 141.56 (C8), 139.11 (ipso 
SCH2Ph), 136.30, 136.24 (C10-Naph), 130.14, 130.12, 129.57, 129.54, 128.19, 
128.16 (CH Naph and SCH2Ph), 127.86, 127.81 (C9-Naph), 127.73, 127.48, 127.47, 
127.44, 126.60, 126.51, 125.94, 125.87, 122.80, 122.74  (CH Naph), 119.61 (C5), 
116.47 (d, 3JC-C-O-P= 2.5 Hz, C2-Naph), 116.16 (d, 3JC-C-O-P= 3.8 Hz, C2-Naph), 93.55, 
93.47 (C1’), 82.37, 82.30 (2d, 3JC-C-O-P= 8.8 Hz, C4’), 80.06, 79.98 (C2’), 75.47, 75.39 
(OCH2C(CH3)3), 74.74, 74.52 (C3’), 67.94 (d, 2JC-O-P= 5.0 Hz, C-5’),  67.54 (d, 2JC-O-
P= 3.8 Hz, C-5’), 55.08 (6OCH3), 51.83, 51.74 (CHCH3), 36.70, 36.68 (SCH2Ph), 
32.28, 32.25 (OCH2C(CH3)3), 26.81, 26.76 (OCH2C(CH3)3), 20.97 (d, 3JC-C-N-P= 6.3 
Hz, CHCH3), 20.74 (d, 3JC-C-N-P= 7.5 Hz, CHCH3), 20.45, 20.42 (2’CCH3). 
HPLC ( System 1) tR = 25.62, 26.02 min. 
HRMS calculated for C37H44N5O9PSNa: 788.2532; found 788.2513. 
 
Synthesis of 2-C-thiophenyl-2’-C-methylguanosine 5’-O-[!-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl)] phosphate (10.26a). 
  
Prepared according to the Standard 
Procedure 14, from: 10.25a (36 
mg, 0.047 mmol) was dissolved in 
dry acetonitrile (3 ml) under argon 
atmosphere and NaI (7.7 mg, 0.052 
mmol) was added, followed by the 
addition of trimethylsilyl chloride (0.007 ml, 0.052 mmol). The reaction mixture was 
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preparative TLC, using CHCl3/MeOH (96:4) as an eluent. The pure compound 10.26a 
was obtained as off white solid (12 mg, 34%). 
 
31P NMR (202 MHz, MeOD) ! 4.32, 4.29. 
1H NMR (500 MHz, MeOD) ! 8.22-8.19 (m, 1H, H8-Naph), 8.11, 8.09 (2s, 1H, H8), 
7.91-7.86 (m, 1H, H5-Naph), 7.72, 7.70 (2d, J=8.5 Hz, H4-Naph), 7.55-7.49 (m, 5H, 
H7, H6, H2-Naph and SCH2Ph), 7.43-7.40 (m, 1H, H3-Naph), 7.36-7.32 (m, 2H, CH 
SCH2Ph), 7.28-7.25 (m, 1H, SCH2Ph), 6.17, 6.16 (2s, 1H, H1’), 4.68-4.55 (m, 4H, H5’ 
and SCH2Ph), 4.30-4.25 (m, 1H, H4’), 4.15-4.05 (m, 2H, H3’ and CHCH3), 3.77 3.767, 
3.75, 3.66, 3.61 (2AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 1.38, 1.34 (2d, J=7.0 Hz, 
3H, CHCH3), 0.98, 0.95 (2s, 3H, 2’CCH3), 0.88, 0.87 (2s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.04, 174.80 (C=O), 159.38 (C-6), 159.21 (C2), 
149.95 (C4), 147.99, 147.93 (ipso Naph), 139.04, 138.84 (C8), 137.89 (ipso 
SCH2Ph), 136.32, 136.30 (C10-Naph), 130.41, 130.40, 129.72, 129.70 (SCH2Ph), 
128.87, 128.81, 128.63, 128.61 (CH Naph), 127.87, 127.76 (C9-Naph), 127.56, 
127.51, 126.49, 126.00, 122.83, 122.69 (CH Naph), 122.37, 122.33 (C5), 116.19 (C2-
Naph), 93.08, 93.03 (C1’), 82.02, 81.93 (2d, 3JC-C-O-P=8.8 Hz, C4’), 80.03, 79.95 
(C2’), 75.37, 75.35 (OCH2C(CH3)3), 74.40, 74.11 (C3’), 67.56 (d, 2JC-O-P= 6.3 Hz, 
C5’),  67.00 (d, 2JC-O-P=5.0 Hz, C5’), 51.83, 51.73 (CHCH3), 36.16, 36.14 (SCH2Ph), 
32.26, 32.22 (OCH2C(CH3)3), 26.67 (OCH2C(CH3)3), 20.84 (d, 3JC-C-N-P= 5.0 Hz, 
CHCH3), 20.55 (d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.41 (2’CCH3). 
HPLC ( System 1) tR = 21.02, 21.24 min. 
MS (ES+) m/z: 751.23 (MH+, 100%). 
 
Synthesis of 2-C-chloro-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) purine 5’-
O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (10.27a). 
 
Prepared according to the Standard 
Procedure 7 from: 2-C-chloro-6-O-methyl-
9-(2’-C-methyl-"-D-ribofuranosyl) purine 
(10.12, 300 mg, 0.91 mmol), !-naphthyl-
(2,2-dimethylpropoxy-L-alaninyl) 
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mmol), and tBuMgCl (1.81 ml, 1.81 mmol) in 5 ml of dry THF. The crude mixture 
was purified by column chromatography, using CHCl3/MeOH (0 to 5%, gradient) as 
en eluent. To give a pure product 10.25a as white foam (78 mg, 13%). 
 
31P NMR (202 MHz, MeOD) ! 4.04, 3.98. 
1H NMR (500 MHz, MeOD) ! 8.40, 8.38 (2s, 1H, H8), 8.18-8.10 (m, 1H, H8-Naph), 
7.85, 7.82 (2d, J=8.0 Hz, 2H, H5-Naph), 7.66, 7.63 (2d, J=7.5 Hz, 1H, H4-Naph), 
7.52-7.41 (m, 3H, H7, H6, H2-Naph), 7.37, 7.36 (2t, J=8.0 Hz, 1H, H3-Naph), 6.11, 
6.10 (2s, 1H, H1’), 4.73-4.58 (m, 2H, H5’), 4.35-4.28 (m, 2H, H3’ and H4’), 4.14 (s, 3H, 
6OCH3), 4.10-4.05 (m, 1H, CHCH3), 3.74, 3.72, 3.63, 3.60 (2AB, JAB=10.5 Hz, 2H, 
OCH2C(CH3)3), 1.36, 1.33 (2d, J=7.0 Hz, 3H, CHCH3), 0.96, 0.94 (2s, 3H, 2’CCH3), 
0.86 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.01 (d, 3JC-C-N-P= 5.0 Hz, C=O), 174.76 (d, 3JC-C-N-
P= 6.3 Hz, C=O), 162.62 (C6), 154.33 (C2), 153.59, 153.55 (C4), 147.96, 147.90 
(ipso Naph), 143.79, 143.50 (C8), 136.22, 136.19 (C10-Naph), 128.84, 128.76 (CH 
Naph), 127.79, 127.73 (C9-Naph), 127.44, 127.37, 126.46, 125.88, 125.85, 122.71, 
122.71 (CH Naph), 121.56 (C5), 116.12, 116.07 (2d, 3JC-C-O-P= 3.8 Hz, C2-Naph), 
94.02, 93.91 (C1’), 82.70 (d, 3JC-C-O-P= 7.5 Hz, C4’), 82.60 (d, 3JC-C-O-P= 8.8 Hz, C4’), 
80.01, 79.95 (C2’), 75.37 (OCH2C(CH3)3), 74.81, 74.62 (C-3’), 67.97, 67.62 (2d, 2JC-
O-P= 5.0 Hz, C5’), 59.54 (6OCH3), 51.81, 51.71 (CHCH3), 32.25 (OCH2C(CH3)3), 
26.72 (OCH2C(CH3)3), 20.91, 20.68 (2d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.27, 20.24 
(2’CCH3). 
HPLC ( System 1) tR = 17.65, 17.89 min. 
MS (ES+) m/z: 677.20 (MH+, 100%). 
 
Synthesis of 2-O-methyl-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) purine 
(10.28). 
To a suspension of 2-C-chloro-6-O-methyl-9-(2’-C-
methyl-2,3,5-tri-O-benzoyl-"-D-ribofuranosyl)purine 
(10.11, 1.40 g, 3.06 mmol) in anhydrous methanol (36 
ml) at 0 oC NaOMe in methanol (0.99 g, 18.38 mmol) 
was added. The mixture was stirred at room 
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amberlite (H+). The mixture was then filtrated and solvent was removed under 
reduced pressure. The residue was purified by silica gel chromatography 
(CHCl3/MeOH, 85:15) to give the pure compound 10.28 (0.86g, 86 %) as a white 
solid. 
 
1H (500 MHz, DMSO) ! 8.05 (s, 1H, H8), 5.93 (s, 1H, H1’), 5.25 (s, 1H, 2’OH), 5.23 
(bs, 1H, 3’OH), 5.14 (t, J=5.0 Hz, 1H, 5’OH), 4.11-4.08 (m, 1H, H3’), 4.06 (s, 3H, 
6OCH3), 3.95 (s, 3H, 2OCH3), 3.94-3.91 (m, 1H, H4’), 3.86-3.82 (m, 1H, H5’a), 3.72-
3.68 (m, 1H, H5’b), 0.82 (s, 3H, 2’CCH3). 
13C (126 MHz, DMSO) ! 161.28 (C6), 160.99 (C2), 152.84 (C4), 140.17 (C8), 116.57 
(C5), 90.92 (C1’), 82.73 (C4’), 78.49 (C2’), 71.80 (C3’), 59.66 (C5’), 54.72 (2OCH3), 
53.94 (6OCH3), 19.83 (2’CCH3). 
HPLC ( System 1) tR = 9.36 min 
HRMS calculated for C13H18N4O6: 326.1258; found 326.1247. 
 
Synthesis of 2-C-chloro-6-O-methyl-9-(2’-C-methyl-"-D-ribofuranosyl) purine 5’-
O-[!-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate (10.29a). 
  
Prepared according to the Standard 
Procedure 7 from: 2-C-chloro-6-O-methyl-
9-(2’-C-methyl-"-D-ribofuranosyl) purine 
(10.12, 200 mg, 0.62 mmol), !-naphthyl-
(2,2-dimethylpropoxy-L-alaninyl) 
phosphorochloridate (3.3e, 406 mg, 1.23 
mmol), and tBuMgCl (1.23 ml, 1.23 
mmol) in 5 ml of dry THF. The crude mixture was purified by column 
chromatography, using CHCl3/MeOH (0 to 5%, gradient) as en eluent. To give a pure 
product 10.25a as white foam (72 mg, 17%). 
 
31P NMR (202 MHz, MeOD) ! 4.12, 4.08. 
1H NMR (500 MHz, MeOD) ! 8.20, 8.19 (2s, 1H, H8), 8.16, 8.10 (2d, J=8.0 Hz, 1H, 
H8-Naph), 7.87, 7.84 (2d, J=8.0 Hz, 1H, H5-Naph), 7.68, 7.65 (2d, J=7.5 Hz, 1H, H4-
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6.06, 6.05 (2s, 1H, H1’), 4.64-4.54 (m, 2H, H5’), 4.41, 4.36 (2d, J=8.50 Hz, 1H, H3’), 
4.31-4.26 (m, 1H, H4’), 4.12, 4.11 (2s, 3H, 6OCH3), 4.08-4.04 (m, 1H, CHCH3), 4.03, 
3.97 (2s, 3H, 2OCH3), 3.75, 3.71, 3.64, 3.63 (2AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 
1.33, 1.32 (2d, J=7.5 Hz, 3H, CHCH3), 1.00, 0.98 (2s, 3H, 2’CCH3), 0.87, 0.86 (2s, 
9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 175.09, 175.06 (C=O), 163.35, 163.26 (C6), 162.99, 
162.92 (C2), 154.00, 153.89 (C4), 147.91 (ipso Naph), 141.90, 141.63 (C8), 136.26, 
136.22 (C10-Naph), 128.84, 128.76 (CH Naph), 127.73, 127.67 (C9-Naph), 127.43, 
127.38, 126.43, 125.88, 122,72, 122.68 (CH Naph), 118.27 (C5), 116.12, 116.09 (2d, 
3JC-C-O-P= 3.8 Hz, C2-Naph), 93.85, 93.72 (C1’), 82.39 (d, 3JC-C-O-P= 7.5 Hz, C4’), 
82.28 (d, 3JC-C-O-P= 8.8 Hz, C4’), 79.94, 79.87 (C2’), 75.34, 75.31 (OCH2C(CH3)3), 
74.87, 74.63 (C3’), 68.12, 67.74 (2d, 2JC-O-P= 5.0 Hz, C5’), 55.93, 55.85 (2OCH3), 
54.96 (6OCH3), 51.77, 51.64 (CHCH3), 32.25 (OCH2C(CH3)3), 26.70, 26.67 
(OCH2C(CH3)3), 20.80, 20.60 (2d, 3JC-C-N-P= 6.3 Hz, CHCH3), 20.25 (2’CCH3). 
HPLC ( System 1) tR = 19.71, 20.05 min 
HRMS calculated for C31H40N5O10PNa: 696.2484; found 696.2477 
 
Synthesis of 6-O-methyl-2’-C-methylxanthosine 5’-O-[!-naphthyl-(2,2-
dimethylpropoxy-L-alaninyl)] phosphate (10.30a). 
  
Prepared according to the Standard Procedure 
14, from: 10.29a (30 mg, 0.045 mmol) was 
dissolved in dry acetonitrile (5 ml) under 
argon atmosphere and NaI (14 mg, 0.098 
mmol) was added, followed by the addition of 
trimethylsilyl chloride (0.012 ml, 0.098 
mmol). The reaction mixture was stirred at ambient temperature for 4 h. After work 
up, the residue was purified by preparative TLC, using CHCl3/MeOH (96:4) as an 
eluent. The pure compound 10.30a was obtained as off white solid (17 mg, 58%). 
 
31P NMR (202 MHz, MeOD) ! 4.22. 
1H NMR (500 MHz, MeOD) ! 8.15 (d, J=8.5 Hz, H8-Naph), 8.02 (s, 1H, H8), 7.85 (d, 














Karolina Made!a                                                                                     Chapter Twelve  
 471 
H2-Naph), 7.38 (t, J=8.0 Hz, 1H, H3-Naph), 5.99 (s, 1H, H1’), 4.63-4.52 (m, 2H, H5’), 
4.29-4.24 (m, 2H, H3’, H4’), 4.05 (q, J=7.0 Hz, 1H, CHCH3), 4.00 (s, 3H, 2OCH3), 
3.78, 3.76, 3.70, 3.65 (AB, JAB=10.5 Hz, 2H, OCH2C(CH3)3), 1.34 (d, J=7.0 Hz, 3H, 
CHCH3), 1.00 (s, 3H, 2’CCH3), 0.89 (s, 9H, OCH2C(CH3)3). 
13C NMR (126 MHz, MeOD) ! 173.63 (C=O), 162.56 (C6), 162.99, 162.92 (C2), 
154.15, 153.90 (C4), 147.91 (ipso Naph), 139.14 (C8), 136.26 (C10-Naph), 128.81, 
128.49 (CH Naph), 127.75 (C9-Naph), 127.48, 126.44, 125.95, 122.78 (CH Naph), 
118.37 (C5), 116.16 (d, 3JC-C-O-P= 3.8 Hz, C2-Naph), 93.61 (C1’), 82.10 (d, 3JC-C-O-P= 
8.8 Hz, C4’), 79.95 (C2’), 75.38 (OCH2C(CH3)3), 74.47 (C3’), 67.60 (d, 2JC-O-P= 5.0 
Hz,C5’), 56.33 (6OCH3), 51.78 (CHCH3), 32.28 (OCH2C(CH3)3), 26.72 
(OCH2C(CH3)3), 20.59 (d, 3JC-C-N-P= 7.5 Hz, CHCH3), 20.33 (2’CCH3). 
HPLC ( System 1) tR = 16.79, 17.01 min. 
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a b s t r a c t
b-20-C-Methyl purines (1, 2) are known inhibitors of hepatitis C virus (HCV). We herein report the syn-
thesis, biological and enzymatic evaluation of their 50-phosphoramidate ProTides. Described herein are
seven L-alanine phosphoramidate derivatives with variations to the amino acid ester. The 1-naphthyl
phosphoramidate of b-20-methylguanosine containing the benzyl ester (20) was the most active at
0.12 lM, an 84-fold of increase in activity compared to the parent nucleoside (2) with no increase of cyto-
toxicity. The carboxypeptidase mediated hydrolysis of several ProTides showed a predictive correlation
with their activity versus HCV in replicon.
! 2009 Elsevier Ltd. All rights reserved.
The hepatitis C virus (HCV) was identified in 1989 as a member
of the family of the Flaviviridae.1 An estimated 180 million people
are chronically infected with HCV and thus at increased risk of
developing life threatening liver disease (including cirrhosis and
hepatocellular carcinoma). HCV infections are the major reason
for liver transplantation in industrialized countries. The current
therapy for HCV (pegylated interferon and ribavirin) has limited
efficacy and major side-effects.2 Several examples of modified
nucleosides have already been reported with potential anti-HCV
activity.3,4 Modified nucleosides need to be phosphorylated to their
corresponding 50-triphosphates by the host cell kinases. In many
cases, however, nucleoside analogues are poor substrates for the
kinases and the pharmacologically active triphosphate species can-
not be considered as possible drug candidates due to their high
instability and poor cellular permeation.5 In many cases, the limit-
ing step in this process is represented by the conversion to the
corresponding 50-monophosphate. Our group has developed in
the past the aryloxy-phosphoramidate ProTide approach which
allows the delivery of the monophosphorylated nucleoside ana-
logue into the cell, bypassing the need of the first phosphorylation
step.5 We have previously reported the successful application of
the ProTide approach to different nucleoside analogues6,7,10,11
20-Methylpurines (adenosine and guanosine) have been shown to
be potent anti-HCV agents:3 b-20-Methyladenosine (1) (Fig. 1)
showed EC50 = 0.3 lM against HCV in replicon assay, and its corre-
sponding 50-triphosphate inhibited HCV RNA polymerase at
1.9 lM. b-20-Methylguanosine (2), instead, showed IC50 = 0.13 lM
(inhibition of RdRp), EC50 = 3.5 lM against HCV, but most impor-
tantly the detected level of its corresponding 50-triphosphate was
rather poor.3 In the case of b-20-methylguanosine (2), the low level
of its intracellular 50-triphosphate may be an indication that this
nucleoside is a poor substrate for nucleoside kinases, limiting its
antiviral efficacy.
We decided to apply the aryloxy-phosphoramidate approach to
these two nucleoside analogues in order to explore the possibility
of further increasing their activity against HCV. In the first instance,
b-20-methyladenosine (1) and b-20-methylguanosine (2) were
synthesized and evaluated for their effect on HCV (sub genomic)
replicon replication.
0960-894X/$ - see front matter ! 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2009.05.122
* Corresponding author. Tel./fax: +44 0 2920874537.

















Figure 1. b-20-Methyladenosine (1) and b-20-methylguanosine (2).
Bioorganic & Medicinal Chemistry Letters 19 (2009) 4316–4320
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Bioorganic & Medicinal Chemistry Letters
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The synthesis of b-20-methyladenosine (1) and b-20-methylgu-
anosine (2) was planned following the reported procedure (Fig. 2).3
The oxidation in the 2-position of the tri-benzoylated ribose (3)
was performed in the presence of the synthesized Dess–Martin
reagent.7 The stereoselective addition of the methyl group in the
b-2-position was performed by the addition of 4 to a solution of
methyl titanium trichloride, synthesized in situ from an anhydrous
solution of titanium tetrachloride and methylmagnesium bromide
in diethyl ether, to give a mixture of 5 and 6 (Fig. 2).8 The next ben-
zoylation reaction was performed under standard conditions to
give 7.3 In the case of b-20-methyladenosine (1), in order to avoid
a problem of selectivity in N7- and N9-positions, it was necessary
to protect the NH2 with the pivaloyl group. The following coupling
reaction was performed in the presence of DBU and trimethylsilyl
trifluoromethanesulfonate (Fig. 2). Heteronuclear multiple bond
correlation (HMBC) showed the correlation between C4 and H10,
confirming the presence of the N9-regioisomer. Nuclear Overhaus-
er Enhancement Spectroscopy (NOESY), showed no correlation
between the proton of H10 and the three protons of the methyl
group in the 20-position confirming the presence of the b-nucleo-
side; instead, the correlation between H20 and the three protons
of the methyl group in the 20-position confirmed the presence of
the methyl group in the b-position. The final step was the removal
of the pivaloyl group using NH3/CH3OH at room temperature in a
sealed tube (Fig. 2). The fully benzoylated b-20-methyl sugar (7)
was also the substrate for the synthesis of 20-methylguanosine
(2). In order to avoid N9- and N7-regioisomers, the coupling reac-
tion was performed in two steps: synthesis of the totally silylated
acetylguanine and coupling reaction in the presence of the appro-
priate 2-methylribosugar (7) and trimethylsilyl trifluoromethane-
sulfonate (TMS-triflate) using para-xylene as solvent (Fig. 2).9 The
N9-regioisomer was isolated without any traces of N7-isomer. Also
in this case the final step required the use of NH3/CH3OH to give
the desired product (2) in quantitative yield (Fig. 2). In our previ-
ous work,10,11 the phosphoramidate synthesis was greatly
improved with the presence of a protecting group in the 20- and
30-position of the nucleoside. Consequently, the N6-pivaloyl-
20,30,50-tribenzoate-b-20methyladenosine (8) was selectively
deprotected in the 20-, 30-, and 50-position whilst keeping the piva-
loyl group in the N6-position, followed by introduction of the
cyclopentylidene group in the 20- and 30-positions in the presence
of 1,1-dimethoxypentane and p-TSA. The final deprotection of the
6-amino group was performed in the presence of NH3/CH3OH at
room temperature in a sealed tube (Fig. 3).
The introduction of the cyclopentylidene group was attempted
also in the case of b-20-methylguanosine: this attempt was unsuc-
cessful and consequently the use of isopropylidene as protecting
group was considered. The synthesis was performed in the pres-
ence of a catalytic amount of perchloric acid in a solution of dry
acetone (Fig. 4).
The synthesis of the phosphoramidate was performed following
the Uchiyama procedure,12 in the presence of t-butyl magnesium
chloride (Figs. 5 and 6).13
The sugar deprotection in the case of the cyclopentylidene
group (synthesis of b-20-methyladenosine phosphoramidates, 15–
17) required an acidic hydrolysis using 80% formic acid at room
temperature (Fig. 5).14
The hydrolysis of isopropylidene group (synthesis of b-20-meth-
yladenosine phosphoramidates, 20–23), instead, was performed
using acetic acid at 90 !C (Fig. 6).15 The yields of the coupling reac-
tion for the synthesis of b-20-methyladenosine phosphoramidates
(15–17) were 40–50%, whilst the deprotection reaction yields were
50–60%. Instead, in the case of the synthesis of b-20-methylguano-
sine phosphoramidates (20–23) the yields for the coupling reaction









































Figure 2. Synthesis of b-20-methyladenosine (1) and b-20-methylguanosine (2).
Reagents: (a) Dess–Martin reagent, CH2Cl2 dry; (b) CH3TiCl3, Et2O dry; (c) BzCl,
DMAP, Et3N; (d) (1) N2-acethylguanine, HMDS, TMS-triflate, p-xylene; (2) CH3OH/
NH3; (e) (1) N6-pivaloyladenine, DBU, TMS-triflate, CH3CN; (2) CH3OH/NH3.
Figure 3. Synthesis of 20 ,30-protected-b-20-methyladenosine (11). Reagents: (a) 1 M
NaOH, ethanol, pyridine; (b) 1,1-dimethoxypentane, p-TSA; (c) NH3, CH3OH.
Figure 4. Synthesis of 20 ,30-protected-b-20-methylguanosine (12). Reagents: HClO4,
acetone.
C. McGuigan et al. / Bioorg. Med. Chem. Lett. 19 (2009) 4316–4320 4317
20- and 30-positions were 30–50%. In most of the cases, for both
nucleosides, purification by column chromatography and a semi-
preparative HPLC were required to obtain the pure products. In
each case, the phosphoramidates were isolated as mixtures of
phosphorus diastereoisomers (ratio 1:1) with two signals present
in the 31P NMR spectra.
Each of the phosphoramidates (15–17 and 20–23) and their
parent nucleosides (1 and 2) were tested in vitro as inhibitors of
HCV replication in the HCV replicon assay using similar conditions
as described (Table 1).16
None of the compounds showed toxicity at 50 lM concentra-
tion. The two nucleosides (1 and 2) inhibited HCV replication with
EC50 values of at 0.25 and 10.1 lM, respectively. The phosphoram-
idate approach in the case of 1 was unsuccessful, with at best a
maintenance of biological activity compared to the parent nucleo-
side. This result confirms that the conversion of b-20-methyladeno-
sine (1) to its corresponding 50-monophosphate in the cell is
efficient; consequently, the ProTide approach does not improve
this process. However, compound 15 and 16 showed a biological
activity similar to their parent nucleoside (1), indicating that in this
case, the phosphoramidate approach does successfully deliver the
50-monophosphate with a similar efficiency to the nucleoside itself.
In contrast, the phosphoramidates of b-20-methylguanosine (20–
22) showed a significant increase in inhibition of HCV replication
compared to the parent nucleoside (2). This result supports the no-
tion that: the phosphoramidate approach allows the efficient deliv-

































































































Figure 6. Synthesis of b-20-methyladenosine phosphoramidates (20–23).
Table 1
Biological activity of b-20-methyladenosine (1) and b-20-methylguanosine (2) and
their corresponding phosphoramidates
Compd Nucleoside R HCV HUH 5-2
EC50(lM) CC50 (lM)
1 20Me-A — 0.25 >50
15 20Me-A Ethyl 0.24 >50
16 20Me-A Benzyl 0.27 >50
17 20-Me-A t-Butyl 4.18 >50
2 20-Me-G — 10.1 >50
20 20-Me-G Benzyl 0.12 >50
21 20-Me-G Ethyl 0.28 >50
22 20-Me-G Methyl 0.23 >50
23 20-Me-G t-Butyl 27 >50
4318 C. McGuigan et al. / Bioorg. Med. Chem. Lett. 19 (2009) 4316–4320
substrate for the nucleoside kinases in replicon cells, and the
corresponding 50-monophosphate is efficiently phosphorylated to
the corresponding 50-triphosphate in vitro. Among the four esters,
the t-butyl (17 and 23) phosphoramidates were found to be less
active compared to benzyl, methyl and ethyl esters. This reduced
antiviral activity may be related to the relative stability of tertiary
esters to enzyme-mediated hydrolysis. The effect is particularly
notable for the guanosine series, where the tertiary ester causes
a >100-fold loss of activity.
There was no significant difference in antiviral potency consid-
ering ethyl, methyl and benzyl esters, indicating that these esters
are well tolerated by the enzyme involved in the phosphoramidate
conversion. To further understand the high activity of these com-
pounds we carried out an enzyme incubation designed to mimic
the first stages of the putative activation of these ProTides
in vivo. Thus compound (20) was incubated with carboxypeptidase
Y in TRIZMA buffer and the metabolism of (20) monitored by P-31
NMR.17 Spectra were recorded at periodic intervals and selected
scans are reproduced in Figure 7.
Two P-31 NMR signals are noted for (20) at dP ca. 4.0, corre-
sponding to the two phosphate diastereoisomers of the ProTide.
After ca. 0.2 h the signals for the parent have disappeared and an
intermediate is noted at dP ca. 4.5. This material must likely be
chiral at the phosphate, as evidenced by the presence of 2 peaks.
Parallel work in our laboratories on other compounds indicates this
species to be the ester hydrolysed analogue of (20) with a free
carboxylate, compound (24).18 This material is then converted to
the final product in this assay, with a single peak at dP ca. 7. This
is achiral at the phosphate and considered to be the key aminoacyl
intermediate, which lacks the ester and aryl moieties; it is the
50-alaninyl phosphate of (2), compound (25) (Fig. 8).
Our previous work has indicated that this may be a substrate for
the HINT family of enzymes, to liberate to free 50-monophosphate
in vivo.19 As such, its appearance in the enzyme assay is seen as a
necessary pre-requisite for antiviral action in vivo. Thus, for com-
parison purposes we carried out the same study with the poorly
active t-butyl ester (23). Similar data for the carboxypeptidase
assay on (23) are shown in Figure 9.
Several clear differences are noted between the enzyme stabil-
ity assays of (20) and (23). Most striking is the difference in rate.
Thus, while both proceed to give the same putative amino acyl
metabolite (25), the t-butyl ester (23) is massively slower. The
benzyl ester (20) shows only ca. 7% of parent ProTide remaining
after 10 min, with a calculated first order half life of 3 min. By

































Figure 8. Putative metabolites in the processing of ProTide (20).
Figure 9. Sequential P-31 NMR scans of (23) incubated with carboxypeptidase Y.
C. McGuigan et al. / Bioorg. Med. Chem. Lett. 19 (2009) 4316–4320 4319
contrast the t-butyl ester is only ca. 24% hydrolysed after 13 h, with
an estimated half life of 33 h. Thus the (active) benzyl ester is
processed ca. 700-fold more efficiently to the key amino acyl
metabolite in this assay than is the (poorly active) t-butyl ester.
Secondly, it is notable that the intermediate (24) observed in
Figure 7, corresponding to the ester cleaved ProTide, is not
observed in Figure 9; presumably the ester cleavage is greatly rate
limiting in the case of (23) and aryl loss is much more rapid, so
intermediate (24) never builds up to detectable levels.
In conclusion, we have reported the synthesis of 1 and 2 and a
small series of their corresponding phosphoramidates. The most
potent compounds were the 1-naphthyl derivatives with benzyl
(20), ethyl (21) or methyl (22) ester moieties with 84-fold increase
in activity against HCV compared to the parent nucleoside (2). The
application of phosphoramidate approach to 1 did not significantly
improve the activity against HCV compared to the parent nucleo-
side (1). We also note the valuable predictive power of a P-31
NMR based enzyme metabolic assay for the activity of these Pro-
Tides versus HCV in vitro.
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Hepatitis C virus infection constitutes a serious health problem in need of more effective therapies.
Nucleoside analogues with improved exposure, efficacy, and selectivity are recognized as likely key
components of future HCV therapy. 20-C-Methylguanosine triphosphate has been known as a potent
inhibitor of HCV RNA polymerase for some time, but the parent nucleoside is only moderately active
due to poor intracellular phosphorylation. We herein report the application of phosphoramidate
ProTide technology to bypass the rate-limiting initial phosphorylation of this nucleoside. Over 30 novel
ProTides are reported, with variations in the aryl, ester, and amino acid regions. L-Alanine compounds
are recognized as potent and selective inhibitors of HCV in replicon assay but lack rodent plasma
stability despite considerable ester variation. Amino acid variation retaining the lead benzyl estermoiety
gives an increase in rodent stability but at the cost of potency. Finally L-valine esters with ester variation
lead to potent, stable compounds. Pharmacokinetic studies on these agents in the mouse reveal liver
exposure to the bioactive triphosphate species following single oral dosing. Systemic exposure of the
ProTide and parent nucleoside are low, indicating possible low toxicity in vivo, while liver concentra-
tions of the active species may be predictive of efficacy in the clinic. This represents one of the most
thorough cross-species studies of ProTides to date.
Introduction
An estimated 200million people, or ca. 3.5% of the world’s
population, are chronically infected with the hepatitis C virus
(HCVa) and at risk of developing life threatening liver disease
such as cirrhosis or liver carcinoma. HCV infection is the
major cause of liver transplantation in industrialized coun-
tries. The current therapy for HCV consists of pegylated
interferon and ribavirin, neither of which are specific inhibi-
tors of HCV, and a regimen which has side effects and limited
efficacy in at least half of the patient population.1
The HCV genome offers several clear targets for specific
anti-HCV therapy; these include an RNA polymerase and a
serine protease, both of which have attracted considerable
academic and industrial attention.2
The RNA dependent HCV polymerase is considered to be
an attractive target for therapy on account of a high degree of
conservation across the six HCV genotypes, and agents tar-
geted at the active site, such as nucleoside analogues, may
be particularly advantageous with respect to the barrier to
resistance.3
Several families of nucleoside analogues have emergedwith
apparent selectivity forHCV, these include 40-modified agents
such as 40-azidocytidine (R1479, 1a, Figure 1) developed as
an oral pro-drug by Roche4 and 20-C-methyl adenosine (1b,
Figure 1) and related deaza compounds developed byMerck.5
Interestingly, the Merck team observed that the guanine
analogue 1cwasmore potent (>10-fold) as an inhibitor of the
HCVRNApolymerase, as its bioactive 50-triphosphate form,
than was the triphosphate of the adenosine lead 1b. However,
poor cell entry by 1c coupled with apparently poor phospho-
rylation lead to it being >10-fold less active than 1b in HCV
replicon (1b EC50 0.26 μM, 1c 3.5 μM).
5
Unfortunately, despite the reasonable in vitro potency and
selectivity of 1b, the compound could not be progressed due to
it being a good substrate for metabolic enzymes (adenosine
deaminase and purine nucleoside phosphorylase), leading to
low oral bioavailability.5
To overcome these PK liabilities of 1b, the Merck team
progressed with several unnatural base modifications, such as
the 7-deaza family, leading to their late preclinical candidate
MK-0608. As recently highlighted, a lack of data on this family
for over three years nowmay place a query over their progres-
sion.3 We were concerned that such base modifications could
carry with them the possibility of toxicity, and we sought to
retainanatural base and to seek toovercome the limitationsof
the guanosine compound 1c in particular. Because the first
phosphorylation of 1c was considered to be rate-limiting, we
*To whom correspondence should be addressed. Phone/Fax:þ44 29
20874537. E-mail: mcguigan@cardiff.ac.uk.
aAbbreviations: HCV, hepatitis C virus; TLC, thin layer chromato-
graphy; HPLC, high performance, liquid chromatography; ClogP,
calculated logarithm of octanol-water partition coefficient; PK, phar-
macokinetics; SI, selectivity index; DNAUC, dose normalized area
under the curve; NTP, nucleoside triphosphate; THF, tetrahydrofuran.
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wondered if a pro-drug of the 50-monophosphate of 1cmaybe
active, and thus we applied our phosphoramidate ProTide
approach6 to this nucleoside.We first introduced this ProTide
motif in 19967 and have exemplified it considerably,6 includ-
ing very recently to 1a8 and briefly to 1b-c.9 Our approach
has also been adopted by Pharmasset for their 20-modified
nucleoside HCV family10 and adapted to acyclic nucleoside
phosphonates by Gilead.11 The Pharmasset nucleoside is
also 20-C-methyl based, but is a uridine compound, also with
a 20-R-fluorine. This company are using a ProTide based on
isopropylalanine phenyl phosphate,12 rather parallel to our
earlyworkon anti-HIVProTides13 Idenix have also pursued a
ProTide approach on 1C, although the precise structure of
their lead IDX-184 has yet to issue.14
Following an early indication that the ProTides may suc-
cessfully impact on 1c,9 we herein report an extensive study
thereof. We report over 30 novel analogues with extensive
variation in the aryl, ester, and amino acid regions of the Pro-
Tide, and we study these extensively across species for their
stability. We note that the benzyl alanine motif continues7-9
to exhibit good potency in replicon, but there is poor stability
and PK in this series, which can only be solved by a novel
combined variation in both the amino acid and ester regions
as we will describe. The basic structure of a phosphoramidate
motif is shown in Figure 2.
Chemistry
The target ProTides of 1c were prepared using phosphoro-
chloridate chemistry as we have extensively reported.6-9 To
aid in both the 50-regioselectivity of phosphorylation and the
general organic solubility of the nucleoside, we investigated
various protecting groups for the 20,30-diol unit. One key issue
is the ability to remove this protecting group after construc-
tion of the 50-ProTide unit, and the relative chemical fragility
of this group dictates the nature of the diol protecting group
that might be acceptable. Indeed, the somewhat surprising
acid-stable nature of ProTides15means that acid sensitive diol
protectionmay be acceptable, and this led us to the use of iso-
propylidene protection.
Thus 1c was allowed to react with acetone and perchloric
acid at ambient temperatureovernight to give1d (Scheme1) in
93% yield. This proved to be significantly more soluble than
1c and readily reacted with the appropriate phosphorochlo-
ridate reagents6-9,15 inorganic solvents suchasTHF(Scheme1).
Various bases could be used to aid the reaction; the Grignard
Figure 1. Some anti-HCV nucleosides.
Figure 2. A general ProTide structure.
Scheme 1a
aFor 2a-n, 3a-g, 4a-j, see Tables 1, 3, 5.
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reagent tBuMgCl was among the most effective, and prefer-
ably used in ca. 2 molar equivalence, along with the phos-
phorochloridate. Reaction overnight at ambient temperature
followed by flash column chromatography on silica gave the
isopropylidene protected intermediates (Scheme 1) in 30-
88% yield. These were deprotected using 60% acetic acid at
95 !C overnight. The relative stability of the ProTide motif
under these conditions was taken as further support of their
surprising acid stability and may be taken as further evidence
of their possible compatibility with oral dosing. The final
compounds 2a-n, 3a-g, and 4a-j (Tables 1, 3, and 5) were
each isolated after column chromatography, sometimes fol-
lowed by preparative TLC and/or HPLC. Standard methods
are given below and spectroscopic and analytical data on 2a
only; full detail on other analogues is given as Supporting
Information. In each case, the final products were isolated as
mixtures of diastereoisomers at the phosphate, as evidenced
bymultiple (in most cases 2) peaks in the P-31NMRand also
in the HPLC. The approximate ratio of peaks (fast eluting on
reverse phase, i.e., polar to nonpolar) as determined byHPLC
is given in Tables 1, 3, and 5, where peaks were sufficiently
clearly resolved. The approximate ratios from P-31 NMR
roughly mirrored those determined by HPLC and allowed a
correlation betweenHPLCmobility/polarity andNMR shift,
such that the most predominant isomer in most cases was the
downfield NMR peak, corresponding to the more nonpolar
stereoisomer. The HPLC retention time data confirmed that
the ProTides were in every case considerably more lipophilic
thanparent1c. Calculated lipophilicity (ClogP) values16 for 1c
and 2a are-2.6 and-0.52, respectively, indicating a roughly
100-fold lipophilicity enhancement for 2a. BecauseMerckhad
noted apparently poor cell uptake by 1c,5 we considered the
enhancement in this parameter for the ProTides potentially
useful in vivo. However, the figure for the methylalanine ester
2a was still somewhat lower than that considered optimal
for passive cell uptake, and thus we varied the ester moiety to
enhance lipophilicity further and also to probe the putative
ester cleavage step considered to be key to the in vivo activation
of these agents.6,15 In the L-alanine series2a-n, the lengthening,
branching, and aromatization of the estermoiety lead to agents
such as the benzyl ester 2i with a ClogP of 1.2 and branched
analogues of this, such as 2m and 2n, with perhaps near ideal
values of 1.5. Notably, in the case of 2m, the introduction of a
further variable chiral center in the ester led to amixture of four
diastereomers, as evidenced by P-31 NMR and HPLC.
Besides ester variation, we prepared one analogue, 2j, with
2-naphthyl as the aryl moiety in place of 1-naphthyl. We also
varied the amino acid unit from L-alanine (2a-n), to valine
(3a), leucine (3b), methionine (3c-d), phenylalanine (3e),
isoleucine (3f), and theunnatural achiral aminoacid dimethyl-
glycine (3g) (Table 3). In most cases, these were prepared as
the benzyl ester, except for 3d, being the iPr ester of Met.
Aswill be discussed below, L-valine emerged as a promising
amino acid from these earlier studies. This is notable, as it had
previously been observed by us to be among the least effective
amino acids when applied to several families of ProTides.6,17
However, in this case, promising biological data necessitated
the preparation of a family of L-valine esters (4a-j, Table 5).
These included some unusual esters not previously widely
reported for ProTides: the substituted benzyl family (4f-i)
and the neopentyl compound (4j).
Activity in Replicon Assay and Plasma Stability
As is common in anti-HCV drug development, we used
subgenomic HCV replicon as a primary biological readout.
Data are reported for the initial L-alanine family 2a-n in
Table 1, alongwith comparator data for 1c in this assay. Each
data point represents the mean of at least three independent
assays. As noted in Table 1, all of the L-alanine ProTides were
active sub-μMin the replicon assay,while 1cwasonly active at
3.5 μM. Thus, the initial family of esters was 4-50-fold more
potent than 1c. This was taken as an early indication that the
ProTides successfully improved the intracellular delivery of the
eventual 50-triphosphate pharmacophore of 1c, presumably
by a combination of enhanced passive diffusion of the lipo-
philic ProTides into cells and the delivery of the monophos-
phate therein by a nucleoside kinase-independent process.
There was no clear correlation between ProTide lipophilicity
and biological potency in this family, with several diverse
esters showing activity in the 40-60 nM range.
All the ProTides displayed minimal toxicity in the Huh7
cells expressing the HCV genotype 1b bicistronic subgenomic
replicon. When replicon 1b cells were incubated with the
different ProTides for 72 h and cell viability was measured
using the CellTiter-Glo assay (Promega,Madison,WI), CC50
values greater than 100 μMwere routinely observed. This was
true even for the most potent compounds like 2g, thus leading
Table 1. HCV Replicon Activity of L-Alanines Ester Derivatives
ProTide aryl ester isomersa EC50/μM
b CC50/μM
1c 3.5 >100
2a 1-Nap Me 38:62 0.21 >50
2b 1-Nap nBu 43:57 0.10 >100
2c 1-Nap nPnt 37:63 0.091 ND
2d 1-Nap iPr 40:60 0.17 >100
2e 1-Nap 2-Bu 38:62 0.12 >100
2f 1-Nap cPnt 48:52 0.07 >100
2g 1-Nap cHx 34:66 0.045 >100
2h 1-Nap tBuCH2 31:69 0.057 >100
2i 1-Nap Bn 45:55 0.062 >100
2j 2-Nap Bn 43:57 0.17 >50
2k 1-Nap BnCH2 44:56 0.09 >100
2l 1-Nap BnCH2CH2 40:60 0.17 >100
2m 1-Nap R/S PhEt 33, 14, 35, 18c 0.095 >100
2n 1-Nap S PhEt 42:58 0.08 >100
a Isomer ratio fromHPLC; polar:nonpolar. bReplicon data for geno-
type 1b in HUH7 cells with 48 h exposure. cFour stereoisomers.
Table 2. Plasma Stability of L-Alanine Estersa
% remaining in plasma at 2-4 !C
ProTide ester time human cyno canine rat mouse
2a Me 30 min ND ND ND ND 1.7
2b nBu 30 min 100 98 95 0.4 0
4 h 97 81 90 0 0
2c nPnt 30 min 100 94 98 0 0
4 h 96 94 98 0 0
2d iPr 30 min ND ND ND ND 14
2e 2-Bu 30 min ND ND ND ND 10
2g cHx 30 min 100 100 100 2.5 2.9
4 h 100 100 100 0.5 0
2h tBuCH2 30 min ND ND ND ND 0.3
2i Bn 30 min 58 54 67 1.3 1.1
2jb Bn 30 min ND ND ND ND 0.7
2m (R/S)-1-
PhEt
30 min 86 100 97 0.7 2.2
4 h 86 88 93 0.3 0
2n S-PhEt 30 min 100 100 97 0.8 3.1
4 h 99 100 92 0 0
aND: not determined. b 2-Naphthyl.
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to high selectivity indexes in these cells. Several compounds
were also tested against MT4, CEM, HepG2, Huh7, HEL,
293, IEC-6, and CaCo2 cells. All cell lines tested were in log
phase of growth throughout the cell cytotoxicity experiments
(data not shown). A similar lack of toxicity was observed
in these diverse cell lines. For example, compound 2n had
CC50 values >100 μM for all the above cell lines except MT4
(CC50=87 μM) and CEM (CC50=82 μM). This gives 2n an
SI of ca. g1000.
Thus, to progress hit to lead selection, we sought other
assays that may be informative of in vivo PK. Prior to
investigating the PK of the various ProTides, we examined
the plasma stability of the L-alanine esters in mouse, rat, dog,
monkey, and human plasma (Table 2). The plasma stability
studies were carried out at 2-4 !Cbecause they were intended
to confirm sufficient stability for calibration curves, not
necessarily for understanding stability at the physiologically
more relevant 37 !C. Perhaps not surprisingly, the various
esters of the L-alanine ProTides all were very unstable in
rodent plasma even at these lower temperatures. The data
are reported as% remaining after either 30min or 4 h. All the
L-alanine esters synthesized were essentially completely
cleaved in 30 min. The most stable esters were the branched
isopropyl and 2-butyl esters, which still were greater than80%
consumed in 30 min even at this lower temperature. Because
of this profound plasma instability, it became clear we would
not be able to generate calibration curves in rodent plasma
and as a result we would not be able to measure ProTide
plasma concentrations in either mouse or rat. On the other
hand, the L-alanine esters for the most part had sufficient
plasma stability in other species to generate calibration curves
and measure exposure. The benzyl ester 2i was the notable
exception, with nearly 40% degradation in 30 min in human,
monkey, and dog plasma. However, substitution at the
benzylic position, as in the case of the 2-phenylethyl derivative
2m and 2n, led to substantially improved plasma stability in
these three species with up to 100% remaining even after 4 h.
Because modification of the ester group did not readily
provide rodent plasma stability, and because being able to do
initial pharmacokinetic studies in rodents was considered
desirable, the amino acid core of the ProTides was varied to
investigate both potency and plasma stability. Thus, as noted
in Table 3, we prepared several ProTides, mainly as their
benzyl esters, of six different amino acids. Benzyl esters were
selected because we believed they provided the best chance
of showing potency in the replicon assay. We particularly
selected bulky aminoacids, partly to enhance lipophilicity and
partly to seek to induce some steric hindrance to degradation
of the ProTide. As noted in Table 3, this lead to a significant
(2-10-fold) loss of activity in the best cases and a 20-fold
decrease in the worst case. Disubstitution of the R carbon
of the amino acid lead to a 20-fold decrease in activity, while
amino acids such as the L-leucine derivative 3b were the
most potent EC50 = 120 nM. Branching at the β carbon of
the amino acid as in the L-valine and L-isoleucine derivatives
3a and 3f, resulted in a 10-fold decrease in activity, however,
these ProTides retained sub-μM activity and thus were still
more active than 1c. Compound 3b was ca. 30 times more
active than 1c.
The plasma stability of these alternate amino acid ProTides
was examined in the hope of finding improved rodent plasma
stability. The results of testing in mouse plasma for com-
pounds 3a-3g are reported in Table 4. Disubstitution of the
R carbon of the amino acid, 3g, did not noticeably improve
mouse plasma stability relative to the L-alanine derivative 2i.
Longer chain amino acids also failed to provide plasma
stability. However, branching at the β carbon did provide
significantly improved plasma stability. Thus, the Val and Ile
derivatives 3a and 3f provided 66% and 95% stability in
mouse plasma even after 4 h. This stability was measured at
2-4 !C and clearly would be worse at 37 !C. However, this
level of stability would at least allow generation of calibration
curves and subsequent measurement of plasma ProTide levels
in rodents. These branched ProTides maintained their stabi-
lity in the plasma from other species, but their activity in the
replicon assay was somewhat less than that of the L-alanine
analogues.
Thus, we subsequently prepared a small family of L-valine
analogues with ester variations to examine whether we could
improve antiviral activity and maintain rodent plasma stabi-
lity. The derivatives made are listed in Table 5 and are
compared to compound 3a. Table 5 includes a 2-naphthyl
derivative 4a and the D-valine derivative 4b, both of which are
Table 4. Plasma Stabilities of Amino Acid Derivatives
% remaining in plasma at 2-4 !C
ProTide ester AA time human cyno canine rat mouse
3a Bn L-Val 30 min 89
4 h 66
3b Bn L-Leu 30 min 2
3c Me L-Met 30 min 34
3d iPr L-Met 30 min 77 96 100 2.3 76
4 h 79 93 100 0.5 32
3e Bn L-Phe 30 min 1
3f Bn L-Ile 30 min 100
4 h 95
3g Bn Me2Gly 30 min 100 92 100 0 0
4 h 41 83 100 0 0
Table 5. HCV Replicon Activity of L-Valine Ester Derivativesa
ProTide aryl ester AA isomersb EC50/μM
b CC50/μM
3a 1-Nap Bn Val 32:68 0.76 >100
4a 2-Nap Bn Val 56:44 1.7 >100
4b 1-Nap Bn D-Val 68:32 >3 >100
4c 1-Nap cHx Val 65:35 1.0 >100
4d 1-Nap (R/S)-1-
PhEt




4f 1-Nap o-ClBn Val 33:67 0.43 >100
4g 1-Nap m-ClBn Val 31, 25, 44 0.68 ND
4h 1-Nap p-ClBn Val 35:65 0.62 ND
4i 1-Nap o-MeBn Val 36:64 1.0 100
4j 1-Nap tBuCH2 Val NA
c 1.5 >100
aNA: not available. ND: not determined. b See Table 1. cSee Table 3.
Table 3. HCVReplicon Activity of Different Amino Acid Derivativesa
ProTide aryl ester AA isomersb EC50/μM
b CC50/μM
3a 1-Nap Bn L-Val 32:68 0.76 >100
3b 1-Nap Bn L-Leu NAc 0.12 >50
3c 1-Nap Me L-Met 31:69 0.28 >100
3d 1-Nap iPr L-Met 36:64 0.34 >100
3e 1-Nap Bn L-Phe 34:66 1.2 >100
3f 1-Nap Bn L-Ile NAc 0.9 >50
3g 1-Nap Bn Me2Gly 31:69 1.5 ND
aNA: not available. ND: not determined. b See Table 1. cPeaks
merged on HPLC.
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less active in replicon assay. The other ester derivatives, 4c-4j,
are similar in activity to the lead compound 3a, with simple
aliphatic esters perhaps falling off slightly in potency and
benzyl esterswith an electronwithdrawing grouportho,meta,
or para, all being somewhatmore potent.However, branching
at the benzylic position, as in the (R/S)-1-phenylethyl deriva-
tive 4d, resulted in a substantial decrease in activity, whichwas
not observed in the L-alanine series.
Plasma stabilities were examined across this series and are
listed in Table 6. A number of interesting observations can be
made fromtherodentplasmastabilitydata.While the2-naphthol
derivative 4a has similar stability to the 1-naphthol derivative,
the D-valine benzyl ester 4bwas observed to be less stable than
the L-valine analogue in rodent plasma. The other L-valine
esters maintained rodent, and other species, plasma stabilities
with the possible exceptions of the ortho chloro and ortho
methyl substituted benzyl esters 4f and 4i, which showed
minor decreases in stability relative to the para-substituted
and unsubstituted benzyl esters.
Discussion of in Vitro S9 Stability Studies
Human, dog, cynomolgus monkey, and rat liver and intes-
tinal S9 stability data, asmeasuredbydisappearance of parent
compound, were obtained for selected compounds (Table 7).
Mouse data were not collected because of difficulty in obtain-
ing mouse liver S9 preparations. All samples were run with
and without cofactor (NADPH) and expressed as % remain-
ing compound after 60min incubations. BecauseNADPH is a
cofactor for P450 isozymes, metabolism in the absence of
cofactor was considered non-P450 dependent metabolism.
We were interested in identifying which species compared
closest to humanS9 data andwhich compounds gave themost
desirable profile in human intestinal and liver S9 experiments.
Compounds were compared across species mainly by look-
ing at the ratios of liver vs intestinalmetabolism as opposed to
absolute numbers in each category. When considered this
way, it became clear that rat and monkey were reasonable
comparators to the human data, but that the dog in vitro data
was the outlier. As an example of this, compound 2d (Table 7)
shows more liver cleavage than intestinal cleavage in human,
monkey, and rat, but in the dog it is reversed.
Human S9 data were collected for the majority of project
compounds but only a portion of the data are reported here.
Wewere looking for compoundswith good stability in human
intestinal S9 preparations, but with rapid cleavage in liver, in
the presence of cofactor. In addition to looking at the ratio
between liver and intestinal cleavage, we also paid attention
to the overall degree of cleavage. The majority of compounds
demonstrated greater stability in intestinal S9 preps than in
liver, as was desired (Table 7). In this general sense, these
compounds could be considered as liver targeting. The lone
exception was the benzyl ester of L-alanine, compound 2i,
whichwas highly cleaved in the intestine. Stability in intestinal
cells was considered important because we wanted the Pro-
Tide to pass through the gut and intestine and be absorbed
and cleaved by the liver. The intestinal stabilities, asmeasured
by% remaining after 60min incubations, ranged from 0% to
65%. The most stable of this set of compounds was 2d, the
isopropyl ester of L-alanine.
As noted above, the compounds in Table 7 were all
incubatedwith andwithout cofactor. Looking across the data
in the table, there is a trend toward greater cofactor depen-
dence in the liver than in the intestine. Because P450 isozymes
require a cofactor, and because P450 levels are high in liver,
this is taken as a further subtle indication of liver targeting.
The benzyl ester derivatives such as compound 3a showed a
large degree of cofactor dependent liver cleavage, as did the
neopentyl ester derivative compound 2h.
Mouse DMPK Results and Discussion
Aseries of ester and amino acid derivativeswere selected for
in vivo studies based on a combination of factors including
potency, plasma stability, and SAR. Primarily L-valine deri-
vatives were investigated because they had the most rodent
plasma stability. The in vivo work focused on oral dosing not
only because it is a desired route of administration in gene-
ral but also because HCV is a liver disease and absorbed
ProTide would pass directly into the liver via the portal vein.
For HCV, the general problem of first pass metabolism may
work in our favor to produce high levels of the active agent.
The overall goal would be to find a compound with low
systemic nucleoside exposure but good therapeutic liver tri-
phosphate levels.
For all the ProTides, systemic levels of the parent ProTides
were not detectable in the mouse (data not shown). Even for
the L-valine derivatives, which demonstrated much improved
Table 6. Plasma Stability of L-Valine Esters
% remaining in plasma at 2-4 !C
ProTide ester time human cyno canine rat mouse
4a Bna 30 min 93 100 95 49 99
4 h 100 95 99 22 76
4b Bnb 30 min 70 68 69 82 51
4 h 82 80 61 56 8
4c cHx 30 min 97 95 95
4d (S)-1-PhEt 30 min 97 100 100
4f o-ClBn 30 min 77 100 69
4g m-ClBn 30 min 100 90 79
4h p-ClBn 30 min 95 89 94
4i o-MeBn 30 min 100 100 67
4j tBuCH2 30 min 91 79 77
a 2-Naphthol derivative. bD-Val derivative.
Table 7. Multiple Species Liver and Intestinal S9 Data for Selected
Compounds with 60 min Incubations (% Remaining)
ProTide S9% remaining human dog monkey rat
2a liver ( 20/40 67/85 ND ND
intestine ( 60/63 50/54 ND ND
2d liver ( 27/41 81/91 0/86 25/28
intestine ( 65/85 66/68 48/87 77/76
2e liver ( 16/50 53/80 ND ND
intestine ( 42/48 82/100 ND ND
2h liver ( 7/59 49/87 16/88 5/31
intestine ( 28/49 42/56 20/68 57/86
2i liver ( 27/41a 16/53 0/32a 0/0a
intestine ( 0/49a 8/29 0/30a 30/46a
2j liver ( 14/29 33/28 ND ND
intestine ( 24/33 23/27 ND ND
3a liver ( 0/78 56/75 0/77a 8/62
intestine ( 24/70 56/72 25/77a 65/81
3b liver ( 0/44a 14/48 ND ND
intestine ( 8/28a 12/33 ND ND
3c liver ( 3/14 27/40 ND ND
intestine ( 42/59 57/86 ND ND
3e liver ( 0/20a 4/15a ND ND
intestine ( 0/5a 0/0a ND ND
3f liver ( 29/83 64/84 0/89a 37/78
intestine ( 52/74 87/96 29/95 71/70
a Incubated for 30 min. (refers to with/without cofactor.
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rodent plasma stability, ProTides were not observed in sys-
temic circulation.
Table 8 reports the plasma levels of parent nucleoside (1c)
that result from a po dose of ProTide. Mice were orally dosed
at 50 mg/kg in an experimental formulation of 5% DMA,
20% Solutol HS 15, 20% PEG 400, 55% 50 mM sodium
acetate, pH 4.0. Plasma nucleoside levels were measured at
0.25, 0.5, 1, 2, 4, 6, and 24 h and are compared to the oral PK
of the parent nucleoside itself. The parent nucleoside (1c)
demonstrates only modest bioavailability from a 50 mg/kg
oral dose. However, the percent oral bioavailability, calcu-
lated from the po and iv (data not shown)DNAUCs values, is
quite high (F=85%). The dose normalized AUC (DNAUC)
for the nucleoside 1c is 411 ng 3 h/mL/mg/kg, which is higher
than theDNAUCs for anyof the different ProTides. It should
be noted that the oral doses of the different compounds were
not molar equivalent doses, so the reported values are not
exact comparisons. However, it is clear from the Table 8 data
that all the ProTides result in lower systemic exposure of
parent nucleoside. The ProTides all have nucleoside DNAUCs
that are all 5-10-fold lower than parent nucleoside. This is
consistent with the substantially lower nucleosideCmax values
that were also observed. It is considered possible that these
lower systemic exposures to the parent nucleoside may lead to
lower in vivo toxicity.
Comparing theProTides to eachother, the highest nucleoside
Cmax andDNAUCvalues belong to the L-alanine derivative 2n,
while the lowest come from the L-valine derivative 4c. The
selection of the ester group also makes a significant diffe-
rence in Cmax and DNAUC. For the two L-alanine derivatives
2h and 2n, the (S)-1-phenylethyl ester 2n resulted in a 5-fold
increase in Cmax and 2-fold increase in DNAUC over the
neopentyl ester 2h. A similar comparison in the L-valine series
is not possiblebecause the (S)-1-phenyl ethyl ester in the L-valine
series was inactive and not tested. Comparison of the neopentyl
esters in the L-alanine, and L-valine series shows a higher
nucleoside Cmax and DNAUC for the L-valine (4j) than the
L-alanine (2h). The benzyl ester derivatives 3a, 4f, 4g, 4h, and 4i,
were the most potent compounds in the L-valine series. These
compounds along with the primary alcohol ester 4j, produced
the highestCmax values for parent nucleoside. Interestingly, the
secondary alcohol derivative 4chas amuch lowerCmax andover
all nucleoside exposure than the other L-valine esters.
Although the very potent neopentyl L-alanine derivative 2h
showed low systemic levels of nucleoside, aswasdesired, because
of their inherent rodent plasma instability, the L-alanine
derivatives were not further studied in the mouse. Several of
the L-alanines were later studied in cynomolgous monkeys,
and their data will be reported elsewhere.
Although maintaining low systemic nucleoside levels is
desirable, it only makes sense if sufficient liver triphosphate
levels are achieved. Table 9 reports the 20-C-methyl guanosine
triphosphate levels in mouse liver. Liver levels were deter-
mined at0.25, 0.5, 1, 2,4, and 6h.For three compounds,1c, 4c,
and 4h, the 24 h liver levels were also measured. The NTP
DNAUC values were calculated based on actual values not
projections to 24 h. This results in significantly lower DNAUC
values for several of the compoundswith only 6 h data points.
Once again, these doses are nonequivalent on a molar basis,
and as a result the triphosphate levels of 1c are approximately
2-fold higher than if dosed at an equivalent level.
Asmentioned above, we have observed the nucleoside 1c to
have excellent oral bioavailabilty in the mouse (F=∼85%).
It is rapidly absorbed, and its metabolism in mouse liver is
modest, leading to similar exposure from an oral dose as from
an iv dose. On the other hand, oral bioavailability in the cyno-
molgus monkey is poor (F ∼ 10%, data not shown). Clearly,
there are major differences in how the mouse and nonhuman
primates absorb andmetabolize 20-C-methylguanosine and its
ProTides, and themousemaynot be anappropriatemodel for
studying 20-C-methylguanosine ProTide pharmacokinetics.
However, liver triphosphate levels canbemeasured in themouse
at multiple time points so very valuable data can be obtained.
The liver triphosphate levels from the parent nucleoside in
the mouse were substantially higher than those from the Pro-
Tides,mimicking the systemic nucleoside levels. Even accoun-
ting for dosing differences, and extrapolating out the 6 h
DNAUC values to 24 h, all ProTides provide 2-5-fold less
liver triphosphate, as measured by DNAUC, than does the
nucleoside itself.
However, in considering the ratio of the triphosphate
DNAUC to the nucleoside DNAUC, several ProTides have
similar, to perhaps better, ratios than the nucleoside 1c. The
ProTides2n,4a, and2chave triphosphateDNAUCtonucleo-
sideDNAUCratios of about 2, similar to1c. For the L-alanine
derivative 2h, or the L-valine derivative 3a, the DNAUCvalues
are calculated only using 6 h data. If the DNAUC values are
Table 8. Mouse Systemic Nucleoside Levels from 50 mg/kg PO Dose of ProTide
ProTide Cmax ng/mL Clast ng/mL (h) T1/2 h AUC0-t ng 3 h/mL AUC0-inf ng 3 h/mL DNAUC
1c 5203 22 (24 h) 5.4 20390 20567 411
2h 262 103 (6 h) 5.2 1008 1920 38
2n 1380 222 (6 h) 1.8 3722 4269 85
3a 504 130 (6 h) 2.3 1611 2012 40
4c 185 1.5 (24 h) 3.0 1664 1670 33
4f 518 202 (6 h) 3.5 1600 2447 49
4g 388 388 (6 h) 1650 >33
4h 339 43 (24 h) 6.9 3990 4420 88
4i 668 688 (6 h) >6 2590 52
4j 652 244 (6 h) 3.0 2269 >45
Table 9. Comparison of 20-C-Methyl Guanosine Triphosphate Liver










1c 3470 (2) 390 (24) 16510 36868 737
2h 370 (6) 370 (6) 1584 32
2n, no. 1 1950 (4) 1158 (6) 6980 140
2n no. 2 670 (4) 134 (16) 2596 5390 108
3a 512 (4) 470 (6) 1940 97
4c 275 (4) 74 (24) 815 3860 77
4f 290 (6) 290 (6) 880 18
4g 216 (6)
4h 225 (4) 166 (6) 920 18
4i 91 (6)
4j
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extrapolated out to 24 h, it is quite possible that the triphos-
phate to nucleoside ratio for these two compounds would be
better than that obtained for the nucleoside.
The best overall triphosphate exposure appears to come
from the (S)-1-phenyl ethyl ester of L-alanine phosphorami-
date (2n). This compound was examined in an additional
experiment out to 16 h. A certain amount of interexperiment
variation was observed due to the extreme difficulty of mea-
suring triphosphate levels in the liver. The DNAUC from the
second experiment was 140 ng 3 h/mL/mg/kg. Nucleoside sys-
temic exposure was also measured in the second experiment,
and the DNAUC for nucleoside was 71 ng 3 h/mL/mg/kg.
In summary of the mouse DMPK work, the ProTides
produce significantly lower liver triphosphate levels than the
parent nucleoside, however, several compounds could be
identified with improved ratios of liver triphosphate to sys-
temic nucleoside levels. Themouse is considered a nonoptimal
model for studying ProTides of 20-C-methyl guanosine be-
cause of the observed rapid breakdown of the ProTides in
the mouse and because of the good absorption and meta-
bolic stability of the resulting 20-C-methyl guanosine. How-
ever, very useful data were obtained comparing different
ProTides to each other and parent nucleoside. Further work
on ProTides and other pro-drugs of 20-C-methyl guanosine is
underway in the cynomolgus monkey, and will be reported
elsewhere.
Conclusions
We have reported herein an extensive ProTide study of
20-C-methylguanosine, with variations in the aryl, ester, and
amino acid region of the ProTide. In almost every case, the
ProTides are more active in the HCV replicon assay, than the
parent nucleoside, often by 10-30-fold. We have extensively
studied the compounds for stability in plasma from multiple
species and also in liver and intestinal preparations from seve-
ral species. A combination of ester and amino acid changes
gives rodent plasma-stable compounds. Several analogues
were further evaluated for oral PK in mouse and reveal rapid
uptake and metabolism to triphosphate in the liver. The data
are somewhat suggestive of liver targeting by these ProTides.
This, and their inherent potency and selectivity against HCV
in vitro, suggests that their continued preclinical evaluation is
warranted.
Experimental Section
General. Anhydrous solvents were purchased from Aldrich
and usedwithout further purification. All reactions were carried
out under an argon atmosphere. Reactions weremonitoredwith
analytical TLC on silica gel 60-F254 precoated aluminum plates
and visualized under UV (254 nm) and/or with 31P NMR
spectra. Column chromatography was performed on silica gel
(35-70 μM). Proton (1H), carbon (13C), and phosphorus (31P)
NMR spectra were recorded on a Bruker Avance 500 spectro-
meter at 25 !C. Spectra were autocalibrated to the deuterated
solvent peak and all 13CNMR, 31PNMRwere proton-decoupled.
Analytical and semipreparative HPLC were conducted by Varian
Prostar (LC Workstation-Varian prostar 335 LC detector) using
Varian Polaris C18-A (10 μM) as an analytic column andVarian
Polaris C18-A (10μM)as a semipreparative column; elutionwas
performed using a mobile phase consisting of water/acetonitrile
ingradient (system1,100/0 to0/100v/v in30min) orwater/methanol
(system 2, 100/0 to 0/100 v/v in 30 min). High resolution mass
spectra was performed as a service by Cardiff University, using
electrospray (ES). CHN microanalysis were performed as a
service by the School of Pharmacy at the University of London
and by MEDAC Ltd., Surrey. 20-C-Methyl guanosine 50-triphos-
phate was purchased from Carbosynth, Berkshire, UK.
Compound purity was assured by a combination of high field
multinuclear NMR (H,C,P) andHPLC. Purity by the latter was
always>95%with no detectable parent nucleoside, for all final
products.
Replicon Potency. Huh7 cells expressing the HCV genotype
1b bicistronic subgenomic relicon (Apath, LLC, Brooklyn, NY)
were seeded into white 96-well plates (Nunc/VWR) at a density
of 2 ! 104 cells/well in medium without G-418. A Stacker
multidrop liquid dispenser (MTX Lab Systems, Vienna, VA)
was employed to ensure uniform and fast cell seeding into
multiple plates. Then 18-24 h after cell plating, inhibitors were
added and cells were incubated for additional 48 h. Compounds
were tested in triplicates and quadruplicates at 3! or 4! serial
dilutions over a range of 0.0001-10 μM concentrations. HCV
replication wasmonitored byRenilla luciferase reporter activity
assay using Renilla luciferase reporter (Promega,Madison,WI)
and a Veritas luminometer (Turner Biosystems, Sunnyvale,
CA). Then 50% inhibitory concentration (EC50) values were
calculated as the concentration of compound that results in 50%
decrease in the reporter expression as compared to untreated
cells. The values were determined by nonlinear regression (four-
parameter sigmoidal curve fitting) analysis. For any one IC50
determination, the replicon assay was run in triplicate and stan-
dard deviation was calculated from the three repeats and this
standard deviation is usually less than 20%of the IC50.A second
standard deviation is determined when multiple IC50s are
obtained from different batches of replicon cells. When more
than three independent IC50 values have been obtained, this
second standard deviation is calculated. Because of the diffe-
rences in the different batches of replicon cells, this standard
deviation is often ca. 100% of the IC50.
Cytotoxicity Assays. The same cells used in the replicon assay
were seeded into 96-well plates at a density of 2 ! 104 cells per
well. Twenty-four h after cell plating, 11 serial 2! compound
dilutions, starting with 100 μM, were applied to the testing
plates (three repeats per compound dilution). Each testing plate
was run with a “no-compound” control. Incubation with com-
pounds was continued at 37 !C in a CO2 incubator for 72 h. The
cells were in log phase of growth throughout the cell cytotoxicity
experiments. To determine cell viability, the CellTiter-Glo assay
(Promega, Madison, WI) was performed according to the manu-
facturer’s protocol. The compound concentration resulting in
50% luminescent signal was reported as theCC50 concentration.
Plasma Stability. Stability experiments were performed in
duplicate using human, cynomolgus monkey, canine, rat, and
mouse plasma (Bioreclamation, Inc., Long island, NY). Pro-
Tides were added to a final concentration of 1 μg/mL in 1 mL of
plasma preincubated at 2-4 !C. The reaction mixture was
maintained at 2-4 !C, and 50 μL samples were taken at 30 or
240 min of incubation and transferred to a 96-well V-bottom
plate. Then 200 μL of ice cold acetonitrile was added to each
sample. The precipitated samples were centrifuged at 2500 rpm,
4 !C, for 20 min in a Sorvall RT6000S centrifuge (Thermo
Scientific, WalthamMA). Then 50 μL of supernatant from each
sample was transferred to a 96-deep well plate followed by the
addition of 50 μLofH2O to each sample. Samples were covered,
mixed well by vortexing, and maintained at 2-8 !C before and
during analysis. Fifteen μL of each test sample was analyzed for
compound concentrations by LC-MS/MS. Liquid chromatog-
raphy was performed with an Agilent 1100 series HPLC system
equipped with a Synergi 4 μm Polar-RP, 30 mm ! 2.0 mm
column (Phenomenex, Torrance, CA). Linear gradient (100%
mobile phaseA (H2Oþ 0.1%HCOOH) to 100%B (acetonitrile
þ 0.1% HCOOH) over 3 min, flow rate 1.0 mL/min) was used
for the analyte elution. The HPLC system was coupled to an
API 4000 triple quadrupole mass spectrometer (Applied Bio-
systems, Framingham, MA). Mass spectrometry analysis was
performed in positive ion mode (MHþ 659.2, transition 166.1).
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Data was analyzed using Analyst v1.4.2 software (Applied
Biosystems, Framingham, MA), Microsoft Office Excel 2007,
and GraphPad Prism 5 (GraphPad Software, La Jolla, CA
S9Clearance Assay.All liver and intestinal S9 tissue fractions
were purchased fromXenotech (Lenexa,KS) and stored at-80 !C
until time of use. NRS (NADPH-Regenerating System) was
purchased from BD Gentest (BD Biosciences, San Jose, CA)
and was used as cofactor. Reagents including NRS components
and liver or intestinal S9 tissue fractions were thawed and
immediately placed on ice. S9 fractions, 50 mM potassium
phosphate buffer with or without NRS were placed in wells of
a 96-well deep-well plate for final concentrations of 1mg/mLS9,
1.3 mM NADP, 3.3 mM glucose-6-phosphate, 0.4 U/mL glu-
cose-6-phosphate dehydrogenase, and 3.3 mM magnesium
chloride. The plate was preincubated in an orbital shaker at 37 !C
for 10 min. The reaction was then initiated by addition of com-
pound at a final concentration of 10 μM. The suspensions were
thoroughly mixed by pipetting and an initial sample was with-
drawn and added to equal volume of cold acetonitrile (for a
calculation of starting concentration). The plate was placed
back in the 37 !C shaker, and at 60min a sample was withdrawn
and added to equal volume cold acetonitrile. Following quench-
ing by acetonitrile, samples were kept on ice and precipitate
was pelleted in all samples by centrifugation at 3000 rpm for
15 min. Supernatant was removed and transferred to vials for
HPLC analysis.
Pharmacokinetic Studies. Compounds were formulated in
5% dimethylacetamide, 20% Solutol HS15, 20% polyethylene
glycol 400, 55% 50 mM sodium acetate, (pH 4) (D/S/P) and
administered by oral gavage to female ICR mice (Taconic
Farms, Germantown, NY). Blood and tissue collections were
performed at various time points as terminal procedures. Blood
was collected into EDTA containing tubes (1.6 mg EDTA/mL
blood, Sarstedt, Inc., Newton, NC), and the plasma was sepa-
rated by centrifugation within 30 min of collection. Liver sam-
ples were immediately frozen upon collection in liquid nitrogen.
Plasma and liver samples were stored frozen at e -80 !C prior
to analysis.
Measurement of Plasma Nucleoside Concentrations. Plasma
samples were prepared for analysis as follows. First, 400 μL of
50 mM ammonium acetate was added to 100 μL of each plasma
sample. Calibration curves were prepared by serial dilution of a
stock solution of 20-C-methyl guanosine (1c) into control plas-
ma. Solid phase extraction of the samples was performed with
H2O-Philic speeddisk columns (J.T. Baker) which were pre-
viously solvated with 1 mL of methanol followed by equilibra-
tion with 1mL of 50mMammonium acetate. The columns were
rinsed with 1 mL of 50 mM ammonium acetate:methanol (95:5,
v/v), and samples were eluted with 1 mL of methanol:ammo-
nium hydroxide (95:5, v/v). The samples were dried under
nitrogen and reconstituted in 80 μL of H2O. A volume of 10 μL
of each test sample was analyzed for 20-C-methyl guanosine (1c)
concentrations by liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS). Liquid chromatography was
performed with an Agilent 1100 series HPLC system equipped
with aBetasil 2.1mm! 100mm5 μmcolumn (ThermoScientific).
Mass spectrometry analysis was in positive ion mode as des-
cribed above.
Measurement of Liver Triphosphate Concentrations. Liver
samples were snap-frozen in liquid nitrogen and pulverized with
a steel mortar and pestle on dry ice with liquid nitrogen. Frozen,
pulverized tissue sampleswereweighed and 5 equiv of 70%metha-
nol containing 50 mM thenoyltrifluoroacetone was added.
Samples were then homogenized twice in a bead mill (FastPrep
Homogenizer) using Silicone-Carbide Sharp Particles (BioSpec
Products, Inc., Bartlesville, OK) at 4 !C at an agitating speed of
6 for 30 s. The homogenates were centrifuged at 15000 rpm for
30 min at 4 !C. The supernatants were collected and dried in
Masterblock polypropylene deep-well plates (SPEware Corp.,
Baldwin Park, CA) under a stream of nitrogen. The dried extracts
were reconstituted with 100 μL of 10 mM N,N-dimethylhexyl-
amine, 3 mM ammonium formate in H2O, vortexed, and cen-
trifuged at 3500 rpm for 30 min at 4 !C. Calibration curves were
constructed by spiking varying concentrations of 20-C-methyl
guanosine 50-triphosphate (Carbosynth, Berkshire, UK) into
control liver samples prior to homogenization. Fifteen μL of each
test sample was analyzed for 20-C-methyl guanosine 50-triphos-
phate concentrations by liquid chromatography coupled to
tandem mass spectrometry (LC-MS/MS). Reverse phase liquid
chromatography was performed with an Agilent 1100 series
HPLC system equipped with an. XTerra MS C18, 3.5 μM,
2.1 mm ! 50 mm Column (Waters, Milford, MA). Mass spec-
trometry analysis was performed in negative ion mode and data
were analyzed as above. The levels (peak areas) of endogenous
adenosine 50-triphosphate and guanosine 50-triphosphate were
also monitored as internal quality controls for the liver samples.
Pharmacokinetic Analysis. Plasma and liver concentration
data was analyzed for standard pharmacokinetic parameters
using Win-Nonlin v5.2 software (Pharsight, St. Louis, MO).
Standard Procedure A: ProTide Synthesis. To the 20,30-O,O-
isopropylidene-20-C-β-methylguanosine (1 equiv) in anhydrous
THF (6 mL/g of nucleoside) was added dropwise a solution of
tBuMgCl in THF (1M, 2 equiv). After stirring for 20 min, a
solution of the phosphorochloridate (2 equiv) in anhydrous
THF (6 mL/g of phosphorochloridate) was slowly added. The
resulting solution was stirred overnight at room temperature,
then the solvent was removed under reduced pressure. The resul-
ting foamy residue was purified by silica gel column chromato-
graphy (eluent: CHCl3/MeOH 92:8, v/v) to afford the pure
protected ProTide.
Standard Procedure B: ProTide Deprotection. A solution of
the protected ProTide in a 60% acetic acid in water solution
(∼10 mL/200 mg of protected protide) was stirred at 95 !C
overnight. The solvent was then removed under reduced pres-
sure to dryness (can also be coevaporatedwith hexane or toluene
to remove traces of AcOH), and the resulting residue was puri-
fied by silica gel column chromatography (eluent: CHCl3/MeOH
9:1, v/v) to give after lyophilization the pure ProTide.
Example: Synthesis of 20-C-Methylguanosine-50-O-[naphthyl-
(methyloxy-L-alaninyl)]phosphate (2a). Step 1: Synthesis of the
protected ProTide
Prepared using standard procedure A. Starting from 181 mg of
protected nucleoside. Yield: 37%.
31P NMR (202 MHz, CD3OD) δ 4.49, 4.40.
1H NMR (500
MHz, CD3OD) δ 8.17 (2d, J=8.0, 1H, H8-napht), 7.85 (m, 2H,
H5-napht and H8), 7.70 (m, 1H, H4-napht), 7.58-7.48 (m, 3H,
H7,H6,H2-napht), 7.42 (m, 1H,H3-napht), 6.08 and 6.07 (s, 1H,
H10), 4.62-4.54 (m, 2H,H30 andH50), 4.48-4.36 (m, 2H,H40 and
H50 0), 4.09 (m, 1H,HR), 3.61 (s, 3H,CH3 ester), 1.59 and 1.57 (2s,
3H, CH3 isopropylidene), 1.36 (m, 6H, CH3 isopropylidene and
CH3 Ala), 1.03 and 1.00 (s, 3H, 2
0-CH3).
Step 2: Deprotection of the ProTide
Prepared using standard procedure B. Starting from 70.5 mg.
Yield: 45% (30 mg).
31P NMR (202 MHz, CD3OD) δ 4.36, 4.27.
1H NMR (500
MHz, CD3OD) δ 8.18 (m, 1H, H8-napht), 7.93-7.83 (m, 2H,
H5-napht and H8), 7.69 (m, 1H, H4-napht), 7.56-7.49 (m, 3H,
H7, H6, H2-napht), 7.40 (m, 1H, H3-napht), 5.94 (s, 1H, H10),
4.57 (m, 2H, H50 and H50 0), 4.29-4.23 (m, 2H, H40 and H30),
4.10-3.98 (m, 1H, HR), 3.56 and 3.55 (2s, 3H, CH3 ester), 1.30
(m, 3H,CH3Ala), 1.01 and 0.99 (2s, 3H, 2
0-CH3).HPLC, system
1, RT 13.00, 13.43 min.
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a b s t r a c t
We herein report a novel double pro-drug approach applied to the anti-HCV agent 20-b-C-methyl guano-
sine. A phosphoramidate ProTide motif and a 6-O-methoxy base pro-drug moiety are combined to gen-
erate lipophilic prodrugs of the monophosphate of the guanine nucleoside. Modification of the ester and
amino acid moieties lead to a compound INX-08189 that exhibits 10 nM potency in the HCV genotype 1b
subgenomic replicon, thus being 500 times more potent than the parent nucleoside. The potency of the
lead compound INX-08189 was shown to be consistent with intracellular 20-C-methyl guanosine triphos-
phate levels in primary human hepatocytes. The separated diastereomers of INX-08189 were shown to
have similar activity in the replicon assay and were also shown to be similar substrates for enzyme pro-
cessing. INX-08189 has completed investigational new drug enabling studies and has been progressed
into human clinical trials for the treatment of chronic HCV infection.
! 2010 Elsevier Ltd. All rights reserved.
Over 180 million people are chronically infected with hepatitis
C virus (HCV) and at risk of developing life threatening liver dis-
ease.1 The current therapy consists of pegylated interferon and
ribavirin.2 Neither agent is specific for HCV, side effects are com-
mon, and efficacy is limited in certain genotypes.2 As with antivi-
rals in general, nucleoside analogues are amongst the leading
classes of compounds being developed as new agents for the treat-
ment of HCV infection. Several 20-C-ribonucleoside analogues,
including 20-C-methyladenosine and 20-C-methyl guanosine, (1)
have been shown to possess activity against HCV in the replicon as-
say as well as antiviral activity against several members of the Fla-
vivirus family3,4 20-C-methyl guanosine was evaluated further in a
series of nonclinical studies, which indicated the absence of detect-
able cytotoxicity, potent inhibition of the HCV RNA-dependent
RNA polymerase as its triphosphate, and oral bioavailability in rats
of 82%.5,10 Unfortunately, its potential as a therapeutically useful
nucleoside was limited due to low oral bioavailability in non-ro-
dent species, inefficient cellular uptake and poor intracellular
metabolism of 20-C-methyl guanosine to its active triphosphate
form.5 We have previously reported the application of our ProTide,
phosphoramidate pro-drug approach6 to 20-C-methyl guanosine
(1) to overcome these limitations.7,8 In this publication we describe
a series of novel double pro-drugs of 20-C-methyl guanosine for
HCV therapy.
The HCV antiviral activities of our phosphoramidates were eval-
uated against HCV genotype 1b, in a Huh7 cell line expressing a
stable, bicistronic subgenomic replicon encoding the Renilla lucif-
erase reporter gene.9 HCV replication in this cell line was moni-
tored by measuring the luminescence produced by luciferase
activity. From the initial series of compounds, the naphthyl benzyl-
alanine phosphoramidate of (1), in the assay described above, is ac-
tive at 0.062 lM, being ca. 16 times more active than (1) which has
an EC50 of 1.0 lM. However, subsequent work to address the ro-
dent plasma instability of these compounds lead to L-valine phos-
phoramidate derivatives of (1) such as the naphthyl benzyl L-valine
phosphoramidate, which demonstrated much improved rodent
plasma stability.8 Unfortunately, with the improved rodent plasma
stability of the branched amino acids, came a significant decrease
in HCV replicon activity. Extensive modification of the ester func-
tionality did not improve HCV potency significantly.8 We then
turned to modifications of the purine base as a means of
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potentially affecting potency without changing the inherent plas-
ma stability of the L-valine phosphoramidates. Modifications were
made at the C-6 and C-2 positions using an HCV polymerase model
as a guide.10 SAR development is underway at the C-2 position and
will be discussed elsewhere. We considered whether simple C-6
modifications could maintain binding of the corresponding tri-
phosphate to HCV RNA polymerase, and in particular, whether a
6-O-methoxy substituent as in 2 could be tolerated in the model.
It was considered that the likely increase in lipophilicity of (2)
could enhance the poor cell uptake of (1).
To test this, an HCV polymerase model was built according to the
literature10 and docking studies with the phosphorylated forms of
various C-6 substituted derivatives were performed. These studies
showed that the triphosphate of nucleoside 2, docks only poorly
into the NS5b active site, suggesting that it would be a poor inhib-
itor of the NS5B polymerase.11 The replicon activity of 6-O-methyl-
20-C-methyl guanosine (2) was determined and is reported, for the
first time, in Table 1 along with the modelling results and replicon
activity of a number of other C-6 substituted analogues. The modest
replicon activity observed for these derivatives may be ascribed to
their slow intracellular conversion to 20-C-methyl guanosine by
deaminase activity, which might be at the nucleoside level (e.g.,









Compounds in Table 1 were synthesized from the C-6 chloro 2-
amino 20-C-methyl purine riboside, and phosphoramidate deriva-
tives were made of each. Full details of this work will be reported
elsewhere.
In spite of the reduced replicon activity of 6-O-methyl-20-C-
methyl guanosine, and the prediction from the modelling that
the corresponding triphosphate would be inactive, we sought to
prepare a series of ProTides of (2) to investigate the effect of the
phosphorylation by-pass strategy on the replicon activity of this
modified purine. The hope was that phosphoramidates of 2 would
show improved cellular uptake, and would be metabolically con-
verted to the active 20-C-methyl guanosine triphosphate.13
Target compound (2) was prepared in an overall yield of 60% via
the 6-chloro nucleoside generated by the TMS triflate mediated
condensation of the tetrabenzoyl 2-C-methyl sugar and chloro base
(Fig. 1).
Compound (2) was converted to 50-ProTides following our
established methods.14 In brief, 1-naphthol and POCl3 were reacted
to generate the naphthyloxy phosphorodichloridate and this was
allowed to react with various amino acid ester salts to generate
the phosphorochloridates (3) as key synthons. As shown in Figure 2,
reaction of (3) with nucleoside (2) in THF in the presence of N-
methyl imidazole gave the target compounds (4a–m) in moderate
yield. Notably, use of the 6-O-methylated nucleoside as opposed to
the guanine nucleoside, allows coupling with the chlorophosph-
oramidate to proceed without prior protection of the nucleoside
sugar hydroxyl groups, saving a deprotection step in the linear syn-
thetic sequence and saving two steps in the overall synthesis.
Compounds (4) were purified by flash column chromatography
and HPLC as necessary. They were routinely isolated as roughly 1:1
mixtures of phosphate diastereoisomers as evidenced by splitting
of HPLC peaks and 31P NMR signals. Compounds were tested as
mixtures of diastereomers in the first instance. 13C NMR and mass
spectrometry data also confirmed the structure and purity of (4a–
m).15 Compounds (4a–h), being the alanine series, were evaluated
versus HCV in replicon assay, with data shown in Table 2.
Thus, in general the data in Table 2 show a significant increase in
the cell based potency from this family of ProTides, in comparison to
the parent nucleoside (2). Themost active ester is the neopentyl (4g)
with EC50 of 0.01 lM and EC90 of 0.04 lM. This is ca. 500–550-fold
more active than the parent nucleoside (2). Notably, comparing
the Ala benzyl ester ProTide of (2), compound4a, with its equivalent
ProTideof theguanineparent (1)7 showsa ca. fourfoldpotencyboost
for the6-methoxyanalogue. In part, thismaybedue to theenhanced
lipophilicity and consequent cellular uptake for 4a; calculated
C log P values are 3.1 and 1.9, respectively. Themuch reduced activ-
ity of the isopropyl ester derivative (4c) highlights the importance of
synthesizing multiple phosphoramidate derivatives.
Given the high potency of the neopentyl ester 4g of the 6-meth-
oxy nucleoside 2, we also prepared the equivalent ProTide of 1. The
data on this compound, 5 are presented alongside 4g in Table 3.
Thus, the 6-methoxy analogue shows a calculated lipophilicity
some 100 times that of the guanine parent. This translates into a
P5-fold enhancement in membrane transport as measured by
Caco-2 permeation and a >5-fold boost in HCV potency. This sup-
ports the idea that phosphoramidates of 2 have improved cellular
uptake over phosphoramidates of 1.
To pursue this family of phosphoramidates further, we em-
barked on selective amino acid variation, while retaining the neo-
pentyl ester of the lead (4g). Data are shown in Table 4.
From the data in Table 4, it is clear that L-Ala (4g) is strongly
(24!) preferred over D-Ala (4i). This highlights the importance of
intracellular metabolism in the activity of these phosphoramidates
because both have very similar C log P values. Increasing the over-
all size of the amino acid side chain as for the L-Met (4j) and L-Leu
(4k) derivatives decreases HCV activity somewhat, but the most
dramatic decrease in activity comes with branching at the amino
acid beta carbon as in L-Ile (4l) and L-Val (4m). Overall, the 6-O-
methyl modification consistently improves the HCV replicon activ-
ity relative to the guanine derivatives for the different amino acid
derivatives in Table 4. For example, the corresponding guanine ver-
sion of the L-Val derivative, 4m, is 10-fold less active (EC50 = 1.5
lM) in the replicon assay than is the 6-O-methyl L-Val derivative.8
From this survey of amino acid and ester variations, the neopen-
tyl alanine ProTide (4g) emerged as one of themore interesting com-
pounds. To further characterize 4g as a lead compound and to more
fully define its potency, it was repeated multiple times in the HCV
replicon assay. As shown in Figure 3, replicate assays revealed a
Table 1
Comparison of modelling predictions of the nucleoside triphosphate and HCV replicon
activity of C-6 substituted derivatives of 20-C-methyl guanosine
R Modelling prediction Replicon activity (lM)
OH Good binding 1
OCH3 Poor binding 5
OEt Poor binding 9
SMe Poor binding 11
NHMe Poor binding 13
NHBn Poor binding 27
Cl Poor binding 8
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highly potent inhibitor of HCV replicationwith EC50 and EC90 values
ranging from 0.003–0.024 lM (mean = 0.01 lM) and 0.019–
0.095 lM (mean = 0.04 lM), respectively. These data confirm 4g as
Figure 1. Synthesis of 6-OMe nucleoside (2)
Figure 2. Synthesis of ProTides of (2).
Table 2
Anti-HCV activity (EC50, EC90) and cell cytotoxicity (CC50) of alanine ProTides of (2)
Compd R Genotype 1b replicon Huh7 CC50 (lM)
EC50 (lM) EC90 (lM)
4a Bn 0.03 0.10 12
4b n-Pr 0.03 0.10 13
4c i-Pr 0.54 1.70 >100
4d cHex 0.03 0.09 6
4e cPnt 0.03 0.08 9
4f S-PhEt 0.04 0.13 14
4g t-BuCH2 0.01 0.04 7
4h t-BuCH2CH2 0.02 0.08 14
2 — 5.2 21 >100
Table 3
Anti-HCV activity, cytotoxicity, calculated lipophilicity and observed Caco-2 perme-
ation for 4a and 5
Compd Replicon CC50 (lM) C log Pa Caco-2%b
EC50 (lM) EC90 (lM)
4g 0.010 0.038 7 3.3 2.7
5 0.072 0.27 >100 1.3 <0.5
a log P from Chemdraw Ultra 11.0.1.
b % Transport in 80 min across Caco-2 cells grown for 27 days (resistance 600
ohms/cm2), measured apical to basal. Permeability measured for 4a = 4.02 ± 0.1 !
10"6 cm/s.
Table 4
Anti HCV activity (EC50, EC90) and cell cytotoxicity (CC50) of ProTides of (2) with
amino acid variations
Compd AA Genotype 1b replicon Huh7 CC50 (lM)
EC50 (lM) EC90 (lM)
4g L-Ala 0.01 0.04 7
4i D-Ala 0.24 0.58 51
4j L-Met 0.06 0.19 28
4k L-Leu 0.07 0.23 14
4l L-Ile 0.86 2.53 18
4m Val 0.19 0.64 33
2 — 5.71 24.57 >100
Figure 3. Potency of 4g in the HCV genotype 1b replicon assay. Data represent 16
replicates.
Figure 4. Conversion of 2 lM Phosphoramidate 4g and 1 into 20-C-methyl
guanosine triphosphate in primary human hepatocytes. EC90 line is defined as the
amount of intra cellular triphosphate necessary to achieve 90% inhibition in the
HCV replicon assay.
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the most potent nucleoside analogue based inhibitor of the HCV
NS5b RNA dependent RNA polymerase reported to date. In addition,
4ghasalsobeen testedagainstHCVgenotypes1aand2andshownto
be very active, 12 and 1 nM, respectively.
To confirm that the phosphoramidate, 4g, was being converted
to the known HCV NS5b enzyme inhibitor 20-C-methyl guanosine
triphosphate, 4g was incubated in primary human hepatocytes at
an arbitrary concentration of 2 lM, and triphosphate levels were
measured over a period of 48 h. In addition, the triphosphate levels
resulting from incubation with 2 lM 20-C-methyl guanosine were
also measured (Fig. 4).
The data indicates that 4g produces a substantial Cmax of 20-C-
methyl guanosine triphosphate of 80 pmol/106 cells within the
first 8 h, then decays with a half-life estimated to be over 24 h.
The triphosphate of 6-O-methyl-20-C-methyl guanosine (2) was
synthesized (CarboSynth, Inc.), and used as an analytical standard,
but none of this triphosphate was detected in multiple experi-
ments. The nucleoside (1), on the other hand, slowly builds to a
much delayed and lower Cmax at 32 h compared to 4g, consistent
with its modest activity. Further work to understand the metabo-
lism of the 6-O-methyl-20-C-methyl guanosine phosphoramidates
is underway and will be discussed in later publications. Similar
to for the anti-leukaemic agent nelarabine,13 it appears that a 6-
methoxy base group is a good pro-drug for a guanine nucleoside
analogue, but here at the monophosphate metabolic level, possibly
utilizing adenylate deaminase (EC 3.5.4.6) or some other cellular
Table 5
Data on separated diasteromers of 4g
Inx Chirality Peak Replicon EC50 (lM) dp T½a (min)
4g–1 Sp 1st 0.044 4.28 (D) 20
4g–2 Rp 2nd 0.019 4.23 (E) 17
a Half-life in carboxypeptidase assay—see Figure 5.
Figure 5. CPY assay on separated isomers of 4g. Upper isomer 4g–1, lower isomer 4g–2. Conditions: 5 mg of compound in 200 ll of acetone + 400 ll of Trizma buffer
0.3–0.5 mg of carboxypeptidase A (purchased from SIGMA) in 200 ll of Trizma buffer.
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deaminase16 These data, together with the potent HCV replicon
inhibition data, demonstrate that 4g can be metabolised rapidly
in vitro to the active 20-C-methyl guanosine triphosphate; a direct
inhibitor of the HCV RNA dependent RNA polymerase NS5b.
Given the considerable interest in 4g, the two diastereoisomers
were separated on a preparative scale using a Chiral Pak AD chiral
chromatography column with 1:1 ethanol/hexane as eluant (Chiral
Technologies, West Chester, PA). The absolute configuration of
each of the two diastereomers was determined by Vibrational Cir-
cular Dichroism (VCD) (BioTools, Inc., Jupiter, FL). Replicon data on
the separate isomers are given in Table 5.
Interestingly the HCV replicon activities of the two separated
diastereomers are within twofold, suggesting that the initial cleav-
age of the amino acid ester and subsequent elimination of the
naphthol, to give the common amino acid monophosphate metab-
olite, happens at similar rates. A Carboxypeptidase A assay has
proved a useful in vitro model of the initial metabolism of such
ProTides.7 Thus, we carried out such an assay on the separated iso-
mers of 4g. The data shown in Figure 5 is a series of 31P NMRs taken
over a 3.5 h incubation of each diastereomer (10 mM) with Car-
boxypeptidase A in Trizma buffer.
The 31P NMR traces show the parent phosphoramidate near
4.2 ppm at time zero, is rapidly cleaved by Carboxypeptidase A to
the free amino acid carboxylate (peak 2/20) with a 31P NMR shift
near 5 ppm, and then to the aminoacyl phosphate intermediate
(peak 3/30) with a 31P NMR shift near 7.0 ppm. The formation of
this intermediate is considered essential for the activity of Pro-
Tides.6,7 Consistent with the replicon assay data, the estimated
T1/2 values of 4g–1 and 4g–2 are similar, 20 and 17 min, respec-
tively. Further work is underway on 4g–1 and 4g–2 that may dis-
tinguish the two diastereomers, and will be reported elsewhere.
Based on the exceptional HCV antiviral activity of 4g (INX-
08189), along with other advantageous properties, such as cell per-
meability, ease of synthesis, and bioavailability, it was advanced
into in vivo studies supporting its selection as a clinical candidate
for HCV. Full details on the DMPK studies used to support the
selection of 4g will be reported elsewhere. The agent has now pro-
gressed into human clinical trials for HCV.
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was added dropwise. The reaction mixture was heated at 65 !C for 4–6 h,
allowed to cool down to room temperature, poured into saturated aqueous
sodium bicarbonate (300 ml), and extracted with dichloromethane
(3 ! 150 ml). The combined organic phase was dried over sodium sulfate and
evaporated under reduced pressure. The residue was precipitated from
dichloromethane and methanol. Precipitate was filtered and washed with
methanol, to give the desired compound (8.5 g, 79%) as a white solid. 1H NMR
(500 MHz, CDCl3) d 8.13 (dd, J = 1.2, 8.3, 2H), 8.02–7.94 (m, 5H), 7.65–7.60 (m,
1H), 7.58–7.45 (m, 4H), 7.35 (q, J = 7.7, 4H), 6.65 (s, 1H), 6.40 (d, J = 6.7, 1H),
5.31 (s, 2H), 5.08 (dd, J = 4.2, 11.6, 1H), 4.79 (dd, J = 6.4, 11.6, 1H), 4.74 (td,
J = 4.2, 6.5, 1H), 1.60 (s, 3H). 13C NMR (126 MHz, CDCl3) d 166.31 (C@O), 165.38
(C@O), 165.32 (C@O), 159.13 (C2), 152.87 (C6), 152.06 (C4), 141.42 (C8),
133.77 (C–H Bn), 133.69 (C–H Bn), 133.28 (C–H Bn), 129.90 (C–H Bn), 129.82
(C–H Bn), 129.78 (C Bn), 129.70 (C–H Bn), 129.41 (C Bn), 128.78 (C Bn), 128.61
(C–H Bn), 128.50 (C–H Bn), 128.41 (C–H Bn), 126.00 (C5), 88.84 (C10), 85.68
(C20), 79.43 (C40), 76.07 (C30), 63.57 (C50), 17.77 (20-Me).
Synthesis of 2-amino-6-methoxy-9-(2-C-methyl-b-D-ribofuranosyl) purine
To a suspension of 2-amino-6-chloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-b-D-
ribofuranosyl)purine (3.0 g, 4.78 mmol) in anhydrous methanol (36 ml) at 0 !C
NaOMe in methanol (5.4 ml, 25% w/w) was added. The mixture was stirred at
room temperature for 24 h then quenched by addition of amberlite (H+). The
mixture was then filtrated and solvent was removed under reduced pressure.
The resultant residue was dissolved in water (50 ml) and extracted with
hexane (50 ml). The organic layer was then extracted with water (50 ml), and
the combined water fractions were concentrated under reduced pressure. The
residue was purified by silica gel chromatography (CHCl3/MeOH 85:15) to give
the pure compound (1.125 g, 76%) as a white solid. 1H NMR (500 MHz, MeOD)
d 8.26 (s, 1H, H8), 5.99 (s, 1H), 4.24 (d, J = 9.1, 1H), 4.08 (s, 3H), 4.04 (ddd, J = 2.3,
5.7, 8.6, 2H), 3.87 (dd, J = 3.0, 12.4, 1H), 0.96 (s, 3H). 13C NMR (126 MHz, MeOD)
d 162.75 (C6), 161.86 (C2), 154.50 (C4), 139.35 (C8), 115.36 (C5), 93.00 (C10),
84.15 (C40), 80.34 (C20), 73.57 (C30), 61.17 (C50), 54.25 (6-OMe), 20.35 (20-Me).
HPLC: tR = 9.00 min. (solvent gradient needed O?100% ACN in H2O 30 mins).
HRMS (ESI): calcd for C12H17N5O5+Na+ 334.1127, found 334.1125. Calcd for
C12H17N5O5"0.75 H2O: C, 44.37; H, 5.74; N, 21.56. Found: C, 44.24; H, 5.49; N,
20.83.
Synthesis of 2-amino-6-methoxy-9-(2-C-methyl-b-D-ribofuranosyl) purine 50-O-
[a-naphthyl-(2,2-dimethylpropoxy-L-alaninyl)] phosphate 4g
To 2-amino-6-methoxy-9-(2-C-methyl-b-D-ribofuranosyl) purine (1.35 g,
4.34 mmol) in THF (35 ml), phosphorochloridate (10.83 mmol, 1 M solution
in THF)) in THF was added, followed by addition of N-methyl-imidazole
(1.71 ml, 21.7 mmol). The mixture was stirred overnight and the solvent was
removed under reduced pressure. To remove the N-methyl-imidazole, the
phosphoramidate was dissolved in chloroform and washed 3 times with
hydrochloric acid (HCl 0.5 N). The organic layer was then dried over sodium
sulfate and evaporated under reduce pressure. The residue was then purified
on silica gel using CHCl3 to CHCl3/MeOH 95:5 as an eluent, to give the pure
phosphoramidate as a white solid (510 mg, 18%). 31P NMR (202 MHz, CDCl3) d
4.33, 4.29. 1H NMR (500 MHz, MeOD) d 8.19–8.15 (m, 1H, H8-naph), 7.98, 7.96
(2 ! s, 1H, H8), 7.86–7.82 (m, 1H, H5-napht), 7.68, 7.65 (2 ! d, J= 7.0 Hz, 1H, H4-
napht), 7.53–7.44 (m, 3H, H2, H7, H6-napht), 7.39, 7.37 (2 ! t, J= 8.0 Hz, 1H, H3-
napht), 6.01, 6.00 (2 ! s, 1H, H10), 4.67–4.64 (m, 1H, H50), 4.63- 4.59 (m, 1H, H30 ,
H40), 4.09–4.05 (m, 1H, Ha), 4.04 (s, 3H, 6OCH3), 3.75, 3.72, 3.64, 3.58 (2 ! AB,
JAB = 10.5 Hz, 2H, CH2 ester), 1.33 (d, J = 7.5 Hz, 3H, CH3 Ala), 0.98, 0.96 (2 ! s,
3H, 20CCH3), 0.85, 0.84 (2 ! s, 9H, 3 ! CH3 ester). 13C NMR (126 MHz, MeOD) d
175.06, 174.80 (2 ! d, 3JC–C–N–P = 5.0 Hz, C@O ester), 162.73 (C6), 161.86 (C2),
154.55, 154.51 (C4), 148.00, 147.95 (d, 2JC–O–P = 3.8 Hz, ipso naph), 139.36,
139.08 (CH8), 136.27, 136.25 (C10-naph), 128.86, 128.80 (CH-naph), 127.88,
127.73 (2 ! d, 3JC–C–O–P = 6.3 Hz, C9-naph), 127.48, 126.53, 126.49, 125.97,
122.81, 122.76 (CH-naph), 116.24, 116.22 (C2-naph), 116.19, 115.63 (C5),
93.34, 93.18 (C10), 82.32, 82.16 (2 ! d, 3JC–C–O–P = 8.8 Hz, C40), 79.99, 79.95
(C20), 75.52, 75.37 (CH2 ester), 74.95, 74.70 (C30), 68.11, 67.62 (2 ! d, 2JC–O–
P = 5.0 Hz, C50), 54.28, 54.07 (6OCH3)51.79, 51.71 (Ca Ala), 32.26, 32.22 (C
ester), 26.74, 26.71 (3 ! CH3 ester), 20.89, 20.69 (2 ! d, 3JC–C–N–P = 6.3 Hz, CH3
Ala), 20.39, 20.35 (20CCH3). HPLC Rt = 20.95, 21.48 min.
16. Faletto, M. B.; Miller, W. H.; Garvey, E. P.; St. Clair, M. H.; Daluge, S. M.; Good, S.
S. Antimicrobial Agents Chemother. 1997, 41, 1099.
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INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2!-C-Methyl
Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with
Excellent Pharmacokinetic and Pharmacodynamic Properties!
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INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2!-C-methyl guanosine. INX-08189 was highly potent
in replicon assays, with a 50% effective concentration of 10! 6 nM against hepatitis C genotype 1b at 72 h. The
inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC50) of 35 ! 8 nM at 24 h.
An intracellular 2!-C-methyl guanosine triphosphate (2!-C-MeGTP) concentration of 2.43 ! 0.42 pmol/106
cells was sufficient to achieve 90% inhibition of viral replication. In vitro resistance studies confirmed that the
S282T mutation in the NS5b gene conferred an approximately 10-fold reduction in sensitivity to INX-08189.
However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344 ! 170
nM. Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency
both in wild-type and S282T-expressing replicons. Genotype 1b replicons could be cleared after 14 days of
culture when exposed to as little as 20 nM INX-08189. No evidence of mitochondrial toxicity was observed after
14 days of INX-08189 exposure in both HepG2 and CEM human cell lines. In vivo studies of rats and
cynomolgus monkeys demonstrated that 2!-C-MeGTP concentrations in liver equivalent to the EC90 could be
attained after a single oral dose of INX-08189. Rat liver 2!-C-MeGTP concentrations were proportional to dose,
sustained for greater than 24 h, and correlated with plasma concentrations of the nucleoside metabolite
2!-C-methyl guanosine. The characteristics displayed by INX-08189 support its continued development as a
clinical candidate for the treatment of chronic HCV infection.
Hepatitis C virus (HCV) is one of the most important causes
of chronic liver disease worldwide (36). In the United States
alone, an estimated 3.9 million people are infected with HCV
(16), and an estimated 10,000 to 12,000 HCV-related deaths
occur annually (http://digestive.niddk.nih.gov/ddiseases/pubs
/chronichepc/).
The HCV inhibitory activity of 2!-C-modified nucleosides
has been well studied and has been shown to specifically inhibit
HCV RNA replication both in biochemical assays and in cell-
based replicon assays (6). The corresponding intracellular
triphosphates of these 2!-substituted nucleosides were potent,
competitive inhibitors of NS5B-catalyzed reactions in vitro.
The incorporation of the 2!-modified monophosphates onto
the 3! end of the RNA strand resulted in the efficient termi-
nation of the elongation of the growing RNA chain. Accord-
ingly, 2!-substituted nucleosides have been shown to function
as nonobligate chain terminators (5). Despite the potential of
2!-C-modified nucleosides in the inhibition of RNA-dependent
RNA polymerase (RdRp) activity, they have failed to progress
as drug candidates due to one or more of the following: lack of
oral bioavailability, poor pharmacokinetic characteristics, lack
of cell penetration, and inefficient intracellular conversion to
the active triphosphate (6, 12, 28). For example, the triphos-
phate of 2!-C-methyl guanosine (2!-C-MeGTP) has been
shown to be a highly potent inhibitor of RdRp activity in
biochemical assays, and the nucleoside analog 2!-C-methyl-
guanosine (2!-C-MeG) had high oral bioavailability in rats,
but it lacked potency in cell-based subgenomic replicon as-
says (12, 28).
In an effort to unlock the potential of nucleoside NS5B
inhibitors, we have employed a phosphoramidate prodrug ap-
proach to improve upon the characteristics of cellular uptake
and intracellular activation. This approach is designed to by-
pass the rate-limiting initial phosphorylation step of activation
by delivering the monophosphate form of the nucleoside ana-
log to the liver, where it can be efficiently converted to the
active triphosphate (24). INX-08189 is a phosphoramidate of
O-6-methyl-2!-C-methyl guanosine (Fig. 1) (26). This com-
pound was selected from a number of phosphoramidate can-
didates because of its significant potency in replicon assays and
its ability to efficiently generate intracellular triphosphate in
primary human hepatocytes (26).
The current study reports a detailed characterization of
INX-08189, including a description of its potency against mul-
* Corresponding author. Mailing address: Inhibitex, Inc., 9005
Westside Parkway, Alpharetta, GA 30009. Phone: (678) 746-1100. Fax:
(678) 746-1299. E-mail: jvernachio@inhibitex.com.
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tiple HCV genotypes, the relationship between potency and
intracellular 2!-C-MeGTP production, the resistance geno-
types selected by the compound, and its pharmacokinetic and
pharmacodynamic properties in rats and primates.
MATERIALS AND METHODS
INX-08189. INX-08189 was synthesized in the laboratory of Christopher
McGuigan at the Welsh School of Pharmacy, Cardiff University, as described
previously (26).
Replicon assays. The HCV inhibitory activity of INX-08189 was evaluated in
replicon cell culture systems (Apath, LLC, Brooklyn, NY). For HCV genotype
1b (Con1), a Huh-7 cell line (29) expressing a stable, bicistronic subgenomic
replicon encoding the Renilla luciferase reporter gene was utilized (2). For HCV
genotype 2a (J6/JFH), Huh-7 cells were transfected transiently with a full-length,
monocistronic HCV genome construct expressing Renilla luciferase. The inhib-
itory effect on HCV RNA replication using the luciferase assay and the cytotoxic
effect of compounds were performed as previously described (24). For HCV
genotype 1a (H77), a stable, full-length, bicistronic replicon cell line was used (3).
Genotype 1a HCV RNA replication was monitored in this cell line using a
quantitative reverse transcriptase PCR assay (qRT-PCR; TaqMan) as follows.
Total RNA was isolated using the RNeasy 96 kit (Qiagen, Valencia, CA). The
RNA preparations were quantified using the RiboGreen RNA quantitation kit
(Invitrogen) and were used as the template in a qRT-PCRmixture containing 1"
EZ buffer, 1"Mn acetate, 300 #M deoxynucleoside triphosphates (dNTPs), 1 #l
(2.5 U) rTh, 300 nM primers specific for the HCV 3!-untranslated region (UTR)
(forward, 5!-GGCTCCATCTTAGCCCTAGTC-3!; HCV-R, reverse, 5!-AGTA
TCGGCACTCTCTGCAGT-3!) and 150 nM TaqMan probe (6-carboxyfluores-
cein [FAM]-ATGCGGCTCACGGACC) (MGB probe). Amplification was per-
formed using an ABI 7500 real-time PCR system and the following thermal
cycling program: 95°C for 60 s and 60°C for 35 min, followed by 40 cycles of 95°C
for 45 s and 60°C for 45 s. The HCV RNA copy number was calculated from a
standard curve generated with synthetic HCV RNA standards of known concen-
trations.
Generation of NS5B mutant replicons. Mutations in the NS5B gene were
generated in the HCV genotype 1b (Con1) subgenomic replicon. To introduce
the S282T mutation in NS5B, a plasmid containing a restriction fragment incor-
porating the mutation (pT7GG-1b-S282T) was synthesized (Geneart Inc., Bur-
lingame, CA), and the restriction fragment was purified and used to replace the
corresponding fragment in the wild-type replicon. NS5B mutations I585T and
P540T were generated by in vitro mutagenesis using the QuikChange site-di-
rected mutagenesis kit (Stratagene, La Jolla, CA). Briefly, an XhoI/SpeI frag-
ment from the HCV genotype 1b replicon plasmid was cloned into pBluescript
SKII and used as the template for mutagenesis using the primers 5!-TCTGTA
GGGGTAGGCACCTATCTACTCCCCAAC-3! and 5!-GTTGGGGAGTAGA
TAGGTGCCTACCCCTACAGA-3! for I585T and 5!-AACTCACTCCAATCA
CGGCTGCGTCCCAG-3! and 5!-CTGGGACGCAGCCGTGATTGGAGTG
AGTT-3! for P540T. The XhoI/SpeI fragments containing the mutations then
were cloned into the HCV genotype 1b replicon plasmid. To generate the HCV
genotype 1b replicon carrying the NS5B double mutation S282T$I585T, an SfiI
restriction fragment carrying the S282T mutation was used to replace the SfiI
fragment in the replicon containing the I585T mutation. The replicon carrying
NS5B mutations S96T and N142T was generated as follows. The S96T mutation
was generated by overlap extension PCR. In the first step, two overlapping PCR
fragments were amplified from the wild-type replicon using primers XhoI-F1
(5!-GAA ATT CCC TCG AGC GAT GC-3!), S96T-R1 (5!-TTA GAT CTG
GCC GtA TGT GGG GGC GT-3!), S96T-F2 (5!-ACG CCC CCA CAT aCG
GCC AGA TCT AA-3!), and MfeI-R2 (5!-CAT GAT GGT GGT GTC AAT
TGG T-3!) (underlining indicates the introduced restriction enzyme sites and
lowercase lettering indicates point mutations introduced by the oligonucleo-
tides). In the second step, the aforementioned overlapping PCR fragments were
used as the template in a PCR mixture containing primers XhoI-F1 (5!-GAA
ATT CCC TCG AGC GAT GC-3!) and MfeI-R2 (5!-CAT GAT GGT GGT
GTC AAT TGG T-3!). The N142T mutation was generated by PCR using
primers N142T-MfeI-F3 (5!-ACC AAT TGA CAC CAC CAT CAT GGC AAA
AAcTGA GGT TTT CTG CG-3!) and SfiI-R3 (5!-TCG ACA GGC CGC AGC
GGC CTT-3!). The two PCR fragments independently carrying S96T and N142T
were cloned into the genotype 1b replicon. All replicons containing altered NS5B
genes were confirmed by sequencing (SeqWright, Houston, TX).
Transient transfection of NS5B mutant replicons. Replicon RNA for trans-
fection was prepared as follows. Replicon plasmid DNA was linearized with ScaI
(Fermentas, Glen Burnie, MD) and used for in vitro reverse transcription using
the T7 MegaScript kit (Ambion, Austin, TX). The DNA template was removed
by digestion with Turbo DNase, and the RNA was precipitated with 2.5 M LiCl.
RNA was quantified using the Quant-iT RiboGreen RNA kit (Molecular Probes,
Eugene, OR). In preparation for transfection, Huh-7 cells were cured of repli-
cons by prolonged treatment with alpha interferon 2A (IFN-%-2A). Cured Huh-7
cells were treated with trypsin, washed three times with ice-cold phosphate-
buffered saline (PBS; Invitrogen, Carlsbad, CA), and resuspended at 1.6 "107
cells/ml in PBS. Ten #g of replicon RNA was combined with 0.35 ml of cell
suspension and immediately pulsed three times (800 V, 100 #s) using a BTX
ElectroSquare Porator ECM 830 (Harvard Apparatus, Holliston, MA). Electro-
porated cells were incubated at room temperature for 10 min prior to resuspen-
sion in 20 ml of Dulbecco’s modified essential medium (DMEM)-high glucose
medium (HyClone, Logan, UT) supplemented with 9% fetal bovine serum (FBS)
(HyClone), 2 mM glutamine (Invitrogen), and 100 U/ml PenStrep (Invitrogen).
Resuspended cells were plated into 96-well BioCoat collagen-treated tissue cul-
ture plates (VWR, West Chester, PA).
HCV replicon clearance studies. HCV replicon 1b cells were seeded in 6-well
plates at 1 " 105 cells/well without the selective antibiotic G418. INX-08189 was
added to cell cultures 4 h after seeding at the following final concentrations: 0
nM (control), 5, 10, 20, 40, and 80 nM. The medium was changed daily, and the
cells were subcultured on days 5 and 10. On days 0, 5, 8, 10, 12, and 14, the cell
cultures were analyzed for HCV genome-encoded Renilla luciferase expression
with the Renilla luciferase assay kit (Promega, Madison, WI) using a Veritas
luminometer (Turner Biosystems, Sunnyvale, CA). On days 5, 10, and 14, a
portion of the INX-08189-treated and control cell cultures were seeded into T-75
tissue culture flasks and incubated without INX-08189 but in the presence of 0.5
mg/ml of the selective antibiotic G418 (Invitrogen, Carlsbad, CA). As these
secondary cultures grew, individual flasks were fixed and stained with crystal
violet. For cultures where there were no visible surviving colonies, the flasks were
stained after 5 weeks of G418 selection.
Measurement of intracellular 2!-C-methyl-GTP in vitro. Genotype 1b replicon
cells were seeded into six-well plates at 6 " 105 cells/well for 18 h before being
cultured in the presence of INX-08189 for 6 h. Cell samples were harvested and
extracted with 70% ethanol overnight at 4°C, and extracts were dried overnight
under a stream of nitrogen. The dried extracts were reconstituted with 50 #l of
10 mM N,N-dimethylhexylamine, 3 mM ammonium formate in H2O. A standard
curve was generated by spiking blank cell extract samples with known concen-
trations of 2!-C-MeGTP. Spiked samples were treated identically to the test
samples, and processed samples were kept at 2 to 8°C before and during analysis.
Endogenous ATP and GTP levels were monitored as internal quality controls of
cell viability and extraction efficiency. Liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS) analysis was performed with an Agilent 1100
series high-performance liquid chromatograph (HPLC) equipped with an
XTerra MS C18, 3.5 #M, 2.1- by 50-mm column (Waters, Milford, MA) and an
API 4000 mass spectrometer (Aplied Biosystems, Carlsbad, CA) using negative-
ion polarity. The assay was linear (r2 ! 0.99) in the concentration range of 1 to
1,000 ng per 106 cells, with !90% accuracy and "10% coefficient of variation
(CV).
Drug combination studies in genotype 1b replicon assay. Compounds were
tested both as single agents and in the following combinations: INX-08189 with
IFN-%-2B (ProspecBio, Rehovot, Israel) and INX-08189 with ribavirin (Rbv;
Research Products, Mt. Prospect, IL). Inhibition data from the replicon cultures
was analyzed for drug interactions using a three-dimensional surface model
based on the Bliss independence effects definition for additivity (MacSynergy II;
obtained from M. N. Prichard, K. R. Aseltine, and C. Shipman, University of
Michigan) (32). As suggested by the software authors and as utilized by others,
volumes of synergy or antagonism greater than 25 #M2% were considered minor
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but significant, volumes greater than 50 !M2% were considered moderate and
potentially important in vivo, and values greater than 100 !M2% indicate strong
synergy and probable importance in vivo (10).
Pharmacokinetic studies of rats. Rat studies were conducted at Inhibitex, Inc.,
in accordance with NIH guidelines and by following protocols approved by the
Institutional Animal Care and Use Committee (IACUC) of Inhibitex, Inc. INX-
08189 was formulated in 95% Capmul MCM (Abitec Corp., Janesville, WI)–5%
Tween 80 (Sigma, St. Louis, MO) and administered by oral gavage to male
Sprague-Dawley rats (Taconic Farms, Germantown, NY). Blood and tissue col-
lections were performed as a terminal procedure. Oral doses ranged from 3 to 25
mg/kg of body weight, and sampling times were 1, 2, 4, 8, 16, 24, 72, 96, and 168 h
postadministration. Time points were selected to measure 2"-C-MeGTP concen-
trations at both the time to maximum concentration of drug in serum (Tmax) and
at the trough (24 h). To study the relationship between liver 2"-C-MeGTP levels
and plasma 2"-C-MeG concentrations, the oral dose range was expanded to 3 to
300 mg/kg, approximating human equivalent doses of 30 to 3,000 mg. Plasma
samples were collected at 1, 2, 4, 8, 16, 24, 72, 96, and 168 h postadministration
and correlated to trough levels of 2"-C-MeGTP in liver samples collected 24 h
postadministration. Blood was collected into EDTA-containing tubes (1.6 mg
EDTA/ml blood; Sarstedt, Inc., Newton, NC), and the plasma was separated by
centrifugation within 30 min of collection. Liver samples were snap frozen im-
mediately upon collection in liquid nitrogen. Plasma and liver samples were
stored frozen at !#80°C prior to analysis.
Pharmacokinetic studies of cynomolgus monkeys. Primate studies were con-
ducted at MPI Research Inc., of Mattawan, MI, in accordance with protocols
approved by the IACUC of MPI Research Inc. INX-08189 was formulated in 5%
(vol/vol) dimethylacetamide–20% (vol/vol) Solutol HS 15–20% (vol/vol) poly-
ethylene glycol 400–55% (vol/vol) 50 mM sodium acetate, pH 4.0, and was
administered as a single oral gavage dose. The dose level of 25 mg/kg was chosen
for comparison to the equivalent dose of 50 mg/kg in rats. Liver biopsy samples
(four to five samples/animal) were collected from two animals/group/time point
at 3 and 8 h postdose in an effort to measure 2"-C-MeGTP levels near the Tmax.
Anesthesia was induced and maintained, and pre- and postoperative procedures
were performed according to MPI Research standard operating procedures. The
liver biopsy samples were pooled for each animal. Blood samples (approximately
1.2 to 2.0 ml) were collected into tubes containing sodium heparin from the
femoral artery/vein or from the portal vein cannula at 0.5, 1, 2, 3, 4, 8, 12, and
24 h postadministration. Time points were selected to measure 2"-C-MeG con-
centrations at both the Tmax and at the trough (24 h). Plasma was separated by
centrifugation and stored frozen until analysis.
Bioanalysis of pharmacokinetic samples. The concentration of 2"-C-MeGTP
in liver samples and the concentration of 2"-C-MeG in plasma samples from rats
and primates was performed by LC-MS/MS as described previously (24). The
assay measuring 2"-C-MeGTP in rat or primate liver was linear (r2 " 0.99) in the
concentration range of 100 to 4, 000 ng per g of tissue, with "85% accuracy and
!2% CV. The assay measuring 2"-C-MeG in rat or primate plasma was linear (r2
" 0.99) in the concentration range of 2 to 1,250 ng/ml, with "90% accuracy and
!2% CV. The concentrations of INX-08189 in plasma samples collected from
primates were measured by LC-MS/MS as follows. Fifty !l of each test sample
was added to 200 !l of acetonitrile containing an internal standard. The samples
were centrifuged at 1,300 $ g at 4°C for 20 min, and 50 !l of supernatant from
each sample was diluted with 50 !l H2O. Samples were covered, mixed by being
vortexed, and maintained at 2 to 8°C before and during analysis. Calibration
curves were generated by spiking various concentrations of INX-08189 into
control plasma samples. Fifteen !l of each test sample was analyzed by LC-MS/
MS. Liquid chromatography was performed with an Agilent 1100 series HPLC
system equipped with a Synergi 4-!m Polar-RP 30- by 2.0-mm column (Phe-
nomenex, Torrance, CA). The HPLC system was coupled to an API 4000 triple-
quadrupole mass spectrometer (Applied Biosystems, Framingham, MA). Mass
spectrometry was performed in positive-ion mode, and data were analyzed using
Analyst v1.4.2 software (Applied Biosystems, Framingham, MA). The assay was
linear (r2 " 0.99) in the concentration range of 10 to 1,000 ng/ml, with "90%
accuracy and !10% CV.
Pharmacokinetic analysis. Noncompartmental pharmacokinetic analyses were
performed on the plasma and liver concentration data for the analytes using
WinNonlin v5.2 software (Pharsight, St. Louis, MO). The extravascular dosing
pharmacokinetic model was used to calculate the pharmacokinetic parameters,
which included maximum observed concentration (Cmax), time at maximal con-
centration (Tmax), terminal half-life (t1/2), and trapezoidal area determined from
the plasma concentration time data from time zero to last observed concentra-
tion (AUC0-t), from time 0 to 24 h (AUC0-24), and from time 0 extrapolated to
infinity (AUC0-%). Estimates for the terminal half lives were obtained using
regression analysis. Values that were below the lower limit of quantitation were
assigned the value of zero for the analyses.
Mitochondrial toxicity assay. Mitochondrial toxicity was measured by analyz-
ing the ratio of the mitochondrial genome copy number to a nuclear gene copy
number before and after drug treatment. The mitochondrial target sequence
corresponded to the region between the genes TRNL1, encoding tRNA-leu, and
ND1, encoding NADH dehydrogenase subunit 1, and the cellular genome com-
parator was the ß-globin gene (7). Total DNA from untreated CEM cells was
serially diluted and used to generate a standard curve for determining the
absolute copy number of the gene targets. After drug treatment, total DNA was
isolated from treated cells using the DNeasy tissue kit (Qiagen, Valencia, CA).
The purified DNA was quantified by spectrophotometry using a Spectramax M2
plate reader (Molecular Devices, Sunnyvale, CA). Duplex quantitative PCR was
performed in an ABI 7500 real-time PCR system (Applied Biosystems, Foster
City, CA) using a 25-!l reaction volume containing 1$ QuantiTect multiplex
PCR (with 6-carboxy-X-rhodamine) mix; 250 nMmitochondrion-specific primers
5"-CCACCCAAGAACAGGGTTTG-3" (forward) and 5"-TAAGAAGAGGAA
TTGAACCTCTGACTG-3" (reverse); 250 nM mitochondrion-specific probe
FAM-5"-TAAGATGGCAGAGCCCGGTA-3"-minor groove binding nonfluo-
rescent quencher (MGBNFQ); 500 nM &-globin-specific primers 5"-GTGGAT
GAAGTTGGTGGTGAGG-3" (forward) and 5"-CTCCACATGCCCAGTTTC
TATTG-3" (reverse); 250 nM globin-specific probe VIC-5"-CCTGGGCAGGT
TGGTA-3"-MGBNFQ (Integrated DNA Technologies, Coralville, IA); and
genomic DNA template. Amplification was carried out using the following ther-
mal cycling program: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and
then 60°C for 1 min. The ratios between mitochondrial and cellular genome copy
numbers were derived for each sample and compared to those of control cul-
tures. Changes in mitochondrial copy number were expressed as a percent
difference from the control value.
RESULTS
Activity of INX-08189 against wild-type HCV replicons. The
HCV inhibitory activity of INX-08189 was evaluated in repli-
cons expressing HCV genomes from genotypes 1a, 1b, and 2a.
INX-08189 was found to be a highly potent inhibitor of HCV
replication, with EC50s of 10 nM against genotype 1b, 12 nM
against genotype 1a, and 0.9 nM against genotype 2a after 72 h
of exposure (Table 1). Following 72 h of exposure, the con-
centration resulting in 50% cellular cytotoxicity (CC50) in cul-
tured Huh-7 cells was 7.01 !M, resulting in therapeutic indices
ranging from 584 to 7,778.
To determine the magnitude of HCV inhibitory activity that
could be achieved with less than 72 h of incubation, genotype
1b replicon cells were incubated with INX-08189 for 24 or 48 h,
and the EC50s and EC90s were determined (Table 1). Similar
levels of potency were observed when cells were incubated with
INX-08189 for 48 or 72 h. If exposure time was reduced to only
24 h, the concentration required to achieve the EC50 level
increased 3.5-fold; however, INX-08189 still was able to inhibit
HCV replication by 90% (EC90 ' 0.6 !M).
Intracellular metabolism in HCV replicon cells. The intra-
cellular conversion of INX-08189 to 2"-C-MeGTP was deter-




period (h) EC50 (!M) EC90 (!M)
CC50 (!M)
for Huh-7
1b 24 0.035( 0.008 0.600 ( 0.453
1b 48 0.011( 0.005 0.061 ( 0.033
1b 72 0.010 ( 0.006 0.038 ( 0.020 7.01 ( 1.97
1a 72 0.012( 0.004 0.042 ( 0.011 7.01 ( 1.97
2a 72 0.0009( 0.0001 0.0065( 0.001 7.01( 1.97
a All data are means ( standard deviations from at least three independent
experiments.
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mined in genotype 1b replicon cells. Replicon cells were incu-
bated with concentrations of INX-08189 that produce 50%
inhibition of HCV replication (EC50! 10 nM), 90% inhibition
(EC90 ! 40 nM), and twice the EC90 (2" EC90 ! 80 nM).
Cells were harvested after 6 h of exposure to INX-08189, and
the intracellular 2#-C-MeGTP concentrations were measured
(Table 2). There was a linear relationship (R2 ! 0.91) between
the measured intracellular 2#-C-MeGTP concentrations and
the concentrations of INX-08189. At 40 nM INX-08189, the
concentration of 2#-C-MeGTP in Huh-7 cells was 2.43 $ 0.42
pmol/1 " 106 cells. Given an estimated liver cellularity of 1 "
108 cells per g (37), the intracellular concentration of 2#-C-
MeGTP that would be expected to result in 90% viral inhibi-
tion in liver tissue was calculated to be 243 pmol/g of tissue.
This value was useful for interpreting the relevance of liver
2#-C-MeGTP levels measured in subsequent in vivo pharma-
cokinetic studies.
To determine the intracellular half-life of 2#-C-MeGTP, ac-
tively dividing genotype 1b replicon cells were incubated with
1 %M INX-08189 for 8 h, at which time the drug was removed.
Intracellular 2#-C-MeGTP levels were measured at 12, 24, 32,
48, and 56 h after the drug was initially added (Fig. 2). Based
on these data, the half-life of intracellular 2#-C-MeGTP in
Huh-7 cells was calculated to be approximately 24 h.
Selection and characterization of mutants resistant to INX-
08189. To determine the resistance mutations selected by INX-
08189, long-term cultures of genotype 1b and 1a replicons were
performed in the presence of G418 and with concentrations of
INX-08189 that were increased up to eight times the EC50 (80
nM) in the 1b replicon and 4" the EC50 (40 nM) in the 1a
replicon. The establishment of stable INX-08189 escape mu-
tants was significantly delayed, requiring selection during a 6-
to 9-week span in culture. In total, five single-colony-derived
resistant cell lines were selected in the genotype 1b back-
ground, and one was selected in the genotype 1a background.
The nucleotide sequences of the NS5B genes from these clones
were determined. Two consistent NS5B mutations, a codon
282 alteration from serine to threonine (S282T) and a change
in amino acid position 585 from isoleucine to threonine
(I585T), were identified in drug-resistant clones from the ge-
notype 1b background. The S282T substitution had been iden-
tified previously as a resistance mutant for 2#-C-Me-GTP (28).
In the single clone derived from the genotype 1a replicon
selection, the only alteration in the NS5B gene sequence was a
codon change from alanine to threonine in amino acid position
540 (A540T in genotype 1a). To determine if these amino acid
substitutions were sufficient to confer resistance to INX-08189,
they were introduced singly or in combination into the geno-
type 1b replicon background, and potency was assessed in a
transient replication assay. For comparative purposes, a repli-
con carrying the substitutions S96T and N142T that has been
shown to confer resistance to 4#-azidocytidine (R1479) (20)
was tested in parallel. INX-08189 potency against each of these
mutant replicons and their relative replication competencies
are summarized in Table 3. The presence of the S282T muta-
tion resulted in drastically reduced replication efficiency, at
approximately 4% of the rate of the wild-type replicon. Com-
bining the I585T mutation with S282T improved replication
efficiency to 8% of the wild-type level. INX-08189 potency
against S282T mutant replicons was reduced approximately
10-fold, while INX-08189 potency against all other mutant
replicons tested was unaffected, suggesting that S282T was
sufficient to produce an INX-08189-resistant phenotype. De-
spite the shift in potency observed, exposure to INX-08189 still
could significantly inhibit HCV replication in the S282T mu-
tant replicons with an EC90 of 344 $ 170 nM (Fig. 3).
Effect of combining INX-08189 and Rbv. In clinical trials,
INX-08189 likely will be used in combination with standard
therapy, which currently consists of pegylated interferon and
Rbv. We therefore characterized the INX-08189 resistance
mutant S282T as well as the other mutant replicons for their
sensitivity to both Rbv and alpha interferon 2b (Table 3).
Replicons expressing S282T proved to be more sensitive to the
inhibitory activity of ribavirin, with an approximately 6-fold
improvement in the EC50, whereas the potency of IFN-& was
equivalent across all mutants tested. The difference in ribavirin
potency between wild-type and S282T mutants was significant
(P ! 0.0093, unpaired t test with Welch’s correction.) To ex-
plore this effect further, drug combination studies of INX-
08189 paired with Rbv were carried out in both wild-type and
transiently expressed S282T replicons (Table 3). The combi-
nation of INX-08189 and Rbv was highly synergistic in the
wild-type replicon, with a synergy volume of 808 %M2%. Like-
wise, INX-08189 combined with Rbv against replicons express-
ing the S282T mutation was found to be significantly synergis-
tic (117 %M2%).
Clearance of replicons. To assess the antiviral effect of long-
term treatment with INX-08189 on HCV replication, genotype
FIG. 2. Determination of 2#-C-MeGTP intracellular half-life in ge-
notype 1b replicon. Genotype 1b replicon cells were incubated with 1
%M INX-08189 for 8 h, at which point the drug was removed. Intra-
cellular 2#-C-MeGTP concentrations were measured by LC-MS/MS.
Symbols are means $ SD for triplicate determinations in a single
experiment.
TABLE 2. Intracellular 2#-C-methyl GTP in genotype 1b replicon









1" EC50 (10) 0.84 $ 0.36 84
1" EC90 (40) 2.43 $ 0.42 243
2" EC90 (80) 4.97 $ 0.80 497
a All values are means $ standard deviation from six determinations, all mea-
sured at 6 h of incubation with INX-08189.
b Estimates are based on a liver cellularity of 1 " 108 cells per g.
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1b replicon cells were cultured in the presence of 0 (control),
5, 10, 20, 40, or 80 nM INX-08189 for 14 days in the absence
of G418 selection. At various time points during the culture
period, cell samples were harvested and luciferase expression
was determined as a measure of HCV replication activity. As
summarized in Fig. 4A, luciferase activity in treated cultures
decreased over time compared to that of the control, and
inhibition was concentration dependent. Culturing in the pres-
ence of 10 nM INX-08189 resulted in a !2 log10 reduction in
HCV replication activity. Culturing in the presence of!20 nM
("2# EC50) resulted in a !5 log10 reduction in HCV replica-
tion activity after 12 days. After 14 days of culture at concen-
trations of !40 nM (1# EC90), HCV replication activity was
reduced to background levels. Samples of the treated cells
were harvested at days 5, 10, and 14 and subcultured without
INX-08189 but in the presence of G418. Any cells remaining in
the cultures that retained the expression of the replicon ge-
nome would be resistant to G418 selection and after sufficient
time in culture would be detected as visibly growing colonies
(Fig. 4B). Cultures that were incubated in the presence of
INX-08189 for only 5 days retained the expression of the rep-
licon at all concentrations tested, although the frequency of
expressing colonies diminished with increasing INX-08189
concentration. After 10 days of INX-08189 treatment, repli-
con-expressing cells were completely eliminated at concentra-
tions of !40 nM (1# EC90). After 14 days of INX-08189
treatment, replicon-expressing cells were completely elimi-
nated from the culture at concentrations of !20 nM ("2#
EC50).
Mitochondrial toxicity. Mitochondrial toxicity has been de-
scribed as a manifestation of an adverse effect associated with
the long-term use of certain nucleoside analogs (15). To eval-
FIG. 3. Inhibition of HCV replication. Representative inhibition
curves are plotted for replicons expressing wild-type (●), S282T ($),
I585T (f), A540T (!), S282T/I585T ("), and S96T/N142T (}) NS5B
sequences. Concentrations of INX-08189 are indicated on the x axis,
and the measured luminescent signals are expressed as a percentage of
signal obtained in no-treatment controls on the y axis. Symbols are
means % SD for triplicate determinations in a single experiment.
TABLE 3. INX-08189 potency against transient replicons expressing mutant NS5Ba
NS5B sequence Replicationefficiencyc (%)
EC50 of: INX-08189 & Rbv
synergyd ('M2%)INX-08189 ('M) Rbv ('M) IFN-( EC50 (IU)
Con1 WT 100 0.006% 0.003 12.157 % 1.753 4.974% 1.511 808
S282T 4 0.074% 0.026 1.728 % 0.016 3.116% 0.439 117
I585T 165 0.005% 0.001 15.247 % 1.639 3.380% 1.383
A540Tb 86 0.004% 0.001 17.250 % 3.235 3.294% 1.251
S282T/I585T 8 0.055% 0.018 1.736 % 0.110 1.937% 0.662
S96T/N142T 102 0.006% 0.001
a All data are averages % standard deviations from at least three independent experiments.
b The genotype 1b strain Con1 encodes a proline at position 540, as opposed to the alanine in genotype 1a strain H77.
c Percent luciferase activity compared to activity of the wild-type replicon.
d Bliss independence effects definition for additivity (MacSynergy II).
FIG. 4. Clearance of wild-type replicons in vitro with INX-08189.
(A) Huh-7 genotype 1b replicons cells were cultured in the presence of
INX-08189 without G418 for 14 days at concentrations of 5 (●), 10 ("),
20 (f), 40 (E), and 80 nM (}). Luciferase expression was monitored in
the cultures at the indicated time points and expressed as log10 change in
luminescence. (B) Cells were subcultured under G418 selection for up to
5 weeks, and surviving colonies were fixed and stained with crystal violet.
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uate the effect of INX-08189 on the relative mitochondrial
genome copy number in the human cell lines CEM and
HepG2, both a 3- and 14-day study were conducted. Mitochon-
drial copy numbers were determined after treatment with
INX-08189 in CEM, a lymphocyte cell line, and HepG2, a
human hepatocyte cell line. To distinguish mitochondrion-spe-
cific toxicity from general cellular cytotoxicity, increasing con-
centrations of INX-08189 were evaluated in the cell lines for 3
and 14 days. INX-08189 concentrations that did not affect
overall cell viability were selected for the mitochondrial toxic-
ity assessment. The maximum INX-08189 concentrations eval-
uated for mitochondrion-specific toxicity were 20 and 5 !M in
CEM and HepG2 cells, respectively, treated for 3 days. In the
14-day experiments, the maximum INX-08189 concentration
was 1 !M in both CEM and HepG2 cells. In CEM cells treated
with a 20 !M concentration of INX-08189 for 3 days, the
reduction in relative mitochondrial copy number was approx-
imately 11% (Table 4). There were no effects on mitochondrial
copy number observed in CEM cells at 1 !M for 14 days. The
relative mitochondrial copy number in HepG2 cells was calcu-
lated to be 129 and 115% at 5 and 1 !M drug in 3- and 14-day
treatments, respectively, demonstrating that INX-08189 did
not alter the relative mitochondrial copy number in HepG2
cells. In contrast, a positive-control compound, dideoxycyto-
sine (ddC), reduced the relative mitochondrial numbers by 56
and 69% in the 3-day study in CEM and HepG2 cells, respec-
tively. Culturing CEM and HepG2 cells for 14 days with ddC
resulted in mitochondrial copy number reductions of 80 and
99%, respectively (Table 4).
Pharmacokinetics in rats. The ability of INX-08189 to de-
liver a monophosphate form to the liver that subsequently is
converted to 2"-C-Me-GTP after oral administration was
tested in Sprague-Dawley rats. 2"-C-MeGTP concentrations
were measured in rat liver samples harvested during a 7-day
period (Fig. 5). At doses of !5 mg/kg, the concentrations of
2"-C-MeGTP in the liver exceeded the EC90 soon after dosing
and remained at or above this level for 72 h.
The measurement of 2"-C-MeGTP in liver tissue is the most
direct approach for determining the bioavailability of INX-
08189; however, the use of this analytical tool is limited in
higher species, as it can be employed only at a few time points
and is impractical for pharmacokinetic studies of humans. An-
other approach is to monitor the generation of a metabolite of
INX-08189 in the plasma that is proportional to the production
of 2"-C-MeGTP in the liver. To this end, the plasma levels of
2"-C-MeG, a major metabolite of INX-08189, were measured
in the rat. The plasma AUC0-24 (in ng ! h/ml) values of 2"-C-
MeG were compared to the 2"-C-MeGTP C24 (ng/g) concen-
trations after the administration of oral doses ranging from 3
to 300 mg/kg (Table 5). At doses between 3 and 150 mg/kg,
both the 2"-C-MeG plasma AUCs (ng ! h/ml) and the 2"-C-
MeGTP liver concentrations (ng/g) at 24 h were found to be
dose proportional and linear, with R2 values equal to 0.96 and
0.99, respectively. In addition, the 2"-C-MeG plasma AUCs
and the 2"-C-MeGTP liver C24 also were found to be highly
correlative (R2# 0.97) at doses between 3 and 150 mg/kg. This
correlation was not maintained at the 300-mg/kg dose. These
data validate the utility of measuring 2"-C-MeG exposure in
the plasma as a biomarker to monitor the liver pharmacoki-
netics of 2"-C-MeGTP in vivo.
TABLE 4. Mitochondrial toxicity
Cell line Compound
Relative mitochondrial copy
no.a (% of control) on
treatment day:
3 14
CEMb INX-08189 89$ 11 102 $ 14
2"-C-MeG 109$ 43 133 $ 4
ddC 31 $ 5 1 $ 1
HepG2c INX-08189 129$ 22 115 $ 23
2"-C-MeG 103$ 57 137 $ 2
ddC 44 $ 16 20 $ 24
a Measured as the ratio between mitochondrial genome copy number and
cellular genome copy number compared to values for untreated control cultures.
Values are averages from at least two experiments $ standard deviations.
b Concentrations used for 3-day cultures were 20!M INX08189, 100 !M
2"-C-MeG, and 5!M ddC, and those for 14-day cultures were 1 !M INX08189,
100 !M 2"-C-MeG, and 0.5 !M ddC.
c Concentrations used for 3-day cultures were 5!M INX08189, 100 !M 2"-C-
MeG, and 10!M ddC, and those for 14-day cultures were 1 !M INX08189, 100
!M 2"-C-MeG, and 2!M ddC.
FIG. 5. Concentrations of 2"-C-methyl GTP in rat liver following
oral dosing with INX-08189. Each line represents a separate dose
level: 25 mg/kg (}), 10 mg/kg ("), 5 mg/kg (f), and 3 mg/kg (E).
Symbols represent averages from two rats with the exception of the
3-mg/kg dose group, which included data from six rats. The EC90
determined for Huh-7 cells (243 pmol/g) is indicated by the dotted line.
TABLE 5. Relationship between 2"-C-MeGTP concentration in
liver to 2"-C-MeG exposure in plasma following a single






AUC0-24 (ng ! h/ml)
3 6 159 73.4
5 2 412 145.6
10 2 658 322.5
25 2 774 707.9
30 3 1,263 1,024.3
50 3 2,880 2,085.3
150 3 7,130 3,979.2
300 3 10,610 4,309.3
a Mean concentrations for 2"-C-MeGTP measured at 24 h.
b Area under the curve values covering 0 to 24 h (AUC0-24) were calculated
from average 2"-C-MeG plasma concentrations measured at six time points.
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Pharmacokinetics in cynomolgus monkeys. To determine
the concentration of 2!-C-MeGTP in the liver upon INX-08189
oral dosing, four animals were administered 25 mg/kg, and
surgical liver biopsy specimens were collected under anesthesia
at 3 and 8 h postdose. The mean liver 2!-C-MeGTP concen-
tration at 3 h was 282 ng/g and increased to 624 ng/g at 8 h
(Table 6). The in vitro EC90 (130.5 ng/g) was exceeded by 2.16-
and 4.78-fold at the respective sample time points.
In an effort to determine the efficiency of INX-08189 extrac-
tion by the liver, cynomolgus monkeys with surgically im-
planted portal vein cannulas were administered 25 mg/kg INX-
08189 by oral gavage. INX-08189 concentrations were
measured in plasma collected from either the portal vein or the
systemic circulation (femoral vein). Following a single oral
dose, INX-08189 was detected in the portal circulation within
30 min of dosing and continued to be measured for up to 4 h
(Fig. 6). At this dose level, INX-08189 was not detected in the
systemic circulation of this animal at any of the time points
tested, whereas the metabolite 2!-C-MeG was detected in the
systemic circulation beginning at 1 h postdose. These data
suggest that INX-08189 is efficiently extracted from the portal
circulation by the liver following oral administration, which
results in the formation of the active HCV polymerase inhib-
itor 2!-C-MeGTP in liver tissue.
DISCUSSION
The HCV RNA-dependent RNA polymerase encoded by
NS5B is an attractive target for antiviral therapy. The active
site of the enzyme maintains a high degree of sequence con-
servation across all HCV genotypes, allowing the potential for
a pangenotype inhibitor with a high barrier to resistance (22,
23). Some of the most promising and widely studied NS5B
inhibitors are 2!-C-methyl nucleoside analogs (5, 6, 34). Within
this family of NS5B inhibitors, the triphosphate form of 2!-C-
MeG has been shown to be one of the most potent inhibitors
of NS5B enzyme activity, with an 50% inhibitory concentration
(IC50) of 0.13 "M (28). However, the high potency of the
active 2!-C-methyl GTP at the biochemical level was not re-
flected in the cell-based replicon assay due to poor cell pene-
tration and a low rate of conversion of the nucleoside to the
active triphosphate (13, 28).
To overcome these limitations, we have utilized an aryloxy-
phosphoramidate approach to modify 2!-C-methyl guanosine
analogues. This approach facilitates the direct delivery of the
monophosphorylated nucleoside analogue into the cell, by-
passing the first rate-limiting phosphorylation step (4). The
phosphoramidate prodrug strategy has been used successfully
to improve the HCV antiviral potency of several modified
nucleosides (14, 19, 25, 27). In the case of 2!-C-MeG, a striking
improvement in cell-based potency over that of the parent
nucleoside can be achieved (#80 fold) with phosphoramidates
incorporating 1-naphthyl as the aryl-leaving group (27). These
prodrugs of 2!-C-MeG also have been shown to generate high
concentrations of the active 2!-C-MeG triphosphate in liver
tissue following oral administration in mice (24). To further
improve the performance of these compounds, alterations at
the C-2 and C-6 positions of the base were investigated. It was
found that phosphoramidate derivates of 6-O-methyl-2!-C-
methyl guanosine demonstrated improvements in cell-based
potency, enhanced lipophilicity, cell permeability, and rapid
intracellular conversion to the active triphosphate in human
hepatocyte cultures (26). As a result of these studies, one
compound that embodied all of these improvements, INX-
08189, was selected for further characterization.
In the current study, the antiviral activity of INX-08189 was
evaluated in the cell-based replicon assay against three HCV
genotypes. The calculated EC50s in genotype 1a, 1b, and 2a
replicons were 12, 10, and 0.9 nM, respectively, making INX-
08189 one of the most potent nucleoside-based NS5B inhibi-
tors characterized to date. This magnitude of potency has been
observed previously only with HCV protease inhibitors and
nonnucleoside polymerase inhibitors (34). The kinetics of
INX-08189 antiviral activity were observed to be rapid, with an
EC50 of 35 nM after only 24 h of exposure with genotype 1b
replicon-containing cells. Coupled with the rapid production of
2!-C-methyl GTP observed previously with INX-08189 in hu-
man hepatocytes (26), it is clear that cell entry and the meta-
bolic conversion of INX-08189 is enhanced compared to that
of the parent nucleoside, 2!-C-MeG. To determine the con-
centration of intracellular triphosphate required to achieve
viral inhibition, 2!-C-MeGTP was quantified in genotype 1b
replicon-expressing Huh-7 cells by LC-MS/MS analysis. After
6 h of incubation, a linear relationship was observed between
INX-08189 concentrations and intracellular 2!-C-MeGTP con-
centrations (Table 3). Given these measurements and assum-
ing a hepatocellularity of 1 $ 108 cells in 1 g of liver (37), we
calculated that 84 and 243 pmol of 2!-C-MeGTP per g of liver
tissue would provide 50 and 90% levels of viral inhibition,
respectively. These values were used to interpret the pharma-
FIG. 6. Concentrations of INX-08189 and 2!-C-methyl guanosine
in plasma after the oral dosing of INX-08189 in cynomolgus monkeys.
Cynomolgus monkeys surgically fitted with portal vein cannulas were
dosed orally with INX-08189 at 25 mg/kg. The analytes measured were
2!-C-methyl guanosine concentration in systemic plasma (●), INX-
08189 in portal plasma ("), and INX-08189 in systemic plasma (f).
TABLE 6. Intracellular 2!-C-MeGTP concentration in liver samples




pmol/g ng/g Avg % SD (ng/g)
3 758 407 282% 177
292 157
8 1,377 740 624% 165
944 507
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codynamic relevance of the liver concentrations achieved after
the oral administration of INX-08189 in vivo as discussed be-
low. The intracellular half-life of 2!-C-MeGTP also was mea-
sured in the replicon cells with a value of approximately 24 h.
This finding is consistent with the half-life of 2!-C-MeGTP
observed in primary human hepatocyte cultures (26). The long
intracellular half-life of the active triphosphate suggests that
2!-C-MeGTP concentrations in liver sufficient for antiviral ac-
tivity are achievable with once-a-day dosing of INX-08189.
The ability to reduce viral loads rapidly and prevent the
emergence of resistant clones during a lengthy treatment pe-
riod is critical to establishing a robust sustained viral response
in patients. We used the clearance of the genotype 1b replicon
from Huh-7 cells as an in vitro surrogate to measure these
characteristics of INX-08189. In the absence of G418 selection,
concentrations as low as 10 nM INX-08189 ("1# EC50) re-
sulted in a !2 log10 decrease in luciferase activity, and at 40
nM INX-08189 (1# EC90) a !7 log10 decrease was observed
during the 14-day culture period. Culture in the presence of
G418 demonstrated that replicon-expressing cells were com-
pletely eliminated after 14 days of treatment with as little as 20
nM INX-08189 ("2# EC50). The ability to clear the replicon
and eliminate the rebound of viral replication at such low
concentrations of inhibitor are significant in light of the fact
that other direct-acting antivirals, such as VX-950 (telaprevir)
and HCV-796, were unable to clear the genotype 1b sub-
genomic replicon with up to 15 times their respective EC50s
(23), and PSI-7851, a phosphoramidate nucleotide of 2!-F-2!-
C-methyl uridine, required $10 times its EC50 to clear the
genotype 1b replicon at day 21 (19).
The S282T substitution in the HCV NS5B gene had been
identified previously as a resistance mutant for 2!-C-methyl-
modified nucleosides (20, 28, 30). To determine if INX-08189
selects for this and other mutations in vitro, long-term cultures
of Huh-7 cells containing genotype 1a or 1b replicons were
performed. As expected, the S282T mutation was observed and
confirmed as a resistance mutation leading to an approximately
10-fold change in the EC50. Despite this shift in potency, INX-
08189 still was capable of the complete inhibition of HCV
replication in the S282T mutant replicon, with an EC90 of 344
nM, suggesting only partial resistance to the inhibitory effect of
INX-08189. Since the current standard of care for the treat-
ment of HCV is a combination of IFN-% and Rbv, we were
interested in determining what effects the S282T mutation
would have on the potency of these antiviral compounds in
combination. There have been previous reports of enhanced
potency for Rbv against the S282T mutant both at the bio-
chemical and cellular levels (9). Our data confirm these obser-
vations, in that we observed a 6-fold increase in potency for
Rbv against HCV replicons carrying the S282T mutation. It is
well documented that the S282T mutation severely limits the
replication efficiency of HCV (20, 22, 28). A second mutation,
I585T, was observed in the selection studies with INX-08189.
As has been reported previously, the I585T mutation does not
confer drug resistance; however, the presence of this amino
acid change in the genotype 1b replicon improves HCV repli-
cation efficiency (35). We have shown that while compensation
by I585T occurs in both wild-type and S282T-expressing rep-
licons, it does not affect the potency of any of the treatment
drugs tested. Additionally, replicon inhibition studies combin-
ing INX-08189 with Rbv demonstrated a high degree of syn-
ergy against both the wild-type and S282T mutant replicons.
This is unlike some other 2!-substituted nucleosides, which are
additive or antagonistic when combined with ribavirin (8).
Whether the synergistic effect is due to the cooperative inhi-
bition of RdRp enzymatic activity by metabolites of INX-08189
and Rbv or is a consequence of the downregulation of com-
peting endogenous nucleotides by Rbv (31) remains to be
determined. These data, coupled with the fact that the S282T
mutation has not been detected in chronically infected HCV
patients at baseline (11) or after treatment with experimental
2!-C-methyl-modified nucleoside analogues (21, 33), suggests
that the combination of INX-08189 with Rbv will prove to be
a highly successful strategy to minimize the generation of re-
sistant HCV isolates clinically while at the same time optimiz-
ing viral clearance.
Mitochondrial toxicity has been observed with certain
classes of nucleoside analog drugs that inhibit the activity of
the mitochondrial DNA polymerase &, and this effect has been
well studied in the case of reverse transcriptase inhibitors used
to treat HIV infection (1, 15). The potential liability of INX-
08189 with regard to mitochondrial toxicity therefore was as-
sessed in tissue culture studies with both a liver-derived cell
line and a lymphocyte cell line. Incubation in the presence of
INX-08189 for 3 or 14 days indicated no change in the ratio of
mitochondrial genome copy number to cellular DNA. The
results indicate a lack of mitochondrion-specific toxicity for
INX-08189.
The prodrug strategy embodied by INX-08189 complicates
the analysis of pharmacokinetic and pharmacodynamic prop-
erties of the molecule. In rodents, the prodrug is short lived in
the plasma and cannot be measured systemically. In cynomol-
gus monkeys, we have shown that at a dose of 25 mg/kg, the
intact prodrug was present in the portal circulation for a short
time postadministration but was not detected in the systemic
circulation, suggesting that at this concentration of INX-08189
the molecule was efficiently extracted by the liver. Therefore, a
surrogate marker of INX-08189 bioavailability was required to
study its pharmacokinetic and pharmacodynamic properties. In
clinical trials using a similar prodrug strategy to deliver 2!-C-
MeGTP to the liver, the nucleoside metabolite 2!-C-MeG was
utilized as a surrogate analyte to monitor pharmacokinetics in
HCV patients (17, 18). To validate this approach for INX-
08189, we measured the generation of 2!-C-MeGTP, the active
inhibitor of NS5b RdRp, which is present in the liver, and
2!-C-MeG in the plasma. In rats where both metabolites could
be measured in the same animals, the data clearly indicate a
linear relationship between the 2!-C-MeG AUC24 values and
the concentration of 2!-C-MeGTP in the liver at 24 h. The data
for cynomolgus monkeys, although more limited than those of
the rodent studies, were consistent with this finding. The cor-
relative relationship between the two metabolites suggests that
2!-C-MeG plasma AUC0-24 values can be used to assess the
delivery of 2!-C-MeGTP to the liver in vivo. The rodent data
also showed very good dose proportionality for INX-08189,
demonstrating a linear relationship in the exposure of both
metabolites across a wide range of doses. Based on the mea-
surements of 2!-C-MeGTP concentrations required to achieve
90% viral inhibition in vitro, we evaluated if liver 2!-C-MeGTP
concentrations achieved in vivo would be sufficient to inhibit
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viral replication. In rats, the concentration of 2!-C-MeGTP in
the liver 24 h postdose sufficient for 90% viral inhibition was
achieved after a single oral dose of 3 mg/kg. Since this repre-
sents a trough level of 2!-C-MeGTP, multiple dosing would be
expected to further improve triphosphate liver exposures. In
monkeys, concentrations greater than the triphosphate EC90
were measured 6 h after a single dose of 25 mg/kg. 2!-C-
MeGTP in rodent liver was found to be long lived, with a
half-life estimated to be greater than 24 h.
Taken together, the in vitro and in vivo data indicate that
INX-08189 is a highly potent inhibitor of HCV with a high
barrier for resistance and good oral pharmacokinetic proper-
ties. The data support the continued advancement of INX-
08189 in clinical development for the treatment of chronic
HCV infections.
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a b s t r a c t
We have previously reported the power of combining a 50-phosphoramidate ProTide, phosphate pro-
drug, motif with a 6-methoxy purine pro-drug entity to generate highly potent anti-HCV agents, leading
to agents in clinical trial. We herein extend this work with the disclosure that a variety of alternative 6-
substituents are tolerated. Several compounds exceed the potency of the prior 6-methoxy leads, and in
almost every case the ProTide is several orders of magnitude more potent than the parent nucleoside.
We also demonstrate that these agents act as pro-drugs of 20-C-methyl guanosine monophosphate. We
have also reported the novel use of hepatocyte cell lysate as an ex vivo model for ProTide metabolism.
! 2011 Elsevier Ltd. All rights reserved.
Nucleoside analogues continue to play a vital role in the search
for improved therapies for hepatitis C Virus (HCV) infection.1 Sev-
eral families of modified nucleosides have been reported as inhib-
itors of the HCV NS5B RNA polymerase, including 40-modified2 and
20-modified3 nucleosides. All of these nucleosides act following
sequential phosphorylation to their bioactive 50-triphosphate
forms. As with many nucleoside analogues this phosphorylation,
and particularly the first, nucleoside kinase-mediated, step may
be limiting to their bio-activity.3 In these circumstances one of a
number of phosphate pro-drug methods may be used.4 We have
developed a phosphoramidate ProTide approach5 and applied it
extensively to a variety of bioactive nucleosides. Recently we re-
ported its effectiveness when applied to the anti-HCV agent 20-C-
methylguanosine (1).6 We further reported that combining the
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50-phosphate ProTide moiety with a C6 methoxy pro-drug entity
further significantly boosted the potency of the compound to give
the clinical candidate INX-189 (2) with nanomolar activity against
HCV.7 This agent has recently successfully completed phase 1b
clinical trial in HCV infected patients.
Several reasons were suggested for the potency boost presented
on C6 modification. Amongst them was the ca 2-log increase in
lipophilicity upon this modification, and potential consequential
enhancements in passive cell uptake.7
Since the ProTide motif is thought to function by intracellular
50-monophosphate release it was considered that the 50-mono-
phosphate from (2) was a substrate for adenylate deaminase to lib-
erate 20-methylguanosine monophosphate as an essential
precursor to the bioactive 50-triphosphate. Given the known wide
substrate specificity of adenylate deaminase8 we wondered if
alternative 6-substituents might substitute for the 6-methoxy
and might further boost lipophilicity and enhance potency. We
herein report the notable success of this approach.
As shown in Figure 1 we used the 6-chloro nucleoside as a route
into various 6-substituted analogues. Thus, tetrabenzoyl 20-C-
methyl-D-ribose (3) was condensed with 2-amino-6-chloropurine
(4) in the presence of TMS triflate to give the protected beta nucle-
oside (5) in 76% yield. This was deprotected with methanolic
ammonia to give (6a) in 78% yield. Use of alternatives deprotec-
tion/substitution conditions gave the various 6-substituted
analogues (6b–i) as shown in Figure 1. Thus, sodium methoxide
and ethoxide respectively gave (6b–c), methylamine (6d), and
thiomethoxide gave (6e). Other analogues were similarly
prepared.
The anti-HCV activity of (6a–i) was studied in sub-genomic rep-
licon assay and the data are reported in Table 1. In general the
compounds are active at lM levels; activity decreasing for larger
C6 substituents.
Following the discovery of the power of the naphthyl neopen-
tylalanine ProTide motif in (2) we now applied this moiety to
(6a–i) as shown in Figure 2. Thus, 1-naphthyl neopentylalaninyl
phosphorochloridate was allowed to react with (6a–i) to generate
the corresponding ProTides (7a–i) in moderate yield.
All compounds were isolated as roughly equimolar mixtures of
phosphorus diastereoisomers as evidenced by 31P NMR and HPLC.9
The ProTides were tested as inhibitors of HCV as noted above,
with data being shown in Table 2.
Figure 1. Reagents and conditions: (a) DBU, TMSOTf, ACN, 65 !C, 4–6 h, 76%; (b) NH3/MeOH, 12 h, rt, 90% (for 6a); NaOMe, MeOH, rt, 12 h, 78% (for 6b); NaOEt/EtOH, 50 !C,
5 h, 84% (for 6c); MeNH2/Et3N/EtOH, 85 !C, sealed tube, 92% (for 6d); NaSMe/EtOH, rt, 18 h, 87% (for 6e); NH3/MeOH, rt, 12 h, 90%, NaH, 3-methoxy-1-propanol, 50% (for 6f);
BnCH2NH2, EtOH, reflux, 16 h, 55%, NH3/MeOH, rt, 94% (for 6g); BnNH2, EtOH, reflux, 16 h, 98%, NH3/MeOH, rt, 89% (for 6h); NaOCH(Me)2, rt, 18 h then NaOMe, rt, 18 h, 70%
(for 6i).
Figure 2. Reagents and conditions: (a) N-methylimidazole, THF, 16 h, rt, 11–28%; (b) tBuMgCl, THF, 22-25%.
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It is striking that while all of the parent nucleosides (6a–i) are
poorly active, with EC50 values of ca 5–30 lM, all of the ProTides
are active sub-lM. Particularly active are the 6-ethoxy, 6-methoxy
and 6-chloro compounds with EC90values of <100 nM. The largest
C6 substituted compounds such as (7h) seem to lose some activity,
implying some size restrictions at C6, but even here the ProTide re-
mains 30-fold more active than the parent (6h). The ProTides are
cytotoxic at lM levels but their high potency still leads to thera-
peutic index values in the 1000 range. Given the extremely high
potency of the 6-O-ethoxy analogue we decided to vary the ProTide
motif on (7c). Following the same procedures as in Figure 2 but
varying the phosphorochloridate we converted (6c) to (8a–f)
(Table 3).
All of these compounds show sub-lM activity in replicon but
none are as active as (7c). In general, the alanine compounds are
more active than the valine ones as we have previously noted.6
To confirm the possible mode of action of these compounds we
conducted a number of assays. In the first instance we performed a
Carboxypeptidase Y assay, an in vitro probe of ProTides activation
pathway (Fig. 3).
The data shown in Figures 4 and 5 represent 31P NMR spectra
recorded every 7 min during 14 h incubation period of (8a) and
(8e) with Carboxypeptidase Y in acetone-d6 and Trizma buffer
(pH 7.6).
In case of the naphthyl benzylalanine compound (8a) (Fig. 4),
the experiment showed fast hydrolysis of starting material
(dP = 3.62, 4.11 ppm) to the intermediate lacking the ester group
(dP = 4.69, 4.83 ppm). Both diastereoisomers of (8a) appear to be
processed with roughly similar efficacy as far as the data
allow us to discern. The single peak at 6.95 ppm corresponds to
the final product of the hydrolysis—the achiral aminoacyl phos-
phate. The estimated half-life of (8a) was less than 5 min. In case
Figure 3. Putative mechanism of ProTide activation.
Figure 4. Carboxypeptidase Y mediated hydrolysis of (8a) followed by 31P NMR.
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of the isopropyl analogue (8e) (Fig. 5) conversion of the starting
material was slower, with a half-life of 4 h and in this case one
of the diastereoisomers of (8e) seems to be processed rather more
rapidly.
These results are consistent with the replicon data, showing
that (8a), which is processed faster, is also found to be more active
(EC50 = 0.04 lM vs 0.14 lM for (8e)). The carboxypeptidase assay is
thus a potentially useful predictive model for the in vitro bio-acti-
vation of these agents.
HuH7 cell lysates have been prepared to examine monophos-
phate formation during the ProTide hydrolysis. An NMR based as-
say was performed on (8c) using HuH7 cell lysate (107 cells) in
acetone-d6 and Trizma buffer (pH 7.6) at 37 !C. 31P NMR spectra
were recorded every 1 h for 11 h. After 1 h of incubation, the pres-
ence of newly formed peak at 0.98 ppm was observed suggesting
successful liberation of the monophosphate species (Fig. 6). This
signal had the same chemical shift as an authentic monophosphate
under these conditions. Given that its release is considered to be a
pre-requisite for antiviral action, via the triphosphate, we view
these data as encouraging and consistent with the replicon data
in Tables 1–3 above.
As far as we are aware, this is the first time that P-31 NMR of
hepatocyte lysate has been used as an ex vivo assay of anti-HCV
ProTide metabolism.
Since we regard each of these 6-modified nucleotides as pro-
drugs of the guanine nucleotides, we also conducted an adenosine
deaminase (ADA) assay on (6b), with spectra recorded each min-
ute.10 The results are shown in Fig 7.
Figure 6. Metabolism of (8c) in HuH7 cell lysate followed by 31P NMR.
Figure 5. Carboxypeptidase Y mediated hydrolysis of (8e) followed by 31P NMR.
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These data demonstrate that (6b) is an excellent substrate for
adenosine deaminase-mediated deamination. The final product
has an identical UV spectrum to (1) as expected. Compound (6c)
was found to be suitable substrate for the enzyme, however the
conversion rate to (1) was much slower than for (6b). We expect
that the monophosphates of (6a–c) released from the ProTide
in vitro, may similarly be substrates for adenylate deaminase, giv-
ing the 20-C-methylguanosine monophosphate in each case. ADA
assay performed on (6d) and (6e) showed no transformation with-
in the reaction time of 24 h which may suggest that broader sub-
strate specificity might operate at the adenylate deaminase level
or that the deamination of these nucleoside analogues and their
corresponding monophosphates is catalysed by a different type
of deaminase for example, human abacavir monophosphate deam-
inase.11 To further pursue this notion we conducted the replicon
anti-viral assay in the presence and absence of pentostatin, a
known inhibitor of both adenosine and adenylate deaminase (data
not shown) and noted that each of the ProTides herein described
lost entirely their activity in the presence of pentostatin, clearly
confirming an absolute need for ‘deamination’ to be active.
In conclusion, we herein report that a wide range of 6-substitu-
ents is acceptable at the ProTide level of 20-C-methyl guanosine
based anti-HCV agents. In every case, the parent nucleosides are
poorly active, being active at only high lM levels. In every case
their ProTides are active sub-lM; in most cases the potency of
the nucleoside is enhanced >100 fold. Alanine emerges again as
the preferred amino acid, and several ester variants lead to very
potent compounds. In some cases the potency and selectivity
in vitro exceeds that of the clinical candidate (2), INX-08189. In
every case ‘deamination’ at the C6-position, presumably at the
monophosphate level, is implicated as essential for activity, and
thus these compounds are dual pro-drugs. We have also reported
the novel use of hepatocyte cell lysate as an ex vivo model for
ProTide metabolism.
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ABSTRACT: We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven
phosphorodiamidates are reported of two 6-O-alkyl 2′-C-methyl guanosines, with significant variation in the diamidate structure.
Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both D and L,
and also from various simple amines. All of the compounds were evaluated versus hepatitis C virus in replicon assay, and
nanomolar activity levels were observed. Many compounds were noncytotoxic at 100 ￿M, leading to high antiviral selectivities.
The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing
by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells. On the basis of in vitro data, eight leads
were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies.
This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the
advantages of phosphoramidate ProTides but without the chirality issues present in most cases.
■ INTRODUCTION
There is an urgent ongoing need for improved therapeutic
agents for hepatitis C Virus (HCV) infection, with an
increasing emphasis on direct acting antivirals (DAAs), and in
particular, inhibitors of the viral NS5B RNA polymerase.1
Nucleoside-based inhibitors of the polymerase are considered
particularly valuable on the basis of the high genetic barrier to
resistance.2 Thus, a number of nucleoside modifications (1−4,
Figure 1) have emerged with anti-HCV activity in vitro, and
several have progressed to clinical evaluation.
One issue common to all nucleoside analogues, either
antiviral or anticancer, is an absolute need for nucleoside
kinase-mediated activation to their 5′-monophosphate forms. In
some cases, as in the present anti-HCV field, further
phosphorylation to the 5′-triphosphate is also required, and in
general the first phosphorylation step is considered rate-
limiting.3 With this in mind, and given that the free phosphate
derivatives are not considered useful drug entities due to poor
cell uptake, a number of phosphate (nucleotide) prodrug motifs
have emerged.4 These have included our aryl phosphoramidate
(“ProTide”) approach,5 the amidate diester method of Wagner6
and McKenna,7 the lipid diester approach of Hosteller,8
thioester approaches of Gosselin,9 cytochrome based meth-
ods,10 and the chemical driven cycloSAL method of Meier.11
Each of these methods has its strengths and weaknesses. In
general, fully blocked prodrugs (ProTides, CycloSAL, etc.) may
give better delivery but do often generate a chiral phosphate
center leading to isomer issues. Phosphate diester methods
avoid the chirality issue but may have delivery challenges.4
Despite this, several phosphate prodrugs of antiviral nucleosides
have progressed into clinical trials. This includes Inhibitex’s
INX-18912 (5, Figure 2) and Pharmasset’s PSI-797713 (6), both
based directly on phosphoramidate ProTides, and Idenix’s
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IDX18414 (7), which is a hybrid phosphoramidate/SATE
prodrug. Each of these is now in human trials for efficacy versus
HCV.
Most chiral nucleotide prodrugs that have entered into the
clinic to date have been progressed as diastereoisomeric
mixtures at the phosphate center. NewBiotics’ anticancer
agent NB1011 is a further example in this category.15 In
general, when tested, both stereoisomers often display similar
biological activity in vitro and always release the same
pharmacophore after initial metabolism.16 One exception to
this in the HCV field to date is Pharmasset, who has developed
a large scale separation technique for their mixed compound
PSI-7851, now pursued as the single stereoisomer 6 as above.13
With this in mind, we sought to revisit the notion of an
achiral phosphate prodrug motif with a phosphoramidate core.
In addition, we particularly wanted to formulate a prodrug
whose promoieties were nontoxic and preferably natural. Thus
our attention turned to phosphorodiamidates. Indeed, over 20
years ago, our group was among the first to report
phosphorodiamidate-based nucleotide prodrugs. Thus, seeking
to deliver the 5′-monophosphate of the anti-HIV agent AZT
into cells, we prepared a series of L-amino acid phosphor-
odiamidates with a variety of esters.17 There have since been
reports of this motif on phosphonates18 and non-nucleosides19
but little further work on nucleosides.20−22
In this paper, we report the very promising profile of a family
of such phosphorodiamidates of 2′-C-methylguanosine and its
derivatives, leading toward selection of a clinical candidate.
■ CHEMISTRY
Following the success of 5 in early clinical trials for HCV23 and
our recent disclosure that alternative 6-alkoxy (and other)
groups may be equally effective,24 we used the 6-alkoxy
derivatives of 2′-C-methylguanosine as our starting point. These
were prepared by methods we have described.12 Following our
much earlier reports on phosphoramidates of AZT,17 we used a
single synthetic route based on treating the unprotected
nucleoside with phosphoryl chloride to generate the
intermediate dichloridate which was not isolated (Scheme 1).
In the first instance, we used the 6-methoxy analogue 8, the
base nucleoside behind 5. Reaction with POCl3 in THF in the
presence of Et3N for 45 min (when
31P NMR showed no
presence of POCl3) followed by addition of an excess of various
amino acid esters (or other amines), lead to compounds 10−76
as shown in Table 1.
As L-alanine is often a preferred motif in phosphoramidate
ProTides and the final putative activating step for these
diamidates would be the same loss of amino acid, we thought
that L-alanine may be beneficial here, so our first SAR family
was symmetrical substituted L-alanines with linear esters
methyl-(10), ethyl-(11), n-propyl-(12), n-butyl-(13), and n-
pentyl-(14); branched esters isopropyl-(15) and (R,S)-2-butyl-
(16), and 3,3-dimethylbutyl-(17); followed by cyclic esters
cyclobutyl-(18), cyclopentyl-(19) cyclohexyl-(20), and 2-
tetrahydropyranyl-(24). We have often reported that benzyl
esters can be rather effective in ProTides, so we prepared the
benzyl-(21), S-phenethyl-(22), 2,4-difluorobenzyl-(23), and 2-
indanyl-(25) L-alanine esters. Given the extremely high potency
Figure 1. Some anti-HCV nucleoside analogues.
Figure 2. Some anti-HCV phosphate prodrug compounds in clinical trials.
Scheme 1. Synthetic Route to Phosphorodiamidatesa
aReagents and conditions: (a) Et3N (1 equiv), POCl3 (1 equiv), dry THF; (b) for symmetrical diamidates, amine (5 equiv), Et3N (10 equiv), dry
DCM; for asymmetric diamidates, amine 1 (1 equiv), Et3N (2 equiv) then amine 2 (5 equiv), Et3N (10 equiv), dry DCM.
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Table 1. Replicon Data and Cytotoxicity of Nucleoside Analogues and Phosphorodiamidates
EC50 (￿M) EC90 (￿M)
compd AA ester/amine AA ester/amine nucleoside av SD av SD CC50 (￿M)
4 2′CMeG 2.2 1.4 8.3 7.5 >100
8 6OMe2′CMeG 4.4 2.2 19.4 10.2 >100
9 6OEt2′CMeG 9.5 1.84 24.5 1.78 >100
5 L-Ala OCH2tBu NaphO 6OMe2′CMeG 0.01 0.01 0.04 0.02 7.01
10 L-Ala OMe L-Ala OMe 6OMe2′CMeG 5.90 0.76 >10 >100
11 L-Ala OEt L-Ala OEt 6OMe2′CMeG 1.20 0.08 4.10 0.09 >100
12 L-Ala OnPr L-Ala OnPr 6OMe2′CMeG 0.28 0.05 1.20 0.53 >100
13 L-Ala OButyl L-Ala OButyl 6OMe2′CMeG 0.07 0.01 0.23 0.02 >100
14 L-Ala OPentyl L-Ala OPentyl 6OMe2′CMeG 0.03 0.01 0.11 0.02 65
15 L-Ala OiPr L-Ala OiPr 6OMe2′CMeG 0.49 0.18 2.10 0.09 >100
16 L-Ala O-(R,S)-2Bu L-Ala O-(R,S)-2Bu 6OMe2′CMeG 0.15 0.00 0.53 0.10 >100
17 L-Ala O-3,3-dimethylbutyl L-Ala O-3,3-dimethylbutyl 6OMe2′CMeG 0.02 0.01 0.09 0.07 71
18 L-Ala OcBu L-Ala OcBu 6OMe2′CMeG 0.32 0.05 0.80 >100
19 L-Ala OcPentyl L-Ala OcPentyl 6OMe2′CMeG 0.06 0.01 0.22 0.03 >100
20 L-Ala OcHx L-Ala OcHx 6OMe2′CMeG 0.05 0.02 0.19 0.08 >100
21 L-Ala OBn L-Ala OBn 6OMe2′CMeG 0.49 1.60 >100
22 L-Ala OSPhEt L-Ala OSPhEt 6OMe2′CMeG 0.49 1.70 88
23 L-Ala O-2,4-diFBn L-Ala O-2,4-diFBn 6OMe2′CMeG 0.26 0.21 1.07 0.92 54
24 L-Ala OTHP L-Ala OTHP 6OMe2′CMeG 13.33 13.02 29.30 15.14 >100
25 L-Ala OIndanol L-Ala OIndanol 6OMe2′CMeG 0.58 0.39 1.30 0.10 70
26 L-Ala OCH2tBu L-Ala OCH2tBu 6OMe2′CMeG 0.06 0.04 0.20 0.12 >100
27 L-Ala OCH2iPr L-Ala OCH2iPr 6OMe2′CMeG 0.07 0.01 0.26 0.01 >100
28 L-Ala OCH2cPropyl L-Ala OCH2cPropyl 6OMe2′CMeG 0.21 0.00 0.66 0.001 >100
29 D-Ala OCH2tBu D-Ala OCH2tBu 6OMe2′CMeG 0.11 0.03 0.50 0.19 >100
30 L-Asp OMe L-Asp OMe 6OMe2′CMeG 10.18 3.17 >40 >100
31 L-Asp OBn L-Asp OBn 6OMe2′CMeG 0.61 0.08 1.90 0.14 >100
32 L-Gly OBn L-Gly OBn 6OMe2′CMeG 0.60 0.13 1.80 0.09 >100
33 L-Gly OCH2tBu L-Gly OCH2tBu 6OMe2′CMeG 0.13 0.02 0.60 0.20 >100
34 L-Leu OcHx L-Leu OcHx 6OMe2′CMeG 0.45 0.52 2.00 2.15 20
35 L-Leu OBn L-Leu OBn 6OMe2′CMeG 0.38 0.02 1.31 0.21 39
36 L-Leu OCH2tBu L-Leu OCH2tBu 6OMe2′CMeG 0.47 0.15 2.40 0.71 27
37 L-Ile OMe L-Ile OMe 6OMe2′CMeG 5.17 1.94 29.5 2.66 >100
38 L-Ile OcHx L-Ile OcHx 6OMe2′CMeG 4.00 0.47 7.10 1.16 14
39 L-Ile OBn L-Ile OBn 6OMe2′CMeG 0.40 0.11 1.56 0.10 24
40 L-Ile OCH2tBu L-Ile OCH2tBu 6OMe2′CMeG 2.90 0.33 6.30 1.36 15
41 L-Met OcHx L-Met OcHx 6OMe2′CMeG 0.60 0.17 2.60 0.11 51
42 L-Met OBn L-Met OBn 6OMe2′CMeG 0.25 0.04 0.77 0.24 >100
43 L-Met OCH2tBu L-Met OCH2tBu 6OMe2′CMeG 2.22 5.00 >100
44 L-Phe OcHx L-Phe OcHx 6OMe2′CMeG 0.50 0.59 2.00 2.20 25
45 L-Phe OBn L-Phe OBn 6OMe2′CMeG 0.32 0.14 1.35 1.07 67
46 L-Phe OCH2tBu L-Phe OCH2tBu 6OMe2′CMeG 0.05 0.02 0.21 0.12 24
47 L-Pro OBn L-Pro OBn 6OMe2′CMeG 0.52 0.21 1.80 0.23 >100
48 L-Pro OCH2tBu L-Pro OCH2tBu 6OMe2′CMeG 0.81 0.05 2.00 0.21 56
49 L-Val OcHx L-Val OcHx 6OMe2′CMeG 2.50 0.35 10.00 0.72 20
50 L-Val OBn L-Val OBn 6OMe2′CMeG 0.12 0.04 0.66 0.35 49
51 L-Val OCH2tBu L-Val OCH2tBu 6OMe2′CMeG 0.72 2.50 32
52 L-Tyr (tBu) OMe L-Tyr (tBu) OMe 6OMe2′CMeG 0.11 0.04 0.50 0.10 89
53 L-PhG OcHx L-PhG OcHx 6OMe2′CMeG 0.32 0.00 1.80 0.04 18
54 L-PhG OCH2tBu L-PhG OCH2tBu 6OMe2′CMeG 0.27 0.03 1.50 0.09 24
55 L-Val-L-Ala OCH2tBu L-Val-L-Ala OCH2tBu 6OMe2′CMeG 0.54 0.26 2.40 0.46 >100
56 β-Ala OBn β-Ala OBn 6OMe2′CMeG 3.80 2.03 >10 >100
57 butylamine butylamine 6OMe2′CMeG 37.80 3.80 >40 >100
58 morpholine morpholine 6OMe2′CMeG >100 >100 >100
59 L-Ala OcPentyl L-Ala OcHx 6OMe2′CMeG 0.04 0.01 0.16 0.03 >100
60 L-Ala OCH2tBu L-Ala OBn 6OMe2′CMeG 0.15 0.04 0.40 0.07 >100
61 L-Ala OCH2tBu L-Ala OtBu 6OMe2′CMeG 0.15 0.01 0.57 0.08 >100
62 L-Ala OCH2tBu L-Ala OcHx 6OMe2′CMeG 0.04 0.01 0.15 0.02 >100
63 L-Ala OCH2tBu L-Pro OMe 6OMe2′CMeG 0.49 2.20 >100
64 L-Ala OCH2tBu L-Val OMe 6OMe2′CMeG 0.17 0.06 0.69 0.15 >100
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of the neopentyl alanine compound as a naphthyl ProTide
(5),12 we were keen to explore the methylene bridged family
starting with the neopentyl-(26) and 2-methylpropyl-(27)
compounds and also the methylene cyclopropyl-(28).
On the basis of our recent report that the 6-ethoxy group can
well substitute for the purine 6-methoxy as a core nucleoside
for anti-HCV ProTides,21 we applied the diamidate method to
the O6-ethyl-2′-C-methylguanosine nucleoside, preparing the
symmetrical cyclohexyl-(74), benzyl-(75), and neopentyl-(76)
L-alanine analogues.
In aryl phosphoramidate ProTides, we have reported on
several occasions the sometimes strong preference, for L-amino
acids over D-analogues,25 and all of the first examples reported
here are L-amino acid derived. However, we did synthesize the
neopentyl-D-alanine analogue 29 of 8.
Although L-alanine is generally strongly preferred, other
natural and unnatural amino acids are also effective as
ProTides,26 and so we did vary the amino acid motif itself.
An attempt was made to consistently select from the same three
ester groups, neopentyl, cyclohexyl, and benzyl, for each new
amino acid to facilitate comparison. Thus, symmetrical
diamidates were prepared from dimethyl-(30) and dibenzyl-
(31) L-aspartic acid, benzyl-(32) and neopentyl-(33) glycine,
cyclohexyl-(34), benzyl-(35), and neopentyl-(36) L-leucine,
methyl-(37), cyclohexyl-(38), benzyl-(39), and neopentyl-(40)
L-isoleucine, cyclohexyl-(41), benzyl-(42), and neopentyl-(43)
L-methionine, cyclohexyl-(44), benzyl-(45), and neopentyl-
(46) L-phenylalanine, benzyl-(47) and neopentyl-(48) L-
proline, and cyclohexyl-(49), benzyl-(50), and neopentyl-(51)
L-valine. The tyrosine methyl ester diamidate was also prepared
as its para-O-tert-butyl ether-(52). Diamidates of the unnatural
amino acid L-phenylglycine were prepared as its cyclohexyl-
(53) and neopentyl-(54) esters. In a prior program on
ProTides of d4T for HIV, we reported a complete loss of
activity on extending from alanine to β-alanine and beyond,27
but it was unclear whether similar restrictions would apply here,
hence we prepared the symmetrical benzyl-β-alanine diamidate-
(56).
Finally, in this series, we wondered if the chemistry
methodology would extend to a dipeptide and whether such
an adduct might be active and so we successfully incorporated
an L-valyl-L-alanine neopentyl ester (55).
Simple amines have not been found to be useful as the amino
component of aryl phosphoramidates, although Idenix has
successfully incorporated benzylamine into their clinical
analogue IDX184.14 However, for diamidates, the SAR was
unknown, and so we prepared the symmetrical butylamine-(57)
and morpholinyl-(58) diamidates. Notably, from a synthetic
perspective, none of the above amino acid and amine variations
presented particular challenges although the yields from these
reactions were not high and remain unoptimized.
Besides seeking to probe the SAR and potential advantages
of symmetrical diamidates, as above, we also wondered if the
synthetic method would allow access to asymmetrically mixed
diamidates. To do this, we slightly adapted the synthetic route
(Scheme 1) to allow the stepwise introduction of two separate
amino acids or one amino acid and one amine. To limit the
large number of possible combinations, and to facilitate
interpretation of the data, one of the amines was generally
kept constant as neopentyl L-alanine and variations were made
in the second amine. Initially, different L-alanine esters, benzyl-
(60), tert-butyl-(61), and cyclohexyl-(62), were combined with
neopentyl L-alanine, followed by different amino acids methyl L-
proline-(63) and methyl L-valine-(64), and then a number of
different simple amines (65−73). Synthetically, it did not
matter much which amine was introduced first. Each of these
asymmetric diamidates was isolated as a roughly 1:1 mixture of
phosphate diastereoisomers as revealed by 31P NMR and
HPLC. No attempt was made to separate the diastereoisomers,
and they were tested as mixtures.
In this way, a substantial set of symmetrical and asymmetric
phosphorodiamidates of 6-O-methyl-2′-C-methylguanosine and
three derivatives of the 6-O-ethyl analogue were prepared and
fully characterized. As expected, all of the symmetrical
diamidates reported above were observed as one peak by 31P
NMR and one signal on analytical HPLC. The 31P NMR shifts
of the symmetrical amino aryl diamidates were ca. 13 ppm,
being rather downfield of our usual aryloxy phosphoramidate
ProTides.28 The asymmetric diamidates gave two peaks by 31P
NMR and for HPLC, in roughly 1:1 ratios, as typically observed
for phosphoramidate ProTides. Other spectroscopic and
analytical data fully confirmed the structure and purity of the
diamidates herein reported.
■ BIOLOGICAL ACTIVITY IN REPLICON
Each of the diamidates described above were tested for HCV
inhibition in a replicon assay, with the clinical anti-HCV
ProTide (5) as positive control (Table 1). Both EC50 and EC90
values are reported, along with standard deviations, in a 72 h
HCV replicon assay. In general EC90 values were 2−5-fold
higher than EC50 values, and the discussion below will focus on
Table 1. continued
EC50 (￿M) EC90 (￿M)
compd AA ester/amine AA ester/amine nucleoside av SD av SD CC50 (￿M)
65 L-Ala OBn butylamine 6OMe2′CMeG 0.44 0.28 1.68 0.94 >100
66 L-Ala OCH2tBu butylamine 6OMe2′CMeG 0.41 0.28 1.50 0.75 >100
67 L-Ala OCH2tBu pentylamine 6OMe2′CMeG 0.11 0.02 0.52 0.05 >100
68 L-Ala OCH2tBu cyclopropylamine 6OMe2′CMeG 0.87 0.11 4.70 0.45 >100
69 L-Ala OCH2tBu BnNH 6OMe2′CMeG 0.43 0.02 1.90 0.11 >100
70 L-Ala OCH2tBu PhNH 6OMe2′CMeG 0.27 0.01 0.82 0.00 >100
71 L-Ala OCH2tBu NaphNH 6OMe2′CMeG 0.13 0.05 0.56 0.18 >100
72 L-Ala OCH2tBu diethylamine 6OMe2′CMeG 3.70 >10 >100
73 L-Ala OCH2tBu pyrrolidine 6OMe2′CMeG 0.87 0.02 4.00 0.16 >100
74 L-Ala OcHx L-Ala OcHx 6OEt2′CMeG 0.05 0.00 0.15 0.02 69
75 L-Ala OBn L-Ala OBn 6OEt2′CMeG 0.29 0.04 1.00 0.29 62
76 L-Ala OCH2tBu L-Ala OCH2tBu 6OEt2′CMeG 0.04 0.01 0.11 0.04 72
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the EC50 numbers. In addition, the cell cytotoxicities (CC50) in
the replicon cell line (Huh7) are reported.
As noted in Table 1, the three parent nucleosides, 2′-C-
methyl guanosine 4 and the 6-methoxy 8 and 6-ethoxyl 9
analogues, display only modest anti-HCV activity, with EC50
values in the 2−10 ￿M range. By comparison, 5 is active at
nanomolar levels, with an EC50 of 10 nM and an EC90 of 40
nM, representing a ca. 400-fold potency boost over the
respective nucleoside.12 Compound 5 does show some
cytotoxicity to Huh7 cells in this assay at 7 ￿M, but its high
potency still leads to a significant SI of ca. 700.
Examining the potency of the first family of symmetrical L-
alanine phosphorodiamidates, we note a consistent and clear
increase in potency for the n-alkyl esters as they extended from
methyl (10 EC50 = 6 ￿M) to n-pentyl (14 EC50 = 0.03 ￿M).
The n-pentyl L-alanine 14 is thus about 3 times less active than
5, but notably it is also about 10 times less cytotoxic. It is
interesting to note that the calculated lipophilicity (ClogP)
values for this series range from 0.5 (methyl) to 4.7 (n-pentyl).
It maybe that lipophilicity and potency correlate, however,
there are exceptions. Clearly, the n-pentyl 14 is an interesting
compound with a very attractive SI.
Branching the amino acid ester at the α (Table 1, 15, 16), β
(26, 27), or γ (17) position does not significantly change
activity or toxicity relative to the straight chain compounds.
Thus, the isopropyl ester 15 and the n-propyl ester 12 have
Table 2. Replicon Activity for Symmetrical Phosphorodiamidates
replicon EC50 (￿M)
(R2)
amino acid compd cyclohexyl benzyl neopentyl CC50 in Huh7 cells (￿M)
L-alanine 20 0.05 >100
21 0.49 >100
19 0.06 >100
D-alanine 29 0.11 >100
glycine 32 0.60 >100
33 0.13 >100
L-leucine 34 0.45a 20
35 0.38 39
36 0.47 27
L-isoleucine 38 4.0 14
39 0.40 24
40 2.9 15
L-valine 49 2.5 20
50 0.12 49
51 0.72b 32
L-proline 47 0.52 >100
48 0.81 56
L-methionine 41 0.60 51
42 0.25 >100
43 2.22b >100
L-phenylglycine 53 0.32 18
54 0.27 24
L-phenylalanine 44 0.50a 25
45 0.32 67
46 0.05 24
L-aspartic (OBn) 31 0.61 >100
aLarge standard deviation. bSingle assay result.
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similar activities, and the β branched neopentyl ester 26 is
similar to the n-pentyl ester 14. Indeed, several of these
branched esters such as compounds 17 and 27 are very potent,
with excellent SI values. We were particularly interested in the
neopentyl L-alanine analogue 26 given its similarity to our
clinical agent 5. This compound reveals an EC50 of 0.06 ￿M
and EC90 of 0.2 ￿M and is only 5-fold less active in this assay
than 5. However, in common with many of the phosphor-
odiamidates, this compound is significantly less cytotoxic, with
CC50 >100 ￿M. Thus, the SI for 26 is >1600, which exceeds
that of 5.
Cyclic esters of L-alanine such as cyclopentyl-(19) and
cyclohexyl-(20) are also very potent in the replicon assay and
show no Huh7 cell toxicity at 100 ￿M. However, the cyclobutyl
derivative 18 is about 5-fold less active with an EC50 of 0.32
￿M, and the tetrahydropyranyl ester 24 is more than 200-fold
less active compared to 20.
Interestingly, the benzyl ester derivatives of L-alanine (Table
1, 21−23) are somewhat less active than many of the alkyl ester
analogues, being 5−10-times less active than the cyclohexyl
compound for example. This is in marked contrast to the
phosphoramidate ProTides SAR and much of our prior
experience.28
An observation from our phosphoramidate SAR is that the
purine C-6-substituent can be varied considerably and that the
6-ethoxy may be particularly effective.24 As noted in Table 1,
the same applies to this series, with the cyclohexyl-(74), benzyl-
(75), and neopentyl-(76) purine C-6-ethoxy derivatives all
being equipotent with their C-6-methoxy analogues. Indeed,
with an EC90 of 110 nM, the neopentyl L-alanine analogue of
the 6-ethoxy nucleoside 76 emerged as one of the most potent
compounds in the present study.
The SAR next turned to symmetrical phosphorodiamidates
with amino acids other than L-alanine. The subtlest change was
to make the D-alanine analogue as its neopentyl ester 29. In
contrast to our earlier work on D-amino acids in aryl
phosphoramidate ProTides,25 here we see only a slight (ca.
2-fold) loss of activity. This again points to quite a new and
separate SAR for these diamidates as compared to aryloxy
phosphoramidates.
In generating the amino acid SAR in this series of
symmetrically substituted phosphorodiamidates, effort was
made to use three similar esters for each different amino acid
derivative to facilitate comparison. The three ester groups
selected were the cyclohexyl, benzyl, and neopentyl. Table 2
shows the compiled data.
A number of observations can be made from the data in
Table 2. First, the benzyl esters do not greatly distinguish the
different amino acids. The replicon activities for nine amino
acids with benzyl ester groups range from 0.25 to 0.61 ￿M, only
2- to 3-fold, which is similar to the variability in the replicon
assay.
The neopentyl and cyclohexyl ester groups distinguish the
different amino acids and give a similar rank order. Thus, the
best amino acid for both the cyclohexyl and the neopentyl
esters is the L-alanine, whereas the worst is L-isoleucine.
Overall evaluation of the amino acid SAR leads to conclusion
that small amino acid substituents like glycine or alanine are
preferred and that increasing the size of the amino acid R1
group as for L-leucine and L-methionine is detrimental to
replicon activity, as is branching of the amino acid as for L-
valine, L-isoleucine, and L-phenylglycine.
The exception to this rule is that the neopentyl L-
phenylalanine derivative 46 is very potent (EC50 = 0.05 ￿M)
in the replicon assay. The cyclohexyl L-phenylalanine derivative
44 was tested twice, and one value was 10-fold higher than the
other (EC50 = 0.083 and 0.92). It is possible that further testing
would refine these data. Further supporting this surprising L-
phenylalanine SAR, the L-tyrosine derivative 52, as the para-O-
tert-butyl ether, also had good activity and limited toxicity in the
replicon assay (EC50 = 0.11 ￿M, CC50 = 89 ￿M).
A further observation in this series of symmetrical
phosphorodiamidates is that some cytotoxicity is observed in
Huh7 cells for the amino acids other than alanine and glycine.
In fact, the cyclohexyl L-isoleucine 38 demonstrates that not all
phosphorodiamidates are equivalent. Compound 38 has an
EC50 of 4 ￿M and a CC50 of 14 ￿M, for an SI of only ca. 4, and
being the most cytotoxic diamidate studied.
As an extension of the growing symmetrical phosphorodia-
midate SAR, a more complicated, dipeptide, L-Val-L-Ala
neopentyl ester 55, in which the L-valine nitrogen forms the
phosphoramidate linkage, was prepared. Testing in the replicon
assay shows that 55 has similar replicon activity (Table 1, EC50
= 0.54 ￿M) as the neopentyl L-valine derivative 51. It is unclear
how this dipeptide would fit in with the putative metabolic
process (see Scheme 2) and may suggest the existence of
another metabolic pathway leading to the triphosphate
formation for this compound.
Working the SAR in the opposite direction, simple amine
substituted phosphorodiamidates were tested in the replicon
assay. The n-butyl amine analogue 57, which may be
Scheme 2. Putative Initial Activation Route of
Phosphorodiamidates
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considered similar to the L-leucine derivatives, but without the
α carboxylate, has a replicon EC50 of 38 ￿M, which is about
100-fold less active than the L-leucine derivatives. This is
consistent with the proposed metabolic route (Scheme 2)
where the carboxylate anion plays a key role. The positioning of
the carboxylate β to the amine, as for the β-alanine analogue 56,
results in moderate activity in the replicon assay (Table 1, EC50
= 3.8 ￿M). The morpholino phosphorodiamidate 58, an
example of a secondary amine, is inactive even at 100 ￿M in the
replicon assay. Both of these simple amine phosphorodiami-
dates 57 and 58 are much less active than the parent nucleoside
8 in the replicon assay, supporting our understanding that there
is a limited direct cleavage of the P−O bond, leading to free
nucleoside, in the replicon assay.
Although one of the key motivations for this new ProTide
motif was to generate an achiral phosphate center, we were
interested in understanding some aspects of the asymmetric
diamidate SAR. Our synthetic route (Scheme 1) did allow the
stepwise addition of two different amines. Each of these
asymmetric diamidates were isolated as a roughly 1:1 mixture of
phosphorus diastereoisomers, and no attempt was made to
separate them and they were tested as mixtures. To facilitate
comparison, generally, one of the two amines was maintained as
the L-alanine neopentyl ester (Table 1).
From this basis, our SAR study was focused in three areas.
First, we explored compounds 60−62 in which the second
amine was also L-alanine but with different ester groups. The
replicon results indicated that the presence of the L-alanine
neopentyl ester provides good antiviral potency even in the
presence of difficult to cleave29 tert-butyl L-alanine ester 61.
The presence of two easily cleavable esters such as for
derivatives 59 and 62 slightly increased the replicon activity
comparing to 61 but one “cleavable” group was sufficient.
Next, the SAR of asymmetrical phosphorodiamidates, where
the neopentyl L-alanine is combined with different amino acids
was briefly explored. The methyl L-proline 63 and the methyl L-
valine 64 amino acids had moderate replicon activity (Table 1),
more similar to the symmetrical L-prolines and L-valines than
the very potent symmetrical neopentyl L-alanine 26. It might be
that compounds 63 and 64 have different metabolic
intermediates (78, Scheme 2) than does 26.
Third, the phosphorodiamidate SAR of simple amines
combined with neopentyl L-alanine was extensively studied
(66−73, Table 1). In general, these compounds had moderate
to good activity, with EC50 values ranging from 0.1 to 0.9 ￿M
for monosubstituted amines, more active than the symmetrical
simple amines, but less active than the symmetrical neopentyl L-
alanine derivative (26). Presumably, conversion of compounds
66−73 involves cleavage of the L-alanine neopentyl ester
followed by the elimination of the simple amine to form the key
metabolic intermediate (78, Scheme 2). Thus, it might be
expected that the amines that make the best leaving groups
such as phenylamine 70 and naphthylamine 71, would be the
most active (EC50 = 0.27 and 0.13 ￿M) and that a poor leaving
group such as diethyl amine, in derivative 72, would be the least
active (EC50 = 3.7 ￿M, Table 1).
In conclusion, all but one of the 67 phosphorodiamidates
tested in the replicon assay were active at or below micromolar
concentrations, with 55 of them active below 1 ￿M and 12
active below 100 nM. Many are noncytotoxic at high ￿M levels,
some at 100 ￿M, giving attractive SI values for many
compounds. Clearly several of these compounds were worthy
of advancing to in vivo studies.
■ STABILITY ASSAYS
Given the new structural motif we are reporting and the very
promising replicon data (as described above), we sought to
establish some outline stability data under a variety of
conditions. To begin with, the lead symmetrical neopentylala-
nine compound 26 was dissolved in pH 7 phosphate buffer at
Figure 3. 31P NMR kinetic study of 26 in the presence of carboxypeptidase Y. Conditions: 5.0 mg of 26 in 200 ￿L of acetone-d6 + 400 ￿L of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 ￿L of Trizma buffer (pH 7.4).
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25 °C and monitored by 31P NMR over 14 h. Compound 26
was observed at 13.2 ppm, and no additional signal(s) appeared
over the course of the experiment (see Supporting Information
for stability spectra). HPLC also indicated no detectable
decomposition. We have previously reported acid stability
data27 for several acyclovir aryloxy phosphoramidate ProTides.
As a representative example, the phosphorodiamidate (26) was
dissolved in citric acid−HCl buffer at pH 2 and maintained at
either 37 or 47 °C while being monitored by 31P NMR over 14
h. Despite the acidic pH and elevated temperatures, the
samples remained entirely stable over the course of the assay. A
base stability study was conducted on compound 26 at pH 8.5/
37 °C and pH 11/37 °C, and these studies revealed slow
decomposition. After 17 h at pH 11, the majority species was
still unchanged (26), with only minor peaks at 6.9 ppm and
−4.3 ppm. The peak at 6.9 ppm corresponds to an amino acid
phosphoramidate derivative similar to compound 77 (see
Scheme 2 below), suggesting one phosphorodiamidate P−N
bond on compound 26 had been hydrolyzed under the aqueous
basic conditions. However, the decomposition is rather slow,
with a half-life exceeding 100 h (if first order). From this initial
stability data, it seems possible that the phosphorodiamidates
have a pH stability profile that is consistent with oral dosing.
Next, we studied the stability of compound 26 with human
serum at 37 °C. As before, the solution was monitored at 1 h
intervals over by 31P NMR over 12 h. The phosphorodiamidate
26 gave a peak at 14.5 ppm under these conditions, and no sign
of degradation was observed by 31P NMR. Thus, as noted for
aryloxy phosphoramidates,30 the present phosphorodiamidates
seem essentially stable in human serum, certainly for periods of
hours appropriate for human dosing.
As we have reported previously,12,30 the initial step of the
conversion of aryloxy amino acid ester phosphoramidates
(ProTides) to phosphates is thought to involve an enzyme-
mediated cleavage of the amino acid ester group. We have also
reported on the use of 31P NMR and a buffered solution of the
enzyme carboxypeptidase Y as an in vitro model for studying
the initial steps of ProTide30 activation. We sought to apply this
method to our new family of anti-HCV phosphorodiamidates.
Thus, compounds of interest were dissolved in acetone-d6 and
TRIZMA buffer at pH 7.4, and the 31P NMR spectrum was
recorded as the baseline. Then carboxypeptidase Y (cathepsin)
was added and spectra recorded at intervals up to 13 h (Figure
3). The data from these experiments were used to map a
possible phosphorodiamidate metabolic pathway (Scheme 2).
The first compound studied was the symmetrical neopentyl
ester of L-alanine 26, which has a 31P NMR shift of 14.2 ppm at
baseline (Figure 3). After 10 min, a small downfield metabolite
peak is observed at 14.9 ppm, which is consistent with cleavage
of the neopentyl ester. The peak at 14.9 ppm builds up for
approximately one hour, then diminishes, with a new peak
emerging at 6.95 ppm. This is first observed at ca. 40 min and
continues to grow through the course of the experiment. The
peak at 6.95 corresponds to the key amino acid phosphate
derivative 77 (R = CH3) (Scheme 2). This was determined by
synthesizing compound 77 (R = CH3) and using it as an
analytical reference standard (data not shown). Intermediate 77
could form by intramolecular attack of the amino acid
carboxylate anion onto the phosphorus, with elimination of
the second amino acid, followed by spontaneous hydrolysis of
the cyclic, mixed anhydride intermediate 78a,b. No direct 31P
NMR evidence (Figure 3) was obtained for this cyclic
compound, consistent with it being a short-lived metabolic
intermediate. As discussed in our publications on aryloxy amino
acid phosphoramidates, final conversion to the nucleoside
monophosphate is generally thought to be effected by enzymes
of the histidine triad nucleotide binding (Hint) family (Scheme
2).30,33
This initial evidence indicates that nucleoside phosphor-
odiamidates are converted to nucleoside monophosphates in a
similar fashion as aryl phosphoramidates, that is, via metabolite
77. To further support this hypothesis, a second phosphor-
Figure 4. 31P NMR kinetic study of 21 in the presence of carboxypetidase Y. Conditions: 5.1 mg of 21 in 200 ￿L of acetone-d6 + 400 ￿L of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 ￿L of Trizma buffer (pH 7.4).
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odiamidate, the symmetrical benzyl L-alanine derivative 21, was
studied in the same system (Figure 4). In this case, a similar 31P
NMR pattern, with the formation of the same key metabolite at
6.94 ppm (77, R = CH3) is observed, but there are subtle
differences. Parent 21 shows one phosphorus 31P NMR peak at
14.08 ppm at baseline, which disappears within the first 30 min
upon incubation with enzyme. However, in this case, two
downfield singlet peaks are observed, one small and transient at
14.46 ppm and the other larger and longer lived at 14.78 ppm.
Three possibilities exist to explain these two new downfield
peaks: (a) one specific benzyl ester is cleaved by carbox-
ypeptidase Y to give either 79a or 79b, but not both, followed
by a second ester cleavage to give 80; (b) both pro-pR and pro-
pS benzyl esters are cleaved by carboxypeptidase Y and both
79a and 79b are observed, but cleavage of both benzyl esters
does not occur; (c) the peak at 14.46 ppm represents mono
ester cleavage, where the 31P NMR signals of 79a and 79b
overlap, and the peak at 14.78 represents diester cleavage to
give 80.
Regardless of how the amino acid ester groups are cleaved by
this particular enzyme, the important information from the 31P
NMR experiments is that compound 21 goes through the same
common intermediate 77 (R = CH3) as does compound 26.
In Supporting Information, we present further detail of the
kinetics of appearance of each species in the carboxypeptidase Y
mediated cleavage of 21.
It should be noted that 26 is nearly 10-fold more active than
21 in the HCV replicon assay (Table 1), however comparison
Figure 5. 31P NMR kinetic study of 65 in the presence of carboxypetidase Y. Conditions: 4.9 mg of 65 in 200 ￿L of acetone-d6 + 400 ￿L of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 ￿L of Trizma buffer (pH 7.4). * Phosphate impurity in Trizma buffer; in blank and
remains unchanged throughout.
Figure 6. 31P NMR kinetic study of 73 in the presence of carboxypetidase Y. Conditions: 5.3 mg of 73 in 200 ￿L of acetone-d6 + 400 ￿L of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 ￿L of Trizma buffer (pH 7.4).
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of Figures 3 and 4 shows that the speed of carboxypeptidase Y
processing is very similar for the two prodrugs, and thus the
replicon and enzyme assays do not correlated directly, but we
do regard enzyme mediated ester cleavage as a useful tool to
study our prodrugs in vitro.
If a carboxylate anion intermediate such as 79a, 79b, or 80
can eliminate an amino acid moeity to give intermediate 77, we
wondered if simple primary or secondary amines could likewise
be eliminated from asymmetric phosphorodiamidates such as
65 and 73. Figure 5 shows the 31P NMR traces for an
experiment with the benzyl L-alanine, n-butyl amine derivative
65, and carboxypeptidase Y.
Because 65 is asymmetrical, two peaks are seen in the
baseline 31P NMR (16.59 and 16.75 ppm). Both peaks
disappear within 120 min, but the diastereomer at 16.75 is
cleaved faster. Once again. a peak at 6.94, identified as
compound (77, R = CH3), is observed growing in magnitude
during the course of the experiment. A very similar pattern is
observed in Figure 6, when the neopentyl L-alanine, pyrrolidine
asymmetrical phosphoramidate 73 was incubated with
carboxypeptidase Y. Again compound 77 (R = CH3) is
observed at 6.94 ppm and grows in over 14 h. Interestingly, in
this case, only one of the two diastereomers of compound 73
(31P NMR δ = 15.54 ppm) is cleaved by carboxypeptidase Y
over the course of the experiment.
Summarizing this portion or our work, we have built on our
previous understanding that aryloxy groups are eliminated from
asymmetrical phosphoramidates containing an amino acid
carboxylate by showing that a second amino acid or a primary
amine or a secondary amine can also be eliminated to give the
key intermediate 77. The data on 21, 26, 65, and 73 supports
the notion that only one ester cleavage is necessary and that the
second amine loss is rapid following the first ester cleavage.
Docking Studies. To further support the above, we
conducted some docking studies on several asymmetric
diamidates, using published31 crystal structure of carboxypepti-
dase Y. Thus, as shown in Figure 7a,b the Sp diastereomer of
65 binds significantly better than the Rp diastereomer.
In the case of the Sp isomer, the stabilization by H-binding of
two glycine residues (Gly52, 53) is notable and the nucleophilic
active site of Ser146 is also well positioned. These docking data
would then suggest that one diastereoisomer of 65 might be
processed better than the other. On the basis of the clear
kinetic difference noted above (Figure 5), perhaps the more
downfield species in 31P NMR of 65 is the Sp isomer. It is
interesting to wonder if the differing kinetics of metabolism
here may lead to a difference in biological potency as we have
noted in some cases for aryl phosphoramidates.5 However, we
were unable to separate the compound 65 diastereomers to test
this hypothesis.
Pharmacokinetics. The HCV replicon, stability, and
carboxypeptidase Y data suggests that our new phosphor-
odiamidate prodrug strategy may be a promising means of
delivering 2′-C-methylguanosine triphosphate into cells. The
Figure 7. (a) Docking of compound 65−Rp isomer within the catalytic site of carboxypeptidase Y. (b) Docking of compound 65−Sp isomer within
the catalytic site of carboxypeptidase Y.
Table 3. Rat Liver Triphosphate Levels from PK Analysis of Phosphorodiamidates





5e L-Ala OCH2tBu 0.01 1446.7 983.3 8.0 24557
26 L-Ala OCH2tBu 0.06 1580.0 800.0 8.0 25147
13 L-Ala O-n-butyl 0.07 1553.3 719.7 8.0 27671
14 L-Ala O-n-pentyl 0.03 1042.3 506.0 8.0 18600
16 L-Ala O-(R,S)-2-butyl 0.15 907.7 538.7 8.0 16252
19 L-Ala O￿cyclopentyl 0.06 1523.3 610.0 8.0 24546
25 L-Ala O-2￿indanol 0.58 632.0 632.0 24.0 10642
29 D-Ala OCH2tBu 0.11 598.3 441.7 8.0 11608
50 L-Val OBn 0.12 359.5 73.6 4.0 4478
aCmax: Maximum observed concentration.
bClast: Concentration at the last measurable time-point.
cTmax: Time at which maximum concentration was
observed. dAUC0−t: area under the concentration−time curve from time 0 to the last measurable concentration. eCompound 5 is a the
phosphoramidate INX-189 (see Figure 2).
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next hurdle was to determine if this prodrug strategy works in
vivo in a rodent. Because of our growing experience with
phosphoramidates such as 5 in rats, we decided to continue
with the rat as our initial PK model for the phosphorodiami-
dates. Eight symmetrical derivatives were selected for rat PK
studies (13, 14, 16, 19, 25, 26, 29, and 50, Table 3) based on
activity in the replicon assay and structural considerations. We
focused on symmetrical diamidates because they are
represented by single diastereoisomers, which would simplify
further development. All but two were L-alanine derivatives
because we wanted to fully explore the ability of these relatively
simple derivatives to provide sufficient liver triphosphate levels.
Compounds were formulated in 95% Capmul MCM/5%
Tween 80, and doses of 10 mg/kg were administered by oral
gavage to male Sprague−Dawley rats. Liver samples were
collected up to 24 h postadministration and were snap-frozen in
liquid nitrogen. Liver concentrations of 2′-C-methylguanosine
triphosphate were determined by LC-MS/MS. Results for these
eight phosphorodiamidates are compared to 5 in Table 3.
The main observation is that all compounds tested produced
significant levels of triphosphate in rat livers from a 10 mg/kg
dose, further validating phosphorodiamidates as effective
phosphate prodrugs. In addition, several of the phosphor-
odiamidates provide similar liver triphosphate exposures as the
clinical compound 5, which has shown efficacy against HCV in
phase Ib clinical trials.23 The amount of 2′-C-methylguanosine
triphosphate necessary to achieve an EC90 in the replicon assay
can be determined by measuring triphosphate levels in the
replicon cells upon incubation with a 2′-C-methylguanosine
based inhibitor such as 5. This EC90 triphosphate level in cells
can be extrapolated to EC90 triphosphate levels in the liver, as
measured in ng of triphosphate/gram of liver tissue. The value
we have calculated is 243 pmol of triphosphate per gram of liver
(equal to 131 ng/g).32 Thus, for all phosphorodiamidates
tested, except for 50, the level of triphosphate 24 h post dose, is
several fold above 131 ng/g level necessary to achieve 90%
inhibition of HCV replication (Table 3).
An important part of our evaluation of any new prodrug
approach for delivering 2′-C-methylguanosine triphosphate,
including these phosphorodiamidates, is measurement of
systemic nucleoside (2′-C-methylguanosine, 4) levels after
oral dosing of the prodrug. Our desire is to limit the systemic
exposure of this nucleoside. The plasma 2′-C-methylguanosine
levels for these eight phosphorodiamidates were measured, and
all but compound 13 had lower nucleoside Cmax values than 5
(<100 nM), and it is only slightly higher (data not shown).
The neopentyl L-alanine diamidate 26 has both the highest
Cmax and Clast of any diamidate tested. Figure 8 shows rat liver
triphosphate levels after a 10 mg/kg dose for the clinical
compound 5 and for 26. Triphosphate levels were measured at
eight time points over 24 h. It is clear that both prodrug
strategies produce similarly high levels of triphosphate. The n-
butyl L-alanine ester 13 has the highest overall triphosphate
AUC (Table 3), and the cyclopentyl ester 19 also has excellent
AUC and Clast values. These compounds along with the n-
pentyl ester 14 were advanced to monkey PK studies. A
combination of rat PK, monkey PK, and preliminary rodent
toxicology studies will be used to help select a clinical
candidate. These additional studies will be reported elsewhere
upon completion.
■ CONCLUSIONS
In conclusion, we report on a new family of phosphate
prodrugs based on phosphorodiamidates. This type of 5′-
monophosphate prodrug has the advantage that it can be
designed to be achiral at the phosphate center if desired. We
report on a range of novel prodrugs derived from amino acids
and simple amines and build a substantial HCV replicon SAR
for both symmetrical and asymmetrical phosphorodiamidates of
2′-C-methyl-6-O-methylguanosine. The replicon data suggests
that one aminoacyl ester is essential for potent activity versus
HCV. The phosphorodiamidates are stable in acid and mild
base and also in human serum. Carboxypeptidase Y is able to
activate these compounds to a nucleoside aminoacid phosphate
key intermediate, which is also the essential metabolic
intermediate for our earlier aryloxy ProTides. Many of the
novel compounds in this study show low nanomolar activity
versus HCV in replicon coupled with low cytotoxicity in the
Huh7 replicon cell line. Eight potent HCV inhibitors were
advanced to PK studies in Sprague−Dawley rats, and it was
demonstrated that they all provided substantial 2′-C-methyl-
guanosine triphosphate levels, in rat livers, that were
maintained over a period of 24 h. This body of work has
validated phosphorodiamidates as prodrugs for 2′-C-methyl-
guanosine both at the in vitro and the in vivo levels. Further in
vivo studies are underway that are intended to lead toward
selection of a phosphorodiamidate prodrug for HCV clinical
studies.
■ EXPERIMENTAL SECTION
General. Anhydrous solvents were purchased from Aldrich and
used without further purification. All reactions were carried out under
an argon atmosphere. Reactions were monitored with analytical TLC
on silica gel 60-F254 precoated aluminum plates and visualized under
UV (254 nm) and/or with 31P NMR spectra. Column chromatography
was performed on silica gel (35−70 ￿M). Proton (1H), carbon (13C),
and phosphorus (31P) NMR spectra were recorded on a Bruker
Avance 500 spectrometer at 25 °C. Spectra were autocalibrated to the
deuterated solvent peak, and all 13C NMR and 31P NMR were proton-
decoupled. Analytical and semipreparative HPLC were conducted by
Varian Prostar (LC Workstation-Varian prostar 335 LC detector)
using Varian Polaris C18-A (10 ￿M) as an analytic column and Varian
Polaris C18-A (10 ￿M) as a semipreparative column; elution was
performed using a mobile phase consisting of water/acetonitrile in
gradient (system1, 90/10 to 0/100 v/v in 30 min) or water/methanol
(system 2, 90/10 to 0/100 v/v in 30 min). High-resolution mass
spectra (HRMS) was performed as a service by Cardiff University,
using electrospray (ES). Compound purity was assured by a
Figure 8. Rat liver 2′-C′-methyl guanosine triphosphate levels from
compounds 5 and 26.
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combination of high field multinuclear NMR (H, C, P) and HPLC.
Purity by the latter was always >95% with no detectable parent
nucleoside for all final products.
Standard Procedure A: Synthesis Of Symmetrical Diami-
dates. To a suspension of the nucleoside (1.0 mol equiv) in
anhydrous tetrahydrofuran, triethylamine (1.0−1.2 mol equiv) was
added. After stirring for 30 min at room temperature, phosphoryl
chloride (1.0−1.2 mol equiv) was added dropwise at −78 °C. The
reaction mixture was stirred for 30 min at −78 °C and then allowed to
warm to room temperature. Anhydrous dichloromethane was added,
followed by amino acid ester (5.0 mol equiv) and triethylamine (10.0
mol equiv) at −78 °C. After stirring at room temperature for 20 h,
water was added and the layers are separated. The aqueous phase was
extracted with dichloromethane and the organic phase washed with
brine. The combined organic layers were dried over anhydrous sodium
sulfate, filtered, and evaporated to dryness. The resulting residue was
purified by silica gel column chromatography using as an eluent a
gradient of methanol in dichloromethane or chloroform. In some
cases, a subsequent repurification was necessary either by preparative
HPLC (gradient of methanol in water) or preparative TLC.
Standard Procedure B: Synthesis of Symmetrical Diami-
dates. To a solution of the nucleoside (1.0 mol equiv) in anhydrous
triethylphosphate was added phosphoryl chloride (2.0 mol equiv) at 0
°C. The reaction mixture was stirred for 24 h at 5 °C. Anhydrous
dichloromethane was added to the reaction mixture followed by amino
acid ester (5.0 mol equiv) and diisopropylethylamine (10.0 mol equiv)
at 0 °C. After stirring at 5 °C for 5 days, water was added and the
layers were separated. The aqueous phase was extracted with
dichloromethane and the organic phase washed with brine. The
combined organic layers were dried over anhydrous sodium sulfate,
filtered, and evaporated to dryness. The resulting residue was purified
by silica gel column chromatography using as an eluent a gradient of
methanol in dichloromethane. A subsequent repurification, if
necessary, was accomplished either by preparative HPLC (gradient
of methanol in water) or preparative TLC.
Standard Procedure C: Synthesis of Asymmetrical Diami-
dates. To a suspension of the nucleoside (1.0 mol equiv) in
anhydrous tetrahydrofuran, triethylamine (1.0 mol equiv) was added.
After stirring for 30 min at room temperature, phosphoryl chloride
(1.0 mol equiv) was added dropwise at −78 °C. The reaction mixture
was stirred for 30 min at −78 °C and then allowed to warm to room
temperature. Anhydrous dichloromethane was added, followed by the
addition of amino acid ester or amine (1 mol equiv) and anhydrous
triethylamine (2 or 1 mol equiv, respectively) at −78 °C. Reaction was
warmed to room temperature and monitored by 31P NMR. When
NMR indicated completion of the reaction (no starting material,
presence of monosubstituted product), a second amino acid ester or
amine (5 mol equiv) was added followed by the addition of
triethylamine (10 or 5 mol equiv, respectively) at −78 °C. After
stirring at room temperature for 16−20 h, water was added and the
layers were separated. The aqueous phase was extracted with
dichloromethane. The combined organic layers were dried over
anhydrous sodium sulfate, filtered, and evaporated to dryness. The
resulting residue is purified by silica gel column chromatography using
as an eluent a gradient of methanol in chloroform.
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-Bis(methoxy-L-alaninyl) Phos-
phate (10). The phosphorodiamidate 10 was prepared according to
the standard procedure B.
In a first step, a suspension of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous tetrahydrofuran (4 mL) was
reacted with triethylamine (135 ￿L, 0.964 mmol) and phosphorus
oxychloride (89 ￿L, 0.964 mmol). In a second step, anhydrous
dichloromethane (4 mL), L-alanine methyl ester hydrochloride salt
(561.1 mg, 4.02 mmol), and triethylamine (1.12 mL, 8.03 mmol) were
added.
After workup, silica gel column chromatography and preparative
HPLC, 19.8 mg of (10) was obtained in 4.4% yield as an off-white
solid. 1H NMR (500 MHz, MeOD-d4) δ 7.99 (s, 1H, H-8), 5.99 (s,
1H, H1′), 4.44−4.34 (m, 2H, H5′), 4.31 (d, 1H, J = 8.9 Hz, H3′),
4.21−4.16 (m, 1H, H4′), 4.07 (s, 3H, OCH3), 3.98−3.89 (m, 2H, 2×
CHα Ala), 3.70, 3.69 (2s, 6H, 2× OCH3 ester), 1.33 and 1.32 (2d, 6H,
J = 7.1 Hz, CH3 Ala), 1.00 (s, 3H, CH3).
13C NMR (126 MHz, MeOD-d4) δ 176.10 (2d,
3JC−C−N−P = 4.8 Hz,
2× C￿O Ala), 162.75 (C6), 161.95 (C2), 154.21 (C4), 139.33 (C8),
115.54 (C5), 93.19 (C1′), 82.33 (d, 3JC−C−O−P = 7.6 Hz, C4′), 80.02
(C2′), 74.73 (C3′), 66.13 (d, 2JC−O−P = 4.8 Hz, C-5′), 54.21 (OCH3),
52.72 (2× CH3 ester), 51.01, 50.93 (2d, 2JC−N−P = 2.3 Hz, 2× CH Ala),
20.86, 20.67 (2d, 3JC−C−N−P = 6.2 Hz, 2× CH3 Ala), 20.27 (2′-CH3).
31P NMR (202 MHz, MeOD-d4) δ 14.00. HPLC tR = 8.86 min
(system 1).
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-Bis(benzoxy-L-alaninyl) Phos-
phate (21). The phosphorodiamidate 21 was prepared according to
the standard procedure B.
In the first step, a solution of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous triethylphosphate (1 mL) was
reacted with phosphorus oxychloride (148 ￿L, 1.61 mmol). In the
second step, anhydrous dichloromethane (4 mL), the tosylate salt of
benzoxy-L-alanine (1.41 g, 4.02 mmol), and diisopropylethylamine
(1.40 mL, 8.03 mmol) were added to the previous mixture. After
workup, silica gel column chromatography and preparative HPLC,
50.1 mg of 21 was obtained in 8.7% yield as an off white solid. 1H
NMR (500 MHz, MeOD-d4) δ 7.96 (s, 1H, H-8), 7.34−7.25 (m, 10H,
2× Ph), 5.99 (s, 1H, H1′), 5.16−5.02 (m, 4H, 2× CH2 ester), 4.41−
4.31 (m, 2H, H-5′), 4.29 (d, 1H, J = 9.0 Hz, H3′), 4.21−4.15 (m, 1H,
H4′), 4.04 (s, 3H, OCH3), 4.02−3.94 (m, 2H, 2× CH Ala), 1.33 (d,
6H, J = 7.1 Hz, 2× CH3 Ala), 0.99 (s, 3H, CH3). 13C NMR (126 MHz,
MeOD-d4) δ 175.42, 175.36 (2d, 2× C￿O, 3JC−C−N−P = 6.3 Hz,
ester), 162.72 (C6), 161.91 (C2), 154.56 (C4), 139.31 (C8), 137.32,
137.29 (d, 2× C ipso OCH2Ph), 129.55, 129.5, 129.24, 129.21
(OCH2Ph), 115.55 (C5), 93.17 (C1′), 82.37 (C4′), 80.01 (C2′), 74.81
(C3′), 67.89,67.87 (2× OCH2Ph), 66.26 (C5′), 54.19 (OCH3), 51.13,
51.08 (2d, 2× Cα Ala), 20.79−20.58 (2d, 3JC−C−N−P = 6.3 Hz, 2× CH3
Ala), 20.26 (2′CCH3).
31P NMR (202 MHz, MeOD-d4) δ 13.93.
HPLC tR = 13.16 min (system 1).
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-[(Benzoxy-L-alaninyl)-(2,2-dime-
thylpropoxy-L-alaninyl)] Phosphate (60). The phosphorodiami-
date 60 was prepared according to the standard procedure C.
In the first step, a solution of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous tetrahydrofuran (5 mL) was
allowed to react with triethylamine (110 ￿L, 0.803 mmol) and
phosphorus oxychloride (70 ￿L, 0.803 mmol). The tosylate salt of
benzoxy-L-alanine (282 mg, 0.803 mmol) and triethylamine (110 ￿L,
0.803 mmol) were added. Anhydrous dichloromethane (4 mL) and
the tosylate salt of neopentyloxy-L-alanine (1.33 g, 4.02 mmol) and
triethylamine (1.12 mL, 8.03 mmol) were added as described in
method C. After workup and silica gel column chromatography, 25 mg
of the prodrug was obtained in 4% yield as an off-white solid. 1H NMR
(500 MHz, MeOH-d4) 7.97, 7.96 (2s, 1H, H8), 7.36−7.30 (m, 5H,
OCH2Ph), 5.98, 5.97 (2s, 1H, H1′), 5.18- 5.09 (m, 2H, OCH2Ph),
4.39−4.33 (m, 2H, H5′), 4.28 (2d, J= 8.00 Hz, 1H, H3′), 4.20−4.16
(m, 1H, H4′), 4.06, 4.05 (2s, 3H, 6OCH3), 4.02−3.94 (m, 2H, 2×
CHα Ala), 3.84, 3.82, 3.72, 3.67 (2AB, JAB= 10.50 Hz, 2H,
CH2C(CH3)3), 1.39−1.32 (m, 6H, 2× CH3 Ala), 0.97 (s, 3H,
2′CCH3), 0.93, 0.91 (2s, 9H, CH2C(CH3)3).
13C NMR (126 MHz,
MeOH-d4) 175.54, 175.43, 175.39 (C￿O ester), 162.73, 162.71
(C6), 161.93, 161.89 (C2), 154.57, 154.55 (C4), 139.32, 139.08 (C8),
137.39 (ipso OCH2Ph), 129.55, 129.35, 129.25, 129.23, 129.20,
129.16, 128.27, 128.00 (OCH2Ph), 116.19, 115.54 (C5), 93.34, 93.18
(C1′), 82.39, 82.33 (C4′), 80.01, 79.99 (C2′), 75.34, 75.04 (CH2C-
(CH3)3), 74.84, 74.82 (C3′), 67.88, 67.85 (OCH2Ph), 67.86 (d,
2JC−O−P = 3.75 Hz, C5′), 66.36 (d,
2JC−O−P = 5.50 Hz, C5′), 54.18,
54.01 (6OCH3), 49.69, 49.64, 49.52, 49.46 (2× Cα Ala), 32.28, 32.25
(CH2C(CH3)3), 26.74, 26.71 (CH2C(CH3)3), 21.07, 20.90, 20.79,
20.66 (4d, 3JC−C−N−P = 6.25 Hz, 2× CH3 Ala), 20.39, 20.25 (2′CCH3).
31P NMR (202 MHz, MeOH-d4) 13.98, 13.94. HPLC tR = 16.11, 16.80
min (system 1). MS (TOF ES+) m/z: 716.28 (M + Na+, 100%).
HRMS C30H44N7O10P1 calculated, 694.2966; found, 694.2956
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Biological Methods. Replicon Assays. The HCV inhibitory
activity of compounds was evaluated in an Huh7 cell line expressing a
stable, bicistronic subgenomic HCV genotype 1b (Con1) replicon
encoding the Renilla luciferase reporter gene (Apath, LLC, Brooklyn,
NY) as previously described.32 Cellular cytotoxicity was evaluated
using the CellTiter-Glo Luciferase assay (Promega, Madison WI). A
day before testing, 2 × 104 Huh7 cells were seeded in 96-well flat
bottom white plates (Nunc, Roskilde, Denmark). Four-fold serial drug
dilutions were made in growth medium and added to the cells. No
drug controls were included in each plate. The plates were incubated
in the presence of test compound for 3 days at 37 °C with 5% CO2.
Luciferase reagent was added to cells and plates were incubated for 20
min before measuring relative luminescent units (RLU) in a
luminometer (Veritas, Turner Biosystems, Sunnyvale, CA).
Pharmacokinetic Studies in Rats. Rat studies were conducted at
Inhibitex, Inc., in accordance with NIH Guidelines and following
protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of Inhibitex, Inc. Studies were carried out as
previously described.32 Test compounds were formulated in 95%
Capmul MCM (ABITEC Corp., Janesville, WI)/5% Tween 80 (Sigma,
St. Louis, MO), and doses of 10 mg/kg were administered by oral
gavage to male Sprague−Dawley rats (Taconic Farms, Germantown,
NY). Liver samples were collected as a terminal procedure up to 24 h
postadministration and were snap-frozen immediately upon collection
in liquid nitrogen. Liver samples were stored frozen at ≤−80 °C prior
to analysis.
Bioanalysis of Pharmacokinetic Samples. The concentration of
2′-C-MeGTP in liver samples from rats was measured by LC-MS/MS
as described previously.28 The assay was linear (r2 ≥ 0.99) in the
concentration range of 100−4000 ng per gram of tissue with ≥85%
accuracy and ≤2% CV. Noncompartmental pharmacokinetic analyses
were performed on the liver concentration data using WinNonlin v5.2
software (Pharsight, St. Louis, MO) as described previously.32
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REVIEW
The hepatitis C virus (HCV) is one of the most 
important global healthcare burdens. Current 
estimates suggest that approximately 180 mil-
lion individuals worldwide are chronically 
infected, with an anticipated 4 million new cases 
of infection each year [1–3]. A significant propor-
tion of untreated patients are at risk of develop-
ing progressive liver diseases including cirrhosis, 
hepatocellular carcinoma and finally liver failure 
over a period of 25–30 years [4]. End-stage liver 
disease due to HCV infection represents the 
major indication for liver transplantation in the 
western world and related mortality has risen 
2–5% per year [4,5].
There is no protective vaccination available 
against HCV. A lack of proper animal models 
has greatly limited the development of HCV 
vaccines. Currently, several different vaccines are 
in preclinical development with some advances 
into Phase I and II clinical trials. Their main 
mode of action is focused not only on antibody 
response but also on generation of cytotoxic 
CD8+ T cells [6].
HCV is a single stranded, positive-sense 
RNA virus belonging to the Flaviviridae fam-
ily [7]. HCV replicates in the cytoplasm of 
liver hepatocytes and primarily targets cells [8]. 
Unrelenting infection relies on rapid production 
of viral particles, a high rate of mutation and a 
lack of effective T-cell immune response to HCV 
antigens [9]. Replication of the positive-stranded 
RNA genome is characterized by error rates of 
approximately 10-5 nucleotide substitutions per 
replicated base. With the estimated 12-log daily 
virion production and turnover rate close to 
99%, the calculated mutation rate is in the range 
of 1.5–2.0 × 10-3 nucleotide substitutions per site, 
per year [10]. This results in a facile generation 
of genetic diversity, such that the virus exists as 
a quasi-species. Based on phylogenetic ana lysis, 
HCV has been classified into six major geno-
types (represented by over 100 viral subtypes). 
Genotypes 1, 2 and 3 are predominant in the 
western world, Australia and east Asia, whilst 
types 4–6 are common in Africa, the Middle East 
and southeast Asia. HCV genotypes are associ-
ated with differing responses to antiviral ther-
apy. Understanding of the clinical relevance and 
therapeutic implications of the HCV genotypes 
is crucial for designing individualized therapies 
for patients with chronic HCV infection [11,12].
Current treatment
The established standard of care (SOC) for 
patients infected with HCV is a combination 
therapy with PEGylated IFN-D (PEG-IFN) and 
the nucleoside analogue (NA) ribavirin (RBV) 
[13]. The antiviral activity of this dual regimen 
relies on enhancing the host’s immune response 
[14]. The main goal of antiviral therapy for the 
hepatitis C infection is to achieve a sustained 
virological response (SVR) [15]. SVR is defined 
as achieving undetectable levels of HCV RNA 
(<50 IU/ml) in serum, at the end of a 24-week 
follow-up period post-therapy, and its contin-
ued absence for at least 6 months after stop-
ping the treatment [16]. For patients infected 
with HCV genotype 1, SVR rates are highly 
Progress in the development of  
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unsatisfactory. The response is achieved in 
approximately 34–52% treated patients after 
48 weeks of therapy. Moreover, the therapy for 
HCV genotype 1-infected patients with relapse 
or nonresponsive to SOC is even more demand-
ing, and the percentage of SVR is much lower. 
In comparison, for patients with HCV geno-
type 2 or 3 infections, SVR can be achieved in 
81–84% after 24 weeks of dual therapy [15,17]. 
Furthermore, PEG-IFN/RBV therapy is often 
connected with side effects such as depression, 
anemia, flu-like symptoms, fatigue, cognitive 
dysfunction, cytopenias, thyroid dysfunction, 
retinopathy and others. Interferon is also admin-
istered as a subcutaneous injection, which is not 
preferred by patients [18].
Virological response rates have been shown 
to depend also on various host and viral fac-
tors such as age, weight, sex, race, liver enzymes, 
stage of fibrosis and HCV-RNA concentrations 
at the baseline [15]. 
To increase SVR rates, different treatment 
approaches are currently under investigation. 
For example, individualized therapy, includ-
ing duration of treatment based on the HCV-
RNA concentration at baseline, and trials with 
direct acting antiviral drugs such as inhibitors 
of HCV-specific NS3 protease and HCV NS5B 
RNA-dependent RNA polymerase (RdRp).
HCV genome
The HCV genome is approximately 9600 base 
pairs long and contains 5 -´ and 3 -´noncoding 
regions. A single, open reading frame encodes 
a large polyprotein of 3010 amino acids. Host 
and viral proteases process this protein into 
three structural (Core, E1 and E2) and seven 
nonstructural (NS2, NS3, NS4A, NS4B, NS5A 
and NS5B) individual, functional proteins 
(FIGURE 1) [19]. 
Most efforts in the development of novel 
HCV antiviral agents have focused mainly on 
two viral, nonstructural targets: the NS3 serine 
protease (responsible for cleavage of the HCV 
proteins from the polyprecursor); and the NS5B 
RdRp, a crucial factor for HCV replication [20].
NS5B, the RdRp 
Structural homology of RdRp across genotypes 
was found to be greater than 60%, with only 
20–25% difference between subtypes [21]. The 
structure of NS5B consists of three sub domains 
referred to as palm, fingers and thumb [22]. 
Catalytic residues of the enzyme active site are 
located in the palm domain, including a Gly-
Asp-Asp highly conserved motif [23]. Interactions 
between the fingers and thumb result in an 
almost completely encircled catalytic site. This 
encircling of the active site creates a channel that 
can accommodate the ssRNA but not dsRNA 
[23]. The two aspartic acid residues from the 
Gly-Asp-Asp motif, take part in the polymeriza-
tion reaction allowing nucleotidyl transfer. They 
bind divalent metal ions (Mn2+and Mg2+) and 
coordinate the attack of the 3 -´hydroxyl group 
of the growing RNA chain on the D-phosphate 
of the incoming nucleotide [22,23]. During the 
replication process, the negative strand of RNA 
serves as a template for the synthesis of the posi-
tive strand. The HCV polymerase is capable of 
starting the RNA synthesis de novo, by use of a 
single nucleotide primer, in part icular guanosine 
5´ -triphosphate, which is the preferred initiating 
nucleotide [24,25].
 16%LQKLELWRUV
HCV NS5B inhibitors can be classified into 
four classes based on their mode of action. The 
first class consists of nucleoside and nucleotide 
analogue inhibitors (NIs). NIs can bind to the 
active site of RdRp and compete with naturally 
occurring nucleoside triphosphates for incorpo-
ration. This class of inhibitors is likely to play a 
prominent role in the development of the new 
anti-HCV strategies. As the active site of NS5B 
is a highly conserved region for all six geno-






of the Flaviviridae family and the 
cause of hepatitis C infection in 
KXPDQV
Nucleoside and nucleotide 
analogue inhibitors: 
Nucleoside analogues that can 
bind to the active site of viral 
polymerase and compete with 




allosteric binding sites of the 
YLUDOSRO\PHUDVH
Prodrug: Pharmaceutical 
substance administered in an 
LQDFWLYHRUVLJQLÀFDQWO\OHVV
DFWLYHIRUP$SURGUXJPXVW
undergo chemical conversion by 
metabolic processes before 
becoming an active 
SKDUPDFRORJLFDODJHQW
5´NTR C E1 E2 p7 NS2 NS4A NS4B NS5A NS5B 3´NTR
Structural proteins Nonstructural proteins










Figure 1. Organization of the hepatitis C virus genome.
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The second group consists of non-nucleoside 
inhibitors (NNIs) acting at allosteric binding 
sites of the viral polymerase [27]. Pyrophosphate 
analogues represent a third class of inhibitors. 
They were designed to mimic the natural pyro-
phosphate released during the nucleotide transfer 
reaction and bind at the active site, disabling the 
binding of the next incoming nucleoside triphos-
phate [28]. Some of these inhibitors act by chelat-
ing the divalent metal ions required by the NS5B 
[29]. The fourth class consists of compounds tar-
geting the cellular proteins required for HCV 
polymerase function [30].
NIs are commonly designed to act as chain 
terminators. Obligate chain terminators lack 
a 3 -´hydroxyl group on the sugar moiety and, 
therefore, the formation of the 3–5´ -phosphodi-
ester linkage is not possible. As a result, further 
extension of the viral RNA is stopped. A second 
class consists of non-obligate chain terminators. 
These nucleos(t)ides possess a 3 -´hydroxyl group, 
however, other modifications of the sugar moiety 
cause conformational changes, sterically hinder-
ing the formation of subsequent phosphodiester 
bonds [31,201].
In general, triphosphates of 3 -´deoxy-modified 
NAs were found to be potent chain terminators 
of the viral RdRp elongation in vitro. 3 -´dCTP 
(1) and 3 -´dGTP (2) were found to be amongst 
the most potent with Ki values of 0.72 ± 0.20 µM 
and 0.93 ± 0.08 µM, respectively (FIGURE 2) [32].
Affinity of the modified nucleoside tri-
phosphates (NTPs) to the RdRp was similar 
to that of the naturally occurring nucleoside 
triphosphates. Single nucleotide incorporation 
assays confirmed that 3 -´deoxytriphosphate ana-
logues could be incorporated with similar effi-
cacy to substrates and could then act as chain 
terminators. However, when the corresponding 
nucleosides were tested in HCV subgenomic rep-
licon assay, they were found to be poorly active, 
with EC50 values greater than 150 µM. Further 
studies confirmed that this class of modified 
nucleosides suffers from poor activation into 
their triphosphate forms [32,33].
In the past decade, a number of ribonucleoside 
analogues with 2 -´O-methyl, 2 -´C-methyl and 
4 -´C-azido modifications have been reported to 
act as non-obligate chain terminators, specifi-
cally inhibiting HCV-RNA replication in rep-
licon based assays. These classes of compounds, 
although potent and selective towards viral 
polymerase, suffer from poor bioavailability, 
liability to metabolic degradation and rela-
tively poor turnover to the biologically active 
triphosphates [34]. Several prodrug strategies, 
both at the nucleoside and nucleotide levels, have 
been implemented to overcome these limitations, 
and several specific reviews dealing with the topic 
have recently been published [26,35–38]. 
Nucleoside ester prodrugs
Several structurally distinct nucleoside inhibi-
tors bearing either 4 -´C-azido or 2 -´C-methyl 
alterations have advanced into clinical trials, 
and simple ester prodrugs of these NAs have 
demonstrated improved pharmacokinetics and 
pharmacodynamics.
 10
NM283 (valopicitabine; 3) was the first HCV 
polymerase inhibitor to reach Phase IIb clinical 
trials. NM283 is an orally available prodrug of 
2 -´C-methylcytidine NM107 (4; FIGURE 3) [39].
2 -´C-methylcytidine triphosphate is a potent 
inhibitor of NS5B with IC50 = 0.09–0.2 µM (5; 
FIGURE 3) [40,41]; however, parent nucleoside 4 
exhibited only modest activity (EC50 = 2–7 µM) 
when tested in replicon assay. Preliminary 
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Figure 2. Structures of 3’-deoxy modified nucleoside analogue 
triphosphates with anti-hepatitis C virus RNA-dependent RNA 
polymerase activity.
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IC50 = 0.09–0.2 µM
Figure 3. 2’-C-methylcytidine nucleoside NM107, triphosphate and 
3’-valinyl ester prodrug NM283.
EC50: 50% effective concentration or compound concentration required to inhibit 
hepatitis C virus replication by 50%; IC50: 50% compound concentration required 
to inhibit activity of hepatitis C virus polymerase by 50%.
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pharmacokinetic studies in animal models 
revealed low oral bioavailability of 4. To over-
come this limitation, the amino acid– 3 -´O-l-
valinyl ester of 2 -´C-methylcytidine was pre-
pared (3) and, as a result, oral bioavailability 
was enhanced [39]. NM283 was advanced into 
clinical trials. A Phase I study showed reduction 
in viral load by 0.7–1.0 log IU/ml after a 2-week 
treatment at a daily dose of 800 mg. Mild to 
moderate gastrointestinal adverse events were 
reported, with nausea and vomiting being the 
most common ones. A subsequent Phase IIb trial 
was carried out on treatment-naive genotype 1 
patients and nonresponders to a PEG-IFN/RBV 
regimen, over 48 weeks (200–800 mg/day). At 
week 24 an approximate 3.3 log IU/ml reduction 
of viraemia was demonstrated. Combination 
treatment with PEG-IFN (double regimen) led 
to a approximate 4.4 log IU/ml decline in HCV 
RNA after 36 weeks. The rapid viral response 
(RVR) was achieved in 18–49% of treated naive 
patients by day 28, and 87–94% of infected 
individuals achieved early viral response by 
week 12. Initial HCV RNA decline for HCV 
genotype 1 nonresponders was poorer than in 
treatment-naive patients (a2 log) using a PEG-
IFN/NM283 regimen. Despite the fact that 
NM283 showed efficacy in clinical studies in 
both treatment-naive patients and PEG-IFN/
RBV nonresponders, when tested in combina-
tion with PEG-IFN the compound was discon-
tinued from further development, due to the 
significant gastrointestinal toxicity [42–44].
 5
4 -´C-azidocytidine R1479 (6) was discovered 
within the group of 4´-modified pyrimidine 
analogues as a specific inhibitor of HCV rep-
lication without noticeable cytotoxicity and 
cytostatic properties. Most of the 4 -´substituted 
analogues were poorly active and nontoxic in 
cell-based HCV replicon assays, apart from 6 
and 13 (TABLE 1) [45].
The 5´-triphosphate of 4´-C-azidocytidine 
(15) was shown to inhibit viral NS5B poly-
merase with IC50 = 0.29 µM. 2 ,´3 ,´5´-tri-O-
isobutyrate ester prodrug of 4 -´C-azidocytidine 
(R1626) was selected for further development 
(16; FIGURE 4) [45]. 
The introduction of isobutyrate groups reduced 
the polarity of R1479 and enhanced uptake of 
6 from the GI tract [45]. Due to the promising 
outcomes of the preclinical development, this 
compound was progressed into clinical trials. 
During Phase Ib, a dose-dependent reduction of 
viral load up to approximately 3.7 log IU/ml was 
observed in genotype 1 patients administered 
at a dose of 500–4500 mg/day. After a 2-week 
treatment, five out of nine patients treated with 
the highest dose had undetectable levels of viral 
RNA. Combination therapy with IFN-D and/
or RBV gave an average of 4.2 log IU/ml reduc-
tions of HCV RNA, with 33–80% of patients 
achieving nondetectable levels of HCV RNA 
at week 4, compared with the 2.4 log IU/ml 
reduction in the placebo/PEG-IFN/RBV con-
trol group, and 5% of RVR within the control 
arm. Efficacy results of the Phase IIa clinical 
trials showed high and rapid clearance of the 
virus; however, high rates of Grade IV neurope-
nia (39–78%) and anemia (32%) were reported 
as dose-dependent side effects. Further devel-
opment of R1626 was discontinued due to 
unspecified adverse events [46–48,301].
Key Term
ProTide: Pronucleotide, 
phosphorylated form of 
nucleoside analogues, which can 
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Compound R Base Replicon inhibition at 20 µM (%) Cytotoxicity at 20 µM (%)
6 N3 C 97 (EC50 = 1.3 µM) 17 (CC50 > 100 µM)
7 N3 U 13 17
8 Et C 20 20
9 C{N C 99 100
10 C{N U 0 0
11 C{CH C 3 0
12 C{CH U 0 0
13 C{CCH3 U 76 19
14 C{CCH3 C 11 0
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit 
hepatitis C virus replication by 50%.
REVIEW |0DGHOD	0F*XLJDQ
Future Med. Chem. (2012) 4(5)628 future science group
 5*
RG7128 (mericitabine; 17) is a 3 ,´5´ -bis-isobutyryl 
ester prodrug of PSI-6130 (18; FIGURE 5) [48].
E-d-2 -´deoxy-2 -´fluoro-2 -´C-methylcytidine 
(PSI-6130) was found to be a potent inhibi-
tor of HCV replication in Huh7 replicon assay 
and its triphosphate (19; FIGURE 5) was found to 
be a selective inhibitor of NS5B in vitro, with-
out any affinity towards human DNA and/or 
RNA polymerases [48]. PSI-6130 showed broad 
activity across all six HCV genotypes without 
apparent cytotoxicity [49]. The compound was 
advanced into clinical trials but showed only 
modest oral bioavailability and an unfavor-
able metabolic pathway leading to the uridine 
metabolite RO2433 [50]. To overcome these out-
comes the bis-isobutyryl ester prodrug of PSI-
6130 was synthesized (7; FIGURE 5). According 
to the published data, RG7128 is the most 
advanced, simple nucleoside prodrug in clinical 
trials [51]. During Phase I study, 17 has shown 
efficacy when tested in patients infected with 
HCV geno types 1, 2 and 3. A 2.7 log IU/ml of 
viral load reduction was observed over 2-week 
monotherapy course (1500 mg b.i.d. dose). A 
4-week combination Phase IIa trial of 1000 and 
1500 mg b.i.d. doses of RG7128 with PEG-IFN/
RBV in 81 genotype 1 treatment-naive patients 
resulted in approximately 5.0 log IU/ml decline 
in viral RNA levels. The SOC control arm gave 
a 2.7 log IU/ml HCV RNA reduction result-
ing in an RVR of 19% versus 85% (88% when 
coadministered with RG7128). The RVR of 
genotype 2 and 3 relapse and/or nonresponders 
(25 patients, 1500 mg b.i.d. over 28 days) was 
found to be enhanced by up to 90% (5 log IU/ml 
reduction) versus 60% (3.7 log IU/ml decline) 
of SOC control arm [51,302]. 
Reported data indicate that the adverse events 
profile during a 28-day study was similar to the 
control arm (for all tested genotypes), with no 
serious adverse events and most adverse events 
being mild. Grade 4 neutropenia was reported in 
5% of patients in the RG7128 cohort compared 
with 10% in the placebo group [302]. RG7128 
was advanced into Phase IIb clinical trials. 
Early reported data (a 12-week ana lysis) indi-
cate an average 83% of complete early virological 
response for the 1000 mg b.i.d./SOC cohort. 
RG7128 is expected to complete this study in 
the near future [302].
ProTides (nucleotide prodrugs)
As already mentioned, NAs can suffer in terms 
of variable aqueous solubility and bioavailability 
following oral administration. Furthermore, 
NA activity depends upon metabolism to form 
sequentially the respective 5´ -mono-, di- and tri-
phosphates. Usually the first phosphorylation of 
NAs is a rate-limiting step (FIGURE 6) [52].
Therapies involving long-term administra-
tion of NAs may lead to decreased activity of 
the kinases responsible for the first phosphoryla-
tion step [53]. Administration of the preformed 
5´ -monophosphates would overcome the prob-
lem; however, at physiological pH the phos-
phates are negatively charged and, therefore, too 
hydrophilic to efficiently cross cell membranes. 
In addition, 5´ -nucleotidases present in the blood 
and cell surface rapidly convert free nucleo-
side 5 -´monophosphates to the corresponding 
nucleosides. Various pronucleotide approaches 
have been investigated in order to deliver 
masked 5´-monophosphates and these have 
improved the potential of NAs as therapeutics 
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Figure 4. 4’-C-azidocytidine nucleoside R1479, 4’-C-azidocytidine 
triphosphate and nucleoside ester prodrug R1626. EC50: 50% effective 
concentration or compound concentration required to inhibit HCV replication by 
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Figure 5. E-D-2’deoxy-2’-fluoro-2’-C-methylcytidine – PSI6130, PSI6130 
triphosphate and bis-isobutyryl ester prodrug, RG7128.
EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; IC50: 50% compound concentration required to inhibit 
activity of HCV polymerase by 50%.
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passive diffusion through the cell membrane. 
They would need to possess reasonable chemical 
stability required for the formulation process. 
ProTides should be stable in gastro intestinal 
fluids and undergo an efficient first-pass meta-
bolic pathway (for HCV activity). Once in hepa-
tocytes, 5 -´monophosphates would have to be 
successfully liberated and phosphorylated to the 
active triphosphate species. Several prodrugs of 
modified nucleotides have demonstrated proof 
of concept, delivering monophosphates into cells 
both in vitro and in vivo [56–58].
 $U\OR[\SKRVSKRUDPLGDWHV
The first example of bioactive aryloxy phos-
phoramidates was reported by McGuigan et al. 
in 1992, as prodrugs of AZT (azidothymi-
dine) [59]. Further development of the approach 
resulted in ProTides containing alkyl or haloal-
kyl esters in place of the aryl moiety and SAR 
studies of the amino acid side chain [60–62]. The 
phosphoramidate approach was later successfully 
applied to a number of different NAs, greatly 
improving their antiviral or anticancer activity. 
ProTide technology was used for the following 
NAs: ddA, d4A [63], AZU [64], AZA [65], d4T 
[66,67], PMEA, PMPA [68], abacavir [69] and car-
bocyclic adenosine derivatives [70]. The applica-
tion of phosphoramidate technology to N-acetyl 
glucosamine is the most recent and the first 
example of ProTides used on sugars [71]. The ary-
loxy phosphoramidate approach was found to be 
very effective in delivering masked monophos-
phates into cells. The release of monophosphate 
was found to be initiated by enzyme-mediated 
hydrolysis of the amino acid ester moiety [72,73], 
which generates a nucleophilic carboxylic acid 
moiety. Intramolecular nucleophilic attack on 
the phosphorus atom would give a putative 
unstable cyclic intermediate with release of 
the aryloxy moiety. The intermediate is then 
rapidly hydrolyzed followed by enzyme medi-
ated P–N bond cleavage to yield nucleoside 
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Figure 7. Possible mechanism of activation of aryloxy-phosphoramidates.
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Wagner et al. developed phosphoramidate 
monoesters as a variation of the aryloxy phos-
phoramidate approach [76]. Phosphoramidate 
monoesters contain an amino acid ester as a 
masking group on one of phosphate charges. 
Application of only one masking group elimi-
nates the chirality issue at phosphorus and pro-
vides better water solubility while simultane-
ously maintaining stability in human plasma. 
Although cellular permeation may be more 
limited, this kind of prodrug can represent an 
alternative method of nucleoside monophos-
phate delivery for intravenous (iv.)applications. 
Activation of phosphoramidate monoesters 
requires phosphoramidase activity to cleave 
the P–N bond and proceeds directly to the 
monophosphate [76].
 6DF\OWKLRHWK\O3UR7LGHV
The S-acyl-2-thioethyl (SATE) approach was 
firstly reported by Imbach and Gosselin. This 
strategy was successfully applied to differ-
ent nucleosides such as ddU, ddA, ddI, AZT, 
isoddA, d4T and ACV [77–80]. The bioenzy-
matic activation of bis(SATE) is initiated by the 
carboxy esterase cleavage of the thioester moiety 
of the SATE groups. The generated mercapto-
ethyl-phosphotriester is unstable and undergoes 
intramolecular nucleophilic attack, releasing 
ethylene sulphide and the monoSATE phospho-
diester. The resultant phosphodiester is further 
hydrolyzed either by a phosphodiesterase or by 
carboxyesterase to release nucleoside 5´ -mono-
phosphate – this step is the same for mono-and 
cyclic-SATE prodrugs (FIGURE 8) [78]. The big-
gest concern of this class of compounds is the 
release of episulfide during activation. Episulfide 
is a highly potent alkylating agent and known 
mutagen; therefore, the toxicity risk associated 
with it has mainly limited further clinical 
development [77].
Application of the bis(SATE) technology 
to the anti-HCV nucleosides was investigated. 
One of the reported examples of this approach 
is bis(SATE) prodrug of 2 -´D-F-2 -´C-methyl-7-
ethynyl-7-deazadenosine [81]. The corresponding 
nucleoside triphosphate (20) was found to be an 
efficient chain terminator of the HCV NS5B poly-
merase with IC50 of 0.4 µM. However, the par-
ent nucleoside (21) had very low activity (24 µM) 
in Huh7 replicon assay. Although delivery of 
masked 5´ -monophosphate using the bis(SATE) 
approach (22) was successful and resulted in a 
modest increase of potency EC50 = 8 µM, no 
additional studies of this family of pronucleotides 
have been reported (FIGURE 9) [81]. 
Benzaria et al. reported application of bis(t-
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Figure 8. Mechanism of activation of bis(SATE) prodrug.
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Figure 9. Structures and anti-hepatitis C virus activity of 2’-D-F-2’-C-methyl-7-ethynyl-7-
deazaadenosine, corresponding triphosphate and S-acyl-2-thioethyl prodrug.
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 
50%; IC50: 50% compound concentration required to inhibit activity of HCV polymerase by 50%.
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and 2´-C-methyluridine. The corresponding 
SATE ProTides exhibited greatly improved 
potency against HCV compared with the parent 
nucleosides (EC50 = 0.7 µM vs EC50 = 2.2 µM 
for 2´-C-methylcytidine, and EC50 = 0.1 µM 
vs EC50 = 46 µM for 2´-C-methyluridine), 
however an increase in cytotoxicity was also 
observed [82].
Further evaluation of S-acyl-2-thioethyl 
ProTides resulted in the synthesis of cyclic- [83] 
and hybrid-SATE ProTides [84] with potent 
anti-HCV activity, to be discussed below.
 Cyclic ProTides
The design of 3 ,´5´ -cyclic ProTides was based on 
naturally occurring cyclic monophosphates such 
as cyclic AMP [85]. Cyclisation of the phosphate 
moiety with the 3 -´hydroxyl group was designed 
to decrease the ionic nature of phosphate and 
improve lipophilicity. It was postulated that 
the 5 -´monophosphate would be released upon 
exposure to phosphodiesterases [86]. Several 
studies have shown that the cell uptake of dif-
ferent cyclic AMP analogues was not efficient, 
presumably due to the remaining charge on 
the phosphate center and/or hydrolysis to the 
parent 5 -´monophosphate prior cell-membrane 
penetration [87]. To overcome this limitation, a 
family of simple neutral triesters of cyclic AMP 
was prepared [86,88]; compounds were found to 
cross cell membranes and be able to deliver 
5 -´monoposphates intracellularly [86,88].
A simple 3 ,´5 -´cyclic triester approach was 
applied to anti-HCV nucleosides giving proof-
of-concept by delivering 5´-monophosphates 
into the cells both in vitro and in vivo [89]. 
Other cyclic approaches including 3 ,´5 -´cyclic 
phosphoramidates [90] and 3 ,´5´-cyclicSATE 
[83] prodrugs were also investigated and will be 
discussed below (FIGURE 10).
 HepDirect prodrugs
In 2004 Erion et al. reported a specific prodrug 
strategy dependent on cytochrome P450 cata-
lyzed cleavage, resulting in high liver-specific 
drug delivery [91]. The HepDirect prodrugs 
are substituted cyclic 1,3-propanyl esters of 
NA phosphates or phosphonates, designed to 
undergo enzyme catalyzed oxidative cleavage in 
the liver [91].
Oxidation of the benzylic carbon by CYP3A4 
results in the formation of a cyclic hemiketal that 
undergoes spontaneous ring opening and then 
E-elimination to give the active monophospory-
lated species and aryl-vinyl ketone by-product 
(FIGURE 11). The released monophosphate is fur-
ther converted to the corresponding triphosphate 
form [91]. The formation of aryl vinyl ketone had 
raised toxicological concerns, due to the possible 
alkylation of DNA and essential proteins. It was 
postulated that high levels of glutathione present 
in the gut and liver could detoxify vinyl ketones 
through a rapid and quantitative 1,4-addition 
reaction and, thus, minimize the toxicity issues 
[91,92]. The HepDirect prodrug approach was 
successfully applied to several different NAs 
resulting in the discovery of pradefovir (prodrug 
of adefovir). This compound was advanced into 
clinical trials for the treatment of hepatitis B [93]. 
Application of the HepDirect technology to 
anti-HCV nucleosides will be discussed below.
ProTides of anti-HCV NAs
 C-methylcytidine ProTides
During the development of NM283, it was noted 
that the triphosphate of 2´-C-methylcytidine 
(5) was highly active against purified viral poly-
merase (IC50 = 0.09–0.2 µM). However, the par-
ent nucleoside was only moderately active when 
tested in HCV replicon cells [39]. Recent stud-
ies indicate that 2 -´C-methylcytidine is a poor 
substrate of 2 -´deoxycytidine kinase and, there-
fore, NM107 was not efficiently converted to its 
active-triphosphate form. To overcome this limi-
tation the aryloxy phosphoramidate approach 
was applied to NM107. Broad investigation of 















































Figure 11. Metabolic activation of HepDirect prodrugs.
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(including substituted and unsubstituted phe-
nols vs 1-naphthol) led to the phosphoramidate 
derivatives (23–25; TABLE 2) [94].
The activity of newly synthesized phos-
phoramidates in most of the cases was greatly 
improved compared with NM283. Their acti-
vation to the nucleoside triphosphate was mea-
sured in hepatocytes of several species (including 
humans, rats and dogs). All of the data showed 
that phosphoramidates could produce higher 
levels of 2 -´C-methylcytidine triphosphate com-
pared with 3. Preparation of phosphoramidate 
monoesters bearing highly lipophilic amino acid 
esters (25) resolved the toxicity issues but with a 
decrease in activity at the same time (a200-fold 
vs the most active [24]). The most interesting com-
pound in this series was compound 25, which 
gave the highest NTP concentrations in human 
hepatocytes (TABLE 2). High liver triphosphate 
levels in hamster were obtained upon subcuta-
neous administration, reaching an AUC0–48h of 
4600 µM/h, after 10 mg/kg dosing. However, 
when the compound was administered orally 
to rats, the levels of nucleoside triphosphate 
in the liver were below the limit of detection, 
suggesting a lack of oral bioavailability [94]. 
The 3´,5´-c yc l ic  phosphoramidate 
approach was another technology applied to 
2 -´C-methylcytidine. The rationale behind this 
family of compounds was a reduction in the 
degree of rotational freedom compared with 
aryloxy phosphoramidates and possible enhance-
ment in cell uptake. Additionally, a lack of aryl 
unit may have a potential impact on cellular 
toxicity. 
A family of different 3 ,´5´-cyclic phos-
phoramidates was synthesized, followed by 
phosphate isomer separation (TABLE 3) [90]. All 
Table 2. SAR of 2’-C-methylcytidine ProTides 3 and 23–25.


















































†Intracellular level of triphosphate after 2 h incubation with human hepatocytes.
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit 
hepatitis C virus replication by 50%.
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reported, newly synthesized 3 ,´5 -´cyclic phos-
phoramidates of 2 -´C-methylcytidine were only 
moderately active and did not provide improve-
ment in antiviral potency compared with 3 or 
2 -´C-methylcytidine itself. Results from human 
hepatocytes revealed that compounds were effi-
ciently converted to the corresponding triphos-
phates in vitro (27 & 28; TABLE 3). Subcutaneous 
administration resulted in up to 50-fold higher 
levels of NTP compared with triphosphate pro-
duced from 2´-C-methylcytidine, but during 
in vivo studies using the hamster animal model, 
low bioavailability and/or instability in GI tract 
were reported [90]. No further development of 
this class of compounds was published.
Recently, a new family of HepDirect prodrugs 
of 2 -´C-methylcytidine has been reported [95]. 
Screening of 1-aryl-1,3-propanediol deriva-
tives led to the identification of compound 33 
(TABLE 4) 3,5-difluorophenyl derivative, provid-
ing the highest levels of 2 -´C-methylcytidine 
5´ -triphosphate in rat liver, following oral dos-
ing across the family. Biological evaluation of 
single isomers of 33 revealed that the rate of NTP 
Table 3. Antiviral activity and conversion to nucleotide triphosphate in human 
















Compound† R1 R2 EC50 (µM) NTP, AUC0-2h
† «-sH	
3 - - 7.6 168
26 SE CH3 Et 4 61
26 FE CH3 Et >20 233
27 SE CH3 c-heptyl >10 9427
28 SE CH3 2-(hexyloxy)-ethyl 14 9414
29 SE CH3 2-ethyl-butyl >20 30
†Intracellular 2’-C-methylcytidine triphosphate (NTP) after incubation at 10 µM with cryopreserved human hepatocytes.
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%; FE: Fast eluting diastereoisomer; SE: Slow eluting diastereoisomer.

















_ 3 0 1.9 <1
3-F-phenyl 30 226 50 1.6
(S)-3-Cl-phenyl 31 310 4.9
3-Br-phenyl 32 148 149 7.5
3,5-F2-phenyl 33 134 192 15.1
3,5- Cl2-phenyl 34 168 71 1.9
2,3- F2-phenyl 35 71 2.5 <1
†Activation of adenosine HepDirect prodrugs in rat hepatocytes (25 µM, 2 h).
‡Activation of adenosine HepDirect prodrugs in rat liver (at 1 or 3 h following intraperitoneal dosing).
§Activation of adenosine HepDirect prodrugs in rat liver (at 3 or 5 h following oral dosing).
¶Nucleoside equivalents, dose normalized to 5 mg/kg i.p. and 10 mg/kg p.o.
NTP: Nucleoside triphosphate.
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formation from the S-isomer was approximately 
fourfold greater then that from the R-isomer 
(based on the AUC of NTP in the liver). Oral 
and iv. administration of single S-isomer to rheus 
macaques in a multiple-dose study showed very 
good plasma exposure following iv. dosing com-
paring to the poor oral bioavailability. Further 
evaluation of efficacy in two HCV-infected 
chimpanzees revealed that oral administration of 
33 S-isomer (10 mg/kg/day for 7 days) resulted 
in 1.3–1.5 log IU/ml reduction in viral RNA 
levels, compared with 3.6–4.8 log IU/ml from 
iv. dosage of 4 mg/kg/day for 5 days. The data 
indicate that the poor antiviral efficacy of 30-S 
isomer following oral administration is likely 
due to the limited oral bioavailability of this 
class of molecules [95].
 E-DGHR[\ÁXRURC-methyluridine 
ProTides 
As already mentioned during metabolic stud-
ies of PSI-6130 in human hepatocytes, cytidine 
analogues can undergo deamination leading to 
the formation of poorly active uridine metabo-
lites, for example RO2433 (PSI-6206; 36) [50]. 
Subsequent studies indicated that the triphos-
phate form of RO2433 was a potent inhibitor 
of viral NS5B polymerase with an IC50 value of 
0.52 µM. The mean half-lives of PSI-6130 tri-
phosphate and RO2433 triphosphate were 4.7 
and 38 h, respectively, indicating that RO2433 
might have an advantage over PSI-6130 when 
tested in vivo, maintaining more constant con-
centrations of the triphosphate over the dosing 
period. Despite the potency exhibited in the 
enzyme assay, 36 was not active in replicon cells 
up to 100 µM in concentration. Additional stud-
ies revealed that the RO2433 is a poor substrate 
for the deoxycytidine kinase and, therefore, the 
formation of RO2433-monophosphate species in 
human hepatocytes was most likely accomplished 
by the deamination of PSI-6130-monophosphate 
(FIGURE 12) [50,96].
To take advantage of the preferable half-life of 
the E-d-2 -´deoxy-2 -´fluoro-2 -´C-methyluridine 
triphosphate, the aryloxy phosphoramidate 
approach was applied to 36 in order to deliver 
the monophosphate intracellularly (TABLE 5) [97]. 
Study of the ester unit (where amino acid 
was l-alanine and phenyl was kept as aryl moi-
ety), showed that the small simple alkyl and 
branched alkyl esters provide the best submi-
cromolar activity. The SAR of the aryl unit dem-
onstrated that 1-naphthyl provided the highest 
potency, however, this substitution also led to 
the significant cytotoxicity (41). Halogenated 
phenyl substitutions provided good activity 
with moderate toxicity. Examination of dif-
ferent amino acids showed that l-alanine was 
preferred. Extensive SAR studies around the 
phosphorus center resulted in the synthesis of 
38, PSI-7851 (as a 1:1 diastereomeric mixture 
at the phosphate), exhibiting submicromolar 
activity in replicon assay (EC90 = 0.52 µM). The 
compound was shown to be stable in simulated 
gastric and intestinal fluids. S9 data predicted 
likely efficient first pass metabolism, desired 
for anti-HCV activity. Pharmacokinetic stud-
ies revealed that 38 can generate high levels of 
PSI-6206–5´ -triphosphate in the liver without 
cellular toxicities (including mitochondrial and 
bone marrow toxicity) [97]. 
In a single ascending-dose trial in healthy 
volunteers, PSI-7851 was shown to be safe and 
well tolerated at all tested doses (25–800 mg). 
Forty treatment-naive patients were enrolled for 
the Phase I multiple ascending-dose study. HCV 
RNA reduction was observed in a dose-depen-
dant manner, with a maximum of 1.01 log IU/ml 
and 1.96 log IU/ml decline at day 3, for 200 mg 
and 400 mg daily doses, respectively. PSI-7851 
was well tolerated across all tested doses with 
no discontinuations. No serious adverse and/or 



























Figure 12. Phosphorylation pathway of PSI6130 and PSI6206 (RO2433).
5’-MP:5’-monophosphate; 5’-DP: 5’-diphosphate; 5’-TP: 5’-triphosphate; 
dCK: Deoxycytidine kinase; dCMP: Deoxycytidylate deaminase; NDPK: Nucleoside 
diphosphate kinase; YMPK: Uridine/cytidine monophosphate kinase.
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Alongside clinical development of PSI-7851, 
further work on separated isomers was carried 
out. In clone A replicon assay, EC90 values of 
7.5 and 0.42 µM (for Rp and Sp [49] isomers, 
respectively) were reported. During the evalua-
tion of intracellular 5´ -triphosphate production 
(in human hepatocytes), the Sp isomer was 
found to produce approximately 14% higher 
concentration of triphosphate than the Rp iso-
mer. Both isomers were found to be nontoxic in 
different cell lines up to 100 µM concentration 
[97,99]. As a result, the single Sp isomer of PSI-
7851 (PSI-7977) progressed into Phase IIa clini-
cal study, where HCV treatment-naive patients 
were dosed with 100, 200 or 400 mg q.d. of PSI-
7977 in combination with SOC, for 28 days. 
Patients achieved an approximate average mean 
of 5.3 log IU/ml decline in viral RNA, however 
dose-dependent activity was not observed. RVR 
in 88–93% of infected patients was achieved. 
There were no serious adverse events reported 
during 4-weeks treatment. All reported adverse 
events were mild to moderate, with fatigue, nau-
sea and joint pains being the most common. 
Following the positive Phase IIa clinical results, 
a Phase IIb was initiated in which PSI-7977 at 
doses of 200 and 400 mg q.d., was combined 
with SOC for 12 weeks, as a treatment regi-
men for patients infected with genotype 1, 2 
and 3 [100–103,303,304].
PSI-7977 is also being studied in combina-
tion with protease inhibitor BMS-790052 and 
another polymerase inhibitor PSI-938 in Phase I 
clinical trials [101,305]. Recently, Pharmasset 
entered into a clinical collaboration agreement 
with Tibotec Pharmaceuticals to evaluate in a 
Phase II study the safety and efficacy of PSI-
7977 in combination with protease inhibitor 
TMC435, during 12-week all oral, q.d., and 
interferon-free regimen in patients infected 
with genotype 1 HCV and PEG-IFN/RBV 
nonresponding patients [306]. 
 CD]LGRF\WLGLQH	CD]LGRXULGLQH
ProTides
As previously mentioned, 4´-C-azidocytidine 
was found to inhibit HCV replication in a 
low micromolar range, when tested in replicon 
assay. The corresponding 5 -´triphosphate (15) 
inhibits NS5B polymerase in a low nanomolar 
range in enzyme-based assay. Interestingly, the 
4 -´C-azidouridine analogue 7 did not exhibit any 
anti-HCV activity in cell-based systems, while 
its triphosphate was found to be an efficient 

















Compound R1 R2 R3 EC90 (µM) Inhibition of cellular rRNA 
replication (%)†
36 3.9 0.0
37 Me CH3 Ph 0.91 0.0
38 i-Pr CH3 Ph 0.52 25.9
39 c-Hex CH3 Ph 0.25 61
40 Bn CH3 Me 0.13 74.3
41 Me CH3 4-F-Ph 0.69 16.8
42 Me CH3 4-Cl-Ph 0.58 62.8
43 Me CH3 1-Napth 0.09 95.4
44 Me CH3 Et >50 16.8
45 Me H Ph 22.11 0.0
46 Me CH(CH3)2 Ph >50 0.0
47 Me CH2CH(CH3)3 Ph 5.4 0.0
48 Me CH2CH2SCH3 Ph 60.13 24.1
49‡ i-Pr CH3 Ph 0.42 ND
†At 50 µM concentrations.
‡Sp isomer.
EC90: 90% effective concentration or compound concentration required to inhibit HCV replication by 90%; 
ND: Not determined.
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inhibitor of HCV RdRp in an enzyme assay, 
with an IC50 of 0.22 µM [45]. The lack of activity 
in the replicon assay was associated with poor 
initial phosphorylation of 7 and, therefore, the 
phosphoramidate approach was investigated as 
a tool for monophosphate delivery of both 6 and 
7. Extensive investigation around the phosphate 
center including different amino acid esters and 
aryl moieties provided novel compounds with 
moderate (for ProTides of 4 -´C-azidocytidine) 
and highly increased (for 4´-C-azidouridine) 
activity (TABLE 6) [102,103].
For the family of 4 -´C-azidocytidine ProTides, 
the most active compound (53) exhibited three-
fold improvement in potency compared with the 
parent nucleoside (6). Most of the reported com-
pounds have either slightly improved or retained 
the potency of 6, suggesting that the first phos-
phorylation of this particular NA is not an issue 
and the phosphoramidate approach cannot 
greatly improve the potency of parent nucleo-
side. By contrast, in the case of 4 -´C-azidouridine 
the phosphoramidate approach greatly enhanced 
anti-HCV activity in vitro (>450-fold for 61), 
without apparent toxicity up to 100 µM; success-
fully bypassing the rate-limiting first phosphory-
lation step [102,103]. No additional data on fur-
ther biological evaluation of 4 -´C-azidouridine 
phosphoramidates have since been reported. 
 C-methyladenosine ProTides
2´-C-methyladenosine (62) was found to be 
a potent inhibitor of viral replication with 
EC50 = 0.26 µM and the corresponding adenos-
ine 5 -´triphosphate (63) inhibited HCV RNA 
polymerase at 1.9 µM (FIGURE 13) [34,104].
2´-C-methyladenosine was found to be a 
substrate for adenosine deaminase, adenylate 
deaminase and purine nucleoside phosphory-
lase, resulting in low metabolic stability and low 
oral bioavailability. The aryl phosphoramidate 
approach was applied to 58 to overcome these 





















EC50 = 0.26 µM
63
IC50 = 1.9 µM
Figure 13. Structures and anti-hepatitis C virus activity of 
2’-C-methyladenosine and the corresponding triphosphate. 
EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; IC50: 50% compound concentration required to inhibit 
activity of HCV polymerase by 50%.

























Compound Base Aryl (Ar) R1 R2 EC50 (µM) CC50 (µM)
6 C - - - 1.28 ND
50 C Ph CH3 Bn 6.0 >100
51 C Ph CH3 Et 0.38 >100
52 C Ph CH3 i-Pr 0.99 >100
53 C p-Me-Ph CH3 Bn 0.51 >100
54 C p-Me-Ph CH3 Et 2.9 >100
7 U - - - >100 >100
55 U Ph CH3 Et 1.3 >100
56 U Ph CH3 i-Pr 0.77 >100
57 U Ph CH3 Bn 0.61 >100
58 U Ph H Bn 1.6 >100
59 U Ph CH2CH(CH3)2 Bn 2.3 >100
60 U Ph CH(CH3)2 Bn <100 >100
61 U Napth CH3 Bn 0.22 >100
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%.
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Application of phosphoramidate technology to 
61 did not improve its potency, although 64 and 
65 showed similar activity to the parent nucleo-
side (62) [105]. Further development of this class 
of phosphoramidates of 2 -´C-methyladenosine 
was not continued.
The HepDirect approach was also applied 
to 2 -´C-methyladenosine in order to deliver the 
5´ -monophosphate into the cells. It was expected 
that preparation of 1-aryl-1,3-propanyl pro-
drugs would improve the metabolic stability 
of the parent nucleoside, especially in terms of 
deamination and, as a result, therapeutic levels 
of 2 -´C-methyladenosine triphosphate would be 
achieved in the liver after oral administration. 
A SAR study of aryl moieties was evaluated 
in rat hepatocytes at 25 µM concentration 
(TABLE 8) [106].
Data indicate that the HepDirect approach 
was successful in delivering high levels of 
2´-C-methyladenosine triphosphates when 
tested in rat hepatocytes in vitro (67–73; TABLE 7; 
NTPD). In general, different halogenated phe-
nols and pyridyl substitutions were well toler-
ated and efficiently oxidized yielding the desired 
monophosphate, which was subsequently phos-
phorylated to the active species. During in vivo 
evaluations, substantial levels of liver triphos-
phate were achieved (67–73; TABLE 8; NTPE), 
where compounds were iv. administered to rats. 












Aryl (Ar) HepDirect HepDirect 2’,3’-carbonate prodrug
Compound NTP† (nmol/g) NTP‡ (nmol/g) Compound NTP† (nmol/g) NTP‡ (nmol/g)
62 209 - 62 209 -
(S)-3-Cl-phenyl 67 389 2.9 74 298 29.2
3,4-Cl2-phenyl 68 396 2.0 75 97 11.8
3,5-Cl2-phenyl 69 585 2.4 76 49 5.0
3-F-phenyl 70 328 4.1 77 313 22.9
2,3- F2-phenyl 71 323 8.2 78 280 14.7
3,5- F2-phenyl 72 139 4.1 79 113 11.2
(S)-4-pyridyl 73 47 3.6 80 185 28.3
†Activation of adenosine HepDirect prodrugs in rat hepatocytes (25 µM, 2 h).
‡Activation of adenosine HepDirect prodrugs in rat liver (at 3 h following oral dosing, 50 mg/kg).
NTP: Nucleoside triphosphate.
Table 7. Biological activity of 2’-C-methyladenosine and corresponding 











Compound R1 R2 EC50 (µM) CC50 (µM)
62 0.25 >50
64 CH3 Et 0.24 >50
65 CH3 Bn 0.27 >50
66 CH3 t-Bu 4.18 >50
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%. 
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However, oral administration to rats resulted in 
a greater than fivefold lower level of liver triphos-
phate (based on the AUC of NTP in liver) and 
bioavailability was found to be less than 5%. To 
overcome bioavailability issues, modifications of 
the N-6 amino and 2 ,´3 -´hydroxyl groups were 
investigated, resulting in compounds (74–80; 
TABLE 8). The 2 ,´3 -´carbonates afforded approxi-
mately tenfold increases in liver triphosphate 
levels (after oral administration to rats) com-
pared with simple HepDirect ProTides [106]. No 
additional data suggesting further development 
of this class of 2 -´C-methyladenosine ProTides 
have been published.
 GHD]DC-methyladenosine ProTides
Modifications of the adenine base of 2 -´C-methyl 
analogue were considered in order to increase 
metabolic stability of 62. The 7-deaza-2´-C-
methyladenosine derivative, MK0608 (81; 
EC50 = 0.25 µM; FIGURE 14) was found to be 
effective against HCV replication and, further-
more, the compound was not a substrate for 
adenosine deaminase or purine nucleoside 
phosphorylase [107].
The compound showed efficacy in geno-
type 1a and 3a infections and reached late pre-
clinical development. Two chimpanzees were 
dosed orally with MK0608 (1 mg/kg, per day) 
for 37 days. This led to a 3–5 log reduction in 
serum HCV RNA levels. After dosing, viral 
rebound occurred in both treated chimpanzees. 
Despite this MK0608 has never progressed into 
clinical trials [107]. 
 C-methylguanosine ProTides
Another member of the 2´-C-methyl purine 
nucleoside family: 2 -´C-methylguanosine (82) 
has also been shown to be a modest anti-HCV 
agent, with an EC50 value of 3.5 µM. The tri-
phosphate of 2´-C-methylguanosine showed 
IC50 = 0.13 µM (FIGURE 15) [104]. Replicon activity 
of 82 was lower than expected from the intrin-
sic polymerase inhibition of the triphosphate 
species (83). Insufficient phosphorylation of 82 
was suggested to limit the antiviral potential of 
2 -´C-methylguanosine [105], therefore two dif-
ferent ProTide approaches were applied to 83, 
resulting in two compounds advanced into 
clinical trials 
 ,';
IDX184 i s  a f i r st  example of a 
2´-C-methylguanosine monophosphate pro-
drug advanced into clinical trials. IDX184 (80) 
is a hybrid SATE prodrug (FIGURE 16) in which 
two different groups, SATE moiety and benzyl-
amine, mask the 5 -´monophosphate [84]. The 
complete metabolic pathway of IDX184 is not 
yet fully disclosed. In vitro mechanistic studies 
indicate that the release of 5 -´monophosphate 
relays on cytochrome-450 dependent and inde-
pendent processes [84]. IDX184 was shown to 
be a potent inhibitor of viral replication in rep-
licon assay EC50 = 0.4 µM without any associated 
toxicity (CC50>100 µM) [108]. 
Preclinical combinatorial studies with SOC 
and protease inhibitor IDX320 resulted in an 
additive effect. Evaluation in animal mod-
els demonstrated the proof-of-concept that 
IDX184 can produce high levels of intracel-
lular 2´-C-methylguanosine 5´-triphosphate 
compared with the parent nucleoside when 
administered orally [109,110]. In a subsequent 
study, a 2.3 log IU/ml decline in viraemia was 
achieved in HCV-infected chimpanzees at a 
10 mg/kg daily dose over a 3-day treatment at 
days 3 and 4. IDX184 was advanced into clini-
cal trials [110]. The aim of the Phase I study was 
to evaluate safety, tolerability and pharmaco-
kinetics of single doses of IDX184 in healthy 
volunteers. A total of 48 healthy volunteers were 
enrolled and divided into six groups of eight 






























EC50 = 3.5 µM 
83
IC50 = 0.13 µM
Figure 15. Structures and anti-HCV activity of 2’-C-methylguanosine and 
corresponding triphosphate.
EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; IC50: 50% compound concentration required to inhibit 
activity of HCV polymerase by 50%.
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During the trial, single doses of 5–100 mg 
(q.d., for 3 days) were generally well-tolerated; 
no serious adverse events or dose-dependent 
toxicities were observed. The highest decline 
of HCV RNA was observed for the 100 mg 
dose = 0.74 log IU/ml. Pharmacokinetic analy-
ses indicate liver targeting, with very low plasma 
concentrations of 2´-C-methylguanosine and 
IDX184. The oral bioavailability of IDX184 
remains unknown, although ≥20% is suggested 
[84]. Successful results of the Phase I trial led to 
the initiation of Phase II trials. Phase IIa was 
a randomized, double blind, placebo-controled 
and sequential dose-escalation study. The objec-
tive was to evaluate safety, tolerability, phar-
macokinetics and antiviral activity of IDX184 
in combination with PEG-IFN/RBV in treat-
ment-naive HCV genotype 1 infected patients 
over 14 days. Patients received a daily dose of 
50–200 mg IDX184 per day. In the 100 and 
200 mg cohorts, b.i.d. and q.d. regimens were 
compared. A 2.7–4.1 log IU/ml dose-dependent 
reduction of viral load was observed at day 14. 
No serious adverse events related to the IDX184 
were observed [111,112]. Additional Phase I com-
bination therapy with NS3 protease inhibitor, 
IDX320, was evaluated in healthy volunteers. 
Safety data showed three cases of serious adverse 
events (liver function abnormalities) during 
a drug–drug interaction study and the pro-
gram was placed on full clinical hold, await-
ing resolution of the adverse events [307]. At the 
beginning of 2011, the US FDA removed full 
clinical hold for IDX184 and the program was 
placed on partial hold. The full toxicological 
data revealed that the toxicity was most likely 
caused by the IDX320. The Phase IIb trial of 
IDX184 in combination with PEG-IFN and 
RBV under a partial clinical hold was initiated 
in July 2011 [308]. 
 ,1;
INX-08189 represents the second example of 
a 2´-C-methylguanosine 5´-monophosphate 
prodrug, also advanced into clinical trials. 
This compound is an aryloxy phosphorami-
date double prodrug of 2 -´C-methylguanosine. 
The development of INX-08189 is based 
on an extensive study of different ProTides 
of 2´-C-methylguanosine, including varia-
tion of ester, amino acid and aryl moieties 
(TABLE 9) [105,113]. 
The initial series of compounds was found 
to be 10–30-fold more potent than the par-
ent nucleoside without any increase in cellular 
toxicity (85–95; TABLE 9). Satisfactory plasma 
stability across different species (mouse, rat, 
dog and human) was observed. In vitro liver 
and intestinal S9 data supports the notion of 
liver targeting by this class of molecules [113]. 
Further investigation of this family led to 
the modifications of the base unit in order to 
increase lipophilicity of these ProTides and, 
therefore, improve their cellular uptake and 
pharmacokinetic properties. Substitutions at 
the C-6 position led to the identification of 
the 6-O-methyl derivative and, subsequently, 
INX-08189 (97; TABLE 10) [114,115]. 
The monophosphate functionality of 
INX-08189 is masked by D-naphthyl and 
2,2-dimethylpropoxy-l-alaninyl moieties. In 
addition to the general phosphoramidate acti-
vation pathway, metabolic conversion of the 
6-O-methyl substitution of the purine base 
also takes place in INX-08189 [116]. Metabolic 
studies confirmed that this conversion is accom-
plished at the monophosphate level. INX-08189 
exhibits nanomolar activity in HCV 1b repli-
con assay (EC50 = 0.01 µM and CC50 = 7 µM) 
and was found to be active against replicon 
1a and 2a with EC50 values of 0.012 µM and 
0.0009 µM, respectively. Supported by preclini-
cal data INX-08189 was advanced into clinical 
trials as a mixture of phosphate diastereoiso-
mers. No difference in antiviral potency of the 
individual isomers was found when tested in 
replicon assay [115–117].
Some 42 healthy volunteers were enrolled for 
the trial. In a single ascending dose, placebo 
controlled study, recipients were administered 
with doses ranging from 3 to 100 mg. INX-
08189 was generally well tolerated at all doses, 


















Figure 16. Structure and anti-hepatitis C 
virus activity of IDX184. 
EC50: 50% effective concentration or 
compound concentration required to inhibit 
HCV replication by 50%; CC50: 50% cytotoxic 
concentration.
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dose-related trends were observed and pharma-
cokinetic data support once a day, oral dosing 
of INX-08189. The compound was progressed 
into Phase Ib trials and the trial carried out on 
70 HCV genotype treatment-naive patients, 
receiving an all-oral regimen of INX-08189 and 
RBV against placebo-controlled group. Patients 
were dosed once daily at 9–100 mg. INX-08189 
demonstrated dose-dependent antiviral activity 
with a decline in HCV RNA of 1.00 log IU/ml 
for dosage as low as 25 mg at day 7 when tested 
alone, and 1.56 log IU/ml when tested with 
RBV double regimen. Additional data from 
the Phase Ib clinical studies indicated that 
INX-08189 was generally well tolerated at all 
tested doses. There were no significant adverse 
events associated with the drug, other reported 
adverse events were mild or moderate, with 
headache being the most common. There were 
no discontinuations of treatment due to adverse 
events. INX-08189 entered Phase II clinical 




methylribofuranose have been successful in 
delivering potent and selective anti-HCV pyrim-
idine nucleosides (NM283, R1626 or RG7128). 
As a part of continuing effort to discover new 
and potent inhibitors of HCV replication, 
2´-deoxy-2´-D-f luoro-2´-C-methylguanosine 
(101) was investigated. The compound exhib-
ited only modest activity in replicon assay 
(EC50 = 69.2 µM) but its triphosphate demon-
strated good activity against viral polymerase 
(102; IC50 = 5.94 µM; FIGURE 17) [119]. 























82 - - - 3.5 >100 ND
85 Me CH3 1-Napth 0.21 >50 2
86 Neopentyl CH3 1-Napth 0.06 >100 1
87 i-Pr CH3 1-Napth 0.17 >100 14
88 c-Hex CH3 1-Napth 0.045 >100 3
89 Bn CH3 1-Napth 0.062 >100 1
90 Bn CH3 1-Napth 0.76 >100 89
91 Bn CH3 1-Napth 0.12 >50 2
92 Bn CH(CH3)CH2CH3 1-Napth 0.9 >100 100
93 i-Pr CH2CH2SCH3 1-Napth 0.34 >100 76
94 Bn CH3 2-Napth 0.17 >50 1
95 Bn CH(CH3)2 2-Napth 1.7 >100 99
†Percentage remaining in mouse plasma (at 2–4qC, during 30 min incubation, final concentration of 1 µg/ml in 1 ml of 
plasma). 
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%. 















Compound R1 EC50 (µM) CC50 (µM)
86 OH 0.06 >100
96 Cl 0.012 16
97 OMe 0.01 7
98 OEt 0.01 10
99 NHMe 0.035 49
100 SMe 0.037 41
EC50: 50% effective concentration or compound concentration required to inhibit HCV replication by 
50%; CC50: 50% cytotoxic concentration.
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 36,
Several 6-modifications significantly improved 
antiviral activity of 101. A 3 ,´5 -´cyclic ProTide 
strategy was applied to the latter. It was shown, 
that 3 ,´5´-cyclic prodrugs of 6-substituted 
purine nucleosides are metabolized into the 
2´-deoxy-2´-D-f luoro-2´-C-methylguanosine 
triphosphate. Extensive studies of different 
simple alkyl and aryl esters combined with dif-
ferent modifications in the 6-position showed 
that both alkoxy and alkyl amine substituents 
are accepted at C-6 position, while methyl 
was found to be the best as a cyclic phosphate 
masking moiety (TABLE 11) [120]. 
Biological evaluation led to the identifica-
tion of PSI-352938 (109; Rp isomer) as a potent 
inhibitor of HCV replication in replicon assay 
(EC90 = 1.37 µM) without any cytotoxicity 
across different cell lines (including mitochon-
drial and bone marrow toxicity) up to 100 µM. 
PSI-352938 was found to be active against all 
six genotypes. In vitro studies with PEG-IFN 
and RBV demonstrated that 109 could be com-
bined to produce an additive or synergistic anti-
viral effect. Studies in animal models revealed 
production of high levels of 2´-deoxy-2´-D-
fluoro-2´-C-methylguanosine triphosphate in 
rat liver, after oral administration of 50 mg/kg. 
The metabolic pathway of 109 is not yet fully 
disclosed [120].
PSI-352938 was advanced into Phase I clini-
cal trials to evaluate its safety profile, tolerability 
and pharmacokinetics in healthy subjects. The 
compound was administered once daily, rang-
ing from 100–800 mg against placebo. The 
compound was generally well tolerated at all 
tested doses. No serious adverse events or dis-
continuations were recorded. No dose-related 
or dose-limiting adverse events/toxicities were 
observed, with pharmacokinetic ana lysis sup-
porting q.d. dosing. PSI-352938 was progressed 
into Phase Ib clinical trials in 40 treatment-
naive HCV genotype 1 patients. In a blind, 
randomized and placebo controlled study, 109 
was administered at doses of 100–300 mg 
q.d. and 100 mg b.i.d. over 7 days. At day 8, 
a mean HCV RNA change from baseline of 
4.31 log IU/ml, 4.64 log IU/ml, 3.94 log IU/
ml and 4.59 log IU/ml in patients receiving 
100 mg q.d., 200 mg q.d., 300 mg q.d. and 
100 mg b.i.d., respectively, was found. 11 out 
of 16 patients from the 200–300 mg groups 
achieved RVR. Pharmacokinetic parameters 
were similar to the ones reported for the healthy 
subjects, providing good systemic exposure and 
further supporting once-daily dosing. PSI-938 
was generally welltolerated at all tested doses. 
There were no reported adverse events or 
discontinuations over the study [121,310].
 36,
As an outcome of the positive results of PSI-
938, further development of the 6-modified 
2´-deoxy-2´-D-f luoro-2´-C-methylguanosine 
phosphoramidates was carried out (TABLE 12). 
Synthesized phosphoramidates were shown to 
possess very good anti-HCV activity in HCV 
clone A replicon assay, without significant 
toxicity in different cell lines [119,122]. 










Compound R1 R2 EC90 (µM) CC50 (µM)
103 OH Me 11.75 >65
104 OEt Me 0.41 >30
105 OPr Me 0.83 >30
106 OEt Me 0.01 10
107 NHPr Me 0.92 >30
108 OEt n-Pr 13.27 ND
109, Rp OEt i-Pr 1.37 >100
109, Sp OEt i-Pr 0.69 >100
110, Rp OPr n-Pr 23.83 ND
110, Sp OPr n-Pr 5.27 >11
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration 
























EC50 = 69.2 µM
102
IC50 = 5.94 µM
Figure 17. Structures and anti-HCV activity of 2’-deoxy-2’-D-fluoro-2’-C-
methylguanosine and corresponding triphosphate. 
EC50: 50% effective concentration or compound concentration required to inhibit 
HCV replication by 50%; IC50: 50% compound concentration required to inhibit 
activity of HCV polymerase by 50%.
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After comprehensive evaluation of metabolic 
stability and cellular triphosphate formation, 
PSI-353661 (single Sp isomer of 113) was iden-
tified as a clinical candidate for the treatment 
of HCV infection. Extensive biological evalu-
ations demonstrate lack of cellular and mito-
chondrial toxicity up to 100 µM, without signif-
icant toxicity towards bone marrow progenitor 
cells (45 µM). Cross-resistance study showed 
that PSI-353661 retains activity against dif-
ferent cell lines conferring resistance to NS5B 
inhibitors (both NI and NNIs). During in vitro 
studies with PEG-IFN and RBV, PSI-353661 
demonstrated promising synergistic or additive 
antiviral effect. PSI-353661 is awaiting the start 
of clinical evaluation [119,122].
 +\GUD]LQRPHWK\OVXOIRQ\O
C-methylpurine
6-Hydrazinopurine-methylsulfonyl 2 -´C-methyl 
nucleosides, 120 and 121, were essentially inac-
tive against HCV with no observed cytotoxicity 
(FIGURE 18) [83]. 
Compounds were not good substrates for 
adenosine kinase and a lack of phosphorylation 
to the corresponding 5 -´monophosphates was 
postulated. To by-pass the first phosphorylation 
step and deliver masked 5´-monophosphates 
into the cells, SATE technology was applied to 
both NAs resulting in significant improvement 
in replicon potency (TABLE 13) [83,123]. 
For the most active prodrug (127), the 
potency enhancement was higher than 11,000-
fold. It was demonstrated that the antiviral effi-
cacy of these compounds was correlated with 
their lipophilicity, probably due to the increased 
permeability through the cell membrane. The 
stability of 127 was checked in plasma from 
different species. During 1 h incubation in rat 
plasma only 4% of 127 were found. The major 
detected metabolite was the cyclic-monophos-
phate (59%), whereas the parent nucleoside 
121 was found in 18% and its monophosphate 
in only 19%. Compound 127 was found to be 
stable in monkey and human plasma during 
1 h incubation period. It was suggested that 















Compound R1 R2 EC90 (µM) CC50 (µM)
101 OH - 69.2 >100
111 OH i-Pr 0.75 >100
112 OMe Me 0.008 >100
113 OMe i-Pr 0.02 >100
114 OEt Me 0.016 >100
115 OEt i-Pr 0.02 59
116 OPr Me 0.015 39
117 OPr i-Pr 0.033 49
118 N(CH2)3 Me 0.09 >100
119 N(CH2)3 i-Pr 0.019 53































EC50 = 94 µM; CC50 > 300 µM
Figure 18. Anti-hepatitis C virus activity of 6-hydrazinopurine-
methylsulfonyl 2’-C-methyl nucleosides.
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compounds may be able to reach hepatocytes 
after iv. administration [83,123]. No further data 
regarding development of these compounds 
have been reported.
Antiviral resistance for nucleoside 
inhibitors of RdRp
The development of resistance is dependent on a 
number of factors. Single nucleotide mutations 
are more common to occur than those requir-
ing multiple nucleotide changes [124]. As noted 
earlier, the HCV virus can produce high rates of 
spontaneous mutations each day and, therefore, 
a high-resistance profile to other direct-acting 
antivirals should be expected [10]. The compari-
son between NIs and NNIs suggests that muta-
tions in the allosteric site are more common 
than those in the active site. It is presumed that 
only a limited range of amino acid substitutions 
in the catalytic site would be accepted in order 
to maintain catalytic-site function and replica-
tion fitness. These functional restrictions can 
result in low levels of resistant mutants within 
the nontreated patients (in the absence of a drug 
selective pressure) [125,126].
There are several reported key resistant muta-
tions for the clinical stage anti-HCV nucleo-
sides. For the 4 -´C-azido nucleosides (6 & 7), 
the most important isolated resistant mutants 
are S96T and N142T, and for the 2 -´C-methyl 
substituted nucleosides (4, 18, 58, 77 or 79), 
this is the S282T mutant. It has been reported 
that all of these mutations have been associ-
ated with decreased replication fitness in vitro. 
However, it is unknown whether these primary 
mutants can develop compensatory mutations, 
which could restore deficiencies in replication 
fitness [127]. The 2 -´C-methyl related resistant 
mutations lack cross-resistance with 4 -´C-azido 
analogues [128]. However, with the discontinu-
ation of the clinical development of 4 -´C-azido 
analogues, all candidates that are still in devel-
opment possess 2´-C-methyl substitutions. 
Thus far, reported in vitro and in vivo data for 
the 2 -´C-methyl modified clinical candidates 
are showing high barrier to resistance for this 
class of nucleosides [43,116,128–130]. Nevertheless, 
a lack of variety in the structure of potential 
clinical candidates may result in the emer-
gence of S282T slow-to-clear HCV strains or 
‘breakthrough’ strains in treated patients.
Future perspective
We have presented an overview of the current 
development status of the anti-HCV nucleoside 
and nucleotide prodrugs. Anti-HCV NAs that 
are designed to specifically target viral NS5B 
polymerase each present different clinical 










































Compound R1 R2 EC50 (µM) CC50 (µM)
120 H - 300 300
121 NH2 - 94 300
122 H - 0.06 ND
123 NH2 - 0.024 ND
124 H 0.145 >50
125 NH2 0.022 >50
126 H O 0.039 >50
127 NH2 O 0.008 >50
CC50: 50% cytotoxic concentration; EC50: 50% effective concentration or compound concentration required to inhibit HCV 
replication by 50%.
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Executive summary
NS5B inhibitors
 Nucleoside analogues (NAs) have been found to be potent and effective inhibitors of hepatitis C virus replication both in vitro and 
in vivo. Furthermore, they were found to be active against all HCV genotypes with high barriers to resistance.
 It has been demonstrated that different modifications of both the sugar and base unit can be tolerated, and high antiviral potency and 
selectivity can be achieved. 
 2´- and 4´-modified ribonucleoside analogues have demonstrated promising antiviral potency and selectivity as anti-HCV inhibitors; 
however, their polar nature may be a limitation when oral administration is required.
Nucleoside ester prodrugs
 It has been shown that simple ester prodrugs of NAs can improve their bioavailability and pharmacokinetic profiles. RG7128, the 
bis-isobutyryl ester of E-D-2´-deoxy-2´-fluoro-2´-C-methylcytidine, is an example of the most advanced nucleoside-ester prodrug in 
clinical trials.
ProTides of anti-HCV nucleoside analogues
 The conversion to the active triphosphates for most of the NAs was found to be problematic, with the first phosphorylation being the 
rate-limiting step. Several different strategies have been applied to NAs in order to deliver masked monophosphates intracellularly. Due 
to the nature of HCV infection a ProTide that would undergo first-pass metabolism would be preferred, as it could generate high levels 
of active species in the target organ (liver) without unnecessary systemic exposure.
 The use of 5´-monophosphate prodrugs has greatly enhanced inhibitory activity of several NAs in replicon assays, and the levels of the 
active triphosphate species were found to be much higher both in cell cultures and in liver of animal models, when dosed orally.
 During clinical studies, different ProTides (IDX184, INX08189 and PSI938) demonstrated efficacy while dosed orally, with significant rates 
of rapid viral response and, in some cases, sustained viral response amongst HCV infected patients. In each case, Phase II/III data are 
now emerging.
advantages and challenges. Optimization of 
the NA is highly challenging and multifacto-
rial. There has to be a balance between the 
ability of the modified nucleoside to interact 
with the multiple cellular enzymes required 
for phosphorylation to the active triphos-
phate, whilst retaining metabolic stability and 
delivery. Furthermore, modified nucleoside 
triphosphates have to possess high selectivity 
towards viral RdRp without affinity to human 
polymerases. 
One of the challenges associated with NAs 
is that their triphosphate form has to compete 
with relatively high concentrations of natu-
rally occurring nucleoside triphosphates [131] 
and, therefore, elevated concentrations of the 
therapeutic nucleosides may need to be used to 
compensate for this unfavorable ratio. 
The most significant advantage of NAs over 
NNIs is high potency across all six genotypes 
(pan-genotype coverage), whereas protease 
inhibitors may be limited by genotype [26]. In 
addition, a high genetic barrier to resistance has 
been reported for HCV NAs compared with the 
likely low genetic barriers to resistance for prote-
ase inhibitors, and particularly non-nucleoside 
polymerase inhibitors [115,117]. Future trends in 
the field of nucleoside prodrugs may include 
new structural classes of nucleosides that could 
provide better treatment options, especially for 
resistant strains, exhibiting increased potency 
and reduced toxicity with consequent reduc-
tion of the daily dose and treatment duration. 
The success of directly acting anti-HCV agents 
will also depend on their ability to prevent the 
emergence of escape mutants. The evaluation 
of efficient nucleotide prodrugs is essential to 
this progress.
It is most likely that HCV eradication will be 
achieved not by monotherapy but by the com-
binations of drugs from different mechanistic 
classes, attacking various viral and possibly host 
factors, with non-cross-resistance patterns. It 
is also possible that two different purine and 
pyrimidine nucleosides/nucleotides, possessing 
different resistance profiles, may be used for 
the treatment of pre-existing resistant variants. 
Although most of the current clinical trials 
involve addition of PEG-IFN and/or RBV to 
the treatment regimens, the goal of the second-
generation therapy is to shift away interferon-
based regimens to use exclusively direct act-
ing antiviral agents. The future of hepatitis 
C therapy will probably involve personalized 
treatment regimens, with duration time based 
on viral load at the baseline, liver stage, specific 
enzyme levels and other parameters. 
It seems likely that nucleotide prodrugs will 
form a key element of such therapies going 
forward.
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